PUBLIC_ID	line	trtname	trtshnm	catname	trtstdy	trtendy	trtgroup	thername	thershnm	therstdy	thercat	therendy	therclass	trtclass	thersub	bmtx_day	bmtx_type	bmtx_seq	bmtx_rec	MMTX_REASONFORTREA	trtrsn	pddy5	pddy9	frespcd	frespdy	bestrespcd	brespdy	pddy	bestresp	bestrespsh	fresp	frespsh	response	therbresp	therfresp	trtbresp	trtdurcyc	trtdurdy	trtfresp	ttbrespcyc	ttbrespdy	ttrespcyc	ttrespdy	therftrt	nagents	enr
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	65	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	65	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	3	65	0	28	781	28	781	1	2	1
MMRF_1014	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	66	106	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	2	41	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	107	185	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	185	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	3	79	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	186	365	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex	1	Proteasome/Steroid/IMID	365	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	PLATEAUED RESPONSE				4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	7	180	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	366	380	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	380	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	1	15	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Vincristine/Dexamethasone/Doxorubicin	Bor-Vin-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	381	407	6	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox	1	Proteasome/Steroid/IMID/Chemotherapy	407	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	1	27	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	408	448	7	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	448	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	2	41	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Carfilzomib/Dexamethasone	Bor-Car-Dex	Proteasome/Proteasome/Steroid	449	535	8	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	535	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Investigator decision for other reasons	5			4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	3	87	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	536	539	9	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone + Bortezomib/Dexamethason	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	539	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	0	4	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	540	752	10	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone + Bortezomib/Dexamethason	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex + Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	752	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	8	213	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	753	813	11	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone + Bortezomib/Dexamethason	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex + Bor-Dex + Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	813	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	1	1	1	2	61	1	28	781	28	781			1
MMRF_1014	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	814	815	12	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone + Bortezomib/Dexamethason	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex + Bor-Dex + Bor-Cyc-Dex + Bor-Dex + Bor-Mel-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	815	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	0	2	0	28	781	28	781			1
MMRF_1014	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	816	819	13	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone + Bortezomib/Dexamethason	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex + Bor-Dex + Bor-Cyc-Dex + Bor-Dex + Bor-Mel-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	819	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	816	Stem cell, Autologous	1	1	Completed regimen	4			4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	0	4	0	28	781	28	781			1
MMRF_1014	1	Thalidomide	Thal	IMID	977	1157	14	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Vincristine/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Bortezomib/Carfilzomib/Dexamethasone + Bortezomib/Dexamethason	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Thal-Dex + Bor-Dex + Bor-Vin-Dex-Dox + Bor-Dex + Bor-Car-Dex + Bor-Dex + Bor-Cyc-Dex + Bor-Dex + Bor-Mel-Dex + Bor-Dex + Thal	1	Proteasome/Steroid/IMID/Chemotherapy	1157	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	781	4	781		Partial Response	PR	Partial Response	PR	1	0	0	0	7	181	0	28	781	28	781			1
MMRF_1017	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	508	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	508	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH				4	82	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	18	508	1	6	162	3	82	1	2	1
MMRF_1024	1	Thalidomide/Melphalan/Prednisone	Thal-Mel-Pred	IMID/Chemotherapy/Steroid	1	149	1	Thalidomide/Melphalan/Prednisone	Thal-Mel-Pred	1	IMID/Chemotherapy/Steroid	149	IMIDs-based	IMIDs-based	Thal-Mel-Pred				0	Lack of response	1			4	439	4	439	353	Partial Response	PR	Partial Response	PR	1	0	0	0	6	149	0	16	439	16	439	1	3	1
MMRF_1024	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	162	240	2	Thalidomide/Melphalan/Prednisone + Lenalidomide/Dexamethasone	Thal-Mel-Pred + Len-Dex	1	IMID/Chemotherapy/Steroid	240	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			4	439	4	439	353	Partial Response	PR	Partial Response	PR	1	0	0	0	3	79	0	16	439	16	439			1
MMRF_1024	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	295	582	3	Thalidomide/Melphalan/Prednisone + Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Thal-Mel-Pred + Len-Dex + Bor-Dex	1	IMID/Chemotherapy/Steroid/Proteasome	582	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	439	4	439	353	Partial Response	PR	Partial Response	PR	1	1	1	1	11	288	1	16	439	16	439			1
MMRF_1024	2	Lenalidomide	Len	IMID	659	2907	1	Lenalidomide	Len	659	IMID	2907	IMIDs-based	IMIDs-based	Len-Dex				0					4	1233	4	1233		Partial Response	PR	Partial Response	PR	1	1	1	1	81	2249	1	21	575	21	575	1	1	1
MMRF_1038	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	1738	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	1738	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH				4	68	3	258		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	62	1738	1	10	258	3	68	1	2	1
MMRF_1033	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	123	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	123	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	89	4	89	218	Partial Response	PR	Partial Response	PR	1	1	1	1	5	123	1	4	89	4	89	1	2	1
MMRF_1033	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	2713	2825	1	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	2713	Proteasome/IMID/Steroid	2825	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	Completed regimen	4			4	2883	4	2883		Partial Response	PR	Partial Response	PR	1	1	1	1	4	113	1	7	171	7	171	1	3	1
MMRF_1007	1	Thalidomide/Melphalan/Prednisone	Thal-Mel-Pred	IMID/Chemotherapy/Steroid	1	85	1	Thalidomide/Melphalan/Prednisone	Thal-Mel-Pred	1	IMID/Chemotherapy/Steroid	85	IMIDs-based	IMIDs-based	Thal-Mel-Pred				0	Adverse Event or co-morbidity	2					5	87		Stable Disease	SD			0	1	0	1	3	85	0	4	87			1	3	1
MMRF_1007	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	92	145	2	Thalidomide/Melphalan/Prednisone + Lenalidomide/Dexamethasone	Thal-Mel-Pred + Len-Dex	1	IMID/Chemotherapy/Steroid	145	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2					5	87		Stable Disease	SD			0	0	0	0	2	54	0	4	87					1
MMRF_1007	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	155	208	3	Thalidomide/Melphalan/Prednisone + Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Thal-Mel-Pred + Len-Dex + Bor-Dex	1	IMID/Chemotherapy/Steroid/Proteasome	208	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2					5	87		Stable Disease	SD			0	0	0	0	2	54	0	4	87					1
MMRF_1052	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	51	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	51	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	273	4	273		Partial Response	PR	Partial Response	PR	1	0	0	0	2	51	0	10	273	10	273	1	2	1
MMRF_1052	1	Thalidomide/Dexamethasone	Thal-Dex	IMID/Steroid	119	162	2	Lenalidomide/Dexamethasone + Thalidomide/Dexamethasone	Len-Dex + Thal-Dex	1	IMID/Steroid	162	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			4	273	4	273		Partial Response	PR	Partial Response	PR	1	0	0	0	2	44	0	10	273	10	273			1
MMRF_1052	1	Bortezomib	Bor	Proteasome	174	273	3	Lenalidomide/Dexamethasone + Thalidomide/Dexamethasone + Bortezomib	Len-Dex + Thal-Dex + Bor	1	IMID/Steroid/Proteasome	273	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	273	4	273		Partial Response	PR	Partial Response	PR	1	1	1	1	4	100	1	10	273	10	273			1
MMRF_1082	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	274	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	274	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				0	Investigator decision for other reasons	5			4	52	3	157	255	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	274	1	6	157	2	52	1	3	1
MMRF_1082	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	288	326	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	288	Proteasome/IMID/Steroid	326	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	373	Stem cell, Autologous	1	1	Investigator decision for other reasons	5					5	359	598	Stable Disease	SD			0	1	0	1	2	39	0	3	72			1	3	1
MMRF_1082	2	Lenalidomide	Len	IMID	500	582	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	288	Proteasome/IMID/Steroid	582	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4					5	359	598	Stable Disease	SD			0	0	0	0	3	83	0	3	72					1
MMRF_1082	2	Pomalidomide	Pom	IMID	588	680	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Pomalidomide	Bor-Len-Dex + Len + Pom	288	Proteasome/IMID/Steroid	680	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3					5	359	598	Stable Disease	SD			0	0	0	0	4	93	0	3	72					1
MMRF_1082	3	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	661	750	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	661	Chemotherapy/Steroid	750	Other therapies	Other treatments					0	Completed regimen	4					6	801	801	Progressive Disease	PD			0	1	0	1	4	90	0	6	141					1
MMRF_1094	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	95	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	95	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	144	Stem cell, Autologous	1	1	Completed regimen	4	2712		3	99	3	99	757	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	95	1	4	99	4	99	1	3	1
MMRF_1094	2	Acalabrutinib/Pembrolizumab	Aca-Pemb	BTK/Checkpoint Inhibitor	1327	1454	1	Acalabrutinib/Pembrolizumab	Aca-Pemb	1327	BTK/Checkpoint Inhibitor	1454	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2	2712				5	1432	1341	Stable Disease	SD			0	1	0	1	5	128	0	4	106					1
MMRF_1094	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1829	2061	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1829	CD38/IMID/Steroid	2061	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Investigator decision for other reasons	5	2712		4	1971	4	1971	2270	Partial Response	PR	Partial Response	PR	1	1	1	1	9	233	1	6	143	6	143	1	3	1
MMRF_1094	4	Daratumumab	Dar	CD38	2361	2521	1	Daratumumab	Dar	2361	CD38	2521	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3	2712				6	2544	2544	Progressive Disease	PD			0	1	0	1	6	161	0	7	184					1
MMRF_1094	5	Carfilzomib	Car	Proteasome	2565	2573	1	Carfilzomib	Car	2565	Proteasome	2573	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3	2712				6	2712	2712	Progressive Disease	PD			0	0	0	0	1	9	0	6	148			1	1	1
MMRF_1094	9	STRO-001	STRO-001	CD74	2683	2698	1	STRO-001	STRO-001	2683	CD74	2698	Other therapies	Other treatments					0	Disease progression/Relapse	3	2712											0	0	0	0	1	16	0							1
MMRF_1093	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	185	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	185	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			4	33	3	943		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	185	1	34	943	2	33	1	2	1
MMRF_1129	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	249	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	249	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			3	49	3	49		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	249	1	2	49	2	49	1	2	1
MMRF_1129	1	Lenalidomide	Len	IMID	250	610	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	610	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH				3	49	3	49		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	13	361	0	2	49	2	49			1
MMRF_1130	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	351	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	351	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	106	4	106	703	Partial Response	PR	Partial Response	PR	1	1	1	1	13	351	1	4	106	4	106	1	3	1
MMRF_1130	1	Lenalidomide	Len	IMID	352	541	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	541	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	106	4	106	703	Partial Response	PR	Partial Response	PR	1	0	0	0	7	190	0	4	106	4	106			1
MMRF_1130	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	879	1243	1	Lenalidomide/Dexamethasone	Len-Dex	879	IMID/Steroid	1243	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1			4	1256	4	1256	943	Partial Response	PR	Partial Response	PR	1	1	1	1	13	365	1	14	378	14	378	1	2	1
MMRF_1130	3	Pomalidomide	Pom	IMID	1373	2004	1	Pomalidomide	Pom	1373	IMID	2004	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3			4	1957	4	1957	1650	Partial Response	PR	Partial Response	PR	1	1	1	1	23	632	1	21	585	21	585	1	1	1
MMRF_1130	4	Daratumumab	Dar	CD38	2087	2894	1	Daratumumab	Dar	2087	CD38	2894	daratumumab-based	daratumumab-based	Dar				0					4	2139	4	2139		Partial Response	PR	Partial Response	PR	1	1	1	1	29	808	1	2	53	2	53			1
MMRF_1137	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	195	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	195	IMIDs-based	IMIDs-based	Len-Dex	225	Stem cell, Autologous	1	1	Completed regimen	4			3	206	3	206	572	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	195	1	8	206	8	206	1	2	1
MMRF_1137	1	Lenalidomide	Len	IMID	337	501	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	501	IMIDs-based	IMIDs-based	Len-Dex				1	Adverse Event or co-morbidity	2			3	206	3	206	572	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	165	0	8	206	8	206			1
MMRF_1137	2	Lenalidomide	Len	IMID	632	675	1	Lenalidomide	Len	632	IMID	675	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1												0	0	0	0	2	44	0					1	1	1
MMRF_1137	3	Lenalidomide	Len	IMID	676	721	1	Lenalidomide	Len	676	IMID	721	IMIDs-based	IMIDs-based	Len-Dex				0							6	675	675	Progressive Disease	PD			0	0	0	0	2	46	0	0	0			1	1	1
MMRF_1137	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	722	722	2	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Len + Bor-Len-Dex	676	IMID/Proteasome/Steroid	722	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1					6	675	675	Progressive Disease	PD			0	0	0	0	0	1	0	0	0					1
MMRF_1137	3	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	723	764	3	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Len + Bor-Len-Dex + Bor-Dex	676	IMID/Proteasome/Steroid	764	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Disease progression/Relapse	3					6	675	675	Progressive Disease	PD			0	0	0	0	2	42	0	0	0					1
MMRF_1137	4	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	785	1090	1	Pomalidomide/Dexamethasone	Pom-Dex	785	IMID/Steroid	1090	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3			4	897	4	897	785	Partial Response	PR	Partial Response	PR	1	1	1	1	11	306	1	5	113	5	113	1	2	1
MMRF_1132	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	92	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	92	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1			4	92	3	168		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	92	1	6	168	4	92	1	2	1
MMRF_1132	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	103	238	2	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Len-Dex + Bor-Dex	1	IMID/Steroid/Proteasome	238	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	DEATH				4	92	3	168		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	136	0	6	168	4	92			1
MMRF_1178	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	150	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	150	Bortezomib-based	Bortezomib-based	Bor-Dex	163	Stem cell, Autologous	1	1	PROCEEDING WITH AUTOLOGOUS STEM CELL TRANSPLANT				3	269	3	269	1114	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	150	1	10	269	10	269	1	2	1
MMRF_1178	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1870	1988	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1870	Proteasome/IMID/Steroid	1988	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			3	1932	3	1932	2340	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	119	1	3	63	3	63	1	3	1
MMRF_1178	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2712	2879	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2712	CD38/IMID/Steroid	2879	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					6	2914	2914	Progressive Disease	PD			0	1	0	1	6	168	0	8	203			1	3	1
MMRF_1193	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	144	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	144	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	102	3	172	541	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	144	1	7	172	4	102	1	2	1
MMRF_1193	2	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	596	682	1	Bortezomib/Lenalidomide	Bor-Len	596	Proteasome/IMID	682	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	PARTIAL RESPONSE.				4	631	4	631	889	Partial Response	PR	Partial Response	PR	1	1	1	1	3	87	1	2	36	2	36	1	2	1
MMRF_1193	3	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	896	1321	1	Lenalidomide/Dexamethasone	Len-Dex	896	IMID/Steroid	1321	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	982	1284	Stable Disease	SD			0	1	0	1	16	426	0	4	87			1	2	1
MMRF_1193	4	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1379	1437	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1379	SLAMF7/IMID/Steroid	1437	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3					5	1466	1492	Stable Disease	SD			0	1	0	1	2	59	0	4	88			1	3	1
MMRF_1229	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	173	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	173	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1			4	173	4	173	143	Partial Response	PR	Partial Response	PR	1	1	1	1	6	173	1	7	173	7	173	1	3	1
MMRF_1229	2	Bortezomib/Doxorubicin	Bor-Dox	Proteasome/Chemotherapy	183	277	1	Bortezomib/Doxorubicin	Bor-Dox	183	Proteasome/Chemotherapy	277	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Lack of response	1			4	583	4	583	1508	Partial Response	PR	Partial Response	PR	1	0	0	0	4	95	0	15	401	15	401	1	2	1
MMRF_1229	2	Carfilzomib	Car	Proteasome	311	395	2	Bortezomib/Doxorubicin + Carfilzomib	Bor-Dox + Car	183	Proteasome/Chemotherapy	395	combined bortezomib/carfilzomib-based	Carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)	428	Stem cell, Autologous	1	1	Completed regimen	4			4	583	4	583	1508	Partial Response	PR	Partial Response	PR	1	1	1	1	3	85	1	15	401	15	401			1
MMRF_1229	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1538	1619	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1538	Proteasome/IMID/Steroid	1619	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Investigator decision for other reasons	5			4	1678	4	1678	1928	Partial Response	PR	Partial Response	PR	1	1	1	1	3	82	1	6	141	6	141	1	3	1
MMRF_1229	4	Daratumumab	Dar	CD38	2202	2892	1	Daratumumab	Dar	2202	CD38	2892	daratumumab-based	daratumumab-based	Dar				0					3	2663	3	2663		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	25	691	1	17	462	17	462			1
MMRF_1256	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	172	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	172	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	506	3	2565		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	172	0	92	2565	19	506	1	2	1
MMRF_1256	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	206	488	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	488	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	506	3	2565		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	10	283	1	92	2565	19	506			1
MMRF_1256	1	Lenalidomide	Len	IMID	506	2886	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	2886	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	506	3	2565		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	85	2381	1	92	2565	19	506			1
MMRF_1277	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	1	45	1	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	45	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	85	4	85		Partial Response	PR	Partial Response	PR	1	0	0	0	2	45	0	4	85	4	85	1	2	1
MMRF_1277	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	46	77	2	Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	85	4	85		Partial Response	PR	Partial Response	PR	1	1	1	1	1	32	1	4	85	4	85			1
MMRF_1285	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	204	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	204	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	55	3	245	789	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	204	1	9	245	2	55	1	3	1
MMRF_1285	1	Bortezomib	Bor	Proteasome	303	877	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	877	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	55	3	245	789	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	21	575	0	9	245	2	55			1
MMRF_1285	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	898	1051	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	898	Proteasome/IMID/Steroid	1051	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	1062	3	1062	1955	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	154	1	6	165	6	165	1	3	1
MMRF_1285	2	Lenalidomide	Len	IMID	1093	1823	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	898	Proteasome/IMID/Steroid	1823	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	1062	3	1062	1955	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	26	731	0	6	165	6	165			1
MMRF_1285	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1851	2018	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Len + Ixa-Len-Dex	898	Proteasome/IMID/Steroid	2018	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	DEATH				3	1062	3	1062	1955	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	168	0	6	165	6	165			1
MMRF_1359	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	116	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	116	Bortezomib-based	Bortezomib-based	Bor-Dex	170	Stem cell, Autologous	1	1	TO PROCEED WITH TRANSPLANT				3	63	3	63	624	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	116	1	3	63	3	63	1	2	1
MMRF_1359	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	694	876	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	694	Proteasome/Chemotherapy/Steroid	876	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	802	4	802	1072	Partial Response	PR	Partial Response	PR	1	1	1	1	7	183	1	4	109	4	109	1	3	1
MMRF_1359	2	Lenalidomide	Len	IMID	882	1106	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	694	Proteasome/Chemotherapy/Steroid/IMID	1106	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	802	4	802	1072	Partial Response	PR	Partial Response	PR	1	0	0	0	8	225	0	4	109	4	109			1
MMRF_1359	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1123	1162	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1123	Proteasome/IMID/Steroid	1162	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3					6	1170	1170	Progressive Disease	PD			0	1	0	1	2	40	0	2	48			1	3	1
MMRF_1395	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	126	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	191	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			3	67	3	67		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	126	1	3	67	3	67	1	3	1
MMRF_1395	1	Lenalidomide	Len	IMID	1156	2948	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2948	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	67	3	67		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	64	1793	0	3	67	3	67			1
MMRF_1401	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	542	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	542	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4					5	71		Stable Disease	SD			0	1	0	1	20	542	0	3	71			1	3	1
MMRF_1401	2	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	91	260	1	Carfilzomib/Lenalidomide	Car-Len	91	Proteasome/IMID	260	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car				0	Lack of response	1			4	287	4	287	427	Partial Response	PR	Partial Response	PR	1	0	0	0	6	170	0	8	197	8	197	1	2	1
MMRF_1401	2	Lenalidomide	Len	IMID	261	427	2	Carfilzomib/Lenalidomide	Car-Len	91	Proteasome/IMID	427	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car				0	Disease progression/Relapse	3			4	287	4	287	427	Partial Response	PR	Partial Response	PR	1	1	1	1	6	167	1	8	197	8	197			1
MMRF_1401	3	Carfilzomib/Pomalidomide	Car-Pom	Proteasome/IMID	430	500	1	Carfilzomib/Pomalidomide	Car-Pom	430	Proteasome/IMID	500	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	514	514	Progressive Disease	PD			0	1	0	1	3	71	0	4	85			1	2	1
MMRF_1410	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	164	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	164	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	177	Stem cell, Autologous	1	1	Completed regimen	4			4	47	4	47	472	Partial Response	PR	Partial Response	PR	1	1	1	1	6	164	1	2	47	2	47	1	3	1
MMRF_1410	1	Lenalidomide	Len	IMID	245	508	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	508	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	47	4	47	472	Partial Response	PR	Partial Response	PR	1	0	0	0	10	264	0	2	47	2	47			1
MMRF_1598	1	Thalidomide/Dexamethasone	Thal-Dex	IMID/Steroid	1	45	1	Thalidomide/Dexamethasone	Thal-Dex	1	IMID/Steroid	45	IMIDs-based	IMIDs-based	Thal-Dex				0	DEATH													0	0	0	0	2	45	0					1	2	1
MMRF_1670	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	81	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	129	Stem cell, Autologous	1	1	PLAN FOR STEM CELL RESCUE WHEN IN REMISSION		1401		4	81	4	81	446	Partial Response	PR	Partial Response	PR	1	1	1	1	3	81	1	3	81	3	81	1	3	1
MMRF_1670	1	Lenalidomide	Len	IMID	278	477	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	477	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	1401		4	81	4	81	446	Partial Response	PR	Partial Response	PR	1	0	0	0	7	200	0	3	81	3	81			1
MMRF_1670	2	Carfilzomib	Car	Proteasome	484	612	1	Carfilzomib	Car	484	Proteasome	612	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3	1401				5	554	675	Stable Disease	SD			0	1	0	1	5	129	0	3	71			1	1	1
MMRF_1670	3	Acalabrutinib/Pembrolizumab	Aca-Pemb	BTK/Checkpoint Inhibitor	683	773	1	Acalabrutinib/Pembrolizumab	Aca-Pemb	683	BTK/Checkpoint Inhibitor	773	Other therapies	Other treatments					0	Completed regimen	4	1401				5	901		Stable Disease	SD			0	1	0	1	4	91	0	8	219					1
MMRF_1670	4	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	943	1111	1	Bortezomib/Cyclophosphamide	Bor-Cyc	943	Proteasome/Chemotherapy	1111	Bortezomib-based	Bortezomib-based	Bor-Cyc				0	Adverse Event or co-morbidity	2	1401				5	975	1145	Stable Disease	SD			0	1	0	1	6	169	0	2	33			1	2	1
MMRF_1670	5	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1283	1429	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1283	CD38/IMID/Steroid	1429	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3	1401				5	1310	1401	Stable Disease	SD			0	1	0	1	6	147	0	1	28			1	3	1
MMRF_1670	9	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	1436	1473	1	Elotuzumab/Lenalidomide	Elo-Len	1436	SLAMF7/IMID	1473	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1401											0	0	0	0	2	38	0					1	2	1
MMRF_1670	9	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1478	1502	2	Elotuzumab/Lenalidomide + Cyclophosphamide/Dexamethasone	Elo-Len + Cyc-Dex	1436	SLAMF7/IMID/Chemotherapy/Steroid	1502	IMIDs-based	Other treatments	Other Len-based therapies				0	Adverse Event or co-morbidity	2	1401											0	0	0	0	1	25	0							1
MMRF_1670	9	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1562	1656	3	Elotuzumab/Lenalidomide + Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone	Elo-Len + Cyc-Dex + Bor-Dar-Dex	1436	SLAMF7/IMID/Chemotherapy/Steroid/Proteasome/CD38	1656	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2	1401											0	0	0	0	4	95	0							1
MMRF_1670	9	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1804	1877	4	Elotuzumab/Lenalidomide + Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Elo-Len + Cyc-Dex + Bor-Dar-Dex + Ixa-Len-Dex	1436	SLAMF7/IMID/Chemotherapy/Steroid/Proteasome/CD38	1877	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1401											0	0	0	0	3	74	0							1
MMRF_1695	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	197	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	197	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	20	4	20		Partial Response	PR	Partial Response	PR	1	1	1	1	7	197	1	1	20	1	20	1	3	1
MMRF_1695	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	198	198	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	198	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	198	Stem cell, Autologous	1	1	Completed regimen	4			4	20	4	20		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	1	20	1	20			1
MMRF_1695	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	199	214	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	214	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	20	4	20		Partial Response	PR	Partial Response	PR	1	0	0	0	1	16	0	1	20	1	20			1
MMRF_1695	1	Lenalidomide	Len	IMID	471	637	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	637	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	20	4	20		Partial Response	PR	Partial Response	PR	1	0	0	0	6	167	0	1	20	1	20			1
MMRF_1838	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	78	155	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	78	Proteasome/IMID/Steroid	155	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	211	Stem cell, Autologous	1	1	AUTOLOGOUS TRANSPLANT				4	71	3	259	349	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	3	78	0	7	182	0	-6	1	3	1
MMRF_1838	1	Lenalidomide	Len	IMID	316	615	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	78	Proteasome/IMID/Steroid	615	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	71	3	259	349	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	11	300	0	7	182	0	-6			1
MMRF_1838	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	630	1005	1	Carfilzomib/Dexamethasone	Car-Dex	630	Proteasome/Steroid	1005	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	DEATH				4	797	4	797		Partial Response	PR	Partial Response	PR	1	1	1	1	14	376	1	6	168	6	168	1	2	1
MMRF_1866	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	918	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	918	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	UNKNOWN				3	147	1	225	1110	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	33	918	1	9	225	6	147	1	3	1
MMRF_1866	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Thal-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	1173	1183	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Dex + Bor-Thal-Cyc-Dex-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	1183	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	1218	Stem cell, Autologous	1	1	Completed regimen	4			3	147	1	225	1110	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	11	0	9	225	6	147			1
MMRF_1866	2	Daratumumab	Dar	CD38	1296	1347	1	Daratumumab	Dar	1296	CD38	1347	daratumumab-based	daratumumab-based	Dar				0					4	1382	1	1921		Complete Response	CR	Partial Response	PR	1	0	0	0	2	52	0	23	626	4	87			1
MMRF_1866	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1348	1596	2	Daratumumab + Daratumumab/Pomalidomide	Dar + Dar-Pom	1296	CD38/IMID	1596	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0					4	1382	1	1921		Complete Response	CR	Partial Response	PR	1	0	1	0	9	249	1	23	626	4	87	1	2	1
MMRF_1866	2	Bortezomib/Daratumumab/Pomalidomide	Bor-Dar-Pom	Proteasome/CD38/IMID	1597	2765	3	Daratumumab + Daratumumab/Pomalidomide + Bortezomib/Daratumumab/Pomalidomide	Dar + Dar-Pom + Bor-Dar-Pom	1296	CD38/IMID/Proteasome	2765	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc				0					4	1382	1	1921		Complete Response	CR	Partial Response	PR	1	1	0	1	42	1169	0	23	626	4	87			1
MMRF_1950	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	289	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	289	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	93	3	93	950	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	289	1	4	93	4	93	1	3	1
MMRF_1950	2	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1152	1310	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1152	Proteasome/CD38/Steroid	1310	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Investigator decision for other reasons	5			4	1172	3	2131		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	159	1	35	980	1	21	1	3	1
MMRF_1997	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	472	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	472	IMIDs-based	IMIDs-based	Len-Dex				0					4	290	4	290	1186	Partial Response	PR	Partial Response	PR	1	1	1	1	17	472	1	11	290	11	290	1	2	1
MMRF_1997	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	473	621	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	621	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	290	4	290	1186	Partial Response	PR	Partial Response	PR	1	0	0	0	6	149	0	11	290	11	290			1
MMRF_1997	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	622	787	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	787	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Patient decision	6			4	290	4	290	1186	Partial Response	PR	Partial Response	PR	1	0	0	0	6	166	0	11	290	11	290			1
MMRF_1997	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1604	1660	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1604	Proteasome/IMID/Steroid	1660	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Investigator decision for other reasons	5												0	0	0	0	2	57	0					1	3	1
MMRF_2214	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	43	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	43	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	79	3	450	700	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	43	0	17	450	3	79	1	3	1
MMRF_2214	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	44	433	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	433	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			4	79	3	450	700	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	390	1	17	450	3	79			1
MMRF_2230	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	124	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	124	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2					5	81		Stable Disease	SD			0	1	0	1	5	124	0	3	81			1	3	1
MMRF_2258	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	112	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	112	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	525	4	525	331	Partial Response	PR	Partial Response	PR	1	1	1	1	4	112	1	19	525	19	525	1	2	1
MMRF_2442	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	190	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	226	Stem cell, Autologous	1	1	Completed regimen	4			3	94	3	94	1075	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	190	1	4	94	4	94	1	3	1
MMRF_2442	1	Lenalidomide	Len	IMID	406	1040	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1040	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	94	3	94	1075	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	23	635	0	4	94	4	94			1
MMRF_2442	2	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1106	1263	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1106	Proteasome/CD38/Steroid	1263	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3					5	1165		Stable Disease	SD			0	1	0	1	6	158	0	3	60			1	3	1
MMRF_2442	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1274	1543	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1274	CD38/IMID/Steroid	1543	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3					5	1305	1457	Stable Disease	SD			0	1	0	1	10	270	0	2	32			1	3	1
MMRF_2442	4	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1555	1732	1	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	1555	Proteasome/CD38/IMID/Steroid	1732	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0	Disease progression/Relapse	3			4	1598	4	1598	1732	Partial Response	PR	Partial Response	PR	1	1	1	1	7	178	1	2	44	2	44	1	4	1
MMRF_2456	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	124	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	124	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Investigator decision for other reasons	5			4	363	1	488	1793	Complete Response	CR	Partial Response	PR	1	0	0	0	5	124	0	18	488	13	363	1	3	1
MMRF_2456	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	153	472	2	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	472	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	511	Stem cell, Autologous	1	1	Completed regimen	4			4	363	1	488	1793	Complete Response	CR	Partial Response	PR	1	1	1	1	12	320	1	18	488	13	363			1
MMRF_2456	1	Lenalidomide	Len	IMID	596	1803	3	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1803	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Cyc-Dex				1	Disease progression/Relapse	3			4	363	1	488	1793	Complete Response	CR	Partial Response	PR	1	0	0	0	43	1208	0	18	488	13	363			1
MMRF_2456	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1804	2002	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1804	Proteasome/IMID/Steroid	2002	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Investigator decision for other reasons	5					5	2010		Stable Disease	SD			0	0	0	0	7	199	0	8	207			1	3	1
MMRF_2456	2	Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Pom-Dex	Proteasome/IMID/IMID/Steroid	2003	2584	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Pom-Dex	1804	Proteasome/IMID/Steroid	2584	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0							5	2010		Stable Disease	SD			0	1	0	1	21	582	0	8	207					1
MMRF_2471	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	153	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	153	IMIDs-based	IMIDs-based	Len-Dex				0					4	84	3	910	1073	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	153	1	33	910	3	84	1	2	1
MMRF_2471	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	154	231	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	231	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	84	3	910	1073	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	78	0	33	910	3	84			1
MMRF_2471	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	232	597	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	597	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	84	3	910	1073	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	13	366	0	33	910	3	84			1
MMRF_2471	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1136	1988	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1136	Proteasome/IMID/Steroid	1988	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3			4	1257	4	1257	1165	Partial Response	PR	Partial Response	PR	1	1	1	1	31	853	1	5	122	5	122	1	3	1
MMRF_2471	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2011	2109	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	2011	CD38/IMID/Steroid	2109	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3					6	2136	2136	Progressive Disease	PD			0	1	0	1	4	99	0	5	126			1	3	1
MMRF_2471	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	2151	2569	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	2151	Proteasome/IMID/Steroid	2569	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0														0	0	0	0	15	419	0					1	3	1
MMRF_2475	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	222	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	222	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	60	3	60		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	222	1	3	60	3	60	1	3	1
MMRF_2475	2	Lenalidomide	Len	IMID	423	1729	1	Lenalidomide	Len	423	IMID	1729	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			1	1135	1	1135	491	Complete Response	CR	Complete Response	CR	1	1	1	1	47	1307	1	26	713	26	713	1	1	1
MMRF_2475	3	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	1730	2521	1	Elotuzumab/Lenalidomide	Elo-Len	1730	SLAMF7/IMID	2521	IMIDs-based	IMIDs-based	Other Len-based therapies				0							5	1978		Stable Disease	SD			0	1	0	1	29	792	0	9	249			1	2	1
MMRF_2546	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	136	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	136	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	61	282	Stable Disease	SD			0	1	0	1	5	136	0	3	61			1	2	1
MMRF_2546	1	Bortezomib	Bor	Proteasome	197	366	2	Lenalidomide/Dexamethasone + Bortezomib	Len-Dex + Bor	1	IMID/Steroid/Proteasome	366	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Disease progression/Relapse	3					5	61	282	Stable Disease	SD			0	0	0	0	6	170	0	3	61					1
MMRF_2579	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	143	Stem cell, Allogenic	1	1	Completed regimen	4			3	79	1	660		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	105	1	24	660	3	79	1	3	1
MMRF_1021	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	29	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	29	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	85	Stem cell, Autologous	1	1	TOXICITY				4	59	3	141	623	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	1	29	1	6	141	3	59	1	3	1
MMRF_1021	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	630	825	1	Lenalidomide/Dexamethasone	Len-Dex	630	IMID/Steroid	825	IMIDs-based	IMIDs-based	Len-Dex				1	Completed regimen	4			4	686	1	1044	2282	Complete Response	CR	Partial Response	PR	1	0	1	0	7	196	1	15	415	3	57	1	2	1
MMRF_1021	2	Bortezomib/Fludarabine/Melphalan	Bor-Flu-Mel	Proteasome/Chemotherapy/Chemotherapy	844	848	2	Lenalidomide/Dexamethasone + Bortezomib/Fludarabine/Melphalan	Len-Dex + Bor-Flu-Mel	630	IMID/Steroid/Proteasome/Chemotherapy	848	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	849	Stem cell, Allogenic	2	1	Completed regimen	4			4	686	1	1044	2282	Complete Response	CR	Partial Response	PR	1	1	0	1	0	5	0	15	415	3	57			1
MMRF_1021	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2363	2909	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2363	CD38/IMID/Steroid	2909	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2503	4	2503		Partial Response	PR	Partial Response	PR	1	1	1	1	20	547	1	6	141	6	141	1	3	1
MMRF_1030	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PATIENT WENT TO TRANSPLANT		2740		4	80	1	654		Complete Response	CR	Partial Response	PR	1	0	1	0	4	106	1	24	654	3	80	1	3	1
MMRF_1030	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	116	116	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	116	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	141	Stem cell, Autologous	1	1	PATIENT GOING TO TRANSPLANT		2740		4	80	1	654		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	24	654	3	80			1
MMRF_1030	1	Bortezomib/Thalidomide/Melphalan	Bor-Thal-Mel	Proteasome/IMID/Chemotherapy	280	283	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Thal-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	283	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	284	Stem cell, Autologous	2	1	Completed regimen	4	2740		4	80	1	654		Complete Response	CR	Partial Response	PR	1	1	0	1	0	4	0	24	654	3	80			1
MMRF_1030	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1984	2205	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1984	Proteasome/IMID/Steroid	2205	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2	2740		3	2143	3	2143	1984	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	222	1	6	160	6	160	1	3	1
MMRF_1030	3	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	2373	2459	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	2373	Proteasome/IMID/Steroid	2459	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	2740				6	2459	2459	Progressive Disease	PD			0	1	0	1	3	87	0	4	87			1	3	1
MMRF_1030	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	2465	2493	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	2465	Proteasome/IMID/Steroid	2493	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2740				6	2486	2486	Progressive Disease	PD			0	1	0	1	1	29	0	1	22			1	3	1
MMRF_1030	5	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	2493	2760	1	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	2493	Proteasome/IMID/Chemotherapy/Steroid	2760	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2740				6	2740	2740	Progressive Disease	PD			0	1	0	1	10	268	0	9	248			1	4	1
MMRF_1030	9	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2760	2816	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2760	CD38/IMID/Steroid	2816	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2740											0	0	0	0	2	57	0					1	3	1
MMRF_1032	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	52	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	52	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	47	3	47		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	52	1	2	47	2	47	1	3	1
MMRF_1032	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	439	934	1	Lenalidomide/Dexamethasone	Len-Dex	439	IMID/Steroid	934	IMIDs-based	IMIDs-based	Len-Dex				0	DIED				4	544	4	544	908	Partial Response	PR	Partial Response	PR	1	1	1	1	18	496	1	4	106	4	106	1	2	1
MMRF_1072	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	32	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	32	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PT GOING TO TRANSPLANT				3	75	1	200		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	32	0	8	200	3	75	1	3	1
MMRF_1072	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	60	60	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	60	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	87	Stem cell, Autologous	1	1	Completed regimen	4			3	75	1	200		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	8	200	3	75			1
MMRF_1072	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2117	2445	1	Carfilzomib/Dexamethasone	Car-Dex	2117	Proteasome/Steroid	2445	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Investigator decision for other reasons	5			4	2151	3	2333		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	12	329	1	8	217	2	35	1	2	1
MMRF_1079	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	43	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	43	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PROCEED TO TRANSPLANT		2094		4	75	3	180	1302	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	2	43	1	7	180	3	75	1	3	1
MMRF_1079	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	75	75	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	75	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	227	Stem cell, Autologous	2	1	Completed regimen	4	2094		4	75	3	180	1302	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	1	7	180	3	75			1
MMRF_1079	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	75	75	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	75	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	100	Stem cell, Autologous	1	1	Completed regimen	4	2094		4	75	3	180	1302	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	0	1	1	7	180	3	75			1
MMRF_1079	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1331	1752	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1331	Proteasome/IMID/Steroid	1752	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3	2094		3	1520	3	1520	1587	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	15	422	1	7	190	7	190	1	3	1
MMRF_1079	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1887	1971	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1887	CD38/IMID/Steroid	1971	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2094				6	1964	1964	Progressive Disease	PD			0	1	0	1	3	85	0	3	78			1	3	1
MMRF_1079	5	Bortezomib/Panobinostat/Dexamethasone	Bor-Pano-Dex	Proteasome/HDAC/Steroid	1999	2074	1	Bortezomib/Panobinostat/Dexamethasone	Bor-Pano-Dex	1999	Proteasome/HDAC/Steroid	2074	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2094				6	2094	2094	Progressive Disease	PD			0	0	0	0	3	76	0	4	96			1	3	1
MMRF_1079	9	Bortezomib/Nelfinavir Mesylate/Dexamethasone	Bor-Nel-Dex	Proteasome/Steroid	2081	2126	1	Bortezomib/Nelfinavir Mesylate/Dexamethasone	Bor-Nel-Dex	2081	Proteasome/Steroid	2126	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2094											0	0	0	0	2	46	0					1	3	1
MMRF_1098	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	92	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	92	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	13	3	133		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	92	1	5	133	1	13	1	3	1
MMRF_1099	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	285	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	285	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	82	4	82		Partial Response	PR	Partial Response	PR	1	1	1	1	10	285	1	3	82	3	82	1	3	1
MMRF_1099	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	333	588	1	Pomalidomide/Dexamethasone	Pom-Dex	333	IMID/Steroid	588	IMIDs-based	IMIDs-based	Pom-Dex				0	Patient decision	6					5	393		Stable Disease	SD			0	1	0	1	9	256	0	3	61			1	2	1
MMRF_1139	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	53	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	53	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	74	1	2175	2545	Complete Response	CR	Partial Response	PR	1	0	1	0	2	53	1	78	2175	3	74	1	3	1
MMRF_1139	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	74	74	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	74	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	100	Stem cell, Autologous	1	1	Completed regimen	4			4	74	1	2175	2545	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	1	78	2175	3	74			1
MMRF_1139	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	274	277	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	277	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	277	Stem cell, Autologous	2	1	Completed regimen	4			4	74	1	2175	2545	Complete Response	CR	Partial Response	PR	1	1	0	1	0	4	0	78	2175	3	74			1
MMRF_1159	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	92	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	92	Bortezomib-based	Bortezomib-based	Bor-Dex				1	Completed regimen	4			4	85	2	2336		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	92	1	84	2336	4	85	1	2	1
MMRF_1159	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	122	122	2	Bortezomib/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Dex + Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	122	Bortezomib-based	Other treatments	Bor-Cyc-Dex	171	Stem cell, Autologous	1	1	Completed regimen	4			4	85	2	2336		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	1	0	84	2336	4	85			1
MMRF_1177	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	71	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	71	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	INTOLERANCE TO THERAPY				4	61	4	61	706	Partial Response	PR	Partial Response	PR	1	1	1	1	3	71	1	3	61	3	61	1	3	1
MMRF_1177	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	711	819	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	711	Proteasome/Chemotherapy/Steroid	819	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH													0	0	0	0	4	109	0					1	3	1
MMRF_1208	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	66	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	66	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	171	Stem cell, Autologous	1	1	Completed regimen	4			4	70	3	252	682	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	66	1	9	252	3	70	1	3	1
MMRF_1208	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	711	905	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	711	Proteasome/IMID/Steroid	905	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	802	4	802		Partial Response	PR	Partial Response	PR	1	1	1	1	7	195	1	4	92	4	92	1	3	1
MMRF_1208	3	Thalidomide/Cyclophosphamide/Dexamethasone	Thal-Cyc-Dex	IMID/Chemotherapy/Steroid	1074	1114	1	Thalidomide/Cyclophosphamide/Dexamethasone	Thal-Cyc-Dex	1074	IMID/Chemotherapy/Steroid	1114	IMIDs-based	IMIDs-based	Thal-Cyc-Dex				0	Disease progression/Relapse	3			4	1263	4	1263	1074	Partial Response	PR	Partial Response	PR	1	0	0	0	2	41	0	7	190	7	190	1	3	1
MMRF_1208	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1137	1320	2	Thalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Thal-Cyc-Dex + Car-Dex	1074	IMID/Chemotherapy/Steroid/Proteasome	1320	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1263	4	1263	1074	Partial Response	PR	Partial Response	PR	1	1	1	1	7	184	1	7	190	7	190			1
MMRF_1194	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	90	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	90	IMIDs-based	IMIDs-based	Len-Dex				1	Lack of response	1			3	127	2	815		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	4	90	0	30	815	5	127	1	2	1
MMRF_1194	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	91	136	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	136	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	127	2	815		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	2	46	1	30	815	5	127			1
MMRF_1194	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	142	142	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Len-Dex + Bor-Len-Dex + Cyc-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	142	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	182	Stem cell, Autologous	1	1	Completed regimen	4			3	127	2	815		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	30	815	5	127			1
MMRF_1205	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	173	4	173	552	Partial Response	PR	Partial Response	PR	1	0	0	0	4	113	0	7	173	7	173	1	3	1
MMRF_1205	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	114	135	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	135	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	173	4	173	552	Partial Response	PR	Partial Response	PR	1	0	0	0	1	22	0	7	173	7	173			1
MMRF_1205	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	136	142	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	142	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex	189	Stem cell, Autologous	1	1	Completed regimen	4			4	173	4	173	552	Partial Response	PR	Partial Response	PR	1	1	1	1	1	7	1	7	173	7	173			1
MMRF_1205	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	618	685	1	Pomalidomide/Dexamethasone	Pom-Dex	618	IMID/Steroid	685	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			4	685	4	685	801	Partial Response	PR	Partial Response	PR	1	1	1	1	3	68	1	3	68	3	68	1	2	1
MMRF_1211	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	78	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	78	Bortezomib-based	Bortezomib-based	Bor-Dex				1	Investigator decision for other reasons	5			3	87	2	219	2618	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	3	78	1	8	219	4	87	1	2	1
MMRF_1211	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	101	101	2	Bortezomib/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Dex + Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	101	Bortezomib-based	Other treatments	Bor-Cyc-Dex	128	Stem cell, Autologous	1	1	Completed regimen	4			3	87	2	219	2618	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	8	219	4	87			1
MMRF_1221	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	64	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	64	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	96	3	96	617	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	64	1	4	96	4	96	1	3	1
MMRF_1221	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	96	96	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	96	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	129	Stem cell, Autologous	1	1	Completed regimen	4			3	96	3	96	617	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	0	1	1	4	96	4	96			1
MMRF_1221	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	295	298	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Len-Dex + Cyc-Dex + Bor-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	298	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	297	Stem cell, Autologous	2	1	Completed regimen	4			3	96	3	96	617	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	4	96	4	96			1
MMRF_1221	1	TH1 Cell Infusion	TH1 Cell Infusion		352	352	4	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + TH1 Cell Infusion	Bor-Len-Dex + Cyc-Dex + Bor-Mel-Dex + TH1 Cell Infusion	1	Proteasome/IMID/Steroid/Chemotherapy	352	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	96	3	96	617	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	96	4	96			1
MMRF_1221	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	711	760	1	Lenalidomide/Dexamethasone	Len-Dex	711	IMID/Steroid	760	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5					5	821	711	Stable Disease	SD			0	1	0	1	2	50	0	4	111			1	2	1
MMRF_1221	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	851	922	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	851	Proteasome/Chemotherapy/Steroid	922	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3					5	900		Stable Disease	SD			0	1	0	1	3	72	0	2	50			1	3	1
MMRF_1221	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	947	1080	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	947	Proteasome/IMID/Steroid	1080	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	997	1087	Stable Disease	SD			0	1	0	1	5	134	0	2	51			1	3	1
MMRF_1221	5	Bortezomib/Pomalidomide/Panobinostat/Dexamethasone	Bor-Pom-Pano-Dex	Proteasome/IMID/HDAC/Steroid	1093	1164	1	Bortezomib/Pomalidomide/Panobinostat/Dexamethasone	Bor-Pom-Pano-Dex	1093	Proteasome/IMID/HDAC/Steroid	1164	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	ADMITTED				4	1138	4	1138		Partial Response	PR	Partial Response	PR	1	1	1	1	3	72	1	2	46	2	46	1	4	1
MMRF_1230	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	107	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	107	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Investigator decision for other reasons	5			4	97	4	97	617	Partial Response	PR	Partial Response	PR	1	1	1	1	4	107	1	4	97	4	97	1	4	1
MMRF_1230	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	136	136	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	136	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	97	4	97	617	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	97	4	97			1
MMRF_1230	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	168	170	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Melphalan/Dexamethasone	Bor-Len-Cyc-Dex + Mel-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	170	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	170	Stem cell, Autologous	1	1	Completed regimen	4			4	97	4	97	617	Partial Response	PR	Partial Response	PR	1	0	0	0	0	3	0	4	97	4	97			1
MMRF_1257	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	52	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	52	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	100	Stem cell, Autologous	1	1	Completed regimen	4	1610		3	79	3	79	898	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	52	1	3	79	3	79	1	3	1
MMRF_1257	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	905	1214	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	905	Proteasome/Chemotherapy/Steroid	1214	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3	1610		3	995	3	995	1246	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	310	1	4	91	4	91	1	3	1
MMRF_1257	3	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1248	1418	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1248	Proteasome/IMID/Steroid	1418	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1610		3	1372	3	1372	1422	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	171	1	5	125	5	125	1	3	1
MMRF_1257	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1428	1448	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1428	Proteasome/IMID/Steroid	1448	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1610				6	1447	1447	Progressive Disease	PD			0	1	0	1	1	21	0	1	20			1	3	1
MMRF_1257	5	Daratumumab/Thalidomide/Prednisone/Dexamethasone	Dar-Thal-Pred-Dex	CD38/IMID/Steroid/Steroid	1449	1535	1	Daratumumab/Thalidomide/Prednisone/Dexamethasone	Dar-Thal-Pred-Dex	1449	CD38/IMID/Steroid	1535	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Thal-Pred-Dex				0			1610				5	1536	1610	Stable Disease	SD			0	1	0	1	3	87	0	4	88			1	4	1
MMRF_1257	5	Daratumumab/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Dar-Thal-Cyc-Pred-Dex	CD38/IMID/Chemotherapy/Steroid/Steroid	1536	1563	2	Daratumumab/Thalidomide/Prednisone/Dexamethasone + Daratumumab/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Dar-Thal-Pred-Dex + Dar-Thal-Cyc-Pred-Dex	1449	CD38/IMID/Steroid/Chemotherapy	1563	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Thal-Cyc-Pred-Dex				0			1610				5	1536	1610	Stable Disease	SD			0	0	0	1	1	28	0	4	88					1
MMRF_1257	5	Daratumumab/Pomalidomide/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Dar-Pom-Thal-Cyc-Pred-Dex	CD38/IMID/IMID/Chemotherapy/Steroid/Steroid	1564	1578	3	Daratumumab/Thalidomide/Prednisone/Dexamethasone + Daratumumab/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Daratumumab/Pomalidomide/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Dar-Thal-Pred-Dex + Dar-Thal-Cyc-Pred-Dex + Dar-Pom-Thal-Cyc-Pred-Dex	1449	CD38/IMID/Steroid/Chemotherapy	1578	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Thal-Cyc-Pred-Dex				0	Disease progression/Relapse	3	1610				5	1536	1610	Stable Disease	SD			0	0	0	0	1	15	0	4	88					1
MMRF_1257	9	Carfilzomib/Pomalidomide/Pembrolizumab/Bendamustine/Dexamethasone	Car-Pom-Pemb-Bend-Dex	Proteasome/IMID/Checkpoint Inhibitor/Chemotherapy/Steroid	1589	1666	1	Carfilzomib/Pomalidomide/Pembrolizumab/Bendamustine/Dexamethasone	Car-Pom-Pemb-Bend-Dex	1589	Proteasome/IMID/Checkpoint Inhibitor/Chemotherapy/Steroid	1666	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	DEATH		1610											0	0	0	0	3	78	0					1	5	1
MMRF_1274	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	54	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	54	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	92	1	405		Complete Response	CR	Partial Response	PR	1	0	1	0	2	54	1	15	405	4	92	1	3	1
MMRF_1274	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	92	92	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	92	Bortezomib-based	Other treatments	Bor-Cyc-Dex	118	Stem cell, Autologous	1	1	Completed regimen	4			4	92	1	405		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	1	15	405	4	92			1
MMRF_1274	1	Bortezomib/Fludarabine/Melphalan	Bor-Flu-Mel	Proteasome/Chemotherapy/Chemotherapy	288	292	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Fludarabine/Melphalan	Bor-Cyc-Dex + Bor-Flu-Mel	1	Proteasome/Chemotherapy/Steroid	292	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	293	Stem cell, Allogenic	2	1	Completed regimen	4			4	92	1	405		Complete Response	CR	Partial Response	PR	1	1	0	1	0	5	0	15	405	4	92			1
MMRF_1286	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	47	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	47	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4	1920		4	47	4	47	262	Partial Response	PR	Partial Response	PR	1	1	1	1	2	47	1	2	47	2	47	1	3	1
MMRF_1286	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	74	74	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	74	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	100	Stem cell, Autologous	1	1	Completed regimen	4	1920		4	47	4	47	262	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	47	2	47			1
MMRF_1286	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	268	1018	1	Lenalidomide/Dexamethasone	Len-Dex	268	IMID/Steroid	1018	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3	1920		4	323	4	323		Partial Response	PR	Partial Response	PR	1	1	1	1	27	751	1	2	56	2	56	1	2	1
MMRF_1286	3	Pomalidomide	Pom	IMID	941	1107	1	Pomalidomide	Pom	941	IMID	1107	IMIDs-based	IMIDs-based	Pom-Dex				0	Investigator decision for other reasons	5	1920				5	962		Stable Disease	SD			0	1	0	1	6	167	0	1	22			1	1	1
MMRF_1286	4	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1032	1101	1	Bortezomib/Dexamethasone	Bor-Dex	1032	Proteasome/Steroid	1101	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5	1920				5	1053	1207	Stable Disease	SD			0	1	0	1	3	70	0	1	22			1	2	1
MMRF_1286	4	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	1129	1206	2	Bortezomib/Dexamethasone + Ixazomib/Pomalidomide/Dexamethasone	Bor-Dex + Ixa-Pom-Dex	1032	Proteasome/Steroid/IMID	1206	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1920				5	1053	1207	Stable Disease	SD			0	0	0	0	3	78	0	1	22					1
MMRF_1286	5	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1227	2017	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1227	CD38/IMID/Steroid	2017	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	1920				5	1248	1920	Stable Disease	SD			0	1	0	1	29	791	0	1	22			1	3	1
MMRF_1286	9	Bortezomib/Venetoclax/Dexamethasone	Bor-Vent-Dex	Proteasome/BCL2/Steroid	2083	2139	1	Bortezomib/Venetoclax/Dexamethasone	Bor-Vent-Dex	2083	Proteasome/BCL2/Steroid	2139	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1920											0	0	0	0	2	57	0					1	3	1
MMRF_1286	9	Bortezomib/Panobinostat/Dexamethasone	Bor-Pano-Dex	Proteasome/HDAC/Steroid	2146	2153	2	Bortezomib/Venetoclax/Dexamethasone + Bortezomib/Panobinostat/Dexamethasone	Bor-Vent-Dex + Bor-Pano-Dex	2083	Proteasome/BCL2/Steroid/HDAC	2153	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2	1920											0	0	0	0	1	8	0							1
MMRF_1325	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	38	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	38	IMIDs-based	IMIDs-based	Len-Dex				1					4	81	2	2158		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	38	0	78	2158	3	81	1	2	1
MMRF_1325	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	39	78	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	78	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	81	2	2158		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	40	0	78	2158	3	81			1
MMRF_1325	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	79	80	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	80	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	81	2	2158		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	0	2	1	78	2158	3	81			1
MMRF_1325	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	123	123	4	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Len-Dex + Bor-Len-Dex + Cyc-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	123	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	149	Stem cell, Autologous	1	1	Completed regimen	4			4	81	2	2158		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	1	0	78	2158	3	81			1
MMRF_1394	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	77	3	422		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	77	1	16	422	3	77	1	3	1
MMRF_1394	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	87	87	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	87	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	113	Stem cell, Autologous	1	1	Completed regimen	4			4	77	3	422		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	16	422	3	77			1
MMRF_1394	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1366	1414	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1366	Proteasome/IMID/Steroid	1414	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			3	1551	3	1551	1366	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	49	1	7	186	7	186	1	3	1
MMRF_1394	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1821	2135	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1821	Proteasome/CD38/Steroid	2135	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0					4	1962	4	1962		Partial Response	PR	Partial Response	PR	1	1	1	1	12	315	1	6	142	6	142	1	3	1
MMRF_1394	3	Bortezomib/Carfilzomib/Daratumumab/Dexamethasone	Bor-Car-Dar-Dex	Proteasome/Proteasome/CD38/Steroid	2136	2216	2	Bortezomib/Daratumumab/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Dexamethasone	Bor-Dar-Dex + Bor-Car-Dar-Dex	1821	Proteasome/CD38/Steroid	2216	combined bortezomib/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	1962	4	1962		Partial Response	PR	Partial Response	PR	1	0	0	0	3	81	0	6	142	6	142			1
MMRF_1394	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	2217	2929	3	Bortezomib/Daratumumab/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex + Bor-Car-Dar-Dex + Bor-Dar-Dex	1821	Proteasome/CD38/Steroid	2929	combined bortezomib/carfilzomib-based	Bortezomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	1962	4	1962		Partial Response	PR	Partial Response	PR	1	0	0	0	26	713	0	6	142	6	142			1
MMRF_1394	5	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	2683	2929	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	2683	Proteasome/IMID/Steroid	2929	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	2929	4	2929		Partial Response	PR	Partial Response	PR	1	1	1	1	9	247	1	9	247	9	247	1	3	1
MMRF_1408	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	101	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	101	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	78	3	364	1545	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	101	1	13	364	3	78	1	3	1
MMRF_1408	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	121	121	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	121	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	273	Stem cell, Autologous	1	1	Completed regimen	4			4	78	3	364	1545	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	13	364	3	78			1
MMRF_1408	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1624	1722	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1624	Proteasome/IMID/Steroid	1722	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			4	1736	4	1736		Partial Response	PR	Partial Response	PR	1	1	1	1	4	99	1	5	113	5	113	1	3	1
MMRF_1408	3	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1748	2933	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1748	SLAMF7/IMID/Steroid	2933	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1797	4	1797		Partial Response	PR	Partial Response	PR	1	1	1	1	43	1186	1	2	50	2	50	1	3	1
MMRF_1413	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	81	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	81	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	85	3	508		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	81	1	19	508	4	85	1	3	1
MMRF_1413	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	101	101	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	101	Bortezomib-based	Other treatments	Bor-Cyc-Dex	128	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	508		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	19	508	4	85			1
MMRF_1413	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1570	1612	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1570	SLAMF7/IMID/Steroid	1612	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3					6	1591	1591	Progressive Disease	PD			0	1	0	1	2	43	0	1	22			1	3	1
MMRF_1413	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1661	2940	1	Carfilzomib/Dexamethasone	Car-Dex	1661	Proteasome/Steroid	2940	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	1661	4	1661		Partial Response	PR	Partial Response	PR	1	1	1	1	46	1280	1	1	1	1	1	1	2	1
MMRF_1418	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	57	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	107	2	344	1157	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	57	0	13	344	4	107	1	3	1
MMRF_1418	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	80	80	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	80	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	109	Stem cell, Autologous	1	1	Completed regimen	4			4	107	2	344	1157	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	0	1	1	13	344	4	107			1
MMRF_1418	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	284	286	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	286	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	288	Stem cell, Autologous	2	1	Completed regimen	4			4	107	2	344	1157	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	3	0	13	344	4	107			1
MMRF_1418	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1185	2543	4	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Cyc-Dex + Bor-Mel + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2543	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3			4	107	2	344	1157	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	49	1359	0	13	344	4	107			1
MMRF_1418	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	2544	2910	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	2544	Proteasome/IMID/Steroid	2910	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3			4	2551	4	2551	2921	Partial Response	PR	Partial Response	PR	1	1	1	1	13	367	1	1	8	1	8	1	3	1
MMRF_1418	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2928	2928	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2928	CD38/IMID/Steroid	2928	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_1423	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	28	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	28	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	100	Stem cell, Autologous	1	1	Completed regimen	4			3	156	3	156	65	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	28	1	6	156	6	156	1	3	1
MMRF_1426	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	62	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	62	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5			3	91	2	1386	2387	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	3	62	0	50	1386	4	91	1	3	1
MMRF_1426	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	71	92	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	92	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	91	2	1386	2387	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	1	22	1	50	1386	4	91			1
MMRF_1426	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	122	122	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	148	Stem cell, Autologous	1	1	Completed regimen	4			3	91	2	1386	2387	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	50	1386	4	91			1
MMRF_1426	2	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	2723	2726	1	Bortezomib/Melphalan	Bor-Mel	2723	Proteasome/Chemotherapy	2726	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred	2727	Stem cell, Autologous	2	1	Completed regimen	4					5	2886		Stable Disease	SD			0	1	0	1	0	4	0	6	164			1	2	1
MMRF_1433	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	68	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	68	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4	1523		4	184	4	184		Partial Response	PR	Partial Response	PR	1	0	0	0	3	68	0	7	184	7	184	1	3	1
MMRF_1433	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	95	95	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	95	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	122	Stem cell, Autologous	1	1	Completed regimen	4	1523		4	184	4	184		Partial Response	PR	Partial Response	PR	1	1	1	1	0	1	1	7	184	7	184			1
MMRF_1433	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	255	257	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	257	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	257	Stem cell, Autologous	2	1	Completed regimen	4	1523		4	184	4	184		Partial Response	PR	Partial Response	PR	1	0	0	0	0	3	0	7	184	7	184			1
MMRF_1433	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	883	1082	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	883	Proteasome/IMID/Steroid	1082	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2	1523		4	1002	4	1002	883	Partial Response	PR	Partial Response	PR	1	1	1	1	7	200	1	5	120	5	120	1	3	1
MMRF_1433	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1100	1332	1	Pomalidomide/Dexamethasone	Pom-Dex	1100	IMID/Steroid	1332	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3	1523				5	1240	1156	Stable Disease	SD			0	1	0	1	9	233	0	6	141			1	2	1
MMRF_1433	4	Lenalidomide/Pembrolizumab/Dexamethasone	Len-Pemb-Dex	IMID/Checkpoint Inhibitor/Steroid	1359	1472	1	Lenalidomide/Pembrolizumab/Dexamethasone	Len-Pemb-Dex	1359	IMID/Checkpoint Inhibitor/Steroid	1472	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1523				5	1429		Stable Disease	SD			0	1	0	1	4	114	0	3	71			1	3	1
MMRF_1433	5	Ixazomib/Idasanutlin/Dexamethasone	Ixa-Ida-Dex	Proteasome/MDM2/Steroid	1523	1607	1	Ixazomib/Idasanutlin/Dexamethasone	Ixa-Ida-Dex	1523	Proteasome/MDM2/Steroid	1607	Other therapies	Other treatments					0	Disease progression/Relapse	3	1523		4	1709	4	1709	1523	Partial Response	PR	Partial Response	PR	1	0	0	0	3	85	0	7	187	7	187			1
MMRF_1433	9	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1646	2158	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1646	Proteasome/CD38/Steroid	2158	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	PATIENT EXPIRED		1523											0	0	0	0	19	513	0					1	3	1
MMRF_1434	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	57	2	540	1625	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	2	56	1	20	540	3	57	1	3	1
MMRF_1434	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	88	88	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	88	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	114	Stem cell, Autologous	1	1	Completed regimen	4			3	57	2	540	1625	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	20	540	3	57			1
MMRF_1434	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1677	2935	1	Lenalidomide/Dexamethasone	Len-Dex	1677	IMID/Steroid	2935	IMIDs-based	IMIDs-based	Len-Dex				0					4	1705	4	1705	2753	Partial Response	PR	Partial Response	PR	1	1	1	1	45	1259	1	2	29	2	29	1	2	1
MMRF_1452	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	86	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	86	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	76	4	76	170	Partial Response	PR	Partial Response	PR	1	1	1	1	3	86	1	3	76	3	76	1	3	1
MMRF_1452	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	107	107	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	107	Bortezomib-based	Other treatments	Bor-Cyc-Dex	134	Stem cell, Autologous	1	1	Completed regimen	4			4	76	4	76	170	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	76	3	76			1
MMRF_1452	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	177	272	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	177	Proteasome/IMID/Steroid	272	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	272	1	461		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	96	1	11	285	4	96	1	3	1
MMRF_1452	2	Bortezomib/Fludarabine/Melphalan	Bor-Flu-Mel	Proteasome/Chemotherapy/Chemotherapy	288	292	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Fludarabine/Melphalan	Bor-Len-Dex + Bor-Flu-Mel	177	Proteasome/IMID/Steroid/Chemotherapy	292	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	293	Stem cell, Allogenic	2	1	Completed regimen	4			3	272	1	461		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	5	0	11	285	4	96			1
MMRF_1461	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	108	Stem cell, Autologous	1	1	Completed regimen	4	878		3	74	3	74	485	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	56	1	3	74	3	74	1	3	1
MMRF_1461	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	508	815	1	Lenalidomide/Dexamethasone	Len-Dex	508	IMID/Steroid	815	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3	878				6	815	815	Progressive Disease	PD			0	1	0	1	11	308	0	11	308			1	2	1
MMRF_1461	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	823	831	1	Pomalidomide/Dexamethasone	Pom-Dex	823	IMID/Steroid	831	IMIDs-based	IMIDs-based	Pom-Dex				0	Patient decision	6	878				6	823	823	Progressive Disease	PD			0	1	0	1	1	9	0	1	1			1	2	1
MMRF_1461	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	850	865	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	850	Proteasome/Chemotherapy/Steroid	865	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	878											0	0	0	0	1	16	0					1	3	1
MMRF_1461	5	Carfilzomib/Panobinostat/Dexamethasone	Car-Pano-Dex	Proteasome/HDAC/Steroid	878	962	1	Carfilzomib/Panobinostat/Dexamethasone	Car-Pano-Dex	878	Proteasome/HDAC/Steroid	962	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	878		3	997	3	997	878	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	85	0	5	120	5	120	1	3	1
MMRF_1461	9	Carfilzomib/Lenalidomide/Panobinostat/Dexamethasone	Car-Len-Pano-Dex	Proteasome/IMID/HDAC/Steroid	969	1003	1	Carfilzomib/Lenalidomide/Panobinostat/Dexamethasone	Car-Len-Pano-Dex	969	Proteasome/IMID/HDAC/Steroid	1003	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2	878											0	0	0	0	2	35	0					1	4	1
MMRF_1466	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	57	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	88	3	88	738	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	57	1	4	88	4	88	1	3	1
MMRF_1466	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	88	112	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	112	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex				1					3	88	3	88	738	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	1	25	1	4	88	4	88			1
MMRF_1466	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	113	113	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Dex + Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	113	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	88	3	88	738	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	88	4	88			1
MMRF_1466	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	114	116	4	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	116	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	117	Stem cell, Autologous	1	1	Completed regimen	4			3	88	3	88	738	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	3	0	4	88	4	88			1
MMRF_1466	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	745	943	1	Lenalidomide/Dexamethasone	Len-Dex	745	IMID/Steroid	943	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			4	793	3	974	1298	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	199	1	9	230	2	49	1	2	1
MMRF_1466	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1327	2916	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1327	Proteasome/IMID/Steroid	2916	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	1348	1	1699		Complete Response	CR	Partial Response	PR	1	1	1	1	57	1590	1	14	373	1	22	1	3	1
MMRF_1478	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	76	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	76	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	63	1	919		Complete Response	CR	Partial Response	PR	1	0	1	0	3	76	1	33	919	3	63	1	4	1
MMRF_1478	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	91	94	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Dex-Dox	1	Proteasome/IMID/Chemotherapy/Steroid	94	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	119	Stem cell, Autologous	1	1	Completed regimen	4			4	63	1	919		Complete Response	CR	Partial Response	PR	1	0	0	0	0	4	0	33	919	3	63			1
MMRF_1478	1	Fludarabine	Flu	Chemotherapy	305	308	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Fludarabine	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Dex-Dox + Flu	1	Proteasome/IMID/Chemotherapy/Steroid	308	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	311	Stem cell, Allogenic	2	1	Completed regimen	4			4	63	1	919		Complete Response	CR	Partial Response	PR	1	1	0	1	0	4	0	33	919	3	63			1
MMRF_1485	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	15	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	15	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5												0	0	0	0	1	15	0					1	2	1
MMRF_1497	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	22	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	22	IMIDs-based	IMIDs-based	Len-Dex				1	Completed regimen	4			3	207	3	207		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	8	207	8	207	1	2	1
MMRF_1497	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	35	119	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	119	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	207	3	207		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	85	0	8	207	8	207			1
MMRF_1497	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	172	182	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Len-Dex + Bor-Len-Dex + Cyc-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	182	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	209	Stem cell, Autologous	1	1	Completed regimen	4			3	207	3	207		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	11	1	8	207	8	207			1
MMRF_1489	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	107	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	107	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	69	4	69		Partial Response	PR	Partial Response	PR	1	1	1	1	4	107	1	3	69	3	69	1	3	1
MMRF_1489	1	Plerixafor	Pler		334	343	2	Bortezomib/Lenalidomide/Dexamethasone + Plerixafor	Bor-Len-Dex + Pler	1	Proteasome/IMID/Steroid	343	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	358	Stem cell, Autologous	1	1	Completed regimen	4			4	69	4	69		Partial Response	PR	Partial Response	PR	1	0	0	0	1	10	0	3	69	3	69			1
MMRF_1491	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	179	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	179	IMIDs-based	IMIDs-based	Len-Dex				1	Completed regimen	4			4	92	4	92		Partial Response	PR	Partial Response	PR	1	1	1	1	7	179	1	4	92	4	92	1	2	1
MMRF_1491	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	193	193	2	Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Len-Dex + Cyc-Dex	1	IMID/Steroid/Chemotherapy	193	IMIDs-based	Other treatments	Len-Cyc-Dex	235	Stem cell, Autologous	1	1	Completed regimen	4			4	92	4	92		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	92	4	92			1
MMRF_1491	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	390	397	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	390	Proteasome/Chemotherapy/Steroid	397	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	PATIENT DECEASED						6	390	390	Progressive Disease	PD			0	1	0	1	1	8	0	1	1			1	3	1
MMRF_1494	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	35	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	35	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	82	1	2501		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	35	0	90	2501	3	82	1	3	1
MMRF_1494	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	65	65	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	65	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	91	Stem cell, Autologous	1	1	Completed regimen	4			3	82	1	2501		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	0	1	1	90	2501	3	82			1
MMRF_1494	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	264	272	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	272	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	268	Stem cell, Autologous	2	1	Completed regimen	4			3	82	1	2501		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	1	9	0	90	2501	3	82			1
MMRF_1500	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	65	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	65	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	79	3	79	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	65	1	3	79	3	79	1	3	1
MMRF_1500	1	Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	102	122	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Dex + Cyc-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	123	Stem cell, Autologous	1	1	Completed regimen	4			3	79	3	79	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	21	0	3	79	3	79			1
MMRF_1500	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	260	263	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Len-Dex + Cyc-Mel-Dex + Bor-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	263	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	264	Stem cell, Autologous	2	1	Completed regimen	4			3	79	3	79	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	3	79	3	79			1
MMRF_1500	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	947	1198	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	947	Proteasome/IMID/Steroid	1198	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	1215	Stem cell, Autologous	3	1	PATIENT GOIN OT ASTC				3	967	1	1941	1802	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	9	252	1	36	995	1	21	1	3	1
MMRF_1500	2	Ipilimumab/Nivolumab	Ipi-Niv	Checkpoint Inhibitor/Checkpoint Inhibitor	1243	1419	2	Carfilzomib/Lenalidomide/Dexamethasone + Ipilimumab/Nivolumab	Car-Len-Dex + Ipi-Niv	947	Proteasome/IMID/Steroid/Checkpoint Inhibitor	1419	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	967	1	1941	1802	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	7	177	0	36	995	1	21			1
MMRF_1500	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2053	2893	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2053	CD38/IMID/Steroid	2893	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					1	2136	1	2136		Complete Response	CR	Complete Response	CR	1	1	1	1	30	841	1	3	84	3	84	1	3	1
MMRF_1523	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	44	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	44	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	188	1	1650		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	44	0	59	1650	7	188	1	3	1
MMRF_1523	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	79	79	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	79	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	104	Stem cell, Autologous	1	1	Completed regimen	4			3	188	1	1650		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	0	1	1	59	1650	7	188			1
MMRF_1523	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	250	259	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	259	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	261	Stem cell, Autologous	2	1	Completed regimen	4			3	188	1	1650		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	1	10	0	59	1650	7	188			1
MMRF_1523	2	Lenalidomide	Len	IMID	2344	2863	1	Lenalidomide	Len	2344	IMID	2863	IMIDs-based	IMIDs-based	Len-Dex				0					4	2457	4	2457		Partial Response	PR	Partial Response	PR	1	1	1	1	19	520	1	5	114	5	114	1	1	1
MMRF_1537	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	52	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	52	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	56	3	56		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	52	1	2	56	2	56	1	3	1
MMRF_1565	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	104	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	104	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	104	2	521	1130	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	104	1	19	521	4	104	1	3	1
MMRF_1565	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	129	129	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	129	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	163	Stem cell, Autologous	1	1	Completed regimen	4			4	104	2	521	1130	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	1	0	19	521	4	104			1
MMRF_1565	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1183	1281	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1183	Proteasome/IMID/Steroid	1281	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	1210	4	1210		Partial Response	PR	Partial Response	PR	1	1	1	1	4	99	1	1	28	1	28	1	3	1
MMRF_1573	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	111	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	111	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	88	2	459		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	111	1	17	459	4	88	1	3	1
MMRF_1573	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	193	196	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	196	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	196	Stem cell, Autologous	1	1	Completed regimen	4			4	88	2	459		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	4	0	17	459	4	88			1
MMRF_1583	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	53	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	53	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	91	3	91	2417	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	53	0	4	91	4	91	1	3	1
MMRF_1583	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	67	67	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	67	Bortezomib-based	Other treatments	Bor-Cyc-Dex	120	Stem cell, Autologous	1	1	Completed regimen	4			3	91	3	91	2417	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	4	91	4	91			1
MMRF_1583	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	259	262	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Cyc-Dex + Bor-Mel	1	Proteasome/Chemotherapy/Steroid	262	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	263	Stem cell, Autologous	2	1	Completed regimen	4			3	91	3	91	2417	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	4	91	4	91			1
MMRF_1583	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	259	262	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Cyc-Dex + Bor-Mel	1	Proteasome/Chemotherapy/Steroid	262	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	2482	Stem cell, Autologous	3	1	Completed regimen	4			3	91	3	91	2417	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	4	91	4	91			1
MMRF_1625	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	29	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	29	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	168	4	168	237	Partial Response	PR	Partial Response	PR	1	0	0	0	1	29	0	6	168	6	168	1	3	1
MMRF_1625	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	30	32	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex + Bor-Len-Cyc-Dex-Dox	1	Proteasome/Chemotherapy/Steroid/IMID	32	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	168	4	168	237	Partial Response	PR	Partial Response	PR	1	0	0	0	0	3	0	6	168	6	168			1
MMRF_1625	1	Lenalidomide/Cyclophosphamide/Doxorubicin	Len-Cyc-Dox	IMID/Chemotherapy/Chemotherapy	33	34	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Lenalidomide/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dex + Bor-Len-Cyc-Dex-Dox + Len-Cyc-Dox	1	Proteasome/Chemotherapy/Steroid/IMID	34	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	112	Stem cell, Autologous	1	1	Completed regimen	4			4	168	4	168	237	Partial Response	PR	Partial Response	PR	1	1	1	1	0	2	1	6	168	6	168			1
MMRF_1625	2	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	243	246	1	Bortezomib/Melphalan	Bor-Mel	243	Proteasome/Chemotherapy	246	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred	247	Stem cell, Autologous	2	1	Completed regimen	4												0	0	0	0	0	4	0					1	2	1
MMRF_1640	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	34	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	34	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	137	Stem cell, Autologous	1	1	Completed regimen	4			3	107	1	2003	2767	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	2	34	1	72	2003	4	107	1	3	1
MMRF_1640	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2780	2927	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	2780	CD38/IMID/Steroid	2927	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0					4	2927	4	2927		Partial Response	PR	Partial Response	PR	1	1	1	1	6	148	1	6	148	6	148	1	3	1
MMRF_1683	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	136	Stem cell, Autologous	1	1	Completed regimen	4			3	64	2	835		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	30	835	3	64	1	3	1
MMRF_1683	2	Methylprednisolone	Mep	Steroid	1220	1362	1	Methylprednisolone	Mep	1220	Steroid	1362	Other therapies	Other treatments					0							6	1227	1227	Progressive Disease	PD			0	1	0	1	5	143	0	1	8					1
MMRF_1683	2	Daratumumab/Lenalidomide/Methylprednisolone/Dexamethasone	Dar-Len-Mep-Dex	CD38/IMID/Steroid/Steroid	1363	1640	2	Methylprednisolone + Daratumumab/Lenalidomide/Methylprednisolone/Dexamethasone	Mep + Dar-Len-Mep-Dex	1220	Steroid/CD38/IMID	1640	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3					6	1227	1227	Progressive Disease	PD			0	0	0	0	10	278	0	1	8			1	4	1
MMRF_1683	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1653	2178	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1653	Proteasome/IMID/Steroid	2178	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	1747	3	1747	2178	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	19	526	1	4	95	4	95	1	3	1
MMRF_1683	4	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2186	2291	1	Carfilzomib/Dexamethasone	Car-Dex	2186	Proteasome/Steroid	2291	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Investigator decision for other reasons	5												0	0	0	0	4	106	0					1	2	1
MMRF_1714	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	53	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	53	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	94	2	2572		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	2	53	0	92	2572	4	94	1	3	1
MMRF_1714	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	74	74	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	74	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	101	Stem cell, Autologous	1	1	Completed regimen	4			3	94	2	2572		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	92	2572	4	94			1
MMRF_1731	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	23	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	23	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	78	1	364	728	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	23	0	13	364	3	78	1	3	1
MMRF_1731	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	24	35	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	35	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			3	78	1	364	728	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	12	0	13	364	3	78			1
MMRF_1731	1	Lenalidomide	Len	IMID	36	37	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	37	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			3	78	1	364	728	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	13	364	3	78			1
MMRF_1731	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	59	59	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide + Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len + Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	59	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	85	Stem cell, Autologous	1	1	Completed regimen	4			3	78	1	364	728	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	13	364	3	78			1
MMRF_1731	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	755	2147	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	755	Proteasome/IMID/Steroid	2147	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					3	804	1	1609	2106	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	50	1393	1	31	855	2	50	1	3	1
MMRF_1731	2	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	2148	2904	2	Carfilzomib/Pomalidomide/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Pom-Dex + Car-Dar-Pom-Dex	755	Proteasome/IMID/Steroid/CD38	2904	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0					3	804	1	1609	2106	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	27	757	0	31	855	2	50			1
MMRF_1730	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	36	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	36	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	92	3	92	592	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	36	1	4	92	4	92	1	3	1
MMRF_1730	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	92	92	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	92	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	118	Stem cell, Autologous	1	1	Completed regimen	4			3	92	3	92	592	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	0	1	1	4	92	4	92			1
MMRF_1730	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	705	802	1	Lenalidomide/Dexamethasone	Len-Dex	705	IMID/Steroid	802	IMIDs-based	IMIDs-based	Len-Dex				1	Investigator decision for other reasons	5			4	802	3	1063		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	98	1	13	359	4	98	1	2	1
MMRF_1730	2	Fludarabine/Melphalan	Flu-Mel	Chemotherapy/Chemotherapy	848	852	2	Lenalidomide/Dexamethasone + Fludarabine/Melphalan	Len-Dex + Flu-Mel	705	IMID/Steroid/Chemotherapy	852	IMIDs-based	Other treatments	Other Len-based therapies	854	Stem cell, Allogenic	2	1	Completed regimen	4			4	802	3	1063		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	5	0	13	359	4	98			1
MMRF_1730	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1824	2890	3	Lenalidomide/Dexamethasone + Fludarabine/Melphalan + Pomalidomide/Dexamethasone	Len-Dex + Flu-Mel + Pom-Dex	705	IMID/Steroid/Chemotherapy	2890	IMIDs-based	IMIDs-based	Other Len-based therapies				1					4	802	3	1063		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	38	1067	0	13	359	4	98			1
MMRF_1730	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1824	2015	1	Pomalidomide/Dexamethasone	Pom-Dex	1824	IMID/Steroid	2015	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			2	2170	2	2170		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	7	192	0	13	347	13	347	1	2	1
MMRF_1730	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2546	2890	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2546	CD38/IMID/Steroid	2890	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2714	2	2890		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	13	345	1	13	345	7	169	1	3	1
MMRF_1759	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	507	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	507	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			4	86	4	86	724	Partial Response	PR	Partial Response	PR	1	1	1	1	18	507	1	4	86	4	86	1	3	1
MMRF_1759	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	508	714	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	714	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	86	4	86	724	Partial Response	PR	Partial Response	PR	1	0	0	0	8	207	0	4	86	4	86			1
MMRF_1759	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	741	747	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	741	Proteasome/IMID/Steroid	747	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	1	7	0					1	3	1
MMRF_1758	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	65	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	65	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	112	Stem cell, Autologous	1	1	Completed regimen	4			3	106	3	106	1286	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	65	1	4	106	4	106	1	3	1
MMRF_1758	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1300	1589	1	Carfilzomib/Dexamethasone	Car-Dex	1300	Proteasome/Steroid	1589	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2			4	1356	4	1356		Partial Response	PR	Partial Response	PR	1	1	1	1	11	290	1	3	57	3	57	1	2	1
MMRF_1781	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	60	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	60	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	79	2	320	1962	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	2	60	1	12	320	3	79	1	3	1
MMRF_1781	1	Melphalan/Plerixafor	Mel-Pler	Chemotherapy	85	106	2	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Plerixafor	Bor-Len-Dex + Mel-Pler	1	Proteasome/IMID/Steroid/Chemotherapy	106	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	107	Stem cell, Autologous	1	1	Completed regimen	4			3	79	2	320	1962	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	12	320	3	79			1
MMRF_1781	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	295	298	3	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Plerixafor + Bortezomib/Melphalan	Bor-Len-Dex + Mel-Pler + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	298	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	299	Stem cell, Autologous	2	1	Completed regimen	4			3	79	2	320	1962	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	4	0	12	320	3	79			1
MMRF_1781	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1990	2900	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1990	CD38/IMID/Steroid	2900	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2151	3	2333		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	33	911	1	13	344	6	162	1	3	1
MMRF_1787	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	82	2	603	2355	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	2	56	1	22	603	3	82	1	3	1
MMRF_1787	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	82	82	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	82	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	107	Stem cell, Autologous	1	1	Completed regimen	4			3	82	2	603	2355	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	1	1	22	603	3	82			1
MMRF_1802	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	57	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	82	1	608	2345	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	2	57	1	22	608	3	82	1	3	1
MMRF_1802	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	85	85	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	85	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	112	Stem cell, Autologous	1	1	Completed regimen	4			3	82	1	608	2345	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	22	608	3	82			1
MMRF_1802	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	232	235	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	235	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	236	Stem cell, Autologous	2	1	Completed regimen	4			3	82	1	608	2345	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	4	0	22	608	3	82			1
MMRF_1802	2	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	2443	2444	1	Bortezomib/Melphalan	Bor-Mel	2443	Proteasome/Chemotherapy	2444	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred	2445	Stem cell, Autologous	3	1	Completed regimen	4			3	2723	3	2723		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	2	1	11	281	11	281	1	2	1
MMRF_1801	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	87	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	87	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	92	2	450		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	3	87	1	17	450	4	92	1	3	1
MMRF_1801	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	102	102	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	102	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	128	Stem cell, Autologous	1	1	Completed regimen	4			3	92	2	450		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	17	450	4	92			1
MMRF_1801	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	295	298	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	298	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	299	Stem cell, Autologous	2	1	Completed regimen	4			3	92	2	450		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	4	0	17	450	4	92			1
MMRF_1807	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	82	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	82	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	123	Stem cell, Autologous	1	1	Completed regimen	4			4	122	3	340		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	82	1	13	340	5	122	1	3	1
MMRF_1819	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	35	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	35	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4												0	0	0	0	2	35	0					1	3	1
MMRF_1850	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	71	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	71	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	MOVE TO TRANSPLANT				4	44	1	1527		Complete Response	CR	Partial Response	PR	1	0	1	0	3	71	1	55	1527	2	44	1	3	1
MMRF_1850	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	95	95	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	95	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	122	Stem cell, Autologous	1	1	Completed regimen	4			4	44	1	1527		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	55	1527	2	44			1
MMRF_1850	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	274	277	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	277	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	278	Stem cell, Autologous	2	1	Completed regimen	4			4	44	1	1527		Complete Response	CR	Partial Response	PR	1	0	0	0	0	4	0	55	1527	2	44			1
MMRF_1850	1	Lenalidomide	Len	IMID	529	2892	4	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan + Lenalidomide	Bor-Len-Dex + Cyc-Dex + Bor-Mel + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2892	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	44	1	1527		Complete Response	CR	Partial Response	PR	1	1	0	1	85	2364	0	55	1527	2	44			1
MMRF_1860	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	75	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	75	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	90	1	634		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	75	1	23	634	4	90	1	3	1
MMRF_1860	1	Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dox	Proteasome/Chemotherapy/Chemotherapy	95	98	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Len-Dex + Bor-Cyc-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	98	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	124	Stem cell, Autologous	1	1	Completed regimen	4			3	90	1	634		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	23	634	4	90			1
MMRF_1860	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	254	257	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Doxorubicin + Bortezomib/Melphalan	Bor-Len-Dex + Bor-Cyc-Dox + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	257	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	258	Stem cell, Autologous	2	1	Completed regimen	4			3	90	1	634		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	4	0	23	634	4	90			1
MMRF_1865	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	33	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	33	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Lack of response	1			3	624	2	1247		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	33	0	45	1247	23	624	1	3	1
MMRF_1865	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	47	124	2	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Car-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	MOVE TO TRANSPLANT				3	624	2	1247		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	3	78	0	45	1247	23	624			1
MMRF_1865	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	141	166	3	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Car-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	166	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Bor-Len-Car-Cyc-Dex				1					3	624	2	1247		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	26	0	45	1247	23	624			1
MMRF_1865	1	Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	167	167	4	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Dex + Car-Cyc-Dex + Cyc-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	167	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	168	Stem cell, Autologous	1	1	Completed regimen	4			3	624	2	1247		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	45	1247	23	624			1
MMRF_1865	1	Bortezomib/Fludarabine/Melphalan	Bor-Flu-Mel	Proteasome/Chemotherapy/Chemotherapy	324	328	5	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Fludarabine/Melphalan	Bor-Len-Dex + Car-Cyc-Dex + Cyc-Mel-Dex + Bor-Flu-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	328	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	329	Stem cell, Allogenic	2	1	Completed regimen	4			3	624	2	1247		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	0	5	1	45	1247	23	624			1
MMRF_1895	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	98	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	98	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	MOVING TO TRANSPLANT				4	77	1	1348		Complete Response	CR	Partial Response	PR	1	0	1	0	4	98	1	49	1348	3	77	1	3	1
MMRF_1895	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	122	122	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	149	Stem cell, Autologous	1	1	Completed regimen	4			4	77	1	1348		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	49	1348	3	77			1
MMRF_1895	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	287	290	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	290	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	291	Stem cell, Autologous	2	1	Completed regimen	4			4	77	1	1348		Complete Response	CR	Partial Response	PR	1	1	0	1	0	4	0	49	1348	3	77			1
MMRF_1936	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	57	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4	625		3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	57	1	4	91	4	91	1	3	1
MMRF_1936	1	Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dox	Proteasome/Chemotherapy/Chemotherapy	97	99	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Len-Dex + Bor-Cyc-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	99	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	625		3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	3	0	4	91	4	91			1
MMRF_1936	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	155	256	1	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	155	Proteasome/IMID/Steroid	256	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				1	Completed regimen	4	625		3	277	3	277	155	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	102	0	5	123	5	123	1	3	1
MMRF_1936	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	270	270	2	Bortezomib/Pomalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Pom-Dex + Cyc-Dex	155	Proteasome/IMID/Steroid/Chemotherapy	270	combined bortezomib/IMIDs-based	Other treatments	Bor-Pom-Cyc-Dex	295	Stem cell, Autologous	2	1	Completed regimen	4	625		3	277	3	277	155	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	5	123	5	123			1
MMRF_1936	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	270	270	2	Bortezomib/Pomalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Pom-Dex + Cyc-Dex	155	Proteasome/IMID/Steroid/Chemotherapy	270	combined bortezomib/IMIDs-based	Other treatments	Bor-Pom-Cyc-Dex	295	Stem cell, Autologous	1	1	Completed regimen	4	625		3	277	3	277	155	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	0	1	1	5	123	5	123			1
MMRF_1936	3	Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Pom-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	457	529	1	Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Pom-Cyc-Dex	457	Proteasome/IMID/Chemotherapy/Steroid	529	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Lack of response	1	625				6	547	547	Progressive Disease	PD			0	1	0	1	3	73	0	4	91			1	5	1
MMRF_1936	3	Panobinostat	Pano	HDAC	550	556	2	Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Panobinostat	Bor-Car-Pom-Cyc-Dex + Pano	457	Proteasome/IMID/Chemotherapy/Steroid/HDAC	556	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3	625				6	547	547	Progressive Disease	PD			0	0	0	0	1	7	0	4	91					1
MMRF_1936	4	Bortezomib/Panobinostat/Dexamethasone	Bor-Pano-Dex	Proteasome/HDAC/Steroid	557	568	1	Bortezomib/Panobinostat/Dexamethasone	Bor-Pano-Dex	557	Proteasome/HDAC/Steroid	568	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	625											0	0	0	0	1	12	0					1	3	1
MMRF_1936	5	Carmustine/Melphalan/Dexamethasone	Carm-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	578	578	1	Carmustine/Melphalan/Dexamethasone	Carm-Mel-Dex	578	Chemotherapy/Steroid	578	Other therapies	Other treatments					0	Completed regimen	4	625				6	625	625	Progressive Disease	PD			0	0	0	0	0	1	0	2	48			1	3	1
MMRF_1936	9	Daratumumab/Prednisone	Dar-Pred	CD38/Steroid	604	625	1	Daratumumab/Prednisone	Dar-Pred	604	CD38/Steroid	625	daratumumab-based	daratumumab-based	Dar-Pred				0	Disease progression/Relapse	3	625											0	0	0	0	1	22	0							1
MMRF_1941	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	98	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	98	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	MOVE TO TRANSPLANT				3	129	1	1417		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	98	1	51	1417	5	129	1	3	1
MMRF_1941	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	130	130	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	130	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	192	Stem cell, Autologous	1	1	Completed regimen	4			3	129	1	1417		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	51	1417	5	129			1
MMRF_1947	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	74	3	98	978	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	2	56	1	4	98	3	74	1	3	1
MMRF_1947	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	80	80	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	80	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	106	Stem cell, Autologous	1	1	Completed regimen	4			4	74	3	98	978	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	4	98	3	74			1
MMRF_1947	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	287	290	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	290	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	291	Stem cell, Autologous	2	1	Completed regimen	4			4	74	3	98	978	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	4	0	4	98	3	74			1
MMRF_1947	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1218	2136	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1218	CD38/IMID/Steroid	2136	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3			4	1324	4	1324	2157	Partial Response	PR	Partial Response	PR	1	1	1	1	33	919	1	4	107	4	107	1	3	1
MMRF_1947	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	2178	2724	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	2178	Proteasome/IMID/Steroid	2724	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0							5	2346		Stable Disease	SD			0	1	0	1	20	547	0	7	169			1	3	1
MMRF_1951	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	607	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	607	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2	1090		4	102	4	102	593	Partial Response	PR	Partial Response	PR	1	1	1	1	22	607	1	4	102	4	102	1	2	1
MMRF_1951	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	614	617	1	Bortezomib/Dexamethasone	Bor-Dex	614	Proteasome/Steroid	617	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2	1090				6	649	649	Progressive Disease	PD			0	1	0	1	0	4	0	2	36			1	2	1
MMRF_1951	3	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	656	918	1	Ixazomib/Dexamethasone	Ixa-Dex	656	Proteasome/Steroid	918	Other therapies	Other treatments					0	Disease progression/Relapse	3	1090		3	712	3	712		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	263	1	3	57	3	57			1
MMRF_1951	4	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	930	972	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	930	SLAMF7/IMID/Steroid	972	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1090				6	979	979	Progressive Disease	PD			0	1	0	1	2	43	0	2	50			1	3	1
MMRF_1951	5	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	986	1097	1	Pomalidomide/Dexamethasone	Pom-Dex	986	IMID/Steroid	1097	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3	1090		4	1642	4	1642	1090	Partial Response	PR	Partial Response	PR	1	0	0	0	4	112	0	24	657	24	657	1	2	1
MMRF_1951	9	Methylprednisolone	Mep	Steroid	1077	1103	1	Methylprednisolone	Mep	1077	Steroid	1103	Other therapies	Other treatments					0			1090											0	0	0	0	1	27	0							1
MMRF_1951	9	Daratumumab/Pomalidomide/Methylprednisolone/Prednisone	Dar-Pom-Mep-Pred	CD38/IMID/Steroid/Steroid	1104	1468	2	Methylprednisolone + Daratumumab/Pomalidomide/Methylprednisolone/Prednisone	Mep + Dar-Pom-Mep-Pred	1077	Steroid/CD38/IMID	1468	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1090											0	0	0	0	13	365	0					1	4	1
MMRF_1951	9	Daratumumab/Pomalidomide/Methylprednisolone/Dexamethasone	Dar-Pom-Mep-Dex	CD38/IMID/Steroid/Steroid	1475	1538	3	Methylprednisolone + Daratumumab/Pomalidomide/Methylprednisolone/Prednisone + Daratumumab/Pomalidomide/Methylprednisolone/Dexamethasone	Mep + Dar-Pom-Mep-Pred + Dar-Pom-Mep-Dex	1077	Steroid/CD38/IMID	1538	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1090											0	0	0	0	3	64	0							1
MMRF_1951	9	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1579	2027	4	Methylprednisolone + Daratumumab/Pomalidomide/Methylprednisolone/Prednisone + Daratumumab/Pomalidomide/Methylprednisolone/Dexamethasone + Carfilzomib/Dexamethasone	Mep + Dar-Pom-Mep-Pred + Dar-Pom-Mep-Dex + Car-Dex	1077	Steroid/CD38/IMID/Proteasome	2027	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3	1090											0	0	0	0	16	449	0							1
MMRF_1967	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	165	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	165	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	900	1	1362		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	6	165	0	49	1362	33	900	1	3	1
MMRF_1967	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	166	166	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	166	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	900	1	1362		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	49	1362	33	900			1
MMRF_1967	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	167	2693	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2693	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	167	Stem cell, Autologous	1	1					3	900	1	1362		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	91	2527	1	49	1362	33	900			1
MMRF_1965	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	60	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	60	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	61	2	547	831	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	2	60	1	20	547	3	61	1	3	1
MMRF_1965	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	81	84	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Dex + Bor-Len-Cyc-Dex-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	84	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	112	Stem cell, Autologous	1	1	Completed regimen	4			4	61	2	547	831	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	4	0	20	547	3	61			1
MMRF_1965	1	Bortezomib/Fludarabine/Melphalan	Bor-Flu-Mel	Proteasome/Chemotherapy/Chemotherapy	261	265	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Fludarabine/Melphalan	Bor-Len-Dex + Bor-Len-Cyc-Dex-Dox + Bor-Flu-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	265	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	266	Stem cell, Allogenic	2	1	Completed regimen	4			4	61	2	547	831	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	5	0	20	547	3	61			1
MMRF_1965	2	Pomalidomide/Prednisone	Pom-Pred	IMID/Steroid	855	1086	1	Pomalidomide/Prednisone	Pom-Pred	855	IMID/Steroid	1086	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2			3	875	1	2519		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	9	232	1	60	1665	1	21	1	2	1
MMRF_1981	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	76	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	76	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	78	3	78	988	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	76	1	3	78	3	78	1	3	1
MMRF_1981	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	101	101	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	101	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			3	78	3	78	988	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	78	3	78			1
MMRF_1981	2	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1022	1418	1	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	1022	Proteasome/Chemotherapy/Steroid	1418	Other therapies	Other treatments					0	Disease progression/Relapse	3			4	1169	4	1169	1418	Partial Response	PR	Partial Response	PR	1	1	1	1	14	397	1	6	148	6	148			1
MMRF_1981	3	Daratumumab/Ixazomib/Dexamethasone	Dar-Ixa-Dex	CD38/Proteasome/Steroid	1429	2731	1	Daratumumab/Ixazomib/Dexamethasone	Dar-Ixa-Dex	1429	CD38/Proteasome/Steroid	2731	daratumumab-based	daratumumab-based	Dar-Ixa-Dex				0					4	1533	4	1533		Partial Response	PR	Partial Response	PR	1	1	1	1	47	1303	1	4	105	4	105			1
MMRF_1988	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	117	Stem cell, Autologous	1	1	Completed regimen	4			4	15	3	232	1503	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	85	1	9	232	1	15	1	3	1
MMRF_1988	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1573	2672	1	Lenalidomide/Dexamethasone	Len-Dex	1573	IMID/Steroid	2672	IMIDs-based	IMIDs-based	Len-Dex				0					4	1601	4	1601		Partial Response	PR	Partial Response	PR	1	1	1	1	40	1100	1	2	29	2	29	1	2	1
MMRF_2059	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	46	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	46	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	MOVE TO TRANSPLANT				3	83	2	257	798	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	2	46	0	10	257	3	83	1	4	1
MMRF_2059	1	Plerixafor	Pler		74	76	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Plerixafor	Bor-Len-Cyc-Dex + Pler	1	Proteasome/IMID/Chemotherapy/Steroid	76	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	106	Stem cell, Autologous	1	1	Completed regimen	4			3	83	2	257	798	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	0	3	1	10	257	3	83			1
MMRF_2059	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	839	2282	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	839	Proteasome/IMID/Steroid	2282	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	887	3	887		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	52	1444	1	2	49	2	49	1	3	1
MMRF_2059	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2282	2744	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2282	CD38/IMID/Steroid	2744	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2541	4	2541	2282	Partial Response	PR	Partial Response	PR	1	1	1	1	17	463	1	10	260	10	260	1	3	1
MMRF_2061	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	47	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	47	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	86	Stem cell, Autologous	1	1	Completed regimen	4			4	86	3	359		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	2	47	1	13	359	4	86	1	4	1
MMRF_2076	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	42	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	42	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	125	Stem cell, Autologous	1	1	TOXICITY; PERIPHERAL NEUROPATHY				3	74	3	74	900	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	42	1	3	74	3	74	1	3	1
MMRF_2076	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	943	1363	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	943	CD38/IMID/Steroid	1363	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Adverse Event or co-morbidity	2			4	992	3	1222	1817	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	15	421	1	10	280	2	50	1	3	1
MMRF_2076	3	Pomalidomide/Prednisone	Pom-Pred	IMID/Steroid	1846	2678	1	Pomalidomide/Prednisone	Pom-Pred	1846	IMID/Steroid	2678	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					3	1965	3	1965		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	30	833	1	5	120	5	120	1	2	1
MMRF_2129	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	48	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	48	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	168	1	374		Complete Response	CR	Partial Response	PR	1	0	0	0	2	48	0	14	374	6	168	1	3	1
MMRF_2129	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	49	119	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	119	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	MOVE TO TRANSPLANT				4	168	1	374		Complete Response	CR	Partial Response	PR	1	0	0	0	3	71	0	14	374	6	168			1
MMRF_2129	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	120	125	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	125	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	MOVE TO TRANSPLANT				4	168	1	374		Complete Response	CR	Partial Response	PR	1	0	0	0	1	6	0	14	374	6	168			1
MMRF_2129	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	151	151	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	151	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	176	Stem cell, Autologous	1	1	Completed regimen	4			4	168	1	374		Complete Response	CR	Partial Response	PR	1	1	1	1	0	1	1	14	374	6	168			1
MMRF_1755	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	206	Stem cell, Autologous	1	1	Completed regimen	4			4	138	3	256		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	105	1	10	256	5	138	1	3	1
MMRF_2152	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	64	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	64	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	64	1	3	64	3	64	1	3	1
MMRF_2172	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	MOVE TO TRANSPLANT				4	100	4	100		Partial Response	PR	Partial Response	PR	1	1	1	1	3	74	1	4	100	4	100	1	3	1
MMRF_2172	1	Plerixafor	Pler		103	111	2	Bortezomib/Lenalidomide/Dexamethasone + Plerixafor	Bor-Len-Dex + Pler	1	Proteasome/IMID/Steroid	111	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	127	Stem cell, Autologous	1	1	Completed regimen	4			4	100	4	100		Partial Response	PR	Partial Response	PR	1	0	0	0	1	9	0	4	100	4	100			1
MMRF_2172	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	345	445	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	345	Proteasome/IMID/Steroid	445	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	433	4	433	359	Partial Response	PR	Partial Response	PR	1	1	1	1	4	101	1	4	89	4	89	1	3	1
MMRF_2172	2	Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Pom-Dex	Proteasome/IMID/IMID/Steroid	446	473	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Pom-Dex	345	Proteasome/IMID/Steroid	473	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	433	4	433	359	Partial Response	PR	Partial Response	PR	1	0	0	0	1	28	0	4	89	4	89			1
MMRF_2172	2	Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Pom-Cyc-Dex	Proteasome/IMID/IMID/Chemotherapy/Steroid	474	522	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Pom-Dex + Car-Len-Pom-Cyc-Dex	345	Proteasome/IMID/Steroid/Chemotherapy	522	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	433	4	433	359	Partial Response	PR	Partial Response	PR	1	0	0	0	2	49	0	4	89	4	89			1
MMRF_2172	2	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	523	554	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Pom-Dex + Car-Len-Pom-Cyc-Dex + Car-Len-Cyc-Dex	345	Proteasome/IMID/Steroid/Chemotherapy	554	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	433	4	433	359	Partial Response	PR	Partial Response	PR	1	0	0	0	1	32	0	4	89	4	89			1
MMRF_2172	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	555	555	5	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Pom-Dex + Car-Len-Pom-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	345	Proteasome/IMID/Steroid/Chemotherapy	555	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	433	4	433	359	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	89	4	89			1
MMRF_2172	2	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	556	560	6	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Len-Dex + Car-Len-Pom-Dex + Car-Len-Pom-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Car-Len	345	Proteasome/IMID/Steroid/Chemotherapy	560	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	433	4	433	359	Partial Response	PR	Partial Response	PR	1	0	0	0	0	5	0	4	89	4	89			1
MMRF_2231	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	64	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	64	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	64	3	64	1222	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	64	1	3	64	3	64	1	3	1
MMRF_2231	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	130	130	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	130	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	233	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64	1222	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	64	3	64			1
MMRF_2231	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1781	2709	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1781	Proteasome/IMID/Steroid	2709	IMIDs-based	IMIDs-based	Other Len-based therapies				0					3	1929	3	1929		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	33	929	1	6	149	6	149	1	3	1
MMRF_2267	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	61	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	61	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	104	3	104	1104	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	61	0	4	104	4	104	1	3	1
MMRF_2267	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	62	142	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	142	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex	155	Stem cell, Autologous	1	1	Completed regimen	4			3	104	3	104	1104	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	81	1	4	104	4	104			1
MMRF_2267	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1300	1331	1	Pomalidomide/Dexamethasone	Pom-Dex	1300	IMID/Steroid	1331	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			4	1386	4	1386		Partial Response	PR	Partial Response	PR	1	1	1	1	1	32	1	4	87	4	87	1	2	1
MMRF_2267	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1419	2672	1	Carfilzomib/Dexamethasone	Car-Dex	1419	Proteasome/Steroid	2672	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	1436	4	1436	2554	Partial Response	PR	Partial Response	PR	1	1	1	1	45	1254	1	1	18	1	18	1	2	1
MMRF_2291	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	72	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	72	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	64	4	64		Partial Response	PR	Partial Response	PR	1	1	1	1	3	72	1	3	64	3	64	1	3	1
MMRF_2310	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	53	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	53	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			3	78	3	78		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	53	1	3	78	3	78	1	4	1
MMRF_2310	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	95	95	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	95	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	120	Stem cell, Autologous	1	1	Completed regimen	4			3	78	3	78		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	78	3	78			1
MMRF_2310	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	605	655	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	605	SLAMF7/IMID/Steroid	655	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3					6	605	605	Progressive Disease	PD			0	1	0	1	2	51	0	1	1			1	3	1
MMRF_2310	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	666	815	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	666	Proteasome/IMID/Steroid	815	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	715	4	715	808	Partial Response	PR	Partial Response	PR	1	1	1	1	6	150	1	2	50	2	50	1	3	1
MMRF_2310	4	Daratumumab	Dar	CD38	815	815	1	Daratumumab	Dar	815	CD38	815	daratumumab-based	daratumumab-based	Dar				0	Adverse Event or co-morbidity	2												0	0	0	0	0	1	0							1
MMRF_2316	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	102	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	102	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	144	Stem cell, Autologous	1	1	Completed regimen	4			3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	102	1	3	71	3	71	1	3	1
MMRF_2316	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1849	2676	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1849	CD38/IMID/Steroid	2676	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	1947	4	1947	1849	Partial Response	PR	Partial Response	PR	1	1	1	1	30	828	1	4	99	4	99	1	3	1
MMRF_2330	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PROCEED TO TRANSPLANT				4	57	3	264	558	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	77	1	10	264	3	57	1	3	1
MMRF_2330	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	88	88	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	88	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	123	Stem cell, Autologous	1	1	Completed regimen	4			4	57	3	264	558	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	10	264	3	57			1
MMRF_2330	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	234	235	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	235	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	236	Stem cell, Autologous	2	1	Completed regimen	4			4	57	3	264	558	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	2	0	10	264	3	57			1
MMRF_2330	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	607	684	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	607	SLAMF7/IMID/Steroid	684	IMIDs-based	IMIDs-based	Other Len-based therapies				1	Lack of response	1			4	786	4	786		Partial Response	PR	Partial Response	PR	1	0	0	0	3	78	0	7	180	7	180	1	3	1
MMRF_2330	2	Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Pom-Dex	Proteasome/IMID/IMID/Steroid	694	857	2	Elotuzumab/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Elo-Len-Dex + Car-Len-Pom-Dex	607	SLAMF7/IMID/Steroid/Proteasome	857	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	786	4	786		Partial Response	PR	Partial Response	PR	1	1	1	1	6	164	1	7	180	7	180			1
MMRF_2330	2	Fludarabine/Melphalan	Flu-Mel	Chemotherapy/Chemotherapy	874	875	3	Elotuzumab/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Fludarabine/Melphalan	Elo-Len-Dex + Car-Len-Pom-Dex + Flu-Mel	607	SLAMF7/IMID/Steroid/Proteasome/Chemotherapy	875	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	880	Stem cell, Allogenic	3	1	Completed regimen	4			4	786	4	786		Partial Response	PR	Partial Response	PR	1	0	0	0	0	2	0	7	180	7	180			1
MMRF_2330	3	Daratumumab/Pomalidomide/Methylprednisolone	Dar-Pom-Mep	CD38/IMID/Steroid	1186	2538	1	Daratumumab/Pomalidomide/Methylprednisolone	Dar-Pom-Mep	1186	CD38/IMID/Steroid	2538	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0					4	1810	4	1810	1186	Partial Response	PR	Partial Response	PR	1	1	1	1	49	1353	1	23	625	23	625	1	3	1
MMRF_2331	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	64	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	64	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	123	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64	1417	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	64	1	3	64	3	64	1	3	1
MMRF_2331	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1510	2622	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1510	SLAMF7/IMID/Steroid	2622	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1605	4	1605		Partial Response	PR	Partial Response	PR	1	1	1	1	40	1113	1	4	96	4	96	1	3	1
MMRF_2378	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	44	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	44	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	86	Stem cell, Autologous	1	1	Completed regimen	4			4	81	1	1439		Complete Response	CR	Partial Response	PR	1	1	1	1	2	44	1	52	1439	3	81	1	3	1
MMRF_2407	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	36	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	36	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	PROCEED TO TRANSPLANT				3	82	3	82		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	36	0	3	82	3	82	1	4	1
MMRF_2407	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	64	64	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	64	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	90	Stem cell, Autologous	1	1	Completed regimen	4			3	82	3	82		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	3	82	3	82			1
MMRF_2407	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	207	210	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Chemotherapy/Steroid	210	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	211	Stem cell, Autologous	2	1	Completed regimen	4			3	82	3	82		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	3	82	3	82			1
MMRF_2407	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1800	1999	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1800	CD38/IMID/Steroid	1999	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Investigator decision for other reasons	5			4	1992	1	2209	1800	Complete Response	CR	Partial Response	PR	1	1	1	1	7	200	1	15	410	7	193	1	3	1
MMRF_2422	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	85	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	85	Bortezomib-based	Bortezomib-based	Bor-Dex				1	Adverse Event or co-morbidity	2			3	82	1	1705		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	85	1	61	1705	3	82	1	2	1
MMRF_2422	1	Cyclophosphamide/Melphalan	Cyc-Mel	Chemotherapy/Chemotherapy	237	254	2	Bortezomib/Dexamethasone + Cyclophosphamide/Melphalan	Bor-Dex + Cyc-Mel	1	Proteasome/Steroid/Chemotherapy	254	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	255	Stem cell, Autologous	1	1	Completed regimen	4			3	82	1	1705		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	1	18	0	61	1705	3	82			1
MMRF_2437	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	57	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			3	108	1	491	1470	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	57	0	18	491	4	108	1	4	1
MMRF_2437	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	106	106	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Melphalan/Dexamethasone	Bor-Len-Cyc-Dex + Mel-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	106	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	107	Stem cell, Autologous	1	1	Completed regimen	4			3	108	1	491	1470	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	18	491	4	108			1
MMRF_2437	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1499	2545	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1499	CD38/IMID/Steroid	2545	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0					4	1642	4	1642	1550	Partial Response	PR	Partial Response	PR	1	1	1	1	38	1047	1	6	144	6	144	1	3	1
MMRF_2489	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	92	3	519	1295	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	56	0	19	519	4	92	1	3	1
MMRF_2489	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	73	73	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	73	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	99	Stem cell, Autologous	1	1	Completed regimen	4			4	92	3	519	1295	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	0	1	1	19	519	4	92			1
MMRF_2489	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	273	276	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Cyc-Dex + Bor-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	276	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	277	Stem cell, Autologous	2	1	Completed regimen	4			4	92	3	519	1295	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	4	0	19	519	4	92			1
MMRF_2489	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1383	2541	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1383	CD38/IMID/Steroid	2541	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0					3	1463	1	2202	1383	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	42	1159	1	30	820	3	81	1	3	1
MMRF_2499	1	Lenalidomide	Len	IMID	1	27	1	Lenalidomide	Len	1	IMID	27	IMIDs-based	IMIDs-based	Len-Dex				1					4	100	4	100	1550	Partial Response	PR	Partial Response	PR	1	0	0	0	1	27	0	4	100	4	100	1	1	1
MMRF_2499	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	28	57	2	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Len + Bor-Len-Dex	1	IMID/Proteasome/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	100	4	100	1550	Partial Response	PR	Partial Response	PR	1	0	0	0	1	30	0	4	100	4	100			1
MMRF_2499	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	58	58	3	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Len + Bor-Len-Dex + Bor-Len-Cyc-Dex	1	IMID/Proteasome/Steroid/Chemotherapy	58	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	100	4	100	1550	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	100	4	100			1
MMRF_2499	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	59	115	4	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Len + Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	IMID/Proteasome/Steroid/Chemotherapy	115	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex	141	Stem cell, Autologous	1	1	Completed regimen	4			4	100	4	100	1550	Partial Response	PR	Partial Response	PR	1	1	1	1	2	57	1	4	100	4	100			1
MMRF_2499	2	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1561	1892	1	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	1561	Proteasome/Chemotherapy/Steroid	1892	Other therapies	Other treatments					0	WORSENING MARKERS, AND CYTOPENIAS+HYPERCALCEMIA AND INTOLERANCE.				4	1816	3	2372		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	12	332	1	29	812	10	256			1
MMRF_2499	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1899	2522	2	Ixazomib/Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Ixa-Cyc-Dex + Dar-Pom-Dex	1561	Proteasome/Chemotherapy/Steroid/CD38/IMID	2522	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0					4	1816	3	2372		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	23	624	0	29	812	10	256	1	3	1
MMRF_2506	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	371	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	371	IMIDs-based	IMIDs-based	Len-Dex				0	MD TEMPORARILY GIVING PATIENT BREAK FROM TREATMENT				3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	371	1	4	85	4	85	1	2	1
MMRF_2548	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	57	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	PROCEED TO TRANSPLANT				4	98	2	350		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	57	0	13	350	4	98	1	4	1
MMRF_2548	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	79	79	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	79	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	104	Stem cell, Autologous	1	1	Completed regimen	4			4	98	2	350		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	0	1	1	13	350	4	98			1
MMRF_2548	1	Bortezomib/Fludarabine/Melphalan	Bor-Flu-Mel	Proteasome/Chemotherapy/Chemotherapy	247	251	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Fludarabine/Melphalan	Bor-Len-Cyc-Dex + Bor-Flu-Mel	1	Proteasome/IMID/Chemotherapy/Steroid	251	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	252	Stem cell, Allogenic	2	1	Completed regimen	4			4	98	2	350		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	0	5	0	13	350	4	98			1
MMRF_2554	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	102	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	102	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	102	3	102		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	102	1	4	102	4	102	1	3	1
MMRF_2554	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	126	126	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	126	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	162	Stem cell, Autologous	1	1	Completed regimen	4			3	102	3	102		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	102	4	102			1
MMRF_2574	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	54	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	54	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	90	Stem cell, Autologous	1	1	Completed regimen	4			3	172	2	270		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	2	54	1	10	270	7	172	1	3	1
MMRF_2574	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	445	446	1	Carfilzomib/Dexamethasone	Car-Dex	445	Proteasome/Steroid	446	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2					6	445	445	Progressive Disease	PD			0	1	0	1	0	2	0	1	1			1	2	1
MMRF_2593	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	50	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	50	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PROCEED TO TRANSPLANT				4	83	3	168	1072	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	50	0	6	168	3	83	1	3	1
MMRF_2593	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	64	64	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	64	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	91	Stem cell, Autologous	1	1	Completed regimen	4			4	83	3	168	1072	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	0	1	1	6	168	3	83			1
MMRF_2593	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1079	2015	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1079	Proteasome/IMID/Steroid	2015	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1158	4	1158		Partial Response	PR	Partial Response	PR	1	1	1	1	34	937	1	3	80	3	80	1	3	1
MMRF_2596	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	32	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	32	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	79	Stem cell, Autologous	1	1	Completed regimen	4			4	84	4	84		Partial Response	PR	Partial Response	PR	1	1	1	1	1	32	1	3	84	3	84	1	3	1
MMRF_2605	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	37	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	37	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	85	4	85	588	Partial Response	PR	Partial Response	PR	1	0	0	0	2	37	0	4	85	4	85	1	3	1
MMRF_2605	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	65	65	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	65	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	91	Stem cell, Autologous	1	1	Completed regimen	4			4	85	4	85	588	Partial Response	PR	Partial Response	PR	1	1	1	1	0	1	1	4	85	4	85			1
MMRF_2605	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	257	260	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Len-Dex + Cyc-Dex + Bor-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	260	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	261	Stem cell, Autologous	2	1	Completed regimen	4			4	85	4	85	588	Partial Response	PR	Partial Response	PR	1	0	0	0	0	4	0	4	85	4	85			1
MMRF_2605	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	603	884	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	603	Proteasome/IMID/Steroid	884	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3			4	736	3	792	895	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	282	1	7	190	5	134	1	3	1
MMRF_2605	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	901	971	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	901	CD38/IMID/Steroid	971	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					6	992	992	Progressive Disease	PD			0	1	0	1	3	71	0	4	92			1	3	1
MMRF_2605	4	Ixazomib/Idasanutlin/Dexamethasone	Ixa-Ida-Dex	Proteasome/MDM2/Steroid	1016	1030	1	Ixazomib/Idasanutlin/Dexamethasone	Ixa-Ida-Dex	1016	Proteasome/MDM2/Steroid	1030	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	1044	1044	Progressive Disease	PD			0	1	0	1	1	15	0	2	29					1
MMRF_2605	5	CAR-T Cells(Undefined)/Cyclophosphamide/Fludarabine	CAR-T-Cyc-Flu	Chemotherapy/Chemotherapy	1113	1118	1	CAR-T Cells(Undefined)/Cyclophosphamide/Fludarabine	CAR-T-Cyc-Flu	1113	Chemotherapy	1118	Other therapies	Other treatments					0	Completed regimen	4			4	1148	4	1148		Partial Response	PR	Partial Response	PR	1	1	1	1	1	6	1	2	36	2	36			1
MMRF_2619	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	28	35	1	Bortezomib/Cyclophosphamide	Bor-Cyc	28	Proteasome/Chemotherapy	35	Bortezomib-based	Bortezomib-based	Bor-Cyc				1	Adverse Event or co-morbidity	2			3	531	3	531	1453	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	8	0	18	504	18	504	1	2	1
MMRF_2619	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	444	471	2	Bortezomib/Cyclophosphamide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc + Bor-Len-Dex	28	Proteasome/Chemotherapy/IMID/Steroid	471	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					3	531	3	531	1453	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	28	0	18	504	18	504			1
MMRF_2619	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	472	500	3	Bortezomib/Cyclophosphamide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc + Bor-Len-Dex + Bor-Car-Len-Dex	28	Proteasome/Chemotherapy/IMID/Steroid	500	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			3	531	3	531	1453	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	29	0	18	504	18	504			1
MMRF_2619	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	510	510	4	Bortezomib/Cyclophosphamide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Cyc + Bor-Len-Dex + Bor-Car-Len-Dex + Cyc-Dex	28	Proteasome/Chemotherapy/IMID/Steroid	510	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Bor-Len-Car-Cyc-Dex	537	Stem cell, Autologous	1	1	Completed regimen	4			3	531	3	531	1453	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	18	504	18	504			1
MMRF_2619	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1500	1662	5	Bortezomib/Cyclophosphamide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Bor-Cyc + Bor-Len-Dex + Bor-Car-Len-Dex + Cyc-Dex + Dar-Pom-Dex	28	Proteasome/Chemotherapy/IMID/Steroid/CD38	1662	combined bortezomib/IMIDs/carfilzomib-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2			3	531	3	531	1453	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	163	0	18	504	18	504			1
MMRF_2619	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2290	2792	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2290	CD38/IMID/Steroid	2792	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2324	3	2609		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	18	503	1	12	320	2	35	1	3	1
MMRF_1222	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	160	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	160	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Lack of response	1			4	63	4	63	158	Partial Response	PR	Partial Response	PR	1	1	1	1	6	160	1	3	63	3	63	1	2	1
MMRF_1222	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	170	359	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	170	Proteasome/IMID/Steroid	359	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	408	Stem cell, Autologous	1	1	Completed regimen	4			3	343	3	343	493	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	190	1	7	174	7	174	1	3	1
MMRF_1222	3	Bortezomib/Melphalan/Bendamustine/Dexamethasone	Bor-Mel-Bend-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	513	532	1	Bortezomib/Melphalan/Bendamustine/Dexamethasone	Bor-Mel-Bend-Dex	513	Proteasome/Chemotherapy/Steroid	532	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	539	Stem cell, Allogenic	2	1	Completed regimen	4					6	592	592	Progressive Disease	PD			0	1	0	1	1	20	0	3	80			1	4	1
MMRF_1222	4	Bortezomib/Carfilzomib	Bor-Car	Proteasome/Proteasome	597	660	1	Bortezomib/Carfilzomib	Bor-Car	597	Proteasome	660	combined bortezomib/carfilzomib-based	combined bortezomib/carfilzomib-based	Bor-Car				0	STOPPED SO PATIENT COULD RECEIVE XRT TO ORBITAL PLASMACYTOMA						6	714	714	Progressive Disease	PD			0	1	0	1	3	64	0	5	118			1	2	1
MMRF_1222	4	Lenalidomide	Len	IMID	742	823	2	Bortezomib/Carfilzomib + Lenalidomide	Bor-Car + Len	597	Proteasome/IMID	823	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car				0	NO LONGER INDICATED						6	714	714	Progressive Disease	PD			0	0	0	0	3	82	0	5	118					1
MMRF_1264	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	44	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	44	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	186	4	186	92	Partial Response	PR	Partial Response	PR	1	0	0	0	2	44	0	7	186	7	186	1	2	1
MMRF_1264	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	45	58	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	58	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	186	4	186	92	Partial Response	PR	Partial Response	PR	1	0	0	0	1	14	0	7	186	7	186			1
MMRF_1264	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	59	85	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	85	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	186	4	186	92	Partial Response	PR	Partial Response	PR	1	0	0	0	1	27	0	7	186	7	186			1
MMRF_1264	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	86	302	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Mel-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	302	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	186	4	186	92	Partial Response	PR	Partial Response	PR	1	1	1	1	8	217	1	7	186	7	186			1
MMRF_1264	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	303	372	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Mel-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	372	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1			4	186	4	186	92	Partial Response	PR	Partial Response	PR	1	0	0	0	3	70	0	7	186	7	186			1
MMRF_1264	2	Pomalidomide	Pom	IMID	388	1610	1	Pomalidomide	Pom	388	IMID	1610	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			4	532	4	532		Partial Response	PR	Partial Response	PR	1	1	1	1	44	1223	1	6	145	6	145	1	1	1
MMRF_1547	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	148	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	148	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	194	Stem cell, Autologous	1	1	SUBJECT TO BE WORKED UP FOR TRANSPLANT				4	128	1	2949		Complete Response	CR	Partial Response	PR	1	0	1	0	6	148	1	106	2949	5	128	1	3	1
MMRF_1547	1	Bortezomib	Bor	Proteasome	642	865	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	865	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	PATIENT STARTED TO HAVE DIFFICULTIES TOLERATING THERAPY				4	128	1	2949		Complete Response	CR	Partial Response	PR	1	0	0	0	8	224	0	106	2949	5	128			1
MMRF_1547	1	Ixazomib	Ixa	Proteasome	892	1222	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Ixazomib	Bor-Cyc-Dex + Bor + Ixa	1	Proteasome/Chemotherapy/Steroid	1222	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			4	128	1	2949		Complete Response	CR	Partial Response	PR	1	1	0	1	12	331	0	106	2949	5	128			1
MMRF_1570	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	110	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	110	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	155	Stem cell, Autologous	1	1	Completed regimen	4			3	181	3	181	532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	110	1	7	181	7	181	1	3	1
MMRF_1570	1	Bortezomib	Bor	Proteasome	386	546	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	546	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Disease progression/Relapse	3			3	181	3	181	532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	161	0	7	181	7	181			1
MMRF_1570	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	546	546	1	Lenalidomide/Dexamethasone	Len-Dex	546	IMID/Steroid	546	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	638	4	638		Partial Response	PR	Partial Response	PR	1	1	1	1	0	1	1	4	93	4	93	1	2	1
MMRF_1586	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	381	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	381	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	105	3	105	343	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	381	1	4	105	4	105	1	2	1
MMRF_2038	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	34	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	34	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Investigator decision for other reasons	5			4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	34	0	67	1865	4	86	1	3	1
MMRF_2038	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	35	94	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	94	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Lack of response	1			4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	2	60	1	67	1865	4	86			1
MMRF_2038	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Thal-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	121	128	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox	1	Proteasome/Chemotherapy/Steroid/IMID	128	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	1	8	0	67	1865	4	86			1
MMRF_2038	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	158	168	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	168	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	169	Stem cell, Autologous	1	1	Completed regimen	4			4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	1	11	0	67	1865	4	86			1
MMRF_2038	1	Lenalidomide/Thalidomide	Len-Thal	IMID/IMID	275	538	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Melphalan/Dexamethasone + Lenalidomide/Thalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Mel-Dex + Len-Thal	1	Proteasome/Chemotherapy/Steroid/IMID	538	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	10	264	0	67	1865	4	86			1
MMRF_2038	1	Lenalidomide/Thalidomide/Dexamethasone	Len-Thal-Dex	IMID/IMID/Steroid	539	632	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Melphalan/Dexamethasone + Lenalidomide/Thalidomide + Lenalidomide/Thalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Mel-Dex + Len-Thal + Len-Thal-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	632	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	4	94	0	67	1865	4	86			1
MMRF_2038	1	Lenalidomide/Thalidomide	Len-Thal	IMID/IMID	633	666	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Melphalan/Dexamethasone + Lenalidomide/Thalidomide + Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Mel-Dex + Len-Thal + Len-Thal-Dex + Len-Thal	1	Proteasome/Chemotherapy/Steroid/IMID	666	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	34	0	67	1865	4	86			1
MMRF_2038	1	Pomalidomide	Pom	IMID	698	1675	8	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Melphalan/Dexamethasone + Lenalidomide/Thalidomide + Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide + Pomalidomi	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Mel-Dex + Len-Thal + Len-Thal-Dex + Len-Thal + Pom	1	Proteasome/Chemotherapy/Steroid/IMID	1675	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	OUTSIDE PROVIDER DECIDED PATIENT DOING WELL OFF TREATMENT AND IN SCR				4	86	2	1865		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	35	978	0	67	1865	4	86			1
MMRF_2168	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	134	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	134	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	134	0	15	415	10	253	1	2	1
MMRF_2168	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	135	276	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	276	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5			4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	142	1	15	415	10	253			1
MMRF_2168	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	277	287	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	287	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	11	0	15	415	10	253			1
MMRF_2168	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	288	308	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	308	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	21	0	15	415	10	253			1
MMRF_2168	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	309	322	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Mel-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	322	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	309	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	1	14	0	15	415	10	253			1
MMRF_2168	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	430	542	6	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Mel-Dex + Bor-Dex + Ixa-Len-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	542	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	113	0	15	415	10	253			1
MMRF_2168	1	Daratumumab	Dar	CD38	626	2045	7	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Daratumumab	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Mel-Dex + Bor-Dex + Ixa-Len-Dex + Dar	1	Proteasome/Steroid/IMID/Chemotherapy/CD38	2045	combined bortezomib/IMIDs-based	daratumumab-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	51	1420	0	15	415	10	253			1
MMRF_2168	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2046	2704	8	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Daratumumab + Daratumumab/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Mel-Dex + Bor-Dex + Ixa-Len-Dex + Dar + Dar-Len-Dex	1	Proteasome/Steroid/IMID/Chemotherapy/CD38	2704	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	253	3	415		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	24	659	0	15	415	10	253			1
MMRF_2215	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	94	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	94	Bortezomib-based	Bortezomib-based	Bor-Dex	129	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	94	1	3	71	3	71	1	2	1
MMRF_2215	1	Lenalidomide	Len	IMID	242	2668	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	2668	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	87	2427	0	3	71	3	71			1
MMRF_1011	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	74	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	74	Bortezomib-based	Bortezomib-based	Bor-Dex				1	GRADE 2 NEUROPATHY				4	73	3	253	1613	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	74	1	10	253	3	73	1	2	1
MMRF_1011	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	131	131	2	Bortezomib/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Dex + Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	131	Bortezomib-based	Other treatments	Bor-Cyc-Dex				1	Completed regimen	4			4	73	3	253	1613	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	10	253	3	73			1
MMRF_1011	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	153	153	3	Bortezomib/Dexamethasone + Cyclophosphamide/Dexamethasone + Melphalan/Dexamethasone	Bor-Dex + Cyc-Dex + Mel-Dex	1	Proteasome/Steroid/Chemotherapy	153	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	155	Stem cell, Autologous	1	1	Completed regimen	4			4	73	3	253	1613	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	10	253	3	73			1
MMRF_1011	1	Lenalidomide	Len	IMID	253	925	4	Bortezomib/Dexamethasone + Cyclophosphamide/Dexamethasone + Melphalan/Dexamethasone + Lenalidomide	Bor-Dex + Cyc-Dex + Mel-Dex + Len	1	Proteasome/Steroid/Chemotherapy/IMID	925	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	PATIENT DIAGNOSED WITH COLON CANCER				4	73	3	253	1613	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	24	673	0	10	253	3	73			1
MMRF_1011	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1726	1909	1	Carfilzomib/Dexamethasone	Car-Dex	1726	Proteasome/Steroid	1909	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	1782	4	1782		Partial Response	PR	Partial Response	PR	1	1	1	1	7	184	1	3	57	3	57	1	2	1
MMRF_1011	2	Pomalidomide	Pom	IMID	1933	1969	2	Carfilzomib/Dexamethasone + Pomalidomide	Car-Dex + Pom	1726	Proteasome/Steroid/IMID	1969	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	1782	4	1782		Partial Response	PR	Partial Response	PR	1	0	0	0	2	37	0	3	57	3	57			1
MMRF_1034	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	114	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	114	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	80	1	1283		Complete Response	CR	Partial Response	PR	1	0	1	0	4	114	1	46	1283	3	80	1	2	1
MMRF_1034	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	115	115	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	115	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PATIENT DEVELOPED HYPERCALCEMIA				4	80	1	1283		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	46	1283	3	80			1
MMRF_1034	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	116	249	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	249	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	BEGINNING STEM CELL MOBLIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT				4	80	1	1283		Complete Response	CR	Partial Response	PR	1	0	0	0	5	134	0	46	1283	3	80			1
MMRF_1034	1	Melphalan/Plerixafor	Mel-Pler	Chemotherapy	254	258	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Plerixafor	Bor-Dex + Bor-Len-Dex + Mel-Pler	1	Proteasome/Steroid/IMID/Chemotherapy	258	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	260	Stem cell, Autologous	1	1	Completed regimen	4			4	80	1	1283		Complete Response	CR	Partial Response	PR	1	1	0	1	0	5	0	46	1283	3	80			1
MMRF_1029	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	560	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	560	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	85	3	995		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	20	560	1	36	995	4	85	1	3	1
MMRF_1029	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	561	995	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	995	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	85	3	995		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	16	435	0	36	995	4	85			1
MMRF_1042	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	148	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	148	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PATIENT'S RESPONSE REACHED A PLATEAU				4	92	4	92	455	Partial Response	PR	Partial Response	PR	1	1	1	1	6	148	1	4	92	4	92	1	2	1
MMRF_1042	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	581	882	1	Lenalidomide/Dexamethasone	Len-Dex	581	IMID/Steroid	882	IMIDs-based	IMIDs-based	Len-Dex				0	LOWERED DOSAGE				3	581	3	581	1541	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	302	1	1	1	1	1	1	2	1
MMRF_1042	2	Lenalidomide	Len	IMID	883	1428	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	581	IMID/Steroid	1428	IMIDs-based	IMIDs-based	Len-Dex				0					3	581	3	581	1541	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	20	546	0	1	1	1	1			1
MMRF_1042	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1429	1764	3	Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Len-Dex + Len + Len-Dex	581	IMID/Steroid	1764	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			3	581	3	581	1541	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	336	0	1	1	1	1			1
MMRF_1042	2	Lenalidomide	Len	IMID	1765	2008	4	Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len + Len-Dex + Len	581	IMID/Steroid	2008	IMIDs-based	IMIDs-based	Len-Dex				0					3	581	3	581	1541	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	9	244	0	1	1	1	1			1
MMRF_1039	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	101	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	101	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	86	4	86	995	Partial Response	PR	Partial Response	PR	1	1	1	1	4	101	1	4	86	4	86	1	2	1
MMRF_1039	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	102	210	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	210	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	86	4	86	995	Partial Response	PR	Partial Response	PR	1	0	0	0	4	109	0	4	86	4	86			1
MMRF_1039	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	211	242	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	242	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	86	4	86	995	Partial Response	PR	Partial Response	PR	1	0	0	0	1	32	0	4	86	4	86			1
MMRF_1039	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	243	243	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Mel-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	243	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	86	4	86	995	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	86	4	86			1
MMRF_1039	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	244	246	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Mel-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	246	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	245	Stem cell, Autologous	1	1	Completed regimen	4			4	86	4	86	995	Partial Response	PR	Partial Response	PR	1	0	0	0	0	3	0	4	86	4	86			1
MMRF_1039	2	Lenalidomide	Len	IMID	998	1037	1	Lenalidomide	Len	998	IMID	1037	IMIDs-based	IMIDs-based	Len-Dex				0					4	1429	4	1429		Partial Response	PR	Partial Response	PR	1	0	0	0	2	40	0	16	432	16	432	1	1	1
MMRF_1039	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1038	1358	2	Lenalidomide + Lenalidomide/Dexamethasone	Len + Len-Dex	998	IMID/Steroid	1358	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	1429	4	1429		Partial Response	PR	Partial Response	PR	1	0	0	0	12	321	0	16	432	16	432			1
MMRF_1039	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1403	1779	3	Lenalidomide + Lenalidomide/Dexamethasone + Pomalidomide/Dexamethasone	Len + Len-Dex + Pom-Dex	998	IMID/Steroid	1779	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1429	4	1429		Partial Response	PR	Partial Response	PR	1	1	1	1	14	377	1	16	432	16	432			1
MMRF_1055	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	142	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	142	Bortezomib-based	Bortezomib-based	Bor-Dex	167	Stem cell, Autologous	1	1	Completed regimen	4			4	149	4	149	244	Partial Response	PR	Partial Response	PR	1	1	1	1	5	142	1	6	149	6	149	1	2	1
MMRF_1055	2	Lenalidomide	Len	IMID	296	444	1	Lenalidomide	Len	296	IMID	444	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	443	350	Stable Disease	SD			0	1	0	1	6	149	0	6	148			1	1	1
MMRF_1124	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	379	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	379	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Patient decision	6			4	81	4	81	256	Partial Response	PR	Partial Response	PR	1	1	1	1	14	379	1	3	81	3	81	1	2	1
MMRF_1166	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	106	3	106		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	4	106	4	106	1	3	1
MMRF_1209	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	320	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	320	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH				4	204	4	204		Partial Response	PR	Partial Response	PR	1	1	1	1	12	320	1	8	204	8	204	1	3	1
MMRF_1333	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	176	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	176	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	155	4	155		Partial Response	PR	Partial Response	PR	1	1	1	1	7	176	1	6	155	6	155	1	3	1
MMRF_1342	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	747	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	747	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	85	3	246		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	27	747	1	9	246	4	85	1	3	1
MMRF_1383	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	135	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	135	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	169	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	205		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	135	1	8	205	4	85	1	3	1
MMRF_1383	1	Bortezomib	Bor	Proteasome	276	1009	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	1009	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	85	3	205		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	27	734	0	8	205	4	85			1
MMRF_1550	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	204	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	204	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	86	3	366	706	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	8	204	1	14	366	4	86	1	3	1
MMRF_1550	1	Lenalidomide	Len	IMID	310	708	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	708	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	86	3	366	706	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	15	399	0	14	366	4	86			1
MMRF_1550	2	Carfilzomib	Car	Proteasome	709	827	1	Carfilzomib	Car	709	Proteasome	827	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Lack of response	1			4	916	4	916	827	Partial Response	PR	Partial Response	PR	1	0	0	0	5	119	0	8	208	8	208	1	1	1
MMRF_1550	2	Daratumumab	Dar	CD38	838	1232	2	Carfilzomib + Daratumumab	Car + Dar	709	Proteasome/CD38	1232	Carfilzomib-based	daratumumab-based	Car-Dar-Dex				0	Lack of response	1			4	916	4	916	827	Partial Response	PR	Partial Response	PR	1	1	1	1	14	395	1	8	208	8	208			1
MMRF_1550	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1328	1346	3	Carfilzomib + Daratumumab + Pomalidomide/Dexamethasone	Car + Dar + Pom-Dex	709	Proteasome/CD38/IMID/Steroid	1346	combined daratumumab/IMIDs/carfilzomib-based	IMIDs-based	Dar-Car-Pom-Dex				0					4	916	4	916	827	Partial Response	PR	Partial Response	PR	1	0	0	0	1	19	0	8	208	8	208			1
MMRF_1568	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	173	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			3	85	3	85	1023	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	113	1	4	85	4	85	1	3	1
MMRF_1568	1	Lenalidomide	Len	IMID	285	441	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	441	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			3	85	3	85	1023	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	157	0	4	85	4	85			1
MMRF_1568	2	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1275	2071	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1275	Proteasome/CD38/Steroid	2071	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0							5	1356		Stable Disease	SD			0	1	0	1	29	797	0	3	82			1	3	1
MMRF_1721	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	TROUBLE SLEEPING				4	29	4	29		Partial Response	PR	Partial Response	PR	1	1	1	1	5	120	1	2	29	2	29	1	3	1
MMRF_1834	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	69	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	69	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	147	Stem cell, Autologous	1	1	Completed regimen	4			4	107	1	1094		Complete Response	CR	Partial Response	PR	1	0	1	0	3	69	1	40	1094	4	107	1	3	1
MMRF_1834	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	222	940	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	940	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	107	1	1094		Complete Response	CR	Partial Response	PR	1	1	0	1	26	719	0	40	1094	4	107			1
MMRF_1970	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	176	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	176	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	85	4	85		Partial Response	PR	Partial Response	PR	1	1	1	1	7	176	1	4	85	4	85	1	2	1
MMRF_2057	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	246	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	246	IMIDs-based	IMIDs-based	Len-Dex				0					4	85	3	246		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	246	1	9	246	4	85	1	2	1
MMRF_2454	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	74	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	74	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	3	74	0					1	2	1
MMRF_2480	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	141	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	141	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH						5	92		Stable Disease	SD			0	1	0	1	5	141	0	4	92			1	2	1
MMRF_2560	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	865	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	865	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	137	Stem cell, Autologous	1	1					4	43	4	43		Partial Response	PR	Partial Response	PR	1	1	1	1	31	865	1	2	43	2	43	1	3	1
MMRF_1031	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	61	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	61	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	104	3	104	1329	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	61	1	4	104	4	104	1	3	1
MMRF_1031	1	MAGE-A3	MAGE-A3	Vaccine	185	1339	2	Bortezomib/Lenalidomide/Dexamethasone + MAGE-A3	Bor-Len-Dex + MAGE-A3	1	Proteasome/IMID/Steroid/Vaccine	1339	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	104	3	104	1329	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	42	1155	0	4	104	4	104			1
MMRF_1031	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1339	1581	1	Lenalidomide/Dexamethasone	Len-Dex	1339	IMID/Steroid	1581	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	1392	3	1437		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	243	1	4	99	2	54	1	2	1
MMRF_1031	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1581	1670	1	Carfilzomib/Dexamethasone	Car-Dex	1581	Proteasome/Steroid	1670	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2					6	1581	1581	Progressive Disease	PD			0	1	0	1	4	90	0	1	1			1	2	1
MMRF_1018	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	43	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	43	IMIDs-based	IMIDs-based	Len-Dex				0					4	219	3	281		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	43	0	11	281	8	219	1	2	1
MMRF_1018	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	44	105	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	219	3	281		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	62	0	11	281	8	219			1
MMRF_1018	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	106	1543	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	1543	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	219	3	281		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	52	1438	1	11	281	8	219			1
MMRF_1041	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	259	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	259	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Cyc-Dex				0					3	85	3	85	351	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	259	1	4	85	4	85	1	4	1
MMRF_1041	1	Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Thal-Cyc-Dex	Proteasome/IMID/IMID/Chemotherapy/Steroid	260	406	2	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex + Bor-Len-Thal-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	406	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	85	3	85	351	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	147	0	4	85	4	85			1
MMRF_1041	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	407	432	3	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex + Bor-Len-Thal-Cyc-Dex + Bor-Thal-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	432	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1			3	85	3	85	351	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	26	0	4	85	4	85			1
MMRF_1041	2	Carfilzomib/Cyclophosphamide	Car-Cyc	Proteasome/Chemotherapy	432	953	1	Carfilzomib/Cyclophosphamide	Car-Cyc	432	Proteasome/Chemotherapy	953	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	526	4	526	449	Partial Response	PR	Partial Response	PR	1	1	1	1	19	522	1	4	95	4	95	1	2	1
MMRF_1041	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	981	1060	1	Pomalidomide/Dexamethasone	Pom-Dex	981	IMID/Steroid	1060	IMIDs-based	IMIDs-based	Pom-Dex				0							6	1002	1002	Progressive Disease	PD			0	1	0	1	3	80	0	1	22			1	2	1
MMRF_1041	3	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	1061	1084	2	Pomalidomide/Dexamethasone + Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Dex + Pom-Cyc-Dex	981	IMID/Steroid/Chemotherapy	1084	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3					6	1002	1002	Progressive Disease	PD			0	0	0	0	1	24	0	1	22					1
MMRF_1041	3	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1085	1095	3	Pomalidomide/Dexamethasone + Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Dex + Pom-Cyc-Dex	981	IMID/Steroid/Chemotherapy	1095	IMIDs-based	Other treatments	Pom-Cyc-Dex				0	Investigator decision for other reasons	5					6	1002	1002	Progressive Disease	PD			0	0	0	0	1	11	0	1	22					1
MMRF_1016	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	42	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	42	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	42	0	4	103	4	103	1	3	1
MMRF_1016	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	43	43	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	43	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	103	4	103			1
MMRF_1016	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	44	112	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	112	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	69	1	4	103	4	103			1
MMRF_1016	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	113	113	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	113	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	103	4	103			1
MMRF_1016	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	114	158	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	158	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	45	0	4	103	4	103			1
MMRF_1016	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	234	546	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	546	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	11	313	0	4	103	4	103			1
MMRF_1016	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	547	673	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilz	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	673	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	127	0	4	103	4	103			1
MMRF_1054	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	28	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	28	IMIDs-based	IMIDs-based	Len-Dex				0					4	50	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	28	0	13	358	2	50	1	2	1
MMRF_1054	1	Lenalidomide/Prednisone/Dexamethasone	Len-Pred-Dex	IMID/Steroid/Steroid	29	111	2	Lenalidomide/Dexamethasone + Lenalidomide/Prednisone/Dexamethasone	Len-Dex + Len-Pred-Dex	1	IMID/Steroid	111	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	50	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	83	1	13	358	2	50			1
MMRF_1054	1	Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Cyc-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	112	112	3	Lenalidomide/Dexamethasone + Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Len-Dex + Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	112	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	50	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	13	358	2	50			1
MMRF_1054	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	113	166	4	Lenalidomide/Dexamethasone + Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Len-Dex + Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Cyc-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	166	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	50	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	54	0	13	358	2	50			1
MMRF_1054	1	Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Cyc-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	167	568	5	Lenalidomide/Dexamethasone + Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Len-Dex + Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Pred-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	568	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	50	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	15	402	0	13	358	2	50			1
MMRF_1054	1	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	569	2948	6	Lenalidomide/Dexamethasone + Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Lenalidomide/Prednisone	Len-Dex + Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Pred-Dex + Len-Pred	1	IMID/Steroid/Proteasome/Chemotherapy	2948	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	50	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	85	2380	0	13	358	2	50			1
MMRF_1049	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	183	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	183	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4	2515	3019	4	179	4	179		Partial Response	PR	Partial Response	PR	1	1	1	1	7	183	1	7	179	7	179	1	3	1
MMRF_1049	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	218	1079	1	Bortezomib/Dexamethasone	Bor-Dex	218	Proteasome/Steroid	1079	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4	2515	3019	4	291	3	546	1079	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	31	862	1	12	329	3	74	1	2	1
MMRF_1049	3	Lenalidomide/Panobinostat/Dexamethasone	Len-Pano-Dex	IMID/HDAC/Steroid	1084	1224	1	Lenalidomide/Panobinostat/Dexamethasone	Len-Pano-Dex	1084	IMID/HDAC/Steroid	1224	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	2515	3019			5	1169	1255	Stable Disease	SD			0	1	0	1	5	141	0	4	86			1	3	1
MMRF_1049	4	Atezolizumab	Atez	Checkpoint Inhibitor	1291	2818	1	Atezolizumab	Atez	1291	Checkpoint Inhibitor	2818	Other therapies	Other treatments					0	Disease progression/Relapse	3	2515	3019			6	1336	1336	Progressive Disease	PD			0	1	0	1	55	1528	0	2	46					1
MMRF_1049	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1392	1413	1	Daratumumab/Dexamethasone	Dar-Dex	1392	CD38/Steroid	1413	daratumumab-based	daratumumab-based	Dar-Dex				0			2515	3019	4	1616	3	1700	2515	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	22	0	12	309	9	225			1
MMRF_1049	5	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1414	2078	2	Daratumumab/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Dar-Dex + Dar-Pom-Dex	1392	CD38/Steroid/IMID	2078	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2515	3019	4	1616	3	1700	2515	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	24	665	1	12	309	9	225	1	3	1
MMRF_1049	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	2079	2113	3	Daratumumab/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone + Daratumumab/Dexamethasone	Dar-Dex + Dar-Pom-Dex + Dar-Dex	1392	CD38/Steroid/IMID	2113	combined daratumumab/IMIDs-based	daratumumab-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2515	3019	4	1616	3	1700	2515	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	35	0	12	309	9	225			1
MMRF_1049	9	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	2144	2205	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	2144	Chemotherapy/Steroid	2205	Other therapies	Other treatments					1			2515	3019										0	0	0	0	3	62	0							1
MMRF_1049	9	Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	2206	2206	2	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Dex + Cyc-Mel-Dex	2144	Chemotherapy/Steroid	2206	Other therapies	Other treatments					1	Completed regimen	4	2515	3019										0	0	0	0	0	1	0							1
MMRF_1049	9	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	2207	2207	3	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex	2144	Chemotherapy/Steroid	2207	Other therapies	Other treatments		2207	Stem cell, Autologous	1	1	Completed regimen	4	2515	3019										0	0	0	0	0	1	0							1
MMRF_1049	9	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	2395	2431	4	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex	2144	Chemotherapy/Steroid/SLAMF7/IMID	2431	IMIDs-based	IMIDs-based	Other Pom-based therapies				1	Disease progression/Relapse	3	2515	3019										0	0	0	0	2	37	0					1	3	1
MMRF_1049	9	Belantamab mafodotin	Bela	BCMA	2452	2493	5	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone + Belantamab mafodotin	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex + Bela	2144	Chemotherapy/Steroid/SLAMF7/IMID/BCMA	2493	IMIDs-based	Other treatments	Other Pom-based therapies				1	Disease progression/Relapse	3	2515	3019										0	0	0	0	2	42	0							1
MMRF_1049	9	Iberdomide	Iber	IMID	2731	2807	6	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone + Belantamab mafodotin + Iberdomide	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex + Bela + Iber	2144	Chemotherapy/Steroid/SLAMF7/IMID/BCMA	2807	IMIDs-based	Other treatments	Other Pom-based therapies				1	Disease progression/Relapse	3	2515	3019										0	0	0	0	3	77	0							1
MMRF_1049	9	Carfilzomib/Selinexor/Dexamethasone	Car-Sel-Dex	Proteasome/XPO1/Steroid	2870	2939	7	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone + Belantamab mafodotin + Iberdomide + Carfilzomib/Selinexor/Dexamethasone	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex + Bela + Iber + Car-Sel-Dex	2144	Chemotherapy/Steroid/SLAMF7/IMID/BCMA/Proteasome/XPO1	2939	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2515	3019										0	0	0	0	3	70	0							1
MMRF_1049	9	Bortezomib/Daratumumab/Venetoclax/Dexamethasone	Bor-Dar-Vent-Dex	Proteasome/CD38/BCL2/Steroid	2978	3018	8	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone + Belantamab mafodotin + Iberdomide + Carfilzomib/Selinexor/Dexamethasone + Bortezomib/Daratumumab/Venetoclax/Dexamethasone	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex + Bela + Iber + Car-Sel-Dex + Bor-Dar-Vent-Dex	2144	Chemotherapy/Steroid/SLAMF7/IMID/BCMA/Proteasome/XPO1/CD38/BCL2	3018	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1			2515	3019										0	0	0	0	2	41	0							1
MMRF_1049	9	Bortezomib/Daratumumab/METRO28/Venetoclax/Dexamethasone	Bor-Dar-METRO28-Vent-Dex	Proteasome/CD38/BCL2/Steroid	3019	3021	9	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone + Belantamab mafodotin + Iberdomide + Carfilzomib/Selinexor/Dexamethasone + Bortezomib/Daratumumab/Venetoclax/Dexamethasone + Bortezomib/Daratumumab/METR	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex + Bela + Iber + Car-Sel-Dex + Bor-Dar-Vent-Dex + Bor-Dar-METRO28-Vent-Dex	2144	Chemotherapy/Steroid/SLAMF7/IMID/BCMA/Proteasome/XPO1/CD38/BCL2	3021	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3	2515	3019										0	0	0	0	0	3	0							1
MMRF_1049	9	Daratumumab/METRO28	Dar-METRO28	CD38	3022	3037	10	Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone + Belantamab mafodotin + Iberdomide + Carfilzomib/Selinexor/Dexamethasone + Bortezomib/Daratumumab/Venetoclax/Dexamethasone + Bortezomib/Daratumumab/METR	Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex + Elo-Pom-Dex + Bela + Iber + Car-Sel-Dex + Bor-Dar-Vent-Dex + Bor-Dar-METRO28-Vent-Dex + Dar-METRO28	2144	Chemotherapy/Steroid/SLAMF7/IMID/BCMA/Proteasome/XPO1/CD38/BCL2	3037	combined bortezomib/IMIDs/carfilzomib-based	daratumumab-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	DEATH		2515	3019										0	0	0	0	1	16	0							1
MMRF_1064	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	692	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	692	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	78	1	461	1472	Complete Response	CR	Partial Response	PR	1	1	1	1	25	692	1	17	461	3	78	1	3	1
MMRF_1064	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1511	1543	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1511	Proteasome/IMID/Steroid	1543	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3												0	0	0	0	1	33	0					1	3	1
MMRF_1064	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1543	1602	1	Carfilzomib/Dexamethasone	Car-Dex	1543	Proteasome/Steroid	1602	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1617	Stem cell, Autologous	1	1	Completed regimen	4			3	1595	3	1595	1543	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	60	1	2	53	2	53	1	2	1
MMRF_1064	3	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1769	2806	2	Carfilzomib/Dexamethasone + Elotuzumab/Lenalidomide/Dexamethasone	Car-Dex + Elo-Len-Dex	1543	Proteasome/Steroid/SLAMF7/IMID	2806	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	1595	3	1595	1543	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	37	1038	0	2	53	2	53			1
MMRF_1064	3	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	2740	3025	3	Carfilzomib/Dexamethasone + Elotuzumab/Lenalidomide/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dex + Elo-Len-Dex + Car-Dar-Pom-Dex	1543	Proteasome/Steroid/SLAMF7/IMID/CD38	3025	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				1	Completed regimen	4			3	1595	3	1595	1543	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	11	286	0	2	53	2	53			1
MMRF_1071	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	65	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	65	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	64	3	151	840	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	65	1	6	151	3	64	1	3	1
MMRF_1071	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	102	137	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	137	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	64	3	151	840	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	2	36	0	6	151	3	64			1
MMRF_1071	1	MAGE-A3	MAGE-A3	Vaccine	158	197	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + MAGE-A3	Bor-Len-Dex + Bor-Cyc-Dex + MAGE-A3	1	Proteasome/IMID/Steroid/Chemotherapy/Vaccine	197	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	64	3	151	840	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	40	0	6	151	3	64			1
MMRF_1071	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	973	1904	1	Pomalidomide/Dexamethasone	Pom-Dex	973	IMID/Steroid	1904	IMIDs-based	IMIDs-based	Pom-Dex				0	Completed regimen	4			3	1225	3	1225	973	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	34	932	1	10	253	10	253	1	2	1
MMRF_1071	2	Pomalidomide	Pom	IMID	1905	2219	2	Pomalidomide/Dexamethasone + Pomalidomide	Pom-Dex + Pom	973	IMID/Steroid	2219	IMIDs-based	IMIDs-based	Pom-Dex				0	Completed regimen	4			3	1225	3	1225	973	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	315	0	10	253	10	253			1
MMRF_1084	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	93	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	93	3	267	624	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	93	1	10	267	4	93	1	3	1
MMRF_1084	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	200	313	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	313	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	93	3	267	624	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	114	0	10	267	4	93			1
MMRF_1084	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	631	996	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	631	Proteasome/Chemotherapy/Steroid	996	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			3	709	3	709		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	13	366	1	3	79	3	79	1	3	1
MMRF_1084	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	996	1101	1	Pomalidomide/Dexamethasone	Pom-Dex	996	IMID/Steroid	1101	IMIDs-based	IMIDs-based	Pom-Dex				0							6	996	996	Progressive Disease	PD			0	1	0	1	4	106	0	1	1			1	2	1
MMRF_1084	3	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	1102	1142	2	Pomalidomide/Dexamethasone + Bortezomib/Pomalidomide/Dexamethasone	Pom-Dex + Bor-Pom-Dex	996	IMID/Steroid/Proteasome	1142	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	Disease progression/Relapse	3					6	996	996	Progressive Disease	PD			0	0	0	0	2	41	0	1	1					1
MMRF_1084	4	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	1166	1338	1	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	1166	Chemotherapy/Steroid	1338	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	1198	1198	Progressive Disease	PD			0	1	0	1	6	173	0	2	33					1
MMRF_1084	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1363	1648	1	Daratumumab/Dexamethasone	Dar-Dex	1363	CD38/Steroid	1648	daratumumab-based	daratumumab-based	Dar-Dex				0	Disease progression/Relapse	3					5	1478		Stable Disease	SD			0	1	0	1	11	286	0	5	116					1
MMRF_1100	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	127	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	127	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	73	3	459		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	127	1	17	459	3	73	1	3	1
MMRF_1100	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	128	128	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	128	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	73	3	459		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	17	459	3	73			1
MMRF_1100	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	129	155	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	155	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	73	3	459		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	27	0	17	459	3	73			1
MMRF_1100	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	190	974	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	974	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	975	Stem cell, Autologous	1	1	Lack of response	1			4	73	3	459		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	28	785	0	17	459	3	73			1
MMRF_1100	3	Daratumumab	Dar	CD38	1187	1383	1	Daratumumab	Dar	1187	CD38	1383	daratumumab-based	daratumumab-based	Dar				0					4	1244	1	1720		Complete Response	CR	Partial Response	PR	1	0	1	0	7	197	1	20	534	3	58			1
MMRF_1100	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1384	1800	2	Daratumumab + Daratumumab/Pomalidomide	Dar + Dar-Pom	1187	CD38/IMID	1800	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Adverse Event or co-morbidity	2			4	1244	1	1720		Complete Response	CR	Partial Response	PR	1	1	0	1	15	417	0	20	534	3	58	1	2	1
MMRF_1100	3	Daratumumab	Dar	CD38	1801	1927	3	Daratumumab + Daratumumab/Pomalidomide + Daratumumab	Dar + Dar-Pom + Dar	1187	CD38/IMID	1927	combined daratumumab/IMIDs-based	daratumumab-based	Dar-Pom				0	Completed regimen	4			4	1244	1	1720		Complete Response	CR	Partial Response	PR	1	0	0	0	5	127	0	20	534	3	58			1
MMRF_1101	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	49	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	49	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	99	1	422		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	49	0	16	422	4	99	1	3	1
MMRF_1101	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	50	422	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	422	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	99	1	422		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	14	373	1	16	422	4	99			1
MMRF_1101	1	Lenalidomide	Len	IMID	423	562	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	562	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	CR				3	99	1	422		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	5	140	0	16	422	4	99			1
MMRF_1111	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	25	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	25	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	25	0	4	103	4	103	1	3	1
MMRF_1111	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	26	553	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	553	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	19	528	1	4	103	4	103			1
MMRF_1111	1	Lenalidomide	Len	IMID	554	2223	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2223	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	103	3	103		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	60	1670	0	4	103	4	103			1
MMRF_1111	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	2349	2923	1	Daratumumab/Pomalidomide	Dar-Pom	2349	CD38/IMID	2923	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0					3	2407	3	2407		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	21	575	1	3	59	3	59	1	2	1
MMRF_1127	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	82	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	82	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	265	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	82	3	369	1958	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	82	1	14	369	3	82	1	3	1
MMRF_1127	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	2018	2045	1	Bortezomib/Dexamethasone	Bor-Dex	2018	Proteasome/Steroid	2045	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	2091	2	2310		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	1	28	0	11	293	3	74	1	2	1
MMRF_1127	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	2046	2878	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	2018	Proteasome/Steroid/IMID	2878	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	2091	2	2310		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	30	833	1	11	293	3	74			1
MMRF_1151	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	37	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	37	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	182	4	182		Partial Response	PR	Partial Response	PR	1	0	0	0	2	37	0	7	182	7	182	1	3	1
MMRF_1151	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	70	250	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	250	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH				4	182	4	182		Partial Response	PR	Partial Response	PR	1	1	1	1	7	181	1	7	182	7	182			1
MMRF_1156	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	86	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	86	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	84	3	371		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	86	1	14	371	3	84	1	3	1
MMRF_1156	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	87	204	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	204	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	212	Stem cell, Autologous	1	1	INDUCTION				4	84	3	371		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	118	0	14	371	3	84			1
MMRF_1156	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	315	1368	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1368	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	84	3	371		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	38	1054	0	14	371	3	84			1
MMRF_1156	3	Lenalidomide/Atezolizumab	Len-Atez	IMID/Checkpoint Inhibitor	1746	1991	1	Lenalidomide/Atezolizumab	Len-Atez	1746	IMID/Checkpoint Inhibitor	1991	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2					6	1746	1746	Progressive Disease	PD			0	1	0	1	9	246	0	1	1			1	2	1
MMRF_1156	4	Daratumumab	Dar	CD38	1924	1981	1	Daratumumab	Dar	1924	CD38	1981	daratumumab-based	daratumumab-based	Dar				0					3	2177	3	2177	1991	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	58	0	10	254	10	254			1
MMRF_1156	4	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1982	2950	2	Daratumumab + Daratumumab/Pomalidomide	Dar + Dar-Pom	1924	CD38/IMID	2950	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0					3	2177	3	2177	1991	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	35	969	1	10	254	10	254	1	2	1
MMRF_1157	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	42	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	42	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1			2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	42	0	13	353	13	353	1	3	1
MMRF_1157	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	43	222	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	222	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	INDUCTION		2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	180	0	13	353	13	353			1
MMRF_1157	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	223	238	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	238	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				1			2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	16	0	13	353	13	353			1
MMRF_1157	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	239	239	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	239	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4	2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	13	353	13	353			1
MMRF_1157	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	240	240	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	240	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	240	Stem cell, Autologous	1	1	Completed regimen	4	2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	13	353	13	353			1
MMRF_1157	1	Lenalidomide	Len	IMID	326	414	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	414	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1			2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	89	1	13	353	13	353			1
MMRF_1157	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	415	556	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex + Len + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	556	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2360		3	353	3	353	534	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	142	0	13	353	13	353			1
MMRF_1157	2	Carfilzomib/Ibrutinib	Car-Ibru	Proteasome/BTK	591	681	1	Carfilzomib/Ibrutinib	Car-Ibru	591	Proteasome/BTK	681	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			2360				5	794	675	Stable Disease	SD			0	0	0	0	4	91	0	8	204			1	2	1
MMRF_1157	2	Carfilzomib/Ibrutinib/Dexamethasone	Car-Ibru-Dex	Proteasome/BTK/Steroid	682	682	2	Carfilzomib/Ibrutinib + Carfilzomib/Ibrutinib/Dexamethasone	Car-Ibru + Car-Ibru-Dex	591	Proteasome/BTK/Steroid	682	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2360				5	794	675	Stable Disease	SD			0	0	0	0	0	1	0	8	204					1
MMRF_1157	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	683	921	3	Carfilzomib/Ibrutinib + Carfilzomib/Ibrutinib/Dexamethasone + Carfilzomib/Dexamethasone	Car-Ibru + Car-Ibru-Dex + Car-Dex	591	Proteasome/BTK/Steroid	921	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2360				5	794	675	Stable Disease	SD			0	1	0	1	9	239	0	8	204					1
MMRF_1157	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	960	1578	1	Daratumumab/Pomalidomide	Dar-Pom	960	CD38/IMID	1578	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Disease progression/Relapse	3	2360		3	1088	3	1088		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	22	619	1	5	129	5	129	1	2	1
MMRF_1157	4	Selinexor/Dexamethasone	Sel-Dex	XPO1/Steroid	1626	1836	1	Selinexor/Dexamethasone	Sel-Dex	1626	XPO1/Steroid	1836	Other therapies	Other treatments					0	Disease progression/Relapse	3	2360		3	1683	3	1683	1626	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	211	1	3	58	3	58			1
MMRF_1157	5	TAS4464	TAS4464	Other	1870	1927	1	TAS4464	TAS4464	1870	Other	1927	Other therapies	Other treatments					0	Disease progression/Relapse	3	2360				5	1964	2360	Stable Disease	SD			0	0	0	0	2	58	0	4	95					1
MMRF_1157	9	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	1944	2129	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	1944	Proteasome/CD38/Steroid	2129	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	7	186	0					1	3	1
MMRF_1157	9	Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone	Car-Dar-JNJ-64407564-Dex	Proteasome/CD38/GPRC5D/Steroid	2130	2270	2	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex	1944	Proteasome/CD38/Steroid/GPRC5D	2270	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	5	141	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone	Car-Dar-Bela-JNJ-64407564-Dex	Proteasome/CD38/BCMA/GPRC5D/Steroid	2271	2397	3	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA	2397	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2360											0	0	0	0	5	127	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone	Car-Dar-JNJ-64407564-Dex	Proteasome/CD38/GPRC5D/Steroid	2398	2444	4	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA	2444	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	2	47	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone	Car-Dar-JNJ-64407564-ONC201-Dex	Proteasome/CD38/GPRC5D/Other/Steroid	2445	2466	5	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other	2466	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2360											0	0	0	0	1	22	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone	Car-Dar-JNJ-64407564-Dex	Proteasome/CD38/GPRC5D/Steroid	2467	2507	6	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone + Carfilzomib/Daratumu	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex + Car-Dar-JNJ-64407564-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other	2507	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	2	41	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/Lenalidomide/JNJ-64407564/Dexamethasone	Car-Dar-Len-JNJ-64407564-Dex	Proteasome/CD38/IMID/GPRC5D/Steroid	2508	2633	7	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone + Carfilzomib/Daratumu	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Len-JNJ-64407564-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other/IMID	2633	Carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	5	126	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/Ixazomib/Lenalidomide/JNJ-64407564/ONC201/Dexamethasone	Car-Dar-Ixa-Len-JNJ-64407564-ONC201-Dex	Proteasome/CD38/Proteasome/IMID/GPRC5D/Other/Steroid	2634	2634	8	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone + Carfilzomib/Daratumu	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Len-JNJ-64407564-Dex + Car-Dar-Ixa-Len-JNJ-64407564-ONC201-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other/IMID	2634	Carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4	2360											0	0	0	0	0	1	0							1
MMRF_1157	9	Carfilzomib/Daratumumab/Ixazomib/JNJ-64407564/ONC201/Dexamethasone	Car-Dar-Ixa-JNJ-64407564-ONC201-Dex	Proteasome/CD38/Proteasome/GPRC5D/Other/Steroid	2635	2738	9	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone + Carfilzomib/Daratumu	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Len-JNJ-64407564-Dex + Car-Dar-Ixa-Len-JNJ-64407564-ONC201-Dex + Car-Dar-Ixa-JNJ-64407564-ONC201-Dex	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other/IMID	2738	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	4	104	0							1
MMRF_1157	9	Bortezomib/Carfilzomib/Daratumumab/Ixazomib/JNJ-64407564/ONC201/Venetoclax/Dexamethasone	Bor-Car-Dar-Ixa-JNJ-64407564-ONC201-Vent-Dex	Proteasome/Proteasome/CD38/Proteasome/GPRC5D/Other/BCL2/Steroid	2739	2746	10	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone + Carfilzomib/Daratumu	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Len-JNJ-64407564-Dex + Car-Dar-Ixa-Len-JNJ-64407564-ONC201-Dex + Car-Dar-Ixa-JNJ-64407564-ONC201-Dex + Bor-Car-Dar-Ixa-JNJ-64407564	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other/IMID/BCL2	2746	Carfilzomib-based	combined bortezomib/carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2360											0	0	0	0	1	8	0							1
MMRF_1157	9	Bortezomib/Carfilzomib/Daratumumab/JNJ-64407564/Venetoclax/Dexamethasone	Bor-Car-Dar-JNJ-64407564-Vent-Dex	Proteasome/Proteasome/CD38/GPRC5D/BCL2/Steroid	2747	2922	11	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/Belantamab mafodotin/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/Dexamethasone + Carfilzomib/Daratumumab/JNJ-64407564/ONC201/Dexamethasone + Carfilzomib/Daratumu	Car-Dar-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Bela-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-JNJ-64407564-ONC201-Dex + Car-Dar-JNJ-64407564-Dex + Car-Dar-Len-JNJ-64407564-Dex + Car-Dar-Ixa-Len-JNJ-64407564-ONC201-Dex + Car-Dar-Ixa-JNJ-64407564-ONC201-Dex + Bor-Car-Dar-Ixa-JNJ-64407564	1944	Proteasome/CD38/Steroid/GPRC5D/BCMA/Other/IMID/BCL2	2922	Carfilzomib-based	combined bortezomib/carfilzomib-based	Other Cafilzomib-based therapies				0			2360											0	0	0	0	7	176	0							1
MMRF_1179	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	686	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	686	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	149	3	149	710	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	25	686	1	6	149	6	149	1	3	1
MMRF_1179	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	687	715	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	715	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			3	149	3	149	710	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	29	0	6	149	6	149			1
MMRF_1179	2	Carfilzomib	Car	Proteasome	715	842	1	Carfilzomib	Car	715	Proteasome	842	Carfilzomib-based	Carfilzomib-based	Car-Dex				0					4	907	4	907		Partial Response	PR	Partial Response	PR	1	0	0	0	5	128	0	7	193	7	193	1	1	1
MMRF_1179	2	Carfilzomib/Thalidomide	Car-Thal	Proteasome/IMID	843	1024	2	Carfilzomib + Carfilzomib/Thalidomide	Car + Car-Thal	715	Proteasome/IMID	1024	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	907	4	907		Partial Response	PR	Partial Response	PR	1	1	1	1	7	182	1	7	193	7	193			1
MMRF_1179	3	Daratumumab	Dar	CD38	1087	1709	1	Daratumumab	Dar	1087	CD38	1709	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3					5	1143	1087	Stable Disease	SD			0	1	0	1	23	623	0	3	57					1
MMRF_1179	4	Pomalidomide	Pom	IMID	1356	1693	1	Pomalidomide	Pom	1356	IMID	1693	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3					5	1426	1719	Stable Disease	SD			0	1	0	1	12	338	0	3	71			1	1	1
MMRF_1179	5	Venetoclax	Vent	BCL2	1732	1766	1	Venetoclax	Vent	1732	BCL2	1766	Other therapies	Other treatments					0														0	0	0	0	2	35	0							1
MMRF_1179	5	Ixazomib/Venetoclax	Ixa-Vent	Proteasome/BCL2	1767	1773	2	Venetoclax + Ixazomib/Venetoclax	Vent + Ixa-Vent	1732	BCL2/Proteasome	1773	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2												0	0	0	0	1	7	0							1
MMRF_1212	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	119	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	119	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	119	1	7	181	4	90	1	3	1
MMRF_1212	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	120	127	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	127	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	8	0	7	181	4	90			1
MMRF_1212	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	128	175	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	175	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0					4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	48	0	7	181	4	90			1
MMRF_1212	1	Bortezomib/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Thal-Cyc-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	176	233	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Thal-Cyc-Pred-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	233	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	2	58	0	7	181	4	90			1
MMRF_1212	1	Bortezomib/Thalidomide/Cyclophosphamide/Prednisone	Bor-Thal-Cyc-Pred	Proteasome/IMID/Chemotherapy/Steroid	234	657	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Thal-Cyc-Pred-Dex + Bor-Thal-Cyc-Pred	1	Proteasome/Chemotherapy/Steroid/IMID	657	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	15	424	0	7	181	4	90			1
MMRF_1212	1	Thalidomide/Cyclophosphamide/Prednisone	Thal-Cyc-Pred	IMID/Chemotherapy/Steroid	658	947	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone + Thalidomide/Cyclophosphamide/Predni	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Thal-Cyc-Pred-Dex + Bor-Thal-Cyc-Pred	1	Proteasome/Chemotherapy/Steroid/IMID	947	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	LOST TO FOLLOW UP				4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	11	290	0	7	181	4	90			1
MMRF_1212	1	Thalidomide/Prednisone	Thal-Pred	IMID/Steroid	948	1252	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Prednisone + Thalidomide/Cyclophosphamide/Predni	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Thal-Cyc-Pred-Dex + Bor-Thal-Cyc-Pred + Thal-Pred	1	Proteasome/Chemotherapy/Steroid/IMID	1252	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	90	3	181	1252	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	11	305	0	7	181	4	90			1
MMRF_1223	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	94	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	94	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Cyc-Dex				1			2380		4	88	3	174	579	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	94	1	7	174	4	88	1	4	1
MMRF_1223	1	Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Thal-Cyc-Dex	Proteasome/IMID/IMID/Chemotherapy/Steroid	95	508	2	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex + Bor-Len-Thal-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	508	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2	2380		4	88	3	174	579	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	15	414	0	7	174	4	88			1
MMRF_1223	1	Lenalidomide	Len	IMID	509	606	3	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Thal-Cyc-Dex + Bor-Len-Thal-Cyc-Dex + Len	1	Proteasome/IMID/Chemotherapy/Steroid	606	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	607	Stem cell, Autologous	1	1	Completed regimen	4	2380		4	88	3	174	579	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	98	0	7	174	4	88			1
MMRF_1223	2	Carfilzomib	Car	Proteasome	742	839	1	Carfilzomib	Car	742	Proteasome	839	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Lack of response	1	2380		4	700	3	788	933	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	98	0	2	47	-1	-41	1	1	1
MMRF_1223	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	942	1453	1	Daratumumab/Dexamethasone	Dar-Dex	942	CD38/Steroid	1453	daratumumab-based	daratumumab-based	Dar-Dex				0	Disease progression/Relapse	3	2380		3	1026	3	1026		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	19	512	1	4	85	4	85			1
MMRF_1223	4	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1476	1508	1	Pomalidomide/Dexamethasone	Pom-Dex	1476	IMID/Steroid	1508	IMIDs-based	IMIDs-based	Pom-Dex				0			2380		3	1629	3	1629	1481	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	33	0	6	154	6	154	1	2	1
MMRF_1223	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1509	1592	2	Pomalidomide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Pom-Dex + Dar-Pom-Dex	1476	IMID/Steroid/CD38	1592	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0			2380		3	1629	3	1629	1481	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	6	154	6	154			1
MMRF_1223	4	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1593	2020	3	Pomalidomide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Pom-Dex + Dar-Pom-Dex + Car-Dar-Pom-Dex	1476	IMID/Steroid/CD38/Proteasome	2020	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0	Disease progression/Relapse	3	2380		3	1629	3	1629	1481	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	16	428	1	6	154	6	154			1
MMRF_1223	5	Carfilzomib/Selinexor/Dexamethasone	Car-Sel-Dex	Proteasome/XPO1/Steroid	2042	2941	1	Carfilzomib/Selinexor/Dexamethasone	Car-Sel-Dex	2042	Proteasome/XPO1/Steroid	2941	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2380		3	2154	3	2154	2380	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	32	900	1	5	113	5	113	1	3	1
MMRF_1223	9	Carfilzomib/Venetoclax/Dexamethasone	Car-Vent-Dex	Proteasome/BCL2/Steroid	2297	2363	1	Carfilzomib/Venetoclax/Dexamethasone	Car-Vent-Dex	2297	Proteasome/BCL2/Steroid	2363	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1			2380											0	0	0	0	3	67	0					1	3	1
MMRF_1223	9	Carfilzomib/Elotuzumab/Pomalidomide/Palbociclib/Panobinostat/Venetoclax/Dexamethasone	Car-Elo-Pom-Palb-Pano-Vent-Dex	Proteasome/SLAMF7/IMID/CDK4/6/HDAC/BCL2/Steroid	2364	2373	2	Carfilzomib/Venetoclax/Dexamethasone + Carfilzomib/Elotuzumab/Pomalidomide/Palbociclib/Panobinostat/Venetoclax/Dexamethasone	Car-Vent-Dex + Car-Elo-Pom-Palb-Pano-Vent-Dex	2297	Proteasome/BCL2/Steroid/SLAMF7/IMID/CDK4/6/HDAC	2373	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2380											0	0	0	0	1	10	0							1
MMRF_1223	9	Elotuzumab/Pomalidomide/Palbociclib/Panobinostat	Elo-Pom-Palb-Pano	SLAMF7/IMID/CDK4/6/HDAC	2374	2471	3	Carfilzomib/Venetoclax/Dexamethasone + Carfilzomib/Elotuzumab/Pomalidomide/Palbociclib/Panobinostat/Venetoclax/Dexamethasone + Elotuzumab/Pomalidomide/Palbociclib/Panobinostat	Car-Vent-Dex + Car-Elo-Pom-Palb-Pano-Vent-Dex + Elo-Pom-Palb-Pano	2297	Proteasome/BCL2/Steroid/SLAMF7/IMID/CDK4/6/HDAC	2471	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2380											0	0	0	0	4	98	0							1
MMRF_1223	9	Carmustine/Melphalan	Carm-Mel	Chemotherapy/Chemotherapy	2497	2498	4	Carfilzomib/Venetoclax/Dexamethasone + Carfilzomib/Elotuzumab/Pomalidomide/Palbociclib/Panobinostat/Venetoclax/Dexamethasone + Elotuzumab/Pomalidomide/Palbociclib/Panobinostat + Carmustine/Melphalan	Car-Vent-Dex + Car-Elo-Pom-Palb-Pano-Vent-Dex + Elo-Pom-Palb-Pano + Carm-Mel	2297	Proteasome/BCL2/Steroid/SLAMF7/IMID/CDK4/6/HDAC/Chemotherapy	2498	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	2500	Stem cell, Autologous	2	1	Disease progression/Relapse	3	2380											0	0	0	0	0	2	0							1
MMRF_1223	9	Carmustine/Melphalan	Carm-Mel	Chemotherapy/Chemotherapy	2497	2498	4	Carfilzomib/Venetoclax/Dexamethasone + Carfilzomib/Elotuzumab/Pomalidomide/Palbociclib/Panobinostat/Venetoclax/Dexamethasone + Elotuzumab/Pomalidomide/Palbociclib/Panobinostat + Carmustine/Melphalan	Car-Vent-Dex + Car-Elo-Pom-Palb-Pano-Vent-Dex + Elo-Pom-Palb-Pano + Carm-Mel	2297	Proteasome/BCL2/Steroid/SLAMF7/IMID/CDK4/6/HDAC/Chemotherapy	2498	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	2512	Stem cell, Autologous	3	1	Disease progression/Relapse	3	2380											0	0	0	0	0	2	0							1
MMRF_1224	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	203	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	203	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	SCH		2163	2356	3	63	1	720		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	8	203	1	26	720	3	63	1	3	1
MMRF_1224	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	226	780	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	780	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex	1056	Stem cell, Autologous	1	1	Completed regimen	4	2163	2356	3	63	1	720		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	20	555	0	26	720	3	63			1
MMRF_1224	1	Elotuzumab	Elo	SLAMF7	1178	1492	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Elotuzumab	Bor-Cyc-Dex + Len-Dex + Elo	1	Proteasome/Chemotherapy/Steroid/IMID/SLAMF7	1492	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2	2163	2356	3	63	1	720		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	12	315	0	26	720	3	63			1
MMRF_1224	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1178	1492	1	Lenalidomide/Dexamethasone	Len-Dex	1178	IMID/Steroid	1492	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2	2163	2356	4	1246	4	1246	1519	Partial Response	PR	Partial Response	PR	1	1	1	1	12	315	1	3	69	3	69	1	2	1
MMRF_1224	3	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	1525	1890	1	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	1525	IMID/Chemotherapy/Steroid	1890	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3	2163	2356			5	1613	1890	Stable Disease	SD			0	1	0	1	13	366	0	4	89			1	3	1
MMRF_1224	4	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1967	2002	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1967	Proteasome/CD38/Steroid	2002	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3	2163	2356										0	0	0	0	2	36	0					1	3	1
MMRF_1224	5	Bortezomib/Daratumumab/Vincristine/Dexamethasone/Doxorubicin	Bor-Dar-Vin-Dex-Dox	Proteasome/CD38/Chemotherapy/Steroid/Chemotherapy	2002	2193	1	Bortezomib/Daratumumab/Vincristine/Dexamethasone/Doxorubicin	Bor-Dar-Vin-Dex-Dox	2002	Proteasome/CD38/Chemotherapy/Steroid	2193	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2163	2356			6	2163	2163	Progressive Disease	PD			0	1	0	1	7	192	0	6	162			1	5	1
MMRF_1224	9	METRO28	METRO28		2206	2233	1	METRO28	METRO28	2206		2233	Other therapies	Other treatments					0			2163	2356										0	0	0	0	1	28	0							1
MMRF_1224	9	METRO28/Bendamustine	METRO28-Bend	Chemotherapy	2234	2237	2	METRO28 + METRO28/Bendamustine	METRO28 + METRO28-Bend	2206	Chemotherapy	2237	Other therapies	Other treatments					0	Disease progression/Relapse	3	2163	2356										0	0	0	0	0	4	0							1
MMRF_1224	9	METRO28	METRO28		2238	2331	3	METRO28 + METRO28/Bendamustine + METRO28	METRO28 + METRO28-Bend + METRO28	2206	Chemotherapy	2331	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2	2163	2356										0	0	0	0	4	94	0							1
MMRF_1231	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	85	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	85	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH													0	0	0	0	3	85	0					1	3	1
MMRF_1232	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	32	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	32	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	88	3	88	627	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	32	0	4	88	4	88	1	2	1
MMRF_1232	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	33	86	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	86	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	88	3	88	627	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	54	1	4	88	4	88			1
MMRF_1232	1	MAGE-A3	MAGE-A3	Vaccine	109	417	3	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + MAGE-A3	Bor-Dex + Bor-Cyc-Dex + MAGE-A3	1	Proteasome/Steroid/Chemotherapy/Vaccine	417	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	88	3	88	627	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	11	309	0	4	88	4	88			1
MMRF_1232	1	Lenalidomide	Len	IMID	522	559	4	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + MAGE-A3 + Lenalidomide	Bor-Dex + Bor-Cyc-Dex + MAGE-A3 + Len	1	Proteasome/Steroid/Chemotherapy/Vaccine/IMID	559	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					3	88	3	88	627	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	38	0	4	88	4	88			1
MMRF_1232	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	560	707	5	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + MAGE-A3 + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex + MAGE-A3 + Len + Len-Dex	1	Proteasome/Steroid/Chemotherapy/Vaccine/IMID	707	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			3	88	3	88	627	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	148	0	4	88	4	88			1
MMRF_1232	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	783	847	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	783	Proteasome/Chemotherapy/Steroid	847	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4												0	0	0	0	3	65	0					1	3	1
MMRF_1232	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	847	951	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	847	Proteasome/IMID/Steroid	951	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	847	847	Progressive Disease	PD			0	1	0	1	4	105	0	1	1			1	3	1
MMRF_1244	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	158	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	158	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	UNKNOWN				4	172	4	172		Partial Response	PR	Partial Response	PR	1	1	1	1	6	158	1	7	172	7	172	1	3	1
MMRF_1252	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	44	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	44	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	101	3	101	283	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	44	0	4	101	4	101	1	3	1
MMRF_1252	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	45	45	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	45	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	101	3	101	283	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	101	4	101			1
MMRF_1252	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	46	333	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	333	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			3	101	3	101	283	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	288	1	4	101	4	101			1
MMRF_1252	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	338	366	1	Pomalidomide/Dexamethasone	Pom-Dex	338	IMID/Steroid	366	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3			3	400	3	400		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	29	1	3	63	3	63	1	2	1
MMRF_1266	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1313	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1313	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	78	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	47	1313	1	39	1079	3	78	1	3	1
MMRF_1266	1	Bortezomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Ixa-Len-Dex	Proteasome/Proteasome/IMID/Steroid	1314	1437	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Ixa-Len-Dex	1	Proteasome/IMID/Steroid	1437	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	78	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	5	124	0	39	1079	3	78			1
MMRF_1266	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1438	1632	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Ixa-Len-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	1632	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	78	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	7	195	0	39	1079	3	78			1
MMRF_1266	2	Pomalidomide	Pom	IMID	2269	2644	1	Pomalidomide	Pom	2269	IMID	2644	IMIDs-based	IMIDs-based	Pom-Dex				0					3	2392	3	2392		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	376	1	5	124	5	124	1	1	1
MMRF_1266	9	Daratumumab	Dar	CD38	2269	2644	1	Daratumumab	Dar	2269	CD38	2644	daratumumab-based	daratumumab-based	Dar				0														0	0	0	0	14	376	0							1
MMRF_1267	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	183	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	183	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3	1080		3	84	3	84	183	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	183	1	3	84	3	84	1	3	1
MMRF_1267	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	191	224	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	191	Proteasome/IMID/Steroid	224	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	371	Stem cell, Autologous	2	1	Disease progression/Relapse	3	1080		3	330	3	330	576	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	34	1	5	140	5	140	1	3	1
MMRF_1267	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	191	224	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	191	Proteasome/IMID/Steroid	224	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	235	Stem cell, Autologous	1	1	Disease progression/Relapse	3	1080		3	330	3	330	576	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	2	34	1	5	140	5	140			1
MMRF_1267	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	472	1066	2	Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Bor-Len-Dex	191	Proteasome/IMID/Steroid	1066	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Bor-Len-Car-Dex				1	Disease progression/Relapse	3	1080		3	330	3	330	576	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	595	0	5	140	5	140			1
MMRF_1267	3	Pomalidomide/Bendamustine/Dexamethasone	Pom-Bend-Dex	IMID/Chemotherapy/Steroid	901	945	1	Pomalidomide/Bendamustine/Dexamethasone	Pom-Bend-Dex	901	IMID/Chemotherapy/Steroid	945	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3	1080											0	0	0	0	2	45	0					1	3	1
MMRF_1267	4	Carmustine/Melphalan	Carm-Mel	Chemotherapy/Chemotherapy	945	963	1	Carmustine/Melphalan	Carm-Mel	945	Chemotherapy	963	Other therapies	Other treatments		962	Stem cell, Autologous	3	1	Disease progression/Relapse	3	1080											0	0	0	0	1	19	0					1	2	1
MMRF_1267	5	Pomalidomide	Pom	IMID	985	1009	1	Pomalidomide	Pom	985	IMID	1009	IMIDs-based	IMIDs-based	Pom-Dex				0			1080				5	996	1080	Stable Disease	SD			0	1	0	1	1	25	0	1	12			1	1	1
MMRF_1267	5	Pomalidomide/Nivolumab	Pom-Niv	IMID/Checkpoint Inhibitor	1010	1016	2	Pomalidomide + Pomalidomide/Nivolumab	Pom + Pom-Niv	985	IMID/Checkpoint Inhibitor	1016	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3	1080				5	996	1080	Stable Disease	SD			0	0	0	0	1	7	0	1	12					1
MMRF_1267	9	Daratumumab	Dar	CD38	1036	1065	1	Daratumumab	Dar	1036	CD38	1065	daratumumab-based	daratumumab-based	Dar				0			1080											0	0	0	0	1	30	0							1
MMRF_1267	9	Bortezomib/Daratumumab/Thalidomide/Dexamethasone/Doxorubicin	Bor-Dar-Thal-Dex-Dox	Proteasome/CD38/IMID/Steroid/Chemotherapy	1066	1066	2	Daratumumab + Bortezomib/Daratumumab/Thalidomide/Dexamethasone/Doxorubicin	Dar + Bor-Dar-Thal-Dex-Dox	1036	CD38/Proteasome/IMID/Steroid/Chemotherapy	1066	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Thal-Dex-Dox				0	Disease progression/Relapse	3	1080											0	0	0	0	0	1	0					1	5	1
MMRF_1267	9	Bortezomib/Thalidomide/Dexamethasone/Doxorubicin	Bor-Thal-Dex-Dox	Proteasome/IMID/Steroid/Chemotherapy	1067	1094	3	Daratumumab + Bortezomib/Daratumumab/Thalidomide/Dexamethasone/Doxorubicin + Bortezomib/Thalidomide/Dexamethasone/Doxorubicin	Dar + Bor-Dar-Thal-Dex-Dox + Bor-Thal-Dex-Dox	1036	CD38/Proteasome/IMID/Steroid/Chemotherapy	1094	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Thal-Dex-Dox				0	Disease progression/Relapse	3	1080											0	0	0	0	1	28	0							1
MMRF_1275	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	1	391	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	391	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	401	Stem cell, Autologous	1	1	Completed regimen	4			4	89	3	120	505	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	391	1	5	120	4	89	1	5	1
MMRF_1275	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	557	637	1	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	557	Proteasome/IMID/Steroid	637	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0							5	557	620	Stable Disease	SD			0	1	0	1	3	81	0	1	1			1	3	1
MMRF_1275	2	Bortezomib/Carfilzomib/Pomalidomide/Dexamethasone	Bor-Car-Pom-Dex	Proteasome/Proteasome/IMID/Steroid	638	663	2	Bortezomib/Pomalidomide/Dexamethasone + Bortezomib/Carfilzomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex + Bor-Car-Pom-Dex	557	Proteasome/IMID/Steroid	663	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3					5	557	620	Stable Disease	SD			0	0	0	0	1	26	0	1	1					1
MMRF_1275	3	Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dox	Proteasome/Chemotherapy/Chemotherapy	663	694	1	Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dox	663	Proteasome/Chemotherapy	694	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1														0	0	0	0	1	32	0					1	3	1
MMRF_1275	3	Bortezomib/Cyclophosphamide/Bendamustine/Doxorubicin	Bor-Cyc-Bend-Dox	Proteasome/Chemotherapy/Chemotherapy/Chemotherapy	695	695	2	Bortezomib/Cyclophosphamide/Doxorubicin + Bortezomib/Cyclophosphamide/Bendamustine/Doxorubicin	Bor-Cyc-Dox + Bor-Cyc-Bend-Dox	663	Proteasome/Chemotherapy	695	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3												0	0	0	0	0	1	0							1
MMRF_1275	3	Bortezomib/Bendamustine	Bor-Bend	Proteasome/Chemotherapy	696	733	3	Bortezomib/Cyclophosphamide/Doxorubicin + Bortezomib/Cyclophosphamide/Bendamustine/Doxorubicin + Bortezomib/Bendamustine	Bor-Cyc-Dox + Bor-Cyc-Bend-Dox + Bor-Bend	663	Proteasome/Chemotherapy	733	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	793	Stem cell, Autologous	2	1	Disease progression/Relapse	3												0	0	0	0	2	38	0							1
MMRF_1280	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	36	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	36	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	139	3	408	331	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	36	0	15	408	5	139	1	3	1
MMRF_1280	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	37	349	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	349	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	139	3	408	331	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	11	313	1	15	408	5	139			1
MMRF_1280	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Mel-Dex	Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	350	350	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	350	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	139	3	408	331	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	15	408	5	139			1
MMRF_1280	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	351	351	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	351	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	351	Stem cell, Autologous	1	1	Completed regimen	4			4	139	3	408	331	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	15	408	5	139			1
MMRF_1280	1	Bortezomib	Bor	Proteasome	589	645	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid/IMID	645	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	139	3	408	331	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	57	0	15	408	5	139			1
MMRF_1280	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	997	1023	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	997	Chemotherapy/Steroid	1023	Other therapies	Other treatments					0							5	1039	1221	Stable Disease	SD			0	0	0	0	1	27	0	2	43					1
MMRF_1280	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1024	1129	2	Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Cyc-Dex + Bor-Cyc-Dex	997	Chemotherapy/Steroid/Proteasome	1129	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0							5	1039	1221	Stable Disease	SD			0	1	0	1	4	106	0	2	43			1	3	1
MMRF_1280	2	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1130	1130	3	Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Cyc-Dex + Bor-Cyc-Dex + Bor-Thal-Cyc-Dex	997	Chemotherapy/Steroid/Proteasome/IMID	1130	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Cyc-Dex				0	Patient decision	6					5	1039	1221	Stable Disease	SD			0	0	0	0	0	1	0	2	43					1
MMRF_1280	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1131	1193	4	Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Cyc-Dex + Bor-Cyc-Dex + Bor-Thal-Cyc-Dex + Bor-Cyc-Dex	997	Chemotherapy/Steroid/Proteasome/IMID	1193	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Thal-Cyc-Dex				0	Lack of response	1					5	1039	1221	Stable Disease	SD			0	0	0	0	3	63	0	2	43					1
MMRF_1280	3	Daratumumab	Dar	CD38	1235	1900	1	Daratumumab	Dar	1235	CD38	1900	daratumumab-based	daratumumab-based	Dar				0	Completed regimen	4					5	1347	1494	Stable Disease	SD			0	1	0	1	24	666	0	5	113					1
MMRF_1280	4	Bortezomib	Bor	Proteasome	1522	1935	1	Bortezomib	Bor	1522	Proteasome	1935	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4					5	1606		Stable Disease	SD			0	1	0	1	15	414	0	4	85			1	1	1
MMRF_1280	5	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	2089	2093	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	2089	Chemotherapy/Steroid	2093	Other therapies	Other treatments					0	Completed regimen	4			4	2544	3	2920		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	5	0	30	832	17	456			1
MMRF_1280	9	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2256	2608	1	Carfilzomib/Dexamethasone	Car-Dex	2256	Proteasome/Steroid	2608	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3												0	0	0	0	13	353	0					1	2	1
MMRF_1280	9	REGN5458	REGN5458	BCMA	2773	2920	2	Carfilzomib/Dexamethasone + REGN5458	Car-Dex + REGN5458	2256	Proteasome/Steroid/BCMA	2920	Carfilzomib-based	Other treatments	Other Cafilzomib-based therapies				0														0	0	0	0	6	148	0							1
MMRF_1308	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	25	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	25	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	102	3	172	271	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	25	0	7	172	4	102	1	3	1
MMRF_1308	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	26	102	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	102	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			4	102	3	172	271	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	77	1	7	172	4	102			1
MMRF_1308	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	103	232	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	232	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	102	3	172	271	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	130	0	7	172	4	102			1
MMRF_1308	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	283	353	1	Pomalidomide/Dexamethasone	Pom-Dex	283	IMID/Steroid	353	IMIDs-based	IMIDs-based	Pom-Dex				0							6	344	344	Progressive Disease	PD			0	1	0	1	3	71	0	3	62			1	2	1
MMRF_1308	2	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	354	563	2	Pomalidomide/Dexamethasone + Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Dex + Pom-Cyc-Dex	283	IMID/Steroid/Chemotherapy	563	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3					6	344	344	Progressive Disease	PD			0	0	0	0	8	210	0	3	62					1
MMRF_1308	3	Lenalidomide/Panobinostat/Dexamethasone	Len-Pano-Dex	IMID/HDAC/Steroid	563	1670	1	Lenalidomide/Panobinostat/Dexamethasone	Len-Pano-Dex	563	IMID/HDAC/Steroid	1670	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	1139	4	1139		Partial Response	PR	Partial Response	PR	1	1	1	1	40	1108	1	21	577	21	577	1	3	1
MMRF_1308	4	Carfilzomib	Car	Proteasome	1328	1692	1	Carfilzomib	Car	1328	Proteasome	1692	Carfilzomib-based	Carfilzomib-based	Car-Dex				0					4	1524	1	2168		Complete Response	CR	Partial Response	PR	1	0	1	0	13	365	1	31	841	8	197	1	1	1
MMRF_1308	4	Carfilzomib/Isatuximab/Dexamethasone	Car-Isa-Dex	Proteasome/CD38/Steroid	1693	2911	2	Carfilzomib + Carfilzomib/Isatuximab/Dexamethasone	Car + Car-Isa-Dex	1328	Proteasome/CD38/Steroid	2911	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	1524	1	2168		Complete Response	CR	Partial Response	PR	1	1	0	1	44	1219	0	31	841	8	197			1
MMRF_1307	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1141	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1141	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	93	1	539		Complete Response	CR	Partial Response	PR	1	1	1	1	41	1141	1	20	539	4	93	1	3	1
MMRF_1307	1	Bortezomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Ixa-Len-Dex	Proteasome/Proteasome/IMID/Steroid	1142	1724	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Ixa-Len-Dex	1	Proteasome/IMID/Steroid	1724	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	93	1	539		Complete Response	CR	Partial Response	PR	1	0	0	0	21	583	0	20	539	4	93			1
MMRF_1314	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	1430	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	1430	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	67	1	1430		Complete Response	CR	Partial Response	PR	1	1	1	1	51	1430	1	52	1430	3	67	1	4	1
MMRF_1314	1	Bortezomib	Bor	Proteasome	2712	2929	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Len-Cyc-Dex + Bor	1	Proteasome/IMID/Chemotherapy/Steroid	2929	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0					4	67	1	1430		Complete Response	CR	Partial Response	PR	1	0	0	0	8	218	0	52	1430	3	67			1
MMRF_1314	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	2712	2929	1	Lenalidomide/Dexamethasone	Len-Dex	2712	IMID/Steroid	2929	IMIDs-based	IMIDs-based	Len-Dex				0					1	2929	1	2929		Complete Response	CR	Complete Response	CR	1	1	1	1	8	218	1	8	218	8	218	1	2	1
MMRF_1311	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1010	1261	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1010	Proteasome/IMID/Steroid	1261	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	1291	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	9	252	0					1	3	1
MMRF_1311	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	1450	1452	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Melphalan	Bor-Len-Dex + Bor-Mel	1010	Proteasome/IMID/Steroid/Chemotherapy	1452	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	1454	Stem cell, Autologous	2	1	Completed regimen	4												0	0	0	0	0	3	0							1
MMRF_1311	2	Bortezomib/Fludarabine	Bor-Flu	Proteasome/Chemotherapy	2554	2557	1	Bortezomib/Fludarabine	Bor-Flu	2554	Proteasome/Chemotherapy	2557	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	2559	Stem cell, Allogenic	3	1	Completed regimen	4			4	1108	1	2924		Complete Response	CR	Partial Response	PR	1	1	0	1	0	4	0	14	371	-51	-1445	1	2	1
MMRF_1324	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	322	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	322	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	75	3	75	612	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	12	322	1	3	75	3	75	1	4	1
MMRF_1324	1	Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Cyc-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	323	607	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Pred-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	607	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	75	3	75	612	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	10	285	0	3	75	3	75			1
MMRF_1324	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	608	2540	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	2540	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	75	3	75	612	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	69	1933	0	3	75	3	75			1
MMRF_1324	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	623	773	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	623	Proteasome/Chemotherapy/Steroid	773	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					1	718	1	718	1796	Complete Response	CR	Complete Response	CR	1	1	1	1	6	151	1	4	96	4	96	1	3	1
MMRF_1324	2	Carfilzomib/Cyclophosphamide/Melphalan/Dexamethasone	Car-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	774	774	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Cyclophosphamide/Melphalan/Dexamethasone	Car-Cyc-Dex + Car-Cyc-Mel-Dex	623	Proteasome/Chemotherapy/Steroid	774	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			1	718	1	718	1796	Complete Response	CR	Complete Response	CR	1	0	0	0	0	1	0	4	96	4	96			1
MMRF_1324	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	775	1310	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Cyclophosphamide/Melphalan/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Cyc-Mel-Dex + Car-Cyc-Dex	623	Proteasome/Chemotherapy/Steroid	1310	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	775	Stem cell, Autologous	1	1	Completed regimen	4			1	718	1	718	1796	Complete Response	CR	Complete Response	CR	1	0	0	0	19	536	0	4	96	4	96			1
MMRF_1324	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1311	2427	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Cyclophosphamide/Melphalan/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Car-Cyc-Dex + Car-Cyc-Mel-Dex + Car-Cyc-Dex + Car-Dex	623	Proteasome/Chemotherapy/Steroid	2427	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			1	718	1	718	1796	Complete Response	CR	Complete Response	CR	1	0	0	0	40	1117	0	4	96	4	96			1
MMRF_1345	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	94	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	94	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	73	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	94	1	6	155	3	73	1	3	1
MMRF_1345	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	95	218	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	218	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	219	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	73	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	124	0	6	155	3	73			1
MMRF_1345	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	911	1085	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	911	Proteasome/Chemotherapy/Steroid	1085	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	981	3	1086	911	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	175	1	7	176	3	71	1	3	1
MMRF_1345	2	Bortezomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1086	1598	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Pom-Cyc-Dex	911	Proteasome/Chemotherapy/Steroid/IMID	1598	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc-Dex				0	Disease progression/Relapse	3			4	981	3	1086	911	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	19	513	0	7	176	3	71			1
MMRF_1345	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1674	1751	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1674	CD38/IMID/Steroid	1751	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3			4	1716	4	1716		Partial Response	PR	Partial Response	PR	1	1	1	1	3	78	1	2	43	2	43	1	3	1
MMRF_1345	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1774	1810	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1774	Proteasome/IMID/Steroid	1810	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	1793	1793	Progressive Disease	PD			0	1	0	1	2	37	0	1	20			1	3	1
MMRF_1345	5	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1819	1823	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	1819	Chemotherapy/Steroid	1823	Other therapies	Other treatments					0	Disease progression/Relapse	3			4	1926	4	1926		Partial Response	PR	Partial Response	PR	1	0	0	0	0	5	0	4	108	4	108			1
MMRF_1345	9	Pomalidomide/Nivolumab	Pom-Niv	IMID/Checkpoint Inhibitor	1828	1925	1	Pomalidomide/Nivolumab	Pom-Niv	1828	IMID/Checkpoint Inhibitor	1925	IMIDs-based	IMIDs-based	Other Pom-based therapies				0														0	0	0	0	4	98	0					1	2	1
MMRF_1345	9	Daratumumab/Pomalidomide/Nivolumab	Dar-Pom-Niv	CD38/IMID/Checkpoint Inhibitor	1926	2881	2	Pomalidomide/Nivolumab + Daratumumab/Pomalidomide/Nivolumab	Pom-Niv + Dar-Pom-Niv	1828	IMID/Checkpoint Inhibitor/CD38	2881	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Niv				0														0	0	0	0	34	956	0							1
MMRF_1352	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	189	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	189	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	87	3	542		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	7	189	1	20	542	4	87	1	3	1
MMRF_1352	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	190	218	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	218	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	87	3	542		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	29	0	20	542	4	87			1
MMRF_1352	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	219	233	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	233	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	267	Stem cell, Autologous	1	1	Completed regimen	4			4	87	3	542		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	15	0	20	542	4	87			1
MMRF_1352	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	374	1515	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1515	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	87	3	542		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	41	1142	0	20	542	4	87			1
MMRF_1354	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	389	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	389	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			3	103	1	204	389	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	14	389	1	8	204	4	103	1	4	1
MMRF_1354	2	Elotuzumab/Prednisone	Elo-Pred	SLAMF7/Steroid	1089	1174	1	Elotuzumab/Prednisone	Elo-Pred	1089	SLAMF7/Steroid	1174	Other therapies	Other treatments					0					3	467	1	651		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	86	0	-15	-437	-22	-621			1
MMRF_1354	2	Elotuzumab/Lenalidomide/Prednisone	Elo-Len-Pred	SLAMF7/IMID/Steroid	1175	2905	2	Elotuzumab/Prednisone + Elotuzumab/Lenalidomide/Prednisone	Elo-Pred + Elo-Len-Pred	1089	SLAMF7/Steroid/IMID	2905	IMIDs-based	IMIDs-based	Other Len-based therapies				0					3	467	1	651		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	62	1731	0	-15	-437	-22	-621	1	3	1
MMRF_1089	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	546	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	546	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	149	3	149		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	20	546	1	6	149	6	149	1	2	1
MMRF_1089	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	547	547	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	547	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	149	3	149		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	6	149	6	149			1
MMRF_1089	1	Lenalidomide	Len	IMID	548	1333	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	1333	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					3	149	3	149		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	28	786	0	6	149	6	149			1
MMRF_1387	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_1389	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	78	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	78	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	183	Stem cell, Autologous	1	1	Completed regimen	4			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	78	1	4	92	4	92	1	3	1
MMRF_1391	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	148	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	148	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	162	Stem cell, Autologous	1	1	PT MOVING TO FLORIDA.				3	87	1	518		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	6	148	1	19	518	4	87	1	3	1
MMRF_1391	1	Lenalidomide	Len	IMID	1026	1031	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1031	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	87	1	518		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	6	0	19	518	4	87			1
MMRF_1446	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	105	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	105	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	182	4	182	438	Partial Response	PR	Partial Response	PR	1	0	0	0	4	105	0	7	182	7	182	1	3	1
MMRF_1446	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	106	189	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	189	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1					4	182	4	182	438	Partial Response	PR	Partial Response	PR	1	1	1	1	3	84	1	7	182	7	182			1
MMRF_1446	1	Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Thal-Cyc-Dex	Proteasome/Proteasome/IMID/IMID/Chemotherapy/Steroid	190	239	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	239	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3			4	182	4	182	438	Partial Response	PR	Partial Response	PR	1	0	0	0	2	50	0	7	182	7	182			1
MMRF_1446	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	240	344	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	344	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	182	4	182	438	Partial Response	PR	Partial Response	PR	1	0	0	0	4	105	0	7	182	7	182			1
MMRF_1446	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Car-Len-Cyc-Mel-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	345	345	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/C	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	345	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	182	4	182	438	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	7	182	7	182			1
MMRF_1446	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	346	346	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/C	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Cyc-Mel-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	346	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	346	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	182	4	182	438	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	7	182	7	182			1
MMRF_1446	2	Pomalidomide/Ricolinostat/Dexamethasone	Pom-Roc-Dex	IMID/HDAC/Steroid	805	1682	1	Pomalidomide/Ricolinostat/Dexamethasone	Pom-Roc-Dex	805	IMID/HDAC/Steroid	1682	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2			4	891	3	1234	812	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	32	878	1	16	430	4	87	1	3	1
MMRF_1450	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	16	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	16	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DEATH													0	0	0	0	1	16	0					1	2	1
MMRF_1455	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	140	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	140	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	147	Stem cell, Autologous	1	1	Completed regimen	4			3	55	1	2745		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	140	1	99	2745	2	55	1	3	1
MMRF_1455	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	247	2835	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2835	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	55	1	2745		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	93	2589	0	99	2745	2	55			1
MMRF_1454	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	159	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	159	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	161	Stem cell, Autologous	1	1	Completed regimen	4			3	134	3	134		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	159	1	5	134	5	134	1	3	1
MMRF_1454	1	Bortezomib	Bor	Proteasome	337	524	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	524	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Completed regimen	4			3	134	3	134		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	188	0	5	134	5	134			1
MMRF_1474	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	204	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	204	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	85	3	183	1173	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	204	1	7	183	4	85	1	2	1
MMRF_1474	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	205	205	2	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Dex + Bor-Mel-Dex	1	Proteasome/Steroid/Chemotherapy	205	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	205	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	183	1173	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	7	183	4	85			1
MMRF_1474	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	206	388	3	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Mel-Dex + Bor-Dex	1	Proteasome/Steroid/Chemotherapy	388	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					4	85	3	183	1173	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	183	0	7	183	4	85			1
MMRF_1474	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	389	947	4	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Mel-Dex + Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/Chemotherapy/IMID	947	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	85	3	183	1173	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	20	559	0	7	183	4	85			1
MMRF_1474	1	Lenalidomide	Len	IMID	948	1030	5	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Mel-Dex + Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/Chemotherapy/IMID	1030	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	85	3	183	1173	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	83	0	7	183	4	85			1
MMRF_1474	2	Daratumumab/Atezolizumab	Dar-Atez	CD38/Checkpoint Inhibitor	1187	1457	1	Daratumumab/Atezolizumab	Dar-Atez	1187	CD38/Checkpoint Inhibitor	1457	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0	Patient decision	6					5	1244	1604	Stable Disease	SD			0	1	0	1	10	271	0	3	58					1
MMRF_1474	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1691	2930	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1691	Proteasome/IMID/Steroid	2930	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	1786	4	1786	1691	Partial Response	PR	Partial Response	PR	1	1	1	1	45	1240	1	4	96	4	96	1	3	1
MMRF_1479	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	190	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	205	Stem cell, Autologous	1	1	Completed regimen	4			4	55	3	255		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	190	1	10	255	2	55	1	3	1
MMRF_1479	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	314	1166	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1166	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	55	3	255		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	31	853	0	10	255	2	55			1
MMRF_1479	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1185	1254	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1185	Proteasome/IMID/Steroid	1254	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3					5	1185	1240	Stable Disease	SD			0	1	0	1	3	70	0	1	1			1	3	1
MMRF_1479	3	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone	Car-Dar-Pom-Tram-Dex	Proteasome/CD38/IMID/MEK/Steroid	1272	1697	1	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone	Car-Dar-Pom-Tram-Dex	1272	Proteasome/CD38/IMID/MEK/Steroid	1697	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3			1	1612	1	1612	1688	Complete Response	CR	Complete Response	CR	1	1	1	1	16	426	1	13	341	13	341	1	5	1
MMRF_1479	3	Pomalidomide	Pom	IMID	1698	1712	2	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone + Pomalidomide	Car-Dar-Pom-Tram-Dex + Pom	1272	Proteasome/CD38/IMID/MEK/Steroid	1712	combined daratumumab/IMIDs/carfilzomib-based	IMIDs-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0					1	1612	1	1612	1688	Complete Response	CR	Complete Response	CR	1	0	0	0	1	15	0	13	341	13	341			1
MMRF_1479	3	Pomalidomide/Trametinib	Pom-Tram	IMID/MEK	1713	1912	3	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone + Pomalidomide + Pomalidomide/Trametinib	Car-Dar-Pom-Tram-Dex + Pom + Pom-Tram	1272	Proteasome/CD38/IMID/MEK/Steroid	1912	combined daratumumab/IMIDs/carfilzomib-based	IMIDs-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3			1	1612	1	1612	1688	Complete Response	CR	Complete Response	CR	1	0	0	0	7	200	0	13	341	13	341			1
MMRF_1502	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	47	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	47	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	219	Stem cell, Autologous	1	1	Completed regimen	4			3	93	1	289	792	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	2	47	1	11	289	4	93	1	3	1
MMRF_1502	1	Bortezomib	Bor	Proteasome	368	764	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	764	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Disease progression/Relapse	3			3	93	1	289	792	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	14	397	0	11	289	4	93			1
MMRF_1502	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	812	1182	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	812	SLAMF7/IMID/Steroid	1182	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	912	4	912		Partial Response	PR	Partial Response	PR	1	1	1	1	14	371	1	4	101	4	101	1	3	1
MMRF_1502	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1130	1197	1	Pomalidomide/Dexamethasone	Pom-Dex	1130	IMID/Steroid	1197	IMIDs-based	IMIDs-based	Pom-Dex				0							5	1254	1149	Stable Disease	SD			0	0	0	0	3	68	0	5	125			1	2	1
MMRF_1502	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1198	1283	2	Pomalidomide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Pom-Dex + Dar-Pom-Dex	1130	IMID/Steroid/CD38	1283	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					5	1254	1149	Stable Disease	SD			0	1	0	1	3	86	0	5	125					1
MMRF_1502	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1284	1311	3	Pomalidomide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Pom-Dex + Dar-Pom-Dex	1130	IMID/Steroid/CD38	1311	combined daratumumab/IMIDs-based	IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					5	1254	1149	Stable Disease	SD			0	0	0	0	1	28	0	5	125					1
MMRF_1502	4	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1346	1402	1	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	1346	Proteasome/CD38/IMID/Steroid	1402	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0							5	1499		Stable Disease	SD			0	0	0	0	2	57	0	6	154			1	4	1
MMRF_1502	4	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone	Car-Dar-Pom-Tram-Dex	Proteasome/CD38/IMID/MEK/Steroid	1403	1403	2	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone	Car-Dar-Pom-Dex + Car-Dar-Pom-Tram-Dex	1346	Proteasome/CD38/IMID/Steroid/MEK	1403	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3					5	1499		Stable Disease	SD			0	0	0	0	0	1	0	6	154					1
MMRF_1502	4	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1404	1620	3	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex + Car-Dar-Pom-Tram-Dex + Car-Dar-Pom-Dex	1346	Proteasome/CD38/IMID/Steroid/MEK	1620	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0							5	1499		Stable Disease	SD			0	1	0	1	8	217	0	6	154					1
MMRF_1510	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	726	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	726	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	84	3	84		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	26	726	1	3	84	3	84	1	3	1
MMRF_1510	1	Lenalidomide	Len	IMID	727	1447	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1447	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Patient decision	6			3	84	3	84		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	26	721	0	3	84	3	84			1
MMRF_1510	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1470	1671	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1470	Proteasome/Chemotherapy/Steroid	1671	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1745	Stem cell, Autologous	1	1	Completed regimen	4			3	1725	2	2075	1472	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	8	202	1	22	606	10	256	1	3	1
MMRF_1510	3	Venetoclax	Vent	BCL2	2283	2436	1	Venetoclax	Vent	2283	BCL2	2436	Other therapies	Other treatments					0	Disease progression/Relapse	3			2	2383	2	2383	2508	Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	6	154	1	4	101	4	101			1
MMRF_1510	4	Carfilzomib/Daratumumab/Pomalidomide	Car-Dar-Pom	Proteasome/CD38/IMID	2551	2934	1	Carfilzomib/Daratumumab/Pomalidomide	Car-Dar-Pom	2551	Proteasome/CD38/IMID	2934	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0					2	2731	2	2731		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	14	384	1	7	181	7	181	1	3	1
MMRF_1513	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	889	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	889	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	906	Stem cell, Autologous	1	1	Disease progression/Relapse	3			3	80	1	169	889	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	32	889	1	7	169	3	80	1	3	1
MMRF_1513	2	Ixazomib	Ixa	Proteasome	1022	1639	1	Ixazomib	Ixa	1022	Proteasome	1639	Other therapies	Other treatments					0	Disease progression/Relapse	3			3	996	1	1058	1605	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	22	618	0	2	37	0	-25			1
MMRF_1513	3	Daratumumab/Atezolizumab	Dar-Atez	CD38/Checkpoint Inhibitor	1646	1717	1	Daratumumab/Atezolizumab	Dar-Atez	1646	CD38/Checkpoint Inhibitor	1717	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	1703	1703	Progressive Disease	PD			0	1	0	1	3	72	0	3	58					1
MMRF_1513	4	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1722	1722	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	1722	Chemotherapy/Steroid	1722	Other therapies	Other treatments					0	Completed regimen	4			3	1780	3	1780	1948	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	59	3	59			1
MMRF_1513	4	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1757	1816	2	Cyclophosphamide/Dexamethasone + Pomalidomide/Dexamethasone	Cyc-Dex + Pom-Dex	1722	Chemotherapy/Steroid/IMID	1816	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3			3	1780	3	1780	1948	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	60	1	3	59	3	59	1	2	1
MMRF_1516	1	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	1	1175	1	Lenalidomide/Prednisone	Len-Pred	1	IMID/Steroid	1175	IMIDs-based	IMIDs-based	Other Len-based therapies				0					3	94	3	94		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	42	1175	1	4	94	4	94	1	2	1
MMRF_1622	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	305	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	305	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	119	2	2030		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	11	305	1	73	2030	5	119	1	4	1
MMRF_1622	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Mel-Dex	Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	306	306	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	306	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	119	2	2030		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	1	0	73	2030	5	119			1
MMRF_1622	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	307	637	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	637	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	307	Stem cell, Autologous	1	1					4	119	2	2030		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	12	331	0	73	2030	5	119			1
MMRF_1622	1	Bortezomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Pom-Cyc-Dex	Proteasome/IMID/IMID/Chemotherapy/Steroid	638	638	4	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex + Bor-Len-Pom-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	638	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Lack of response	1			4	119	2	2030		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	1	0	73	2030	5	119			1
MMRF_1622	1	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	639	2898	5	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Pomalidomide/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex + Bor-Len-Pom-Cyc-Dex + Pom-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	2898	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	119	2	2030		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	81	2260	0	73	2030	5	119			1
MMRF_1628	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	404	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	404	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	103	4	103		Partial Response	PR	Partial Response	PR	1	1	1	1	15	404	1	4	103	4	103	1	2	1
MMRF_1628	1	Carfilzomib/Lenalidomide/Prednisone	Car-Len-Pred	Proteasome/IMID/Steroid	430	1027	2	Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Prednisone	Len-Dex + Car-Len-Pred	1	IMID/Steroid/Proteasome	1027	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	103	4	103		Partial Response	PR	Partial Response	PR	1	0	0	0	22	598	0	4	103	4	103			1
MMRF_1628	2	Carfilzomib	Car	Proteasome	1028	1061	1	Carfilzomib	Car	1028	Proteasome	1061	Carfilzomib-based	Carfilzomib-based	Car-Dex	1159	Stem cell, Autologous	1	1	Completed regimen	4			4	493	3	691	1050	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	34	0	-12	-336	-19	-534	1	1	1
MMRF_1628	3	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone	Car-Dar-Pom-Tram-Dex	Proteasome/CD38/IMID/MEK/Steroid	1560	1715	1	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Dexamethasone	Car-Dar-Pom-Tram-Dex	1560	Proteasome/CD38/IMID/MEK/Steroid	1715	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Adverse Event or co-morbidity	2					6	1683	1683	Progressive Disease	PD			0	1	0	1	6	156	0	5	124			1	5	1
MMRF_1628	4	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1748	1762	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1748	Proteasome/IMID/Steroid	1762	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4					5	1790	2188	Stable Disease	SD			0	1	0	1	1	15	0	2	43			1	3	1
MMRF_1634	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	16	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	16	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DEATH													0	0	0	0	1	16	0					1	3	1
MMRF_1637	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	205	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	205	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1			1272		4	186	3	430		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	8	205	1	16	430	7	186	1	3	1
MMRF_1637	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	206	206	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	206	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4	1272		4	186	3	430		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	16	430	7	186			1
MMRF_1637	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	207	596	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	596	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	207	Stem cell, Autologous	1	1	Disease progression/Relapse	3	1272		4	186	3	430		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	14	390	0	16	430	7	186			1
MMRF_1637	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	597	621	1	Pomalidomide/Dexamethasone	Pom-Dex	597	IMID/Steroid	621	IMIDs-based	IMIDs-based	Pom-Dex				0	Patient decision	6	1272				5	621	719	Stable Disease	SD			0	1	0	1	1	25	0	1	25			1	2	1
MMRF_1637	2	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	662	719	2	Pomalidomide/Dexamethasone + Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Dex + Pom-Cyc-Dex	597	IMID/Steroid/Chemotherapy	719	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3	1272				5	621	719	Stable Disease	SD			0	0	0	0	2	58	0	1	25					1
MMRF_1637	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	721	963	1	Carfilzomib/Dexamethasone	Car-Dex	721	Proteasome/Steroid	963	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			1272											0	0	0	0	9	243	0					1	2	1
MMRF_1637	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	964	1073	2	Carfilzomib/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Car-Dex + Car-Pom-Dex	721	Proteasome/Steroid/IMID	1073	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1272											0	0	0	0	4	110	0							1
MMRF_1637	5	Daratumumab/Pomalidomide/Panobinostat	Dar-Pom-Pano	CD38/IMID/HDAC	1272	1432	1	Daratumumab/Pomalidomide/Panobinostat	Dar-Pom-Pano	1272	CD38/IMID/HDAC	1432	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Pano				0			1272		4	1335	2	2531	1272	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	6	161	1	45	1260	3	64	1	3	1
MMRF_1637	5	Panobinostat	Pano	HDAC	1289	1346	2	Daratumumab/Pomalidomide/Panobinostat	Dar-Pom-Pano	1272	CD38/IMID/HDAC	1346	combined daratumumab/IMIDs-based	Other treatments	Dar-Pom-Pano				0	Adverse Event or co-morbidity	2	1272		4	1335	2	2531	1272	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	2	58	1	45	1260	3	64			1
MMRF_1637	5	Carfilzomib/Daratumumab/Pomalidomide/Panobinostat/Venetoclax	Car-Dar-Pom-Pano-Vent	Proteasome/CD38/IMID/HDAC/BCL2	1433	1510	3	Daratumumab/Pomalidomide/Panobinostat + Carfilzomib/Daratumumab/Pomalidomide/Panobinostat/Venetoclax	Dar-Pom-Pano + Car-Dar-Pom-Pano-Vent	1272	CD38/IMID/HDAC/Proteasome/BCL2	1510	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3	1272		4	1335	2	2531	1272	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	3	78	0	45	1260	3	64			1
MMRF_1637	9	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	1510	1517	1	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	1510	Chemotherapy/Steroid	1517	Other therapies	Other treatments					1	Completed regimen	4	1272											0	0	0	0	1	8	0							1
MMRF_1637	9	Carmustine/Melphalan	Carm-Mel	Chemotherapy/Chemotherapy	1566	1567	2	Cyclophosphamide/Dexamethasone/Doxorubicin + Carmustine/Melphalan	Cyc-Dex-Dox + Carm-Mel	1510	Chemotherapy/Steroid	1567	Other therapies	Other treatments		1569	Stem cell, Autologous	2	1	Completed regimen	4	1272											0	0	0	0	0	2	0					1	2	1
MMRF_1643	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	632	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	632	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	106	3	311		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	23	632	1	12	311	4	106	1	3	1
MMRF_1648	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	58	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	58	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0							5	58		Stable Disease	SD			0	1	0	1	2	58	0	3	58			1	3	1
MMRF_1665	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	308	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	308	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	295	3	551		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	11	308	1	20	551	11	295	1	4	1
MMRF_1665	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Mel-Dex	Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	309	309	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	309	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	310	Stem cell, Autologous	1	1	Completed regimen	4			4	295	3	551		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	20	551	11	295			1
MMRF_1665	1	Bortezomib/Lenalidomide/Prednisone	Bor-Len-Pred	Proteasome/IMID/Steroid	432	932	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Prednisone	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Pred	1	Proteasome/IMID/Chemotherapy/Steroid	932	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	295	3	551		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	18	501	0	20	551	11	295			1
MMRF_1665	1	Ixazomib	Ixa	Proteasome	936	1016	4	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Prednisone + Ixazomib	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Pred + Ixa	1	Proteasome/IMID/Chemotherapy/Steroid	1016	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	295	3	551		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	81	0	20	551	11	295			1
MMRF_1665	1	Carfilzomib	Car	Proteasome	1648	1674	5	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Prednisone + Ixazomib + Carfilzomib	Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Pred + Ixa + Car	1	Proteasome/IMID/Chemotherapy/Steroid	1674	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2			4	295	3	551		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	27	0	20	551	11	295			1
MMRF_1665	2	Carfilzomib	Car	Proteasome	1675	1774	1	Carfilzomib	Car	1675	Proteasome	1774	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	POOR TOLERANCE				4	1695	4	1695		Partial Response	PR	Partial Response	PR	1	1	1	1	4	100	1	1	21	1	21	1	1	1
MMRF_1677	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	147	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	147	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	147	1	21	574	5	132	1	3	1
MMRF_1677	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	148	175	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	28	0	21	574	5	132			1
MMRF_1677	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	176	217	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	217	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	42	0	21	574	5	132			1
MMRF_1677	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	218	218	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	218	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	21	574	5	132			1
MMRF_1677	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	219	273	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	273	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	55	0	21	574	5	132			1
MMRF_1677	1	Melphalan/Doxorubicin	Mel-Dox	Chemotherapy/Chemotherapy	300	300	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Melphalan/Doxorubicin	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex + Mel-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	300	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	301	Stem cell, Autologous	1	1	Completed regimen	4			4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	21	574	5	132			1
MMRF_1677	1	Elotuzumab/Dexamethasone	Elo-Dex	SLAMF7/Steroid	1121	1135	7	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Melphalan/Doxorubicin + Elotuzumab/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex + Mel-Dox + Elo-Dex	1	Proteasome/IMID/Steroid/Chemotherapy/SLAMF7	1135	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	15	0	21	574	5	132			1
MMRF_1677	1	Elotuzumab	Elo	SLAMF7	1136	1282	8	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Melphalan/Doxorubicin + Elotuzumab/Dexamethasone + Elotuzumab	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex + Mel-Dox + Elo-Dex + Elo	1	Proteasome/IMID/Steroid/Chemotherapy/SLAMF7	1282	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	147	0	21	574	5	132			1
MMRF_1677	1	Bortezomib/Venetoclax/Dexamethasone	Bor-Vent-Dex	Proteasome/BCL2/Steroid	1375	2017	9	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Melphalan/Doxorubicin + Elotuzumab/Dexamethasone + Elotuzumab + Bortez	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex + Mel-Dox + Elo-Dex + Elo + Bor-Vent-Dex	1	Proteasome/IMID/Steroid/Chemotherapy/SLAMF7/BCL2	2017	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	132	3	574		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	23	643	0	21	574	5	132			1
MMRF_1686	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	84	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	84	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	261	3	1192		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	84	0	43	1192	10	261	1	3	1
MMRF_1686	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	85	172	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	172	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	ADMITTED FOR C2 FRACTURE, TREATMENT PUT ON HOLD.				4	261	3	1192		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	88	0	43	1192	10	261			1
MMRF_1686	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	173	214	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	214	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex	225	Stem cell, Autologous	1	1	PATIENT HAD TRANSPLANT.				4	261	3	1192		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	2	42	1	43	1192	10	261			1
MMRF_1686	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	275	380	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	380	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	9/10 MATCHED UNRELATED DONOR IDENTIFIED.	9			4	261	3	1192		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	106	0	43	1192	10	261			1
MMRF_1710	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	235	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	235	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	98	3	98		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	235	1	4	98	4	98	1	3	1
MMRF_1710	1	Bortezomib	Bor	Proteasome	253	579	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	579	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	98	3	98		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	327	0	4	98	4	98			1
MMRF_1710	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	580	617	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	617	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	98	3	98		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	38	0	4	98	4	98			1
MMRF_1710	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	618	796	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor + Bor-Len + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	796	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	98	3	98		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	179	0	4	98	4	98			1
MMRF_1698	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	60	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	60	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	129	Stem cell, Autologous	1	1	Completed regimen	4			4	270	3	466		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	60	0	17	466	10	270	1	3	1
MMRF_1698	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	204	270	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	270	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	270	3	466		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	67	1	17	466	10	270			1
MMRF_1698	1	Lenalidomide	Len	IMID	271	900	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	900	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	270	3	466		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	23	630	0	17	466	10	270			1
MMRF_1746	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	153	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	153	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	161	Stem cell, Autologous	1	1	Completed regimen	4			3	138	1	365		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	153	1	14	365	5	138	1	3	1
MMRF_1746	1	Lenalidomide	Len	IMID	274	1007	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1007	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	138	1	365		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	27	734	0	14	365	5	138			1
MMRF_1744	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	29	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	29	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0			1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	0	0	0	1	29	0	18	503	18	503	1	3	1
MMRF_1744	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Thal-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	30	64	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox	1	Proteasome/Chemotherapy/Steroid/IMID	64	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	0	0	0	2	35	0	18	503	18	503			1
MMRF_1744	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	65	119	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	119	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0			1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	0	0	0	2	55	0	18	503	18	503			1
MMRF_1744	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	120	726	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	726	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0			1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	1	1	1	22	607	1	18	503	18	503			1
MMRF_1744	1	Bortezomib/Elotuzumab/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Elo-Len-Cyc-Dex	Proteasome/SLAMF7/IMID/Chemotherapy/Steroid	727	854	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Elo-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/SLAMF7	854	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	0	0	0	5	128	0	18	503	18	503			1
MMRF_1744	1	Bortezomib/Elotuzumab/Cyclophosphamide/Dexamethasone	Bor-Elo-Cyc-Dex	Proteasome/SLAMF7/Chemotherapy/Steroid	855	867	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzum	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Elo-Len-Cyc-Dex + Bor-Elo-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/SLAMF7	867	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	0	0	0	1	13	0	18	503	18	503			1
MMRF_1744	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	868	874	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzum	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex-Dox + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Elo-Len-Cyc-Dex + Bor-Elo-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/SLAMF7	874	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1722		4	503	4	503	846	Partial Response	PR	Partial Response	PR	1	0	0	0	1	7	0	18	503	18	503			1
MMRF_1744	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	875	1074	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	875	CD38/IMID/Steroid	1074	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0			1722				5	947	1078	Stable Disease	SD			0	1	0	1	7	200	0	3	73			1	3	1
MMRF_1744	2	Bortezomib/Daratumumab/Pomalidomide/Nelfinavir Mesylate/Dexamethasone	Bor-Dar-Pom-Nel-Dex	Proteasome/CD38/IMID/Steroid	1075	1155	2	Daratumumab/Pomalidomide/Dexamethasone + Bortezomib/Daratumumab/Pomalidomide/Nelfinavir Mesylate/Dexamethasone	Dar-Pom-Dex + Bor-Dar-Pom-Nel-Dex	875	CD38/IMID/Steroid/Proteasome	1155	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1722				5	947	1078	Stable Disease	SD			0	0	0	0	3	81	0	3	73					1
MMRF_1744	3	Carfilzomib/Daratumumab/Venetoclax	Car-Dar-Vent	Proteasome/CD38/BCL2	1155	1532	1	Carfilzomib/Daratumumab/Venetoclax	Car-Dar-Vent	1155	Proteasome/CD38/BCL2	1532	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1722				5	1155	1456	Stable Disease	SD			0	0	0	1	14	378	0	1	1			1	3	1
MMRF_1744	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1156	1156	2	Carfilzomib/Daratumumab/Venetoclax + Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Vent + Dar-Pom-Dex	1155	Proteasome/CD38/BCL2/IMID/Steroid	1156	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3	1722				5	1155	1456	Stable Disease	SD			0	1	0	0	0	1	0	1	1					1
MMRF_1744	4	Carfilzomib/Melphalan	Car-Mel	Proteasome/Chemotherapy	1550	1551	1	Carfilzomib/Melphalan	Car-Mel	1550	Proteasome/Chemotherapy	1551	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1553	Stem cell, Autologous	1	1	Completed regimen	4	1722				6	1644	1644	Progressive Disease	PD			0	1	0	1	0	2	0	4	95			1	2	1
MMRF_1744	5	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1696	1700	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	1696	Chemotherapy/Steroid	1700	Other therapies	Other treatments					0	Completed regimen	4	1722		4	1829	4	1829	1722	Partial Response	PR	Partial Response	PR	1	0	0	0	0	5	0	5	134	5	134			1
MMRF_1744	5	Belantamab mafodotin	Bela	BCMA	1724	1870	2	Cyclophosphamide/Dexamethasone + Belantamab mafodotin	Cyc-Dex + Bela	1696	Chemotherapy/Steroid/BCMA	1870	Other therapies	Other treatments					0	Disease progression/Relapse	3	1722		4	1829	4	1829	1722	Partial Response	PR	Partial Response	PR	1	1	1	1	6	147	1	5	134	5	134			1
MMRF_1744	9	Anti-GPRC5D	Anti-GPRC5D	GPRC5D	1980	2219	1	Anti-GPRC5D	Anti-GPRC5D	1980	GPRC5D	2219	Other therapies	Other treatments					0	Disease progression/Relapse	3	1722											0	0	0	0	9	240	0							1
MMRF_1744	9	Bortezomib/Ixazomib/Selinexor	Bor-Ixa-Sel	Proteasome/Proteasome/XPO1	2226	2326	2	Anti-GPRC5D + Bortezomib/Ixazomib/Selinexor	Anti-GPRC5D + Bor-Ixa-Sel	1980	GPRC5D/Proteasome/XPO1	2326	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1722											0	0	0	0	4	101	0					1	3	1
MMRF_1768	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	147	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	147	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	77	3	77		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	147	1	3	77	3	77	1	3	1
MMRF_1768	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	148	148	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	148	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	149	Stem cell, Autologous	1	1	Completed regimen	4			3	77	3	77		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	77	3	77			1
MMRF_1808	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	32	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	32	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	442	4	442		Partial Response	PR	Partial Response	PR	1	0	0	0	1	32	0	16	442	16	442	1	3	1
MMRF_1808	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	33	71	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	71	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	442	4	442		Partial Response	PR	Partial Response	PR	1	0	0	0	2	39	0	16	442	16	442			1
MMRF_1808	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	72	78	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	78	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				1					4	442	4	442		Partial Response	PR	Partial Response	PR	1	0	0	0	1	7	0	16	442	16	442			1
MMRF_1808	1	Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Car-Cyc-Dex	Proteasome/Proteasome/Chemotherapy/Steroid	79	122	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	122	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/carfilzomib-based	Bor-Len-Car-Cyc-Dex	175	Stem cell, Autologous	1	1	Completed regimen	4			4	442	4	442		Partial Response	PR	Partial Response	PR	1	0	0	0	2	44	0	16	442	16	442			1
MMRF_1808	1	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	267	366	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Prednisone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Car-Cyc-Dex + Len-Pred	1	Proteasome/Chemotherapy/Steroid/IMID	366	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	442	4	442		Partial Response	PR	Partial Response	PR	1	0	0	0	4	100	0	16	442	16	442			1
MMRF_1808	1	Carfilzomib/Lenalidomide/Prednisone/Dexamethasone	Car-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	367	396	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Prednisone + Carfilzomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Car-Cyc-Dex + Len-Pred + Car-Len-Pred-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	396	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2			4	442	4	442		Partial Response	PR	Partial Response	PR	1	0	0	0	1	30	0	16	442	16	442			1
MMRF_1808	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	397	501	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Prednisone + Carfilzomib/Lenalidomide/Prednisone/Dexamethasone + Carfilzomib/Dexametha	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Car-Cyc-Dex + Len-Pred + Car-Len-Pred-Dex + Car-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	501	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	612	Stem cell, Allogenic	2	1	Completed regimen	4			4	442	4	442		Partial Response	PR	Partial Response	PR	1	1	1	1	4	105	1	16	442	16	442			1
MMRF_1830	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	122	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	122	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	92	1	751		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	122	1	27	751	4	92	1	3	1
MMRF_1830	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	862	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	862	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	92	1	751		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	27	740	0	27	751	4	92			1
MMRF_1830	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Ixa-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	863	1317	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1317	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	92	1	751		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	17	455	0	27	751	4	92			1
MMRF_1830	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1318	2900	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Ixa-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	2900	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					3	92	1	751		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	57	1583	0	27	751	4	92			1
MMRF_1859	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	161	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	161	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	99	1	1450		Complete Response	CR	Partial Response	PR	1	0	1	0	6	161	1	52	1450	4	99	1	3	1
MMRF_1859	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	234	261	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide	Bor-Len-Dex + Bor-Cyc	1	Proteasome/IMID/Steroid/Chemotherapy	261	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0					4	99	1	1450		Complete Response	CR	Partial Response	PR	1	0	0	0	1	28	0	52	1450	4	99			1
MMRF_1859	1	Bortezomib/Lenalidomide/Cyclophosphamide	Bor-Len-Cyc	Proteasome/IMID/Chemotherapy	262	547	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide + Bortezomib/Lenalidomide/Cyclophosphamide	Bor-Len-Dex + Bor-Cyc + Bor-Len-Cyc	1	Proteasome/IMID/Steroid/Chemotherapy	547	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	99	1	1450		Complete Response	CR	Partial Response	PR	1	0	0	0	11	286	0	52	1450	4	99			1
MMRF_1859	1	Lenalidomide	Len	IMID	548	945	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide + Bortezomib/Lenalidomide/Cyclophosphamide + Lenalidomide	Bor-Len-Dex + Bor-Cyc + Bor-Len-Cyc + Len	1	Proteasome/IMID/Steroid/Chemotherapy	945	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	99	1	1450		Complete Response	CR	Partial Response	PR	1	1	0	1	15	398	0	52	1450	4	99			1
MMRF_1871	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	165	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	165	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	93	1	1771		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	165	1	64	1771	4	93	1	3	1
MMRF_1871	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	166	166	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	166	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	93	1	1771		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	64	1771	4	93			1
MMRF_1871	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	167	2730	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	2730	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	167	Stem cell, Autologous	1	1					3	93	1	1771		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	92	2564	0	64	1771	4	93			1
MMRF_1921	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	33	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	33	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	95	3	344	1266	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	33	0	13	344	4	95	1	3	1
MMRF_1921	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	34	207	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	207	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	95	3	344	1266	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	7	174	1	13	344	4	95			1
MMRF_1921	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	208	220	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	220	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	95	3	344	1266	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	13	0	13	344	4	95			1
MMRF_1921	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	221	221	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	221	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	95	3	344	1266	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	13	344	4	95			1
MMRF_1921	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	222	720	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	720	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	222	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	95	3	344	1266	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	18	499	0	13	344	4	95			1
MMRF_1921	1	Ixazomib	Ixa	Proteasome	724	1307	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Ixazomib	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Ixa	1	Proteasome/IMID/Steroid/Chemotherapy	1307	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	95	3	344	1266	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	21	584	0	13	344	4	95			1
MMRF_1921	2	Carfilzomib/Isatuximab/Dexamethasone	Car-Isa-Dex	Proteasome/CD38/Steroid	1342	2911	1	Carfilzomib/Isatuximab/Dexamethasone	Car-Isa-Dex	1342	Proteasome/CD38/Steroid	2911	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1679	Stem cell, Autologous	2	1					4	1432	3	1614	1342	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	56	1570	1	10	273	4	91	1	3	1
MMRF_1963	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	305	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	305	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	70	3	70		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	305	1	3	70	3	70	1	3	1
MMRF_1992	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	113	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	113	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	167	Stem cell, Autologous	1	1	Completed regimen	4	1644		4	90	4	90	450	Partial Response	PR	Partial Response	PR	1	1	1	1	4	113	1	4	90	4	90	1	4	1
MMRF_1992	2	Lenalidomide/Panobinostat/Dexamethasone	Len-Pano-Dex	IMID/HDAC/Steroid	467	659	1	Lenalidomide/Panobinostat/Dexamethasone	Len-Pano-Dex	467	IMID/HDAC/Steroid	659	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1644		4	534	4	534	681	Partial Response	PR	Partial Response	PR	1	1	1	1	7	193	1	3	68	3	68	1	3	1
MMRF_1992	3	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	701	786	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	701	SLAMF7/IMID/Steroid	786	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Investigator decision for other reasons	5	1644				5	800		Stable Disease	SD			0	1	0	1	3	86	0	4	100			1	3	1
MMRF_1992	4	Daratumumab	Dar	CD38	811	961	1	Daratumumab	Dar	811	CD38	961	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3	1644				5	894	961	Stable Disease	SD			0	1	0	1	6	151	0	3	84					1
MMRF_1992	4	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	975	1051	2	Daratumumab + Daratumumab/Pomalidomide	Dar + Dar-Pom	811	CD38/IMID	1051	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Disease progression/Relapse	3	1644				5	894	961	Stable Disease	SD			0	0	0	0	3	77	0	3	84			1	2	1
MMRF_1992	5	Carfilzomib/Ibrutinib/Dexamethasone	Car-Ibru-Dex	Proteasome/BTK/Steroid	1198	1498	1	Carfilzomib/Ibrutinib/Dexamethasone	Car-Ibru-Dex	1198	Proteasome/BTK/Steroid	1498	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1644		4	1345	4	1345	1644	Partial Response	PR	Partial Response	PR	1	1	1	1	11	301	1	6	148	6	148	1	3	1
MMRF_1992	5	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1506	1569	2	Carfilzomib/Ibrutinib/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Ibru-Dex + Car-Cyc-Dex	1198	Proteasome/BTK/Steroid/Chemotherapy	1569	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1644		4	1345	4	1345	1644	Partial Response	PR	Partial Response	PR	1	0	0	0	3	64	0	6	148	6	148			1
MMRF_1992	9	JNJ-64407564	JNJ-64407564	GPRC5D	1596	1694	1	JNJ-64407564	JNJ-64407564	1596	GPRC5D	1694	Other therapies	Other treatments					0	Disease progression/Relapse	3	1644											0	0	0	0	4	99	0							1
MMRF_1992	9	Carfilzomib/Selinexor	Car-Sel	Proteasome/XPO1	1717	1847	2	JNJ-64407564 + Carfilzomib/Selinexor	JNJ-64407564 + Car-Sel	1596	GPRC5D/Proteasome/XPO1	1847	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			1644											0	0	0	0	5	131	0					1	2	1
MMRF_1992	9	Carfilzomib/Daratumumab/Pomalidomide/Selinexor/Dexamethasone	Car-Dar-Pom-Sel-Dex	Proteasome/CD38/IMID/XPO1/Steroid	1848	1849	3	JNJ-64407564 + Carfilzomib/Selinexor + Carfilzomib/Daratumumab/Pomalidomide/Selinexor/Dexamethasone	JNJ-64407564 + Car-Sel + Car-Dar-Pom-Sel-Dex	1596	GPRC5D/Proteasome/XPO1/CD38/IMID/Steroid	1849	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3	1644											0	0	0	0	0	2	0							1
MMRF_1992	9	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1850	2002	4	JNJ-64407564 + Carfilzomib/Selinexor + Carfilzomib/Daratumumab/Pomalidomide/Selinexor/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	JNJ-64407564 + Car-Sel + Car-Dar-Pom-Sel-Dex + Car-Dar-Pom-Dex	1596	GPRC5D/Proteasome/XPO1/CD38/IMID/Steroid	2002	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3	1644											0	0	0	0	6	153	0							1
MMRF_1992	9	REGN5458	REGN5458	BCMA	2217	2390	5	JNJ-64407564 + Carfilzomib/Selinexor + Carfilzomib/Daratumumab/Pomalidomide/Selinexor/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone + REGN5458	JNJ-64407564 + Car-Sel + Car-Dar-Pom-Sel-Dex + Car-Dar-Pom-Dex + REGN5458	1596	GPRC5D/Proteasome/XPO1/CD38/IMID/Steroid/BCMA	2390	combined daratumumab/IMIDs/carfilzomib-based	Other treatments	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0			1644											0	0	0	0	7	174	0							1
MMRF_1998	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	161	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	161	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	164	3	164		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	161	0	6	164	6	164	1	3	1
MMRF_1998	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	162	252	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	252	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	164	3	164		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	91	1	6	164	6	164			1
MMRF_1998	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	253	292	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	292	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	DEATH				3	164	3	164		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	40	0	6	164	6	164			1
MMRF_2000	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	93	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	126	Stem cell, Autologous	1	1	Completed regimen	4			4	107	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	93	1	7	175	4	107	1	4	1
MMRF_2000	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	287	1177	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Len-Cyc-Dex + Len-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	1177	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					4	107	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	32	891	0	7	175	4	107			1
MMRF_2000	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1178	2546	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Elotuzumab/Lenalidomide/Dexamethasone	Bor-Len-Cyc-Dex + Len-Dex + Elo-Len-Dex	1	Proteasome/IMID/Chemotherapy/Steroid/SLAMF7	2546	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	107	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	49	1369	0	7	175	4	107			1
MMRF_2002	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	79	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	79	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	80	4	80		Partial Response	PR	Partial Response	PR	1	1	1	1	3	79	1	3	80	3	80	1	3	1
MMRF_2002	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	80	450	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	450	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	80	4	80		Partial Response	PR	Partial Response	PR	1	0	0	1	14	371	1	3	80	3	80			1
MMRF_2018	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	28	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	28	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	80	3	204	2556	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	28	0	8	204	3	80	1	3	1
MMRF_2018	1	Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Thal-Cyc-Dex	Proteasome/IMID/IMID/Chemotherapy/Steroid	29	125	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Thal-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	125	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	80	3	204	2556	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	97	1	8	204	3	80			1
MMRF_2018	1	Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Thal-Cyc-Dex	Proteasome/Proteasome/IMID/IMID/Chemotherapy/Steroid	126	126	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Thal-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	126	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Lack of response	1			4	80	3	204	2556	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	8	204	3	80			1
MMRF_2018	1	Carfilzomib/Thalidomide/Cyclophosphamide/Dexamethasone	Car-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	127	211	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Thal-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex + Car-Thal-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	211	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4			4	80	3	204	2556	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	3	85	0	8	204	3	80			1
MMRF_2018	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	212	1113	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Thalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Bor-Len-Dex + Bor-Len-Thal-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex + Car-Thal-Cyc-Dex + Car-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1113	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4			4	80	3	204	2556	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	33	902	0	8	204	3	80			1
MMRF_2018	1	Ixazomib	Ixa	Proteasome	1120	2733	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Thalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Thalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone + Ixazomib	Bor-Len-Dex + Bor-Len-Thal-Cyc-Dex + Bor-Car-Len-Thal-Cyc-Dex + Car-Thal-Cyc-Dex + Car-Dex + Ixa	1	Proteasome/IMID/Steroid/Chemotherapy	2733	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0					4	80	3	204	2556	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	58	1614	0	8	204	3	80			1
MMRF_2081	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	100	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	100	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	180	Stem cell, Autologous	1	1	Completed regimen	4			3	99	1	415	1699	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	100	1	15	415	4	99	1	3	1
MMRF_2081	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	373	735	2	Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	735	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Bor-Len-Car-Dex				1					3	99	1	415	1699	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	13	363	0	15	415	4	99			1
MMRF_2081	1	Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Bor-Elo-Len-Dex	Proteasome/SLAMF7/IMID/Steroid	736	736	3	Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Car-Len-Dex + Bor-Len-Dex + Bor-Elo-Len-Dex	1	Proteasome/IMID/Steroid/SLAMF7	736	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			3	99	1	415	1699	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	15	415	4	99			1
MMRF_2081	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	737	1814	4	Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Car-Len-Dex + Bor-Len-Dex + Bor-Elo-Len-Dex	1	Proteasome/IMID/Steroid/SLAMF7	1814	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			3	99	1	415	1699	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	39	1078	0	15	415	4	99			1
MMRF_2081	2	Carfilzomib/Daratumumab/Pomalidomide	Car-Dar-Pom	Proteasome/CD38/IMID	1717	2735	1	Carfilzomib/Daratumumab/Pomalidomide	Car-Dar-Pom	1717	Proteasome/CD38/IMID	2735	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0					3	2536	3	2536		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	37	1019	1	30	820	30	820	1	3	1
MMRF_2082	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	284	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	284	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	57	4	57		Partial Response	PR	Partial Response	PR	1	1	1	1	10	284	1	3	57	3	57	1	3	1
MMRF_2082	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	437	498	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	437	Proteasome/IMID/Steroid	498	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	510	Stem cell, Autologous	1	1	Completed regimen	4			4	526	4	526	926	Partial Response	PR	Partial Response	PR	1	1	1	1	3	62	1	4	90	4	90	1	3	1
MMRF_2082	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1307	2715	1	Daratumumab/Dexamethasone	Dar-Dex	1307	CD38/Steroid	2715	daratumumab-based	daratumumab-based	Dar-Dex				0					3	1421	1	1531		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	51	1409	1	9	225	5	115			1
MMRF_2107	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1161	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1161	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	85	1	1473		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	42	1161	1	53	1473	4	85	1	3	1
MMRF_2107	1	Lenalidomide	Len	IMID	1162	1844	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1844	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					3	85	1	1473		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	25	683	0	53	1473	4	85			1
MMRF_2144	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	68	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	68	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	57	2	2503		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	3	68	1	90	2503	3	57	1	3	1
MMRF_2144	1	Lenalidomide	Len	IMID	253	2672	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2672	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	57	2	2503		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	87	2420	0	90	2503	3	57			1
MMRF_2176	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	2562	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2562	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	40	1	1039		Complete Response	CR	Partial Response	PR	1	1	1	1	92	2562	1	38	1039	2	40	1	3	1
MMRF_2180	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	101	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	101	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	353	4	353	757	Partial Response	PR	Partial Response	PR	1	0	0	0	4	101	0	13	353	13	353	1	3	1
MMRF_2180	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	102	175	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					4	353	4	353	757	Partial Response	PR	Partial Response	PR	1	0	0	0	3	74	0	13	353	13	353			1
MMRF_2180	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Car-Len-Cyc-Pred-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid/Steroid	176	176	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Car-Len-Cyc-Pred-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	176	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Lack of response	1			4	353	4	353	757	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	13	353	13	353			1
MMRF_2180	1	Carfilzomib/Lenalidomide/Prednisone	Car-Len-Pred	Proteasome/IMID/Steroid	177	380	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Carfilzomib/Lenalidomide/Prednisone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Car-Len-Cyc-Pred-Dex + Car-Len-Pred	1	Proteasome/IMID/Steroid/Chemotherapy	380	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4			4	353	4	353	757	Partial Response	PR	Partial Response	PR	1	1	1	1	8	204	1	13	353	13	353			1
MMRF_2180	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1033	1311	1	Daratumumab/Dexamethasone	Dar-Dex	1033	CD38/Steroid	1311	daratumumab-based	daratumumab-based	Dar-Dex				0					3	1086	1	1542		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	10	279	1	19	510	2	54			1
MMRF_2180	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1312	1697	2	Daratumumab/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Dar-Dex + Dar-Pom-Dex	1033	CD38/Steroid/IMID	1697	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					3	1086	1	1542		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	14	386	0	19	510	2	54	1	3	1
MMRF_2199	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	236	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	236	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	127	1	1093		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	9	236	1	40	1093	5	127	1	3	1
MMRF_2199	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	237	461	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Pred-Dex	1	Proteasome/IMID/Steroid	461	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	127	1	1093		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	8	225	0	40	1093	5	127			1
MMRF_2199	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	462	2730	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	2730	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					3	127	1	1093		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	81	2269	0	40	1093	5	127			1
MMRF_2207	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	122	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	173	Stem cell, Autologous	1	1	Completed regimen	4			4	82	1	1219		Complete Response	CR	Partial Response	PR	1	0	1	0	5	122	1	44	1219	3	82	1	3	1
MMRF_2207	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	323	801	2	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid	801	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Dex				1					4	82	1	1219		Complete Response	CR	Partial Response	PR	1	0	0	0	17	479	0	44	1219	3	82			1
MMRF_2207	1	Carfilzomib/Ixazomib/Lenalidomide/Dexamethasone	Car-Ixa-Len-Dex	Proteasome/Proteasome/IMID/Steroid	802	2553	3	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Car-Len-Dex + Car-Ixa-Len-Dex	1	Proteasome/IMID/Steroid	2553	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	82	1	1219		Complete Response	CR	Partial Response	PR	1	1	0	1	63	1752	0	44	1219	3	82			1
MMRF_2240	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	90	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	90	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Lack of response	1			4	256	4	256		Partial Response	PR	Partial Response	PR	1	0	0	0	4	90	0	10	256	10	256	1	3	1
MMRF_2240	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	91	91	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	91	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Lack of response	1			4	256	4	256		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	10	256	10	256			1
MMRF_2240	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	92	201	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	201	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	256	4	256		Partial Response	PR	Partial Response	PR	1	0	0	0	4	110	0	10	256	10	256			1
MMRF_2240	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	202	202	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	202	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Lack of response	1			4	256	4	256		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	10	256	10	256			1
MMRF_2240	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	203	672	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	672	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	735	Stem cell, Autologous	1	1	Completed regimen	4			4	256	4	256		Partial Response	PR	Partial Response	PR	1	1	1	1	17	470	1	10	256	10	256			1
MMRF_2240	2	Daratumumab/Pomalidomide/Trametinib	Dar-Pom-Tram	CD38/IMID/MEK	825	1014	1	Daratumumab/Pomalidomide/Trametinib	Dar-Pom-Tram	825	CD38/IMID/MEK	1014	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0					4	935	4	935	832	Partial Response	PR	Partial Response	PR	1	1	1	1	7	190	1	4	111	4	111	1	3	1
MMRF_2240	2	Daratumumab/Pomalidomide/Trametinib/Venetoclax	Dar-Pom-Tram-Vent	CD38/IMID/MEK/BCL2	1015	1069	2	Daratumumab/Pomalidomide/Trametinib + Daratumumab/Pomalidomide/Trametinib/Venetoclax	Dar-Pom-Tram + Dar-Pom-Tram-Vent	825	CD38/IMID/MEK/BCL2	1069	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0					4	935	4	935	832	Partial Response	PR	Partial Response	PR	1	0	0	0	2	55	0	4	111	4	111			1
MMRF_2240	2	Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Venetoclax	Car-Dar-Pom-Tram-Vent	Proteasome/CD38/IMID/MEK/BCL2	1070	1128	3	Daratumumab/Pomalidomide/Trametinib + Daratumumab/Pomalidomide/Trametinib/Venetoclax + Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Venetoclax	Dar-Pom-Tram + Dar-Pom-Tram-Vent + Car-Dar-Pom-Tram-Vent	825	CD38/IMID/MEK/BCL2/Proteasome	1128	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3			4	935	4	935	832	Partial Response	PR	Partial Response	PR	1	0	0	0	2	59	0	4	111	4	111			1
MMRF_2240	2	Daratumumab/Pomalidomide/Trametinib	Dar-Pom-Tram	CD38/IMID/MEK	1129	1141	4	Daratumumab/Pomalidomide/Trametinib + Daratumumab/Pomalidomide/Trametinib/Venetoclax + Carfilzomib/Daratumumab/Pomalidomide/Trametinib/Venetoclax + Daratumumab/Pomalidomide/Trametinib	Dar-Pom-Tram + Dar-Pom-Tram-Vent + Car-Dar-Pom-Tram-Vent + Dar-Pom-Tram	825	CD38/IMID/MEK/BCL2/Proteasome	1141	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3			4	935	4	935	832	Partial Response	PR	Partial Response	PR	1	0	0	0	1	13	0	4	111	4	111			1
MMRF_2240	4	Bortezomib/Venetoclax	Bor-Vent	Proteasome/BCL2	1176	1544	1	Bortezomib/Venetoclax	Bor-Vent	1176	Proteasome/BCL2	1544	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1344	4	1344	1163	Partial Response	PR	Partial Response	PR	1	1	1	1	13	369	1	7	169	7	169	1	2	1
MMRF_2289	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	239	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	239	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	82	3	82	351	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	239	1	3	82	3	82	1	3	1
MMRF_2289	1	Lenalidomide	Len	IMID	240	358	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	358	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	82	3	82	351	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	119	0	3	82	3	82			1
MMRF_2289	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	359	431	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	359	Proteasome/Chemotherapy/Steroid	431	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	443	Stem cell, Autologous	1	1	Completed regimen	4			4	431	1	946		Complete Response	CR	Partial Response	PR	1	0	1	0	3	73	1	21	588	3	73	1	3	1
MMRF_2289	2	Ixazomib	Ixa	Proteasome	550	1033	2	Bortezomib/Cyclophosphamide/Dexamethasone + Ixazomib	Bor-Cyc-Dex + Ixa	359	Proteasome/Chemotherapy/Steroid	1033	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	431	1	946		Complete Response	CR	Partial Response	PR	1	1	0	1	18	484	0	21	588	3	73			1
MMRF_2289	3	Carfilzomib/Isatuximab/Dexamethasone	Car-Isa-Dex	Proteasome/CD38/Steroid	1047	2419	1	Carfilzomib/Isatuximab/Dexamethasone	Car-Isa-Dex	1047	Proteasome/CD38/Steroid	2419	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					3	1075	2	2363	1466	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	49	1373	1	48	1317	2	29	1	3	1
MMRF_2341	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4					5	86		Stable Disease	SD			0	1	0	1	3	85	0	4	86			1	3	1
MMRF_2344	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	571	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	571	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					4	216	4	216		Partial Response	PR	Partial Response	PR	1	1	1	1	21	571	1	8	216	8	216	1	4	1
MMRF_2344	2	Lenalidomide/Cyclophosphamide	Len-Cyc	IMID/Chemotherapy	279	328	1	Lenalidomide/Cyclophosphamide	Len-Cyc	279	IMID/Chemotherapy	328	IMIDs-based	IMIDs-based	Len-Cyc				1	Lack of response	1			4	426	1	1197	279	Complete Response	CR	Partial Response	PR	1	0	0	0	2	50	0	33	919	6	148	1	2	1
MMRF_2344	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	338	568	2	Lenalidomide/Cyclophosphamide + Daratumumab/Pomalidomide	Len-Cyc + Dar-Pom	279	IMID/Chemotherapy/CD38	568	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				1	Completed regimen	4			4	426	1	1197	279	Complete Response	CR	Partial Response	PR	1	0	1	0	9	231	1	33	919	6	148			1
MMRF_2344	2	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Mel-Dex	Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	572	572	3	Lenalidomide/Cyclophosphamide + Daratumumab/Pomalidomide + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Len-Cyc + Dar-Pom + Bor-Len-Cyc-Mel-Dex	279	IMID/Chemotherapy/CD38/Proteasome/Steroid	572	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	426	1	1197	279	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	33	919	6	148			1
MMRF_2344	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	573	596	4	Lenalidomide/Cyclophosphamide + Daratumumab/Pomalidomide + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Cyc + Dar-Pom + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex	279	IMID/Chemotherapy/CD38/Proteasome/Steroid	596	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	573	Stem cell, Autologous	1	1	Patient decision	6			4	426	1	1197	279	Complete Response	CR	Partial Response	PR	1	1	0	1	1	24	0	33	919	6	148			1
MMRF_2344	3	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1241	2555	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1241	SLAMF7/IMID/Steroid	2555	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					3	1295	3	1295		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	47	1315	1	2	55	2	55	1	3	1
MMRF_2353	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	175	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	78	3	408	1419	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	7	175	1	15	408	3	78	1	3	1
MMRF_2353	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	176	288	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	288	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Lack of response	1			4	78	3	408	1419	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	113	0	15	408	3	78			1
MMRF_2353	1	Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Cyc-Dex	IMID/Chemotherapy/Steroid	289	394	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	394	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex	444	Stem cell, Autologous	1	1	Completed regimen	4			4	78	3	408	1419	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	106	0	15	408	3	78			1
MMRF_2366	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	42	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	42	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3												0	0	0	0	2	42	0					1	3	1
MMRF_2366	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	80	261	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	80	Proteasome/IMID/Steroid	261	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	170	4	170	80	Partial Response	PR	Partial Response	PR	1	1	1	1	7	182	1	4	91	4	91	1	3	1
MMRF_2366	3	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	261	287	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	261	Proteasome/Chemotherapy/Steroid	287	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	261	261	Progressive Disease	PD			0	1	0	1	1	27	0	1	1			1	3	1
MMRF_2366	4	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	324	907	1	Carfilzomib/Dexamethasone	Car-Dex	324	Proteasome/Steroid	907	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	352	4	352		Partial Response	PR	Partial Response	PR	1	1	1	1	21	584	1	2	29	2	29	1	2	1
MMRF_2373	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	146	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	146	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3	529											0	0	0	0	6	146	0					1	3	1
MMRF_2373	2	Lenalidomide	Len	IMID	147	174	1	Lenalidomide	Len	147	IMID	174	IMIDs-based	IMIDs-based	Len-Dex				1			529		4	79	4	79	170	Partial Response	PR	Partial Response	PR	1	0	0	0	1	28	0	-2	-67	-2	-67	1	1	1
MMRF_2373	2	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	175	273	2	Lenalidomide + Lenalidomide/Melphalan/Dexamethasone	Len + Len-Mel-Dex	147	IMID/Chemotherapy/Steroid	273	IMIDs-based	IMIDs-based	Other Len-based therapies	175	Stem cell, Autologous	1	1			529		4	79	4	79	170	Partial Response	PR	Partial Response	PR	1	0	0	0	4	99	0	-2	-67	-2	-67			1
MMRF_2373	2	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	274	351	3	Lenalidomide + Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Len + Len-Mel-Dex + Car-Len-Mel-Dex	147	IMID/Chemotherapy/Steroid/Proteasome	351	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	529		4	79	4	79	170	Partial Response	PR	Partial Response	PR	1	0	0	0	3	78	0	-2	-67	-2	-67			1
MMRF_2373	2	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	352	415	4	Lenalidomide + Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Len + Len-Mel-Dex + Car-Len-Mel-Dex	147	IMID/Chemotherapy/Steroid/Proteasome	415	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	529		4	79	4	79	170	Partial Response	PR	Partial Response	PR	1	0	0	0	3	64	0	-2	-67	-2	-67			1
MMRF_2373	3	Carfilzomib	Car	Proteasome	352	515	1	Carfilzomib	Car	352	Proteasome	515	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3	529				6	361	361	Progressive Disease	PD			0	1	0	1	6	164	0	1	10			1	1	1
MMRF_2373	3	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	416	536	2	Carfilzomib + Melphalan/Dexamethasone	Car + Mel-Dex	352	Proteasome/Chemotherapy/Steroid	536	Carfilzomib-based	Other treatments	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	529				6	361	361	Progressive Disease	PD			0	0	0	0	5	121	0	1	10					1
MMRF_2373	4	Daratumumab/Carmustine/Melphalan	Dar-Carm-Mel	CD38/Chemotherapy/Chemotherapy	445	493	1	Daratumumab/Carmustine/Melphalan	Dar-Carm-Mel	445	CD38/Chemotherapy	493	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	529											0	0	0	0	2	49	0					1	3	1
MMRF_2373	5	Bortezomib/Daratumumab/Pomalidomide/Dexamethasone	Bor-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	500	536	1	Bortezomib/Daratumumab/Pomalidomide/Dexamethasone	Bor-Dar-Pom-Dex	500	Proteasome/CD38/IMID/Steroid	536	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Pom-Pred-Dex				0	Disease progression/Relapse	3	529				6	529	529	Progressive Disease	PD			0	1	0	1	2	37	0	2	30			1	4	1
MMRF_2404	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	29	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	29	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Disease progression/Relapse	3			4	81	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	29	0	6	162	3	81	1	3	1
MMRF_2404	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	33	102	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	102	Bortezomib-based	Other treatments	Bor-Cyc-Dex				1					4	81	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	70	1	6	162	3	81			1
MMRF_2404	1	Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	103	103	3	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	103	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	81	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	6	162	3	81			1
MMRF_2404	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	104	202	4	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Cyc-Mel-Dex + Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	202	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	104	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	81	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	99	0	6	162	3	81			1
MMRF_2404	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	207	245	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	207	Proteasome/IMID/Steroid	245	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3					6	245	245	Progressive Disease	PD			0	1	0	1	2	39	0	2	39			1	3	1
MMRF_2410	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	68	3	68		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	3	68	3	68	1	3	1
MMRF_2445	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	115	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	115	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	39	3	263		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	115	1	10	263	2	39	1	2	1
MMRF_2445	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	116	479	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	479	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	39	3	263		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	13	364	0	10	263	2	39			1
MMRF_2445	2	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	585	704	1	Elotuzumab/Lenalidomide	Elo-Len	585	SLAMF7/IMID	704	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3					5	613	737	Stable Disease	SD			0	1	0	1	5	120	0	2	29			1	2	1
MMRF_2445	3	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	779	782	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	779	Chemotherapy/Steroid	782	Other therapies	Other treatments					0	Completed regimen	4			3	837	3	837	1102	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	3	59	3	59			1
MMRF_2445	3	Daratumumab	Dar	CD38	802	1110	2	Cyclophosphamide/Dexamethasone + Daratumumab	Cyc-Dex + Dar	779	Chemotherapy/Steroid/CD38	1110	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	837	3	837	1102	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	309	1	3	59	3	59			1
MMRF_2445	4	Dabrafenib/Trametinib/Venetoclax	Dab-Tram-Vent	BRAF/MEK/BCL2	1120	1500	1	Dabrafenib/Trametinib/Venetoclax	Dab-Tram-Vent	1120	BRAF/MEK/BCL2	1500	Other therapies	Other treatments					0					3	1313	1	2289	1701	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	14	381	1	42	1170	7	194			1
MMRF_2445	4	Daratumumab/Dabrafenib/Trametinib/Venetoclax	Dar-Dab-Tram-Vent	CD38/BRAF/MEK/BCL2	1501	2479	2	Dabrafenib/Trametinib/Venetoclax + Daratumumab/Dabrafenib/Trametinib/Venetoclax	Dab-Tram-Vent + Dar-Dab-Tram-Vent	1120	BRAF/MEK/BCL2/CD38	2479	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0					3	1313	1	2289	1701	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	35	979	0	42	1170	7	194			1
MMRF_2457	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	1	84	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	1	Proteasome/IMID/Steroid	84	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1			1051		4	79	3	163	324	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	84	1	6	163	3	79	1	4	1
MMRF_2457	1	Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Cyc-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	85	331	2	Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	331	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	369	Stem cell, Autologous	1	1	Disease progression/Relapse	3	1051		4	79	3	163	324	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	9	247	0	6	163	3	79			1
MMRF_2457	3	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	587	699	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	587	SLAMF7/IMID/Steroid	699	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3	1051				5	671	587	Stable Disease	SD			0	1	0	1	4	113	0	4	85			1	3	1
MMRF_2457	3	Daratumumab	Dar	CD38	734	805	2	Elotuzumab/Pomalidomide/Dexamethasone + Daratumumab	Elo-Pom-Dex + Dar	587	SLAMF7/IMID/Steroid/CD38	805	combined daratumumab/IMIDs-based	daratumumab-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1051				5	671	587	Stable Disease	SD			0	0	0	0	3	72	0	4	85					1
MMRF_2457	4	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	825	828	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	825	Chemotherapy/Steroid	828	Other therapies	Other treatments					0	Completed regimen	4	1051				5	849	929	Stable Disease	SD			0	1	0	1	0	4	0	1	25					1
MMRF_2457	4	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	881	904	2	Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide	Cyc-Dex + Dar-Pom	825	Chemotherapy/Steroid/CD38/IMID	904	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Cyc-Dex				0			1051				5	849	929	Stable Disease	SD			0	0	0	0	1	24	0	1	25			1	2	1
MMRF_2457	4	Daratumumab/Pomalidomide/Panobinostat	Dar-Pom-Pano	CD38/IMID/HDAC	905	916	3	Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide + Daratumumab/Pomalidomide/Panobinostat	Cyc-Dex + Dar-Pom + Dar-Pom-Pano	825	Chemotherapy/Steroid/CD38/IMID/HDAC	916	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1051				5	849	929	Stable Disease	SD			0	0	0	0	1	12	0	1	25					1
MMRF_2457	4	Panobinostat	Pano	HDAC	917	929	4	Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide + Daratumumab/Pomalidomide/Panobinostat	Cyc-Dex + Dar-Pom + Dar-Pom-Pano	825	Chemotherapy/Steroid/CD38/IMID/HDAC	929	combined daratumumab/IMIDs-based	Other treatments	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1051				5	849	929	Stable Disease	SD			0	0	0	0	1	13	0	1	25					1
MMRF_2457	5	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1051	1058	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1051	Proteasome/IMID/Steroid	1058	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1051				5	1107	1051	Stable Disease	SD			0	1	0	1	1	8	0	3	57			1	3	1
MMRF_2469	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	235	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	235	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	352	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	9	235	1	39	1079	13	352	1	3	1
MMRF_2469	1	Elotuzumab/Melphalan	Elo-Mel	SLAMF7/Chemotherapy	396	708	2	Bortezomib/Lenalidomide/Dexamethasone + Elotuzumab/Melphalan	Bor-Len-Dex + Elo-Mel	1	Proteasome/IMID/Steroid/SLAMF7/Chemotherapy	708	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	397	Stem cell, Autologous	1	1	Completed regimen	4			3	352	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	11	313	0	39	1079	13	352			1
MMRF_2469	1	Lenalidomide	Len	IMID	736	2558	3	Bortezomib/Lenalidomide/Dexamethasone + Elotuzumab/Melphalan + Lenalidomide	Bor-Len-Dex + Elo-Mel + Len	1	Proteasome/IMID/Steroid/SLAMF7/Chemotherapy	2558	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	352	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	65	1823	0	39	1079	13	352			1
MMRF_2472	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	35	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	35	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	92	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	35	0	39	1079	4	92	1	3	1
MMRF_2472	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	36	2540	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	2540	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	92	1	1079		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	90	2505	1	39	1079	4	92			1
MMRF_2498	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	111	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	111	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	175	Stem cell, Autologous	1	1	Completed regimen	4			4	55	3	153		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	111	1	6	153	2	55	1	3	1
MMRF_2498	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	288	333	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	333	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	55	3	153		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	46	0	6	153	2	55			1
MMRF_2498	1	Bortezomib/Ixazomib/Dexamethasone	Bor-Ixa-Dex	Proteasome/Proteasome/Steroid	334	343	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Ixa-Dex	1	Proteasome/IMID/Steroid	343	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	55	3	153		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	10	0	6	153	2	55			1
MMRF_2498	1	Ixazomib	Ixa	Proteasome	344	664	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone + Ixazomib	Bor-Len-Dex + Bor-Dex + Bor-Ixa-Dex + Ixa	1	Proteasome/IMID/Steroid	664	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	55	3	153		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	12	321	0	6	153	2	55			1
MMRF_2498	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1347	1377	1	Daratumumab/Pomalidomide	Dar-Pom	1347	CD38/IMID	1377	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Adverse Event or co-morbidity	2			3	1452	3	1452	1358	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	31	0	4	106	4	106	1	2	1
MMRF_2498	2	Bortezomib	Bor	Proteasome	1410	1878	2	Daratumumab/Pomalidomide + Bortezomib	Dar-Pom + Bor	1347	CD38/IMID/Proteasome	1878	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Pom-Cyc				0	Completed regimen	4			3	1452	3	1452	1358	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	17	469	1	4	106	4	106			1
MMRF_2538	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	91	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	91	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	82	1	305	970	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	91	1	11	305	3	82	1	3	1
MMRF_2538	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	92	99	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	99	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	82	1	305	970	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	8	0	11	305	3	82			1
MMRF_2538	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	100	161	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	161	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					3	82	1	305	970	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	62	0	11	305	3	82			1
MMRF_2538	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	162	726	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Pred-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	726	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					3	82	1	305	970	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	20	565	0	11	305	3	82			1
MMRF_2538	1	Bortezomib/Elotuzumab/Lenalidomide/Prednisone/Dexamethasone	Bor-Elo-Len-Pred-Dex	Proteasome/SLAMF7/IMID/Steroid/Steroid	727	727	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Elo-Len-Pred-Dex	1	Proteasome/IMID/Steroid/Chemotherapy/SLAMF7	727	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	82	1	305	970	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	11	305	3	82			1
MMRF_2538	1	Elotuzumab/Lenalidomide/Prednisone	Elo-Len-Pred	SLAMF7/IMID/Steroid	728	977	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Prednisone/Dexamethasone + Elotuzumab/Lenalidomide/Prednisone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Elo-Len-Pred-Dex + Elo-Len-Pred	1	Proteasome/IMID/Steroid/Chemotherapy/SLAMF7	977	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	82	1	305	970	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	9	250	0	11	305	3	82			1
MMRF_2538	2	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	1075	1326	1	Bortezomib/Daratumumab	Bor-Dar	1075	Proteasome/CD38	1326	Bortezomib-based	Bortezomib-based	Bor-Dar				0	Disease progression/Relapse	3			3	1168	3	1168		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	252	1	4	94	4	94	1	2	1
MMRF_2538	4	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1326	1404	1	Daratumumab/Pomalidomide	Dar-Pom	1326	CD38/IMID	1404	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Disease progression/Relapse	3					6	1343	1343	Progressive Disease	PD			0	1	0	1	3	79	0	1	18			1	2	1
MMRF_2550	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	249	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	249	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	102	3	200		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	249	1	8	200	4	102	1	3	1
MMRF_2564	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	117	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	117	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	62	1	953		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	117	1	35	953	3	62	1	3	1
MMRF_2564	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	118	118	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	118	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	62	1	953		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	35	953	3	62			1
MMRF_2564	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	119	414	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	414	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	120	Stem cell, Autologous	1	1	Completed regimen	4			3	62	1	953		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	11	296	0	35	953	3	62			1
MMRF_2564	2	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	1110	1367	1	Daratumumab/Lenalidomide	Dar-Len	1110	CD38/IMID	1367	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0	Disease progression/Relapse	3					5	1311		Stable Disease	SD			0	1	0	1	10	258	0	8	202			1	2	1
MMRF_2564	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1367	1513	1	Daratumumab/Pomalidomide	Dar-Pom	1367	CD38/IMID	1513	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0					4	1455	4	1455		Partial Response	PR	Partial Response	PR	1	1	1	1	6	147	1	4	89	4	89	1	2	1
MMRF_2564	3	Bortezomib/Daratumumab/Pomalidomide	Bor-Dar-Pom	Proteasome/CD38/IMID	1514	2357	2	Daratumumab/Pomalidomide + Bortezomib/Daratumumab/Pomalidomide	Dar-Pom + Bor-Dar-Pom	1367	CD38/IMID/Proteasome	2357	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc				0					4	1455	4	1455		Partial Response	PR	Partial Response	PR	1	0	0	0	30	844	0	4	89	4	89			1
MMRF_2577	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	140	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	140	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	1	0	5	140	1	32	884	3	80	1	3	1
MMRF_2577	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	184	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	184	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	2	44	0	32	884	3	80			1
MMRF_2577	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Ixa-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	185	469	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	469	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	10	285	0	32	884	3	80			1
MMRF_2577	1	Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Dar-Ixa-Len-Cyc-Dex	Proteasome/CD38/Proteasome/IMID/Chemotherapy/Steroid	470	703	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	703	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	9	234	0	32	884	3	80			1
MMRF_2577	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Ixa-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	704	778	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexam	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	778	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	3	75	0	32	884	3	80			1
MMRF_2577	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Ixa-Len-Cyc-Mel-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	779	779	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexam	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	779	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	32	884	3	80			1
MMRF_2577	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Ixa-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	780	792	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexam	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Mel-Dex + Bor-Ixa-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	792	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	780	Stem cell, Autologous	1	1	Completed regimen	4			4	80	1	884		Complete Response	CR	Partial Response	PR	1	1	0	1	1	13	0	32	884	3	80			1
MMRF_2577	1	Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Ixa-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	780	792	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexam	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Mel-Dex + Bor-Ixa-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	792	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	780	Stem cell, Autologous	2	1	Completed regimen	4			4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	1	1	13	0	32	884	3	80			1
MMRF_2577	1	Ixazomib	Ixa	Proteasome	948	1123	8	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexam	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Mel-Dex + Bor-Ixa-Len-Cyc-Dex + Ixa	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	1123	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	7	176	0	32	884	3	80			1
MMRF_2577	1	Lenalidomide	Len	IMID	1151	1375	9	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Ixazomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Cyclophosphamide/Dexam	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Dar-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Dex + Bor-Ixa-Len-Cyc-Mel-Dex + Bor-Ixa-Len-Cyc-Dex + Ixa + Len	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	1375	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	80	1	884		Complete Response	CR	Partial Response	PR	1	0	0	0	8	225	0	32	884	3	80			1
MMRF_2577	2	Daratumumab	Dar	CD38	1396	1737	1	Daratumumab	Dar	1396	CD38	1737	daratumumab-based	daratumumab-based	Dar				0	Completed regimen	4					6	1661	1661	Progressive Disease	PD			0	1	0	1	13	342	0	10	266					1
MMRF_2577	3	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1737	2382	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	1737	Chemotherapy/Steroid	2382	Other therapies	Other treatments					0					3	1997	3	1997		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	23	646	1	10	261	10	261			1
MMRF_2614	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	34	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	34	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	57	1	881		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	34	0	32	881	3	57	1	3	1
MMRF_2614	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	35	141	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Pred-Dex	1	Proteasome/IMID/Steroid	141	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	57	1	881		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	107	1	32	881	3	57			1
MMRF_2614	1	Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Cyc-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	142	171	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	171	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	57	1	881		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	30	0	32	881	3	57			1
MMRF_2614	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	172	180	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Len-Pred-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	180	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	57	1	881		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	9	0	32	881	3	57			1
MMRF_2614	1	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	181	181	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Melphalan/Prednisone	Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Len-Pred-Dex + Mel-Pred	1	Proteasome/IMID/Steroid/Chemotherapy	181	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	184	Stem cell, Autologous	1	1	Completed regimen	4			3	57	1	881		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	32	881	3	57			1
MMRF_2614	1	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	300	1252	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Prednisone/Dexamethasone + Melphalan/Prednisone + Lenalidomide/Prednisone	Bor-Len-Dex + Bor-Len-Pred-Dex + Bor-Len-Cyc-Pred-Dex + Bor-Len-Pred-Dex + Mel-Pred + Len-Pred	1	Proteasome/IMID/Steroid/Chemotherapy	1252	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			3	57	1	881		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	34	953	0	32	881	3	57			1
MMRF_2614	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1267	1483	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1267	SLAMF7/IMID/Steroid	1483	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Investigator decision for other reasons	5			3	1371	3	1371		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	217	1	4	105	4	105	1	3	1
MMRF_2614	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1486	2410	1	Daratumumab/Pomalidomide	Dar-Pom	1486	CD38/IMID	2410	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0					4	1535	1	2143		Complete Response	CR	Partial Response	PR	1	1	1	1	33	925	1	24	658	2	50	1	2	1
MMRF_1037	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	88	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	88	IMIDs-based	IMIDs-based	Len-Dex				0	Patient decision	6					5	96		Stable Disease	SD			0	1	0	1	3	88	0	4	96			1	2	1
MMRF_1088	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	87	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	87	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	159	4	159		Partial Response	PR	Partial Response	PR	1	0	0	0	3	87	0	6	159	6	159	1	2	1
MMRF_1088	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	109	126	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide	Bor-Dex + Bor-Len	1	Proteasome/Steroid/IMID	126	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	159	4	159		Partial Response	PR	Partial Response	PR	1	1	1	1	1	18	1	6	159	6	159			1
MMRF_1102	1	Thalidomide	Thal	IMID	28	34	1	Thalidomide	Thal	28	IMID	34	IMIDs-based	IMIDs-based	Thal-Dex				0	Patient decision	6												0	0	0	0	1	7	0					1	1	1
MMRF_1128	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	61	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	61	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	62	1	2057		Complete Response	CR	Partial Response	PR	1	0	1	0	2	61	1	74	2057	3	62	1	3	1
MMRF_1128	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	62	117	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	117	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Cyc-Dex				1	Completed regimen	4			4	62	1	2057		Complete Response	CR	Partial Response	PR	1	0	0	0	2	56	1	74	2057	3	62			1
MMRF_1128	1	Thalidomide	Thal	IMID	118	147	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Thalidomide	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex + Thal	1	Proteasome/Chemotherapy/Steroid/IMID	147	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Thal-Cyc-Dex	214	Stem cell, Autologous	1	1	Completed regimen	4			4	62	1	2057		Complete Response	CR	Partial Response	PR	1	0	0	0	1	30	0	74	2057	3	62			1
MMRF_1128	1	Lenalidomide	Len	IMID	313	1118	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Thalidomide + Lenalidomide	Bor-Cyc-Dex + Bor-Thal-Cyc-Dex + Thal + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1118	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Patient decision	6			4	62	1	2057		Complete Response	CR	Partial Response	PR	1	1	0	1	29	806	0	74	2057	3	62			1
MMRF_1475	1	Lenalidomide	Len	IMID	1	1	1	Lenalidomide	Len	1	IMID	1	IMIDs-based	IMIDs-based	Len-Dex				0														0	0	0	0	0	1	0					1	1	1
MMRF_1735	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	106	Stem cell, Autologous	1	1	Completed regimen	4			4	176	4	176	507	Partial Response	PR	Partial Response	PR	1	1	1	1	3	85	1	7	176	7	176	1	3	1
MMRF_1735	1	Lenalidomide	Len	IMID	176	507	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	507	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	176	4	176	507	Partial Response	PR	Partial Response	PR	1	0	0	1	12	332	1	7	176	7	176			1
MMRF_1735	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	516	1011	1	Pomalidomide/Dexamethasone	Pom-Dex	516	IMID/Steroid	1011	IMIDs-based	IMIDs-based	Pom-Dex				0	Investigator decision for other reasons	5			4	718	4	718	1935	Partial Response	PR	Partial Response	PR	1	1	1	1	18	496	1	8	203	8	203	1	2	1
MMRF_1735	3	Bortezomib/Daratumumab/Pomalidomide/Dexamethasone	Bor-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1937	2921	1	Bortezomib/Daratumumab/Pomalidomide/Dexamethasone	Bor-Dar-Pom-Dex	1937	Proteasome/CD38/IMID/Steroid	2921	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Pom-Pred-Dex				0					3	2202	1	2375		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	35	985	1	16	439	10	266	1	4	1
MMRF_1061	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	120	Stem cell, Autologous	1	1	AUTOLOGOUS BONE MARROW TRANSPLANT				4	99	3	325	1382	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	74	1	12	325	4	99	1	3	1
MMRF_1061	2	Carfilzomib	Car	Proteasome	2061	2061	1	Carfilzomib	Car	2061	Proteasome	2061	Carfilzomib-based	Carfilzomib-based	Car-Dex				0					4	2081	4	2081		Partial Response	PR	Partial Response	PR	1	1	1	1	0	1	1	1	21	1	21	1	1	1
MMRF_1068	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	78	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	78	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4					5	85		Stable Disease	SD			0	1	0	1	3	78	0	4	85			1	3	1
MMRF_1068	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	239	407	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	407	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4					5	85		Stable Disease	SD			0	0	0	0	6	169	0	4	85					1
MMRF_1068	2	Carfilzomib	Car	Proteasome	477	535	1	Carfilzomib	Car	477	Proteasome	535	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3					6	521	521	Progressive Disease	PD			0	1	0	1	2	59	0	2	45			1	1	1
MMRF_1065	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	123	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			4	50	1	998		Complete Response	CR	Partial Response	PR	1	0	1	0	5	123	1	36	998	2	50	1	3	1
MMRF_1065	1	Lenalidomide	Len	IMID	230	2391	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2391	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	50	1	998		Complete Response	CR	Partial Response	PR	1	1	0	1	78	2162	0	36	998	2	50			1
MMRF_1065	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2465	2850	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	2465	CD38/IMID/Steroid	2850	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	PATIENT EXPIRED													0	0	0	0	14	386	0					1	3	1
MMRF_1368	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	116	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	116	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	92	2	808		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	116	1	29	808	4	92	1	3	1
MMRF_1368	1	Plerixafor	Pler		148	150	2	Bortezomib/Lenalidomide/Dexamethasone + Plerixafor	Bor-Len-Dex + Pler	1	Proteasome/IMID/Steroid	150	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	194	Stem cell, Autologous	1	1	Completed regimen	4			4	92	2	808		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	3	0	29	808	4	92			1
MMRF_1368	1	Lenalidomide	Len	IMID	299	2861	3	Bortezomib/Lenalidomide/Dexamethasone + Plerixafor + Lenalidomide	Bor-Len-Dex + Pler + Len	1	Proteasome/IMID/Steroid	2861	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	92	2	808		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	92	2563	0	29	808	4	92			1
MMRF_1180	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	193	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	193	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	193	1	4	91	4	91	1	3	1
MMRF_1180	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	194	194	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	194	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	91	4	91			1
MMRF_1180	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	195	539	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	539	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	196	Stem cell, Autologous	1	1	Completed regimen	4			3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	13	345	0	4	91	4	91			1
MMRF_1188	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	1	1197	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	1	Proteasome/Chemotherapy/Steroid	1197	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0					3	163	3	163	1240	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	43	1197	1	6	163	6	163	1	3	1
MMRF_1188	1	Bortezomib/Elotuzumab/Bendamustine/Dexamethasone	Bor-Elo-Bend-Dex	Proteasome/SLAMF7/Chemotherapy/Steroid	1198	1331	2	Bortezomib/Bendamustine/Dexamethasone + Bortezomib/Elotuzumab/Bendamustine/Dexamethasone	Bor-Bend-Dex + Bor-Elo-Bend-Dex	1	Proteasome/Chemotherapy/Steroid/SLAMF7	1331	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	163	3	163	1240	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	134	0	6	163	6	163			1
MMRF_1188	2	Lenalidomide	Len	IMID	1303	1352	1	Lenalidomide	Len	1303	IMID	1352	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			4	1331	4	1331	1493	Partial Response	PR	Partial Response	PR	1	1	1	1	2	50	1	2	29	2	29	1	1	1
MMRF_1188	2	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	1332	1777	2	Lenalidomide + Bortezomib/Bendamustine/Dexamethasone	Len + Bor-Bend-Dex	1303	IMID/Proteasome/Chemotherapy/Steroid	1777	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	SUBJECT IS DECEASED.				4	1331	4	1331	1493	Partial Response	PR	Partial Response	PR	1	0	0	0	16	446	0	2	29	2	29			1
MMRF_1188	2	Ixazomib	Ixa	Proteasome	1479	1647	3	Lenalidomide + Bortezomib/Bendamustine/Dexamethasone + Ixazomib	Len + Bor-Bend-Dex + Ixa	1303	IMID/Proteasome/Chemotherapy/Steroid	1647	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1331	4	1331	1493	Partial Response	PR	Partial Response	PR	1	0	0	0	6	169	0	2	29	2	29			1
MMRF_1213	1	Lenalidomide	Len	IMID	1	33	1	Lenalidomide	Len	1	IMID	33	IMIDs-based	IMIDs-based	Len-Dex				0							5	245	441	Stable Disease	SD			0	0	0	0	1	33	0	9	245			1	1	1
MMRF_1213	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	34	209	2	Lenalidomide + Bortezomib/Lenalidomide	Len + Bor-Len	1	IMID/Proteasome	209	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0							5	245	441	Stable Disease	SD			0	0	0	0	7	176	0	9	245					1
MMRF_1213	1	Bortezomib/Lenalidomide/Pomalidomide/Dexamethasone	Bor-Len-Pom-Dex	Proteasome/IMID/IMID/Steroid	210	217	3	Lenalidomide + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Pomalidomide/Dexamethasone	Len + Bor-Len + Bor-Len-Pom-Dex	1	IMID/Proteasome/Steroid	217	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	245	441	Stable Disease	SD			0	0	0	0	1	8	0	9	245					1
MMRF_1213	1	Lenalidomide/Pomalidomide/Dexamethasone	Len-Pom-Dex	IMID/IMID/Steroid	218	1638	4	Lenalidomide + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Pomalidomide/Dexamethasone	Len + Bor-Len + Bor-Len-Pom-Dex	1	IMID/Proteasome/Steroid	1638	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5					5	245	441	Stable Disease	SD			0	1	0	1	51	1421	0	9	245					1
MMRF_1213	2	Carfilzomib	Car	Proteasome	1055	1270	1	Carfilzomib	Car	1055	Proteasome	1270	Carfilzomib-based	Carfilzomib-based	Car-Dex				0							5	1069	1355	Stable Disease	SD			0	1	0	1	8	216	0	1	15			1	1	1
MMRF_1213	2	Carfilzomib/Elotuzumab	Car-Elo	Proteasome/SLAMF7	1271	1384	2	Carfilzomib + Carfilzomib/Elotuzumab	Car + Car-Elo	1055	Proteasome/SLAMF7	1384	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2					5	1069	1355	Stable Disease	SD			0	0	0	0	4	114	0	1	15					1
MMRF_1213	2	Elotuzumab	Elo	SLAMF7	1385	1450	3	Carfilzomib + Carfilzomib/Elotuzumab	Car + Car-Elo	1055	Proteasome/SLAMF7	1450	Carfilzomib-based	Other treatments	Other Cafilzomib-based therapies				0	LACK OF INSURANCE						5	1069	1355	Stable Disease	SD			0	0	0	0	3	66	0	1	15					1
MMRF_1213	3	Daratumumab	Dar	CD38	1462	1694	1	Daratumumab	Dar	1462	CD38	1694	daratumumab-based	daratumumab-based	Dar				0	DEATH						5	1615		Stable Disease	SD			0	1	0	1	9	233	0	6	154					1
MMRF_1213	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1639	1694	2	Daratumumab + Pomalidomide/Dexamethasone	Dar + Pom-Dex	1462	CD38/IMID/Steroid	1694	combined daratumumab/IMIDs-based	IMIDs-based	Dar-Pom-Dex				0	DEATH						5	1615		Stable Disease	SD			0	0	0	0	2	56	0	6	154			1	2	1
MMRF_1268	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	1	100	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	1	Proteasome/Chemotherapy/Steroid	100	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	89	4	89		Partial Response	PR	Partial Response	PR	1	1	1	1	4	100	1	4	89	4	89	1	3	1
MMRF_1331	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	99	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	99	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1					5	99	284	Stable Disease	SD			0	1	0	1	4	99	0	4	99			1	3	1
MMRF_1331	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	102	324	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	324	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0							5	99	284	Stable Disease	SD			0	0	0	0	8	223	0	4	99					1
MMRF_1487	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	183	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	183	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					1	907	1	907		Complete Response	CR	Complete Response	CR	1	0	0	0	7	183	0	33	907	33	907	1	3	1
MMRF_1487	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	184	185	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	185	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			1	907	1	907		Complete Response	CR	Complete Response	CR	1	0	0	0	0	2	0	33	907	33	907			1
MMRF_1487	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	186	970	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	970	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	186	Stem cell, Autologous	1	1	Completed regimen	4			1	907	1	907		Complete Response	CR	Complete Response	CR	1	1	1	1	28	785	1	33	907	33	907			1
MMRF_1541	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	204	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	204	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3	1199		4	141	4	141	323	Partial Response	PR	Partial Response	PR	1	1	1	1	8	204	1	6	141	6	141	1	3	1
MMRF_1541	2	Pomalidomide	Pom	IMID	379	561	1	Pomalidomide	Pom	379	IMID	561	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3	1199		4	491	4	491		Partial Response	PR	Partial Response	PR	1	1	1	1	7	183	1	5	113	5	113	1	1	1
MMRF_1541	3	Selinexor	Sel	XPO1	561	645	1	Selinexor	Sel	561	XPO1	645	Other therapies	Other treatments					0	Disease progression/Relapse	3	1199				5	666	582	Stable Disease	SD			0	1	0	1	3	85	0	4	106					1
MMRF_1541	4	Carfilzomib	Car	Proteasome	676	860	1	Carfilzomib	Car	676	Proteasome	860	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Completed regimen	4	1199				5	825		Stable Disease	SD			0	1	0	1	7	185	0	6	150			1	1	1
MMRF_1541	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	902	1788	1	Daratumumab/Dexamethasone	Dar-Dex	902	CD38/Steroid	1788	daratumumab-based	daratumumab-based	Dar-Dex				0	SUBJECT IS DECEASED		1199		4	1773	4	1773	1199	Partial Response	PR	Partial Response	PR	1	1	1	1	32	887	1	32	872	32	872			1
MMRF_1541	9	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	1295	1788	1	Daratumumab/Lenalidomide	Dar-Len	1295	CD38/IMID	1788	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0	SUBJECT IS DECEASED		1199											0	0	0	0	18	494	0					1	2	1
MMRF_1603	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	279	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	279	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	259	3	259		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	279	1	10	259	10	259	1	3	1
MMRF_1603	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	280	280	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	280	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	259	3	259		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	10	259	10	259			1
MMRF_1603	1	Lenalidomide	Len	IMID	281	403	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	403	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			3	259	3	259		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	123	0	10	259	10	259			1
MMRF_1603	1	Bortezomib	Bor	Proteasome	731	819	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide + Bortezomib	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len + Bor	1	Proteasome/Chemotherapy/Steroid/IMID	819	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			3	259	3	259		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	89	0	10	259	10	259			1
MMRF_1664	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	173	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	173	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	101	1	1851	1529	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	173	1	67	1851	4	101	1	3	1
MMRF_1664	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	174	175	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	175	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	101	1	1851	1529	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	67	1851	4	101			1
MMRF_1664	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	176	940	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	940	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	177	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			3	101	1	1851	1529	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	28	765	0	67	1851	4	101			1
MMRF_1664	1	Lenalidomide	Len	IMID	941	2169	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2169	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	SUBJECT IS DECEASED.				3	101	1	1851	1529	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	44	1229	0	67	1851	4	101			1
MMRF_1719	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	197	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	197	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	79	1	814		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	7	197	1	30	814	3	79	1	3	1
MMRF_1719	1	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	199	310	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	310	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	79	1	814		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	112	0	30	814	3	79			1
MMRF_1719	1	Lenalidomide	Len	IMID	311	419	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len-Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	419	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	79	1	814		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	4	109	0	30	814	3	79			1
MMRF_1815	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	117	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	117	IMIDs-based	IMIDs-based	Len-Dex				0	Patient decision	6												0	0	0	0	4	117	0					1	2	1
MMRF_1880	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	142	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	142	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	190	Stem cell, Autologous	1	1	Completed regimen	4			4	98	3	343		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	142	1	13	343	4	98	1	3	1
MMRF_1949	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	183	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	183	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	84	3	84	707	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	183	1	3	84	3	84	1	3	1
MMRF_1949	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	184	184	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	184	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	184	Stem cell, Autologous	1	1	Completed regimen	4			3	84	3	84	707	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	84	3	84			1
MMRF_1949	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	185	2576	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2576	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1					3	84	3	84	707	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	86	2392	0	3	84	3	84			1
MMRF_1949	2	Elotuzumab/Pomalidomide	Elo-Pom	SLAMF7/IMID	708	1369	1	Elotuzumab/Pomalidomide	Elo-Pom	708	SLAMF7/IMID	1369	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3			4	791	4	791	1356	Partial Response	PR	Partial Response	PR	1	1	1	1	24	662	1	3	84	3	84	1	2	1
MMRF_1949	3	Daratumumab	Dar	CD38	1374	2576	1	Daratumumab	Dar	1374	CD38	2576	daratumumab-based	daratumumab-based	Dar				0							5	1430		Stable Disease	SD			0	1	0	1	43	1203	0	3	57					1
MMRF_2216	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	385	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	385	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3					5	231	265	Stable Disease	SD			0	1	0	1	14	385	0	9	231			1	2	1
MMRF_2429	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	2367	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	2367	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	147	Stem cell, Autologous	1	1														0	0	0	0	85	2367	0					1	3	1
MMRF_2539	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	2180	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2180	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	117	Stem cell, Autologous	1	1					3	84	3	84		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	78	2180	1	3	84	3	84	1	3	1
MMRF_2562	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	137	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	137	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	80	4	80		Partial Response	PR	Partial Response	PR	1	1	1	1	5	137	1	3	80	3	80	1	3	1
MMRF_2562	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	199	396	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	199	Proteasome/IMID/Steroid	396	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	439	Stem cell, Autologous	1	1	PATIENT RECEIVED ASCT				4	501	4	501	199	Partial Response	PR	Partial Response	PR	1	1	1	1	7	198	1	11	303	11	303	1	3	1
MMRF_2562	2	Ixazomib	Ixa	Proteasome	585	661	2	Carfilzomib/Lenalidomide/Dexamethasone + Ixazomib	Car-Len-Dex + Ixa	199	Proteasome/IMID/Steroid	661	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	501	4	501	199	Partial Response	PR	Partial Response	PR	1	0	0	0	3	77	0	11	303	11	303			1
MMRF_2562	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	704	1004	1	Pomalidomide/Dexamethasone	Pom-Dex	704	IMID/Steroid	1004	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3			4	809	4	809	1018	Partial Response	PR	Partial Response	PR	1	1	1	1	11	301	1	4	106	4	106	1	2	1
MMRF_2562	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1038	1117	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1038	CD38/IMID/Steroid	1117	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					5	1068	1156	Stable Disease	SD			0	1	0	1	3	80	0	2	31			1	3	1
MMRF_1020	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	91	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	91	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	135	Stem cell, Allogenic	1	1	Completed regimen	4			3	92	1	234	714	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	91	1	9	234	4	92	1	3	1
MMRF_1020	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	827	986	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	827	Proteasome/IMID/Steroid	986	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	917	3	917	1246	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	160	1	4	91	4	91	1	3	1
MMRF_1020	2	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	987	988	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	827	Proteasome/IMID/Steroid/Chemotherapy	988	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	917	3	917	1246	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	4	91	4	91			1
MMRF_1020	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	989	1360	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	827	Proteasome/IMID/Steroid/Chemotherapy	1360	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	990	Stem cell, Allogenic	2	1	Disease progression/Relapse	3			3	917	3	917	1246	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	14	372	0	4	91	4	91			1
MMRF_1020	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1370	2150	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1370	Proteasome/Chemotherapy/Steroid	2150	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	PT DEATH						5	1428	1623	Stable Disease	SD			0	1	0	1	28	781	0	3	59			1	3	1
MMRF_1020	4	Daratumumab	Dar	CD38	1638	2142	1	Daratumumab	Dar	1638	CD38	2142	daratumumab-based	daratumumab-based	Dar				0	PT DEATH				4	1686	4	1686		Partial Response	PR	Partial Response	PR	1	1	1	1	18	505	1	2	49	2	49			1
MMRF_1045	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	229	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	229	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	74	3	74	609	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	229	1	3	74	3	74	1	2	1
MMRF_1045	1	Lenalidomide	Len	IMID	230	322	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	322	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	74	3	74	609	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	93	0	3	74	3	74			1
MMRF_1044	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	541	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	541	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	78	1	458		Complete Response	CR	Partial Response	PR	1	1	1	1	20	541	1	17	458	3	78	1	3	1
MMRF_1044	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	542	567	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len	1	Proteasome/IMID/Steroid	567	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	78	1	458		Complete Response	CR	Partial Response	PR	1	0	0	0	1	26	0	17	458	3	78			1
MMRF_1044	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	568	1688	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	1688	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	78	1	458		Complete Response	CR	Partial Response	PR	1	0	0	0	40	1121	0	17	458	3	78			1
MMRF_1044	1	Lenalidomide	Len	IMID	1689	2877	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2877	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	78	1	458		Complete Response	CR	Partial Response	PR	1	0	0	0	43	1189	0	17	458	3	78			1
MMRF_1044	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	2878	2912	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len + Bor-Len-Dex + Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	2912	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	78	1	458		Complete Response	CR	Partial Response	PR	1	0	0	0	2	35	0	17	458	3	78			1
MMRF_1046	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	137	Stem cell, Autologous	1	1	Completed regimen	4			3	92	1	1947		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	105	1	70	1947	4	92	1	3	1
MMRF_1046	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	218	306	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	306	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	92	1	1947		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	89	0	70	1947	4	92			1
MMRF_1046	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	307	308	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len	1	Proteasome/IMID/Steroid	308	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	92	1	1947		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	70	1947	4	92			1
MMRF_1046	1	Lenalidomide	Len	IMID	323	2940	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len	1	Proteasome/IMID/Steroid	2940	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	92	1	1947		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	94	2618	0	70	1947	4	92			1
MMRF_1059	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	73	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	73	Bortezomib-based	Bortezomib-based	Bor-Dex				1					3	82	3	82	1532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	73	0	3	82	3	82	1	2	1
MMRF_1059	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	74	175	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	82	3	82	1532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	102	1	3	82	3	82			1
MMRF_1059	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	176	176	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	176	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	82	3	82	1532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	82	3	82			1
MMRF_1059	1	Lenalidomide	Len	IMID	177	181	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	181	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	207	Stem cell, Autologous	1	1	Completed regimen	4			3	82	3	82	1532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	5	0	3	82	3	82			1
MMRF_1059	1	Lenalidomide	Len	IMID	287	2430	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	2430	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	PT STARTED NEW DRUG				3	82	3	82	1532	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	77	2144	0	3	82	3	82			1
MMRF_1059	3	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	2483	2610	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	2483	Proteasome/CD38/Steroid	2610	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					2	2667	2	2667	2483	Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	5	128	0	7	185	7	185	1	3	1
MMRF_1059	3	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	2611	2912	2	Carfilzomib/Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Dex + Car-Dar-Pom-Dex	2483	Proteasome/CD38/Steroid/IMID	2912	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0					2	2667	2	2667	2483	Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	11	302	1	7	185	7	185			1
MMRF_1074	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	98	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	98	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	129	Stem cell, Autologous	1	1	Completed regimen	4			3	85	3	85	303	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	98	1	4	85	4	85	1	3	1
MMRF_1074	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	204	319	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	319	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	85	3	85	303	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	116	0	4	85	4	85			1
MMRF_1074	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	319	413	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	319	Proteasome/Chemotherapy/Steroid	413	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0							6	417	417	Progressive Disease	PD			0	0	0	0	4	95	0	4	99			1	3	1
MMRF_1074	2	Carfilzomib/Cyclophosphamide/Methotrexate/Dexamethasone	Car-Cyc-MTX-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	414	415	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Cyclophosphamide/Methotrexate/Dexamethasone	Car-Cyc-Dex + Car-Cyc-MTX-Dex	319	Proteasome/Chemotherapy/Steroid	415	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1					6	417	417	Progressive Disease	PD			0	0	0	0	0	2	0	4	99					1
MMRF_1074	2	Carfilzomib/Methotrexate/Dexamethasone	Car-MTX-Dex	Proteasome/Chemotherapy/Steroid	416	417	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Cyclophosphamide/Methotrexate/Dexamethasone + Carfilzomib/Methotrexate/Dexamethasone	Car-Cyc-Dex + Car-Cyc-MTX-Dex + Car-MTX-Dex	319	Proteasome/Chemotherapy/Steroid	417	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Patient decision	6					6	417	417	Progressive Disease	PD			0	1	0	1	0	2	0	4	99					1
MMRF_1150	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	406	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	406	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	223	4	223		Partial Response	PR	Partial Response	PR	1	1	1	1	15	406	1	8	223	8	223	1	3	1
MMRF_1181	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	39	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	39	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	PATIENT DIED													0	0	0	0	2	39	0					1	3	1
MMRF_1242	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	140	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	140	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	85	3	281	554	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	140	1	11	281	4	85	1	3	1
MMRF_1242	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	190	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	235	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	85	3	281	554	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	2	50	0	11	281	4	85			1
MMRF_1242	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	190	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	305	Stem cell, Autologous	2	1	Disease progression/Relapse	3			4	85	3	281	554	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	2	50	0	11	281	4	85			1
MMRF_1242	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	386	540	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	540	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	85	3	281	554	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	155	0	11	281	4	85			1
MMRF_1258	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	268	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	268	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	55	4	55		Partial Response	PR	Partial Response	PR	1	1	1	1	10	268	1	2	55	2	55	1	2	1
MMRF_1281	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	153	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	153	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	73	4	73		Partial Response	PR	Partial Response	PR	1	1	1	1	6	153	1	3	73	3	73	1	3	1
MMRF_1318	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	28	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	28	IMIDs-based	IMIDs-based	Len-Dex				0					4	85	1	729		Complete Response	CR	Partial Response	PR	1	0	0	0	1	28	0	27	729	4	85	1	2	1
MMRF_1318	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	29	2927	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	2927	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	85	1	729		Complete Response	CR	Partial Response	PR	1	1	1	1	104	2899	1	27	729	4	85			1
MMRF_1355	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1	1282	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1	SLAMF7/IMID/Steroid	1282	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Investigator decision for other reasons	5			4	85	1	421		Complete Response	CR	Partial Response	PR	1	1	1	1	46	1282	1	16	421	4	85	1	3	1
MMRF_1355	2	Daratumumab	Dar	CD38	1824	2919	1	Daratumumab	Dar	1824	CD38	2919	daratumumab-based	daratumumab-based	Dar				0					1	1966	1	1966	2698	Complete Response	CR	Complete Response	CR	1	1	1	1	39	1096	1	6	143	6	143			1
MMRF_1355	2	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	2920	2920	2	Daratumumab + Daratumumab/Lenalidomide	Dar + Dar-Len	1824	CD38/IMID	2920	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0					1	1966	1	1966	2698	Complete Response	CR	Complete Response	CR	1	0	0	0	0	1	0	6	143	6	143	1	2	1
MMRF_1358	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	193	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	193	IMIDs-based	IMIDs-based	Len-Dex				0					4	149	4	149	394	Partial Response	PR	Partial Response	PR	1	1	1	1	7	193	1	6	149	6	149	1	2	1
MMRF_1358	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	194	194	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	194	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	149	4	149	394	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	6	149	6	149			1
MMRF_1358	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	195	326	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Len-Dex + Bor-Len-Dex + Bor-Dex	1	IMID/Steroid/Proteasome	326	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	149	4	149	394	Partial Response	PR	Partial Response	PR	1	0	0	0	5	132	0	6	149	6	149			1
MMRF_1358	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	327	327	4	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex + Bor-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	327	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	149	4	149	394	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	6	149	6	149			1
MMRF_1358	1	Lenalidomide	Len	IMID	328	523	5	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Len	1	IMID/Steroid/Proteasome	523	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	149	4	149	394	Partial Response	PR	Partial Response	PR	1	0	0	0	7	196	0	6	149	6	149			1
MMRF_1361	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	46	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	46	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	158	4	158		Partial Response	PR	Partial Response	PR	1	0	0	0	2	46	0	6	158	6	158	1	3	1
MMRF_1361	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	47	68	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	68	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				0	Investigator decision for other reasons	5			4	158	4	158		Partial Response	PR	Partial Response	PR	1	0	0	0	1	22	0	6	158	6	158			1
MMRF_1361	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	69	116	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	116	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				0					4	158	4	158		Partial Response	PR	Partial Response	PR	1	0	0	0	2	48	0	6	158	6	158			1
MMRF_1361	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	117	153	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	153	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				0	Completed regimen	4			4	158	4	158		Partial Response	PR	Partial Response	PR	1	0	0	0	2	37	0	6	158	6	158			1
MMRF_1361	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	154	160	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	160	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				0	Completed regimen	4			4	158	4	158		Partial Response	PR	Partial Response	PR	1	1	1	1	1	7	1	6	158	6	158			1
MMRF_1392	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	463	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	463	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	507	Stem cell, Autologous	1	1	Completed regimen	4			4	84	1	168		Complete Response	CR	Partial Response	PR	1	1	1	1	17	463	1	6	168	3	84	1	3	1
MMRF_1392	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	595	769	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	769	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Adverse Event or co-morbidity	2			4	84	1	168		Complete Response	CR	Partial Response	PR	1	0	0	0	7	175	0	6	168	3	84			1
MMRF_1393	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	85	2	621	2148	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	5	130	1	23	621	4	85	1	3	1
MMRF_1393	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	132	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	132	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	85	2	621	2148	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	2	0	23	621	4	85			1
MMRF_1393	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	133	1209	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1209	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	134	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	85	2	621	2148	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	39	1077	0	23	621	4	85			1
MMRF_1393	1	Lenalidomide	Len	IMID	1210	2931	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2931	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1					4	85	2	621	2148	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	62	1722	0	23	621	4	85			1
MMRF_1420	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	98	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	98	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	85	2	631		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	98	1	23	631	4	85	1	3	1
MMRF_1420	1	Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Car-Cyc-Dex	Proteasome/Proteasome/Chemotherapy/Steroid	99	134	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	134	combined bortezomib/carfilzomib-based	combined bortezomib/carfilzomib-based	Bor-Car-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	85	2	631		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	36	0	23	631	4	85			1
MMRF_1420	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	135	273	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	273	combined bortezomib/carfilzomib-based	Bortezomib-based	Bor-Car-Cyc-Dex				0					4	85	2	631		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	5	139	0	23	631	4	85			1
MMRF_1420	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	274	1205	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Cyc-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1205	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Bor-Len-Car-Cyc-Dex				0	Investigator decision for other reasons	5			4	85	2	631		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	34	932	0	23	631	4	85			1
MMRF_1520	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	106	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	150	Stem cell, Autologous	1	1	Completed regimen	4			4	85	1	2583		Complete Response	CR	Partial Response	PR	1	0	1	0	4	106	1	93	2583	4	85	1	3	1
MMRF_1520	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	225	607	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	607	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Completed regimen	4			4	85	1	2583		Complete Response	CR	Partial Response	PR	1	0	0	0	14	383	0	93	2583	4	85			1
MMRF_1520	1	Lenalidomide	Len	IMID	608	2898	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	2898	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1					4	85	1	2583		Complete Response	CR	Partial Response	PR	1	1	0	1	82	2291	0	93	2583	4	85			1
MMRF_1540	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	518	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	518	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	141	1	316	57	Complete Response	CR	Partial Response	PR	1	1	1	1	19	518	1	12	316	6	141	1	3	1
MMRF_1576	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	21	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	21	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	1	21	0					1	2	1
MMRF_1621	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	136	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	136	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	1	309		Complete Response	CR	Partial Response	PR	1	0	1	0	5	136	1	12	309	2	29	1	3	1
MMRF_1621	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	137	138	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	138	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	29	1	309		Complete Response	CR	Partial Response	PR	1	0	0	0	0	2	0	12	309	2	29			1
MMRF_1621	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	139	2892	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2892	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	140	Stem cell, Autologous	1	1					4	29	1	309		Complete Response	CR	Partial Response	PR	1	1	0	1	99	2754	0	12	309	2	29			1
MMRF_1630	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	170	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	170	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	84	2	371		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	6	170	1	14	371	3	84	1	3	1
MMRF_1630	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	171	172	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	172	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	84	2	371		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	2	0	14	371	3	84			1
MMRF_1630	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	173	867	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	867	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	174	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	84	2	371		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	25	695	0	14	371	3	84			1
MMRF_1630	1	Lenalidomide	Len	IMID	868	2932	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2932	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1					4	84	2	371		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	74	2065	0	14	371	3	84			1
MMRF_1652	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	100	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	100	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	142	Stem cell, Autologous	1	1	Completed regimen	4			4	64	2	302		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	100	1	11	302	3	64	1	3	1
MMRF_1652	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	246	2938	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	2938	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	64	2	302		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	96	2693	0	11	302	3	64			1
MMRF_1690	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	107	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	107	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	141	Stem cell, Autologous	1	1	Completed regimen	4			1	86	1	86	2213	Complete Response	CR	Complete Response	CR	1	1	1	1	4	107	1	4	86	4	86	1	3	1
MMRF_1690	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	226	653	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	653	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Investigator decision for other reasons	5			1	86	1	86	2213	Complete Response	CR	Complete Response	CR	1	0	0	0	16	428	0	4	86	4	86			1
MMRF_1690	1	Lenalidomide	Len	IMID	654	2921	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	2921	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1					1	86	1	86	2213	Complete Response	CR	Complete Response	CR	1	0	0	0	81	2268	0	4	86	4	86			1
MMRF_1749	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	106	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	147	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	120		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	5	120	4	85	1	3	1
MMRF_1749	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	231	258	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Car-Len-Dex + Car-Dex	1	Proteasome/IMID/Steroid	258	combined IMIDs/carfilzomib-based	Carfilzomib-based	Len-Car-Dex				1					3	85	1	120		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	28	0	5	120	4	85			1
MMRF_1749	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	259	1274	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid	1274	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Adverse Event or co-morbidity	2			3	85	1	120		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	37	1016	0	5	120	4	85			1
MMRF_1749	1	Lenalidomide	Len	IMID	1275	2821	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	2821	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1					3	85	1	120		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	56	1547	0	5	120	4	85			1
MMRF_1773	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	115	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	115	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	115	1	13	358	4	85	1	3	1
MMRF_1773	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	116	117	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	117	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	13	358	4	85			1
MMRF_1773	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	118	216	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	216	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	119	Stem cell, Autologous	1	1					3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	99	0	13	358	4	85			1
MMRF_1773	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	217	218	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	218	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	13	358	4	85			1
MMRF_1773	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	219	302	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	302	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	220	Stem cell, Autologous	2	1					3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	13	358	4	85			1
MMRF_1773	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	303	710	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	710	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	15	408	0	13	358	4	85			1
MMRF_1773	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	711	2962	7	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexa	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Car-Len-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2962	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					3	85	1	358		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	81	2252	0	13	358	4	85			1
MMRF_1797	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	224	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	224	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	57	2	259		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	8	224	1	10	259	3	57	1	3	1
MMRF_1797	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	225	226	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	226	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	57	2	259		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	2	0	10	259	3	57			1
MMRF_1797	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	227	567	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	567	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	228	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			4	57	2	259		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	12	341	0	10	259	3	57			1
MMRF_1822	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	136	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	136	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Patient decision	6			3	80	1	178	710	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	5	136	1	7	178	3	80	1	3	1
MMRF_1822	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	185	284	2	Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	284	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Bor-Len-Car-Dex				0	Patient decision	6			3	80	1	178	710	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	100	0	7	178	3	80			1
MMRF_1822	2	Ixazomib	Ixa	Proteasome	746	962	1	Ixazomib	Ixa	746	Proteasome	962	Other therapies	Other treatments					0	INSURANCE REASONS				4	780	4	780	833	Partial Response	PR	Partial Response	PR	1	1	1	1	8	217	1	2	35	2	35			1
MMRF_1822	4	Bortezomib/Pomalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Pom-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	1591	1612	1	Bortezomib/Pomalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Pom-Cyc-Dex-Dox	1591	Proteasome/IMID/Chemotherapy/Steroid	1612	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0							6	1590	1590	Progressive Disease	PD			0	0	0	0	1	22	0	0	0			1	5	1
MMRF_1822	4	Bortezomib/Daratumumab/Pomalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Dar-Pom-Cyc-Dex-Dox	Proteasome/CD38/IMID/Chemotherapy/Steroid/Chemotherapy	1613	1688	2	Bortezomib/Pomalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Daratumumab/Pomalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Pom-Cyc-Dex-Dox + Bor-Dar-Pom-Cyc-Dex-Dox	1591	Proteasome/IMID/Chemotherapy/Steroid/CD38	1688	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	1590	1590	Progressive Disease	PD			0	0	0	0	3	76	0	0	0					1
MMRF_1822	5	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1690	1795	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1690	Proteasome/Chemotherapy/Steroid	1795	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3												0	0	0	0	4	106	0					1	3	1
MMRF_2005	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	112	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	112	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Completed regimen	4			4	57	2	407		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	112	1	15	407	3	57	1	3	1
MMRF_2005	1	Carfilzomib	Car	Proteasome	113	113	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib	Car-Len-Dex + Car	1	Proteasome/IMID/Steroid	113	combined IMIDs/carfilzomib-based	Carfilzomib-based	Len-Car-Dex	151	Stem cell, Autologous	1	1	Completed regimen	4			4	57	2	407		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	1	0	15	407	3	57			1
MMRF_2005	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	239	2551	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car + Car-Len-Dex	1	Proteasome/IMID/Steroid	2551	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	57	2	407		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	83	2313	0	15	407	3	57			1
MMRF_2021	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	105	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	146	Stem cell, Autologous	1	1	Completed regimen	4			4	84	2	630		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	105	1	23	630	3	84	1	3	1
MMRF_2021	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	224	687	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	687	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Completed regimen	4			4	84	2	630		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	17	464	0	23	630	3	84			1
MMRF_2021	1	Lenalidomide	Len	IMID	688	2716	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	2716	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1					4	84	2	630		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	73	2029	0	23	630	3	84			1
MMRF_2056	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	140	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	140	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	85	1	557		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	140	1	20	557	4	85	1	3	1
MMRF_2056	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	142	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	142	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	85	1	557		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	20	557	4	85			1
MMRF_2056	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	143	1247	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1247	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	144	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	557		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	40	1105	0	20	557	4	85			1
MMRF_2056	1	Lenalidomide	Len	IMID	1248	1687	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	1687	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	85	1	557		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	16	440	0	20	557	4	85			1
MMRF_2056	2	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1715	2696	1	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	1715	Proteasome/CD38/IMID/Steroid	2696	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0					4	1743	2	1834		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	35	982	1	5	120	2	29	1	4	1
MMRF_2091	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	140	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	140	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	85	2	330		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	5	140	1	12	330	4	85	1	3	1
MMRF_2091	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	142	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	142	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	85	2	330		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	2	0	12	330	4	85			1
MMRF_2091	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	143	1080	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1080	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	144	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	85	2	330		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	34	938	0	12	330	4	85			1
MMRF_2091	2	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	Proteasome/CD38/IMID/Steroid	1149	1562	1	Carfilzomib/Daratumumab/Pomalidomide/Dexamethasone	Car-Dar-Pom-Dex	1149	Proteasome/CD38/IMID/Steroid	1562	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0	Disease progression/Relapse	3			4	1240	3	1415	1149	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	15	414	1	10	267	4	92	1	4	1
MMRF_2091	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1585	1619	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1585	Proteasome/IMID/Steroid	1619	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	1625		Stable Disease	SD			0	1	0	1	2	35	0	2	41			1	3	1
MMRF_2091	4	CAR-T Cells(Undefined)	CAR-T		1752	1752	1	CAR-T Cells(Undefined)	CAR-T	1752		1752	Other therapies	Other treatments					0	Completed regimen	4			4	1828	2	2192		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	0	1	1	16	441	3	77			1
MMRF_2098	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	216	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	216	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	82	4	82		Partial Response	PR	Partial Response	PR	1	1	1	1	8	216	1	3	82	3	82	1	2	1
MMRF_2122	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	264	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	264	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	104	3	194	349	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	264	1	7	194	4	104	1	3	1
MMRF_2122	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	602	2757	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	602	Proteasome/IMID/Steroid	2757	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	621	1	1651		Complete Response	CR	Partial Response	PR	1	1	1	1	77	2156	1	38	1050	1	20	1	3	1
MMRF_2238	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	27	118	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	27	Proteasome/Chemotherapy/Steroid	118	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	143	Stem cell, Autologous	1	1	Completed regimen	4			3	111	1	1361	1703	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	92	1	48	1335	4	85	1	3	1
MMRF_2238	1	Lenalidomide	Len	IMID	230	1722	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	27	Proteasome/Chemotherapy/Steroid/IMID	1722	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			3	111	1	1361	1703	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	54	1493	0	48	1335	4	85			1
MMRF_2238	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1777	2723	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1777	CD38/IMID/Steroid	2723	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	2170	2	2373		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	34	947	1	22	597	15	394	1	3	1
MMRF_2238	3	CAR-T Cells(Undefined)	CAR-T		2723	2723	1	CAR-T Cells(Undefined)	CAR-T	2723		2723	Other therapies	Other treatments					0	Disease progression/Relapse	3												0	0	0	0	0	1	0							1
MMRF_2570	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	107	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	107	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	148	Stem cell, Autologous	1	1	Completed regimen	4			4	85	1	1003		Complete Response	CR	Partial Response	PR	1	0	1	0	4	107	1	36	1003	4	85	1	3	1
MMRF_2570	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	225	625	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	625	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Completed regimen	4			4	85	1	1003		Complete Response	CR	Partial Response	PR	1	0	0	0	15	401	0	36	1003	4	85			1
MMRF_2570	1	Lenalidomide	Len	IMID	626	2389	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	2389	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1					4	85	1	1003		Complete Response	CR	Partial Response	PR	1	1	0	1	63	1764	0	36	1003	4	85			1
MMRF_1085	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	217	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	217	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	106	1	253	435	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	8	217	1	10	253	4	106	1	3	1
MMRF_1085	1	Lenalidomide	Len	IMID	218	413	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	413	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	106	1	253	435	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	7	196	0	10	253	4	106			1
MMRF_1085	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	449	841	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	449	Proteasome/IMID/Steroid	841	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	871	Stem cell, Autologous	1	1	Disease progression/Relapse	3			3	594	3	594	841	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	393	1	6	146	6	146	1	3	1
MMRF_1085	3	Bortezomib/Bendamustine	Bor-Bend	Proteasome/Chemotherapy	1105	1162	1	Bortezomib/Bendamustine	Bor-Bend	1105	Proteasome/Chemotherapy	1162	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	1162	1162	Progressive Disease	PD			0	1	0	1	2	58	0	3	58			1	2	1
MMRF_1085	4	Selinexor/Dexamethasone	Sel-Dex	XPO1/Steroid	1182	1217	1	Selinexor/Dexamethasone	Sel-Dex	1182	XPO1/Steroid	1217	Other therapies	Other treatments					0	DIFFICULTY TOLERATING THERAPY						6	1217	1217	Progressive Disease	PD			0	1	0	1	2	36	0	2	36					1
MMRF_1233	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	319	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	319	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			4	92	4	92	540	Partial Response	PR	Partial Response	PR	1	1	1	1	12	319	1	4	92	4	92	1	3	1
MMRF_1233	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	477	589	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	589	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	92	4	92	540	Partial Response	PR	Partial Response	PR	1	0	0	0	4	113	0	4	92	4	92			1
MMRF_1233	2	Pomalidomide	Pom	IMID	589	2684	1	Pomalidomide	Pom	589	IMID	2684	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			4	1131	4	1131	897	Partial Response	PR	Partial Response	PR	1	1	1	1	75	2096	1	20	543	20	543	1	1	1
MMRF_1233	3	Daratumumab	Dar	CD38	2723	2895	1	Daratumumab	Dar	2723	CD38	2895	daratumumab-based	daratumumab-based	Dar				0							5	2895		Stable Disease	SD			0	1	0	1	6	173	0	7	173					1
MMRF_1327	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	1	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_1700	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	46	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	46	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	89	4	89	279	Partial Response	PR	Partial Response	PR	1	0	0	0	2	46	0	4	89	4	89	1	3	1
MMRF_1700	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	47	194	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	194	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			4	89	4	89	279	Partial Response	PR	Partial Response	PR	1	1	1	1	6	148	1	4	89	4	89			1
MMRF_1700	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	195	481	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	481	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Lack of response	1			4	89	4	89	279	Partial Response	PR	Partial Response	PR	1	0	0	0	11	287	0	4	89	4	89			1
MMRF_1700	2	Carfilzomib	Car	Proteasome	439	481	1	Carfilzomib	Car	439	Proteasome	481	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Lack of response	1					6	461	461	Progressive Disease	PD			0	1	0	1	2	43	0	1	23			1	1	1
MMRF_1700	3	Pomalidomide	Pom	IMID	481	559	1	Pomalidomide	Pom	481	IMID	559	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2					6	530	530	Progressive Disease	PD			0	1	0	1	3	79	0	2	50			1	1	1
MMRF_1739	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	170	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	170	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	281	1	652	1086	Complete Response	CR	Partial Response	PR	1	0	0	0	6	170	0	24	652	11	281	1	3	1
MMRF_1739	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	171	253	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	253	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	281	1	652	1086	Complete Response	CR	Partial Response	PR	1	0	0	0	3	83	0	24	652	11	281			1
MMRF_1739	1	Lenalidomide	Len	IMID	254	733	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	733	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex	289	Stem cell, Autologous	1	1					4	281	1	652	1086	Complete Response	CR	Partial Response	PR	1	1	1	1	17	480	1	24	652	11	281			1
MMRF_1739	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	734	1100	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1100	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	281	1	652	1086	Complete Response	CR	Partial Response	PR	1	0	0	0	13	367	0	24	652	11	281			1
MMRF_1739	1	Lenalidomide	Len	IMID	1101	1878	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len + Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1878	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	281	1	652	1086	Complete Response	CR	Partial Response	PR	1	0	0	0	28	778	0	24	652	11	281			1
MMRF_1739	2	Daratumumab	Dar	CD38	1101	1195	1	Daratumumab	Dar	1101	CD38	1195	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3					6	1170	1170	Progressive Disease	PD			0	1	0	1	4	95	0	3	70					1
MMRF_1739	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1193	1878	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1193	Proteasome/IMID/Steroid	1878	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1254	1	1730	2960	Complete Response	CR	Partial Response	PR	1	1	1	1	25	686	1	20	538	3	62	1	3	1
MMRF_1774	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	214	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	214	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4	1974		4	69	1	250	979	Complete Response	CR	Partial Response	PR	1	0	1	0	8	214	1	9	250	3	69	1	3	1
MMRF_1774	1	Lenalidomide	Len	IMID	215	954	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	954	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3	1974		4	69	1	250	979	Complete Response	CR	Partial Response	PR	1	1	0	1	27	740	0	9	250	3	69			1
MMRF_1774	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	986	1012	1	Bortezomib/Dexamethasone	Bor-Dex	986	Proteasome/Steroid	1012	Bortezomib-based	Bortezomib-based	Bor-Dex				1			1974		4	1183	4	1183	1435	Partial Response	PR	Partial Response	PR	1	0	0	0	1	27	0	8	198	8	198	1	2	1
MMRF_1774	2	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	1013	1013	2	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone	Bor-Dex + Bor-Mel-Dex	986	Proteasome/Steroid/Chemotherapy	1013	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	GIVEN IN PREOARATION FOR TRANSPLANT		1974		4	1183	4	1183	1435	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	8	198	8	198			1
MMRF_1774	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1014	1435	3	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Mel-Dex + Bor-Dex	986	Proteasome/Steroid/Chemotherapy	1435	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	1015	Stem cell, Autologous	1	1	Disease progression/Relapse	3	1974		4	1183	4	1183	1435	Partial Response	PR	Partial Response	PR	1	1	1	1	15	422	1	8	198	8	198			1
MMRF_1774	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1461	1591	1	Pomalidomide/Dexamethasone	Pom-Dex	1461	IMID/Steroid	1591	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3	1974		4	1518	4	1518	1609	Partial Response	PR	Partial Response	PR	1	1	1	1	5	131	1	3	58	3	58	1	2	1
MMRF_1774	4	Daratumumab	Dar	CD38	1628	1660	1	Daratumumab	Dar	1628	CD38	1660	daratumumab-based	daratumumab-based	Dar				0	Adverse Event or co-morbidity	2	1974											0	0	0	0	1	33	0							1
MMRF_1774	5	Carfilzomib	Car	Proteasome	1660	1958	1	Carfilzomib	Car	1660	Proteasome	1958	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3	1974		3	1699	3	1699	1974	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	299	1	2	40	2	40	1	1	1
MMRF_1814	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Patient decision	6			3	85	3	85	776	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	113	1	4	85	4	85	1	3	1
MMRF_1823	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	141	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	141	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	198	Stem cell, Autologous	1	1	PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT				3	85	1	398		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	141	1	15	398	4	85	1	3	1
MMRF_1823	1	Lenalidomide	Len	IMID	293	743	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	743	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	85	1	398		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	16	451	0	15	398	4	85			1
MMRF_1823	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	714	887	1	Lenalidomide/Dexamethasone	Len-Dex	714	IMID/Steroid	887	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3					5	825	715	Stable Disease	SD			0	1	0	1	7	174	0	4	112			1	2	1
MMRF_1823	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	888	1345	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	888	Proteasome/IMID/Steroid	1345	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	1001	3	1084	888	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	17	458	1	8	197	5	114	1	3	1
MMRF_1832	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1188	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1188	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DEATH				3	89	3	89		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	43	1188	1	4	89	4	89	1	2	1
MMRF_1841	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	162	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	162	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	179	Stem cell, Autologous	1	1	Completed regimen	4			3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	162	1	4	85	4	85	1	3	1
MMRF_1841	1	Lenalidomide	Len	IMID	288	438	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	438	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	151	0	4	85	4	85			1
MMRF_1841	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	439	2933	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide	Bor-Len-Dex + Len + Bor-Len	1	Proteasome/IMID/Steroid	2933	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	89	2495	0	4	85	4	85			1
MMRF_2080	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	212	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	212	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	108	Stem cell, Autologous	1	1	Completed regimen	4			3	70	1	260		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	8	212	1	10	260	3	70	1	3	1
MMRF_2080	1	Lenalidomide	Len	IMID	213	2718	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2718	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	70	1	260		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	90	2506	0	10	260	3	70			1
MMRF_2104	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	1983	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	1983	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	2145	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	86	1	450	1976	Complete Response	CR	Partial Response	PR	1	1	1	1	71	1983	1	17	450	4	86	1	3	1
MMRF_2104	2	Pomalidomide	Pom	IMID	2234	2500	1	Pomalidomide	Pom	2234	IMID	2500	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3					6	2467	2467	Progressive Disease	PD			0	1	0	1	10	267	0	9	234			1	1	1
MMRF_2104	3	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	2500	2719	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	2500	Proteasome/CD38/Steroid	2719	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0							6	2726	2726	Progressive Disease	PD			0	1	0	1	8	220	0	9	227			1	3	1
MMRF_2190	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1295	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1295	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	108	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	77	1	170	1262	Complete Response	CR	Partial Response	PR	1	1	1	1	47	1295	1	7	170	3	77	1	3	1
MMRF_2190	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1305	1764	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1305	CD38/IMID/Steroid	1764	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Adverse Event or co-morbidity	2			3	1333	3	1333		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	17	460	1	2	29	2	29	1	3	1
MMRF_2250	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	64	3	64	1057	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	3	64	3	64	1	3	1
MMRF_2250	1	Lenalidomide	Len	IMID	107	1066	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1066	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	64	3	64	1057	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	35	960	0	3	64	3	64			1
MMRF_2250	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1072	1278	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1072	CD38/IMID/Steroid	1278	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3												0	0	0	0	8	207	0					1	3	1
MMRF_2250	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1291	1362	1	Carfilzomib/Dexamethasone	Car-Dex	1291	Proteasome/Steroid	1362	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1439	Stem cell, Autologous	1	1	CONSIDERATION FOR TRANSPLANT				2	1891	1	2325	1765	Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	3	72	0	37	1035	22	601	1	2	1
MMRF_2250	3	Bortezomib	Bor	Proteasome	1545	1765	2	Carfilzomib/Dexamethasone + Bortezomib	Car-Dex + Bor	1291	Proteasome/Steroid	1765	combined bortezomib/carfilzomib-based	Bortezomib-based	Bor-Car-Dex				1	Disease progression/Relapse	3			2	1891	1	2325	1765	Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	8	221	0	37	1035	22	601			1
MMRF_2250	3	REGN5458	REGN5458	BCMA	1807	2523	3	Carfilzomib/Dexamethasone + Bortezomib + REGN5458	Car-Dex + Bor + REGN5458	1291	Proteasome/Steroid/BCMA	2523	combined bortezomib/carfilzomib-based	Other treatments	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				1					2	1891	1	2325	1765	Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	26	717	1	37	1035	22	601			1
MMRF_2333	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	2531	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2531	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	120	3	120		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	91	2531	1	5	120	5	120	1	3	1
MMRF_2511	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	216	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	216	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	266	4	266	1579	Partial Response	PR	Partial Response	PR	1	0	0	0	8	216	0	10	266	10	266	1	3	1
MMRF_2511	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	217	308	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	308	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex	393	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			4	266	4	266	1579	Partial Response	PR	Partial Response	PR	1	1	1	1	4	92	1	10	266	10	266			1
MMRF_2511	1	Lenalidomide	Len	IMID	484	1566	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	1566	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Dex				1	Disease progression/Relapse	3			4	266	4	266	1579	Partial Response	PR	Partial Response	PR	1	0	0	0	39	1083	0	10	266	10	266			1
MMRF_2511	2	Daratumumab/Ixazomib/Pomalidomide	Dar-Ixa-Pom	CD38/Proteasome/IMID	1639	2363	1	Daratumumab/Ixazomib/Pomalidomide	Dar-Ixa-Pom	1639	CD38/Proteasome/IMID	2363	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0					3	1789	3	1789		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	26	725	1	6	151	6	151	1	3	1
MMRF_1056	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	69	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	69	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	108	Stem cell, Autologous	1	1	Completed regimen	4	1710		3	58	3	58		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	69	1	3	58	3	58	1	3	1
MMRF_1056	1	Lenalidomide	Len	IMID	215	445	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	445	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1			1710		3	58	3	58		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	9	231	0	3	58	3	58			1
MMRF_1056	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	446	446	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide	Bor-Len-Dex + Len + Bor-Len	1	Proteasome/IMID/Steroid	446	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5	1710		3	58	3	58		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	58	3	58			1
MMRF_1056	1	Bortezomib	Bor	Proteasome	447	635	4	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide + Bortezomib	Bor-Len-Dex + Len + Bor-Len + Bor	1	Proteasome/IMID/Steroid	635	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Disease progression/Relapse	3	1710		3	58	3	58		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	189	0	3	58	3	58			1
MMRF_1056	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	635	1396	1	Bortezomib/Dexamethasone	Bor-Dex	635	Proteasome/Steroid	1396	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Lack of response	1	1710		4	737	4	737	635	Partial Response	PR	Partial Response	PR	1	1	1	1	28	762	1	4	103	4	103	1	2	1
MMRF_1056	4	Oprozomib	Opro	Proteasome	1170	1237	1	Oprozomib	Opro	1170	Proteasome	1237	Other therapies	Other treatments					0	Lack of response	1	1710				6	1248	1248	Progressive Disease	PD			0	1	0	1	3	68	0	3	79					1
MMRF_1056	4	Lenalidomide/Isatuximab	Len-Isa	IMID/CD38	1269	1396	2	Oprozomib + Lenalidomide/Isatuximab	Opro + Len-Isa	1170	Proteasome/IMID/CD38	1396	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Lack of response	1	1710				6	1248	1248	Progressive Disease	PD			0	0	0	0	5	128	0	3	79			1	2	1
MMRF_1056	5	Pomalidomide/Clarithromycin/Dexamethasone	Pom-Clar-Dex	IMID/Antibiotic/Steroid	1397	1766	1	Pomalidomide/Clarithromycin/Dexamethasone	Pom-Clar-Dex	1397	IMID/Antibiotic/Steroid	1766	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3	1710		4	1499	4	1499	1710	Partial Response	PR	Partial Response	PR	1	1	1	1	14	370	1	4	103	4	103	1	3	1
MMRF_1056	9	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1780	1912	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1780	Proteasome/Chemotherapy/Steroid	1912	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1	1710											0	0	0	0	5	133	0					1	3	1
MMRF_1056	9	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1929	2312	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Car-Cyc-Dex + Dar-Pom-Dex	1780	Proteasome/Chemotherapy/Steroid/CD38/IMID	2312	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3	1710											0	0	0	0	14	384	0							1
MMRF_1048	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	80	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	80	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	29	3	173	1770	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	80	1	7	173	2	29	1	3	1
MMRF_1048	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	81	81	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	84	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	173	1770	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	7	173	2	29			1
MMRF_1048	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	192	953	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len	1	Proteasome/IMID/Steroid/Chemotherapy	953	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	29	3	173	1770	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	28	762	0	7	173	2	29			1
MMRF_1048	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1832	2917	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1832	SLAMF7/IMID/Steroid	2917	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1972	4	1972		Partial Response	PR	Partial Response	PR	1	1	1	1	39	1086	1	6	141	6	141	1	3	1
MMRF_1057	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	103	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	103	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	134	Stem cell, Allogenic	1	1	MOVED TO SCT				4	68	3	233		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	103	1	9	233	3	68	1	3	1
MMRF_1057	1	Lenalidomide	Len	IMID	233	954	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	954	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	68	3	233		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	26	722	0	9	233	3	68			1
MMRF_1060	1	Cyclophosphamide/Vincristine/Dexamethasone	Cyc-Vin-Dex	Chemotherapy/Chemotherapy/Steroid	1	53	1	Cyclophosphamide/Vincristine/Dexamethasone	Cyc-Vin-Dex	1	Chemotherapy/Steroid	53	Other therapies	Other treatments					1					4	54	1	453		Complete Response	CR	Partial Response	PR	1	0	1	0	2	53	1	17	453	2	54			1
MMRF_1060	1	Bortezomib/Cyclophosphamide/Vincristine/Dexamethasone	Bor-Cyc-Vin-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	54	138	2	Cyclophosphamide/Vincristine/Dexamethasone + Bortezomib/Cyclophosphamide/Vincristine/Dexamethasone	Cyc-Vin-Dex + Bor-Cyc-Vin-Dex	1	Chemotherapy/Steroid/Proteasome	138	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	164	Stem cell, Autologous	1	1	Completed regimen	4			4	54	1	453		Complete Response	CR	Partial Response	PR	1	0	0	0	3	85	1	17	453	2	54	1	4	1
MMRF_1060	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	285	716	3	Cyclophosphamide/Vincristine/Dexamethasone + Bortezomib/Cyclophosphamide/Vincristine/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Cyc-Vin-Dex + Bor-Cyc-Vin-Dex + Bor-Len-Dex	1	Chemotherapy/Steroid/Proteasome/IMID	716	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	54	1	453		Complete Response	CR	Partial Response	PR	1	1	0	1	16	432	0	17	453	2	54			1
MMRF_1060	1	Lenalidomide	Len	IMID	717	898	4	Cyclophosphamide/Vincristine/Dexamethasone + Bortezomib/Cyclophosphamide/Vincristine/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Cyc-Vin-Dex + Bor-Cyc-Vin-Dex + Bor-Len-Dex + Len	1	Chemotherapy/Steroid/Proteasome/IMID	898	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	54	1	453		Complete Response	CR	Partial Response	PR	1	0	0	0	7	182	0	17	453	2	54			1
MMRF_1060	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1990	2088	1	Ixazomib/Dexamethasone	Ixa-Dex	1990	Proteasome/Steroid	2088	Other therapies	Other treatments					0	PERIPHERAL NEUROPATHY						5	2179	1990	Stable Disease	SD			0	1	0	1	4	99	0	7	190					1
MMRF_1070	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	93	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	95	Stem cell, Autologous	1	1	Completed regimen	4			4	68	3	390		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	93	1	14	390	3	68	1	3	1
MMRF_1070	1	Bortezomib	Bor	Proteasome	208	796	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	796	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	68	3	390		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	21	589	0	14	390	3	68			1
MMRF_1086	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	142	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	142	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	176	Stem cell, Autologous	1	1	MOVED TO AUTO SCT				3	107	3	107	1879	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	142	1	4	107	4	107	1	3	1
MMRF_1086	1	Lenalidomide	Len	IMID	257	479	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	479	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	107	3	107	1879	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	8	223	0	4	107	4	107			1
MMRF_1086	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1900	1955	1	Ixazomib/Dexamethasone	Ixa-Dex	1900	Proteasome/Steroid	1955	Other therapies	Other treatments					0					4	1970	4	1970	2633	Partial Response	PR	Partial Response	PR	1	0	0	0	2	56	0	3	71	3	71			1
MMRF_1086	2	Bortezomib/Ixazomib/Dexamethasone	Bor-Ixa-Dex	Proteasome/Proteasome/Steroid	1956	2203	2	Ixazomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone	Ixa-Dex + Bor-Ixa-Dex	1900	Proteasome/Steroid	2203	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1970	4	1970	2633	Partial Response	PR	Partial Response	PR	1	1	1	1	9	248	1	3	71	3	71	1	3	1
MMRF_1086	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2206	2507	3	Ixazomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone + Carfilzomib/Dexamethasone	Ixa-Dex + Bor-Ixa-Dex + Car-Dex	1900	Proteasome/Steroid	2507	combined bortezomib/carfilzomib-based	Carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1970	4	1970	2633	Partial Response	PR	Partial Response	PR	1	0	0	0	11	302	0	3	71	3	71			1
MMRF_1086	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2648	2885	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	2648	CD38/IMID/Steroid	2885	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0					4	2683	4	2683		Partial Response	PR	Partial Response	PR	1	1	1	1	9	238	1	2	36	2	36	1	3	1
MMRF_1097	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	81	3	81	1187	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	3	81	3	81	1	3	1
MMRF_1097	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1196	1492	1	Bortezomib/Dexamethasone	Bor-Dex	1196	Proteasome/Steroid	1492	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DOCTOR DECISION				4	1261	3	1492		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	11	297	1	11	297	3	66	1	2	1
MMRF_1110	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	71	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	71	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	96	Stem cell, Autologous	1	1	MOVED TO AUTO SCT		2304		3	51	3	51	1219	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	71	1	2	51	2	51	1	3	1
MMRF_1110	1	Lenalidomide	Len	IMID	204	876	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	876	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5	2304		3	51	3	51	1219	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	24	673	0	2	51	2	51			1
MMRF_1110	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1331	1496	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1331	Proteasome/Chemotherapy/Steroid	1496	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1503	Stem cell, Autologous	2	1	Completed regimen	4	2304		4	1542	4	1542	1702	Partial Response	PR	Partial Response	PR	1	1	1	1	6	166	1	8	212	8	212	1	3	1
MMRF_1110	2	Pomalidomide	Pom	IMID	1635	1822	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Pomalidomide	Car-Cyc-Dex + Pom	1331	Proteasome/Chemotherapy/Steroid/IMID	1822	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2304		4	1542	4	1542	1702	Partial Response	PR	Partial Response	PR	1	0	0	0	7	188	0	8	212	8	212			1
MMRF_1110	3	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1846	1895	1	Ixazomib/Dexamethasone	Ixa-Dex	1846	Proteasome/Steroid	1895	Other therapies	Other treatments					0	Disease progression/Relapse	3	2304				6	1905	1905	Progressive Disease	PD			0	1	0	1	2	50	0	3	60					1
MMRF_1110	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1909	2142	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1909	CD38/IMID/Steroid	2142	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Adverse Event or co-morbidity	2	2304											0	0	0	0	9	234	0					1	3	1
MMRF_1110	5	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2304	2350	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2304	CD38/IMID/Steroid	2350	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Adverse Event or co-morbidity	2	2304				6	2304	2304	Progressive Disease	PD			0	1	0	1	2	47	0	1	1			1	3	1
MMRF_1119	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	70	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	70	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	109	Stem cell, Autologous	1	1	MOVED TO AUTO SCT				4	43	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	70	1	6	162	2	43	1	3	1
MMRF_1119	1	Lenalidomide	Len	IMID	207	2944	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2944	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	43	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	98	2738	0	6	162	2	43			1
MMRF_1138	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	60	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	60	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	117	Stem cell, Autologous	1	1	MOVED TO SCT				4	609	4	609		Partial Response	PR	Partial Response	PR	1	0	0	0	2	60	0	22	609	22	609	1	3	1
MMRF_1138	1	Lenalidomide	Len	IMID	258	811	2	Bortezomib/Thalidomide/Dexamethasone + Lenalidomide	Bor-Thal-Dex + Len	1	Proteasome/IMID/Steroid	811	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	609	4	609		Partial Response	PR	Partial Response	PR	1	1	1	1	20	554	1	22	609	22	609			1
MMRF_1141	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	175	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	175	1	4	91	4	91	1	3	1
MMRF_1142	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	63	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	63	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	MOVED TO SCT				3	70	3	70		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	63	1	3	70	3	70	1	3	1
MMRF_1142	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	103	105	2	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Dexamethasone	Bor-Len-Dex + Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	105	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	106	Stem cell, Autologous	1	1	Completed regimen	4			3	70	3	70		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	3	0	3	70	3	70			1
MMRF_1142	1	Lenalidomide	Len	IMID	216	948	3	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	948	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	70	3	70		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	26	733	0	3	70	3	70			1
MMRF_1143	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	187	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	187	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			3	89	3	89	656	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	187	1	4	89	4	89	1	2	1
MMRF_1143	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	997	1090	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	997	Proteasome/IMID/Steroid	1090	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	1100	Stem cell, Autologous	1	1	Completed regimen	4			4	1081	4	1081		Partial Response	PR	Partial Response	PR	1	1	1	1	4	94	1	4	85	4	85	1	3	1
MMRF_1143	3	Lenalidomide	Len	IMID	1202	1652	1	Lenalidomide	Len	1202	IMID	1652	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	1482	4	1482	1202	Partial Response	PR	Partial Response	PR	1	1	1	1	16	451	1	11	281	11	281	1	1	1
MMRF_1143	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2887	2908	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2887	CD38/IMID/Steroid	2908	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					3	2930	3	2930		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	22	1	2	44	2	44	1	3	1
MMRF_1155	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	67	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	67	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	105	Stem cell, Autologous	1	1	MOVED TO SCT				4	84	3	543	718	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	67	1	20	543	3	84	1	3	1
MMRF_1155	1	Lenalidomide	Len	IMID	238	596	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	596	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	84	3	543	718	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	13	359	0	20	543	3	84			1
MMRF_1155	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1473	1586	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1473	Proteasome/Chemotherapy/Steroid	1586	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	1593	Stem cell, Autologous	2	1	Completed regimen	4			4	1635	3	1694	2468	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	114	1	8	222	6	163	1	3	1
MMRF_1155	2	Ixazomib	Ixa	Proteasome	1771	2468	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Ixazomib	Car-Cyc-Dex + Ixa	1473	Proteasome/Chemotherapy/Steroid	2468	Carfilzomib-based	Other treatments	Other Cafilzomib-based therapies				1	Disease progression/Relapse	3			4	1635	3	1694	2468	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	25	698	0	8	222	6	163			1
MMRF_1155	3	TAK-079/Dexamethasone	TAK-079-Dex	CD38/Steroid	2482	2713	1	TAK-079/Dexamethasone	TAK-079-Dex	2482	CD38/Steroid	2713	Other therapies	Other treatments					0	Disease progression/Relapse	3					5	2545	2713	Stable Disease	SD			0	1	0	1	9	232	0	3	64					1
MMRF_1155	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	2748	2895	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	2748	Proteasome/IMID/Steroid	2895	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	2895	4	2895		Partial Response	PR	Partial Response	PR	1	1	1	1	6	148	1	6	148	6	148	1	3	1
MMRF_1160	1	Bortezomib	Bor	Proteasome	1	69	1	Bortezomib	Bor	1	Proteasome	69	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	3	69	0					1	1	1
MMRF_1173	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	126	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	133	Stem cell, Autologous	1	1	Completed regimen	4			4	186	3	274		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	126	1	10	274	7	186	1	3	1
MMRF_1173	1	Lenalidomide	Len	IMID	248	2976	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2976	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	186	3	274		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	98	2729	0	10	274	7	186			1
MMRF_1195	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	88	1	268		Complete Response	CR	Partial Response	PR	1	0	1	0	4	105	1	10	268	4	88	1	3	1
MMRF_1195	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	106	108	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	108	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	88	1	268		Complete Response	CR	Partial Response	PR	1	0	0	0	0	3	0	10	268	4	88			1
MMRF_1195	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	109	676	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	676	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	109	Stem cell, Autologous	1	1					4	88	1	268		Complete Response	CR	Partial Response	PR	1	1	0	1	21	568	0	10	268	4	88			1
MMRF_1219	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	95	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	95	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			4	68	4	68		Partial Response	PR	Partial Response	PR	1	1	1	1	4	95	1	3	68	3	68	1	3	1
MMRF_1219	2	Carfilzomib/Doxorubicin	Car-Dox	Proteasome/Chemotherapy	278	1307	1	Carfilzomib/Doxorubicin	Car-Dox	278	Proteasome/Chemotherapy	1307	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	362	4	362	278	Partial Response	PR	Partial Response	PR	1	1	1	1	37	1030	1	4	85	4	85	1	2	1
MMRF_1219	3	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1377	2945	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1377	SLAMF7/IMID/Steroid	2945	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					4	1601	4	1601		Partial Response	PR	Partial Response	PR	1	1	1	1	56	1569	1	9	225	9	225	1	3	1
MMRF_1225	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	132	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	132	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	158	Stem cell, Autologous	1	1	MOVED TO SCT				4	74	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	132	1	13	358	3	74	1	3	1
MMRF_1225	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	267	344	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	344	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	74	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	78	0	13	358	3	74			1
MMRF_1225	1	Lenalidomide	Len	IMID	345	394	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	394	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	74	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	2	50	0	13	358	3	74			1
MMRF_1225	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	410	960	4	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide	Bor-Len-Dex + Len + Bor-Len	1	Proteasome/IMID/Steroid	960	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Patient decision	6			4	74	3	358		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	20	551	0	13	358	3	74			1
MMRF_1225	3	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1669	2489	1	Ixazomib/Dexamethasone	Ixa-Dex	1669	Proteasome/Steroid	2489	Other therapies	Other treatments					0	Disease progression/Relapse	3					5	1816	2461	Stable Disease	SD			0	1	0	1	30	821	0	6	148					1
MMRF_1225	4	TAK-079/Dexamethasone	TAK-079-Dex	CD38/Steroid	2507	2899	1	TAK-079/Dexamethasone	TAK-079-Dex	2507	CD38/Steroid	2899	Other therapies	Other treatments					0					4	2535	3	2703		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	393	1	8	197	2	29			1
MMRF_1226	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	68	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	68	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	99	Stem cell, Autologous	1	1	Completed regimen	4			1	78	1	78	1377	Complete Response	CR	Complete Response	CR	1	1	1	1	3	68	1	3	78	3	78	1	3	1
MMRF_1226	1	Bortezomib	Bor	Proteasome	218	735	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	735	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					1	78	1	78	1377	Complete Response	CR	Complete Response	CR	1	0	0	0	19	518	0	3	78	3	78			1
MMRF_1226	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	736	1212	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor + Bor-Len	1	Proteasome/IMID/Steroid	1212	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	DOCTOR DECISION				1	78	1	78	1377	Complete Response	CR	Complete Response	CR	1	0	0	0	17	477	0	3	78	3	78			1
MMRF_1226	1	Lenalidomide	Len	IMID	1213	1218	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor + Bor-Len	1	Proteasome/IMID/Steroid	1218	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					1	78	1	78	1377	Complete Response	CR	Complete Response	CR	1	0	0	0	1	6	0	3	78	3	78			1
MMRF_1226	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1219	1798	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide + Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor + Bor-Len + Ixa-Len-Dex	1	Proteasome/IMID/Steroid	1798	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					1	78	1	78	1377	Complete Response	CR	Complete Response	CR	1	0	0	0	21	580	0	3	78	3	78			1
MMRF_1234	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	79	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	79	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	99	3	313		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	79	0	12	313	4	99	1	3	1
MMRF_1234	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	80	82	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	82	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	99	3	313		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	3	0	12	313	4	99			1
MMRF_1234	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	83	203	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	203	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	83	Stem cell, Autologous	1	1					4	99	3	313		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	121	1	12	313	4	99			1
MMRF_1234	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	204	206	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	206	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	99	3	313		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	3	0	12	313	4	99			1
MMRF_1234	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	207	410	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	410	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	99	3	313		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	8	204	0	12	313	4	99			1
MMRF_1269	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	103	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	103	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	138	Stem cell, Autologous	1	1	Completed regimen	4			4	43	4	43	1462	Partial Response	PR	Partial Response	PR	1	1	1	1	4	103	1	2	43	2	43	1	3	1
MMRF_1269	1	Lenalidomide	Len	IMID	236	1462	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1462	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	43	4	43	1462	Partial Response	PR	Partial Response	PR	1	0	0	0	44	1227	0	2	43	2	43			1
MMRF_1269	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1475	1538	1	Carfilzomib/Dexamethasone	Car-Dex	1475	Proteasome/Steroid	1538	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3					5	1502	1538	Stable Disease	SD			0	1	0	1	3	64	0	1	28			1	2	1
MMRF_1269	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1544	1590	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1544	CD38/IMID/Steroid	1590	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	DEATH													0	0	0	0	2	47	0					1	3	1
MMRF_1270	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	45	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	45	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0														0	0	0	0	2	45	0					1	3	1
MMRF_1289	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	49	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	49	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	91	Stem cell, Autologous	1	1	MOVED TO AUTO SCT				3	46	3	46		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	49	1	2	46	2	46	1	3	1
MMRF_1289	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	219	295	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len	1	Proteasome/IMID/Steroid	295	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	46	3	46		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	77	0	2	46	2	46			1
MMRF_1289	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	330	393	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide + Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len + Car-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	393	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Disease progression/Relapse	3			3	46	3	46		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	64	0	2	46	2	46			1
MMRF_1289	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	393	417	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	393	Chemotherapy/Steroid	417	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	393	393	Progressive Disease	PD			0	1	0	1	1	25	0	1	1					1
MMRF_1289	3	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine	Carm-Cyc-Mel-Pred-Vin	Chemotherapy/Chemotherapy/Chemotherapy/Steroid/Chemotherapy	465	477	1	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine	Carm-Cyc-Mel-Pred-Vin	465	Chemotherapy/Steroid	477	Other therapies	Other treatments					0	PATIENT WENT ON HOSPICE													0	0	0	0	1	13	0					1	5	1
MMRF_1356	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	260	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	260	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4					5	176	464	Stable Disease	SD			0	1	0	1	10	260	0	7	176			1	3	1
MMRF_1356	1	Lenalidomide	Len	IMID	261	464	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	464	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	552	Stem cell, Autologous	1	1	Disease progression/Relapse	3					5	176	464	Stable Disease	SD			0	0	0	0	8	204	0	7	176					1
MMRF_1356	2	Bortezomib	Bor	Proteasome	659	1002	1	Bortezomib	Bor	659	Proteasome	1002	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			4	649	4	649	1013	Partial Response	PR	Partial Response	PR	1	0	0	0	13	344	0	0	-9	0	-9	1	1	1
MMRF_1356	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1018	1298	2	Bortezomib + Elotuzumab/Lenalidomide/Dexamethasone	Bor + Elo-Len-Dex	659	Proteasome/SLAMF7/IMID/Steroid	1298	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	649	4	649	1013	Partial Response	PR	Partial Response	PR	1	0	0	0	10	281	0	0	-9	0	-9			1
MMRF_1356	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1424	1501	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1424	Proteasome/IMID/Steroid	1501	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2					5	1487	1675	Stable Disease	SD			0	1	0	1	3	78	0	3	64			1	3	1
MMRF_1356	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1515	1675	2	Carfilzomib/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone	Car-Len-Dex + Dar-Dex	1424	Proteasome/IMID/Steroid/CD38	1675	combined daratumumab/IMIDs/carfilzomib-based	daratumumab-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3					5	1487	1675	Stable Disease	SD			0	0	0	0	6	161	0	3	64					1
MMRF_1373	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	71	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	71	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			3	58	3	58		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	71	1	3	58	3	58	1	3	1
MMRF_1373	1	Lenalidomide	Len	IMID	227	424	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	424	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	58	3	58		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	198	0	3	58	3	58			1
MMRF_1390	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	47	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	47	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Lack of response	1			3	78	3	78		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	47	1	3	78	3	78	1	2	1
MMRF_1441	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	203	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	203	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	85	4	85		Partial Response	PR	Partial Response	PR	1	1	1	1	8	203	1	4	85	4	85	1	3	1
MMRF_1445	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	86	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	86	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	93	4	93		Partial Response	PR	Partial Response	PR	1	1	1	1	3	86	1	4	93	4	93	1	3	1
MMRF_1445	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	133	184	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	184	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	93	4	93		Partial Response	PR	Partial Response	PR	1	0	0	0	2	52	0	4	93	4	93			1
MMRF_1496	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	46	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	46	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	89	3	226	340	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	46	0	9	226	4	89	1	2	1
MMRF_1496	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	47	120	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	120	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	89	3	226	340	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	74	1	9	226	4	89			1
MMRF_1496	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	121	121	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	121	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	124	Stem cell, Autologous	1	1	Completed regimen	4			4	89	3	226	340	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	9	226	4	89			1
MMRF_1496	1	Lenalidomide	Len	IMID	226	288	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Len	1	Proteasome/Steroid/IMID/Chemotherapy	288	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	89	3	226	340	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	3	63	0	9	226	4	89			1
MMRF_1496	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	289	293	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Len + Len-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	293	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	89	3	226	340	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	5	0	9	226	4	89			1
MMRF_1496	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	320	370	6	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Len + Len-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	370	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	89	3	226	340	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	51	0	9	226	4	89			1
MMRF_1496	2	Carfilzomib	Car	Proteasome	342	382	1	Carfilzomib	Car	342	Proteasome	382	Carfilzomib-based	Carfilzomib-based	Car-Dex				1					4	461	4	461		Partial Response	PR	Partial Response	PR	1	0	0	0	2	41	0	5	120	5	120	1	1	1
MMRF_1496	2	Carfilzomib/Pomalidomide	Car-Pom	Proteasome/IMID	383	422	2	Carfilzomib + Carfilzomib/Pomalidomide	Car + Car-Pom	342	Proteasome/IMID	422	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1					4	461	4	461		Partial Response	PR	Partial Response	PR	1	0	0	0	2	40	0	5	120	5	120			1
MMRF_1496	2	Carfilzomib/Pomalidomide/Cyclophosphamide	Car-Pom-Cyc	Proteasome/IMID/Chemotherapy	423	423	3	Carfilzomib + Carfilzomib/Pomalidomide + Carfilzomib/Pomalidomide/Cyclophosphamide	Car + Car-Pom + Car-Pom-Cyc	342	Proteasome/IMID/Chemotherapy	423	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	427	Stem cell, Allogenic	2	1	Completed regimen	4			4	461	4	461		Partial Response	PR	Partial Response	PR	1	1	1	1	0	1	1	5	120	5	120			1
MMRF_1511	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	63	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	63	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	78	Stem cell, Autologous	1	1	MOVED TO SCT				3	110	3	110		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	63	1	4	110	4	110	1	3	1
MMRF_1511	1	Bortezomib	Bor	Proteasome	192	776	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	776	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					3	110	3	110		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	21	585	0	4	110	4	110			1
MMRF_1511	1	Bortezomib/Carfilzomib	Bor-Car	Proteasome/Proteasome	777	777	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Carfilzomib	Bor-Len-Dex + Bor + Bor-Car	1	Proteasome/IMID/Steroid	777	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/carfilzomib-based	Bor-Len-Car-Dex				1	INCREASING NEUROPATHY				3	110	3	110		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	110	4	110			1
MMRF_1511	1	Carfilzomib	Car	Proteasome	778	973	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Carfilzomib	Bor-Len-Dex + Bor + Bor-Car	1	Proteasome/IMID/Steroid	973	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Dex				1	Completed regimen	4			3	110	3	110		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	196	0	4	110	4	110			1
MMRF_1511	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1215	1496	1	Ixazomib/Dexamethasone	Ixa-Dex	1215	Proteasome/Steroid	1496	Other therapies	Other treatments					0	Disease progression/Relapse	3					5	1257	1215	Stable Disease	SD			0	1	0	1	10	282	0	2	43					1
MMRF_1511	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1518	2241	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1518	CD38/IMID/Steroid	2241	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	1581	3	1798	2202	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	26	724	1	11	281	3	64	1	3	1
MMRF_1511	4	Bortezomib/Elotuzumab/Dexamethasone	Bor-Elo-Dex	Proteasome/SLAMF7/Steroid	2252	2367	1	Bortezomib/Elotuzumab/Dexamethasone	Bor-Elo-Dex	2252	Proteasome/SLAMF7/Steroid	2367	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	2350	3	2722	2840	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	116	1	17	471	4	99	1	3	1
MMRF_1511	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2477	2790	2	Bortezomib/Elotuzumab/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Elo-Dex + Car-Cyc-Dex	2252	Proteasome/SLAMF7/Steroid/Chemotherapy	2790	combined bortezomib/carfilzomib-based	Carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	2350	3	2722	2840	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	12	314	0	17	471	4	99			1
MMRF_1511	4	Carfilzomib/Pomalidomide/Cyclophosphamide/Isatuximab/Dexamethasone	Car-Pom-Cyc-Isa-Dex	Proteasome/IMID/Chemotherapy/CD38/Steroid	2791	2791	3	Bortezomib/Elotuzumab/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Isatuximab/Dexamethasone	Bor-Elo-Dex + Car-Cyc-Dex + Car-Pom-Cyc-Isa-Dex	2252	Proteasome/SLAMF7/Steroid/Chemotherapy/IMID/CD38	2791	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Adverse Event or co-morbidity	2			4	2350	3	2722	2840	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	17	471	4	99			1
MMRF_1511	4	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	IMID/CD38/Steroid	2792	2847	4	Bortezomib/Elotuzumab/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Isatuximab/Dexamethasone + Pomalidomide/Isatuximab/Dexamethasone	Bor-Elo-Dex + Car-Cyc-Dex + Car-Pom-Cyc-Isa-Dex + Pom-Isa-Dex	2252	Proteasome/SLAMF7/Steroid/Chemotherapy/IMID/CD38	2847	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3			4	2350	3	2722	2840	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	56	0	17	471	4	99			1
MMRF_1584	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	32	32	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	32	Proteasome/IMID/Steroid	32	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	CHNAGED DOSE													0	0	0	0	0	1	0					1	3	1
MMRF_1624	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	142	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	142	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	184	Stem cell, Autologous	1	1	Completed regimen	4			3	62	1	574	1440	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	142	1	21	574	3	62	1	3	1
MMRF_1624	1	Lenalidomide	Len	IMID	292	1440	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1440	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	62	1	574	1440	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	41	1149	0	21	574	3	62			1
MMRF_1624	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1449	1582	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1449	CD38/IMID/Steroid	1582	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	1472	4	1472	1582	Partial Response	PR	Partial Response	PR	1	1	1	1	5	134	1	1	24	1	24	1	3	1
MMRF_1624	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1616	1839	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1616	Proteasome/IMID/Steroid	1839	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1					3	1692	3	1692	1846	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	224	1	3	77	3	77	1	3	1
MMRF_1624	3	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1840	1861	2	Carfilzomib/Pomalidomide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Dex + Car-Pom-Cyc-Dex	1616	Proteasome/IMID/Steroid/Chemotherapy	1861	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	1924	Stem cell, Autologous	2	1	Disease progression/Relapse	3			3	1692	3	1692	1846	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	3	77	3	77			1
MMRF_1667	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	107	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	107	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	149	Stem cell, Autologous	1	1	MOVED TO SCT				4	68	3	254		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	107	1	10	254	3	68	1	3	1
MMRF_1667	1	Lenalidomide	Len	IMID	259	536	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	536	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	68	3	254		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	10	278	0	10	254	3	68			1
MMRF_1668	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	142	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	142	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			3	77	3	77		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	142	1	3	77	3	77	1	3	1
MMRF_1668	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	142	202	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	142	Proteasome/IMID/Steroid	202	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3					6	142	142	Progressive Disease	PD			0	1	0	1	2	61	0	1	1			1	3	1
MMRF_1668	3	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	209	251	1	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	209	Proteasome/IMID/Chemotherapy/Steroid	251	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	251	Stem cell, Autologous	1	1	Completed regimen	4					6	254	254	Progressive Disease	PD			0	1	0	1	2	43	0	2	46			1	4	1
MMRF_1760	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	134	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	134	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	78	197	Stable Disease	SD			0	1	0	1	5	134	0	3	78			1	2	1
MMRF_1760	1	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	135	197	2	Lenalidomide/Dexamethasone + Melphalan/Prednisone	Len-Dex + Mel-Pred	1	IMID/Steroid/Chemotherapy	197	IMIDs-based	Other treatments	Other Len-based therapies				0	Disease progression/Relapse	3					5	78	197	Stable Disease	SD			0	0	0	0	3	63	0	3	78					1
MMRF_1760	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	211	848	1	Bortezomib/Dexamethasone	Bor-Dex	211	Proteasome/Steroid	848	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	348	4	348	939	Partial Response	PR	Partial Response	PR	1	1	1	1	23	638	1	5	138	5	138	1	2	1
MMRF_1760	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	953	1113	1	Pomalidomide/Dexamethasone	Pom-Dex	953	IMID/Steroid	1113	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2					5	988	1198	Stable Disease	SD			0	1	0	1	6	161	0	2	36			1	2	1
MMRF_1760	4	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1211	2052	1	Daratumumab/Dexamethasone	Dar-Dex	1211	CD38/Steroid	2052	daratumumab-based	daratumumab-based	Dar-Dex				0	Adverse Event or co-morbidity	2			4	1268	3	1450		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	30	842	1	9	240	3	58			1
MMRF_1783	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	156	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	156	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	65	3	65		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	156	1	3	65	3	65	1	3	1
MMRF_1783	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	192	380	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len	1	Proteasome/IMID/Steroid	380	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	65	3	65		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	189	0	3	65	3	65			1
MMRF_1783	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	380	481	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	380	Proteasome/Chemotherapy/Steroid	481	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	495	Stem cell, Autologous	1	1	Completed regimen	4			3	523	3	523	380	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	102	1	6	144	6	144	1	3	1
MMRF_1783	2	Pomalidomide	Pom	IMID	632	718	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Pomalidomide	Car-Cyc-Dex + Pom	380	Proteasome/Chemotherapy/Steroid/IMID	718	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	DEATH				3	523	3	523	380	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	87	0	6	144	6	144			1
MMRF_1784	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	123	Stem cell, Autologous	1	1	MOVED TO SCT		2492		3	71	3	71	1688	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	77	1	3	71	3	71	1	3	1
MMRF_1784	1	Lenalidomide	Len	IMID	204	1688	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1688	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	2492		3	71	3	71	1688	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	53	1485	0	3	71	3	71			1
MMRF_1784	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1702	1814	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1702	SLAMF7/IMID/Steroid	1814	IMIDs-based	IMIDs-based	Other Pom-based therapies	1822	Stem cell, Autologous	2	1	Completed regimen	4	2492		4	1789	3	1957	2108	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	113	1	10	256	4	88	1	3	1
MMRF_1784	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1929	2108	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1702	SLAMF7/IMID/Steroid	2108	IMIDs-based	IMIDs-based	Other Pom-based therapies				1	Disease progression/Relapse	3	2492		4	1789	3	1957	2108	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	7	180	0	10	256	4	88			1
MMRF_1784	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2110	2332	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	2110	Proteasome/Chemotherapy/Steroid	2332	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2492				6	2321	2321	Progressive Disease	PD			0	1	0	1	8	223	0	8	212			1	3	1
MMRF_1784	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2333	2402	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2333	CD38/IMID/Steroid	2402	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2492				6	2402	2402	Progressive Disease	PD			0	1	0	1	3	70	0	3	70			1	3	1
MMRF_1784	5	Belantamab mafodotin	Bela	BCMA	2419	2440	1	Belantamab mafodotin	Bela	2419	BCMA	2440	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2	2492				6	2492	2492	Progressive Disease	PD			0	1	0	1	1	22	0	3	74					1
MMRF_1839	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	102	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	102	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	116	Stem cell, Autologous	1	1	Completed regimen	4			4	50	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	102	1	6	155	2	50	1	3	1
MMRF_1839	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	240	1123	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Len	1	Proteasome/IMID/Steroid	1123	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	50	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	32	884	0	6	155	2	50			1
MMRF_1851	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	25	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	25	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	PATIENT WENT ON HOSPICE													0	0	0	0	1	25	0					1	3	1
MMRF_1876	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	85	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	85	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	149	Stem cell, Autologous	1	1	Completed regimen	4			4	57	3	183	445	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	85	1	7	183	3	57	1	3	1
MMRF_1876	1	Lenalidomide	Len	IMID	239	490	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	490	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	57	3	183	445	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	9	252	0	7	183	3	57			1
MMRF_1876	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	490	564	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	490	Proteasome/Chemotherapy/Steroid	564	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Lack of response	1					6	505	505	Progressive Disease	PD			0	1	0	1	3	75	0	1	16			1	3	1
MMRF_1889	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	106	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	142	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64	407	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	3	64	3	64	1	3	1
MMRF_1889	1	Lenalidomide	Len	IMID	266	421	2	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	421	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1	Disease progression/Relapse	3			3	64	3	64	407	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	156	0	3	64	3	64			1
MMRF_1889	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	421	519	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	421	Proteasome/Chemotherapy/Steroid	519	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3					6	512	512	Progressive Disease	PD			0	1	0	1	4	99	0	4	92			1	3	1
MMRF_1889	3	Carfilzomib/Thalidomide/Dexamethasone	Car-Thal-Dex	Proteasome/IMID/Steroid	519	556	1	Carfilzomib/Thalidomide/Dexamethasone	Car-Thal-Dex	519	Proteasome/IMID/Steroid	556	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	610	4	610	638	Partial Response	PR	Partial Response	PR	1	0	0	0	2	38	0	4	92	4	92	1	3	1
MMRF_1889	3	Carfilzomib/Thalidomide/Bendamustine/Dexamethasone	Car-Thal-Bend-Dex	Proteasome/IMID/Chemotherapy/Steroid	557	638	2	Carfilzomib/Thalidomide/Dexamethasone + Carfilzomib/Thalidomide/Bendamustine/Dexamethasone	Car-Thal-Dex + Car-Thal-Bend-Dex	519	Proteasome/IMID/Steroid/Chemotherapy	638	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	610	4	610	638	Partial Response	PR	Partial Response	PR	1	1	1	1	3	82	1	4	92	4	92			1
MMRF_1889	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	659	800	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	659	CD38/IMID/Steroid	800	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Adverse Event or co-morbidity	2					5	680	785	Stable Disease	SD			0	1	0	1	5	142	0	1	22			1	3	1
MMRF_1891	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	102	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	102	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	43	4	43	634	Partial Response	PR	Partial Response	PR	1	1	1	1	4	102	1	2	43	2	43	1	3	1
MMRF_1891	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	103	103	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	103	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	106	Stem cell, Autologous	1	1	Completed regimen	4			4	43	4	43	634	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	43	2	43			1
MMRF_1891	1	Lenalidomide	Len	IMID	204	599	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	599	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	43	4	43	634	Partial Response	PR	Partial Response	PR	1	0	0	0	14	396	0	2	43	2	43			1
MMRF_1891	2	Azintuxizumab vedotin	Azin	SLAMF7	645	1037	1	Azintuxizumab vedotin	Azin	645	SLAMF7	1037	Other therapies	Other treatments					0	NEUROPATHY				4	1114	4	1114		Partial Response	PR	Partial Response	PR	1	0	0	0	14	393	0	17	470	17	470			1
MMRF_1891	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1058	2878	2	Azintuxizumab vedotin + Elotuzumab/Lenalidomide/Dexamethasone	Azin + Elo-Len-Dex	645	SLAMF7/IMID/Steroid	2878	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1114	4	1114		Partial Response	PR	Partial Response	PR	1	1	1	1	65	1821	1	17	470	17	470	1	3	1
MMRF_1893	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	73	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	73	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	120	Stem cell, Autologous	1	1	Completed regimen	4			4	57	4	57		Partial Response	PR	Partial Response	PR	1	1	1	1	3	73	1	3	57	3	57	1	3	1
MMRF_1893	1	Lenalidomide	Len	IMID	232	802	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	802	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	PATIENT FORGETFULLNESS AND INABILITY/RELUCTANCE TO MEET DEDUCTIBLE				4	57	4	57		Partial Response	PR	Partial Response	PR	1	0	0	0	21	571	0	3	57	3	57			1
MMRF_1900	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	253	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	253	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	288	3	288		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	9	253	0	11	288	11	288	1	3	1
MMRF_1900	1	Lenalidomide	Len	IMID	254	344	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	344	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	288	3	288		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	91	1	11	288	11	288			1
MMRF_1900	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	405	708	1	Lenalidomide/Dexamethasone	Len-Dex	405	IMID/Steroid	708	IMIDs-based	IMIDs-based	Len-Dex				0	DOCTOR DECISION				4	489	4	489	407	Partial Response	PR	Partial Response	PR	1	1	1	1	11	304	1	4	85	4	85	1	2	1
MMRF_1900	3	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	925	1282	1	Lenalidomide/Dexamethasone	Len-Dex	925	IMID/Steroid	1282	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH						5	960	925	Stable Disease	SD			0	1	0	1	13	358	0	2	36			1	2	1
MMRF_1911	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	91	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	91	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	119	Stem cell, Autologous	1	1	Completed regimen	4			1	70	1	70		Complete Response	CR	Complete Response	CR	1	1	1	1	4	91	1	3	70	3	70	1	3	1
MMRF_1911	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	213	317	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	317	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1	Completed regimen	4			1	70	1	70		Complete Response	CR	Complete Response	CR	1	0	0	0	4	105	0	3	70	3	70			1
MMRF_1911	1	Lenalidomide	Len	IMID	360	2698	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	2698	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1	Adverse Event or co-morbidity	2			1	70	1	70		Complete Response	CR	Complete Response	CR	1	0	0	0	84	2339	0	3	70	3	70			1
MMRF_1953	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	65	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	65	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			3	65	3	65		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	65	1	3	65	3	65	1	3	1
MMRF_1953	1	Lenalidomide	Len	IMID	248	940	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	940	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	65	3	65		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	25	693	0	3	65	3	65			1
MMRF_1955	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	162	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	162	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5			3	85	3	85	415	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	162	1	4	85	4	85	1	2	1
MMRF_1974	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	96	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	96	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	106	Stem cell, Autologous	1	1	Completed regimen	4			4	121	3	188		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	96	1	7	188	5	121	1	3	1
MMRF_1974	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	188	363	2	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	363	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Disease progression/Relapse	3			4	121	3	188		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	7	176	0	7	188	5	121			1
MMRF_1974	2	Pomalidomide/Clarithromycin/Dexamethasone	Pom-Clar-Dex	IMID/Antibiotic/Steroid	371	398	1	Pomalidomide/Clarithromycin/Dexamethasone	Pom-Clar-Dex	371	IMID/Antibiotic/Steroid	398	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3			4	534	3	608	384	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	28	0	9	238	6	164	1	3	1
MMRF_1974	2	Cyclophosphamide/Prednisone/Bendamustine/Dexamethasone	Cyc-Pred-Bend-Dex	Chemotherapy/Steroid/Chemotherapy/Steroid	408	545	2	Pomalidomide/Clarithromycin/Dexamethasone + Cyclophosphamide/Prednisone/Bendamustine/Dexamethasone	Pom-Clar-Dex + Cyc-Pred-Bend-Dex	371	IMID/Antibiotic/Steroid/Chemotherapy	545	IMIDs-based	Other treatments	Other Pom-based therapies				0	Investigator decision for other reasons	5			4	534	3	608	384	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	138	1	9	238	6	164			1
MMRF_1974	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	573	713	3	Pomalidomide/Clarithromycin/Dexamethasone + Cyclophosphamide/Prednisone/Bendamustine/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Pom-Clar-Dex + Cyc-Pred-Bend-Dex + Dar-Pom-Dex	371	IMID/Antibiotic/Steroid/Chemotherapy/CD38	713	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3			4	534	3	608	384	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	141	0	9	238	6	164			1
MMRF_1974	3	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	721	842	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	721	Chemotherapy/Steroid	842	Other therapies	Other treatments					0	Disease progression/Relapse	3			3	804	3	804	839	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	122	1	3	84	3	84			1
MMRF_1974	4	Pomalidomide/Nivolumab/Dexamethasone	Pom-Niv-Dex	IMID/Checkpoint Inhibitor/Steroid	863	892	1	Pomalidomide/Nivolumab/Dexamethasone	Pom-Niv-Dex	863	IMID/Checkpoint Inhibitor/Steroid	892	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	DEATH													0	0	0	0	1	30	0					1	3	1
MMRF_1982	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	91	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	91	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	172	Stem cell, Autologous	1	1	Completed regimen	4			4	117	3	206		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	91	1	8	206	5	117	1	3	1
MMRF_1986	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	398	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	398	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DISCONTINUED DUE TO GRADE 2 TRANSAMINITIS				3	195	3	195		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	15	398	1	7	195	7	195	1	3	1
MMRF_1999	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Completed regimen	4			3	56	3	56		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	56	1	2	56	2	56	1	3	1
MMRF_2014	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	93	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	109	Stem cell, Autologous	1	1	Completed regimen	4			4	93	3	332	1010	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	93	1	12	332	4	93	1	3	1
MMRF_2014	1	Lenalidomide	Len	IMID	212	457	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	457	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	93	3	332	1010	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	9	246	0	12	332	4	93			1
MMRF_2014	1	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	458	711	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Prednisone	Bor-Len-Dex + Len + Len-Pred	1	Proteasome/IMID/Steroid	711	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	93	3	332	1010	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	9	254	0	12	332	4	93			1
MMRF_2014	1	Lenalidomide	Len	IMID	712	1010	4	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Prednisone + Lenalidomide	Bor-Len-Dex + Len + Len-Pred + Len	1	Proteasome/IMID/Steroid	1010	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	93	3	332	1010	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	11	299	0	12	332	4	93			1
MMRF_2014	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1066	1320	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1066	SLAMF7/IMID/Steroid	1320	IMIDs-based	IMIDs-based	Other Len-based therapies				0	SHOULDER SURGERY				4	1094	3	1150	2007	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	255	1	4	85	2	29	1	3	1
MMRF_2014	3	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	2042	2094	1	Lenalidomide/Dexamethasone	Len-Dex	2042	IMID/Steroid	2094	IMIDs-based	IMIDs-based	Len-Dex				0	PATIENT DECEASED						6	2042	2042	Progressive Disease	PD			0	1	0	1	2	53	0	1	1			1	2	1
MMRF_2043	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	81	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	105	Stem cell, Autologous	1	1	Completed regimen	4			3	81	3	81	2625	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	81	1	3	81	3	81	1	3	1
MMRF_2043	1	Lenalidomide	Len	IMID	202	254	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	254	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Patient decision	6			3	81	3	81	2625	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	53	0	3	81	3	81			1
MMRF_2043	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	2755	2818	1	Bortezomib/Dexamethasone	Bor-Dex	2755	Proteasome/Steroid	2818	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	2818	4	2818		Partial Response	PR	Partial Response	PR	1	1	1	1	3	64	1	3	64	3	64	1	2	1
MMRF_2063	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	1	46	1	Bortezomib/Cyclophosphamide	Bor-Cyc	1	Proteasome/Chemotherapy	46	Bortezomib-based	Bortezomib-based	Bor-Cyc				0	PATIENT EXPIRED													0	0	0	0	2	46	0					1	2	1
MMRF_2101	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	89	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	89	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	112	Stem cell, Autologous	1	1	Completed regimen	4			4	89	1	252	2461	Complete Response	CR	Partial Response	PR	1	0	1	0	3	89	1	9	252	4	89	1	3	1
MMRF_2101	1	Lenalidomide	Len	IMID	224	2478	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2478	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	89	1	252	2461	Complete Response	CR	Partial Response	PR	1	1	0	1	81	2255	0	9	252	4	89			1
MMRF_2101	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2507	2703	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2507	CD38/IMID/Steroid	2703	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0							5	2703		Stable Disease	SD			0	1	0	1	7	197	0	8	197			1	3	1
MMRF_2124	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	1	159	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	159	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex	167	Stem cell, Autologous	1	1	Completed regimen	4			3	103	1	455	1218	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	159	1	17	455	4	103	1	4	1
MMRF_2124	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	280	679	2	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	679	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Dex				1	Completed regimen	4			3	103	1	455	1218	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	15	400	0	17	455	4	103			1
MMRF_2124	1	Lenalidomide	Len	IMID	680	1218	3	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	1218	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Dex				1	Disease progression/Relapse	3			3	103	1	455	1218	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	20	539	0	17	455	4	103			1
MMRF_2124	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1258	1370	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1258	SLAMF7/IMID/Steroid	1370	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Completed regimen	4			3	1344	3	1344	1370	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	113	1	4	87	4	87	1	3	1
MMRF_2124	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1386	1475	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1386	Proteasome/CD38/Steroid	1475	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				1	Completed regimen	4					5	1530	2587	Stable Disease	SD			0	0	0	0	4	90	0	6	145			1	3	1
MMRF_2124	3	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	1497	1499	2	Bortezomib/Daratumumab/Dexamethasone + Melphalan/Dexamethasone	Bor-Dar-Dex + Mel-Dex	1386	Proteasome/CD38/Steroid/Chemotherapy	1499	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	1499	Stem cell, Autologous	2	1	Completed regimen	4					5	1530	2587	Stable Disease	SD			0	1	0	1	0	3	0	6	145					1
MMRF_2124	3	Ixazomib	Ixa	Proteasome	1624	2587	3	Bortezomib/Daratumumab/Dexamethasone + Melphalan/Dexamethasone + Ixazomib	Bor-Dar-Dex + Mel-Dex + Ixa	1386	Proteasome/CD38/Steroid/Chemotherapy	2587	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3					5	1530	2587	Stable Disease	SD			0	0	0	0	35	964	0	6	145					1
MMRF_2124	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2597	2745	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2597	CD38/IMID/Steroid	2745	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2672	4	2672		Partial Response	PR	Partial Response	PR	1	1	1	1	6	149	1	3	76	3	76	1	3	1
MMRF_2198	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	28	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	28	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0			1629		4	82	4	82	138	Partial Response	PR	Partial Response	PR	1	0	0	0	1	28	0	3	82	3	82	1	3	1
MMRF_2198	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	29	99	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	99	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	TOXICITY		1629		4	82	4	82	138	Partial Response	PR	Partial Response	PR	1	1	1	1	3	71	1	3	82	3	82			1
MMRF_2198	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	141	225	1	Carfilzomib/Dexamethasone	Car-Dex	141	Proteasome/Steroid	225	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	252	Stem cell, Autologous	1	1	Completed regimen	4	1629		4	225	4	225	897	Partial Response	PR	Partial Response	PR	1	1	1	1	3	85	1	4	85	4	85	1	2	1
MMRF_2198	2	Bortezomib	Bor	Proteasome	365	742	2	Carfilzomib/Dexamethasone + Bortezomib	Car-Dex + Bor	141	Proteasome/Steroid	742	combined bortezomib/carfilzomib-based	Bortezomib-based	Bor-Car-Dex				1			1629		4	225	4	225	897	Partial Response	PR	Partial Response	PR	1	0	0	0	14	378	0	4	85	4	85			1
MMRF_2198	2	Bortezomib/Ixazomib	Bor-Ixa	Proteasome/Proteasome	743	743	3	Carfilzomib/Dexamethasone + Bortezomib + Bortezomib/Ixazomib	Car-Dex + Bor + Bor-Ixa	141	Proteasome/Steroid	743	combined bortezomib/carfilzomib-based	Bortezomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				1	FATIGUE		1629		4	225	4	225	897	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	85	4	85			1
MMRF_2198	2	Ixazomib	Ixa	Proteasome	744	897	4	Carfilzomib/Dexamethasone + Bortezomib + Bortezomib/Ixazomib	Car-Dex + Bor + Bor-Ixa	141	Proteasome/Steroid	897	combined bortezomib/carfilzomib-based	Other treatments	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	1629		4	225	4	225	897	Partial Response	PR	Partial Response	PR	1	0	0	0	6	154	0	4	85	4	85			1
MMRF_2198	3	Daratumumab/Durvalumab/Dexamethasone	Dar-Durv-Dex	CD38/Checkpoint Inhibitor/Steroid	943	1170	1	Daratumumab/Durvalumab/Dexamethasone	Dar-Durv-Dex	943	CD38/Checkpoint Inhibitor/Steroid	1170	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1629				5	971	1170	Stable Disease	SD			0	1	0	1	8	228	0	2	29					1
MMRF_2198	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1188	1527	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1188	Proteasome/IMID/Steroid	1527	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1629		4	1275	3	1359	1527	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	12	340	1	7	172	4	88	1	3	1
MMRF_2198	5	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1558	1611	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1558	CD38/IMID/Steroid	1611	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3	1629		4	1730	3	1849	1629	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	54	0	11	292	7	173	1	3	1
MMRF_2198	9	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1635	2078	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	1635	Chemotherapy/Steroid	2078	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2	1629											0	0	0	0	16	444	0							1
MMRF_2198	9	Belantamab mafodotin	Bela	BCMA	2192	2255	2	Cyclophosphamide/Dexamethasone + Belantamab mafodotin	Cyc-Dex + Bela	1635	Chemotherapy/Steroid/BCMA	2255	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2	1629											0	0	0	0	3	64	0							1
MMRF_2226	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_2270	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	99	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	99	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	113	Stem cell, Autologous	1	1	Completed regimen	4			3	71	3	71	1614	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	99	1	3	71	3	71	1	3	1
MMRF_2270	1	Lenalidomide	Len	IMID	226	1991	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1991	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	71	3	71	1614	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	63	1766	0	3	71	3	71			1
MMRF_2270	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2037	2087	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	2037	Proteasome/Chemotherapy/Steroid	2087	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	2117	Stem cell, Autologous	2	1	Completed regimen	4			3	2216	3	2216		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	51	1	7	180	7	180	1	3	1
MMRF_2270	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	2227	2598	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone	Car-Cyc-Dex + Elo-Pom-Dex	2037	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID	2598	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			3	2216	3	2216		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	14	372	0	7	180	7	180			1
MMRF_2271	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	154	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	154	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5			4	518	3	1763	1552	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	154	1	63	1763	19	518	1	2	1
MMRF_2272	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	17	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	17	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3												0	0	0	0	1	17	0					1	2	1
MMRF_2449	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	74	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	74	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	116	Stem cell, Autologous	1	1	Completed regimen	4			3	72	3	72		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	74	1	3	72	3	72	1	3	1
MMRF_2449	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	215	1838	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	1838	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					3	72	3	72		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	58	1624	0	3	72	3	72			1
MMRF_2446	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	93	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	93	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	120	Stem cell, Autologous	1	1	Completed regimen	4			3	97	1	232		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	93	1	9	232	4	97	1	3	1
MMRF_2446	1	Bortezomib	Bor	Proteasome	232	259	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	259	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	97	1	232		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	1	1	28	0	9	232	4	97			1
MMRF_2446	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	260	1814	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	1814	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					3	97	1	232		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	56	1555	0	9	232	4	97			1
MMRF_2514	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	210	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	210	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	56	3	449		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	8	210	1	17	449	2	56	1	3	1
MMRF_2514	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	287	389	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	389	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex	420	Stem cell, Autologous	1	1	Completed regimen	4			4	56	3	449		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	103	0	17	449	2	56			1
MMRF_2514	1	Lenalidomide	Len	IMID	555	651	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Dex + Len	1	Proteasome/IMID/Steroid	651	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	56	3	449		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	97	0	17	449	2	56			1
MMRF_2531	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	151		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	6	151	4	85	1	3	1
MMRF_2531	1	Lenalidomide	Len	IMID	239	413	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	413	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	85	1	151		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	7	175	0	6	151	4	85			1
MMRF_2531	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	423	480	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	423	Proteasome/Chemotherapy/Steroid	480	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3					6	449	449	Progressive Disease	PD			0	1	0	1	2	58	0	1	27			1	3	1
MMRF_2531	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	484	546	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	484	CD38/IMID/Steroid	546	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	DEATH													0	0	0	0	3	63	0					1	3	1
MMRF_2541	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	105	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	105	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1			953		4	154	3	301	560	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	105	0	11	301	6	154	1	3	1
MMRF_2541	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	106	158	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	158	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	163	Stem cell, Autologous	1	1	Completed regimen	4	953		4	154	3	301	560	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	2	53	1	11	301	6	154			1
MMRF_2541	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	273	385	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Ixa-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	385	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4	953		4	154	3	301	560	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	113	0	11	301	6	154			1
MMRF_2541	1	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	386	561	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Ixa-Len-Dex + Ixa-Len	1	Proteasome/Chemotherapy/Steroid/IMID	561	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3	953		4	154	3	301	560	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	176	0	11	301	6	154			1
MMRF_2541	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	571	662	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	571	CD38/IMID/Steroid	662	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Lack of response	1	953		4	694	4	694	788	Partial Response	PR	Partial Response	PR	1	0	0	0	4	92	0	5	124	5	124	1	3	1
MMRF_2541	2	Pomalidomide	Pom	IMID	663	665	2	Daratumumab/Pomalidomide/Dexamethasone + Pomalidomide	Dar-Pom-Dex + Pom	571	CD38/IMID/Steroid	665	combined daratumumab/IMIDs-based	IMIDs-based	Dar-Pom-Dex				0			953		4	694	4	694	788	Partial Response	PR	Partial Response	PR	1	0	0	0	0	3	0	5	124	5	124			1
MMRF_2541	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	666	701	3	Daratumumab/Pomalidomide/Dexamethasone + Pomalidomide + Carfilzomib/Pomalidomide/Dexamethasone	Dar-Pom-Dex + Pom + Car-Pom-Dex	571	CD38/IMID/Steroid/Proteasome	701	combined daratumumab/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0	FREQUENCY CHANGE DUE TO SHORTNESS OF BREATH		953		4	694	4	694	788	Partial Response	PR	Partial Response	PR	1	1	1	1	2	36	1	5	124	5	124			1
MMRF_2541	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	702	760	4	Daratumumab/Pomalidomide/Dexamethasone + Pomalidomide + Carfilzomib/Pomalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Dar-Pom-Dex + Pom + Car-Pom-Dex + Car-Dex	571	CD38/IMID/Steroid/Proteasome	760	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Dar-Car-Pom-Dex				0	Disease progression/Relapse	3	953		4	694	4	694	788	Partial Response	PR	Partial Response	PR	1	0	0	0	2	59	0	5	124	5	124			1
MMRF_2541	3	Bortezomib/Nelfinavir Mesylate/Dexamethasone	Bor-Nel-Dex	Proteasome/Steroid	792	803	1	Bortezomib/Nelfinavir Mesylate/Dexamethasone	Bor-Nel-Dex	792	Proteasome/Steroid	803	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2	953				6	834	834	Progressive Disease	PD			0	0	0	0	1	12	0	2	43			1	3	1
MMRF_2541	3	Prednisone/Bendamustine	Pred-Bend	Steroid/Chemotherapy	819	834	2	Bortezomib/Nelfinavir Mesylate/Dexamethasone + Prednisone/Bendamustine	Bor-Nel-Dex + Pred-Bend	792	Proteasome/Steroid/Chemotherapy	834	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	953				6	834	834	Progressive Disease	PD			0	1	0	1	1	16	0	2	43					1
MMRF_2541	4	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	847	903	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	847	Proteasome/CD38/Steroid	903	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3	953				5	876	903	Stable Disease	SD			0	1	0	1	2	57	0	2	30			1	3	1
MMRF_2541	5	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	926	953	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	926	Chemotherapy/Steroid	953	Other therapies	Other treatments					0	Disease progression/Relapse	3	953				5	974	953	Stable Disease	SD			0	0	0	0	1	28	0	2	49					1
MMRF_2541	9	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine	Carm-Cyc-Mel-Pred-Vin	Chemotherapy/Chemotherapy/Chemotherapy/Steroid/Chemotherapy	968	1029	1	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine	Carm-Cyc-Mel-Pred-Vin	968	Chemotherapy/Steroid	1029	Other therapies	Other treatments					0	Disease progression/Relapse	3	953											0	0	0	0	3	62	0					1	5	1
MMRF_2541	9	Bortezomib/Panobinostat/Dexamethasone	Bor-Pano-Dex	Proteasome/HDAC/Steroid	1043	1064	2	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine + Bortezomib/Panobinostat/Dexamethasone	Carm-Cyc-Mel-Pred-Vin + Bor-Pano-Dex	968	Chemotherapy/Steroid/Proteasome/HDAC	1064	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	953											0	0	0	0	1	22	0							1
MMRF_2592	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	125	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	125	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	168	Stem cell, Autologous	1	1	Completed regimen	4			4	175	1	366	2333	Complete Response	CR	Partial Response	PR	1	0	1	0	5	125	1	14	366	7	175	1	3	1
MMRF_2592	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	282	394	2	Bortezomib/Cyclophosphamide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Ixa-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	394	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	175	1	366	2333	Complete Response	CR	Partial Response	PR	1	1	0	1	4	113	0	14	366	7	175			1
MMRF_2592	1	Lenalidomide	Len	IMID	415	2336	3	Bortezomib/Cyclophosphamide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Ixa-Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2336	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	175	1	366	2333	Complete Response	CR	Partial Response	PR	1	0	0	0	69	1922	0	14	366	7	175			1
MMRF_2592	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	2337	2463	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	2337	SLAMF7/IMID/Steroid	2463	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2												0	0	0	0	5	127	0					1	3	1
MMRF_2611	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	136	Stem cell, Autologous	1	1	Completed regimen	4			4	92	3	169	1481	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	105	1	7	169	4	92	1	3	1
MMRF_2611	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	246	358	2	Bortezomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Ixa-Len-Dex	1	Proteasome/IMID/Steroid	358	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	92	3	169	1481	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	113	0	7	169	4	92			1
MMRF_2611	1	Lenalidomide	Len	IMID	379	1502	3	Bortezomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Ixa-Len-Dex + Len	1	Proteasome/IMID/Steroid	1502	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	92	3	169	1481	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	40	1124	0	7	169	4	92			1
MMRF_2611	2	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1597	2363	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1597	SLAMF7/IMID/Steroid	2363	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					3	1738	3	1738		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	28	767	1	6	142	6	142	1	3	1
MMRF_2621	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	133	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	133	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	43	3	43		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	133	1	2	43	2	43	1	3	1
MMRF_1013	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	96	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	96	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	135	Stem cell, Autologous	1	1	Completed regimen	4			4	107	1	863	1333	Complete Response	CR	Partial Response	PR	1	0	1	0	4	96	1	31	863	4	107	1	3	1
MMRF_1013	1	Lenalidomide	Len	IMID	212	1865	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1865	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	107	1	863	1333	Complete Response	CR	Partial Response	PR	1	1	0	1	59	1654	0	31	863	4	107			1
MMRF_1013	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1655	1865	1	Ixazomib/Dexamethasone	Ixa-Dex	1655	Proteasome/Steroid	1865	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	1688	1688	Progressive Disease	PD			0	1	0	1	8	211	0	2	34					1
MMRF_1013	3	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1896	1957	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1896	SLAMF7/IMID/Steroid	1957	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3					6	1969	1969	Progressive Disease	PD			0	1	0	1	3	62	0	3	74			1	3	1
MMRF_1013	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1986	1989	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1986	Proteasome/Chemotherapy/Steroid	1989	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	4	0					1	3	1
MMRF_1013	4	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	2038	2088	2	Bortezomib/Cyclophosphamide/Dexamethasone + Daratumumab/Dexamethasone	Bor-Cyc-Dex + Dar-Dex	1986	Proteasome/Chemotherapy/Steroid/CD38	2088	Bortezomib-based	daratumumab-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3												0	0	0	0	2	51	0							1
MMRF_1013	5	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2098	2100	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	2098	Proteasome/Chemotherapy/Steroid	2100	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	2126	Stem cell, Autologous	2	1	Adverse Event or co-morbidity	2			4	2167	4	2167		Partial Response	PR	Partial Response	PR	1	1	1	1	0	3	1	3	70	3	70	1	3	1
MMRF_1073	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	92	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	92	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	139	Stem cell, Autologous	1	1	Completed regimen	4			3	96	1	469		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	92	1	17	469	4	96	1	3	1
MMRF_1073	1	Lenalidomide	Len	IMID	265	2886	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2886	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	96	1	469		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	94	2622	0	17	469	4	96			1
MMRF_1076	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	75	3	75	416	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	77	1	3	75	3	75	1	3	1
MMRF_1076	1	Lenalidomide	Len	IMID	78	884	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	884	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	75	3	75	416	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	29	807	0	3	75	3	75			1
MMRF_1076	3	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	927	1030	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	927	Chemotherapy/Steroid	1030	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2					5	1045	968	Stable Disease	SD			0	1	0	1	4	104	0	5	119					1
MMRF_1095	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	59	1	744		Complete Response	CR	Partial Response	PR	1	0	1	0	3	85	1	27	744	3	59	1	3	1
MMRF_1095	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	113	142	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	142	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	288	Stem cell, Autologous	1	1	PLANNED FOR 2 CYCLES, STEM CELL MOBILIZATION, THEN CONTINUE 2 MORE CYCLES				4	59	1	744		Complete Response	CR	Partial Response	PR	1	0	0	0	1	30	0	27	744	3	59			1
MMRF_1095	1	Lenalidomide	Len	IMID	449	899	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	899	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	59	1	744		Complete Response	CR	Partial Response	PR	1	1	0	1	16	451	0	27	744	3	59			1
MMRF_1092	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	161	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	161	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	96	1	1075	1436	Complete Response	CR	Partial Response	PR	1	0	1	0	6	161	1	39	1075	4	96	1	3	1
MMRF_1092	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	191	1539	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1539	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	1551	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	96	1	1075	1436	Complete Response	CR	Partial Response	PR	1	1	0	1	48	1349	0	39	1075	4	96			1
MMRF_1092	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1683	2853	1	Ixazomib/Dexamethasone	Ixa-Dex	1683	Proteasome/Steroid	2853	Other therapies	Other treatments					0					4	1733	3	1994		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	42	1171	1	12	312	2	51			1
MMRF_1115	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	119	Stem cell, Autologous	1	1	Completed regimen	4			4	84	1	218		Complete Response	CR	Partial Response	PR	1	1	1	1	3	85	1	8	218	3	84	1	3	1
MMRF_1134	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	134	Stem cell, Autologous	1	1	Completed regimen	4			1	56	1	56		Complete Response	CR	Complete Response	CR	1	1	1	1	2	56	1	2	56	2	56	1	3	1
MMRF_1134	1	Lenalidomide	Len	IMID	531	2888	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2888	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					1	56	1	56		Complete Response	CR	Complete Response	CR	1	0	0	0	85	2358	0	2	56	2	56			1
MMRF_1153	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	102	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	102	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	185	Stem cell, Autologous	1	1	Completed regimen	4			3	92	1	421	1240	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	102	1	16	421	4	92	1	3	1
MMRF_1153	1	Lenalidomide	Len	IMID	339	875	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	875	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	92	1	421	1240	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	19	537	0	16	421	4	92			1
MMRF_1153	1	Bortezomib	Bor	Proteasome	974	1240	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib	Bor-Len-Dex + Len + Bor	1	Proteasome/IMID/Steroid	1240	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	92	1	421	1240	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	10	267	0	16	421	4	92			1
MMRF_1153	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1317	1380	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1317	Proteasome/IMID/Steroid	1380	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3												0	0	0	0	3	64	0					1	3	1
MMRF_1153	3	Daratumumab/Lenalidomide/Prednisone	Dar-Len-Pred	CD38/IMID/Steroid	1389	2892	1	Daratumumab/Lenalidomide/Prednisone	Dar-Len-Pred	1389	CD38/IMID/Steroid	2892	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0					4	1409	3	1625		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	54	1504	1	9	237	1	21	1	3	1
MMRF_1168	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	156	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	156	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	81	2	2900		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	6	156	1	104	2900	3	81	1	3	1
MMRF_1168	1	Lenalidomide	Len	IMID	187	2900	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2900	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					3	81	2	2900		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	97	2714	0	104	2900	3	81			1
MMRF_1171	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	89	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	89	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	155	Stem cell, Autologous	1	1	Completed regimen	4			4	89	3	272		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	89	1	10	272	4	89	1	3	1
MMRF_1171	1	Lenalidomide	Len	IMID	278	2897	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2897	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	89	3	272		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	94	2620	0	10	272	4	89			1
MMRF_1185	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	81	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	117	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	81	1	3	64	3	64	1	3	1
MMRF_1185	1	Lenalidomide	Len	IMID	256	1211	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1211	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	34	956	0	3	64	3	64			1
MMRF_1196	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	259	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	259	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	329	Stem cell, Autologous	1	1	Completed regimen	4			4	243	4	243	71	Partial Response	PR	Partial Response	PR	1	1	1	1	10	259	1	9	243	9	243	1	3	1
MMRF_1196	2	Lenalidomide	Len	IMID	370	616	1	Lenalidomide	Len	370	IMID	616	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			1	391	1	391	583	Complete Response	CR	Complete Response	CR	1	1	1	1	9	247	1	1	22	1	22	1	1	1
MMRF_1196	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	617	660	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	617	Proteasome/IMID/Steroid	660	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	688	688	Progressive Disease	PD			0	1	0	1	2	44	0	3	72			1	3	1
MMRF_1196	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	702	745	2	Carfilzomib/Pomalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Car-Pom-Dex + Bor-Cyc-Dex	617	Proteasome/IMID/Steroid/Chemotherapy	745	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4					6	688	688	Progressive Disease	PD			0	0	0	0	2	44	0	3	72					1
MMRF_1235	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	72	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	72	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	106	Stem cell, Autologous	1	1	Completed regimen	4			3	72	1	462		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	72	1	17	462	3	72	1	3	1
MMRF_1235	1	Lenalidomide	Len	IMID	254	2303	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2303	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Patient decision	6			3	72	1	462		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	74	2050	0	17	462	3	72			1
MMRF_1235	2	Fludarabine/Melphalan	Flu-Mel	Chemotherapy/Chemotherapy	2426	2431	1	Fludarabine/Melphalan	Flu-Mel	2426	Chemotherapy	2431	Other therapies	Other treatments		2432	Stem cell, Allogenic	2	1	Completed regimen	4												0	0	0	0	1	6	0							1
MMRF_1251	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	112	Stem cell, Autologous	1	1	Completed regimen	4	2920		3	106	3	106	869	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	4	106	4	106	1	3	1
MMRF_1251	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	183	213	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	213	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4	2920		3	106	3	106	869	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	31	0	4	106	4	106			1
MMRF_1251	1	Bortezomib	Bor	Proteasome	232	833	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	833	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1			2920		3	106	3	106	869	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	602	0	4	106	4	106			1
MMRF_1251	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	834	1142	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor + Bor-Len	1	Proteasome/IMID/Steroid	1142	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	2920		3	106	3	106	869	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	11	309	0	4	106	4	106			1
MMRF_1251	1	Lenalidomide	Len	IMID	1143	2165	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor + Bor-Len	1	Proteasome/IMID/Steroid	2165	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	2920		3	106	3	106	869	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	37	1023	0	4	106	4	106			1
MMRF_1251	2	Ixazomib	Ixa	Proteasome	1156	2165	1	Ixazomib	Ixa	1156	Proteasome	2165	Other therapies	Other treatments					0	Disease progression/Relapse	3	2920		4	1807	4	1807	1247	Partial Response	PR	Partial Response	PR	1	1	1	1	36	1010	1	24	652	24	652			1
MMRF_1251	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2165	2486	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2165	CD38/IMID/Steroid	2486	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2920				5	2192		Stable Disease	SD			0	1	0	1	12	322	0	1	28			1	3	1
MMRF_1251	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2488	2739	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	2488	Proteasome/Chemotherapy/Steroid	2739	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2920				5	2584	2739	Stable Disease	SD			0	1	0	1	9	252	0	4	97			1	3	1
MMRF_1290	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	86	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	86	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	131	Stem cell, Autologous	1	1	Completed regimen	4			3	89	1	270		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	86	1	10	270	4	89	1	3	1
MMRF_1290	1	Lenalidomide	Len	IMID	206	2909	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2909	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	89	1	270		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	97	2704	0	10	270	4	89			1
MMRF_1284	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	43	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	43	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION						5	206	82	Stable Disease	SD			0	0	0	0	2	43	0	8	206			1	3	1
MMRF_1284	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	71	74	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	74	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex	108	Stem cell, Autologous	1	1	Completed regimen	4					5	206	82	Stable Disease	SD			0	1	0	1	0	4	0	8	206					1
MMRF_1284	2	Pomalidomide	Pom	IMID	240	2900	1	Pomalidomide	Pom	240	IMID	2900	IMIDs-based	IMIDs-based	Pom-Dex				0					4	261	3	1227		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	95	2661	1	36	988	1	22	1	1	1
MMRF_1304	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	78	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	78	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	122	Stem cell, Autologous	1	1	Completed regimen	4			4	93	1	240		Complete Response	CR	Partial Response	PR	1	1	1	1	3	78	1	9	240	4	93	1	3	1
MMRF_1304	1	Lenalidomide	Len	IMID	288	2920	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2920	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	93	1	240		Complete Response	CR	Partial Response	PR	1	0	0	0	94	2633	0	9	240	4	93			1
MMRF_1323	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	117	Stem cell, Autologous	1	1	Completed regimen	4			3	153	1	265		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	77	1	10	265	6	153	1	3	1
MMRF_1323	1	Lenalidomide	Len	IMID	230	2890	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2890	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	153	1	265		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	95	2661	0	10	265	6	153			1
MMRF_1328	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	215	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	215	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4	1262		1	76	1	76	553	Complete Response	CR	Complete Response	CR	1	1	1	1	8	215	1	3	76	3	76	1	3	1
MMRF_1328	1	Lenalidomide	Len	IMID	216	544	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	544	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	595	Stem cell, Autologous	1	1	Disease progression/Relapse	3	1262		1	76	1	76	553	Complete Response	CR	Complete Response	CR	1	0	0	0	12	329	0	3	76	3	76			1
MMRF_1328	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	684	838	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	684	Proteasome/IMID/Steroid	838	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1262		3	622	1	713		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	6	155	0	2	30	-2	-61	1	3	1
MMRF_1328	3	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	856	897	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex	856	Proteasome/IMID/Chemotherapy/Steroid	897	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Cyc-Dex				0	Completed regimen	4	1262		4	897	4	897	979	Partial Response	PR	Partial Response	PR	1	1	1	1	2	42	1	2	42	2	42	1	4	1
MMRF_1328	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	916	974	2	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone + Pomalidomide/Dexamethasone	Bor-Thal-Cyc-Dex + Pom-Dex	856	Proteasome/IMID/Chemotherapy/Steroid	974	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1262		4	897	4	897	979	Partial Response	PR	Partial Response	PR	1	0	0	0	2	59	0	2	42	2	42			1
MMRF_1328	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	996	1001	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	996	Proteasome/Chemotherapy/Steroid	1001	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4	1262				5	1021	1176	Stable Disease	SD			0	1	0	1	1	6	0	1	26			1	3	1
MMRF_1328	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1038	1252	2	Bortezomib/Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Bor-Cyc-Dex + Dar-Pom-Dex	996	Proteasome/Chemotherapy/Steroid/CD38/IMID	1252	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1262				5	1021	1176	Stable Disease	SD			0	0	0	0	8	215	0	1	26					1
MMRF_1328	5	Nivolumab	Niv	Checkpoint Inhibitor	1182	1252	1	Nivolumab	Niv	1182	Checkpoint Inhibitor	1252	Other therapies	Other treatments					0	Disease progression/Relapse	3	1262				5	1357	1262	Stable Disease	SD			0	0	0	0	3	71	0	7	176					1
MMRF_1328	9	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1268	1296	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1268	Proteasome/Chemotherapy/Steroid	1296	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4	1262											0	0	0	0	1	29	0					1	3	1
MMRF_1328	9	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1334	1356	2	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Car-Pom-Cyc-Dex	1268	Proteasome/Chemotherapy/Steroid/IMID	1356	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0			1262											0	0	0	0	1	23	0							1
MMRF_1328	9	Carfilzomib/Pomalidomide/Cyclophosphamide/Panobinostat/Dexamethasone	Car-Pom-Cyc-Pano-Dex	Proteasome/IMID/Chemotherapy/HDAC/Steroid	1357	1367	3	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Panobinostat/Dexamethasone	Bor-Cyc-Dex + Car-Pom-Cyc-Dex + Car-Pom-Cyc-Pano-Dex	1268	Proteasome/Chemotherapy/Steroid/IMID/HDAC	1367	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3	1262											0	0	0	0	1	11	0							1
MMRF_1328	9	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1368	1371	4	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Panobinostat/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Car-Pom-Cyc-Dex + Car-Pom-Cyc-Pano-Dex + Car-Pom-Cyc-Dex	1268	Proteasome/Chemotherapy/Steroid/IMID/HDAC	1371	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Lack of response	1	1262											0	0	0	0	0	4	0							1
MMRF_1328	9	Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Nivolumab/Dexamethasone	Bor-Elo-Pom-Cyc-Niv-Dex	Proteasome/SLAMF7/IMID/Chemotherapy/Checkpoint Inhibitor/Steroid	1385	1455	5	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Panobinostat/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Nivolumab/Dexamet	Bor-Cyc-Dex + Car-Pom-Cyc-Dex + Car-Pom-Cyc-Pano-Dex + Car-Pom-Cyc-Dex + Bor-Elo-Pom-Cyc-Niv-Dex	1268	Proteasome/Chemotherapy/Steroid/IMID/HDAC/SLAMF7/Checkpoint Inhibitor	1455	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3	1262											0	0	0	0	3	71	0							1
MMRF_1374	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	23	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	23	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	59	Stem cell, Autologous	1	1	Completed regimen	4			4	53	3	119	340	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	1	23	1	5	119	2	53	1	3	1
MMRF_1374	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	144	340	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	340	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	53	3	119	340	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	197	0	5	119	2	53			1
MMRF_1415	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	84	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	84	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	117	Stem cell, Autologous	1	1	Completed regimen	4			3	56	1	291	368	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	84	1	11	291	2	56	1	3	1
MMRF_1415	1	Lenalidomide	Len	IMID	220	309	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	309	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	56	1	291	368	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	4	90	0	11	291	2	56			1
MMRF_1415	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	310	371	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	371	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	56	1	291	368	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	62	0	11	291	2	56			1
MMRF_1415	2	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	Proteasome/Chemotherapy/Steroid	378	381	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	378	Proteasome/Chemotherapy/Steroid	381	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4					6	453	453	Progressive Disease	PD			0	0	0	0	0	4	0	3	76			1	3	1
MMRF_1415	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	402	463	2	Bortezomib/Cyclophosphamide/Prednisone + Carfilzomib/Pomalidomide/Dexamethasone	Bor-Cyc-Pred + Car-Pom-Dex	378	Proteasome/Chemotherapy/Steroid/IMID	463	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Lack of response	1					6	453	453	Progressive Disease	PD			0	1	0	1	3	62	0	3	76					1
MMRF_1430	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	41	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	41	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	91	1	385	875	Complete Response	CR	Partial Response	PR	1	0	0	0	2	41	0	14	385	4	91	1	2	1
MMRF_1430	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	42	119	2	Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Dex + Bor-Thal-Dex	1	Proteasome/Steroid/IMID	119	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	194	Stem cell, Autologous	1	1	Completed regimen	4			4	91	1	385	875	Complete Response	CR	Partial Response	PR	1	0	1	0	3	78	1	14	385	4	91			1
MMRF_1430	1	Lenalidomide	Len	IMID	316	665	3	Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Thal-Dex + Len	1	Proteasome/Steroid/IMID	665	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	91	1	385	875	Complete Response	CR	Partial Response	PR	1	1	0	1	13	350	0	14	385	4	91			1
MMRF_1430	2	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1453	1574	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1453	Proteasome/CD38/Steroid	1574	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	DEATH						6	1470	1470	Progressive Disease	PD			0	1	0	1	5	122	0	1	18			1	3	1
MMRF_1430	3	Pomalidomide	Pom	IMID	1533	1574	1	Pomalidomide	Pom	1533	IMID	1574	IMIDs-based	IMIDs-based	Pom-Dex				0	DEATH						6	1547	1547	Progressive Disease	PD			0	1	0	1	2	42	0	1	15			1	1	1
MMRF_1447	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	81	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	125	Stem cell, Autologous	1	1	Completed regimen	4			3	83	1	342		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	81	1	13	342	3	83	1	3	1
MMRF_1447	1	Lenalidomide	Len	IMID	259	2735	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2735	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	83	1	342		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	89	2477	0	13	342	3	83			1
MMRF_1447	3	Pomalidomide/Daratumumab/Dexamethasone	Pom-Dara-Dex	IMID/CD38/Steroid	2452	2735	1	Pomalidomide/Daratumumab/Dexamethasone	Pom-Dara-Dex	2452	IMID/CD38/Steroid	2735	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0							5	2735		Stable Disease	SD			0	1	0	1	10	284	0	11	284			1	3	1
MMRF_1506	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	106	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	77	1	3	64	3	64	1	3	1
MMRF_1522	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	114	Stem cell, Autologous	1	1	Completed regimen	4			4	59	3	151	1297	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	105	1	6	151	3	59	1	3	1
MMRF_1522	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	205	1291	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1291	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	59	3	151	1297	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	39	1087	0	6	151	3	59			1
MMRF_1522	2	Ixazomib/Pomalidomide	Ixa-Pom	Proteasome/IMID	1322	1565	1	Ixazomib/Pomalidomide	Ixa-Pom	1322	Proteasome/IMID	1565	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3					6	1565	1565	Progressive Disease	PD			0	1	0	1	9	244	0	9	244			1	2	1
MMRF_1522	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1597	2342	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1597	CD38/IMID/Steroid	2342	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	1663	3	1789		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	27	746	1	7	193	3	67	1	3	1
MMRF_1534	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	80	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	80	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	51	3	51	157	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	80	1	2	51	2	51	1	3	1
MMRF_1534	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	107	160	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	160	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	51	3	51	157	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	54	0	2	51	2	51			1
MMRF_1534	1	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	161	161	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	161	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	163	Stem cell, Autologous	1	1	Completed regimen	4			3	51	3	51	157	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	51	2	51			1
MMRF_1534	1	Lenalidomide	Len	IMID	238	1101	4	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len-Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	1101	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	51	3	51	157	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	31	864	0	2	51	2	51			1
MMRF_1534	2	Venetoclax/Dexamethasone	Vent-Dex	BCL2/Steroid	1122	1290	1	Venetoclax/Dexamethasone	Vent-Dex	1122	BCL2/Steroid	1290	Other therapies	Other treatments					0	Disease progression/Relapse	3					5	1248	1319	Stable Disease	SD			0	1	0	1	6	169	0	5	127					1
MMRF_1534	3	Daratumumab	Dar	CD38	1331	1485	1	Daratumumab	Dar	1331	CD38	1485	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3			4	1415	4	1415	1471	Partial Response	PR	Partial Response	PR	1	1	1	1	6	155	1	4	85	4	85			1
MMRF_1534	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1526	2149	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1526	CD38/IMID/Steroid	2149	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	1590	4	1590	2149	Partial Response	PR	Partial Response	PR	1	1	1	1	23	624	1	3	65	3	65	1	3	1
MMRF_1539	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	44	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	44	Bortezomib-based	Bortezomib-based	Bor-Dex				1			2698		4	73	3	110	851	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	44	0	4	110	3	73	1	2	1
MMRF_1539	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	45	175	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	230	Stem cell, Autologous	1	1	Completed regimen	4	2698		4	73	3	110	851	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	131	1	4	110	3	73			1
MMRF_1539	1	Lenalidomide	Len	IMID	327	604	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	604	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1			2698		4	73	3	110	851	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	10	278	0	4	110	3	73			1
MMRF_1539	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	605	878	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide	Bor-Dex + Bor-Len-Dex + Len + Bor-Len	1	Proteasome/Steroid/IMID	878	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	2698		4	73	3	110	851	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	10	274	0	4	110	3	73			1
MMRF_1539	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	878	1181	1	Ixazomib/Dexamethasone	Ixa-Dex	878	Proteasome/Steroid	1181	Other therapies	Other treatments					0	Disease progression/Relapse	3	2698				5	982		Stable Disease	SD			0	1	0	1	11	304	0	4	105					1
MMRF_1539	2	Lenalidomide	Len	IMID	879	1181	2	Ixazomib/Dexamethasone + Lenalidomide	Ixa-Dex + Len	878	Proteasome/Steroid/IMID	1181	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	2698				5	982		Stable Disease	SD			0	0	0	1	11	303	0	4	105			1	1	1
MMRF_1539	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1181	1361	1	Daratumumab/Pomalidomide	Dar-Pom	1181	CD38/IMID	1361	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Disease progression/Relapse	3	2698				6	1242	1242	Progressive Disease	PD			0	1	0	1	7	181	0	3	62			1	2	1
MMRF_1539	4	Venetoclax/Dexamethasone	Vent-Dex	BCL2/Steroid	1398	2733	1	Venetoclax/Dexamethasone	Vent-Dex	1398	BCL2/Steroid	2733	Other therapies	Other treatments					0			2698		3	1431	3	1431	1998	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	48	1336	1	2	34	2	34			1
MMRF_1539	5	Carfilzomib/Cyclophosphamide	Car-Cyc	Proteasome/Chemotherapy	2001	2710	1	Carfilzomib/Cyclophosphamide	Car-Cyc	2001	Proteasome/Chemotherapy	2710	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2698				5	2733	2698	Stable Disease	SD			0	0	0	0	26	710	0	27	733			1	2	1
MMRF_1539	9	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	2711	2733	1	Bortezomib/Cyclophosphamide	Bor-Cyc	2711	Proteasome/Chemotherapy	2733	Bortezomib-based	Bortezomib-based	Bor-Cyc				0			2698											0	0	0	0	1	23	0					1	2	1
MMRF_1543	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	109	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	109	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	144	Stem cell, Autologous	1	1	Completed regimen	4			4	92	1	243	2000	Complete Response	CR	Partial Response	PR	1	1	1	1	4	109	1	9	243	4	92	1	3	1
MMRF_1546	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	84	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	84	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	57	1	266	717	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	84	1	10	266	3	57	1	3	1
MMRF_1546	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	140	680	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	680	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	TO ALLOW OPTIMAL MUSCLE STRENGTHENING				3	57	1	266	717	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	20	541	0	10	266	3	57			1
MMRF_1546	1	Lenalidomide	Len	IMID	681	2734	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2734	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					3	57	1	266	717	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	74	2054	0	10	266	3	57			1
MMRF_1572	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	124	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	124	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	150	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	5	124	0					1	3	1
MMRF_1572	1	Lenalidomide	Len	IMID	268	270	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	270	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2												0	0	0	0	0	3	0							1
MMRF_1572	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2479	2731	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2479	CD38/IMID/Steroid	2731	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0							6	2486	2486	Progressive Disease	PD			0	1	0	1	9	253	0	1	8			1	3	1
MMRF_1595	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	107	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	107	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	113	3	113	581	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	107	0	5	113	5	113	1	3	1
MMRF_1595	1	Lenalidomide	Len	IMID	108	227	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	227	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	113	3	113	581	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	5	113	5	113			1
MMRF_1602	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	83	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	83	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	116	Stem cell, Autologous	1	1	Completed regimen	4			1	106	1	106		Complete Response	CR	Complete Response	CR	1	1	1	1	3	83	1	4	106	4	106	1	3	1
MMRF_1602	1	Lenalidomide	Len	IMID	265	2729	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2729	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					1	106	1	106		Complete Response	CR	Complete Response	CR	1	0	0	0	88	2465	0	4	106	4	106			1
MMRF_1656	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	79	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	79	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	133	Stem cell, Autologous	1	1	Completed regimen	4			4	78	3	161	427	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	79	1	6	161	3	78	1	3	1
MMRF_1656	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	229	260	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	260	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	78	3	161	427	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	32	0	6	161	3	78			1
MMRF_1656	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	444	505	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	444	Proteasome/IMID/Steroid	505	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3					6	505	505	Progressive Disease	PD			0	1	0	1	3	62	0	3	62			1	3	1
MMRF_1656	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	512	515	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	512	Proteasome/Chemotherapy/Steroid	515	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	4	0					1	3	1
MMRF_1674	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	104	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	104	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	140	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	168		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	104	1	6	168	4	85	1	3	1
MMRF_1674	1	Bortezomib	Bor	Proteasome	235	912	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	912	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	MRD NEGATIVE				3	85	1	168		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	25	678	0	6	168	4	85			1
MMRF_1694	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	123	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	170	Stem cell, Autologous	1	1	Completed regimen	4			3	70	1	270	917	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	5	123	1	10	270	3	70	1	3	1
MMRF_1694	1	Lenalidomide	Len	IMID	394	935	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	935	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	70	1	270	917	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	20	542	0	10	270	3	70			1
MMRF_1694	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	935	1509	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	935	Proteasome/IMID/Steroid	1509	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	1026	3	1365	1509	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	21	575	1	16	431	4	92	1	3	1
MMRF_1694	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1514	1517	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1514	Proteasome/Chemotherapy/Steroid	1517	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	1642	3	1642		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	5	129	5	129	1	3	1
MMRF_1694	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1551	1641	2	Bortezomib/Cyclophosphamide/Dexamethasone + Daratumumab/Dexamethasone	Bor-Cyc-Dex + Dar-Dex	1514	Proteasome/Chemotherapy/Steroid/CD38	1641	Bortezomib-based	daratumumab-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					3	1642	3	1642		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	91	1	5	129	5	129			1
MMRF_1694	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1642	2139	3	Bortezomib/Cyclophosphamide/Dexamethasone + Daratumumab/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Bor-Cyc-Dex + Dar-Dex + Dar-Pom-Dex	1514	Proteasome/Chemotherapy/Steroid/CD38/IMID	2139	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	2030	Stem cell, Autologous	2	1					3	1642	3	1642		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	18	498	1	5	129	5	129			1
MMRF_1711	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	82	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	82	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	124	Stem cell, Autologous	1	1	Completed regimen	4	1713		1	67	1	67	1009	Complete Response	CR	Complete Response	CR	1	1	1	1	3	82	1	3	67	3	67	1	3	1
MMRF_1711	1	Lenalidomide	Len	IMID	240	1017	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1017	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	1713		1	67	1	67	1009	Complete Response	CR	Complete Response	CR	1	0	0	0	28	778	0	3	67	3	67			1
MMRF_1711	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1020	1080	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1020	Proteasome/IMID/Steroid	1080	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1713				6	1072	1072	Progressive Disease	PD			0	1	0	1	2	61	0	2	53			1	3	1
MMRF_1711	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1095	1150	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1095	CD38/IMID/Steroid	1150	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	1713				6	1150	1150	Progressive Disease	PD			0	1	0	1	2	56	0	2	56			1	3	1
MMRF_1711	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1157	1303	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1157	Proteasome/Chemotherapy/Steroid	1303	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0			1713		3	1276	3	1276		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	147	1	5	120	5	120	1	3	1
MMRF_1711	4	Carfilzomib/Cyclophosphamide/Prednisone/Dexamethasone	Car-Cyc-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1304	1584	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Cyclophosphamide/Prednisone/Dexamethasone	Car-Cyc-Dex + Car-Cyc-Pred-Dex	1157	Proteasome/Chemotherapy/Steroid	1584	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1713		3	1276	3	1276		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	10	281	0	5	120	5	120			1
MMRF_1711	5	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1593	1593	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1593	Proteasome/Chemotherapy/Steroid	1593	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4	1713				5	1829	1713	Stable Disease	SD			0	0	0	0	0	1	0	9	237			1	3	1
MMRF_1711	9	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1615	1639	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1615	Proteasome/Chemotherapy/Steroid	1639	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0			1713											0	0	0	0	1	25	0					1	3	1
MMRF_1711	9	Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Elo-Pom-Cyc-Dex	Proteasome/SLAMF7/IMID/Chemotherapy/Steroid	1640	1696	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID	1696	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1713											0	0	0	0	2	57	0							1
MMRF_1711	9	Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone	Bor-Car-Dar-Cyc-Leuk-Dex	Proteasome/Proteasome/CD38/Chemotherapy/Steroid	1704	1724	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex + Bor-Car-Dar-Cyc-Leuk-Dex	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID/CD38	1724	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4	1713											0	0	0	0	1	21	0							1
MMRF_1711	9	Cyclophosphamide/Fludarabine/Idecabtagene cicleucel	Cyc-Flu-Ide-cel	Chemotherapy/Chemotherapy/BCMA	1753	1836	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone + Cyclophosphamide/Fludarabine/Idecabtagene cicleucel	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex + Bor-Car-Dar-Cyc-Leuk-Dex + Cyc-Flu-Ide-cel	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID/CD38/BCMA	1836	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4	1713											0	0	0	0	3	84	0							1
MMRF_1711	9	Pomalidomide/Nivolumab	Pom-Niv	IMID/Checkpoint Inhibitor	1873	1941	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone + Cyclophosphamide/Fludarabine/Idecabtagene cicleucel + Pomalidomide/Nivolumab	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex + Bor-Car-Dar-Cyc-Leuk-Dex + Cyc-Flu-Ide-cel + Pom-Niv	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID/CD38/BCMA/Checkpoint Inhibitor	1941	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3	1713											0	0	0	0	3	69	0							1
MMRF_1711	9	TAK-573	TAK-573	CD38	1976	1997	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone + Cyclophosphamide/Fludarabine/Idecabtagene cicleucel + Pomalidomide/Nivolumab + TAK-573	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex + Bor-Car-Dar-Cyc-Leuk-Dex + Cyc-Flu-Ide-cel + Pom-Niv + TAK-573	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID/CD38/BCMA/Checkpoint Inhibitor	1997	combined bortezomib/IMIDs/carfilzomib-based	Other treatments	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0			1713											0	0	0	0	1	22	0							1
MMRF_1711	9	Bortezomib/Cyclophosphamide/TAK-573/Dexamethasone	Bor-Cyc-TAK-573-Dex	Proteasome/Chemotherapy/CD38/Steroid	1998	1998	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone + Cyclophosphamide/Fludarabine/Idecabtagene cicleucel + Pomalidomide/Nivolumab + TAK-573 + Bortezomib/Cyclop	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex + Bor-Car-Dar-Cyc-Leuk-Dex + Cyc-Flu-Ide-cel + Pom-Niv + TAK-573 + Bor-Cyc-TAK-573-Dex	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID/CD38/BCMA/Checkpoint Inhibitor	1998	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3	1713											0	0	0	0	0	1	0							1
MMRF_1711	9	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1999	2001	8	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Elotuzumab/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Daratumumab/Cyclophosphamide/Leukapheresis/Dexamethasone + Cyclophosphamide/Fludarabine/Idecabtagene cicleucel + Pomalidomide/Nivolumab + TAK-573 + Bortezomib/Cyclop	Bor-Cyc-Dex + Bor-Elo-Pom-Cyc-Dex + Bor-Car-Dar-Cyc-Leuk-Dex + Cyc-Flu-Ide-cel + Pom-Niv + TAK-573 + Bor-Cyc-TAK-573-Dex + Bor-Cyc-Dex	1615	Proteasome/Chemotherapy/Steroid/SLAMF7/IMID/CD38/BCMA/Checkpoint Inhibitor	2001	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4	1713											0	0	0	0	0	3	0							1
MMRF_1713	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	126	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	171	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	126	1	3	64	3	64	1	3	1
MMRF_1713	1	Lenalidomide	Len	IMID	281	448	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	448	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Patient decision	6			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	168	0	3	64	3	64			1
MMRF_1713	2	Lenalidomide	Len	IMID	1053	2037	1	Lenalidomide	Len	1053	IMID	2037	IMIDs-based	IMIDs-based	Len-Dex				0							5	1162	1106	Stable Disease	SD			0	1	0	1	35	985	0	4	110			1	1	1
MMRF_1722	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	71	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	71	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	141	Stem cell, Autologous	1	1	Completed regimen	4			1	64	1	64		Complete Response	CR	Complete Response	CR	1	1	1	1	3	71	1	3	64	3	64	1	3	1
MMRF_1722	1	Lenalidomide	Len	IMID	408	2198	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2198	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					1	64	1	64		Complete Response	CR	Complete Response	CR	1	0	0	0	64	1791	0	3	64	3	64			1
MMRF_1736	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	34	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	34	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	41	3	163	502	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	2	34	1	6	163	2	41	1	3	1
MMRF_1736	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1219	2714	1	Daratumumab/Dexamethasone	Dar-Dex	1219	CD38/Steroid	2714	daratumumab-based	daratumumab-based	Dar-Dex				0					4	1330	4	1330		Partial Response	PR	Partial Response	PR	1	1	1	1	54	1496	1	4	112	4	112			1
MMRF_1736	3	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	2256	2714	1	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	2256	Proteasome/IMID/Steroid	2714	IMIDs-based	IMIDs-based	Other Pom-based therapies				0							5	2354		Stable Disease	SD			0	1	0	1	17	459	0	4	99			1	3	1
MMRF_1736	4	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2532	2714	1	Carfilzomib/Dexamethasone	Car-Dex	2532	Proteasome/Steroid	2714	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0							5	2714		Stable Disease	SD			0	1	0	1	7	183	0	7	183			1	2	1
MMRF_1817	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	93	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	170	Stem cell, Autologous	1	1	Completed regimen	4			3	64	1	263	1250	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	93	1	10	263	3	64	1	3	1
MMRF_1817	1	Lenalidomide	Len	IMID	401	1251	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1251	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	64	1	263	1250	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	31	851	0	10	263	3	64			1
MMRF_1817	2	Venetoclax	Vent	BCL2	1293	1404	1	Venetoclax	Vent	1293	BCL2	1404	Other therapies	Other treatments					0	Disease progression/Relapse	3			3	1317	3	1317		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	112	1	1	25	1	25			1
MMRF_1817	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1404	1551	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1404	CD38/IMID/Steroid	1551	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					6	1418	1418	Progressive Disease	PD			0	1	0	1	6	148	0	1	15			1	3	1
MMRF_1817	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1551	1554	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1551	Proteasome/Chemotherapy/Steroid	1554	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4					6	1551	1551	Progressive Disease	PD			0	1	0	1	0	4	0	1	1			1	3	1
MMRF_1837	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	76	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	76	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	125	Stem cell, Autologous	1	1	Completed regimen	4			4	78	1	329	1236	Complete Response	CR	Partial Response	PR	1	0	1	0	3	76	1	12	329	3	78	1	3	1
MMRF_1837	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	216	692	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	692	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	78	1	329	1236	Complete Response	CR	Partial Response	PR	1	1	0	1	17	477	0	12	329	3	78			1
MMRF_1837	1	Bortezomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Ixa-Len-Dex	Proteasome/Proteasome/IMID/Steroid	693	1248	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Ixa-Len-Dex	1	Proteasome/IMID/Steroid	1248	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	78	1	329	1236	Complete Response	CR	Partial Response	PR	1	0	0	0	20	556	0	12	329	3	78			1
MMRF_1837	2	Venetoclax/Dexamethasone	Vent-Dex	BCL2/Steroid	1267	2534	1	Venetoclax/Dexamethasone	Vent-Dex	1267	BCL2/Steroid	2534	Other therapies	Other treatments					0					4	1323	4	1323		Partial Response	PR	Partial Response	PR	1	1	1	1	46	1268	1	3	57	3	57			1
MMRF_1854	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	119	Stem cell, Autologous	1	1	Completed regimen	4			4	78	1	298		Complete Response	CR	Partial Response	PR	1	0	1	0	3	85	1	11	298	3	78	1	3	1
MMRF_1854	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	211	1282	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1282	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	78	1	298		Complete Response	CR	Partial Response	PR	1	1	0	1	39	1072	0	11	298	3	78			1
MMRF_1854	1	Lenalidomide	Len	IMID	1283	2031	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2031	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	78	1	298		Complete Response	CR	Partial Response	PR	1	0	0	0	27	749	0	11	298	3	78			1
MMRF_1906	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	206	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	206	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	84	4	84		Partial Response	PR	Partial Response	PR	1	1	1	1	8	206	1	3	84	3	84	1	3	1
MMRF_1906	1	Lenalidomide	Len	IMID	238	313	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	313	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	84	4	84		Partial Response	PR	Partial Response	PR	1	0	0	0	3	76	0	3	84	3	84			1
MMRF_1906	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	344	420	1	Pomalidomide/Dexamethasone	Pom-Dex	344	IMID/Steroid	420	IMIDs-based	IMIDs-based	Pom-Dex				0							5	449	344	Stable Disease	SD			0	0	0	0	3	77	0	4	106			1	2	1
MMRF_1906	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	421	772	2	Pomalidomide/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Pom-Dex + Car-Pom-Dex	344	IMID/Steroid/Proteasome	772	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	449	344	Stable Disease	SD			0	1	0	1	13	352	0	4	106					1
MMRF_1906	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	792	876	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	792	CD38/IMID/Steroid	876	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Adverse Event or co-morbidity	2			4	876	4	876		Partial Response	PR	Partial Response	PR	1	1	1	1	3	85	1	4	85	4	85	1	3	1
MMRF_1940	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	81	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	161	Stem cell, Autologous	1	1	Completed regimen	4			4	91	4	91		Partial Response	PR	Partial Response	PR	1	1	1	1	3	81	1	4	91	4	91	1	3	1
MMRF_1940	1	Bortezomib	Bor	Proteasome	291	1480	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	1480	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	91	4	91		Partial Response	PR	Partial Response	PR	1	0	0	0	43	1190	0	4	91	4	91			1
MMRF_1940	1	Bortezomib/Ixazomib	Bor-Ixa	Proteasome/Proteasome	1481	1481	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Ixazomib	Bor-Len-Dex + Bor + Bor-Ixa	1	Proteasome/IMID/Steroid	1481	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			4	91	4	91		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	91	4	91			1
MMRF_1940	1	Ixazomib	Ixa	Proteasome	1482	2535	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Ixazomib	Bor-Len-Dex + Bor + Bor-Ixa	1	Proteasome/IMID/Steroid	2535	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	91	4	91		Partial Response	PR	Partial Response	PR	1	0	0	0	38	1054	0	4	91	4	91			1
MMRF_1957	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	144	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	144	IMIDs-based	IMIDs-based	Len-Dex	196	Stem cell, Autologous	1	1	Completed regimen	4			4	83	3	439	978	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	144	1	16	439	3	83	1	2	1
MMRF_1957	1	Lenalidomide	Len	IMID	324	1077	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	1077	IMIDs-based	IMIDs-based	Len-Dex				1	Disease progression/Relapse	3			4	83	3	439	978	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	27	754	0	16	439	3	83			1
MMRF_1957	2	Venetoclax	Vent	BCL2	1226	2563	1	Venetoclax	Vent	1226	BCL2	2563	Other therapies	Other treatments					0					4	1356	4	1356	1245	Partial Response	PR	Partial Response	PR	1	1	1	1	48	1338	1	5	131	5	131			1
MMRF_1957	3	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	2353	2500	1	Ixazomib/Dexamethasone	Ixa-Dex	2353	Proteasome/Steroid	2500	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	2353	2353	Progressive Disease	PD			0	1	0	1	6	148	0	1	1					1
MMRF_1957	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2511	2563	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2511	CD38/IMID/Steroid	2563	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0							5	2561		Stable Disease	SD			0	1	0	1	2	53	0	2	51			1	3	1
MMRF_2001	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	103	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	103	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	170	Stem cell, Autologous	1	1	Completed regimen	4			4	40	3	110	725	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	103	1	4	110	2	40	1	3	1
MMRF_2001	1	Lenalidomide	Len	IMID	404	549	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	549	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	40	3	110	725	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	146	0	4	110	2	40			1
MMRF_2001	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1428	2116	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1428	CD38/IMID/Steroid	2116	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0							6	1115	1115	Progressive Disease	PD			0	0	0	0	25	689	0	-11	-312			1	3	1
MMRF_2090	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	95	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	95	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	140	Stem cell, Autologous	1	1	Completed regimen	4			3	36	3	36		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	95	1	2	36	2	36	1	3	1
MMRF_2090	1	Lenalidomide	Len	IMID	263	1324	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1324	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	36	3	36		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	38	1062	0	2	36	2	36			1
MMRF_2111	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	93	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	154	Stem cell, Autologous	1	1	Completed regimen	4			4	63	3	573		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	93	1	21	573	3	63	1	3	1
MMRF_2111	1	Lenalidomide	Len	IMID	327	1564	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1564	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	63	3	573		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	45	1238	0	21	573	3	63			1
MMRF_2111	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1659	2542	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1659	CD38/IMID/Steroid	2542	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0														0	0	0	0	32	884	0					1	3	1
MMRF_2128	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	162	Stem cell, Autologous	1	1	Completed regimen	4			4	115	3	583	1409	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	106	1	21	583	5	115	1	3	1
MMRF_2128	1	Lenalidomide	Len	IMID	323	343	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	343	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	115	3	583	1409	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	1	21	0	21	583	5	115			1
MMRF_2137	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	107	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	107	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	157	Stem cell, Autologous	1	1	Completed regimen	4			4	-10	1	361		Complete Response	CR	Partial Response	PR	1	1	0	1	4	107	0	13	361	0	-10	1	3	1
MMRF_2137	1	Lenalidomide	Len	IMID	467	2343	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2343	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	-10	1	361		Complete Response	CR	Partial Response	PR	1	0	0	0	67	1877	0	13	361	0	-10			1
MMRF_2140	1	Lenalidomide	Len	IMID	1	94	1	Lenalidomide	Len	1	IMID	94	IMIDs-based	IMIDs-based	Len-Dex				1					4	186	1	451		Complete Response	CR	Partial Response	PR	1	0	0	0	4	94	0	17	451	7	186	1	1	1
MMRF_2140	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	95	200	2	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Len + Bor-Len-Dex	1	IMID/Proteasome/Steroid	200	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	186	1	451		Complete Response	CR	Partial Response	PR	1	0	1	0	4	106	1	17	451	7	186			1
MMRF_2140	1	Lenalidomide	Len	IMID	201	224	3	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Len + Bor-Len-Dex + Len	1	IMID/Proteasome/Steroid	224	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	186	1	451		Complete Response	CR	Partial Response	PR	1	0	0	0	1	24	0	17	451	7	186			1
MMRF_2140	1	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	225	225	4	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Melphalan	Len + Bor-Len-Dex + Len + Len-Mel	1	IMID/Proteasome/Steroid/Chemotherapy	225	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	186	1	451		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	17	451	7	186			1
MMRF_2140	1	Lenalidomide	Len	IMID	226	2484	5	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Melphalan + Lenalidomide	Len + Bor-Len-Dex + Len + Len-Mel + Len	1	IMID/Proteasome/Steroid/Chemotherapy	2484	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	226	Stem cell, Autologous	1	1					4	186	1	451		Complete Response	CR	Partial Response	PR	1	1	0	1	81	2259	0	17	451	7	186			1
MMRF_2211	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	42	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	42	Bortezomib-based	Bortezomib-based	Bor-Dex				1			2374		3	87	1	239	1037	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	42	0	9	239	4	87	1	2	1
MMRF_2211	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	43	74	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Completed regimen	4	2374		3	87	1	239	1037	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	1	32	1	9	239	4	87			1
MMRF_2211	1	Lenalidomide	Len	IMID	249	1054	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	1054	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	2374		3	87	1	239	1037	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	29	806	0	9	239	4	87			1
MMRF_2211	2	Daratumumab/Pomalidomide/Prednisone	Dar-Pom-Pred	CD38/IMID/Steroid	1075	1715	1	Daratumumab/Pomalidomide/Prednisone	Dar-Pom-Pred	1075	CD38/IMID/Steroid	1715	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Pred				0	Disease progression/Relapse	3	2374				5	1131		Stable Disease	SD			0	1	0	1	23	641	0	3	57			1	3	1
MMRF_2211	3	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1722	1796	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1722	Proteasome/IMID/Steroid	1796	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	2374				5	1750		Stable Disease	SD			0	1	0	1	3	75	0	2	29			1	3	1
MMRF_2211	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1838	1936	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1838	Proteasome/Chemotherapy/Steroid	1936	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2374				6	1838	1838	Progressive Disease	PD			0	1	0	1	4	99	0	1	1			1	3	1
MMRF_2211	5	REGN5458/Dexamethasone	REGN5458-Dex	BCMA/Steroid	1968	2348	1	REGN5458/Dexamethasone	REGN5458-Dex	1968	BCMA/Steroid	2348	Other therapies	Other treatments					0	DOSE CHANGE PER TREATMENT ORDERS		2374				5	1997	2374	Stable Disease	SD			0	1	0	1	14	381	0	2	30					1
MMRF_2211	9	AO-176/Dexamethasone	AO-176-Dex	CD47/Steroid	2374	2374	1	AO-176/Dexamethasone	AO-176-Dex	2374	CD47/Steroid	2374	Other therapies	Other treatments					0			2374											0	0	0	0	0	1	0							1
MMRF_2209	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	1	125	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	125	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex	175	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	137		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	5	125	1	5	137	4	85	1	4	1
MMRF_2239	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			3	46	1	188		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	3	74	1	7	188	2	46	1	3	1
MMRF_2239	1	Lenalidomide	Len	IMID	236	1726	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1726	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	46	1	188		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	54	1491	0	7	188	2	46			1
MMRF_2284	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	94	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	94	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	133	Stem cell, Autologous	1	1	Completed regimen	4			3	64	1	161		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	94	1	6	161	3	64	1	3	1
MMRF_2284	1	Lenalidomide	Len	IMID	239	771	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	771	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	64	1	161		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	19	533	0	6	161	3	64			1
MMRF_2284	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1317	1400	1	Ixazomib/Dexamethasone	Ixa-Dex	1317	Proteasome/Steroid	1400	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	1317	1317	Progressive Disease	PD			0	1	0	1	3	84	0	1	1					1
MMRF_2284	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1377	1381	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1377	Proteasome/Chemotherapy/Steroid	1381	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	5	0					1	3	1
MMRF_2284	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1415	1487	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1415	CD38/IMID/Steroid	1487	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	DEATH													0	0	0	0	3	73	0					1	3	1
MMRF_2397	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	53	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	53	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	64	1	165		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	2	53	1	6	165	3	64	1	3	1
MMRF_2397	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	183	218	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	218	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	64	1	165		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	36	0	6	165	3	64			1
MMRF_2397	1	Bortezomib	Bor	Proteasome	284	342	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	342	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					3	64	1	165		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	59	0	6	165	3	64			1
MMRF_2397	1	Bortezomib/Ixazomib	Bor-Ixa	Proteasome/Proteasome	343	343	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Ixazomib	Bor-Len-Dex + Bor + Bor-Ixa	1	Proteasome/IMID/Steroid	343	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			3	64	1	165		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	6	165	3	64			1
MMRF_2397	1	Ixazomib	Ixa	Proteasome	344	1800	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Ixazomib	Bor-Len-Dex + Bor + Bor-Ixa	1	Proteasome/IMID/Steroid	1800	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					3	64	1	165		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	52	1457	0	6	165	3	64			1
MMRF_2383	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	127	Stem cell, Autologous	1	1	Completed regimen	4			3	88	1	331		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	74	1	12	331	4	88	1	3	1
MMRF_2383	1	Lenalidomide	Len	IMID	235	2389	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2389	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	88	1	331		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	77	2155	0	12	331	4	88			1
MMRF_2388	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1242	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1242	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	85	4	85	616	Partial Response	PR	Partial Response	PR	1	1	1	1	45	1242	1	4	85	4	85	1	3	1
MMRF_2388	2	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	633	1088	1	Daratumumab/Lenalidomide	Dar-Len	633	CD38/IMID	1088	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0	Disease progression/Relapse	3			4	822	4	822	1101	Partial Response	PR	Partial Response	PR	1	1	1	1	17	456	1	7	190	7	190	1	2	1
MMRF_2388	3	Ixazomib/Pomalidomide	Ixa-Pom	Proteasome/IMID	1102	1242	1	Ixazomib/Pomalidomide	Ixa-Pom	1102	Proteasome/IMID	1242	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2			4	1169	4	1169	1690	Partial Response	PR	Partial Response	PR	1	1	1	1	5	141	1	3	68	3	68	1	2	1
MMRF_2388	3	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	1243	1557	2	Ixazomib/Pomalidomide + Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom + Ixa-Pom-Dex	1102	Proteasome/IMID/Steroid	1557	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2			4	1169	4	1169	1690	Partial Response	PR	Partial Response	PR	1	0	0	0	12	315	0	3	68	3	68			1
MMRF_2388	3	Ixazomib/Pomalidomide	Ixa-Pom	Proteasome/IMID	1558	1767	3	Ixazomib/Pomalidomide + Ixazomib/Pomalidomide/Dexamethasone + Ixazomib/Pomalidomide	Ixa-Pom + Ixa-Pom-Dex + Ixa-Pom	1102	Proteasome/IMID/Steroid	1767	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3			4	1169	4	1169	1690	Partial Response	PR	Partial Response	PR	1	0	0	0	8	210	0	3	68	3	68			1
MMRF_2388	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1774	2194	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1774	Proteasome/Chemotherapy/Steroid	2194	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0							5	1830		Stable Disease	SD			0	1	0	1	15	421	0	3	57			1	3	1
MMRF_2388	5	Belantamab mafodotin	Bela	BCMA	1999	2059	1	Belantamab mafodotin	Bela	1999	BCMA	2059	Other therapies	Other treatments					0	Completed regimen	4					5	2020		Stable Disease	SD			0	1	0	1	2	61	0	1	22					1
MMRF_2388	9	anti-TIGIT	ANTI-TIGIT	Checkpoint Inhibitor	2083	2109	1	anti-TIGIT	ANTI-TIGIT	2083	Checkpoint Inhibitor	2109	Other therapies	Other treatments					0														0	0	0	0	1	27	0							1
MMRF_2388	9	Pomalidomide/anti-TIGIT/Dexamethasone	Pom-ANTI-TIGIT-Dex	IMID/Checkpoint Inhibitor/Steroid	2110	2194	2	anti-TIGIT + Pomalidomide/anti-TIGIT/Dexamethasone	ANTI-TIGIT + Pom-ANTI-TIGIT-Dex	2083	Checkpoint Inhibitor/IMID/Steroid	2194	IMIDs-based	IMIDs-based	Other Pom-based therapies				0														0	0	0	0	3	85	0					1	4	1
MMRF_2411	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	130	Stem cell, Autologous	1	1	Completed regimen	4	1803		4	64	3	231	897	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	74	1	9	231	3	64	1	3	1
MMRF_2411	1	Lenalidomide	Len	IMID	246	914	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	914	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3	1803		4	64	3	231	897	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	24	669	0	9	231	3	64			1
MMRF_2411	2	Daratumumab/Pomalidomide/Prednisone	Dar-Pom-Pred	CD38/IMID/Steroid	926	1023	1	Daratumumab/Pomalidomide/Prednisone	Dar-Pom-Pred	926	CD38/IMID/Steroid	1023	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Pred				0	Disease progression/Relapse	3	1803				5	967	1051	Stable Disease	SD			0	1	0	1	4	98	0	2	42			1	3	1
MMRF_2411	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1058	1446	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1058	Proteasome/Chemotherapy/Steroid	1446	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1803		4	1142	4	1142	1450	Partial Response	PR	Partial Response	PR	1	1	1	1	14	389	1	4	85	4	85	1	3	1
MMRF_2411	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1578	1602	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1578	Proteasome/Chemotherapy/Steroid	1602	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4	1803				6	1611	1611	Progressive Disease	PD			0	1	0	1	1	25	0	2	34			1	3	1
MMRF_2411	5	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1618	1737	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1618	SLAMF7/IMID/Steroid	1737	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3	1803		4	1716	4	1716	1803	Partial Response	PR	Partial Response	PR	1	1	1	1	5	120	1	4	99	4	99	1	3	1
MMRF_2411	9	Cyclophosphamide/Fludarabine	Cyc-Flu	Chemotherapy/Chemotherapy	1801	2164	1	Cyclophosphamide/Fludarabine	Cyc-Flu	1801	Chemotherapy	2164	Other therapies	Other treatments					0			1803											0	0	0	0	13	364	0							1
MMRF_2459	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	82	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	82	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	136	Stem cell, Autologous	1	1	Completed regimen	4			4	93	4	93		Partial Response	PR	Partial Response	PR	1	1	1	1	3	82	1	4	93	4	93	1	3	1
MMRF_2459	1	Lenalidomide	Len	IMID	224	2007	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2007	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	93	4	93		Partial Response	PR	Partial Response	PR	1	0	0	0	64	1784	0	4	93	4	93			1
MMRF_2516	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			3	78	3	78	1513	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	77	1	3	78	3	78	1	3	1
MMRF_2516	1	Lenalidomide	Len	IMID	245	259	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	259	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	78	3	78	1513	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	15	0	3	78	3	78			1
MMRF_2516	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1589	2163	1	Daratumumab/Dexamethasone	Dar-Dex	1589	CD38/Steroid	2163	daratumumab-based	daratumumab-based	Dar-Dex				0					4	1645	4	1645		Partial Response	PR	Partial Response	PR	1	1	1	1	21	575	1	3	57	3	57			1
MMRF_2532	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	81	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	81	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	135	Stem cell, Autologous	1	1	Completed regimen	4			3	99	1	1016		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	81	1	37	1016	4	99	1	3	1
MMRF_2532	1	Lenalidomide	Len	IMID	239	605	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	605	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Patient decision	6			3	99	1	1016		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	13	367	0	37	1016	4	99			1
MMRF_2559	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	133	Stem cell, Autologous	1	1	Completed regimen	4			3	81	1	155		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	3	74	1	6	155	3	81	1	3	1
MMRF_2559	1	Lenalidomide	Len	IMID	275	2193	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2193	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	81	1	155		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	69	1919	0	6	155	3	81			1
MMRF_1121	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	74	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	131	Stem cell, Autologous	1	1	Completed regimen	4			3	92	1	233		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	3	74	1	9	233	4	92	1	3	1
MMRF_1121	1	Lenalidomide	Len	IMID	345	464	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	464	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	GOING ON VACATION TO CHINA				3	92	1	233		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	5	120	0	9	233	4	92			1
MMRF_1121	1	Lenalidomide	Len	IMID	541	2732	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2732	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	92	1	233		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	79	2192	0	9	233	4	92			1
MMRF_1149	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	186	Stem cell, Autologous	1	1	REFERRED FOR BONE MARROW TRANSPLANT				3	85	3	85	140	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	4	85	4	85	1	3	1
MMRF_1149	2	Lenalidomide	Len	IMID	330	457	1	Lenalidomide	Len	330	IMID	457	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	256	4	256	437	Partial Response	PR	Partial Response	PR	1	0	0	0	5	128	0	-2	-73	-2	-73	1	1	1
MMRF_1149	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	458	563	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	458	Proteasome/IMID/Steroid	563	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	634	4	634	515	Partial Response	PR	Partial Response	PR	1	0	0	0	4	106	0	7	177	7	177	1	3	1
MMRF_1149	3	Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Pom-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	564	564	2	Carfilzomib/Pomalidomide/Dexamethasone + Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Dex + Bor-Car-Pom-Cyc-Dex	458	Proteasome/IMID/Steroid/Chemotherapy	564	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3			4	634	4	634	515	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	7	177	7	177			1
MMRF_1149	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	565	595	3	Carfilzomib/Pomalidomide/Dexamethasone + Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Car-Pom-Dex + Bor-Car-Pom-Cyc-Dex + Bor-Cyc-Dex	458	Proteasome/IMID/Steroid/Chemotherapy	595	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4			4	634	4	634	515	Partial Response	PR	Partial Response	PR	1	0	0	0	1	31	0	7	177	7	177			1
MMRF_1149	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	620	645	4	Carfilzomib/Pomalidomide/Dexamethasone + Bortezomib/Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Car-Pom-Dex + Bor-Car-Pom-Cyc-Dex + Bor-Cyc-Dex + Bor-Len-Dex	458	Proteasome/IMID/Steroid/Chemotherapy	645	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3			4	634	4	634	515	Partial Response	PR	Partial Response	PR	1	1	1	1	1	26	1	7	177	7	177			1
MMRF_1149	4	Bortezomib/Thalidomide/Cyclophosphamide/Vorinostat/Dexamethasone	Bor-Thal-Cyc-Vor-Dex	Proteasome/IMID/Chemotherapy/HDAC/Steroid	701	760	1	Bortezomib/Thalidomide/Cyclophosphamide/Vorinostat/Dexamethasone	Bor-Thal-Cyc-Vor-Dex	701	Proteasome/IMID/Chemotherapy/HDAC/Steroid	760	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	760	760	Progressive Disease	PD			0	1	0	1	2	60	0	3	60			1	5	1
MMRF_1149	9	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Thal-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	772	776	1	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Thal-Cyc-Dex-Dox	772	Proteasome/IMID/Chemotherapy/Steroid	776	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4												0	0	0	0	0	5	0					1	5	1
MMRF_1149	9	Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Bor-Elo-Len-Dex	Proteasome/SLAMF7/IMID/Steroid	809	837	2	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Bor-Thal-Cyc-Dex-Dox + Bor-Elo-Len-Dex	772	Proteasome/IMID/Chemotherapy/Steroid/SLAMF7	837	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3												0	0	0	0	1	29	0							1
MMRF_1149	9	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	844	852	3	Bortezomib/Thalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Bor-Thal-Cyc-Dex-Dox + Bor-Elo-Len-Dex + Car-Cyc-Dex	772	Proteasome/IMID/Chemotherapy/Steroid/SLAMF7	852	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Adverse Event or co-morbidity	2												0	0	0	0	1	9	0							1
MMRF_1080	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	144	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	144	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	159	Stem cell, Autologous	1	1	Completed regimen	4			4	64	3	317		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	144	1	12	317	3	64	1	3	1
MMRF_1080	1	Lenalidomide	Len	IMID	295	617	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	617	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	64	3	317		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	12	323	0	12	317	3	64			1
MMRF_1198	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	309	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	309	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	78	3	262		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	11	309	1	10	262	3	78	1	3	1
MMRF_1198	1	Lenalidomide	Len	IMID	310	434	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	434	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	78	3	262		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	125	0	10	262	3	78			1
MMRF_1255	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	179	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	179	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	88	1	193		Complete Response	CR	Partial Response	PR	1	0	1	0	7	179	1	7	193	4	88	1	3	1
MMRF_1255	1	Lenalidomide	Len	IMID	180	447	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	447	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	88	1	193		Complete Response	CR	Partial Response	PR	1	1	0	1	10	268	0	7	193	4	88			1
MMRF_1339	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	24	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	24	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2					6	138	138	Progressive Disease	PD			0	1	0	1	1	24	0	5	138			1	2	1
MMRF_1236	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	190	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	203	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	123	3	419	1397	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	7	190	1	15	419	5	123	1	3	1
MMRF_1236	1	Pomalidomide	Pom	IMID	313	1027	2	Bortezomib/Lenalidomide/Dexamethasone + Pomalidomide	Bor-Len-Dex + Pom	1	Proteasome/IMID/Steroid	1027	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	123	3	419	1397	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	26	715	0	15	419	5	123			1
MMRF_1236	1	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1028	1397	3	Bortezomib/Lenalidomide/Dexamethasone + Pomalidomide + Pomalidomide/Dexamethasone	Bor-Len-Dex + Pom + Pom-Dex	1	Proteasome/IMID/Steroid	1397	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	123	3	419	1397	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	14	370	0	15	419	5	123			1
MMRF_1236	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1407	1700	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1407	CD38/IMID/Steroid	1700	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	1463	4	1463	1698	Partial Response	PR	Partial Response	PR	1	1	1	1	11	294	1	3	57	3	57	1	3	1
MMRF_1236	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1701	1791	1	Carfilzomib/Dexamethasone	Car-Dex	1701	Proteasome/Steroid	1791	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	1758	4	1758	2098	Partial Response	PR	Partial Response	PR	1	1	1	1	4	91	1	3	58	3	58	1	2	1
MMRF_1236	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1792	2079	2	Carfilzomib/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Dex + Car-Cyc-Dex	1701	Proteasome/Steroid/Chemotherapy	2079	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	1758	4	1758	2098	Partial Response	PR	Partial Response	PR	1	0	0	0	11	288	0	3	58	3	58			1
MMRF_1236	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2080	2086	3	Carfilzomib/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Car-Dex + Car-Cyc-Dex + Car-Dex	1701	Proteasome/Steroid/Chemotherapy	2086	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	1758	4	1758	2098	Partial Response	PR	Partial Response	PR	1	0	0	0	1	7	0	3	58	3	58			1
MMRF_1236	4	Bortezomib/Bendamustine	Bor-Bend	Proteasome/Chemotherapy	2154	2154	1	Bortezomib/Bendamustine	Bor-Bend	2154	Proteasome/Chemotherapy	2154	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	2287	3	2287	2899	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	5	134	5	134	1	2	1
MMRF_1236	4	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	2185	2190	2	Bortezomib/Bendamustine + Lenalidomide/Melphalan	Bor-Bend + Len-Mel	2154	Proteasome/Chemotherapy/IMID	2190	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	2190	Stem cell, Autologous	2	1	Completed regimen	4			3	2287	3	2287	2899	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	6	1	5	134	5	134			1
MMRF_1236	4	Lenalidomide	Len	IMID	2301	2899	3	Bortezomib/Bendamustine + Lenalidomide/Melphalan + Lenalidomide	Bor-Bend + Len-Mel + Len	2154	Proteasome/Chemotherapy/IMID	2899	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	2287	3	2287	2899	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	599	0	5	134	5	134			1
MMRF_1236	5	Belantamab mafodotin	Bela	BCMA	2904	2904	1	Belantamab mafodotin	Bela	2904	BCMA	2904	Other therapies	Other treatments					0														0	0	0	0	0	1	0							1
MMRF_1918	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	91	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	91	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	63	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	91	1	5	113	3	63	1	3	1
MMRF_1918	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	92	99	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	99	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	63	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	8	0	5	113	3	63			1
MMRF_1918	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	100	273	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	273	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	288	Stem cell, Autologous	1	1	REFERRED FOR AUTOLOGOUS TRANSPLANT				4	63	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	7	174	0	5	113	3	63			1
MMRF_1918	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	456	631	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Car-Len	1	Proteasome/IMID/Steroid/Chemotherapy	631	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			4	63	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	176	0	5	113	3	63			1
MMRF_1918	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	659	1627	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide + Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Car-Len + Ixa-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1627	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	63	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	35	969	0	5	113	3	63			1
MMRF_1918	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1634	2080	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide + Ixazomib/Lenalidomide/Dexamethasone + Elotuzumab/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Car-Len + Ixa-Len-Dex + Elo-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy/SLAMF7	2080	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2			4	63	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	16	447	0	5	113	3	63			1
MMRF_2329	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	176	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	176	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	80	3	162	1158	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	176	1	6	162	3	80	1	3	1
MMRF_2329	1	Lenalidomide	Len	IMID	358	1171	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1171	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	80	3	162	1158	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	29	814	0	6	162	3	80			1
MMRF_2329	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1172	1716	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1172	CD38/IMID/Steroid	1716	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA				3	1339	3	1339		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	20	545	1	6	168	6	168	1	3	1
MMRF_1067	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	112	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	112	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	91	3	460	1285	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	112	1	17	460	4	91	1	3	1
MMRF_1067	1	Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	148	161	2	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	161	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	162	Stem cell, Autologous	1	1	Completed regimen	4			4	91	3	460	1285	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	14	0	17	460	4	91			1
MMRF_1067	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	348	421	3	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Cyc-Mel-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	421	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	91	3	460	1285	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	3	74	0	17	460	4	91			1
MMRF_1067	1	Lenalidomide	Len	IMID	545	865	4	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Cyc-Mel-Dex + Bor-Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	865	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	91	3	460	1285	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	12	321	0	17	460	4	91			1
MMRF_1067	2	Daratumumab	Dar	CD38	1294	1343	1	Daratumumab	Dar	1294	CD38	1343	daratumumab-based	daratumumab-based	Dar				0	Adverse Event or co-morbidity	2			4	1343	3	1427	1539	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	2	50	1	5	134	2	50			1
MMRF_1067	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1427	1569	2	Daratumumab + Bortezomib/Dexamethasone	Dar + Bor-Dex	1294	CD38/Proteasome/Steroid	1569	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3			4	1343	3	1427	1539	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	5	143	0	5	134	2	50	1	2	1
MMRF_1067	2	Bortezomib	Bor	Proteasome	1570	1594	3	Daratumumab + Bortezomib/Dexamethasone + Bortezomib	Dar + Bor-Dex + Bor	1294	CD38/Proteasome/Steroid	1594	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0					4	1343	3	1427	1539	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	25	0	5	134	2	50			1
MMRF_1067	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1595	1805	4	Daratumumab + Bortezomib/Dexamethasone + Bortezomib + Bortezomib/Dexamethasone	Dar + Bor-Dex + Bor + Bor-Dex	1294	CD38/Proteasome/Steroid	1805	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3			4	1343	3	1427	1539	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	8	211	0	5	134	2	50			1
MMRF_1067	2	Bortezomib	Bor	Proteasome	1806	1817	5	Daratumumab + Bortezomib/Dexamethasone + Bortezomib + Bortezomib/Dexamethasone + Bortezomib	Dar + Bor-Dex + Bor + Bor-Dex + Bor	1294	CD38/Proteasome/Steroid	1817	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3			4	1343	3	1427	1539	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	12	0	5	134	2	50			1
MMRF_1067	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1835	2429	1	Pomalidomide/Dexamethasone	Pom-Dex	1835	IMID/Steroid	2429	IMIDs-based	IMIDs-based	Pom-Dex				0					4	1967	3	2906		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	22	595	1	39	1072	5	133	1	2	1
MMRF_1067	3	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	2430	2906	2	Pomalidomide/Dexamethasone + Elotuzumab/Pomalidomide/Dexamethasone	Pom-Dex + Elo-Pom-Dex	1835	IMID/Steroid/SLAMF7	2906	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					4	1967	3	2906		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	17	477	0	39	1072	5	133			1
MMRF_1131	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	Proteasome/IMID/Steroid/Steroid	1	345	1	Bortezomib/Lenalidomide/Prednisone/Dexamethasone	Bor-Len-Pred-Dex	1	Proteasome/IMID/Steroid	345	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	86	4	86	206	Partial Response	PR	Partial Response	PR	1	1	1	1	13	345	1	4	86	4	86	1	4	1
MMRF_1131	2	Pomalidomide/Prednisone	Pom-Pred	IMID/Steroid	312	333	1	Pomalidomide/Prednisone	Pom-Pred	312	IMID/Steroid	333	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Patient decision	6					6	336	336	Progressive Disease	PD			0	1	0	1	1	22	0	1	25			1	2	1
MMRF_1245	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	239	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	239	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	66	4	66		Partial Response	PR	Partial Response	PR	1	1	1	1	9	239	1	3	66	3	66	1	2	1
MMRF_1245	1	Bortezomib	Bor	Proteasome	240	295	2	Bortezomib/Dexamethasone + Bortezomib	Bor-Dex + Bor	1	Proteasome/Steroid	295	Bortezomib-based	Bortezomib-based	Bor-Dex				0	MOVED TO OHIO				4	66	4	66		Partial Response	PR	Partial Response	PR	1	0	0	0	2	56	0	3	66	3	66			1
MMRF_1412	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	99	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	99	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	82	1	2519		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	99	1	90	2519	3	82	1	3	1
MMRF_1412	1	Cyclophosphamide/Melphalan	Cyc-Mel	Chemotherapy/Chemotherapy	134	147	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan	Bor-Len-Dex + Cyc-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	147	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	148	Stem cell, Autologous	1	1	Completed regimen	4			3	82	1	2519		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	14	0	90	2519	3	82			1
MMRF_1412	1	Lenalidomide	Len	IMID	294	2904	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan + Lenalidomide	Bor-Len-Dex + Cyc-Mel + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2904	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	82	1	2519		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	94	2611	0	90	2519	3	82			1
MMRF_1680	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	132	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	132	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	116	3	116		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	132	1	5	116	5	116	1	3	1
MMRF_1680	1	Cyclophosphamide/Melphalan	Cyc-Mel	Chemotherapy/Chemotherapy	133	145	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan	Bor-Len-Dex + Cyc-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	145	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	146	Stem cell, Autologous	1	1	Completed regimen	4			3	116	3	116		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	13	0	5	116	5	116			1
MMRF_1680	1	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	1376	1422	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan + Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Dex + Cyc-Mel + Cyc-Dex-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	1422	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	116	3	116		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	47	0	5	116	5	116			1
MMRF_2119	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	165	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	165	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	STRIGENT COMPLETE RESPONSE				4	63	4	63	526	Partial Response	PR	Partial Response	PR	1	1	1	1	6	165	1	3	63	3	63	1	3	1
MMRF_2119	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	191	421	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	421	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	63	4	63	526	Partial Response	PR	Partial Response	PR	1	0	0	0	9	231	0	3	63	3	63			1
MMRF_2119	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	422	530	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	530	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	63	4	63	526	Partial Response	PR	Partial Response	PR	1	0	0	0	4	109	0	3	63	3	63			1
MMRF_2119	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	533	654	1	Ixazomib/Dexamethasone	Ixa-Dex	533	Proteasome/Steroid	654	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	613	613	Progressive Disease	PD			0	1	0	1	5	122	0	3	81					1
MMRF_2119	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	653	716	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	653	Proteasome/Chemotherapy/Steroid	716	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5					6	794	794	Progressive Disease	PD			0	0	0	0	3	64	0	6	142			1	3	1
MMRF_2119	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	736	770	2	Bortezomib/Cyclophosphamide/Dexamethasone + Pomalidomide/Dexamethasone	Bor-Cyc-Dex + Pom-Dex	653	Proteasome/Chemotherapy/Steroid/IMID	770	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Pom-Cyc-Dex				0	Investigator decision for other reasons	5					6	794	794	Progressive Disease	PD			0	0	0	0	2	35	0	6	142					1
MMRF_2119	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	771	785	3	Bortezomib/Cyclophosphamide/Dexamethasone + Pomalidomide/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Bor-Cyc-Dex + Pom-Dex + Car-Pom-Dex	653	Proteasome/Chemotherapy/Steroid/IMID	785	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Investigator decision for other reasons	5					6	794	794	Progressive Disease	PD			0	0	0	0	1	15	0	6	142					1
MMRF_2119	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	786	925	4	Bortezomib/Cyclophosphamide/Dexamethasone + Pomalidomide/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Bor-Cyc-Dex + Pom-Dex + Car-Pom-Dex + Car-Dex	653	Proteasome/Chemotherapy/Steroid/IMID	925	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4					6	794	794	Progressive Disease	PD			0	1	0	1	5	140	0	6	142					1
MMRF_2213	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	99	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	99	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	109	3	109		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	99	1	4	109	4	109	1	3	1
MMRF_2213	1	Lenalidomide	Len	IMID	312	355	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	355	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	109	3	109		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	44	0	4	109	4	109			1
MMRF_2213	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	356	356	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Len + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	356	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	109	3	109		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	109	4	109			1
MMRF_2213	1	Bortezomib	Bor	Proteasome	357	1778	4	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide + Bortezomib	Bor-Cyc-Dex + Len + Bor-Len + Bor	1	Proteasome/Chemotherapy/Steroid/IMID	1778	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			3	109	3	109		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	51	1422	0	4	109	4	109			1
MMRF_2213	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1785	1840	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1785	Proteasome/IMID/Steroid	1840	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			3	2016	3	2016	1785	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	56	0	9	232	9	232	1	3	1
MMRF_2213	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1841	1898	2	Carfilzomib/Pomalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Pom-Dex + Car-Cyc-Dex	1785	Proteasome/IMID/Steroid/Chemotherapy	1898	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	2016	3	2016	1785	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	58	0	9	232	9	232			1
MMRF_2213	2	Ixazomib/Melphalan	Ixa-Mel	Proteasome/Chemotherapy	1918	2720	3	Carfilzomib/Pomalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Ixazomib/Melphalan	Car-Pom-Dex + Car-Cyc-Dex + Ixa-Mel	1785	Proteasome/IMID/Steroid/Chemotherapy	2720	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	1919	Stem cell, Autologous	1	1					3	2016	3	2016	1785	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	29	803	1	9	232	9	232			1
MMRF_2476	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	29	525	1	Lenalidomide/Dexamethasone	Len-Dex	29	IMID/Steroid	525	IMIDs-based	IMIDs-based	Len-Dex				0					4	92	3	525		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	18	497	1	18	497	3	64	1	2	1
MMRF_2549	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	39	285	1	Bortezomib/Dexamethasone	Bor-Dex	39	Proteasome/Steroid	285	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5			4	89	4	89		Partial Response	PR	Partial Response	PR	1	1	1	1	9	247	1	2	51	2	51	1	2	1
MMRF_2549	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	292	453	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	39	Proteasome/Steroid/Chemotherapy	453	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Lack of response	1			4	89	4	89		Partial Response	PR	Partial Response	PR	1	0	0	0	6	162	0	2	51	2	51			1
MMRF_2549	2	Lenalidomide	Len	IMID	467	544	1	Lenalidomide	Len	467	IMID	544	IMIDs-based	IMIDs-based	Len-Dex				0					3	692	3	692	1010	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	78	0	9	226	9	226	1	1	1
MMRF_2549	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	545	879	2	Lenalidomide + Lenalidomide/Dexamethasone	Len + Len-Dex	467	IMID/Steroid	879	IMIDs-based	IMIDs-based	Len-Dex				0					3	692	3	692	1010	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	12	335	1	9	226	9	226			1
MMRF_2549	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	880	985	3	Lenalidomide + Lenalidomide/Dexamethasone + Elotuzumab/Lenalidomide/Dexamethasone	Len + Len-Dex + Elo-Len-Dex	467	IMID/Steroid/SLAMF7	985	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			3	692	3	692	1010	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	106	0	9	226	9	226			1
MMRF_2549	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1020	1101	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1020	CD38/IMID/Steroid	1101	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Patient decision	6					6	1101	1101	Progressive Disease	PD			0	1	0	1	3	82	0	3	82			1	3	1
MMRF_1309	1	Lenalidomide	Len	IMID	1	3	1	Lenalidomide	Len	1	IMID	3	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	244	4	244	517	Partial Response	PR	Partial Response	PR	1	0	0	0	0	3	0	9	244	9	244	1	1	1
MMRF_1309	1	Bortezomib	Bor	Proteasome	34	97	2	Lenalidomide + Bortezomib	Len + Bor	1	IMID/Proteasome	97	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	244	4	244	517	Partial Response	PR	Partial Response	PR	1	1	1	1	3	64	1	9	244	9	244			1
MMRF_1309	2	Bortezomib	Bor	Proteasome	1663	1768	1	Bortezomib	Bor	1663	Proteasome	1768	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2					6	1700	1700	Progressive Disease	PD			0	1	0	1	4	106	0	2	38			1	1	1
MMRF_1431	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	32	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	32	IMIDs-based	IMIDs-based	Len-Dex				0					4	54	3	439		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	32	0	16	439	2	54	1	2	1
MMRF_1431	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	33	837	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	837	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	54	3	439		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	29	805	1	16	439	2	54			1
MMRF_1431	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	838	1230	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	1230	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	54	3	439		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	14	393	0	16	439	2	54			1
MMRF_2308	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	126	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	126	IMIDs-based	IMIDs-based	Len-Dex				0							5	91	830	Stable Disease	SD			0	1	0	1	5	126	0	4	91			1	2	1
MMRF_2308	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	127	1370	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	1370	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0							5	91	830	Stable Disease	SD			0	0	0	0	45	1244	0	4	91					1
MMRF_1077	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	204	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	204	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	154	4	154	1426	Partial Response	PR	Partial Response	PR	1	1	1	1	8	204	1	6	154	6	154	1	3	1
MMRF_1077	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	205	205	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	205	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	154	4	154	1426	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	6	154	6	154			1
MMRF_1077	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	206	1903	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1903	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	267	Stem cell, Autologous	1	1	Lack of response	1			4	154	4	154	1426	Partial Response	PR	Partial Response	PR	1	0	0	0	61	1698	0	6	154	6	154			1
MMRF_1078	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	77	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	77	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	177	Stem cell, Autologous	1	1	Completed regimen	4			3	64	1	1163		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	3	77	1	42	1163	3	64	1	3	1
MMRF_1078	2	Prednisone/Dexamethasone	Pred-Dex	Steroid/Steroid	2290	2311	1	Prednisone/Dexamethasone	Pred-Dex	2290	Steroid	2311	Other therapies	Other treatments					0	Completed regimen	4			4	2591	1	2941	2416	Complete Response	CR	Partial Response	PR	1	0	0	0	1	22	0	24	652	11	302			1
MMRF_1078	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2367	2396	2	Prednisone/Dexamethasone + Carfilzomib/Dexamethasone	Pred-Dex + Car-Dex	2290	Steroid/Proteasome	2396	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	2591	1	2941	2416	Complete Response	CR	Partial Response	PR	1	1	1	1	1	30	1	24	652	11	302	1	2	1
MMRF_1105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	168	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	168	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	43	3	43	309	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	168	1	2	43	2	43	1	3	1
MMRF_1105	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	169	302	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	302	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	43	3	43	309	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	134	0	2	43	2	43			1
MMRF_1105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	303	339	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	339	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	43	3	43	309	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	37	0	2	43	2	43			1
MMRF_1105	1	Lenalidomide	Len	IMID	618	2851	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2851	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	43	3	43	309	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	80	2234	0	2	43	2	43			1
MMRF_1136	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	85	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	85	1	274	365	Complete Response	CR	Partial Response	PR	1	0	1	0	3	85	1	10	274	4	85	1	3	1
MMRF_1136	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	96	131	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined bortezomib/IMIDs-based	Other treatments	Bor-Len-Cyc-Dex	208	Stem cell, Autologous	1	1	Completed regimen	4			4	85	1	274	365	Complete Response	CR	Partial Response	PR	1	1	0	1	2	36	0	10	274	4	85			1
MMRF_1136	1	Carfilzomib	Car	Proteasome	309	309	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Carfilzomib	Bor-Len-Dex + Cyc-Dex + Car	1	Proteasome/IMID/Steroid/Chemotherapy	309	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Investigator decision for other reasons	5			4	85	1	274	365	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	10	274	4	85			1
MMRF_1136	1	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	342	360	4	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Dexamethasone + Carfilzomib + Pomalidomide/Dexamethasone	Bor-Len-Dex + Cyc-Dex + Car + Pom-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	360	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3			4	85	1	274	365	Complete Response	CR	Partial Response	PR	1	0	0	0	1	19	0	10	274	4	85			1
MMRF_1148	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	270	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	270	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	PATIENT DIED						5	56	196	Stable Disease	SD			0	1	0	1	10	270	0	2	56			1	3	1
MMRF_1148	2	Carfilzomib	Car	Proteasome	227	270	1	Carfilzomib	Car	227	Proteasome	270	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	PATIENT DIED													0	0	0	0	2	44	0					1	1	1
MMRF_1189	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	11	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	11	Bortezomib-based	Bortezomib-based	Bor-Dex	228	Stem cell, Autologous	1	1	Completed regimen	4			3	79	3	79		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	11	1	3	79	3	79	1	2	1
MMRF_1189	2	Lenalidomide	Len	IMID	697	1271	1	Lenalidomide	Len	697	IMID	1271	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	935	4	935	697	Partial Response	PR	Partial Response	PR	1	1	1	1	21	575	1	9	239	9	239	1	1	1
MMRF_1189	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1600	1670	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1600	Proteasome/CD38/Steroid	1670	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3					6	1627	1627	Progressive Disease	PD			0	1	0	1	3	71	0	1	28			1	3	1
MMRF_1214	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	1	38	1	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	38	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	810	1	908		Complete Response	CR	Partial Response	PR	1	0	0	0	2	38	0	33	908	29	810	1	2	1
MMRF_1214	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	39	151	2	Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	151	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1			4	810	1	908		Complete Response	CR	Partial Response	PR	1	1	1	1	4	113	1	33	908	29	810			1
MMRF_1335	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	355	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	355	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	463	Stem cell, Autologous	1	1	Completed regimen	4					5	81	343	Stable Disease	SD			0	1	0	1	13	355	0	3	81			1	3	1
MMRF_1335	2	Cyclophosphamide/Doxorubicin	Cyc-Dox	Chemotherapy/Chemotherapy	1202	1202	1	Cyclophosphamide/Doxorubicin	Cyc-Dox	1202	Chemotherapy	1202	Other therapies	Other treatments					0	Completed regimen	4			3	718	3	718	988	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	-17	-483	-17	-483			1
MMRF_1402	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	142	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	142	IMIDs-based	IMIDs-based	Len-Dex				1					4	254	1	430		Complete Response	CR	Partial Response	PR	1	0	0	0	5	142	0	16	430	10	254	1	2	1
MMRF_1402	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	143	243	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	243	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	254	1	430		Complete Response	CR	Partial Response	PR	1	0	0	0	4	101	0	16	430	10	254			1
MMRF_1402	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	244	247	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	247	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	313	Stem cell, Autologous	1	1	Completed regimen	4			4	254	1	430		Complete Response	CR	Partial Response	PR	1	1	1	1	0	4	1	16	430	10	254			1
MMRF_1402	1	Lenalidomide	Len	IMID	558	1152	4	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Bor-Len-Dex + Len	1	IMID/Steroid/Proteasome	1152	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5			4	254	1	430		Complete Response	CR	Partial Response	PR	1	0	0	0	22	595	0	16	430	10	254			1
MMRF_1560	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	43	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	43	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	236	3	236		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	43	0	9	236	9	236	1	3	1
MMRF_1560	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	44	114	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	114	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex	274	Stem cell, Autologous	1	1	Completed regimen	4			3	236	3	236		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	71	1	9	236	9	236			1
MMRF_1560	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	44	114	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	114	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex	327	Stem cell, Autologous	2	1	Completed regimen	4			3	236	3	236		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	3	71	1	9	236	9	236			1
MMRF_1560	2	Lenalidomide	Len	IMID	436	2899	1	Lenalidomide	Len	436	IMID	2899	IMIDs-based	IMIDs-based	Len-Dex				0					3	530	3	530		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	88	2464	1	4	95	4	95	1	1	1
MMRF_1579	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	112	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	112	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	272	3	272	1710	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	112	1	10	272	10	272	1	2	1
MMRF_1579	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	973	1428	2	Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Len-Dex + Car-Cyc-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	1428	combined IMIDs/carfilzomib-based	Carfilzomib-based	Len-Car-Cyc-Dex				0	Investigator decision for other reasons	5			3	272	3	272	1710	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	17	456	0	10	272	10	272			1
MMRF_1579	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1429	1871	3	Lenalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Len-Dex + Car-Cyc-Dex + Car-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	1871	combined IMIDs/carfilzomib-based	Carfilzomib-based	Len-Car-Cyc-Dex				0					3	272	3	272	1710	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	16	443	0	10	272	10	272			1
MMRF_1613	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	118	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	118	Bortezomib-based	Bortezomib-based	Bor-Dex				0	RISK FOR RELAPSE.DOES NOT WANT TRANSPLANT, PURSUING MAINTENANCE- REV ONLY.		1254		4	105	3	261	604	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	118	1	10	261	4	105	1	2	1
MMRF_1613	1	Lenalidomide	Len	IMID	396	491	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	491	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0			1254		4	105	3	261	604	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	96	0	10	261	4	105			1
MMRF_1613	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	492	539	3	Bortezomib/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Dex + Len + Len-Dex	1	Proteasome/Steroid/IMID	539	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Patient decision	6	1254		4	105	3	261	604	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	48	0	10	261	4	105			1
MMRF_1613	1	Lenalidomide	Len	IMID	540	694	4	Bortezomib/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Len + Len-Dex + Len	1	Proteasome/Steroid/IMID	694	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Lack of response	1	1254		4	105	3	261	604	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	155	0	10	261	4	105			1
MMRF_1613	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	684	799	1	Lenalidomide/Dexamethasone	Len-Dex	684	IMID/Steroid	799	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1	1254				6	696	696	Progressive Disease	PD			0	1	0	1	4	116	0	1	13			1	2	1
MMRF_1613	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	799	1254	1	Daratumumab/Dexamethasone	Dar-Dex	799	CD38/Steroid	1254	daratumumab-based	daratumumab-based	Dar-Dex				0	Patient decision	6	1254		4	863	4	863	799	Partial Response	PR	Partial Response	PR	1	1	1	1	17	456	1	3	65	3	65			1
MMRF_1613	9	Elotuzumab	Elo	SLAMF7	1261	1282	1	Elotuzumab	Elo	1261	SLAMF7	1282	Other therapies	Other treatments					0	Patient decision	6	1254											0	0	0	0	1	22	0							1
MMRF_1761	1	Bortezomib	Bor	Proteasome	1	230	1	Bortezomib	Bor	1	Proteasome	230	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	355	3	525		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	9	230	0	19	525	13	355	1	1	1
MMRF_1761	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	231	568	2	Bortezomib + Bortezomib/Lenalidomide/Dexamethasone	Bor + Bor-Len-Dex	1	Proteasome/IMID/Steroid	568	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	355	3	525		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	12	338	1	19	525	13	355			1
MMRF_1761	1	Bortezomib	Bor	Proteasome	569	990	3	Bortezomib + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor + Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	990	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	355	3	525		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	15	422	0	19	525	13	355			1
MMRF_1761	2	Ixazomib	Ixa	Proteasome	1155	1183	1	Ixazomib	Ixa	1155	Proteasome	1183	Other therapies	Other treatments					0					4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	1	1	1	1	29	1	2	29	2	29			1
MMRF_1761	2	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	1184	1205	2	Ixazomib + Ixazomib/Lenalidomide	Ixa + Ixa-Len	1155	Proteasome/IMID	1205	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Completed regimen	4			4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	0	0	0	1	22	0	2	29	2	29	1	2	1
MMRF_1761	2	Ixazomib	Ixa	Proteasome	1206	1449	3	Ixazomib + Ixazomib/Lenalidomide + Ixazomib	Ixa + Ixa-Len + Ixa	1155	Proteasome/IMID	1449	IMIDs-based	Other treatments	Other Len-based therapies				0					4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	0	0	0	9	244	0	2	29	2	29			1
MMRF_1761	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1450	1821	4	Ixazomib + Ixazomib/Lenalidomide + Ixazomib + Ixazomib/Dexamethasone	Ixa + Ixa-Len + Ixa + Ixa-Dex	1155	Proteasome/IMID/Steroid	1821	IMIDs-based	Other treatments	Other Len-based therapies				0					4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	0	0	0	14	372	0	2	29	2	29			1
MMRF_1761	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1822	1822	5	Ixazomib + Ixazomib/Lenalidomide + Ixazomib + Ixazomib/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Ixa + Ixa-Len + Ixa + Ixa-Dex + Ixa-Len-Dex	1155	Proteasome/IMID/Steroid	1822	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Investigator decision for other reasons	5			4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_1761	2	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	1823	1840	6	Ixazomib + Ixazomib/Lenalidomide + Ixazomib + Ixazomib/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide	Ixa + Ixa-Len + Ixa + Ixa-Dex + Ixa-Len-Dex + Ixa-Len	1155	Proteasome/IMID/Steroid	1840	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Patient decision	6			4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	0	0	0	1	18	0	2	29	2	29			1
MMRF_1761	2	Ixazomib	Ixa	Proteasome	1841	2933	7	Ixazomib + Ixazomib/Lenalidomide + Ixazomib + Ixazomib/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide + Ixazomib	Ixa + Ixa-Len + Ixa + Ixa-Dex + Ixa-Len-Dex + Ixa-Len + Ixa	1155	Proteasome/IMID/Steroid	2933	IMIDs-based	Other treatments	Other Len-based therapies				0					4	1183	4	1183	2198	Partial Response	PR	Partial Response	PR	1	0	0	0	39	1093	0	2	29	2	29			1
MMRF_1890	1	Bortezomib	Bor	Proteasome	1	100	1	Bortezomib	Bor	1	Proteasome	100	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			3	79	3	79		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	100	1	3	79	3	79	1	1	1
MMRF_1890	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	119	133	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	119	Chemotherapy/Steroid	133	Other therapies	Other treatments					0	Lack of response	1												0	0	0	0	1	15	0							1
MMRF_2183	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	103	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	103	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	112	4	112	261	Partial Response	PR	Partial Response	PR	1	1	1	1	4	103	1	4	112	4	112	1	2	1
MMRF_2183	1	Lenalidomide	Len	IMID	121	336	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	336	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Patient decision	6			4	112	4	112	261	Partial Response	PR	Partial Response	PR	1	0	0	0	8	216	0	4	112	4	112			1
MMRF_2246	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	23	231	1	Lenalidomide/Dexamethasone	Len-Dex	23	IMID/Steroid	231	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	73	3	220		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	209	1	8	198	2	51	1	2	1
MMRF_2246	9	Bortezomib	Bor	Proteasome	1866	1899	1	Bortezomib	Bor	1866	Proteasome	1899	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	2	34	0					1	1	1
MMRF_2246	9	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1900	1900	2	Bortezomib + Bortezomib/Dexamethasone	Bor + Bor-Dex	1866	Proteasome/Steroid	1900	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2246	9	Bortezomib	Bor	Proteasome	1901	2005	3	Bortezomib + Bortezomib/Dexamethasone + Bortezomib	Bor + Bor-Dex + Bor	1866	Proteasome/Steroid	2005	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	4	105	0							1
MMRF_2246	9	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	2006	2705	4	Bortezomib + Bortezomib/Dexamethasone + Bortezomib + Bortezomib/Daratumumab	Bor + Bor-Dex + Bor + Bor-Dar	1866	Proteasome/Steroid/CD38	2705	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0														0	0	0	0	25	700	0							1
MMRF_2477	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	39	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	39	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	85	3	85	365	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	39	0	4	85	4	85	1	2	1
MMRF_2477	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	40	57	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	85	3	85	365	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	18	0	4	85	4	85			1
MMRF_2477	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	58	71	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	71	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	85	3	85	365	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	14	1	4	85	4	85			1
MMRF_2477	2	Ixazomib	Ixa	Proteasome	382	483	1	Ixazomib	Ixa	382	Proteasome	483	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2												0	0	0	0	4	102	0							1
MMRF_1163	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	136	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	136	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	66	3	66	136	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	136	1	3	66	3	66	1	3	1
MMRF_1163	2	Carfilzomib	Car	Proteasome	150	262	1	Carfilzomib	Car	150	Proteasome	262	Carfilzomib-based	Carfilzomib-based	Car-Dex				0							6	262	262	Progressive Disease	PD			0	1	0	1	4	113	0	5	113			1	1	1
MMRF_1182	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	130	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	68	1	517		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	130	1	19	517	3	68	1	3	1
MMRF_1182	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	131	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	68	1	517		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	19	517	3	68			1
MMRF_1182	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	132	234	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	234	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	133	Stem cell, Autologous	1	1	Completed regimen	4			3	68	1	517		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	103	0	19	517	3	68			1
MMRF_1182	1	Lenalidomide	Len	IMID	264	644	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	644	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Patient decision	6			3	68	1	517		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	14	381	0	19	517	3	68			1
MMRF_1186	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	234	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	234	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	53	4	53	1228	Partial Response	PR	Partial Response	PR	1	1	1	1	9	234	1	2	53	2	53	1	2	1
MMRF_1186	1	Lenalidomide	Len	IMID	312	979	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	979	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	53	4	53	1228	Partial Response	PR	Partial Response	PR	1	0	0	0	24	668	0	2	53	2	53			1
MMRF_1186	2	Lenalidomide	Len	IMID	1264	1850	1	Lenalidomide	Len	1264	IMID	1850	IMIDs-based	IMIDs-based	Len-Dex				0	PATIENT DEATH				4	1551	4	1551		Partial Response	PR	Partial Response	PR	1	1	1	1	21	587	1	11	288	11	288	1	1	1
MMRF_1201	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	194	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	194	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1			1822		3	71	3	71	628	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	194	1	3	71	3	71	1	3	1
MMRF_1201	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	195	196	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	196	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	197	Stem cell, Autologous	1	1	Completed regimen	4	1822		3	71	3	71	628	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	2	0	3	71	3	71			1
MMRF_1201	1	Lenalidomide	Len	IMID	436	789	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	789	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	1822		3	71	3	71	628	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	13	354	0	3	71	3	71			1
MMRF_1201	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	790	923	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	790	Proteasome/Chemotherapy/Steroid	923	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Lack of response	1	1822				6	798	798	Progressive Disease	PD			0	1	0	1	5	134	0	1	9			1	3	1
MMRF_1201	3	CB-5083	CB-5083	Other	1007	1033	1	CB-5083	CB-5083	1007	Other	1033	Other therapies	Other treatments					0			1822		4	1127	4	1127	1037	Partial Response	PR	Partial Response	PR	1	0	0	0	1	27	0	5	121	5	121			1
MMRF_1201	3	Carfilzomib/CB-5083/Panobinostat	Car-CB-5083-Pano	Proteasome/Other/HDAC	1034	1034	2	CB-5083 + Carfilzomib/CB-5083/Panobinostat	CB-5083 + Car-CB-5083-Pano	1007	Other/Proteasome/HDAC	1034	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1	1822		4	1127	4	1127	1037	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	5	121	5	121	1	4	1
MMRF_1201	3	Carfilzomib/Panobinostat	Car-Pano	Proteasome/HDAC	1035	1356	3	CB-5083 + Carfilzomib/CB-5083/Panobinostat + Carfilzomib/Panobinostat	CB-5083 + Car-CB-5083-Pano + Car-Pano	1007	Other/Proteasome/HDAC	1356	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1822		4	1127	4	1127	1037	Partial Response	PR	Partial Response	PR	1	1	1	1	12	322	1	5	121	5	121			1
MMRF_1201	4	CC-90002	CC-90002	CD47	1392	1422	1	CC-90002	CC-90002	1392	CD47	1422	Other therapies	Other treatments					0	Lack of response	1	1822		4	1521	4	1521	1426	Partial Response	PR	Partial Response	PR	1	0	0	0	1	31	0	5	130	5	130			1
MMRF_1201	4	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	1430	1729	2	CC-90002 + Daratumumab/Lenalidomide	CC-90002 + Dar-Len	1392	CD47/CD38/IMID	1729	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1822		4	1521	4	1521	1426	Partial Response	PR	Partial Response	PR	1	1	1	1	11	300	1	5	130	5	130	1	2	1
MMRF_1201	5	Bortezomib/Venetoclax/Dexamethasone	Bor-Vent-Dex	Proteasome/BCL2/Steroid	1731	1773	1	Bortezomib/Venetoclax/Dexamethasone	Bor-Vent-Dex	1731	Proteasome/BCL2/Steroid	1773	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Lack of response	1	1822		4	1987	3	2791	1822	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	43	0	38	1061	10	257	1	3	1
MMRF_1201	5	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	1783	1835	2	Bortezomib/Venetoclax/Dexamethasone + Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Vent-Dex + Pom-Cyc-Dex	1731	Proteasome/BCL2/Steroid/IMID/Chemotherapy	1835	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1	1822		4	1987	3	2791	1822	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	53	0	38	1061	10	257			1
MMRF_1201	5	Pomalidomide/Bendamustine/Dexamethasone	Pom-Bend-Dex	IMID/Chemotherapy/Steroid	1848	2128	3	Bortezomib/Venetoclax/Dexamethasone + Pomalidomide/Cyclophosphamide/Dexamethasone + Pomalidomide/Bendamustine/Dexamethasone	Bor-Vent-Dex + Pom-Cyc-Dex + Pom-Bend-Dex	1731	Proteasome/BCL2/Steroid/IMID/Chemotherapy	2128	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1822		4	1987	3	2791	1822	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	10	281	1	38	1061	10	257			1
MMRF_1201	9	Bendamustine/Dexamethasone	Bend-Dex	Chemotherapy/Steroid	2128	2131	1	Bendamustine/Dexamethasone	Bend-Dex	2128	Chemotherapy/Steroid	2131	Other therapies	Other treatments					0	AWAITING CLINICAL TRIAL SLOT		1822											0	0	0	0	0	4	0							1
MMRF_1201	9	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2233	2252	2	Bendamustine/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Bend-Dex + Dar-Pom-Dex	2128	Chemotherapy/Steroid/CD38/IMID	2252	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Completed regimen	4	1822											0	0	0	0	1	20	0					1	3	1
MMRF_1201	9	Cyclophosphamide/Fludarabine	Cyc-Flu	Chemotherapy/Chemotherapy	2275	2277	3	Bendamustine/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone + Cyclophosphamide/Fludarabine	Bend-Dex + Dar-Pom-Dex + Cyc-Flu	2128	Chemotherapy/Steroid/CD38/IMID	2277	combined daratumumab/IMIDs-based	Other treatments	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Completed regimen	4	1822											0	0	0	0	0	3	0							1
MMRF_1201	9	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2410	2472	4	Bendamustine/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone + Cyclophosphamide/Fludarabine + Daratumumab/Pomalidomide/Dexamethasone	Bend-Dex + Dar-Pom-Dex + Cyc-Flu + Dar-Pom-Dex	2128	Chemotherapy/Steroid/CD38/IMID	2472	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1822											0	0	0	0	3	63	0							1
MMRF_1201	9	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2486	2500	5	Bendamustine/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone + Cyclophosphamide/Fludarabine + Daratumumab/Pomalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone	Bend-Dex + Dar-Pom-Dex + Cyc-Flu + Dar-Pom-Dex + Car-Cyc-Dex	2128	Chemotherapy/Steroid/CD38/IMID/Proteasome	2500	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	STARTING CLINICAL TRIAL		1822											0	0	0	0	1	15	0							1
MMRF_1201	9	Cyclophosphamide/Fludarabine	Cyc-Flu	Chemotherapy/Chemotherapy	2549	2551	6	Bendamustine/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone + Cyclophosphamide/Fludarabine + Daratumumab/Pomalidomide/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Fludarabine	Bend-Dex + Dar-Pom-Dex + Cyc-Flu + Dar-Pom-Dex + Car-Cyc-Dex + Cyc-Flu	2128	Chemotherapy/Steroid/CD38/IMID/Proteasome	2551	combined daratumumab/IMIDs/carfilzomib-based	Other treatments	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Completed regimen	4	1822											0	0	0	0	0	3	0							1
MMRF_1202	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	151	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	151	IMIDs-based	IMIDs-based	Len-Dex				1					4	117	2	501		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	6	151	1	18	501	5	117	1	2	1
MMRF_1202	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	152	227	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	227	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	314	Stem cell, Autologous	1	1	Completed regimen	4			4	117	2	501		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	3	76	0	18	501	5	117			1
MMRF_1202	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	697	810	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	697	Proteasome/IMID/Steroid	810	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	788	4	788	708	Partial Response	PR	Partial Response	PR	1	1	1	1	4	114	1	4	92	4	92	1	3	1
MMRF_1202	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	872	890	1	Carfilzomib/Dexamethasone	Car-Dex	872	Proteasome/Steroid	890	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1					6	883	883	Progressive Disease	PD			0	1	0	1	1	19	0	1	12			1	2	1
MMRF_1210	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	156	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	156	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	125	3	447	1405	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	156	1	16	447	5	125	1	3	1
MMRF_1210	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	171	292	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	292	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Completed regimen	4			4	125	3	447	1405	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	122	0	16	447	5	125			1
MMRF_1210	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	503	1054	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor-Dex + Bor-Len	1	Proteasome/IMID/Steroid	1054	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	125	3	447	1405	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	20	552	0	16	447	5	125			1
MMRF_1210	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1055	1495	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	1495	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	125	3	447	1405	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	16	441	0	16	447	5	125			1
MMRF_1210	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1503	1678	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1503	Proteasome/IMID/Steroid	1678	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					2	1661	2	1661		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	7	176	1	6	159	6	159	1	3	1
MMRF_1210	2	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	1679	1679	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex	1503	Proteasome/IMID/Steroid/Chemotherapy	1679	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			2	1661	2	1661		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	0	1	0	6	159	6	159			1
MMRF_1210	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1680	2955	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1503	Proteasome/IMID/Steroid/Chemotherapy	2955	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	1681	Stem cell, Autologous	1	1					2	1661	2	1661		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	46	1276	0	6	159	6	159			1
MMRF_1293	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	257	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	257	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	57	1	609	886	Complete Response	CR	Partial Response	PR	1	0	1	0	9	257	1	22	609	3	57	1	3	1
MMRF_1293	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	258	258	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	258	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	57	1	609	886	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	22	609	3	57			1
MMRF_1293	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	259	432	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	432	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	260	Stem cell, Autologous	1	1	Completed regimen	4			4	57	1	609	886	Complete Response	CR	Partial Response	PR	1	1	0	1	7	174	0	22	609	3	57			1
MMRF_1293	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	916	1099	1	Lenalidomide/Dexamethasone	Len-Dex	916	IMID/Steroid	1099	IMIDs-based	IMIDs-based	Len-Dex				0							6	991	991	Progressive Disease	PD			0	1	0	1	7	184	0	3	76			1	2	1
MMRF_1293	2	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	1100	1163	2	Lenalidomide/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Len-Dex + Len-Clar-Dex	916	IMID/Steroid/Antibiotic	1163	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Lack of response	1					6	991	991	Progressive Disease	PD			0	0	0	0	3	64	0	3	76					1
MMRF_1293	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1184	1226	3	Lenalidomide/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Carfilzomib/Dexamethasone	Len-Dex + Len-Clar-Dex + Car-Dex	916	IMID/Steroid/Antibiotic/Proteasome	1226	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Lack of response	1					6	991	991	Progressive Disease	PD			0	0	0	0	2	43	0	3	76					1
MMRF_1293	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1245	2383	4	Lenalidomide/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Carfilzomib/Dexamethasone + Cyclophosphamide/Dexamethasone	Len-Dex + Len-Clar-Dex + Car-Dex + Cyc-Dex	916	IMID/Steroid/Antibiotic/Proteasome/Chemotherapy	2383	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	991	991	Progressive Disease	PD			0	0	0	0	41	1139	0	3	76					1
MMRF_1293	3	Lenalidomide/Atezolizumab	Len-Atez	IMID/Checkpoint Inhibitor	1320	1398	1	Lenalidomide/Atezolizumab	Len-Atez	1320	IMID/Checkpoint Inhibitor	1398	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			3	1551	3	1551	2449	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	79	0	9	232	9	232	1	2	1
MMRF_1293	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1450	2451	2	Lenalidomide/Atezolizumab + Daratumumab/Pomalidomide	Len-Atez + Dar-Pom	1320	IMID/Checkpoint Inhibitor/CD38	2451	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3			3	1551	3	1551	2449	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	36	1002	1	9	232	9	232			1
MMRF_1293	4	Cyclophosphamide/Fludarabine	Cyc-Flu	Chemotherapy/Chemotherapy	2527	2529	1	Cyclophosphamide/Fludarabine	Cyc-Flu	2527	Chemotherapy	2529	Other therapies	Other treatments					0	Completed regimen	4			3	2645	1	2870		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	0	3	1	13	344	5	119			1
MMRF_1320	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	45	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	45	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	128	3	818	367	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	45	0	30	818	5	128	1	3	1
MMRF_1320	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	46	46	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	46	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	128	3	818	367	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	30	818	5	128			1
MMRF_1320	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	47	337	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	337	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	128	3	818	367	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	11	291	1	30	818	5	128			1
MMRF_1320	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	338	1073	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	1073	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	128	3	818	367	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	27	736	0	30	818	5	128			1
MMRF_1320	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1149	2123	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1149	Proteasome/Chemotherapy/Steroid	2123	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	1286	3	1459	2115	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	35	975	1	12	311	5	138	1	3	1
MMRF_1320	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2123	2724	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2123	CD38/IMID/Steroid	2724	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3			4	2364	3	2560	2675	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	22	602	1	16	438	9	242	1	3	1
MMRF_1320	4	FOR46/Dexamethasone	FOR46-Dex	CD46/Steroid	2724	2942	1	FOR46/Dexamethasone	FOR46-Dex	2724	CD46/Steroid	2942	Other therapies	Other treatments					0					4	2942	4	2942		Partial Response	PR	Partial Response	PR	1	1	1	1	8	219	1	8	219	8	219			1
MMRF_1300	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	153	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	153	IMIDs-based	IMIDs-based	Len-Dex				0			2370		4	82	4	82	440	Partial Response	PR	Partial Response	PR	1	1	1	1	6	153	1	3	82	3	82	1	2	1
MMRF_1300	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	154	154	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	154	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4	2370		4	82	4	82	440	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	82	3	82			1
MMRF_1300	1	Bortezomib	Bor	Proteasome	155	206	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Len-Dex + Bor-Len-Dex + Bor	1	IMID/Steroid/Proteasome	206	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0			2370		4	82	4	82	440	Partial Response	PR	Partial Response	PR	1	0	0	0	2	52	0	3	82	3	82			1
MMRF_1300	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	207	490	4	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Dexamethasone	Len-Dex + Bor-Len-Dex + Bor + Bor-Dex	1	IMID/Steroid/Proteasome	490	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Disease progression/Relapse	3	2370		4	82	4	82	440	Partial Response	PR	Partial Response	PR	1	0	0	0	10	284	0	3	82	3	82			1
MMRF_1300	2	Bortezomib/Lenalidomide/Clarithromycin/Dexamethasone	Bor-Len-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	490	727	1	Bortezomib/Lenalidomide/Clarithromycin/Dexamethasone	Bor-Len-Clar-Dex	490	Proteasome/IMID/Antibiotic/Steroid	727	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	2370		4	535	3	800	899	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	238	1	12	311	2	46	1	4	1
MMRF_1300	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	910	1479	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	910	Proteasome/IMID/Steroid	1479	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1	2370				6	966	966	Progressive Disease	PD			0	1	0	1	21	570	0	3	57			1	3	1
MMRF_1300	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1063	1097	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1063	Proteasome/Chemotherapy/Steroid	1097	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5	2370				5	1288	1460	Stable Disease	SD			0	0	0	0	2	35	0	9	226			1	3	1
MMRF_1300	4	Bortezomib/Lenalidomide/Clarithromycin/Dexamethasone	Bor-Len-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	1141	1484	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Clarithromycin/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Clar-Dex	1063	Proteasome/Chemotherapy/Steroid/IMID/Antibiotic	1484	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2370				5	1288	1460	Stable Disease	SD			0	1	0	1	13	344	0	9	226					1
MMRF_1300	5	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	1484	1801	1	Bortezomib/Daratumumab	Bor-Dar	1484	Proteasome/CD38	1801	Bortezomib-based	Bortezomib-based	Bor-Dar				0	Disease progression/Relapse	3	2370		4	1509	3	1618	2370	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	12	318	1	5	135	1	26	1	2	1
MMRF_1300	9	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	1801	2385	1	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	1801	IMID/Chemotherapy/Steroid	2385	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				1			2370											0	0	0	0	21	585	0					1	3	1
MMRF_1300	9	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	2386	2386	2	Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex + Car-Pom-Cyc-Dex	1801	IMID/Chemotherapy/Steroid/Proteasome	2386	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2370											0	0	0	0	0	1	0							1
MMRF_1300	9	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2387	2569	3	Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Pom-Cyc-Dex + Car-Pom-Cyc-Dex + Car-Dex	1801	IMID/Chemotherapy/Steroid/Proteasome	2569	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	2370											0	0	0	0	7	183	0							1
MMRF_1300	9	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	2582	2620	4	Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone + Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex + Car-Pom-Cyc-Dex + Car-Dex + Cyc-Dex	1801	IMID/Chemotherapy/Steroid/Proteasome	2620	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	2649	Stem cell, Autologous	1	1	Completed regimen	4	2370											0	0	0	0	2	39	0							1
MMRF_1300	9	Ixazomib	Ixa	Proteasome	2839	2937	5	Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone + Cyclophosphamide/Dexamethasone + Ixazomib	Pom-Cyc-Dex + Car-Pom-Cyc-Dex + Car-Dex + Cyc-Dex + Ixa	1801	IMID/Chemotherapy/Steroid/Proteasome	2937	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1			2370											0	0	0	0	4	99	0							1
MMRF_1338	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	852	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	852	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	110	4	110	845	Partial Response	PR	Partial Response	PR	1	1	1	1	31	852	1	4	110	4	110	1	3	1
MMRF_1375	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	180	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	180	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	35	1	1175		Complete Response	CR	Partial Response	PR	1	0	1	0	7	180	1	42	1175	2	35	1	3	1
MMRF_1375	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	181	181	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	181	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	181	Stem cell, Autologous	1	1	Completed regimen	4			4	35	1	1175		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	42	1175	2	35			1
MMRF_1375	1	Lenalidomide	Len	IMID	360	1218	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	1218	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	35	1	1175		Complete Response	CR	Partial Response	PR	1	1	0	1	31	859	0	42	1175	2	35			1
MMRF_1490	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	1331	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1331	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	141	4	141	470	Partial Response	PR	Partial Response	PR	1	1	1	1	48	1331	1	6	141	6	141	1	3	1
MMRF_1490	2	Pomalidomide	Pom	IMID	514	2002	1	Pomalidomide	Pom	514	IMID	2002	IMIDs-based	IMIDs-based	Pom-Dex				0					3	623	3	623		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	53	1489	1	4	110	4	110	1	1	1
MMRF_1490	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	2003	2652	2	Pomalidomide + Pomalidomide/Dexamethasone	Pom + Pom-Dex	514	IMID/Steroid	2652	IMIDs-based	IMIDs-based	Pom-Dex				0	PRESUMED PROGRESSION, (PATIENT DID NOT END UP HAVING PD)				3	623	3	623		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	24	650	0	4	110	4	110			1
MMRF_1490	3	Carfilzomib	Car	Proteasome	2675	2717	1	Carfilzomib	Car	2675	Proteasome	2717	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	MARROW WITHOUT MYELOMA; TREATMENT NOT NEEDED PER PRIMARY ONCOLOGIST				2	2759	1	2912		Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	2	43	1	9	238	4	85	1	1	1
MMRF_1518	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	97	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	97	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1							6	50	50	Progressive Disease	PD			0	1	0	1	4	97	0	2	50			1	3	1
MMRF_1518	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	98	135	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Len-Dex + Bor-Len-Cyc-Dex-Dox	1	Proteasome/IMID/Steroid/Chemotherapy	135	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	CHANGE IN DOSE						6	50	50	Progressive Disease	PD			0	0	0	0	2	38	0	2	50					1
MMRF_1518	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	136	154	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex-Dox + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	154	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1							6	50	50	Progressive Disease	PD			0	0	0	0	1	19	0	2	50					1
MMRF_1518	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	155	155	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex-Dox + Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	155	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4					6	50	50	Progressive Disease	PD			0	0	0	0	0	1	0	2	50					1
MMRF_1518	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	156	240	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex-Dox + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	240	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	157	Stem cell, Autologous	1	1	PATIENT DEATH						6	50	50	Progressive Disease	PD			0	0	0	0	3	85	0	2	50					1
MMRF_1518	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	221	240	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	221	Proteasome/IMID/Steroid	240	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	PATIENT DEATH													0	0	0	0	1	20	0					1	3	1
MMRF_1772	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	72	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	72	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	260	1	891	1241	Complete Response	CR	Partial Response	PR	1	0	0	0	3	72	0	32	891	10	260	1	3	1
MMRF_1772	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	73	207	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	207	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1					4	260	1	891	1241	Complete Response	CR	Partial Response	PR	1	0	0	0	5	135	0	32	891	10	260			1
MMRF_1772	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Car-Len-Cyc-Mel-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	208	208	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Cyc-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	208	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	260	1	891	1241	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	32	891	10	260			1
MMRF_1772	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	209	1157	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Cyc-Dex + Bor-Car-Len-Cyc-Mel-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1157	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	210	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	260	1	891	1241	Complete Response	CR	Partial Response	PR	1	1	1	1	34	949	1	32	891	10	260			1
MMRF_1772	2	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	1256	1311	1	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	1256	Proteasome/IMID/Steroid	1311	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					4	1332	1	1689		Complete Response	CR	Partial Response	PR	1	0	0	0	2	56	0	16	434	3	77	1	3	1
MMRF_1772	2	Ixazomib/Lenalidomide/Pomalidomide/Dexamethasone	Ixa-Len-Pom-Dex	Proteasome/IMID/IMID/Steroid	1312	2900	2	Ixazomib/Pomalidomide/Dexamethasone + Ixazomib/Lenalidomide/Pomalidomide/Dexamethasone	Ixa-Pom-Dex + Ixa-Len-Pom-Dex	1256	Proteasome/IMID/Steroid	2900	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1332	1	1689		Complete Response	CR	Partial Response	PR	1	1	1	1	57	1589	1	16	434	3	77			1
MMRF_1952	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	309	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	309	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Patient decision	6			4	148	3	439	1545	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	11	309	1	16	439	6	148	1	3	1
MMRF_1952	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	320	1187	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1187	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					4	148	3	439	1545	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	31	868	0	16	439	6	148			1
MMRF_1952	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	1188	1244	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Bor-Cyc-Dex + Len-Dex + Len-Clar-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/Antibiotic	1244	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1			4	148	3	439	1545	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	57	0	16	439	6	148			1
MMRF_1952	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1245	1600	4	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex + Len-Clar-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID/Antibiotic	1600	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	148	3	439	1545	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	13	356	0	16	439	6	148			1
MMRF_1952	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1593	2770	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1593	CD38/IMID/Steroid	2770	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	1657	1	1769		Complete Response	CR	Partial Response	PR	1	1	1	1	42	1178	1	7	177	3	65	1	3	1
MMRF_1983	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	316	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	316	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	142	4	142	1209	Partial Response	PR	Partial Response	PR	1	1	1	1	12	316	1	6	142	6	142	1	2	1
MMRF_1983	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1230	2747	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1230	CD38/IMID/Steroid	2747	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0					4	1258	1	1340		Complete Response	CR	Partial Response	PR	1	1	1	1	55	1518	1	4	111	2	29	1	3	1
MMRF_1991	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	20	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	20	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	142	1	392	507	Complete Response	CR	Partial Response	PR	1	0	1	0	1	20	1	14	392	6	142	1	3	1
MMRF_1991	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	260	507	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	507	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	142	1	392	507	Complete Response	CR	Partial Response	PR	1	1	0	1	9	248	0	14	392	6	142			1
MMRF_1991	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	516	822	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	516	Proteasome/IMID/Steroid	822	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	581	3	581	827	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	307	1	3	66	3	66	1	3	1
MMRF_1991	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	828	871	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	828	Proteasome/Chemotherapy/Steroid	871	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	1004	1	1680		Complete Response	CR	Partial Response	PR	1	0	0	0	2	44	0	31	853	7	177	1	3	1
MMRF_1991	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	876	2772	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Daratumumab/Pomalidomide	Car-Cyc-Dex + Dar-Pom	828	Proteasome/Chemotherapy/Steroid/CD38/IMID	2772	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0					4	1004	1	1680		Complete Response	CR	Partial Response	PR	1	1	1	1	68	1897	1	31	853	7	177			1
MMRF_2097	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	161	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	161	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	63	1	621	1346	Complete Response	CR	Partial Response	PR	1	0	1	0	6	161	1	23	621	3	63	1	3	1
MMRF_2097	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	162	1359	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1359	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					4	63	1	621	1346	Complete Response	CR	Partial Response	PR	1	1	0	1	43	1198	0	23	621	3	63			1
MMRF_2097	1	Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Len-Cyc-Mel-Dex	Proteasome/IMID/Chemotherapy/Chemotherapy/Steroid	1360	1360	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1360	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	1360	Stem cell, Autologous	1	1	Completed regimen	4			4	63	1	621	1346	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	23	621	3	63			1
MMRF_2097	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1361	1373	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1373	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	63	1	621	1346	Complete Response	CR	Partial Response	PR	1	0	0	0	1	13	0	23	621	3	63			1
MMRF_2097	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1374	2757	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Cyc-Mel-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	2757	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	63	1	621	1346	Complete Response	CR	Partial Response	PR	1	0	0	0	50	1384	0	23	621	3	63			1
MMRF_2367	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	612	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	612	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			2	113	1	456	1094	Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	22	612	1	17	456	5	113	1	3	1
MMRF_2367	2	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	1109	2571	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	1109	Proteasome/CD38/Steroid	2571	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					1	1304	1	1304		Complete Response	CR	Complete Response	CR	1	1	1	1	53	1463	1	7	196	7	196	1	3	1
MMRF_2412	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	130	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	130	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Patient decision	6			4	98	4	98	161	Partial Response	PR	Partial Response	PR	1	1	1	1	5	130	1	4	98	4	98	1	3	1
MMRF_2412	2	Daratumumab	Dar	CD38	727	1261	1	Daratumumab	Dar	727	CD38	1261	daratumumab-based	daratumumab-based	Dar				0	Patient decision	6			4	233	1	1443	385	Complete Response	CR	Partial Response	PR	1	1	0	1	19	535	0	26	717	-17	-493			1
MMRF_2433	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	166	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	166	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	82	1	560		Complete Response	CR	Partial Response	PR	1	0	1	0	6	166	1	20	560	3	82	1	3	1
MMRF_2433	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	167	215	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	215	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	248	Stem cell, Autologous	1	1	STARTING SCT				4	82	1	560		Complete Response	CR	Partial Response	PR	1	0	0	0	2	49	0	20	560	3	82			1
MMRF_2433	1	Lenalidomide	Len	IMID	342	2618	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2618	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					4	82	1	560		Complete Response	CR	Partial Response	PR	1	1	0	1	82	2277	0	20	560	3	82			1
MMRF_2458	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	120	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	120	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	84	2	1376	1891	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	5	120	1	50	1376	3	84	1	3	1
MMRF_2458	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	138	436	2	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid	436	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Dex				0	Completed regimen	4			4	84	2	1376	1891	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	11	299	0	50	1376	3	84			1
MMRF_2458	1	Lenalidomide	Len	IMID	437	1793	3	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	1793	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Dex				0	Patient decision	6			4	84	2	1376	1891	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	49	1357	0	50	1376	3	84			1
MMRF_2458	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1968	2570	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1968	CD38/IMID/Steroid	2570	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0					3	2124	3	2124		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	22	603	1	6	157	6	157	1	3	1
MMRF_1112	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	190	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	346	Stem cell, Autologous	1	1	Completed regimen	4			4	90	3	190	1186	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	190	1	7	190	4	90	1	3	1
MMRF_1112	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	489	2354	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2354	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	90	3	190	1186	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	67	1866	0	7	190	4	90			1
MMRF_1112	2	Acalabrutinib/Pembrolizumab	Aca-Pemb	BTK/Checkpoint Inhibitor	1316	1379	1	Acalabrutinib/Pembrolizumab	Aca-Pemb	1316	BTK/Checkpoint Inhibitor	1379	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	1358	1358	Progressive Disease	PD			0	1	0	1	3	64	0	2	43					1
MMRF_1112	3	Carfilzomib	Car	Proteasome	1385	1695	1	Carfilzomib	Car	1385	Proteasome	1695	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Investigator decision for other reasons	5					5	1596		Stable Disease	SD			0	1	0	1	11	311	0	8	212			1	1	1
MMRF_1152	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	107	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	107	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	81	3	81	1503	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	107	1	3	81	3	81	1	2	1
MMRF_1152	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	108	192	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	192	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	81	3	81	1503	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	85	0	3	81	3	81			1
MMRF_1152	1	Lenalidomide	Len	IMID	304	2685	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	2685	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	81	3	81	1503	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	85	2382	0	3	81	3	81			1
MMRF_1283	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	48	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	48	IMIDs-based	IMIDs-based	Len-Dex				0														0	0	0	0	2	48	0					1	2	1
MMRF_1360	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	399	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	399	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	207	Stem cell, Autologous	1	1	Completed regimen	4			4	153	3	432		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	15	399	1	16	432	6	153	1	3	1
MMRF_1484	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1050	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1050	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	249	4	249		Partial Response	PR	Partial Response	PR	1	1	1	1	38	1050	1	9	249	9	249	1	2	1
MMRF_1601	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	16	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	16	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5												0	0	0	0	1	16	0					1	2	1
MMRF_1641	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	506	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	506	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4					6	90	90	Progressive Disease	PD			0	1	0	1	18	506	0	4	90			1	3	1
MMRF_1641	3	Carfilzomib	Car	Proteasome	211	470	1	Carfilzomib	Car	211	Proteasome	470	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Completed regimen	4					5	267	435	Stable Disease	SD			0	1	0	1	10	260	0	3	57			1	1	1
MMRF_2083	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	321	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	321	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	610	3	610		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	321	0	22	610	22	610	1	3	1
MMRF_2083	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	476	630	2	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Bor-Len-Dex + Car-Dex	1	Proteasome/IMID/Steroid	630	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Dex				0	Disease progression/Relapse	3			3	610	3	610		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	155	1	22	610	22	610			1
MMRF_2083	3	Daratumumab/Methylprednisolone	Dar-Mep	CD38/Steroid	659	667	1	Daratumumab/Methylprednisolone	Dar-Mep	659	CD38/Steroid	667	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2												0	0	0	0	1	9	0							1
MMRF_2083	4	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	682	722	1	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	682	Chemotherapy/Steroid	722	Other therapies	Other treatments					0	Disease progression/Relapse	3					5	797		Stable Disease	SD			0	1	0	1	2	41	0	5	116					1
MMRF_2083	5	Elotuzumab/Dexamethasone	Elo-Dex	SLAMF7/Steroid	804	869	1	Elotuzumab/Dexamethasone	Elo-Dex	804	SLAMF7/Steroid	869	Other therapies	Other treatments					0	Patient decision	6												0	0	0	0	3	66	0							1
MMRF_2400	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	620	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	620	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	538	4	538		Partial Response	PR	Partial Response	PR	1	1	1	1	22	620	1	20	538	20	538	1	3	1
MMRF_2473	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	534	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	534	IMIDs-based	IMIDs-based	Len-Dex				0							5	72	343	Stable Disease	SD			0	1	0	1	19	534	0	3	72			1	2	1
MMRF_1310	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1	182	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	182	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	DECREASED DOSE				4	85	1	547	1765	Complete Response	CR	Partial Response	PR	1	0	1	0	7	182	1	20	547	4	85	1	4	1
MMRF_1310	1	Lenalidomide	Len	IMID	183	1751	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Len-Cyc-Dex + Len	1	Proteasome/IMID/Chemotherapy/Steroid	1751	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	85	1	547	1765	Complete Response	CR	Partial Response	PR	1	1	0	1	56	1569	0	20	547	4	85			1
MMRF_1407	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	78	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	78	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Completed regimen	4			3	90	1	440		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	78	1	16	440	4	90	1	3	1
MMRF_1407	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	201	277	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	277	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	90	1	440		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	77	0	16	440	4	90			1
MMRF_1407	1	Lenalidomide	Len	IMID	278	1021	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1021	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	90	1	440		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	27	744	0	16	440	4	90			1
MMRF_1424	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	109	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	109	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	85	1	802	1325	Complete Response	CR	Partial Response	PR	1	0	1	0	4	109	1	29	802	4	85	1	3	1
MMRF_1424	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	150	192	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	192	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex	250	Stem cell, Autologous	1	1	Completed regimen	4			4	85	1	802	1325	Complete Response	CR	Partial Response	PR	1	0	0	0	2	43	0	29	802	4	85			1
MMRF_1424	1	Lenalidomide	Len	IMID	361	926	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Dex + Len	1	Proteasome/IMID/Steroid	926	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	85	1	802	1325	Complete Response	CR	Partial Response	PR	1	1	0	1	21	566	0	29	802	4	85			1
MMRF_1424	1	Bortezomib	Bor	Proteasome	981	1278	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide + Bortezomib	Bor-Len-Dex + Bor-Dex + Len + Bor	1	Proteasome/IMID/Steroid	1278	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	85	1	802	1325	Complete Response	CR	Partial Response	PR	1	0	0	0	11	298	0	29	802	4	85			1
MMRF_1424	2	Carfilzomib/Pomalidomide	Car-Pom	Proteasome/IMID	1376	1495	1	Carfilzomib/Pomalidomide	Car-Pom	1376	Proteasome/IMID	1495	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	1446	4	1446	1495	Partial Response	PR	Partial Response	PR	1	1	1	1	5	120	1	3	71	3	71	1	2	1
MMRF_1424	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1516	1600	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1516	CD38/IMID/Steroid	1600	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					5	1544	1600	Stable Disease	SD			0	1	0	1	3	85	0	2	29			1	3	1
MMRF_1424	4	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1614	1719	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1614	SLAMF7/IMID/Steroid	1719	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3					6	1698	1698	Progressive Disease	PD			0	1	0	1	4	106	0	4	85			1	3	1
MMRF_1424	5	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	1759	1761	1	Busulfan/Melphalan	Bus-Mel	1759	Chemotherapy	1761	Other therapies	Other treatments		1762	Stem cell, Autologous	2	1	Completed regimen	4			3	1976	3	1976		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	3	0	8	218	8	218			1
MMRF_1424	5	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	1919	2144	2	Busulfan/Melphalan + Ixazomib/Pomalidomide/Dexamethasone	Bus-Mel + Ixa-Pom-Dex	1759	Chemotherapy/Proteasome/IMID/Steroid	2144	IMIDs-based	IMIDs-based	Other Pom-based therapies				1	DEATH				3	1976	3	1976		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	226	1	8	218	8	218	1	3	1
MMRF_1556	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			1	184	1	184	1197	Complete Response	CR	Complete Response	CR	1	1	1	1	4	113	1	7	184	7	184	1	3	1
MMRF_1556	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1212	1337	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1212	Proteasome/Chemotherapy/Steroid	1337	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Lack of response	1					5	1524		Stable Disease	SD			0	1	0	1	5	126	0	12	313			1	3	1
MMRF_1617	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	108	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	108	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	149	Stem cell, Autologous	1	1	Completed regimen	4			3	87	3	87	2642	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	108	1	4	87	4	87	1	3	1
MMRF_1617	1	Lenalidomide	Len	IMID	251	2672	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2672	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	87	3	87	2642	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	87	2422	0	4	87	4	87			1
MMRF_1617	2	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	2673	2725	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	2673	Proteasome/CD38/Steroid	2725	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Lack of response	1												0	0	0	0	2	53	0					1	3	1
MMRF_1617	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	2743	2919	1	Daratumumab/Pomalidomide	Dar-Pom	2743	CD38/IMID	2919	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0					3	2919	3	2919		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	177	1	7	177	7	177	1	2	1
MMRF_1723	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	127	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	127	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	113	4	113	1568	Partial Response	PR	Partial Response	PR	1	1	1	1	5	127	1	5	113	5	113	1	3	1
MMRF_1723	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	128	267	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	267	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	113	4	113	1568	Partial Response	PR	Partial Response	PR	1	0	0	0	5	140	0	5	113	5	113			1
MMRF_1723	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	272	2673	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2673	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	113	4	113	1568	Partial Response	PR	Partial Response	PR	1	0	0	0	86	2402	0	5	113	5	113			1
MMRF_1723	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1610	1899	1	Carfilzomib/Dexamethasone	Car-Dex	1610	Proteasome/Steroid	1899	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4					5	1728	2309	Stable Disease	SD			0	1	0	1	11	290	0	5	119			1	2	1
MMRF_1723	2	Pomalidomide	Pom	IMID	1990	2290	2	Carfilzomib/Dexamethasone + Pomalidomide	Car-Dex + Pom	1610	Proteasome/Steroid/IMID	2290	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	1728	2309	Stable Disease	SD			0	0	0	0	11	301	0	5	119					1
MMRF_1723	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	2316	2485	1	Daratumumab/Dexamethasone	Dar-Dex	2316	CD38/Steroid	2485	daratumumab-based	daratumumab-based	Dar-Dex				0	Lack of response	1			4	2359	4	2359	2654	Partial Response	PR	Partial Response	PR	1	1	1	1	6	170	1	2	44	2	44			1
MMRF_1723	3	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	2547	2659	2	Daratumumab/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Dar-Dex + Ixa-Len-Dex	2316	CD38/Steroid/Proteasome/IMID	2659	combined daratumumab/IMIDs-based	IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Lack of response	1			4	2359	4	2359	2654	Partial Response	PR	Partial Response	PR	1	0	0	0	4	113	0	2	44	2	44	1	3	1
MMRF_1723	4	Belantamab mafodotin	Bela	BCMA	2673	2694	1	Belantamab mafodotin	Bela	2673	BCMA	2694	Other therapies	Other treatments					0	Lack of response	1												0	0	0	0	1	22	0							1
MMRF_1723	5	Selinexor	Sel	XPO1	2725	2864	1	Selinexor	Sel	2725	XPO1	2864	Other therapies	Other treatments					0	Lack of response	1					5	2857		Stable Disease	SD			0	1	0	1	5	140	0	5	133					1
MMRF_1984	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	84	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	84	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	84	1	428		Complete Response	CR	Partial Response	PR	1	0	1	0	3	84	1	16	428	3	84	1	3	1
MMRF_1984	1	Lenalidomide	Len	IMID	257	1806	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1806	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	84	1	428		Complete Response	CR	Partial Response	PR	1	1	0	1	56	1550	0	16	428	3	84			1
MMRF_1107	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	94	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	94	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	50	4	50		Partial Response	PR	Partial Response	PR	1	1	1	1	4	94	1	2	50	2	50	1	2	1
MMRF_1227	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	64	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	64	Bortezomib-based	Bortezomib-based	Bor-Dex				0	CHANGE IN FREQUENCY						5	64		Stable Disease	SD			0	1	0	1	3	64	0	3	64			1	2	1
MMRF_1227	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	65	127	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	127	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5					5	64		Stable Disease	SD			0	0	0	0	3	63	0	3	64					1
MMRF_1227	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	128	206	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	206	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3					5	64		Stable Disease	SD			0	0	0	0	3	79	0	3	64					1
MMRF_1227	1	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	207	413	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Pomalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Pom-Dex	1	Proteasome/Steroid/IMID	413	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5					5	64		Stable Disease	SD			0	0	0	0	8	207	0	3	64					1
MMRF_1271	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1	38	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	38	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0					3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	38	0	10	262	10	262	1	4	1
MMRF_1271	1	Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone	Bor-Cyc-Mel-Pred-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid/Steroid	39	269	2	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	269	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	231	1	10	262	10	262			1
MMRF_1271	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	270	291	3	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex + Bor-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	291	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0					3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	10	262	10	262			1
MMRF_1271	1	Bortezomib/Lenalidomide/Melphalan/Prednisone/Dexamethasone	Bor-Len-Mel-Pred-Dex	Proteasome/IMID/Chemotherapy/Steroid/Steroid	292	306	4	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex + Bor-Mel-Pred-Dex + Bor-Len-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	306	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	15	0	10	262	10	262			1
MMRF_1271	1	Lenalidomide	Len	IMID	307	354	5	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Prednisone/Dexamethasone + Lenalidomide	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex + Bor-Mel-Pred-Dex + Bor-Len-Mel-Pred-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	354	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	48	0	10	262	10	262			1
MMRF_1271	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	383	1058	6	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Prednisone/Dexamethasone + Lenalidomide + Bortezomib/Cyclophosphamide	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex + Bor-Mel-Pred-Dex + Bor-Len-Mel-Pred-Dex + Len + Bor-Cyc	1	Proteasome/Chemotherapy/Steroid/IMID	1058	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	24	676	0	10	262	10	262			1
MMRF_1271	1	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	1142	1206	7	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Prednisone/Dexamethasone + Lenalidomide + Bortezomib/Cyclophosphamide + Melphalan/Prednisone	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex + Bor-Mel-Pred-Dex + Bor-Len-Mel-Pred-Dex + Len + Bor-Cyc + Mel-Pred	1	Proteasome/Chemotherapy/Steroid/IMID	1206	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	65	0	10	262	10	262			1
MMRF_1271	1	Daratumumab	Dar	CD38	1262	1320	8	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Prednisone/Dexamethasone + Lenalidomide + Bortezomib/Cyclophosphamide + Melphalan/Prednisone + Daratumuma	Bor-Mel-Pred-Dex + Bor-Cyc-Mel-Pred-Dex + Bor-Mel-Pred-Dex + Bor-Len-Mel-Pred-Dex + Len + Bor-Cyc + Mel-Pred + Dar	1	Proteasome/Chemotherapy/Steroid/IMID/CD38	1320	combined bortezomib/IMIDs-based	daratumumab-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	262	3	262		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	59	0	10	262	10	262			1
MMRF_1440	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	1	149	1	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	149	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	86	3	149	408	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	149	1	6	149	4	86	1	2	1
MMRF_1440	1	Lenalidomide	Len	IMID	192	1786	2	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	1786	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					4	86	3	149	408	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	57	1595	0	6	149	4	86			1
MMRF_1440	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	568	799	1	Bortezomib/Dexamethasone	Bor-Dex	568	Proteasome/Steroid	799	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	1268	4	1268		Partial Response	PR	Partial Response	PR	1	1	1	1	9	232	1	26	701	26	701	1	2	1
MMRF_1687	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	114	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	114	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	114	1	3	71	3	71	1	2	1
MMRF_1687	1	Bortezomib	Bor	Proteasome	146	177	2	Lenalidomide/Dexamethasone + Bortezomib	Len-Dex + Bor	1	IMID/Steroid/Proteasome	177	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	PT BECAME TO ILL				3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	32	0	3	71	3	71			1
MMRF_1929	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	85	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	85	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	113	Stem cell, Autologous	1	1	Completed regimen	4			3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	4	85	4	85	1	3	1
MMRF_1929	1	Lenalidomide	Len	IMID	238	1635	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1635	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	50	1398	0	4	85	4	85			1
MMRF_1929	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1329	1635	1	Ixazomib/Dexamethasone	Ixa-Dex	1329	Proteasome/Steroid	1635	Other therapies	Other treatments					0					1	1618	1	1618	1329	Complete Response	CR	Complete Response	CR	1	1	1	1	11	307	1	11	290	11	290			1
MMRF_2132	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	134	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	134	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PT IN REHAB				4	22	3	106		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	134	1	4	106	1	22	1	2	1
MMRF_2455	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	257	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	257	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DEATH				3	65	3	65	257	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	257	1	3	65	3	65	1	3	1
MMRF_1388	1	Bortezomib	Bor	Proteasome	1	383	1	Bortezomib	Bor	1	Proteasome	383	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Patient decision	6					5	212	1429	Stable Disease	SD			0	1	0	1	14	383	0	8	212			1	1	1
MMRF_2598	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	1690	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	1690	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH						5	72		Stable Disease	SD			0	1	0	1	61	1690	0	3	72			1	2	1
MMRF_1170	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	169	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	169	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Patient decision	6			4	87	4	87		Partial Response	PR	Partial Response	PR	1	1	1	1	6	169	1	4	87	4	87	1	2	1
MMRF_1346	1	Bortezomib	Bor	Proteasome	1	62	1	Bortezomib	Bor	1	Proteasome	62	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	147	4	147		Partial Response	PR	Partial Response	PR	1	1	1	1	3	62	1	6	147	6	147	1	1	1
MMRF_1439	1	Bortezomib	Bor	Proteasome	1	51	1	Bortezomib	Bor	1	Proteasome	51	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PATIENT DID NOT SHOW TO THE CLINIC. LOST TO FOLLOW UP				4	79	4	79		Partial Response	PR	Partial Response	PR	1	1	1	1	2	51	1	3	79	3	79	1	1	1
MMRF_1108	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	39	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	39	IMIDs-based	IMIDs-based	Len-Dex				0					4	90	4	90		Partial Response	PR	Partial Response	PR	1	0	0	0	2	39	0	4	90	4	90	1	2	1
MMRF_1108	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	40	44	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	44	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	90	4	90		Partial Response	PR	Partial Response	PR	1	0	0	0	0	5	0	4	90	4	90			1
MMRF_1108	1	Bortezomib	Bor	Proteasome	45	194	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Len-Dex + Bor-Len-Dex + Bor	1	IMID/Steroid/Proteasome	194	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	PARTIAL RESPONSE				4	90	4	90		Partial Response	PR	Partial Response	PR	1	1	1	1	6	150	1	4	90	4	90			1
MMRF_1108	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	306	1082	1	Bortezomib/Dexamethasone	Bor-Dex	306	Proteasome/Steroid	1082	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	446	4	446		Partial Response	PR	Partial Response	PR	1	1	1	1	28	777	1	6	141	6	141	1	2	1
MMRF_1108	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	1083	1174	2	Bortezomib/Dexamethasone + Bortezomib/Pomalidomide/Dexamethasone	Bor-Dex + Bor-Pom-Dex	306	Proteasome/Steroid/IMID	1174	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	BIOCHEMICAL PROGRESSION				4	446	4	446		Partial Response	PR	Partial Response	PR	1	0	0	0	4	92	0	6	141	6	141			1
MMRF_1108	2	Pomalidomide	Pom	IMID	1175	1187	3	Bortezomib/Dexamethasone + Bortezomib/Pomalidomide/Dexamethasone + Pomalidomide	Bor-Dex + Bor-Pom-Dex + Pom	306	Proteasome/Steroid/IMID	1187	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Pom-Dex				0					4	446	4	446		Partial Response	PR	Partial Response	PR	1	0	0	0	1	13	0	6	141	6	141			1
MMRF_1108	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	1188	1230	4	Bortezomib/Dexamethasone + Bortezomib/Pomalidomide/Dexamethasone + Pomalidomide + Bortezomib/Pomalidomide/Dexamethasone	Bor-Dex + Bor-Pom-Dex + Pom + Bor-Pom-Dex	306	Proteasome/Steroid/IMID	1230	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	Investigator decision for other reasons	5			4	446	4	446		Partial Response	PR	Partial Response	PR	1	0	0	0	2	43	0	6	141	6	141			1
MMRF_1108	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1231	1314	5	Bortezomib/Dexamethasone + Bortezomib/Pomalidomide/Dexamethasone + Pomalidomide + Bortezomib/Pomalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Pom-Dex + Pom + Bor-Pom-Dex + Bor-Dex	306	Proteasome/Steroid/IMID	1314	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Pom-Dex				0	Adverse Event or co-morbidity	2			4	446	4	446		Partial Response	PR	Partial Response	PR	1	0	0	0	3	84	0	6	141	6	141			1
MMRF_1108	3	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1433	1433	1	Ixazomib/Dexamethasone	Ixa-Dex	1433	Proteasome/Steroid	1433	Other therapies	Other treatments					0	UNTIL NEXT TREATMENT						5	1518	1433	Stable Disease	SD			0	1	0	1	0	1	0	4	86					1
MMRF_1113	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	54	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	54	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	2	54	0	30	821	30	821	1	3	1
MMRF_1113	1	Bortezomib/Lenalidomide/Thalidomide/Dexamethasone	Bor-Len-Thal-Dex	Proteasome/IMID/IMID/Steroid	55	101	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Thal-Dex	1	Proteasome/IMID/Steroid	101	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	2	47	0	30	821	30	821			1
MMRF_1113	1	Lenalidomide/Thalidomide	Len-Thal	IMID/IMID	102	111	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide	Bor-Len-Dex + Bor-Len-Thal-Dex + Len-Thal	1	Proteasome/IMID/Steroid	111	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	1	10	0	30	821	30	821			1
MMRF_1113	1	Carfilzomib/Thalidomide	Car-Thal	Proteasome/IMID	114	174	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide + Carfilzomib/Thalidomide	Bor-Len-Dex + Bor-Len-Thal-Dex + Len-Thal + Car-Thal	1	Proteasome/IMID/Steroid	174	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2			4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	2	61	0	30	821	30	821			1
MMRF_1113	1	Thalidomide	Thal	IMID	175	197	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide + Carfilzomib/Thalidomide + Thalidomide	Bor-Len-Dex + Bor-Len-Thal-Dex + Len-Thal + Car-Thal	1	Proteasome/IMID/Steroid	197	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	225	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	1	23	0	30	821	30	821			1
MMRF_1113	1	Thalidomide	Thal	IMID	412	440	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide + Carfilzomib/Thalidomide + Thalidomide + Thalidomide	Bor-Len-Dex + Bor-Len-Thal-Dex + Len-Thal + Car-Thal	1	Proteasome/IMID/Steroid	440	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1					4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	1	29	0	30	821	30	821			1
MMRF_1113	1	Bortezomib/Thalidomide	Bor-Thal	Proteasome/IMID	441	604	7	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide + Carfilzomib/Thalidomide + Thalidomide + Thalidomide + Bortezomib/Thalidomide	Bor-Len-Dex + Bor-Len-Thal-Dex + Len-Thal + Car-Thal + Bor-Thal	1	Proteasome/IMID/Steroid	604	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3			4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	0	0	0	6	164	0	30	821	30	821			1
MMRF_1113	1	Thalidomide	Thal	IMID	678	926	8	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Thalidomide/Dexamethasone + Lenalidomide/Thalidomide + Carfilzomib/Thalidomide + Thalidomide + Thalidomide + Bortezomib/Thalidomide + Thalidomide	Bor-Len-Dex + Bor-Len-Thal-Dex + Len-Thal + Car-Thal + Bor-Thal	1	Proteasome/IMID/Steroid	926	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2			4	821	4	821	905	Partial Response	PR	Partial Response	PR	1	1	1	1	9	249	1	30	821	30	821			1
MMRF_1113	2	Bortezomib	Bor	Proteasome	997	1137	1	Bortezomib	Bor	997	Proteasome	1137	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Lack of response	1					5	1081	1179	Stable Disease	SD			0	1	0	1	5	141	0	4	85			1	1	1
MMRF_1164	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	279	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	279	IMIDs-based	IMIDs-based	Len-Dex				0					4	131	4	131		Partial Response	PR	Partial Response	PR	1	1	1	1	10	279	1	5	131	5	131	1	2	1
MMRF_1164	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	280	372	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	372	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DEATH				4	131	4	131		Partial Response	PR	Partial Response	PR	1	0	0	0	4	93	0	5	131	5	131			1
MMRF_1169	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	120	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	120	IMIDs-based	IMIDs-based	Len-Dex				0					3	87	3	87	177	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	4	87	4	87	1	2	1
MMRF_1169	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	121	139	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	139	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DISEASE PROGRESSION				3	87	3	87	177	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	19	0	4	87	4	87			1
MMRF_1312	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	150	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	150	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	200	Stem cell, Autologous	1	1	PREPARATION FOR TRANSPLANT				4	129	4	129		Partial Response	PR	Partial Response	PR	1	1	1	1	6	150	1	5	129	5	129	1	3	1
MMRF_1312	1	Lenalidomide	Len	IMID	341	739	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	739	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5			4	129	4	129		Partial Response	PR	Partial Response	PR	1	0	0	0	15	399	0	5	129	5	129			1
MMRF_1312	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1569	1869	1	Carfilzomib/Dexamethasone	Car-Dex	1569	Proteasome/Steroid	1869	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					3	1737	3	1737	1569	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	301	1	7	169	7	169	1	2	1
MMRF_1312	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1870	2178	2	Carfilzomib/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Car-Dex + Car-Pom-Dex	1569	Proteasome/Steroid/IMID	2178	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	1737	3	1737	1569	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	11	309	0	7	169	7	169			1
MMRF_1312	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	2179	2794	3	Carfilzomib/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Car-Dex + Car-Pom-Dex	1569	Proteasome/Steroid/IMID	2794	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	1737	3	1737	1569	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	616	0	7	169	7	169			1
MMRF_1796	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	63	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	63	IMIDs-based	IMIDs-based	Len-Dex				0	NOT TOLERATING TREATMENT OF VELCADE + DEX				4	338	4	338	1808	Partial Response	PR	Partial Response	PR	1	0	0	0	3	63	0	13	338	13	338	1	2	1
MMRF_1796	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	66	231	2	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Len-Dex + Bor-Dex	1	IMID/Steroid/Proteasome	231	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	CHEMOTHERAPY HELD UNTIL PATIENT RECOVERED FROM AUTOLOGOUS TRANSPLANT.				4	338	4	338	1808	Partial Response	PR	Partial Response	PR	1	0	0	0	6	166	0	13	338	13	338			1
MMRF_1796	1	Bortezomib	Bor	Proteasome	317	1808	3	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib	Len-Dex + Bor-Dex + Bor	1	IMID/Steroid/Proteasome	1808	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	338	4	338	1808	Partial Response	PR	Partial Response	PR	1	1	1	1	54	1492	1	13	338	13	338			1
MMRF_2186	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	36	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	36	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	90	4	90	1527	Partial Response	PR	Partial Response	PR	1	0	0	0	2	36	0	4	90	4	90	1	2	1
MMRF_2186	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	37	244	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	244	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	TREATMENT ON HOLD FOR HIP SURGERY				4	90	4	90	1527	Partial Response	PR	Partial Response	PR	1	1	1	1	8	208	1	4	90	4	90			1
MMRF_2186	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	245	1694	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	1694	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	90	4	90	1527	Partial Response	PR	Partial Response	PR	1	0	0	0	52	1450	0	4	90	4	90			1
MMRF_2186	2	Bortezomib	Bor	Proteasome	1560	1679	1	Bortezomib	Bor	1560	Proteasome	1679	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2					5	1588	1798	Stable Disease	SD			0	1	0	1	5	120	0	2	29			1	1	1
MMRF_2545	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1681	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1681	Bortezomib-based	Bortezomib-based	Bor-Dex	123	Stem cell, Autologous	1	1	PATIENT EXPIRED 23DEC2019.				3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	60	1681	1	4	85	4	85	1	2	1
MMRF_2545	2	Lenalidomide	Len	IMID	213	1088	1	Lenalidomide	Len	213	IMID	1088	IMIDs-based	IMIDs-based	Len-Dex	1090	Stem cell, Autologous	2	1	Disease progression/Relapse	3			1	578	1	578	1097	Complete Response	CR	Complete Response	CR	1	1	1	1	32	876	1	14	366	14	366	1	1	1
MMRF_2545	3	Carfilzomib	Car	Proteasome	1122	1508	1	Carfilzomib	Car	1122	Proteasome	1508	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3					5	1185	1563	Stable Disease	SD			0	1	0	1	14	387	0	3	64			1	1	1
MMRF_2545	4	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1572	1681	1	Daratumumab/Pomalidomide	Dar-Pom	1572	CD38/IMID	1681	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	PATIENT EXPIRED 23DEC2019.						6	1643	1643	Progressive Disease	PD			0	1	0	1	4	110	0	3	72			1	2	1
MMRF_1239	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	742	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	742	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5					5	92		Stable Disease	SD			0	1	0	1	27	742	0	4	92			1	2	1
MMRF_1436	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	2929	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	2929	IMIDs-based	IMIDs-based	Len-Dex				0					3	1831	3	1831		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	105	2929	1	66	1831	66	1831	1	2	1
MMRF_2595	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	92	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	92	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	116	Stem cell, Autologous	1	1	Completed regimen	4			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	92	1	4	92	4	92	1	3	1
MMRF_2595	1	Bortezomib	Bor	Proteasome	260	344	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	344	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Disease progression/Relapse	3			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	85	0	4	92	4	92			1
MMRF_2595	2	Pomalidomide	Pom	IMID	360	451	1	Pomalidomide	Pom	360	IMID	451	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			4	641	3	801	360	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	92	0	16	442	11	282	1	1	1
MMRF_2595	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	498	1072	2	Pomalidomide + Daratumumab/Lenalidomide/Dexamethasone	Pom + Dar-Len-Dex	360	IMID/CD38/Steroid	1072	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3			4	641	3	801	360	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	21	575	1	16	442	11	282			1
MMRF_2595	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1079	1151	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1079	Proteasome/Chemotherapy/Steroid	1151	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3					6	1138	1138	Progressive Disease	PD			0	1	0	1	3	73	0	3	60			1	3	1
MMRF_2595	4	Bendamustine	Bend	Chemotherapy	1169	1169	1	Bendamustine	Bend	1169	Chemotherapy	1169	Other therapies	Other treatments					0	DEATH													0	0	0	0	0	1	0							1
MMRF_1273	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	1	113	1	Bortezomib/Cyclophosphamide	Bor-Cyc	1	Proteasome/Chemotherapy	113	Bortezomib-based	Bortezomib-based	Bor-Cyc				0	DEATH				4	50	4	50		Partial Response	PR	Partial Response	PR	1	1	1	1	4	113	1	2	50	2	50	1	2	1
MMRF_1109	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	117	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	117	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DEATH													0	0	0	0	4	117	0					1	2	1
MMRF_1117	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	106	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4	1090		3	92	3	92	255	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	4	92	4	92	1	2	1
MMRF_1117	1	Lenalidomide	Len	IMID	321	340	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	340	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Lack of response	1	1090		3	92	3	92	255	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	20	0	4	92	4	92			1
MMRF_1117	2	Lenalidomide	Len	IMID	341	736	1	Lenalidomide	Len	341	IMID	736	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2	1090				5	453	360	Stable Disease	SD			0	1	0	1	14	396	0	5	113			1	1	1
MMRF_1117	3	Lenalidomide	Len	IMID	737	924	1	Lenalidomide	Len	737	IMID	924	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3	1090				5	796	880	Stable Disease	SD			0	1	0	1	7	188	0	3	60			1	1	1
MMRF_1117	4	Lenalidomide	Len	IMID	925	1193	1	Lenalidomide	Len	925	IMID	1193	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4	1090				6	925	925	Progressive Disease	PD			0	1	0	1	10	269	0	1	1			1	1	1
MMRF_1117	5	Pomalidomide	Pom	IMID	1062	1312	1	Pomalidomide	Pom	1062	IMID	1312	IMIDs-based	IMIDs-based	Pom-Dex				0	Investigator decision for other reasons	5	1090		4	1263	4	1263	1090	Partial Response	PR	Partial Response	PR	1	1	1	1	9	251	1	8	202	8	202	1	1	1
MMRF_1146	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	184	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	184	IMIDs-based	IMIDs-based	Len-Dex	201	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			4	86	4	86	1166	Partial Response	PR	Partial Response	PR	1	1	1	1	7	184	1	4	86	4	86	1	2	1
MMRF_1146	1	Lenalidomide	Len	IMID	319	1194	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	1194	IMIDs-based	IMIDs-based	Len-Dex				1	Disease progression/Relapse	3			4	86	4	86	1166	Partial Response	PR	Partial Response	PR	1	0	0	0	32	876	0	4	86	4	86			1
MMRF_1146	2	Bortezomib	Bor	Proteasome	1201	1492	1	Bortezomib	Bor	1201	Proteasome	1492	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	1250	1416	Stable Disease	SD			0	1	0	1	11	292	0	2	50			1	1	1
MMRF_1184	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	199	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	199	IMIDs-based	IMIDs-based	Len-Dex	161	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	253		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	7	199	1	10	253	4	85	1	2	1
MMRF_1184	1	Lenalidomide	Len	IMID	295	1815	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	1815	IMIDs-based	IMIDs-based	Len-Dex				1					3	85	1	253		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	55	1521	0	10	253	4	85			1
MMRF_1250	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	298	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	298	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			4	150	4	150		Partial Response	PR	Partial Response	PR	1	1	1	1	11	298	1	6	150	6	150	1	2	1
MMRF_1250	1	Lenalidomide	Len	IMID	337	2886	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	2886	IMIDs-based	IMIDs-based	Len-Dex				0					4	150	4	150		Partial Response	PR	Partial Response	PR	1	0	0	0	91	2550	0	6	150	6	150			1
MMRF_1261	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	232	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	232	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	246	Stem cell, Autologous	1	1	Completed regimen	4			4	86	4	86		Partial Response	PR	Partial Response	PR	1	1	1	1	9	232	1	4	86	4	86	1	3	1
MMRF_1261	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	351	615	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	615	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	86	4	86		Partial Response	PR	Partial Response	PR	1	0	0	0	10	265	0	4	86	4	86			1
MMRF_1261	2	Carfilzomib	Car	Proteasome	638	757	1	Carfilzomib	Car	638	Proteasome	757	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Disease progression/Relapse	3			4	722	4	722	638	Partial Response	PR	Partial Response	PR	1	1	1	1	5	120	1	4	85	4	85	1	1	1
MMRF_1261	4	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	932	1060	1	Pomalidomide/Dexamethasone	Pom-Dex	932	IMID/Steroid	1060	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3			4	988	4	988	1063	Partial Response	PR	Partial Response	PR	1	1	1	1	5	129	1	3	57	3	57	1	2	1
MMRF_1260	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	106	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	78	3	170		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	106	1	7	170	3	78	1	3	1
MMRF_1260	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	142	1038	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	1038	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	78	3	170		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	32	897	0	7	170	3	78			1
MMRF_1295	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	36	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	36	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	93	1	2041	1355	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	36	0	73	2041	4	93	1	2	1
MMRF_1295	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	37	282	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	282	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	93	1	2041	1355	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	9	246	1	73	2041	4	93			1
MMRF_1295	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	283	381	3	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Steroid/Chemotherapy	381	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	93	1	2041	1355	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	99	0	73	2041	4	93			1
MMRF_1295	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	418	2930	4	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex + Bor-Dex + Len-Dex	1	Proteasome/Steroid/Chemotherapy/IMID	2930	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	93	1	2041	1355	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	90	2513	0	73	2041	4	93			1
MMRF_1344	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	106	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	169	Stem cell, Autologous	1	1	Completed regimen	4			3	85	1	547		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	106	1	20	547	4	85	1	3	1
MMRF_1344	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	361	2929	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	2929	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					3	85	1	547		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	92	2569	0	20	547	4	85			1
MMRF_1453	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	106	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	137	Stem cell, Autologous	1	1	Completed regimen	4			4	75	3	341		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	106	1	13	341	3	75	1	3	1
MMRF_1453	1	Lenalidomide	Len	IMID	236	773	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	773	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					4	75	3	341		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	20	538	0	13	341	3	75			1
MMRF_1538	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	2862	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2862	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	69	1	908		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	103	2862	1	33	908	3	69	1	3	1
MMRF_1588	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	161	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	161	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	206	Stem cell, Autologous	1	1	PREP FOR BONE MARROW TRANSPLANT				4	84	3	161		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	161	1	6	161	3	84	1	3	1
MMRF_1588	2	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	1458	2814	1	Elotuzumab/Lenalidomide	Elo-Len	1458	SLAMF7/IMID	2814	IMIDs-based	IMIDs-based	Other Len-based therapies				0														0	0	0	0	49	1357	0					1	2	1
MMRF_1596	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	186	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	186	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	88	4	88		Partial Response	PR	Partial Response	PR	1	1	1	1	7	186	1	4	88	4	88	1	3	1
MMRF_1596	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	200	249	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	200	Proteasome/Chemotherapy/Steroid	249	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3					6	272	272	Progressive Disease	PD			0	1	0	1	2	50	0	3	73			1	3	1
MMRF_1596	3	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	284	310	1	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	284	Chemotherapy/Steroid	310	Other therapies	Other treatments					0	Lack of response	1												0	0	0	0	1	27	0							1
MMRF_1596	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	327	364	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	327	Proteasome/IMID/Steroid	364	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2					6	347	347	Progressive Disease	PD			0	1	0	1	2	38	0	1	21			1	3	1
MMRF_1740	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	989	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	989	IMIDs-based	IMIDs-based	Len-Dex				0					4	54	3	275	712	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	36	989	1	10	275	2	54	1	2	1
MMRF_1740	2	Bortezomib	Bor	Proteasome	715	989	1	Bortezomib	Bor	715	Proteasome	989	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	806		Stable Disease	SD			0	1	0	1	10	275	0	4	92			1	1	1
MMRF_1794	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	239	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	239	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	57	3	267		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	239	1	10	267	3	57	1	3	1
MMRF_1794	2	Daratumumab	Dar	CD38	1059	1640	1	Daratumumab	Dar	1059	CD38	1640	daratumumab-based	daratumumab-based	Dar				0	Completed regimen	4			4	1186	4	1186		Partial Response	PR	Partial Response	PR	1	1	1	1	21	582	1	5	128	5	128			1
MMRF_1794	3	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1378	1707	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1378	SLAMF7/IMID/Steroid	1707	IMIDs-based	IMIDs-based	Other Len-based therapies				0	DEATH													0	0	0	0	12	330	0					1	3	1
MMRF_1932	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	164	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	164	IMIDs-based	IMIDs-based	Len-Dex				0	PREP FOR BONE MARROW TRANSPLANT				4	80	1	353		Complete Response	CR	Partial Response	PR	1	0	1	0	6	164	1	13	353	3	80	1	2	1
MMRF_1932	1	Lenalidomide	Len	IMID	325	2741	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	2741	IMIDs-based	IMIDs-based	Len-Dex				0					4	80	1	353		Complete Response	CR	Partial Response	PR	1	1	0	1	87	2417	0	13	353	3	80			1
MMRF_1980	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	2556	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	2556	IMIDs-based	IMIDs-based	Len-Dex				0					4	84	3	278	635	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	92	2556	1	10	278	3	84	1	2	1
MMRF_1980	2	Bortezomib	Bor	Proteasome	1020	1194	1	Bortezomib	Bor	1020	Proteasome	1194	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	1153	3	1153		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	175	1	5	134	5	134	1	1	1
MMRF_1980	2	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	1195	2556	2	Bortezomib + Bortezomib/Daratumumab	Bor + Bor-Dar	1020	Proteasome/CD38	2556	Bortezomib-based	Bortezomib-based	Bor-Dar				0					3	1153	3	1153		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	49	1362	0	5	134	5	134			1
MMRF_2173	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	1645	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1645	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3												0	0	0	0	59	1645	0					1	3	1
MMRF_2173	2	Lenalidomide	Len	IMID	42	1986	1	Lenalidomide	Len	42	IMID	1986	IMIDs-based	IMIDs-based	Len-Dex				0	PATIENT DIED				4	331	3	443		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	70	1945	1	15	402	11	290	1	1	1
MMRF_2220	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	2501	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	2501	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	85	1	365		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	90	2501	1	14	365	4	85	1	3	1
MMRF_2220	2	Carfilzomib	Car	Proteasome	1668	2501	1	Carfilzomib	Car	1668	Proteasome	2501	Carfilzomib-based	Carfilzomib-based	Car-Dex				0					1	2107	1	2107		Complete Response	CR	Complete Response	CR	1	1	1	1	30	834	1	16	440	16	440	1	1	1
MMRF_2587	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	133	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	133	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	243	3	243		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	133	0	9	243	9	243	1	3	1
MMRF_2587	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	134	138	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	138	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	138	Stem cell, Autologous	1	1	Completed regimen	4			3	243	3	243		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	5	0	9	243	9	243			1
MMRF_2587	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	139	1442	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1442	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					3	243	3	243		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	47	1304	1	9	243	9	243			1
MMRF_1216	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	116	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	116	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	50	3	428		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	116	1	16	428	2	50	1	2	1
MMRF_1216	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	141	1023	2	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1023	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			4	50	3	428		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	32	883	0	16	428	2	50			1
MMRF_1216	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1024	1108	1	Lenalidomide/Dexamethasone	Len-Dex	1024	IMID/Steroid	1108	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	1075	3	1075	1030	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	85	1	2	52	2	52	1	2	1
MMRF_1216	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1207	1345	1	Carfilzomib/Dexamethasone	Car-Dex	1207	Proteasome/Steroid	1345	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	1249	4	1249		Partial Response	PR	Partial Response	PR	1	1	1	1	5	139	1	2	43	2	43	1	2	1
MMRF_1228	1	Bortezomib/Doxorubicin	Bor-Dox	Proteasome/Chemotherapy	1	102	1	Bortezomib/Doxorubicin	Bor-Dox	1	Proteasome/Chemotherapy	102	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0					4	74	4	74	910	Partial Response	PR	Partial Response	PR	1	1	1	1	4	102	1	3	74	3	74	1	2	1
MMRF_1228	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	Proteasome/Steroid/Chemotherapy	103	915	2	Bortezomib/Doxorubicin + Bortezomib/Dexamethasone/Doxorubicin	Bor-Dox + Bor-Dex-Dox	1	Proteasome/Chemotherapy/Steroid	915	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0					4	74	4	74	910	Partial Response	PR	Partial Response	PR	1	0	0	0	29	813	0	3	74	3	74			1
MMRF_1228	1	Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	916	1098	3	Bortezomib/Doxorubicin + Bortezomib/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Dox + Bor-Dex-Dox + Bor-Cyc-Dex-Dox	1	Proteasome/Chemotherapy/Steroid	1098	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Lack of response	1			4	74	4	74	910	Partial Response	PR	Partial Response	PR	1	0	0	0	7	183	0	3	74	3	74			1
MMRF_1228	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	Proteasome/Steroid/Chemotherapy	1099	1366	4	Bortezomib/Doxorubicin + Bortezomib/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone/Doxorubicin	Bor-Dox + Bor-Dex-Dox + Bor-Cyc-Dex-Dox + Bor-Dex-Dox	1	Proteasome/Chemotherapy/Steroid	1366	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	74	4	74	910	Partial Response	PR	Partial Response	PR	1	0	0	0	10	268	0	3	74	3	74			1
MMRF_1228	2	Daratumumab	Dar	CD38	1218	1366	1	Daratumumab	Dar	1218	CD38	1366	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3					5	1259		Stable Disease	SD			0	1	0	1	6	149	0	2	42					1
MMRF_1296	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	256	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	256	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	71		Stable Disease	SD			0	1	0	1	9	256	0	3	71			1	2	1
MMRF_1364	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	171	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	171	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	174	4	174		Partial Response	PR	Partial Response	PR	1	0	0	0	6	171	0	7	174	7	174	1	3	1
MMRF_1364	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	172	268	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	268	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					4	174	4	174		Partial Response	PR	Partial Response	PR	1	1	1	1	4	97	1	7	174	7	174			1
MMRF_1531	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	520	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	520	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH				3	71	3	71	475	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	19	520	1	3	71	3	71	1	3	1
MMRF_1659	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	589	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	589	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	98	3	98	325	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	21	589	1	4	98	4	98	1	3	1
MMRF_1659	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	331	403	1	Carfilzomib/Dexamethasone	Car-Dex	331	Proteasome/Steroid	403	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Investigator decision for other reasons	5					5	463	497	Stable Disease	SD			0	0	0	0	3	73	0	5	133			1	2	1
MMRF_1659	2	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Car-Len-Cyc-Dex-Dox	Proteasome/IMID/Chemotherapy/Steroid/Chemotherapy	413	589	2	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone/Doxorubicin	Car-Dex + Car-Len-Cyc-Dex-Dox	331	Proteasome/Steroid/IMID/Chemotherapy	589	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	508	Stem cell, Autologous	1	1	Disease progression/Relapse	3					5	463	497	Stable Disease	SD			0	1	0	1	7	177	0	5	133					1
MMRF_1659	4	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	679	679	1	Melphalan/Dexamethasone	Mel-Dex	679	Chemotherapy/Steroid	679	Other therapies	Other treatments		682	Stem cell, Autologous	2	1	Completed regimen	4					6	679	679	Progressive Disease	PD			0	1	0	1	0	1	0	1	1					1
MMRF_1659	5	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	756	1773	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	756	Proteasome/IMID/Steroid	1773	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	981	3	981		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	37	1018	1	9	226	9	226	1	3	1
MMRF_1659	5	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1774	1785	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	756	Proteasome/IMID/Steroid	1785	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	DEATH				3	981	3	981		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	12	0	9	226	9	226			1
MMRF_1691	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	175	4	175		Partial Response	PR	Partial Response	PR	1	0	0	0	4	117	0	7	175	7	175	1	3	1
MMRF_1691	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	118	147	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	147	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			4	175	4	175		Partial Response	PR	Partial Response	PR	1	0	0	0	1	30	0	7	175	7	175			1
MMRF_1691	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	148	372	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	372	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	385	Stem cell, Autologous	1	1	Completed regimen	4			4	175	4	175		Partial Response	PR	Partial Response	PR	1	1	1	1	8	225	1	7	175	7	175			1
MMRF_1691	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	148	372	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	372	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	602	Stem cell, Autologous	2	1	Completed regimen	4			4	175	4	175		Partial Response	PR	Partial Response	PR	1	0	0	1	8	225	1	7	175	7	175			1
MMRF_1691	2	Lenalidomide	Len	IMID	734	2440	1	Lenalidomide	Len	734	IMID	2440	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			3	693	3	693	2435	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	61	1707	0	-1	-40	-1	-40	1	1	1
MMRF_1691	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	2442	2487	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	2442	Proteasome/CD38/Steroid	2487	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	DEATH													0	0	0	0	2	46	0					1	3	1
MMRF_1803	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	139	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	139	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	169	3	245		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	139	0	9	245	7	169	1	3	1
MMRF_1803	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	140	141	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	141	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	169	3	245		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	2	0	9	245	7	169			1
MMRF_1803	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	142	182	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	182	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	143	Stem cell, Autologous	1	1	Completed regimen	4			4	169	3	245		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	2	41	1	9	245	7	169			1
MMRF_1810	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	22	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	22	IMIDs-based	IMIDs-based	Len-Dex				1					3	258	3	258	804	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	10	258	10	258	1	2	1
MMRF_1810	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	23	149	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	149	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	162	Stem cell, Autologous	1	1	Investigator decision for other reasons	5			3	258	3	258	804	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	127	1	10	258	10	258			1
MMRF_1810	2	Bortezomib	Bor	Proteasome	901	935	1	Bortezomib	Bor	901	Proteasome	935	Bortezomib-based	Bortezomib-based	Bor-Dex				0							6	985	985	Progressive Disease	PD			0	0	0	0	2	35	0	4	85			1	1	1
MMRF_1810	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	936	999	2	Bortezomib + Bortezomib/Dexamethasone	Bor + Bor-Dex	901	Proteasome/Steroid	999	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5					6	985	985	Progressive Disease	PD			0	1	0	1	3	64	0	4	85					1
MMRF_1810	3	Elotuzumab/Dexamethasone	Elo-Dex	SLAMF7/Steroid	1090	1132	1	Elotuzumab/Dexamethasone	Elo-Dex	1090	SLAMF7/Steroid	1132	Other therapies	Other treatments		1157	Stem cell, Autologous	2	1	Completed regimen	4			4	1160	4	1160	1525	Partial Response	PR	Partial Response	PR	1	1	1	1	2	43	1	3	71	3	71			1
MMRF_1810	3	Bortezomib	Bor	Proteasome	1258	1693	2	Elotuzumab/Dexamethasone + Bortezomib	Elo-Dex + Bor	1090	SLAMF7/Steroid/Proteasome	1693	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Lack of response	1			4	1160	4	1160	1525	Partial Response	PR	Partial Response	PR	1	0	0	0	16	436	0	3	71	3	71	1	1	1
MMRF_1810	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1707	1826	3	Elotuzumab/Dexamethasone + Bortezomib + Daratumumab/Pomalidomide/Dexamethasone	Elo-Dex + Bor + Dar-Pom-Dex	1090	SLAMF7/Steroid/Proteasome/CD38/IMID	1826	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	1160	4	1160	1525	Partial Response	PR	Partial Response	PR	1	0	0	0	5	120	0	3	71	3	71			1
MMRF_1831	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	Proteasome/Steroid/Chemotherapy	1	80	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	1	Proteasome/Steroid/Chemotherapy	80	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			3	107	3	107		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	80	1	4	107	4	107	1	3	1
MMRF_1831	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	204	1738	2	Bortezomib/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone	Bor-Dex-Dox + Bor-Dex	1	Proteasome/Steroid/Chemotherapy	1738	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Lack of response	1			3	107	3	107		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	55	1535	0	4	107	4	107			1
MMRF_1917	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	315	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	315	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			2	94	2	94	690	Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	12	315	1	4	94	4	94	1	3	1
MMRF_1917	1	Lenalidomide	Len	IMID	316	389	2	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	389	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0	Completed regimen	4			2	94	2	94	690	Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	3	74	0	4	94	4	94			1
MMRF_1917	2	Lenalidomide	Len	IMID	715	718	1	Lenalidomide	Len	715	IMID	718	IMIDs-based	IMIDs-based	Len-Dex				0														0	0	0	0	0	4	0					1	1	1
MMRF_2290	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	139	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	139	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH				4	65	4	65		Partial Response	PR	Partial Response	PR	1	1	1	1	5	139	1	3	65	3	65	1	2	1
MMRF_2461	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	504	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	504	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			4	58	3	245	499	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	18	504	1	9	245	3	58	1	2	1
MMRF_2461	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	505	767	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	505	Proteasome/IMID/Steroid	767	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Patient decision	6			4	617	4	617	890	Partial Response	PR	Partial Response	PR	1	1	1	1	10	263	1	5	113	5	113	1	3	1
MMRF_1254	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	267	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	267	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			4	57	4	57		Partial Response	PR	Partial Response	PR	1	1	1	1	10	267	1	3	57	3	57	1	2	1
MMRF_1254	2	Lenalidomide	Len	IMID	283	967	1	Lenalidomide	Len	283	IMID	967	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	423	283	Stable Disease	SD			0	1	0	1	25	685	0	6	141			1	1	1
MMRF_1254	3	Pomalidomide	Pom	IMID	1386	1719	1	Pomalidomide	Pom	1386	IMID	1719	IMIDs-based	IMIDs-based	Pom-Dex				0	Patient decision	6			4	1533	4	1533		Partial Response	PR	Partial Response	PR	1	1	1	1	12	334	1	6	148	6	148	1	1	1
MMRF_1348	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	274	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	274	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	183	4	183		Partial Response	PR	Partial Response	PR	1	1	1	1	10	274	1	7	183	7	183	1	2	1
MMRF_1371	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	70	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	70	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	70	0	16	440	10	259	1	2	1
MMRF_1371	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	71	208	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	208	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	138	0	16	440	10	259			1
MMRF_1371	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	209	210	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	210	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	2	0	16	440	10	259			1
MMRF_1371	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	211	250	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	250	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	40	0	16	440	10	259			1
MMRF_1371	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	251	263	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	263	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	1	13	1	16	440	10	259			1
MMRF_1371	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	264	264	6	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	264	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	292	Stem cell, Autologous	1	1	Completed regimen	4			4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	16	440	10	259			1
MMRF_1371	1	Lenalidomide	Len	IMID	404	2290	7	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Bor-Dex + Bor-Cyc-Dex + Len	1	Proteasome/Steroid/IMID/Chemotherapy	2290	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	259	3	440	2280	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	68	1887	0	16	440	10	259			1
MMRF_1371	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	2308	2469	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	2308	Proteasome/IMID/Steroid	2469	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	2499	Stem cell, Autologous	2	1	Completed regimen	4												0	0	0	0	6	162	0					1	3	1
MMRF_1371	2	Bortezomib	Bor	Proteasome	2597	2940	2	Carfilzomib/Pomalidomide/Dexamethasone + Bortezomib	Car-Pom-Dex + Bor	2308	Proteasome/IMID/Steroid	2940	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1														0	0	0	0	13	344	0							1
MMRF_1377	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	143	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	143	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	207	Stem cell, Autologous	1	1	Completed regimen	4			4	78	1	310		Complete Response	CR	Partial Response	PR	1	1	1	1	5	143	1	12	310	3	78	1	3	1
MMRF_1377	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	753	1026	1	Lenalidomide/Dexamethasone	Len-Dex	753	IMID/Steroid	1026	IMIDs-based	IMIDs-based	Len-Dex				0	CHANGED DOSE				4	1603	1	1977	774	Complete Response	CR	Partial Response	PR	1	0	0	0	10	274	0	44	1225	31	851	1	2	1
MMRF_1377	2	Lenalidomide	Len	IMID	1027	1799	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	753	IMID/Steroid	1799	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	1603	1	1977	774	Complete Response	CR	Partial Response	PR	1	0	1	0	28	773	1	44	1225	31	851			1
MMRF_1377	2	Bortezomib	Bor	Proteasome	1813	2061	3	Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib	Len-Dex + Len + Bor	753	IMID/Steroid/Proteasome	2061	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	1603	1	1977	774	Complete Response	CR	Partial Response	PR	1	1	0	1	9	249	0	44	1225	31	851			1
MMRF_1377	3	Bendamustine	Bend	Chemotherapy	2705	2733	1	Bendamustine	Bend	2705	Chemotherapy	2733	Other therapies	Other treatments					0														0	0	0	0	1	29	0							1
MMRF_1703	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	163	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	163	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	71	4	71	563	Partial Response	PR	Partial Response	PR	1	1	1	1	6	163	1	3	71	3	71	1	3	1
MMRF_1703	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	164	563	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	563	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			4	71	4	71	563	Partial Response	PR	Partial Response	PR	1	0	0	0	15	400	0	3	71	3	71			1
MMRF_1703	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	564	1318	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	1318	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	71	4	71	563	Partial Response	PR	Partial Response	PR	1	0	0	0	27	755	0	3	71	3	71			1
MMRF_1703	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	606	1318	1	Bortezomib/Dexamethasone	Bor-Dex	606	Proteasome/Steroid	1318	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	647	4	647		Partial Response	PR	Partial Response	PR	1	1	1	1	26	713	1	2	42	2	42	1	2	1
MMRF_2166	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	28	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	28	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	1	28	0					1	2	1
MMRF_2324	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	126	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	155	Stem cell, Autologous	1	1	Completed regimen	4			4	56	1	756		Complete Response	CR	Partial Response	PR	1	0	1	0	5	126	1	27	756	2	56	1	3	1
MMRF_2324	1	Lenalidomide	Len	IMID	275	2522	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2522	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	56	1	756		Complete Response	CR	Partial Response	PR	1	1	0	1	81	2248	0	27	756	2	56			1
MMRF_2326	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	160	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	160	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	57	2	899	1536	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	6	160	1	33	899	3	57	1	3	1
MMRF_2326	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	161	162	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	162	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	57	2	899	1536	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	2	0	33	899	3	57			1
MMRF_2326	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	163	203	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	203	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	163	Stem cell, Autologous	1	1	Completed regimen	4			4	57	2	899	1536	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	41	0	33	899	3	57			1
MMRF_2326	1	Lenalidomide	Len	IMID	281	1543	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	1543	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	57	2	899	1536	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	45	1263	0	33	899	3	57			1
MMRF_2326	2	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	1549	1655	1	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	1549	Proteasome/IMID/Steroid	1655	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	UNDERGOING RECONSTRUCTIVE SURGERY				4	1632	4	1632		Partial Response	PR	Partial Response	PR	1	1	1	1	4	107	1	3	84	3	84	1	3	1
MMRF_2326	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	1763	1933	2	Ixazomib/Pomalidomide/Dexamethasone + Bortezomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex + Bor-Pom-Dex	1549	Proteasome/IMID/Steroid	1933	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	DEATH				4	1632	4	1632		Partial Response	PR	Partial Response	PR	1	0	0	0	6	171	0	3	84	3	84			1
MMRF_1090	1	Bortezomib/Thalidomide/Cyclophosphamide	Bor-Thal-Cyc	Proteasome/IMID/Chemotherapy	1	127	1	Bortezomib/Thalidomide/Cyclophosphamide	Bor-Thal-Cyc	1	Proteasome/IMID/Chemotherapy	127	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Cyc				0	Investigator decision for other reasons	5					5	94		Stable Disease	SD			0	1	0	1	5	127	0	4	94			1	3	1
MMRF_1090	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	134	432	2	Bortezomib/Thalidomide/Cyclophosphamide + Bortezomib/Dexamethasone	Bor-Thal-Cyc + Bor-Dex	1	Proteasome/IMID/Chemotherapy/Steroid	432	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Thal-Cyc-Dex				0	Disease progression/Relapse	3					5	94		Stable Disease	SD			0	0	0	0	11	299	0	4	94					1
MMRF_1090	2	Rituximab/Bendamustine	Rit-Bend	CD20/Chemotherapy	435	681	1	Rituximab/Bendamustine	Rit-Bend	435	CD20/Chemotherapy	681	Other therapies	Other treatments					0	PATIENT DECEASED						5	515	435	Stable Disease	SD			0	1	0	1	9	247	0	3	81					1
MMRF_1122	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	63	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	63	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	128	4	128	143	Partial Response	PR	Partial Response	PR	1	0	0	0	3	63	0	5	128	5	128	1	2	1
MMRF_1122	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	64	123	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	123	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	128	4	128	143	Partial Response	PR	Partial Response	PR	1	1	1	1	2	60	1	5	128	5	128			1
MMRF_1122	2	Lenalidomide	Len	IMID	176	229	1	Lenalidomide	Len	176	IMID	229	IMIDs-based	IMIDs-based	Len-Dex	234	Stem cell, Autologous	1	1	PATIENT TO RECEIVE TRANSPLANT													0	0	0	0	2	54	0					1	1	1
MMRF_1122	3	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	666	697	1	Bortezomib/Dexamethasone	Bor-Dex	666	Proteasome/Steroid	697	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PATIENT DIED						6	666	666	Progressive Disease	PD			0	1	0	1	1	32	0	1	1			1	2	1
MMRF_1386	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	162	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	162	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	85	2	260		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	6	162	1	10	260	4	85	1	2	1
MMRF_1386	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	178	217	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	217	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	PROTOCOL PROCEDURES				3	85	2	260		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	2	40	0	10	260	4	85			1
MMRF_1386	1	Lenalidomide	Len	IMID	234	2919	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	2919	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					3	85	2	260		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	96	2686	0	10	260	4	85			1
MMRF_1403	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	163	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	163	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4	2900		3	85	3	85	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	163	1	4	85	4	85	1	2	1
MMRF_1403	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	178	233	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	233	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	PROTOCOL PROCEDURES		2900		3	85	3	85	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	56	0	4	85	4	85			1
MMRF_1403	1	Lenalidomide	Len	IMID	234	926	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	926	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2900		3	85	3	85	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	25	693	0	4	85	4	85			1
MMRF_1403	2	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	940	944	1	Lenalidomide/Melphalan	Len-Mel	940	IMID/Chemotherapy	944	IMIDs-based	IMIDs-based	Other Len-based therapies	945	Stem cell, Autologous	1	1	Completed regimen	4	2900		3	1101	1	1815		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	5	0	32	876	6	162	1	2	1
MMRF_1403	2	Lenalidomide	Len	IMID	1045	1491	2	Lenalidomide/Melphalan + Lenalidomide	Len-Mel + Len	940	IMID/Chemotherapy	1491	IMIDs-based	IMIDs-based	Other Len-based therapies				1	Adverse Event or co-morbidity	2	2900		3	1101	1	1815		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	16	447	1	32	876	6	162			1
MMRF_1403	2	Ixazomib/Dexamethasone	Ixa-Dex	Proteasome/Steroid	1535	2213	3	Lenalidomide/Melphalan + Lenalidomide + Ixazomib/Dexamethasone	Len-Mel + Len + Ixa-Dex	940	IMID/Chemotherapy/Proteasome/Steroid	2213	IMIDs-based	Other treatments	Other Len-based therapies				1	Disease progression/Relapse	3	2900		3	1101	1	1815		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	25	679	0	32	876	6	162			1
MMRF_1403	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	2234	2317	1	Daratumumab/Dexamethasone	Dar-Dex	2234	CD38/Steroid	2317	daratumumab-based	daratumumab-based	Dar-Dex				0			2900		4	2374	4	2374		Partial Response	PR	Partial Response	PR	1	0	0	0	3	84	0	6	141	6	141			1
MMRF_1403	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	2318	2506	2	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone	Dar-Dex + Bor-Dar-Dex	2234	CD38/Steroid/Proteasome	2506	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0			2900		4	2374	4	2374		Partial Response	PR	Partial Response	PR	1	1	1	1	7	189	1	6	141	6	141	1	3	1
MMRF_1403	3	Bortezomib/Daratumumab/Thalidomide/Dexamethasone	Bor-Dar-Thal-Dex	Proteasome/CD38/IMID/Steroid	2507	2604	3	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Thalidomide/Dexamethasone	Dar-Dex + Bor-Dar-Dex + Bor-Dar-Thal-Dex	2234	CD38/Steroid/Proteasome/IMID	2604	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Thal-Dex				0			2900		4	2374	4	2374		Partial Response	PR	Partial Response	PR	1	0	0	0	4	98	0	6	141	6	141			1
MMRF_1403	3	Bortezomib/Daratumumab/Thalidomide/Cyclophosphamide/Dexamethasone	Bor-Dar-Thal-Cyc-Dex	Proteasome/CD38/IMID/Chemotherapy/Steroid	2605	2731	4	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Thalidomide/Dexamethasone + Bortezomib/Daratumumab/Thalidomide/Cyclophosphamide/Dexamethasone	Dar-Dex + Bor-Dar-Dex + Bor-Dar-Thal-Dex + Bor-Dar-Thal-Cyc-Dex	2234	CD38/Steroid/Proteasome/IMID/Chemotherapy	2731	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5	2900		4	2374	4	2374		Partial Response	PR	Partial Response	PR	1	0	0	0	5	127	0	6	141	6	141			1
MMRF_1403	3	Bortezomib/Daratumumab/Thalidomide/Dexamethasone	Bor-Dar-Thal-Dex	Proteasome/CD38/IMID/Steroid	2732	2759	5	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Thalidomide/Dexamethasone + Bortezomib/Daratumumab/Thalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Daratumumab/Thalidomide/Dexamethasone	Dar-Dex + Bor-Dar-Dex + Bor-Dar-Thal-Dex + Bor-Dar-Thal-Cyc-Dex + Bor-Dar-Thal-Dex	2234	CD38/Steroid/Proteasome/IMID/Chemotherapy	2759	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2900		4	2374	4	2374		Partial Response	PR	Partial Response	PR	1	0	0	0	1	28	0	6	141	6	141			1
MMRF_1403	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2815	2819	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	2815	Proteasome/Chemotherapy/Steroid	2819	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4	2900											0	0	0	0	0	5	0					1	3	1
MMRF_1403	5	Selinexor	Sel	XPO1	2879	2900	1	Selinexor	Sel	2879	XPO1	2900	Other therapies	Other treatments					0			2900				6	2900	2900	Progressive Disease	PD			0	1	0	1	1	22	0	1	22					1
MMRF_1458	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	135	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	135	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	86	1	540	1339	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	135	1	20	540	4	86	1	2	1
MMRF_1458	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	233	540	2	Carfilzomib/Dexamethasone + Lenalidomide/Dexamethasone	Car-Dex + Len-Dex	1	Proteasome/Steroid/IMID	540	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2			3	86	1	540	1339	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	11	308	0	20	540	4	86			1
MMRF_1458	2	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	1342	1837	1	Ixazomib/Lenalidomide	Ixa-Len	1342	Proteasome/IMID	1837	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			4	1459	3	1542		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	18	496	1	8	201	5	118	1	2	1
MMRF_1462	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	107	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	107	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	PROTOCOL PROCEDURES				3	85	1	121	625	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	107	1	5	121	4	85	1	2	1
MMRF_1462	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	122	177	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	177	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	PROTOCOL PROCEDURES				3	85	1	121	625	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	56	0	5	121	4	85			1
MMRF_1462	1	Lenalidomide	Len	IMID	178	627	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	627	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	85	1	121	625	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	16	450	0	5	121	4	85			1
MMRF_1462	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	646	842	1	Bortezomib/Dexamethasone	Bor-Dex	646	Proteasome/Steroid	842	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			3	730	1	822		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	7	197	1	7	177	4	85	1	2	1
MMRF_1462	3	Pomalidomide/Citarinostat/Dexamethasone	Pom-Cita-Dex	IMID/HDAC/Steroid	890	912	1	Pomalidomide/Citarinostat/Dexamethasone	Pom-Cita-Dex	890	IMID/HDAC/Steroid	912	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3												0	0	0	0	1	23	0					1	3	1
MMRF_1462	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	912	1123	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	912	Proteasome/IMID/Steroid	1123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	1130	Stem cell, Autologous	1	1	Disease progression/Relapse	3			3	1003	3	1003	912	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	212	1	4	92	4	92	1	3	1
MMRF_1462	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1195	2907	1	Daratumumab/Dexamethasone	Dar-Dex	1195	CD38/Steroid	2907	daratumumab-based	daratumumab-based	Dar-Dex				0					1	1184	1	1184		Complete Response	CR	Complete Response	CR	1	0	0	0	61	1713	0	0	-10	0	-10			1
MMRF_1493	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	37	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	37	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Patient decision	6			4	85	1	703		Complete Response	CR	Partial Response	PR	1	0	0	0	2	37	0	26	703	4	85	1	2	1
MMRF_1493	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	50	162	2	Carfilzomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Car-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	162	combined bortezomib/carfilzomib-based	Bortezomib-based	Bor-Car-Cyc-Dex				0	Investigator decision for other reasons	5			4	85	1	703		Complete Response	CR	Partial Response	PR	1	0	1	0	4	113	1	26	703	4	85			1
MMRF_1493	1	Lenalidomide	Len	IMID	163	1083	3	Carfilzomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Dex + Bor-Cyc-Dex + Len	1	Proteasome/Steroid/Chemotherapy/IMID	1083	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Cyc-Dex				0					4	85	1	703		Complete Response	CR	Partial Response	PR	1	1	0	1	33	921	0	26	703	4	85			1
MMRF_1608	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	386	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	386	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	168	3	356		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	386	1	13	356	6	168	1	2	1
MMRF_1608	1	Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Cyc-Dex	IMID/Chemotherapy/Steroid	399	539	2	Carfilzomib/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Dex + Len-Cyc-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	539	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	168	3	356		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	141	0	13	356	6	168			1
MMRF_1608	1	Lenalidomide	Len	IMID	540	1772	3	Carfilzomib/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Dex + Len-Cyc-Dex + Len	1	Proteasome/Steroid/IMID/Chemotherapy	1772	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				0	Disease progression/Relapse	3			4	168	3	356		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	44	1233	0	13	356	6	168			1
MMRF_1608	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1772	1973	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1772	CD38/IMID/Steroid	1973	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Investigator decision for other reasons	5			4	1814	2	1988		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	8	202	1	8	217	2	43	1	3	1
MMRF_1608	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1974	1987	2	Daratumumab/Pomalidomide/Dexamethasone + Daratumumab/Dexamethasone	Dar-Pom-Dex + Dar-Dex	1772	CD38/IMID/Steroid	1987	combined daratumumab/IMIDs-based	daratumumab-based	Dar-Pom-Dex				0					4	1814	2	1988		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	1	14	0	8	217	2	43			1
MMRF_1608	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1988	2906	3	Daratumumab/Pomalidomide/Dexamethasone + Daratumumab/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex + Dar-Dex + Dar-Pom-Dex	1772	CD38/IMID/Steroid	2906	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	1814	2	1988		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	1	33	919	0	8	217	2	43			1
MMRF_1662	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	1	356	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	1	IMID/Antibiotic/Steroid	356	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Investigator decision for other reasons	5			4	98	3	720		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	13	356	1	26	720	4	98	1	3	1
MMRF_1662	1	Lenalidomide	Len	IMID	722	2891	2	Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Len-Clar-Dex + Len	1	IMID/Antibiotic/Steroid	2891	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	98	3	720		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	78	2170	0	26	720	4	98			1
MMRF_1689	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	31	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	31	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			4	87	1	267	1198	Complete Response	CR	Partial Response	PR	1	0	0	0	1	31	0	10	267	4	87	1	3	1
MMRF_1689	1	Bortezomib	Bor	Proteasome	32	129	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	129	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	87	1	267	1198	Complete Response	CR	Partial Response	PR	1	0	1	0	4	98	1	10	267	4	87			1
MMRF_1689	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	188	498	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	498	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			4	87	1	267	1198	Complete Response	CR	Partial Response	PR	1	1	0	1	11	311	0	10	267	4	87			1
MMRF_1689	2	Daratumumab	Dar	CD38	1213	2906	1	Daratumumab	Dar	1213	CD38	2906	daratumumab-based	daratumumab-based	Dar				0					4	1261	1	1722		Complete Response	CR	Partial Response	PR	1	1	1	1	61	1694	1	19	510	2	49			1
MMRF_1718	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	183	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	183	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	92	3	92	405	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	183	1	4	92	4	92	1	2	1
MMRF_1718	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	205	288	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	288	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	92	3	92	405	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	4	92	4	92			1
MMRF_1718	1	Lenalidomide	Len	IMID	289	410	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	410	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	92	3	92	405	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	122	0	4	92	4	92			1
MMRF_1718	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	418	449	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	418	Proteasome/Chemotherapy/Steroid	449	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	470	Stem cell, Autologous	1	1	PATIENT WENT TO TRANSPLANT				3	624	3	624		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	32	1	8	207	8	207	1	3	1
MMRF_1733	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	19	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	19	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2			4	92	1	442		Complete Response	CR	Partial Response	PR	1	0	0	0	1	19	0	16	442	4	92	1	2	1
MMRF_1733	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	37	274	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	274	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	442		Complete Response	CR	Partial Response	PR	1	0	1	0	9	238	1	16	442	4	92			1
MMRF_1733	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	275	337	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide/Dexamethasone	Car-Dex + Len-Clar-Dex + Len-Dex	1	Proteasome/Steroid/IMID/Antibiotic	337	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	442		Complete Response	CR	Partial Response	PR	1	0	0	0	3	63	0	16	442	4	92			1
MMRF_1733	1	Lenalidomide	Len	IMID	338	420	4	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	420	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	92	1	442		Complete Response	CR	Partial Response	PR	1	1	0	1	3	83	0	16	442	4	92			1
MMRF_1775	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	168	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	168	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	168	1	4	85	4	85	1	2	1
MMRF_1775	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	184	267	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	267	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	4	85	4	85			1
MMRF_1775	1	Lenalidomide	Len	IMID	268	2689	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	2689	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	87	2422	0	4	85	4	85			1
MMRF_1795	1	Carfilzomib/Melphalan/Prednisone/Dexamethasone	Car-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1	392	1	Carfilzomib/Melphalan/Prednisone/Dexamethasone	Car-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	392	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	85	2	659	1293	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	14	392	1	24	659	4	85	1	4	1
MMRF_1795	2	Elotuzumab/Lenalidomide/Prednisone	Elo-Len-Pred	SLAMF7/IMID/Steroid	1307	1335	1	Elotuzumab/Lenalidomide/Prednisone	Elo-Len-Pred	1307	SLAMF7/IMID/Steroid	1335	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2												0	0	0	0	1	29	0					1	3	1
MMRF_1795	3	Carfilzomib/Lenalidomide/Prednisone	Car-Len-Pred	Proteasome/IMID/Steroid	1342	1600	1	Carfilzomib/Lenalidomide/Prednisone	Car-Len-Pred	1342	Proteasome/IMID/Steroid	1600	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	SWITCHED DOSING SCHEDULE				4	1447	2	1657		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	10	259	1	12	316	4	106	1	3	1
MMRF_1795	3	Carfilzomib/Prednisone	Car-Pred	Proteasome/Steroid	1601	2042	2	Carfilzomib/Lenalidomide/Prednisone + Carfilzomib/Prednisone	Car-Len-Pred + Car-Pred	1342	Proteasome/IMID/Steroid	2042	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	PATIENT PREFERENCE				4	1447	2	1657		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	16	442	0	12	316	4	106			1
MMRF_1795	3	Carfilzomib	Car	Proteasome	2043	2167	3	Carfilzomib/Lenalidomide/Prednisone + Carfilzomib/Prednisone + Carfilzomib	Car-Len-Pred + Car-Pred + Car	1342	Proteasome/IMID/Steroid	2167	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1447	2	1657		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	5	125	0	12	316	4	106			1
MMRF_1825	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	196	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	196	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			4	85	3	183	821	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	196	1	7	183	4	85	1	3	1
MMRF_1825	1	Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Len-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	197	287	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Len-Dex + Car-Len-Clar-Dex	1	Proteasome/IMID/Steroid/Antibiotic	287	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	85	3	183	821	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	91	0	7	183	4	85			1
MMRF_1825	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	288	927	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Clar-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Antibiotic	927	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	85	3	183	821	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	23	640	0	7	183	4	85			1
MMRF_1825	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	889	1088	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	889	SLAMF7/IMID/Steroid	1088	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Patient decision	6			4	1004	4	1004		Partial Response	PR	Partial Response	PR	1	1	1	1	7	200	1	5	116	5	116	1	3	1
MMRF_1825	3	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	1111	1115	1	Lenalidomide/Melphalan	Len-Mel	1111	IMID/Chemotherapy	1115	IMIDs-based	IMIDs-based	Other Len-based therapies	1116	Stem cell, Autologous	1	1	Completed regimen	4			3	1361	2	1661		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	5	0	20	551	9	251	1	2	1
MMRF_1825	3	Lenalidomide	Len	IMID	1215	2830	2	Lenalidomide/Melphalan + Lenalidomide	Len-Mel + Len	1111	IMID/Chemotherapy	2830	IMIDs-based	IMIDs-based	Other Len-based therapies				1	Disease progression/Relapse	3			3	1361	2	1661		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	58	1616	1	20	551	9	251			1
MMRF_1825	4	Pomalidomide/Selinexor/Dexamethasone	Pom-Sel-Dex	IMID/XPO1/Steroid	2851	2935	1	Pomalidomide/Selinexor/Dexamethasone	Pom-Sel-Dex	2851	IMID/XPO1/Steroid	2935	IMIDs-based	IMIDs-based	Other Pom-based therapies				0					4	2935	4	2935		Partial Response	PR	Partial Response	PR	1	1	1	1	3	85	1	4	85	4	85	1	3	1
MMRF_1835	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	282	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	282	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	61	1	906	1969	Complete Response	CR	Partial Response	PR	1	0	1	0	10	282	1	33	906	3	61	1	2	1
MMRF_1835	1	Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Cyc-Dex	IMID/Chemotherapy/Steroid	289	372	2	Carfilzomib/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Dex + Len-Cyc-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	372	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	61	1	906	1969	Complete Response	CR	Partial Response	PR	1	0	0	0	3	84	0	33	906	3	61			1
MMRF_1835	1	Lenalidomide	Len	IMID	373	1934	3	Carfilzomib/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Dex + Len-Cyc-Dex + Len	1	Proteasome/Steroid/IMID/Chemotherapy	1934	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				0	Disease progression/Relapse	3			4	61	1	906	1969	Complete Response	CR	Partial Response	PR	1	1	0	1	56	1562	0	33	906	3	61			1
MMRF_1835	2	Bortezomib/Daratumumab/Pomalidomide	Bor-Dar-Pom	Proteasome/CD38/IMID	1984	2032	1	Bortezomib/Daratumumab/Pomalidomide	Bor-Dar-Pom	1984	Proteasome/CD38/IMID	2032	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc				0					1	2180	1	2180		Complete Response	CR	Complete Response	CR	1	0	0	0	2	49	0	8	197	8	197	1	3	1
MMRF_1835	2	Bortezomib/Carfilzomib/Daratumumab/Pomalidomide	Bor-Car-Dar-Pom	Proteasome/Proteasome/CD38/IMID	2033	2047	2	Bortezomib/Daratumumab/Pomalidomide + Bortezomib/Carfilzomib/Daratumumab/Pomalidomide	Bor-Dar-Pom + Bor-Car-Dar-Pom	1984	Proteasome/CD38/IMID	2047	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Investigator decision for other reasons	5			1	2180	1	2180		Complete Response	CR	Complete Response	CR	1	0	0	0	1	15	0	8	197	8	197			1
MMRF_1835	2	Carfilzomib/Daratumumab	Car-Dar	Proteasome/CD38	2048	2894	3	Bortezomib/Daratumumab/Pomalidomide + Bortezomib/Carfilzomib/Daratumumab/Pomalidomide + Carfilzomib/Daratumumab	Bor-Dar-Pom + Bor-Car-Dar-Pom + Car-Dar	1984	Proteasome/CD38/IMID	2894	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0					1	2180	1	2180		Complete Response	CR	Complete Response	CR	1	1	1	1	31	847	1	8	197	8	197			1
MMRF_1855	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	183	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	183	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	92	3	183		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	183	1	7	183	4	92	1	2	1
MMRF_1855	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	184	239	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	239	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	3	183		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	56	0	7	183	4	92			1
MMRF_1855	1	Lenalidomide	Len	IMID	240	882	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	882	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	PATIENT MOVING AWAY				4	92	3	183		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	23	643	0	7	183	4	92			1
MMRF_1935	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	611	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	611	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	285	Stem cell, Autologous	1	1	Disease progression/Relapse	3	2017		3	91	3	91		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	22	611	1	4	91	4	91	1	3	1
MMRF_1935	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	632	803	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	632	SLAMF7/IMID/Steroid	803	IMIDs-based	IMIDs-based	Other Len-based therapies				0			2017		3	308	3	308	600	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	172	0	-11	-323	-11	-323	1	3	1
MMRF_1935	2	Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Bor-Elo-Len-Dex	Proteasome/SLAMF7/IMID/Steroid	804	1343	2	Elotuzumab/Lenalidomide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex + Bor-Elo-Len-Dex	632	SLAMF7/IMID/Steroid/Proteasome	1343	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1	2017		3	308	3	308	600	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	20	540	0	-11	-323	-11	-323			1
MMRF_1935	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1344	1630	3	Elotuzumab/Lenalidomide/Dexamethasone + Bortezomib/Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex + Bor-Elo-Len-Dex	632	SLAMF7/IMID/Steroid/Proteasome	1630	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	2017		3	308	3	308	600	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	11	287	0	-11	-323	-11	-323			1
MMRF_1935	3	Daratumumab/Pomalidomide/Atezolizumab	Dar-Pom-Atez	CD38/IMID/Checkpoint Inhibitor	1378	1630	1	Daratumumab/Pomalidomide/Atezolizumab	Dar-Pom-Atez	1378	CD38/IMID/Checkpoint Inhibitor	1630	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	2017		4	1434	4	1434	1630	Partial Response	PR	Partial Response	PR	1	1	1	1	9	253	1	3	57	3	57	1	3	1
MMRF_1935	4	JNJ-64407564	JNJ-64407564	GPRC5D	1715	1812	1	JNJ-64407564	JNJ-64407564	1715	GPRC5D	1812	Other therapies	Other treatments					0	Disease progression/Relapse	3	2017				6	1743	1743	Progressive Disease	PD			0	1	0	1	4	98	0	2	29					1
MMRF_1935	5	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	1829	1838	1	Bortezomib/Melphalan	Bor-Mel	1829	Proteasome/Chemotherapy	1838	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4	2017		2	2359	1	2547	2017	Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	1	10	0	26	719	19	531	1	2	1
MMRF_1935	5	Cyclophosphamide/Fludarabine	Cyc-Flu	Chemotherapy/Chemotherapy	1865	1867	2	Bortezomib/Melphalan + Cyclophosphamide/Fludarabine	Bor-Mel + Cyc-Flu	1829	Proteasome/Chemotherapy	1867	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	2017		2	2359	1	2547	2017	Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	0	3	1	26	719	19	531			1
MMRF_1985	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	175	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	175	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	7	175	1	17	449	4	92	1	2	1
MMRF_1985	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	198	252	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	252	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	55	0	17	449	4	92			1
MMRF_1985	1	Lenalidomide	Len	IMID	253	2543	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	2543	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	82	2291	0	17	449	4	92			1
MMRF_2072	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	49	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	49	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	92	1	170		Complete Response	CR	Partial Response	PR	1	0	0	0	2	49	0	7	170	4	92	1	2	1
MMRF_2072	1	Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Len-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	50	135	2	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Car-Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	135	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	170		Complete Response	CR	Partial Response	PR	1	0	1	0	3	86	1	7	170	4	92			1
MMRF_2072	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	136	191	3	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Car-Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	191	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	170		Complete Response	CR	Partial Response	PR	1	1	0	1	2	56	0	7	170	4	92			1
MMRF_2072	1	Lenalidomide/Clarithromycin	Len-Clar	IMID/Antibiotic	192	197	4	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide/Clarithromycin	Car-Dex + Car-Len-Clar-Dex + Len-Clar	1	Proteasome/Steroid/IMID/Antibiotic	197	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	170		Complete Response	CR	Partial Response	PR	1	0	0	0	1	6	0	7	170	4	92			1
MMRF_2072	1	Lenalidomide	Len	IMID	198	1019	5	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide/Clarithromycin + Lenalidomide	Car-Dex + Car-Len-Clar-Dex + Len-Clar + Len	1	Proteasome/Steroid/IMID/Antibiotic	1019	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	92	1	170		Complete Response	CR	Partial Response	PR	1	0	0	0	30	822	0	7	170	4	92			1
MMRF_2072	2	Daratumumab	Dar	CD38	1073	1528	1	Daratumumab	Dar	1073	CD38	1528	daratumumab-based	daratumumab-based	Dar				0					4	1187	4	1187	1096	Partial Response	PR	Partial Response	PR	1	1	1	1	17	456	1	5	115	5	115			1
MMRF_2072	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1529	2143	2	Daratumumab + Daratumumab/Pomalidomide	Dar + Dar-Pom	1073	CD38/IMID	2143	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Disease progression/Relapse	3			4	1187	4	1187	1096	Partial Response	PR	Partial Response	PR	1	0	0	0	22	615	0	5	115	5	115	1	2	1
MMRF_2072	3	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	2144	2144	1	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	2144	Proteasome/IMID/Steroid	2144	IMIDs-based	IMIDs-based	Other Pom-based therapies				0							6	2144	2144	Progressive Disease	PD			0	1	0	1	0	1	0	1	1			1	3	1
MMRF_2095	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	519	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	519	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Disease progression/Relapse	3			4	91	4	91	463	Partial Response	PR	Partial Response	PR	1	1	1	1	19	519	1	4	91	4	91	1	3	1
MMRF_2095	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	877	1079	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	877	Proteasome/IMID/Steroid	1079	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			4	905	4	905	1177	Partial Response	PR	Partial Response	PR	1	1	1	1	8	203	1	2	29	2	29	1	3	1
MMRF_2095	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1534	1856	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1534	Proteasome/CD38/Steroid	1856	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Adverse Event or co-morbidity	2					5	1605	1534	Stable Disease	SD			0	1	0	1	12	323	0	3	72			1	3	1
MMRF_2159	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	90	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	90	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	176	1	261	1079	Complete Response	CR	Partial Response	PR	1	0	0	0	4	90	0	10	261	7	176	1	2	1
MMRF_2159	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	91	455	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	455	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	1151	Stem cell, Autologous	1	1	Patient decision	6			4	176	1	261	1079	Complete Response	CR	Partial Response	PR	1	1	1	1	13	365	1	10	261	7	176			1
MMRF_2159	2	Lenalidomide	Len	IMID	1311	2724	1	Lenalidomide	Len	1311	IMID	2724	IMIDs-based	IMIDs-based	Len-Dex				0					3	1186	2	1472		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	51	1414	0	6	162	-4	-124	1	1	1
MMRF_2237	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	119	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	119	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	92	1	261		Complete Response	CR	Partial Response	PR	1	0	1	0	5	119	1	10	261	4	92	1	2	1
MMRF_2237	1	Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Len-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	120	120	2	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Car-Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	120	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	261		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	10	261	4	92			1
MMRF_2237	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	121	208	3	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Car-Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	208	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	1	261		Complete Response	CR	Partial Response	PR	1	0	0	0	3	88	0	10	261	4	92			1
MMRF_2237	1	Lenalidomide	Len	IMID	233	2501	4	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Car-Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	2501	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	92	1	261		Complete Response	CR	Partial Response	PR	1	1	0	1	81	2269	0	10	261	4	92			1
MMRF_2236	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	827	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	827	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	92	2	540		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	30	827	1	20	540	4	92	1	2	1
MMRF_2244	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	119	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	119	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					3	93	3	93	554	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	119	1	4	93	4	93	1	2	1
MMRF_2244	1	Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Len-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	120	219	2	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Car-Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	219	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	93	3	93	554	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	100	0	4	93	4	93			1
MMRF_2244	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	220	712	3	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Dex + Car-Len-Clar-Dex + Car-Len-Dex	1	Proteasome/Steroid/IMID/Antibiotic	712	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	93	3	93	554	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	18	493	0	4	93	4	93			1
MMRF_2244	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	713	715	4	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Clarithromycin/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Car-Dex + Car-Len-Clar-Dex + Car-Len-Dex + Car-Dex	1	Proteasome/Steroid/IMID/Antibiotic	715	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	93	3	93	554	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	3	0	4	93	4	93			1
MMRF_2244	2	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	786	1863	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	786	IMID/Antibiotic/Steroid	1863	IMIDs-based	IMIDs-based	Other Len-based therapies				0	IGA INCREASE				4	921	3	1776	1181	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	39	1078	1	36	991	5	136	1	3	1
MMRF_2244	2	Pomalidomide/Clarithromycin/Dexamethasone	Pom-Clar-Dex	IMID/Antibiotic/Steroid	1895	2468	2	Lenalidomide/Clarithromycin/Dexamethasone + Pomalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex + Pom-Clar-Dex	786	IMID/Antibiotic/Steroid	2468	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	921	3	1776	1181	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	21	574	0	36	991	5	136			1
MMRF_2281	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	162	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	162	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4	1620		3	93	3	93		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	162	1	4	93	4	93	1	2	1
MMRF_2281	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	178	255	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	255	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1620		3	93	3	93		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	78	0	4	93	4	93			1
MMRF_2281	1	Lenalidomide	Len	IMID	256	864	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	864	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1620		3	93	3	93		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	609	0	4	93	4	93			1
MMRF_2281	2	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	880	1052	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	880	IMID/Antibiotic/Steroid	1052	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1620				5	905		Stable Disease	SD			0	1	0	1	6	173	0	1	26			1	3	1
MMRF_2281	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1054	1129	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1054	CD38/IMID/Steroid	1129	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	1620				6	1081	1081	Progressive Disease	PD			0	1	0	1	3	76	0	1	28			1	3	1
MMRF_2281	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1144	1382	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1144	Proteasome/IMID/Steroid	1382	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	ASCT		1620				5	1185		Stable Disease	SD			0	1	0	1	9	239	0	2	42			1	3	1
MMRF_2281	5	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	1396	1400	1	Lenalidomide/Melphalan	Len-Mel	1396	IMID/Chemotherapy	1400	IMIDs-based	IMIDs-based	Other Len-based therapies	1401	Stem cell, Autologous	1	1	Completed regimen	4	1620		3	1502	3	1502	1620	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	5	1	4	107	4	107	1	2	1
MMRF_2281	5	Lenalidomide	Len	IMID	1502	1605	2	Lenalidomide/Melphalan + Lenalidomide	Len-Mel + Len	1396	IMID/Chemotherapy	1605	IMIDs-based	IMIDs-based	Other Len-based therapies				1	Disease progression/Relapse	3	1620		3	1502	3	1502	1620	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	4	104	1	4	107	4	107			1
MMRF_2281	9	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	1613	1655	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	1613	Proteasome/Chemotherapy/Steroid	1655	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1620											0	0	0	0	2	43	0					1	3	1
MMRF_2281	9	Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Car-Cyc-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	1689	1694	2	Bortezomib/Bendamustine/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Bend-Dex + Car-Cyc-Dex-Dox	1613	Proteasome/Chemotherapy/Steroid	1694	combined bortezomib/carfilzomib-based	Carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1620											0	0	0	0	1	6	0							1
MMRF_2281	9	CAR-T Cells(Undefined)	CAR-T		1731	1731	3	Bortezomib/Bendamustine/Dexamethasone + Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin + CAR-T Cells(Undefined)	Bor-Bend-Dex + Car-Cyc-Dex-Dox + CAR-T	1613	Proteasome/Chemotherapy/Steroid	1731	combined bortezomib/carfilzomib-based	Other treatments	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1620											0	0	0	0	0	1	0							1
MMRF_2292	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	241	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	241	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	241	1	4	92	4	92	1	3	1
MMRF_2292	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	242	428	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	428	Bortezomib-based	Other treatments	Bor-Cyc-Dex				0					3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	187	0	4	92	4	92			1
MMRF_2292	1	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	Proteasome/Chemotherapy/Steroid	429	484	3	Bortezomib/Cyclophosphamide/Dexamethasone + Ixazomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Ixa-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	484	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	56	0	4	92	4	92			1
MMRF_2292	1	Ixazomib	Ixa	Proteasome	485	836	4	Bortezomib/Cyclophosphamide/Dexamethasone + Ixazomib/Cyclophosphamide/Dexamethasone + Ixazomib	Bor-Cyc-Dex + Ixa-Cyc-Dex + Ixa	1	Proteasome/Chemotherapy/Steroid	836	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	13	352	0	4	92	4	92			1
MMRF_2292	2	Daratumumab	Dar	CD38	857	954	1	Daratumumab	Dar	857	CD38	954	daratumumab-based	daratumumab-based	Dar				0					4	1180	3	1627	906	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	98	0	28	771	12	324			1
MMRF_2292	2	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	955	969	2	Daratumumab + Bortezomib/Daratumumab	Dar + Bor-Dar	857	CD38/Proteasome	969	Bortezomib-based	Bortezomib-based	Bor-Dar				0	Adverse Event or co-morbidity	2			4	1180	3	1627	906	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	15	0	28	771	12	324	1	2	1
MMRF_2292	2	Daratumumab	Dar	CD38	970	983	3	Daratumumab + Bortezomib/Daratumumab	Dar + Bor-Dar	857	CD38/Proteasome	983	Bortezomib-based	daratumumab-based	Bor-Dar				0	Investigator decision for other reasons	5			4	1180	3	1627	906	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	14	0	28	771	12	324			1
MMRF_2292	2	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	997	2523	4	Daratumumab + Bortezomib/Daratumumab + Daratumumab/Lenalidomide	Dar + Bor-Dar + Dar-Len	857	CD38/Proteasome/IMID	2523	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	1180	3	1627	906	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	55	1527	1	28	771	12	324			1
MMRF_2325	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	212	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	212	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	92	3	92	2271	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	212	1	4	92	4	92	1	2	1
MMRF_2325	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	234	400	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	400	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	92	3	92	2271	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	167	0	4	92	4	92			1
MMRF_2325	1	Lenalidomide	Len	IMID	401	2290	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	2290	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	92	3	92	2271	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	68	1890	0	4	92	4	92			1
MMRF_2325	2	Bortezomib/Daratumumab/Pomalidomide	Bor-Dar-Pom	Proteasome/CD38/IMID	2297	2535	1	Bortezomib/Daratumumab/Pomalidomide	Bor-Dar-Pom	2297	Proteasome/CD38/IMID	2535	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc				0					3	2535	3	2535		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	239	1	9	239	9	239	1	3	1
MMRF_2363	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	127	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	127	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	91	4	91		Partial Response	PR	Partial Response	PR	1	1	1	1	5	127	1	4	91	4	91	1	2	1
MMRF_2363	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	148	216	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	216	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	91	4	91		Partial Response	PR	Partial Response	PR	1	0	0	0	3	69	0	4	91	4	91			1
MMRF_2363	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	231	364	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	231	Proteasome/Chemotherapy/Steroid	364	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Investigator decision for other reasons	5			4	273	4	273		Partial Response	PR	Partial Response	PR	1	1	1	1	5	134	1	2	43	2	43	1	3	1
MMRF_2363	2	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	381	385	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Melphalan	Bor-Cyc-Dex + Len-Mel	231	Proteasome/Chemotherapy/Steroid/IMID	385	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	386	Stem cell, Autologous	1	1	Completed regimen	4			4	273	4	273		Partial Response	PR	Partial Response	PR	1	0	0	0	0	5	0	2	43	2	43			1
MMRF_2363	2	Ixazomib	Ixa	Proteasome	619	829	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Melphalan + Ixazomib	Bor-Cyc-Dex + Len-Mel + Ixa	231	Proteasome/Chemotherapy/Steroid/IMID	829	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	273	4	273		Partial Response	PR	Partial Response	PR	1	0	0	0	8	211	0	2	43	2	43			1
MMRF_2363	3	Daratumumab	Dar	CD38	728	882	1	Daratumumab	Dar	728	CD38	882	daratumumab-based	daratumumab-based	Dar				0					3	996	1	1179	818	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	6	155	0	17	452	10	269			1
MMRF_2363	3	Carfilzomib/Daratumumab/Pomalidomide	Car-Dar-Pom	Proteasome/CD38/IMID	883	1266	2	Daratumumab + Carfilzomib/Daratumumab/Pomalidomide	Dar + Car-Dar-Pom	728	CD38/Proteasome/IMID	1266	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Dar-Car-Pom-Dex				0					3	996	1	1179	818	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	14	384	1	17	452	10	269	1	3	1
MMRF_2363	3	Carfilzomib/Daratumumab/Pomalidomide/Methylprednisolone	Car-Dar-Pom-Mep	Proteasome/CD38/IMID/Steroid	1267	2542	3	Daratumumab + Carfilzomib/Daratumumab/Pomalidomide + Carfilzomib/Daratumumab/Pomalidomide/Methylprednisolone	Dar + Car-Dar-Pom + Car-Dar-Pom-Mep	728	CD38/Proteasome/IMID/Steroid	2542	combined daratumumab/IMIDs/carfilzomib-based	combined daratumumab/IMIDs/carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0					3	996	1	1179	818	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	46	1276	0	17	452	10	269			1
MMRF_2394	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	104	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	104	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4	1721		3	89	1	376	440	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	104	1	14	376	4	89	1	2	1
MMRF_2394	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	118	173	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	173	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1721		3	89	1	376	440	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	56	0	14	376	4	89			1
MMRF_2394	1	Lenalidomide	Len	IMID	174	425	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	425	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1721		3	89	1	376	440	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	9	252	0	14	376	4	89			1
MMRF_2394	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	454	559	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	454	SLAMF7/IMID/Steroid	559	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	1721		4	545	4	545		Partial Response	PR	Partial Response	PR	1	1	1	1	4	106	1	4	92	4	92	1	3	1
MMRF_2394	3	Carfilzomib/Melphalan/Dexamethasone	Car-Mel-Dex	Proteasome/Chemotherapy/Steroid	582	839	1	Carfilzomib/Melphalan/Dexamethasone	Car-Mel-Dex	582	Proteasome/Chemotherapy/Steroid	839	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1721		4	636	3	728	831	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	258	1	6	147	2	55	1	3	1
MMRF_2394	4	Pomalidomide/Nivolumab/Dexamethasone	Pom-Niv-Dex	IMID/Checkpoint Inhibitor/Steroid	860	873	1	Pomalidomide/Nivolumab/Dexamethasone	Pom-Niv-Dex	860	IMID/Checkpoint Inhibitor/Steroid	873	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2	1721											0	0	0	0	1	14	0					1	3	1
MMRF_2394	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	905	950	1	Daratumumab/Dexamethasone	Dar-Dex	905	CD38/Steroid	950	daratumumab-based	daratumumab-based	Dar-Dex				1			1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	1	1	1	2	46	1	1	8	1	8			1
MMRF_2394	5	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	951	1015	2	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone	Dar-Dex + Bor-Dar-Dex	905	CD38/Steroid/Proteasome	1015	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				1	Disease progression/Relapse	3	1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	3	65	0	1	8	1	8	1	3	1
MMRF_2394	5	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1016	1023	3	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone	Dar-Dex + Bor-Dar-Dex	905	CD38/Steroid/Proteasome	1023	Bortezomib-based	daratumumab-based	Bor-Dar-Dex	1030	Stem cell, Autologous	1	1	Disease progression/Relapse	3	1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	1	8	0	1	8	1	8			1
MMRF_2394	5	Bortezomib	Bor	Proteasome	1148	1223	4	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib	Dar-Dex + Bor-Dar-Dex + Bor	905	CD38/Steroid/Proteasome	1223	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				1			1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	3	76	0	1	8	1	8			1
MMRF_2394	5	Bortezomib/Pomalidomide	Bor-Pom	Proteasome/IMID	1224	1252	5	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib + Bortezomib/Pomalidomide	Dar-Dex + Bor-Dar-Dex + Bor + Bor-Pom	905	CD38/Steroid/Proteasome/IMID	1252	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Pom-Pred-Dex				1			1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	1	29	0	1	8	1	8			1
MMRF_2394	5	Bortezomib/Pomalidomide/Venetoclax/Dexamethasone	Bor-Pom-Vent-Dex	Proteasome/IMID/BCL2/Steroid	1253	1433	6	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib + Bortezomib/Pomalidomide + Bortezomib/Pomalidomide/Venetoclax/Dexamethasone	Dar-Dex + Bor-Dar-Dex + Bor + Bor-Pom + Bor-Pom-Vent-Dex	905	CD38/Steroid/Proteasome/IMID/BCL2	1433	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1			1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	7	181	0	1	8	1	8			1
MMRF_2394	5	Bortezomib/Carfilzomib/Pomalidomide/Venetoclax/Dexamethasone	Bor-Car-Pom-Vent-Dex	Proteasome/Proteasome/IMID/BCL2/Steroid	1434	1610	7	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib + Bortezomib/Pomalidomide + Bortezomib/Pomalidomide/Venetoclax/Dexamethasone + Bortezomib/Carfilzomib/Pomalidomide/Venetoclax/Dexamethasone	Dar-Dex + Bor-Dar-Dex + Bor + Bor-Pom + Bor-Pom-Vent-Dex + Bor-Car-Pom-Vent-Dex	905	CD38/Steroid/Proteasome/IMID/BCL2	1610	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Adverse Event or co-morbidity	2	1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	7	177	0	1	8	1	8			1
MMRF_2394	5	Bortezomib/Carfilzomib/Venetoclax/Dexamethasone	Bor-Car-Vent-Dex	Proteasome/Proteasome/BCL2/Steroid	1611	1707	8	Daratumumab/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib + Bortezomib/Pomalidomide + Bortezomib/Pomalidomide/Venetoclax/Dexamethasone + Bortezomib/Carfilzomib/Pomalidomide/Venetoclax/Dexamethasone + Bortezomib/Carfilzomib/Venetoclax/Dexamethasone	Dar-Dex + Bor-Dar-Dex + Bor + Bor-Pom + Bor-Pom-Vent-Dex + Bor-Car-Pom-Vent-Dex + Bor-Car-Vent-Dex	905	CD38/Steroid/Proteasome/IMID/BCL2	1707	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Disease progression/Relapse	3	1721		4	912	4	912	1721	Partial Response	PR	Partial Response	PR	1	0	0	0	4	97	0	1	8	1	8			1
MMRF_2394	9	SEA-BCMA	SEA-BCMA	BCMA	1728	1756	1	SEA-BCMA	SEA-BCMA	1728	BCMA	1756	Other therapies	Other treatments					0	Disease progression/Relapse	3	1721											0	0	0	0	1	29	0							1
MMRF_2394	9	Bortezomib/Carfilzomib/Selinexor/Bendamustine/Dexamethasone	Bor-Car-Sel-Bend-Dex	Proteasome/Proteasome/XPO1/Chemotherapy/Steroid	1777	1826	2	SEA-BCMA + Bortezomib/Carfilzomib/Selinexor/Bendamustine/Dexamethasone	SEA-BCMA + Bor-Car-Sel-Bend-Dex	1728	BCMA/Proteasome/XPO1/Chemotherapy/Steroid	1826	combined bortezomib/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0			1721											0	0	0	0	2	50	0					1	5	1
MMRF_2399	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	192	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	192	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	192	1	4	92	4	92	1	2	1
MMRF_2399	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	212	379	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	379	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	168	0	4	92	4	92			1
MMRF_2399	1	Lenalidomide	Len	IMID	380	709	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	709	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	330	0	4	92	4	92			1
MMRF_2399	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	711	848	1	Lenalidomide/Dexamethasone	Len-Dex	711	IMID/Steroid	848	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			4	848	4	848		Partial Response	PR	Partial Response	PR	1	1	1	1	5	138	1	5	138	5	138	1	2	1
MMRF_2399	3	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	856	1289	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	856	Proteasome/IMID/Steroid	1289	IMIDs-based	IMIDs-based	Other Len-based therapies				1	Investigator decision for other reasons	5			3	1435	1	1528		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	16	434	0	25	673	21	580	1	3	1
MMRF_2399	3	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	1322	1326	2	Ixazomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan	Ixa-Len-Dex + Len-Mel	856	Proteasome/IMID/Steroid/Chemotherapy	1326	IMIDs-based	IMIDs-based	Other Len-based therapies	1327	Stem cell, Autologous	1	1	Completed regimen	4			3	1435	1	1528		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	0	5	1	25	673	21	580			1
MMRF_2399	3	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	1322	1326	2	Ixazomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan	Ixa-Len-Dex + Len-Mel	856	Proteasome/IMID/Steroid/Chemotherapy	1326	IMIDs-based	IMIDs-based	Other Len-based therapies	1327	Stem cell, Autologous	2	1	Completed regimen	4			3	1435	1	1528		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	5	1	25	673	21	580			1
MMRF_2399	3	Lenalidomide	Len	IMID	1435	2537	3	Ixazomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan + Lenalidomide	Ixa-Len-Dex + Len-Mel + Len	856	Proteasome/IMID/Steroid/Chemotherapy	2537	IMIDs-based	IMIDs-based	Other Len-based therapies				1					3	1435	1	1528		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	40	1103	1	25	673	21	580			1
MMRF_2453	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	301	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	301	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	312	Stem cell, Autologous	1	1	Disease progression/Relapse	3			3	273	3	273		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	301	1	10	273	10	273	1	3	1
MMRF_2453	2	Ixazomib	Ixa	Proteasome	481	2381	1	Ixazomib	Ixa	481	Proteasome	2381	Other therapies	Other treatments					0					2	549	1	1072		Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	68	1901	1	22	592	3	69			1
MMRF_2503	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	163	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	163	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	92	3	260		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	163	1	10	260	4	92	1	2	1
MMRF_2503	1	Lenalidomide/Clarithromycin/Dexamethasone	Len-Clar-Dex	IMID/Antibiotic/Steroid	176	259	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone	Car-Dex + Len-Clar-Dex	1	Proteasome/Steroid/IMID/Antibiotic	259	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	92	3	260		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	3	84	0	10	260	4	92			1
MMRF_2503	1	Lenalidomide	Len	IMID	260	868	3	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin/Dexamethasone + Lenalidomide	Car-Dex + Len-Clar-Dex + Len	1	Proteasome/Steroid/IMID/Antibiotic	868	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	92	3	260		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	22	609	0	10	260	4	92			1
MMRF_2503	2	Avadomide/Dexamethasone	Avad-Dex	IMID/Steroid	1002	1506	1	Avadomide/Dexamethasone	Avad-Dex	1002	IMID/Steroid	1506	Other therapies	Other treatments		1550	Stem cell, Autologous	1	1	Disease progression/Relapse	3			4	1079	4	1079	911	Partial Response	PR	Partial Response	PR	1	1	1	1	18	505	1	3	78	3	78			1
MMRF_2503	2	Avadomide/Dexamethasone	Avad-Dex	IMID/Steroid	1002	1506	1	Avadomide/Dexamethasone	Avad-Dex	1002	IMID/Steroid	1506	Other therapies	Other treatments		1550	Stem cell, Autologous	2	1	Disease progression/Relapse	3			4	1079	4	1079	911	Partial Response	PR	Partial Response	PR	1	0	0	1	18	505	1	3	78	3	78			1
MMRF_2503	3	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	1646	1732	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	1646	Proteasome/CD38/Steroid	1732	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2			4	1590	4	1590		Partial Response	PR	Partial Response	PR	1	0	0	0	3	87	0	-1	-55	-1	-55	1	3	1
MMRF_2503	3	Daratumumab	Dar	CD38	1733	2556	2	Carfilzomib/Daratumumab/Dexamethasone + Daratumumab	Car-Dar-Dex + Dar	1646	Proteasome/CD38/Steroid	2556	Carfilzomib-based	daratumumab-based	Other Cafilzomib-based therapies				0					4	1590	4	1590		Partial Response	PR	Partial Response	PR	1	0	0	0	30	824	0	-1	-55	-1	-55			1
MMRF_2522	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	91	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	91	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					3	92	1	260		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	91	1	10	260	4	92	1	2	1
MMRF_2522	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	92	2528	2	Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Dex + Car-Len-Dex	1	Proteasome/Steroid/IMID	2528	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	92	1	260		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	87	2437	1	10	260	4	92			1
MMRF_2524	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	2514	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	2514	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	92	1	729		Complete Response	CR	Partial Response	PR	1	1	1	1	90	2514	1	27	729	4	92	1	2	1
MMRF_2599	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1	100	1	Carfilzomib/Dexamethasone	Car-Dex	1	Proteasome/Steroid	100	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	100	1	4	92	4	92	1	2	1
MMRF_2599	1	Lenalidomide/Clarithromycin	Len-Clar	IMID/Antibiotic	114	814	2	Carfilzomib/Dexamethasone + Lenalidomide/Clarithromycin	Car-Dex + Len-Clar	1	Proteasome/Steroid/IMID/Antibiotic	814	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	25	701	0	4	92	4	92			1
MMRF_2599	2	Avadomide/Dexamethasone	Avad-Dex	IMID/Steroid	828	2371	1	Avadomide/Dexamethasone	Avad-Dex	828	IMID/Steroid	2371	Other therapies	Other treatments					0					3	912	1	1306		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	55	1544	1	18	479	4	85			1
MMRF_1120	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	236	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	236	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	120	1	280		Complete Response	CR	Partial Response	PR	1	0	1	0	9	236	1	10	280	5	120	1	3	1
MMRF_1120	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	237	237	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	237	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	239	Stem cell, Autologous	1	1	Completed regimen	4			4	120	1	280		Complete Response	CR	Partial Response	PR	1	1	0	1	0	1	0	10	280	5	120			1
MMRF_1120	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	237	237	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	237	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	358	Stem cell, Autologous	2	1	Completed regimen	4			4	120	1	280		Complete Response	CR	Partial Response	PR	1	0	0	1	0	1	0	10	280	5	120			1
MMRF_1120	1	Lenalidomide	Len	IMID	473	2973	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2973	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	120	1	280		Complete Response	CR	Partial Response	PR	1	0	0	0	90	2501	0	10	280	5	120			1
MMRF_1140	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	328	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	328	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					4	78	1	435	1933	Complete Response	CR	Partial Response	PR	1	0	1	0	12	328	1	16	435	3	78	1	3	1
MMRF_1140	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	329	330	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	330	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	331	Stem cell, Autologous	1	1	Completed regimen	4			4	78	1	435	1933	Complete Response	CR	Partial Response	PR	1	1	0	1	0	2	0	16	435	3	78			1
MMRF_1140	1	Bortezomib	Bor	Proteasome	451	1955	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor	1	Proteasome/IMID/Steroid/Chemotherapy	1955	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	78	1	435	1933	Complete Response	CR	Partial Response	PR	1	0	0	0	54	1505	0	16	435	3	78			1
MMRF_1140	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1988	2144	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1988	CD38/IMID/Steroid	2144	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex	2166	Stem cell, Autologous	2	1	Investigator decision for other reasons	5			3	2318	1	2715		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	6	157	1	26	728	12	331	1	3	1
MMRF_1167	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	630	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	630	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			3	190	3	190		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	23	630	1	7	190	7	190	1	2	1
MMRF_1167	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	630	834	1	Lenalidomide/Dexamethasone	Len-Dex	630	IMID/Steroid	834	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	729	4	729	652	Partial Response	PR	Partial Response	PR	1	1	1	1	8	205	1	4	100	4	100	1	2	1
MMRF_1167	2	Lenalidomide	Len	IMID	835	946	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	630	IMID/Steroid	946	IMIDs-based	IMIDs-based	Len-Dex				0	HIGH RISK COMPLICATIONS OF WARFARIN ON TERMINAL, SECOND MALIGNANCY				4	729	4	729	652	Partial Response	PR	Partial Response	PR	1	0	0	0	4	112	0	4	100	4	100			1
MMRF_1336	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	29	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	29	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				1					4	275	3	366		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	29	0	14	366	10	275	1	3	1
MMRF_1336	1	Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone	Bor-Cyc-Mel-Pred-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid/Steroid	30	30	2	Bortezomib/Melphalan/Prednisone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred + Bor-Cyc-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	30	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			4	275	3	366		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	14	366	10	275			1
MMRF_1336	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	31	274	3	Bortezomib/Melphalan/Prednisone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Mel-Pred + Bor-Cyc-Mel-Pred-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	274	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					4	275	3	366		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	9	244	1	14	366	10	275			1
MMRF_1336	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	275	275	4	Bortezomib/Melphalan/Prednisone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Mel-Pred + Bor-Cyc-Mel-Pred-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	275	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Lack of response	1			4	275	3	366		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	1	14	366	10	275			1
MMRF_1336	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	276	360	5	Bortezomib/Melphalan/Prednisone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Mel-Pred + Bor-Cyc-Mel-Pred-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	360	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	408	Stem cell, Autologous	1	1	Completed regimen	4			4	275	3	366		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	3	85	0	14	366	10	275			1
MMRF_1336	1	Bortezomib	Bor	Proteasome	616	933	6	Bortezomib/Melphalan/Prednisone + Bortezomib/Cyclophosphamide/Melphalan/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Mel-Pred + Bor-Cyc-Mel-Pred-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor	1	Proteasome/Chemotherapy/Steroid/IMID	933	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	PATIENT COULD NO LONGER AFFORD TREATMENT				4	275	3	366		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	12	318	0	14	366	10	275			1
MMRF_1587	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	167	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	167	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	85	4	85	204	Partial Response	PR	Partial Response	PR	1	1	1	1	6	167	1	4	85	4	85	1	3	1
MMRF_1587	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	190	234	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	234	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	85	4	85	204	Partial Response	PR	Partial Response	PR	1	0	0	0	2	45	0	4	85	4	85			1
MMRF_1587	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	234	298	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	234	Proteasome/Chemotherapy/Steroid	298	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			4	358	4	358	449	Partial Response	PR	Partial Response	PR	1	0	0	0	3	65	0	5	125	5	125	1	3	1
MMRF_1587	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	309	629	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Dex	234	Proteasome/Chemotherapy/Steroid/IMID	629	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Lack of response	1			4	358	4	358	449	Partial Response	PR	Partial Response	PR	1	1	1	1	12	321	1	5	125	5	125			1
MMRF_1857	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	114	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	114	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Lack of response	1			4	188	3	371		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	114	0	14	371	7	188	1	3	1
MMRF_1857	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	124	219	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	219	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	250	Stem cell, Autologous	1	1	Completed regimen	4			4	188	3	371		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	96	1	14	371	7	188			1
MMRF_1857	1	Lenalidomide	Len	IMID	377	1443	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1443	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					4	188	3	371		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	38	1067	0	14	371	7	188			1
MMRF_2297	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	26	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	26	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	21	1	441	1831	Complete Response	CR	Partial Response	PR	1	0	1	0	1	26	1	16	441	1	21	1	3	1
MMRF_2297	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	105	137	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	137	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1					4	21	1	441	1831	Complete Response	CR	Partial Response	PR	1	0	0	0	1	33	0	16	441	1	21			1
MMRF_2297	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	138	198	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	198	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	21	1	441	1831	Complete Response	CR	Partial Response	PR	1	0	0	0	2	61	0	16	441	1	21			1
MMRF_2297	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	199	210	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	210	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex	276	Stem cell, Autologous	1	1	Completed regimen	4			4	21	1	441	1831	Complete Response	CR	Partial Response	PR	1	0	0	0	1	12	0	16	441	1	21			1
MMRF_2297	1	Bortezomib	Bor	Proteasome	406	1234	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor	1	Proteasome/IMID/Steroid	1234	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	21	1	441	1831	Complete Response	CR	Partial Response	PR	1	1	0	1	30	829	0	16	441	1	21			1
MMRF_2297	1	Lenalidomide	Len	IMID	1248	2148	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib + Lenalidomide	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor + Len	1	Proteasome/IMID/Steroid	2148	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	21	1	441	1831	Complete Response	CR	Partial Response	PR	1	0	0	0	32	901	0	16	441	1	21			1
MMRF_2297	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2191	2557	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2191	CD38/IMID/Steroid	2557	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2361	3	2557	2191	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	13	367	1	14	367	7	171	1	3	1
MMRF_2302	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	264	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	264	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			3	84	3	84	2354	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	264	1	3	84	3	84	1	2	1
MMRF_2302	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	283	325	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	325	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	84	3	84	2354	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	43	0	3	84	3	84			1
MMRF_2302	1	Lenalidomide	Len	IMID	376	1056	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Bor-Len-Dex + Len	1	IMID/Steroid/Proteasome	1056	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Patient decision	6			3	84	3	84	2354	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	25	681	0	3	84	3	84			1
MMRF_2302	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	2404	2557	1	Daratumumab/Dexamethasone	Dar-Dex	2404	CD38/Steroid	2557	daratumumab-based	daratumumab-based	Dar-Dex				0					3	2538	3	2538		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	154	1	5	135	5	135			1
MMRF_2352	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	139	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	139	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	151	Stem cell, Autologous	1	1	Completed regimen	4			3	260	2	337		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	5	139	1	13	337	10	260	1	3	1
MMRF_2352	1	Lenalidomide	Len	IMID	307	2586	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2586	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					3	260	2	337		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	82	2280	0	13	337	10	260			1
MMRF_2464	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	56	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	56	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	121	Stem cell, Autologous	1	1	Completed regimen	4			4	86	2	1346		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	2	56	1	49	1346	4	86	1	3	1
MMRF_2464	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	210	244	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	244	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	86	2	1346		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	2	35	0	49	1346	4	86			1
MMRF_2464	1	Lenalidomide	Len	IMID	245	2549	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2549	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	86	2	1346		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	83	2305	0	49	1346	4	86			1
MMRF_2217	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	373	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	373	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	98	1	128	970	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	14	373	1	5	128	4	98	1	3	1
MMRF_2217	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	374	736	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	736	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Lack of response	1			3	98	1	128	970	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	13	363	0	5	128	4	98			1
MMRF_2217	2	Nivolumab	Niv	Checkpoint Inhibitor	997	1164	1	Nivolumab	Niv	997	Checkpoint Inhibitor	1164	Other therapies	Other treatments					0	Disease progression/Relapse	3			3	1080	3	1080	1164	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	168	1	3	84	3	84			1
MMRF_2217	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1182	1203	2	Nivolumab + Daratumumab/Dexamethasone	Niv + Dar-Dex	997	Checkpoint Inhibitor/CD38/Steroid	1203	daratumumab-based	daratumumab-based	Dar-Niv-Dex				0	Lack of response	1			3	1080	3	1080	1164	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	3	84	3	84			1
MMRF_2217	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1204	1487	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1204	Proteasome/IMID/Steroid	1487	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	1232	3	1232		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	284	1	2	29	2	29	1	3	1
MMRF_2217	4	Anti-BCMA	Anti-BCMA	BCMA	1542	1619	1	Anti-BCMA	Anti-BCMA	1542	BCMA	1619	Other therapies	Other treatments					0	Disease progression/Relapse	3					6	1619	1619	Progressive Disease	PD			0	1	0	1	3	78	0	3	78					1
MMRF_2217	5	Ixazomib/Idasanutlin	Ixa-Ida	Proteasome/MDM2	1633	1667	1	Ixazomib/Idasanutlin	Ixa-Ida	1633	Proteasome/MDM2	1667	Other therapies	Other treatments					0	Disease progression/Relapse	3												0	0	0	0	2	35	0							1
MMRF_1629	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	189	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	189	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	206	Stem cell, Autologous	1	1	MOVED TO SCT				4	84	3	147		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	189	1	6	147	3	84	1	3	1
MMRF_1629	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	350	1707	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	1707	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	84	3	147		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	49	1358	0	6	147	3	84			1
MMRF_1629	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1721	2911	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1721	CD38/IMID/Steroid	2911	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	1833	4	1833	1721	Partial Response	PR	Partial Response	PR	1	1	1	1	43	1191	1	5	113	5	113	1	3	1
MMRF_1380	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	78	1	1815		Complete Response	CR	Partial Response	PR	1	0	1	0	4	105	1	65	1815	3	78	1	3	1
MMRF_1380	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	106	165	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	165	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					4	78	1	1815		Complete Response	CR	Partial Response	PR	1	0	0	0	2	60	0	65	1815	3	78			1
MMRF_1380	1	Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Pom-Cyc-Dex	Proteasome/Proteasome/IMID/IMID/Chemotherapy/Steroid	166	166	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Car-Len-Pom-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	166	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3			4	78	1	1815		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	65	1815	3	78			1
MMRF_1380	1	Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Bor-Car-Len-Pom-Dex	Proteasome/Proteasome/IMID/IMID/Steroid	167	386	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Car-Len-Pom-Cyc-Dex + Bor-Car-Len-Pom-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	386	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Completed regimen	4			4	78	1	1815		Complete Response	CR	Partial Response	PR	1	0	0	0	8	220	0	65	1815	3	78			1
MMRF_1380	1	Carfilzomib/Pomalidomide	Car-Pom	Proteasome/IMID	387	1251	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Carfilzomib/Pomalidomide	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Car-Len-Pom-Cyc-Dex + Bor-Car-Len-Pom-Dex + Car-Pom	1	Proteasome/IMID/Steroid/Chemotherapy	1251	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Investigator decision for other reasons	5			4	78	1	1815		Complete Response	CR	Partial Response	PR	1	0	0	0	31	865	0	65	1815	3	78			1
MMRF_1380	1	Pomalidomide	Pom	IMID	1252	2895	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone + Carfilzomib/Pomalidomide + Pomalidomide	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Car-Len-Pom-Cyc-Dex + Bor-Car-Len-Pom-Dex + Car-Pom	1	Proteasome/IMID/Steroid/Chemotherapy	2895	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0					4	78	1	1815		Complete Response	CR	Partial Response	PR	1	1	0	1	59	1644	0	65	1815	3	78			1
MMRF_1432	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	88	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	88	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	60	3	60	278	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	88	1	3	60	3	60	1	3	1
MMRF_1432	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	89	194	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	194	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Investigator decision for other reasons	5			3	60	3	60	278	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	106	0	3	60	3	60			1
MMRF_1432	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	195	400	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	400	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	PATIENT DIED				3	60	3	60	278	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	8	206	0	3	60	3	60			1
MMRF_1432	2	Pomalidomide/Melphalan	Pom-Mel	IMID/Chemotherapy	337	393	1	Pomalidomide/Melphalan	Pom-Mel	337	IMID/Chemotherapy	393	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Patient decision	6					6	348	348	Progressive Disease	PD			0	1	0	1	2	57	0	1	12			1	2	1
MMRF_1460	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	258	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	258	Bortezomib-based	Bortezomib-based	Bor-Dex				0	TREATMENT DISCONTINUED DUE TO PROGRESSION OF DEMENTIA				3	93	3	93		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	258	1	4	93	4	93	1	2	1
MMRF_1542	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	128	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	128	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Patient decision	6			4	156	3	254	485	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	128	0	10	254	6	156	1	3	1
MMRF_1542	1	Bortezomib	Bor	Proteasome	155	261	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Bor-Len-Dex + Bor	1	Proteasome/IMID/Steroid	261	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	156	3	254	485	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	107	1	10	254	6	156			1
MMRF_1542	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	262	437	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide	Bor-Len-Dex + Bor + Bor-Len	1	Proteasome/IMID/Steroid	437	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	156	3	254	485	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	176	0	10	254	6	156			1
MMRF_1542	1	Bortezomib	Bor	Proteasome	438	1137	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib + Bortezomib/Lenalidomide + Bortezomib	Bor-Len-Dex + Bor + Bor-Len + Bor	1	Proteasome/IMID/Steroid	1137	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	DEATH				4	156	3	254	485	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	25	700	0	10	254	6	156			1
MMRF_1542	2	Pomalidomide/Cyclophosphamide	Pom-Cyc	IMID/Chemotherapy	803	1137	1	Pomalidomide/Cyclophosphamide	Pom-Cyc	803	IMID/Chemotherapy	1137	IMIDs-based	IMIDs-based	Pom-Cyc				0	DEATH				3	597	3	597		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	335	0	-7	-205	-7	-205	1	2	1
MMRF_1646	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	23	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	23	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Patient decision	6												0	0	0	0	1	23	0					1	2	1
MMRF_1647	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	204	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	204	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5			4	78	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	204	1	7	169	3	78	1	2	1
MMRF_1647	1	Lenalidomide	Len	IMID	206	239	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	239	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	78	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	34	0	7	169	3	78			1
MMRF_1647	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	344	766	3	Bortezomib/Dexamethasone + Lenalidomide + Bortezomib/Dexamethasone	Bor-Dex + Len + Bor-Dex	1	Proteasome/Steroid/IMID	766	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Patient decision	6			4	78	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	15	423	0	7	169	3	78			1
MMRF_1778	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	0	1	0					1	2	1
MMRF_2058	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	191	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	191	IMIDs-based	IMIDs-based	Len-Dex				0	PATIENT REACHED VGPR				4	77	3	238		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	7	191	1	9	238	3	77	1	2	1
MMRF_2058	1	Lenalidomide	Len	IMID	192	2689	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	2689	IMIDs-based	IMIDs-based	Len-Dex				0					4	77	3	238		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	90	2498	0	9	238	3	77			1
MMRF_2079	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	64	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	64	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	65	4	65		Partial Response	PR	Partial Response	PR	1	1	1	1	3	64	1	3	65	3	65	1	3	1
MMRF_2079	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	65	157	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	157	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0					4	65	4	65		Partial Response	PR	Partial Response	PR	1	0	0	1	4	93	1	3	65	3	65			1
MMRF_2143	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	42	841	1	Lenalidomide/Dexamethasone	Len-Dex	42	IMID/Steroid	841	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH				4	104	3	168		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	29	800	1	5	127	3	63	1	2	1
MMRF_2204	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	147	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	147	IMIDs-based	IMIDs-based	Len-Dex				0	Patient decision	6					6	93	93	Progressive Disease	PD			0	1	0	1	6	147	0	4	93			1	2	1
MMRF_2204	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	232	374	1	Bortezomib/Dexamethasone	Bor-Dex	232	Proteasome/Steroid	374	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	361	457	Stable Disease	SD			0	1	0	1	5	143	0	5	130			1	2	1
MMRF_2204	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	375	394	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	232	Proteasome/Steroid/Chemotherapy	394	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3					5	361	457	Stable Disease	SD			0	0	0	0	1	20	0	5	130					1
MMRF_2362	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	35	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	35	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	99	3	99	1162	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	35	0	4	99	4	99	1	2	1
MMRF_2362	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	36	527	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	527	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			3	99	3	99	1162	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	18	492	1	4	99	4	99			1
MMRF_2362	2	Carfilzomib	Car	Proteasome	1585	1767	1	Carfilzomib	Car	1585	Proteasome	1767	Carfilzomib-based	Carfilzomib-based	Car-Dex				0					3	1639	3	1639		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	183	1	2	55	2	55	1	1	1
MMRF_2487	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	226	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	226	Bortezomib-based	Bortezomib-based	Bor-Dex	260	Stem cell, Autologous	1	1	BONE MARROW TRANSPLANTATION				4	93	3	848	1283	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	8	226	1	31	848	4	93	1	2	1
MMRF_2487	1	Bortezomib	Bor	Proteasome	435	897	2	Bortezomib/Dexamethasone + Bortezomib	Bor-Dex + Bor	1	Proteasome/Steroid	897	Bortezomib-based	Bortezomib-based	Bor-Dex				1					4	93	3	848	1283	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	17	463	0	31	848	4	93			1
MMRF_2487	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	898	2095	3	Bortezomib/Dexamethasone + Bortezomib + Bortezomib/Dexamethasone	Bor-Dex + Bor + Bor-Dex	1	Proteasome/Steroid	2095	Bortezomib-based	Bortezomib-based	Bor-Dex				1	Disease progression/Relapse	3			4	93	3	848	1283	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	43	1198	0	31	848	4	93			1
MMRF_2487	2	Carfilzomib/Daratumumab/Dexamethasone	Car-Dara-Dex	Proteasome/CD38/Steroid	2102	2536	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dara-Dex	2102	Proteasome/CD38/Steroid	2536	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					3	2200	3	2200		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	16	435	1	4	99	4	99	1	3	1
MMRF_2581	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	83	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	83	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5												0	0	0	0	3	83	0					1	2	1
MMRF_1504	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	158	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	158	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	84	3	172	950	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	158	1	7	172	3	84	1	3	1
MMRF_1504	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	159	178	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	178	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	84	3	172	950	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	1	20	0	7	172	3	84			1
MMRF_1504	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	179	262	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	262	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Patient decision	6			4	84	3	172	950	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	84	0	7	172	3	84			1
MMRF_1504	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	263	308	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	308	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	84	3	172	950	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	46	0	7	172	3	84			1
MMRF_1504	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	309	309	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	309	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Patient decision	6			4	84	3	172	950	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	7	172	3	84			1
MMRF_1504	1	Lenalidomide	Len	IMID	310	675	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	675	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Patient decision	6			4	84	3	172	950	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	13	366	0	7	172	3	84			1
MMRF_1504	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1082	2345	1	Lenalidomide/Dexamethasone	Len-Dex	1082	IMID/Steroid	2345	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1					5	1133		Stable Disease	SD			0	1	0	1	45	1264	0	2	52			1	2	1
MMRF_1504	3	Bortezomib	Bor	Proteasome	1345	2043	1	Bortezomib	Bor	1345	Proteasome	2043	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3					5	1429	1345	Stable Disease	SD			0	1	0	1	25	699	0	4	85			1	1	1
MMRF_1504	4	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2058	2424	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	2058	CD38/IMID/Steroid	2424	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	DEATH						6	2314	2314	Progressive Disease	PD			0	1	0	1	13	367	0	10	257			1	3	1
MMRF_1504	5	Elotuzumab/Pomalidomide	Elo-Pom	SLAMF7/IMID	2353	2386	1	Elotuzumab/Pomalidomide	Elo-Pom	2353	SLAMF7/IMID	2386	IMIDs-based	IMIDs-based	Other Pom-based therapies				0														0	0	0	0	2	34	0					1	2	1
MMRF_1504	5	Carfilzomib/Elotuzumab/Pomalidomide	Car-Elo-Pom	Proteasome/SLAMF7/IMID	2387	2415	2	Elotuzumab/Pomalidomide + Carfilzomib/Elotuzumab/Pomalidomide	Elo-Pom + Car-Elo-Pom	2353	SLAMF7/IMID/Proteasome	2415	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4												0	0	0	0	1	29	0							1
MMRF_1504	5	Elotuzumab/Pomalidomide	Elo-Pom	SLAMF7/IMID	2416	2424	3	Elotuzumab/Pomalidomide + Carfilzomib/Elotuzumab/Pomalidomide	Elo-Pom + Car-Elo-Pom	2353	SLAMF7/IMID/Proteasome	2424	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	DEATH													0	0	0	0	1	9	0							1
MMRF_2055	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	283	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	283	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			4	94	3	433		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	283	1	16	433	4	94	1	2	1
MMRF_2055	2	Lenalidomide	Len	IMID	811	905	1	Lenalidomide	Len	811	IMID	905	IMIDs-based	IMIDs-based	Len-Dex				0							5	899	813	Stable Disease	SD			0	1	0	1	4	95	0	4	89			1	1	1
MMRF_2055	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	906	1177	2	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Len + Bor-Len-Dex	811	IMID/Proteasome/Steroid	1177	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4					5	899	813	Stable Disease	SD			0	0	0	0	10	272	0	4	89					1
MMRF_2055	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1178	1662	3	Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Len + Bor-Len-Dex + Bor-Dex	811	IMID/Proteasome/Steroid	1662	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	DEATH						5	899	813	Stable Disease	SD			0	0	0	0	18	485	0	4	89					1
MMRF_2253	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	157	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	157	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	157	1	3	64	3	64	1	3	1
MMRF_2253	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	164	166	2	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Dexamethasone	Bor-Len-Dex + Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	166	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	166	Stem cell, Autologous	1	1	Completed regimen	4			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	3	0	3	64	3	64			1
MMRF_2253	1	Lenalidomide	Len	IMID	260	495	3	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Dexamethasone + Lenalidomide	Bor-Len-Dex + Mel-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	495	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	9	236	0	3	64	3	64			1
MMRF_2253	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	514	716	4	Bortezomib/Lenalidomide/Dexamethasone + Melphalan/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide	Bor-Len-Dex + Mel-Dex + Len + Bor-Len	1	Proteasome/IMID/Steroid/Chemotherapy	716	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	64	3	64		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	8	203	0	3	64	3	64			1
MMRF_2253	2	Carfilzomib/Pomalidomide	Car-Pom	Proteasome/IMID	716	744	1	Carfilzomib/Pomalidomide	Car-Pom	716	Proteasome/IMID	744	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	DEATH						6	716	716	Progressive Disease	PD			0	1	0	1	1	29	0	1	1			1	2	1
MMRF_1349	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	512	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	512	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			4	53	3	260	772	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	19	512	1	10	260	2	53	1	2	1
MMRF_1332	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	167	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	167	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	201	Stem cell, Autologous	1	1	Completed regimen	4			3	74	1	310		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	6	167	1	12	310	3	74	1	3	1
MMRF_1332	1	Lenalidomide	Len	IMID	310	704	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	704	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	74	1	310		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	1	14	395	0	12	310	3	74			1
MMRF_1365	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	30	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	30	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	DOSE CHANGE													0	0	0	0	1	30	0					1	3	1
MMRF_1365	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	60	375	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide	Bor-Cyc-Dex + Bor-Cyc	1	Proteasome/Chemotherapy/Steroid	375	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	307	Stem cell, Autologous	1	1														0	0	0	0	12	316	0							1
MMRF_1425	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1260	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1260	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DEATH				3	94	3	94		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	45	1260	1	4	94	4	94	1	2	1
MMRF_1451	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	146	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	146	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	91	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	146	1	5	113	4	91	1	2	1
MMRF_1451	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	147	154	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	154	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DEATH				4	91	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	8	0	5	113	4	91			1
MMRF_1501	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	83	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	83	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	94	3	94	370	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	83	0	4	94	4	94	1	2	1
MMRF_1501	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	84	375	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	375	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1			3	94	3	94	370	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	292	1	4	94	4	94			1
MMRF_1501	2	Pomalidomide	Pom	IMID	375	504	1	Pomalidomide	Pom	375	IMID	504	IMIDs-based	IMIDs-based	Pom-Dex				0	Lack of response	1												0	0	0	0	5	130	0					1	1	1
MMRF_1501	2	Lenalidomide	Len	IMID	376	671	2	Pomalidomide + Lenalidomide	Pom + Len	375	IMID	671	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Lack of response	1												0	0	0	0	11	296	0							1
MMRF_1501	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	504	606	1	Carfilzomib/Dexamethasone	Car-Dex	504	Proteasome/Steroid	606	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1					6	448	448	Progressive Disease	PD			0	0	0	0	4	103	0	-1	-55			1	2	1
MMRF_1501	3	Carfilzomib	Car	Proteasome	607	734	2	Carfilzomib/Dexamethasone + Carfilzomib	Car-Dex + Car	504	Proteasome/Steroid	734	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1					6	448	448	Progressive Disease	PD			0	0	0	0	5	128	0	-1	-55					1
MMRF_1525	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	26	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	26	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	90	3	90	979	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	26	0	4	90	4	90	1	2	1
MMRF_1525	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	27	273	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	273	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	90	3	90	979	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	247	1	4	90	4	90			1
MMRF_1525	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	274	888	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	888	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					3	90	3	90	979	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	615	0	4	90	4	90			1
MMRF_1525	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	889	1421	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	1421	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	90	3	90	979	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	19	533	0	4	90	4	90			1
MMRF_1525	2	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	1421	1568	1	Ixazomib/Lenalidomide	Ixa-Len	1421	Proteasome/IMID	1568	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Lack of response	1					6	1442	1442	Progressive Disease	PD			0	1	0	1	6	148	0	1	22			1	2	1
MMRF_1525	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1422	1568	2	Ixazomib/Lenalidomide + Bortezomib/Dexamethasone	Ixa-Len + Bor-Dex	1421	Proteasome/IMID/Steroid	1568	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1					6	1442	1442	Progressive Disease	PD			0	0	0	1	6	147	0	1	22					1
MMRF_1525	3	Carfilzomib	Car	Proteasome	1589	1773	1	Carfilzomib	Car	1589	Proteasome	1773	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Lack of response	1			4	1645	3	1870	1589	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	7	185	1	11	282	3	57	1	1	1
MMRF_1525	3	Pomalidomide	Pom	IMID	1840	2598	2	Carfilzomib + Pomalidomide	Car + Pom	1589	Proteasome/IMID	2598	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	1645	3	1870	1589	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	27	759	0	11	282	3	57			1
MMRF_1519	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	80	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	80	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	174	4	174		Partial Response	PR	Partial Response	PR	1	0	0	0	3	80	0	7	174	7	174	1	2	1
MMRF_1519	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	81	195	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	195	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	174	4	174		Partial Response	PR	Partial Response	PR	1	1	1	1	4	115	1	7	174	7	174			1
MMRF_1519	1	Lenalidomide	Len	IMID	196	391	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	391	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	174	4	174		Partial Response	PR	Partial Response	PR	1	0	0	0	7	196	0	7	174	7	174			1
MMRF_1519	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	265	647	1	Bortezomib/Dexamethasone	Bor-Dex	265	Proteasome/Steroid	647	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PATIENT DEATH				3	361	3	361	279	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	383	1	4	97	4	97	1	2	1
MMRF_1627	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	97	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	97	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5			3	97	1	251	581	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	97	1	9	251	4	97	1	2	1
MMRF_1627	1	Lenalidomide	Len	IMID	103	130	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	130	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					3	97	1	251	581	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	28	0	9	251	4	97			1
MMRF_1627	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	131	160	3	Bortezomib/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Dex + Len + Len-Dex	1	Proteasome/Steroid/IMID	160	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	97	1	251	581	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	30	0	9	251	4	97			1
MMRF_1627	1	Lenalidomide	Len	IMID	161	251	4	Bortezomib/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Len + Len-Dex + Len	1	Proteasome/Steroid/IMID	251	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			3	97	1	251	581	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	4	91	0	9	251	4	97			1
MMRF_1627	2	Lenalidomide	Len	IMID	644	742	1	Lenalidomide	Len	644	IMID	742	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	1080	3	1080	707	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	99	1	16	437	16	437	1	1	1
MMRF_1627	3	Lenalidomide	Len	IMID	1325	1472	1	Lenalidomide	Len	1325	IMID	1472	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					6	1472	1472	Progressive Disease	PD			0	1	0	1	6	148	0	6	148			1	1	1
MMRF_1627	4	Bortezomib	Bor	Proteasome	1526	1568	1	Bortezomib	Bor	1526	Proteasome	1568	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PATIENT DECEASED AFTER THIS LAST DATE OF TREATMENT						6	1526	1526	Progressive Disease	PD			0	1	0	1	2	43	0	1	1			1	1	1
MMRF_1633	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	247	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	247	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	98	3	98		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	247	1	4	98	4	98	1	2	1
MMRF_1639	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	105	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	105	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	84	4	84		Partial Response	PR	Partial Response	PR	1	1	1	1	4	105	1	3	84	3	84	1	2	1
MMRF_1639	1	Lenalidomide	Len	IMID	140	575	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	575	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	84	4	84		Partial Response	PR	Partial Response	PR	1	0	0	0	16	436	0	3	84	3	84			1
MMRF_1639	2	Pomalidomide	Pom	IMID	520	656	1	Pomalidomide	Pom	520	IMID	656	IMIDs-based	IMIDs-based	Pom-Dex				0							6	531	531	Progressive Disease	PD			0	1	0	1	5	137	0	1	12			1	1	1
MMRF_1639	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	657	679	2	Pomalidomide + Carfilzomib/Pomalidomide/Dexamethasone	Pom + Car-Pom-Dex	520	IMID/Proteasome/Steroid	679	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Lack of response	1					6	531	531	Progressive Disease	PD			0	0	0	0	1	23	0	1	12					1
MMRF_1645	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	91	3	91	370	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	117	1	4	91	4	91	1	3	1
MMRF_1645	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	180	439	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	439	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex	440	Stem cell, Autologous	1	1	STEM CELL TRANSPLANT				3	91	3	91	370	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	10	260	0	4	91	4	91			1
MMRF_1645	2	Lenalidomide	Len	IMID	540	1639	1	Lenalidomide	Len	540	IMID	1639	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			3	702	3	702		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	40	1100	1	6	163	6	163	1	1	1
MMRF_1651	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	119	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	119	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	71	3	71	606	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	119	1	3	71	3	71	1	3	1
MMRF_1651	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	120	120	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	120	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	71	3	71	606	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	71	3	71			1
MMRF_1651	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	121	633	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	633	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	71	3	71	606	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	19	513	0	3	71	3	71			1
MMRF_1650	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	36	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	36	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			3	180	3	180	458	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	36	0	7	180	7	180	1	2	1
MMRF_1650	1	Lenalidomide	Len	IMID	106	486	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	486	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	180	3	180	458	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	381	1	7	180	7	180			1
MMRF_1650	2	Lenalidomide	Len	IMID	487	651	1	Lenalidomide	Len	487	IMID	651	IMIDs-based	IMIDs-based	Len-Dex				0							5	561	631	Stable Disease	SD			0	1	0	1	6	165	0	3	75			1	1	1
MMRF_1650	2	Lenalidomide/Pomalidomide/Dexamethasone	Len-Pom-Dex	IMID/IMID/Steroid	652	659	2	Lenalidomide + Lenalidomide/Pomalidomide/Dexamethasone	Len + Len-Pom-Dex	487	IMID/Steroid	659	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2					5	561	631	Stable Disease	SD			0	0	0	0	1	8	0	3	75					1
MMRF_1650	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	660	997	3	Lenalidomide + Lenalidomide/Pomalidomide/Dexamethasone	Len + Len-Pom-Dex	487	IMID/Steroid	997	IMIDs-based	IMIDs-based	Other Len-based therapies				0	HOSPICE						5	561	631	Stable Disease	SD			0	0	0	0	12	338	0	3	75					1
MMRF_1672	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	3	71	3	71	1	3	1
MMRF_1672	1	Lenalidomide	Len	IMID	154	2837	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2837	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	96	2684	0	3	71	3	71			1
MMRF_1693	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	144	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	144	Bortezomib-based	Bortezomib-based	Bor-Dex				1					3	83	3	83	2140	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	144	1	3	83	3	83	1	2	1
MMRF_1693	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	145	166	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	166	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	258	Stem cell, Autologous	1	1	Completed regimen	4			3	83	3	83	2140	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	22	0	3	83	3	83			1
MMRF_1693	1	Lenalidomide	Len	IMID	532	2360	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	2360	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	83	3	83	2140	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	66	1829	0	3	83	3	83			1
MMRF_1693	2	Elotuzumab	Elo	SLAMF7	2182	2324	1	Elotuzumab	Elo	2182	SLAMF7	2324	Other therapies	Other treatments		2515	Stem cell, Autologous	2	1	Completed regimen	4			3	2557	3	2557		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	143	1	14	376	14	376			1
MMRF_1780	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	181	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	181	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	77	3	77		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	181	1	3	77	3	77	1	2	1
MMRF_1780	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	182	259	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	259	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	77	3	77		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	78	0	3	77	3	77			1
MMRF_1780	1	Lenalidomide	Len	IMID	260	629	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	629	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	77	3	77		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	14	370	0	3	77	3	77			1
MMRF_1780	2	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	552	629	1	Bortezomib/Lenalidomide	Bor-Len	552	Proteasome/IMID	629	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3					6	552	552	Progressive Disease	PD			0	1	0	1	3	78	0	1	1			1	2	1
MMRF_1780	3	Carfilzomib	Car	Proteasome	629	644	1	Carfilzomib	Car	629	Proteasome	644	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Completed regimen	4					6	714	714	Progressive Disease	PD			0	0	0	0	1	16	0	4	86			1	1	1
MMRF_1780	3	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	673	687	2	Carfilzomib + Bortezomib/Cyclophosphamide	Car + Bor-Cyc	629	Proteasome/Chemotherapy	687	combined bortezomib/carfilzomib-based	Bortezomib-based	Bor-Car-Cyc				0	Completed regimen	4					6	714	714	Progressive Disease	PD			0	1	0	1	1	15	0	4	86					1
MMRF_1897	1	Bortezomib	Bor	Proteasome	1	24	1	Bortezomib	Bor	1	Proteasome	24	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	1	24	0					1	1	1
MMRF_1897	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	25	26	2	Bortezomib + Bortezomib/Dexamethasone	Bor + Bor-Dex	1	Proteasome/Steroid	26	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4												0	0	0	0	0	2	0							1
MMRF_1922	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	169	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	169	Bortezomib-based	Bortezomib-based	Bor-Dex	236	Stem cell, Autologous	1	1	Completed regimen	4			3	180	3	180		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	169	1	7	180	7	180	1	2	1
MMRF_1922	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	169	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	169	Bortezomib-based	Bortezomib-based	Bor-Dex	265	Stem cell, Autologous	2	1	Completed regimen	4			3	180	3	180		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	6	169	1	7	180	7	180			1
MMRF_1922	1	Lenalidomide	Len	IMID	341	1323	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	1323	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	180	3	180		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	35	983	0	7	180	7	180			1
MMRF_1922	1	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1468	2077	3	Bortezomib/Dexamethasone + Lenalidomide + Daratumumab/Dexamethasone	Bor-Dex + Len + Dar-Dex	1	Proteasome/Steroid/IMID/CD38	2077	combined bortezomib/IMIDs-based	daratumumab-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	180	3	180		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	22	610	0	7	180	7	180			1
MMRF_1922	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2078	2904	4	Bortezomib/Dexamethasone + Lenalidomide + Daratumumab/Dexamethasone + Daratumumab/Pomalidomide/Dexamethasone	Bor-Dex + Len + Dar-Dex + Dar-Pom-Dex	1	Proteasome/Steroid/IMID/CD38	2904	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	180	3	180		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	30	827	0	7	180	7	180			1
MMRF_1945	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	59	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	59	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	2	59	0					1	2	1
MMRF_1994	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	147	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	147	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	78	174	Stable Disease	SD			0	1	0	1	6	147	0	3	78			1	2	1
MMRF_1994	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	148	207	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	207	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2					5	78	174	Stable Disease	SD			0	0	0	0	2	60	0	3	78					1
MMRF_1994	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	208	272	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	272	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	LACK OF RESPONSE AND HOSPICE						5	78	174	Stable Disease	SD			0	0	0	0	3	65	0	3	78					1
MMRF_2160	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	59	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	59	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	2	59	0					1	2	1
MMRF_2160	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	60	71	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	71	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Patient decision	6												0	0	0	0	1	12	0							1
MMRF_2160	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	72	79	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	79	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Disease progression/Relapse	3												0	0	0	0	1	8	0							1
MMRF_2478	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	601	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	601	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	90	4	90		Partial Response	PR	Partial Response	PR	1	1	1	1	22	601	1	4	90	4	90	1	3	1
MMRF_2478	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	174	855	1	Bortezomib/Dexamethasone	Bor-Dex	174	Proteasome/Steroid	855	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			4	601	4	601	174	Partial Response	PR	Partial Response	PR	1	1	1	1	25	682	1	16	428	16	428	1	2	1
MMRF_2478	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	847	910	1	Daratumumab/Pomalidomide	Dar-Pom	847	CD38/IMID	910	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Investigator decision for other reasons	5			4	1077	3	1490		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	64	0	23	644	9	231	1	2	1
MMRF_2478	3	Pomalidomide	Pom	IMID	911	938	2	Daratumumab/Pomalidomide	Dar-Pom	847	CD38/IMID	938	combined daratumumab/IMIDs-based	IMIDs-based	Dar-Pom				0	Investigator decision for other reasons	5			4	1077	3	1490		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	28	0	23	644	9	231			1
MMRF_2478	3	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	1035	2577	3	Daratumumab/Pomalidomide + Elotuzumab/Lenalidomide	Dar-Pom + Elo-Len	847	CD38/IMID/SLAMF7	2577	combined daratumumab/IMIDs-based	IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Adverse Event or co-morbidity	2			4	1077	3	1490		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	55	1543	1	23	644	9	231			1
MMRF_2505	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	73	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	73	IMIDs-based	IMIDs-based	Len-Dex				0					4	104	3	262	703	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	73	0	10	262	4	104	1	2	1
MMRF_2505	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	74	443	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	443	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	104	3	262	703	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	370	1	10	262	4	104			1
MMRF_2505	1	Bortezomib	Bor	Proteasome	444	808	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib	Len-Dex + Bor-Len-Dex + Bor	1	IMID/Steroid/Proteasome	808	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Disease progression/Relapse	3			4	104	3	262	703	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	13	365	0	10	262	4	104			1
MMRF_2505	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	850	865	1	Carfilzomib/Dexamethasone	Car-Dex	850	Proteasome/Steroid	865	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2												0	0	0	0	1	16	0					1	2	1
MMRF_2504	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	53	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	53	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	74	3	74		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	53	0	3	74	3	74	1	3	1
MMRF_2504	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	54	68	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	68	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			3	74	3	74		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	15	0	3	74	3	74			1
MMRF_2504	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	69	101	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	101	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1					3	74	3	74		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	33	1	3	74	3	74			1
MMRF_2504	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	102	118	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	118	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			3	74	3	74		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	17	0	3	74	3	74			1
MMRF_2504	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	119	185	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	185	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	201	Stem cell, Autologous	1	1	Completed regimen	4			3	74	3	74		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	67	0	3	74	3	74			1
MMRF_2523	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	23	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	23	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	66	3	66	584	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	23	0	3	66	3	66	1	2	1
MMRF_2523	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	24	641	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	641	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	66	3	66	584	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	22	618	1	3	66	3	66			1
MMRF_2523	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	642	661	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	1	Proteasome/Steroid/IMID	661	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	66	3	66	584	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	20	0	3	66	3	66			1
MMRF_2589	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	327	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	327	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	376	Stem cell, Autologous	1	1	PREPARE FOR BLOODESS TRANSPLANT				4	152	3	617		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	12	327	1	23	617	6	152	1	3	1
MMRF_2589	1	Lenalidomide	Len	IMID	519	712	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	712	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	PNEUMONIA				4	152	3	617		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	7	194	0	23	617	6	152			1
MMRF_2589	2	Lenalidomide	Len	IMID	766	911	1	Lenalidomide	Len	766	IMID	911	IMIDs-based	IMIDs-based	Len-Dex				0	PATIENT DECEASED						6	794	794	Progressive Disease	PD			0	1	0	1	6	146	0	2	29			1	1	1
MMRF_1607	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	203	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	203	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	203	Stem cell, Autologous	1	1	Completed regimen	4			4	99	3	357		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	203	1	13	357	4	99	1	3	1
MMRF_1605	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	522	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	522	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	252	Stem cell, Autologous	1	1					4	47	3	242		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	19	522	1	9	242	2	47	1	3	1
MMRF_1605	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	523	525	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	525	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex				1	Completed regimen	4			4	47	3	242		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	3	0	9	242	2	47			1
MMRF_1605	1	Carfilzomib	Car	Proteasome	526	578	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib	Bor-Len-Dex + Bor-Car-Len-Dex + Car	1	Proteasome/IMID/Steroid	578	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Dex				1					4	47	3	242		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	53	0	9	242	2	47			1
MMRF_1605	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	579	1636	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex + Car + Car-Len-Dex	1	Proteasome/IMID/Steroid	1636	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Dex				1	DECISION BY ONCOLOGY PHARMACIST				4	47	3	242		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	38	1058	0	9	242	2	47			1
MMRF_1605	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1637	2918	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex + Car + Car-Len-Dex	1	Proteasome/IMID/Steroid	2918	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Dex				1					4	47	3	242		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	46	1282	0	9	242	2	47			1
MMRF_1939	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	295	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	295	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Patient decision	6			3	73	3	73		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	295	1	3	73	3	73	1	3	1
MMRF_2035	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	86	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	86	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	86	3	86		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	86	1	4	86	4	86	1	2	1
MMRF_2493	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	16	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	16	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	105	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	16	0	7	175	4	105	1	2	1
MMRF_2493	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	36	481	2	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Len-Dex + Bor-Dex	1	IMID/Steroid/Proteasome	481	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	105	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	16	446	1	7	175	4	105			1
MMRF_2493	1	Bortezomib/Ixazomib/Dexamethasone	Bor-Ixa-Dex	Proteasome/Proteasome/Steroid	482	573	3	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone	Len-Dex + Bor-Dex + Bor-Ixa-Dex	1	IMID/Steroid/Proteasome	573	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1			4	105	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	92	0	7	175	4	105			1
MMRF_2493	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	574	586	4	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone + Bortezomib/Dexamethasone	Len-Dex + Bor-Dex + Bor-Ixa-Dex + Bor-Dex	1	IMID/Steroid/Proteasome	586	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	105	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	13	0	7	175	4	105			1
MMRF_2493	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	587	982	5	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone	Len-Dex + Bor-Dex + Bor-Ixa-Dex + Bor-Dex + Bor-Dar-Dex	1	IMID/Steroid/Proteasome/CD38	982	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	105	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	14	396	0	7	175	4	105			1
MMRF_2493	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	983	2381	6	Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Ixazomib/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Daratumumab/Dexamethasone + Bortezomib/Dexamethasone	Len-Dex + Bor-Dex + Bor-Ixa-Dex + Bor-Dex + Bor-Dar-Dex + Bor-Dex	1	IMID/Steroid/Proteasome/CD38	2381	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	105	3	175		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	50	1399	0	7	175	4	105			1
MMRF_1470	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	59	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	59	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	347	3	347	964	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	59	0	13	347	13	347	1	2	1
MMRF_1470	1	Lenalidomide	Len	IMID	60	184	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	184	IMIDs-based	IMIDs-based	Len-Dex				0					3	347	3	347	964	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	125	0	13	347	13	347			1
MMRF_1470	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	185	611	3	Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Len-Dex + Len + Len-Dex	1	IMID/Steroid	611	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	347	3	347	964	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	16	427	1	13	347	13	347			1
MMRF_1820	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	106	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	85	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	106	1	11	295	4	85	1	3	1
MMRF_1820	1	Carfilzomib	Car	Proteasome	164	190	2	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib	Bor-Len-Dex + Car	1	Proteasome/IMID/Steroid	190	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Dex				1					4	85	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	27	0	11	295	4	85			1
MMRF_1820	1	Carfilzomib/Melphalan/Bendamustine	Car-Mel-Bend	Proteasome/Chemotherapy/Chemotherapy	191	192	3	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib + Carfilzomib/Melphalan/Bendamustine	Bor-Len-Dex + Car + Car-Mel-Bend	1	Proteasome/IMID/Steroid/Chemotherapy	192	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			4	85	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	2	0	11	295	4	85			1
MMRF_1820	1	Carfilzomib	Car	Proteasome	193	209	4	Bortezomib/Lenalidomide/Dexamethasone + Carfilzomib + Carfilzomib/Melphalan/Bendamustine + Carfilzomib	Bor-Len-Dex + Car + Car-Mel-Bend + Car	1	Proteasome/IMID/Steroid/Chemotherapy	209	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or	193	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	1	17	0	11	295	4	85			1
MMRF_2115	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	21	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	21	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	PATIENT DIED OF NON DISEASE RELATED CAUSES													0	0	0	0	1	21	0					1	3	1
MMRF_2269	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	119	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	119	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4	2495		3	43	3	43	1355	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	119	1	2	43	2	43	1	3	1
MMRF_2269	1	Lenalidomide	Len	IMID	134	1355	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1355	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3	2495		3	43	3	43	1355	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	44	1222	0	2	43	2	43			1
MMRF_2269	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1369	1754	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1369	Proteasome/IMID/Steroid	1754	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3	2495											0	0	0	0	14	386	0					1	3	1
MMRF_2269	3	Daratumumab	Dar	CD38	1760	1844	1	Daratumumab	Dar	1760	CD38	1844	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3	2495											0	0	0	0	3	85	0							1
MMRF_2269	4	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1858	2138	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1858	CD38/IMID/Steroid	2138	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2495				6	2138	2138	Progressive Disease	PD			0	1	0	1	10	281	0	11	281			1	3	1
MMRF_2269	5	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	2159	2495	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	2159	Proteasome/IMID/Steroid	2495	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2	2495				6	2495	2495	Progressive Disease	PD			0	1	0	1	12	337	0	13	337			1	3	1
MMRF_2269	9	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	2495	2523	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	2495	Proteasome/IMID/Steroid	2523	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0			2495											0	0	0	0	1	29	0					1	3	1
MMRF_2026	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	154	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	154	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	612	4	612	917	Partial Response	PR	Partial Response	PR	1	0	0	0	6	154	0	22	612	22	612	1	3	1
MMRF_2026	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	155	917	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	917	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Disease progression/Relapse	3			4	612	4	612	917	Partial Response	PR	Partial Response	PR	1	1	1	1	28	763	1	22	612	22	612			1
MMRF_2026	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	918	938	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	938	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	Patient decision	6			4	612	4	612	917	Partial Response	PR	Partial Response	PR	1	0	0	0	1	21	0	22	612	22	612			1
MMRF_2026	2	Pomalidomide	Pom	IMID	918	938	1	Pomalidomide	Pom	918	IMID	938	IMIDs-based	IMIDs-based	Pom-Dex				0	Patient decision	6					6	1012	1012	Progressive Disease	PD			0	0	0	0	1	21	0	4	95			1	1	1
MMRF_2436	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	26	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	26	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	105	1	510	2127	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	26	0	19	510	4	105	1	2	1
MMRF_2436	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	27	215	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	215	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	105	1	510	2127	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	7	189	1	19	510	4	105			1
MMRF_2436	1	Lenalidomide	Len	IMID	259	2372	3	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Cyc-Dex + Len	1	Proteasome/Steroid/Chemotherapy/IMID	2372	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	105	1	510	2127	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	76	2114	0	19	510	4	105			1
MMRF_1486	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	112	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	112	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	260	4	260		Partial Response	PR	Partial Response	PR	1	0	0	0	4	112	0	10	260	10	260	1	2	1
MMRF_1486	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	113	437	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	437	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	PATIENT DECEASED				4	260	4	260		Partial Response	PR	Partial Response	PR	1	1	1	1	12	325	1	10	260	10	260			1
MMRF_1671	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	394	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	394	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5	1520				6	71	71	Progressive Disease	PD			0	1	0	1	14	394	0	3	71			1	3	1
MMRF_1671	2	Lenalidomide	Len	IMID	141	407	1	Lenalidomide	Len	141	IMID	407	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5	1520		4	239	4	239	316	Partial Response	PR	Partial Response	PR	1	1	1	1	10	267	1	4	99	4	99	1	1	1
MMRF_1671	3	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	449	547	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	449	Proteasome/IMID/Chemotherapy/Steroid	547	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4	1520				5	505	792	Stable Disease	SD			0	1	0	1	4	99	0	3	57			1	4	1
MMRF_1671	3	Lenalidomide	Len	IMID	548	903	2	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Len-Cyc-Dex + Len	449	Proteasome/IMID/Chemotherapy/Steroid	903	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE		1520				5	505	792	Stable Disease	SD			0	0	0	0	13	356	0	3	57					1
MMRF_1671	4	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	877	903	1	Carfilzomib/Dexamethasone	Car-Dex	877	Proteasome/Steroid	903	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE		1520				5	960	1044	Stable Disease	SD			0	0	0	0	1	27	0	3	84			1	2	1
MMRF_1671	4	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	904	1227	2	Carfilzomib/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Car-Dex + Car-Pom-Dex	877	Proteasome/Steroid/IMID	1227	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2	1520				5	960	1044	Stable Disease	SD			0	1	0	1	12	324	0	3	84					1
MMRF_1671	5	Carfilzomib	Car	Proteasome	1129	1155	1	Carfilzomib	Car	1129	Proteasome	1155	Carfilzomib-based	Carfilzomib-based	Car-Dex				0			1520		4	1608	4	1608	1520	Partial Response	PR	Partial Response	PR	1	0	0	0	1	27	0	18	480	18	480	1	1	1
MMRF_1671	5	Carfilzomib/Cyclophosphamide	Car-Cyc	Proteasome/Chemotherapy	1156	1227	2	Carfilzomib + Carfilzomib/Cyclophosphamide	Car + Car-Cyc	1129	Proteasome/Chemotherapy	1227	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2	1520		4	1608	4	1608	1520	Partial Response	PR	Partial Response	PR	1	0	0	0	3	72	0	18	480	18	480			1
MMRF_1671	5	Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car-Pom-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	1303	1507	3	Carfilzomib + Carfilzomib/Cyclophosphamide + Carfilzomib/Pomalidomide/Cyclophosphamide/Dexamethasone	Car + Car-Cyc + Car-Pom-Cyc-Dex	1129	Proteasome/Chemotherapy/IMID/Steroid	1507	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3	1520		4	1608	4	1608	1520	Partial Response	PR	Partial Response	PR	1	0	0	0	8	205	0	18	480	18	480			1
MMRF_1671	9	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1527	1835	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1527	CD38/IMID/Steroid	1835	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	1520											0	0	0	0	11	309	0					1	3	1
MMRF_1671	9	CAR-T Cells(Undefined)	CAR-T		1977	1978	2	Daratumumab/Pomalidomide/Dexamethasone + CAR-T Cells(Undefined)	Dar-Pom-Dex + CAR-T	1527	CD38/IMID/Steroid	1978	combined daratumumab/IMIDs-based	Other treatments	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Completed regimen	4	1520											0	0	0	0	0	2	0							1
MMRF_1671	9	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	2161	2224	3	Daratumumab/Pomalidomide/Dexamethasone + CAR-T Cells(Undefined) + Elotuzumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex + CAR-T + Elo-Pom-Dex	1527	CD38/IMID/Steroid/SLAMF7	2224	combined daratumumab/IMIDs-based	IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0	Disease progression/Relapse	3	1520											0	0	0	0	3	64	0							1
MMRF_1671	9	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	2252	2314	4	Daratumumab/Pomalidomide/Dexamethasone + CAR-T Cells(Undefined) + Elotuzumab/Pomalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Dar-Pom-Dex + CAR-T + Elo-Pom-Dex + Bor-Len-Dex	1527	CD38/IMID/Steroid/SLAMF7/Proteasome	2314	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Lack of response	1	1520											0	0	0	0	3	63	0							1
MMRF_1671	9	Selinexor/Dexamethasone	Sel-Dex	XPO1/Steroid	2320	2335	5	Daratumumab/Pomalidomide/Dexamethasone + CAR-T Cells(Undefined) + Elotuzumab/Pomalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Selinexor/Dexamethasone	Dar-Pom-Dex + CAR-T + Elo-Pom-Dex + Bor-Len-Dex + Sel-Dex	1527	CD38/IMID/Steroid/SLAMF7/Proteasome/XPO1	2335	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2	1520											0	0	0	0	1	16	0							1
MMRF_1671	9	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	2351	2452	6	Daratumumab/Pomalidomide/Dexamethasone + CAR-T Cells(Undefined) + Elotuzumab/Pomalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Selinexor/Dexamethasone + Melphalan/Prednisone	Dar-Pom-Dex + CAR-T + Elo-Pom-Dex + Bor-Len-Dex + Sel-Dex + Mel-Pred	1527	CD38/IMID/Steroid/SLAMF7/Proteasome/XPO1/Chemotherapy	2452	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Patient decision	6	1520											0	0	0	0	4	102	0							1
MMRF_1720	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	38	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	38	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	2	38	0					1	2	1
MMRF_1912	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	204	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	204	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	92	4	92	204	Partial Response	PR	Partial Response	PR	1	1	1	1	8	204	1	4	92	4	92	1	3	1
MMRF_1912	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	211	341	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	211	Proteasome/Chemotherapy/Steroid	341	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3					6	353	353	Progressive Disease	PD			0	1	0	1	5	131	0	6	143			1	3	1
MMRF_1505	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	1	35	1	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	35	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	85	4	85	162	Partial Response	PR	Partial Response	PR	1	0	0	0	2	35	0	4	85	4	85	1	2	1
MMRF_1505	1	Bortezomib/Lenalidomide/Cyclophosphamide	Bor-Len-Cyc	Proteasome/IMID/Chemotherapy	36	127	2	Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Cyclophosphamide	Bor-Len + Bor-Len-Cyc	1	Proteasome/IMID/Chemotherapy	127	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc				0	Completed regimen	4			4	85	4	85	162	Partial Response	PR	Partial Response	PR	1	1	1	1	4	92	1	4	85	4	85			1
MMRF_1505	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	128	162	3	Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Cyclophosphamide + Bortezomib/Lenalidomide	Bor-Len + Bor-Len-Cyc + Bor-Len	1	Proteasome/IMID/Chemotherapy	162	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc				0					4	85	4	85	162	Partial Response	PR	Partial Response	PR	1	0	0	0	2	35	0	4	85	4	85			1
MMRF_1782	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	113	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	113	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	113	1	176	562	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	113	1	7	176	5	113	1	3	1
MMRF_1782	2	Lenalidomide	Len	IMID	574	726	1	Lenalidomide	Len	574	IMID	726	IMIDs-based	IMIDs-based	Len-Dex				0					4	744	3	835		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	153	0	10	262	7	171	1	1	1
MMRF_1782	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	727	727	2	Lenalidomide + Lenalidomide/Dexamethasone	Len + Len-Dex	574	IMID/Steroid	727	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	744	3	835		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	0	1	1	10	262	7	171			1
MMRF_1944	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	84	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	84	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH													0	0	0	0	3	84	0					1	3	1
MMRF_2203	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	144	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	144	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	87	3	87		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	144	1	4	87	4	87	1	3	1
MMRF_1533	1	Bortezomib/Methylprednisolone	Bor-Mep	Proteasome/Steroid	1	685	1	Bortezomib/Methylprednisolone	Bor-Mep	1	Proteasome/Steroid	685	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	189	Stem cell, Autologous	1	1					4	70	3	245	511	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	25	685	1	9	245	3	70	1	2	1
MMRF_1533	2	Pomalidomide	Pom	IMID	581	685	1	Pomalidomide	Pom	581	IMID	685	IMIDs-based	IMIDs-based	Pom-Dex				0														0	0	0	0	4	105	0					1	1	1
MMRF_1580	1	Bortezomib/Prednisone	Bor-Pred	Proteasome/Steroid	1	70	1	Bortezomib/Prednisone	Bor-Pred	1	Proteasome/Steroid	70	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Adverse Event or co-morbidity	2			4	81	4	81		Partial Response	PR	Partial Response	PR	1	0	0	0	3	70	0	3	81	3	81	1	2	1
MMRF_1580	1	Bortezomib	Bor	Proteasome	71	81	2	Bortezomib/Prednisone + Bortezomib	Bor-Pred + Bor	1	Proteasome/Steroid	81	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0					4	81	4	81		Partial Response	PR	Partial Response	PR	1	1	1	1	1	11	1	3	81	3	81			1
MMRF_2113	1	Lenalidomide/Methylprednisolone	Len-Mep	IMID/Steroid	1	122	1	Lenalidomide/Methylprednisolone	Len-Mep	1	IMID/Steroid	122	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	91	3	151		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	122	1	6	151	4	91	1	2	1
MMRF_2113	1	Bortezomib/Lenalidomide/Methylprednisolone	Bor-Len-Mep	Proteasome/IMID/Steroid	123	151	2	Lenalidomide/Methylprednisolone + Bortezomib/Lenalidomide/Methylprednisolone	Len-Mep + Bor-Len-Mep	1	IMID/Steroid/Proteasome	151	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	91	3	151		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	1	29	0	6	151	4	91			1
MMRF_1499	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1	1232	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1	SLAMF7/IMID/Steroid	1232	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	112	3	351	1232	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	44	1232	1	13	351	4	112	1	3	1
MMRF_1499	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1254	1308	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1254	CD38/IMID/Steroid	1308	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3					6	1295	1295	Progressive Disease	PD			0	1	0	1	2	55	0	2	42			1	3	1
MMRF_1499	3	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1309	1778	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1309	Proteasome/Chemotherapy/Steroid	1778	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					4	1441	4	1441		Partial Response	PR	Partial Response	PR	1	1	1	1	17	470	1	5	133	5	133	1	3	1
MMRF_1512	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	84	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	84	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	176	1	818	1364	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	30	818	7	176	1	3	1
MMRF_1512	1	Bortezomib	Bor	Proteasome	85	118	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	118	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	176	1	818	1364	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	34	0	30	818	7	176			1
MMRF_1512	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	119	125	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	125	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	176	1	818	1364	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	7	0	30	818	7	176			1
MMRF_1512	1	Bortezomib	Bor	Proteasome	126	154	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor + Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	154	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	176	1	818	1364	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	29	0	30	818	7	176			1
MMRF_1512	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	155	162	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Melphalan	Bor-Cyc-Dex + Bor + Bor-Cyc-Dex + Bor + Bor-Mel	1	Proteasome/Chemotherapy/Steroid	162	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	160	Stem cell, Autologous	1	1	Completed regimen	4			3	176	1	818	1364	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	1	8	1	30	818	7	176			1
MMRF_1512	1	Lenalidomide	Len	IMID	344	943	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib + Bortezomib/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bor + Bor-Cyc-Dex + Bor + Bor-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	943	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			3	176	1	818	1364	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	22	600	0	30	818	7	176			1
MMRF_1512	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1541	2918	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1541	Proteasome/Chemotherapy/Steroid	2918	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	1623	4	1623		Partial Response	PR	Partial Response	PR	1	1	1	1	50	1378	1	3	83	3	83	1	3	1
MMRF_1512	3	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	1989	2918	1	Daratumumab/Lenalidomide	Dar-Len	1989	CD38/IMID	2918	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0	Disease progression/Relapse	3			4	2015	3	2155		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	34	930	1	6	167	1	27	1	2	1
MMRF_1577	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	85	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	85	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	79	3	253	1039	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	85	1	10	253	3	79	1	3	1
MMRF_1577	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	86	233	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	233	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex	248	Stem cell, Autologous	1	1	Completed regimen	4			4	79	3	253	1039	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	6	148	0	10	253	3	79			1
MMRF_1577	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	340	539	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	539	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Investigator decision for other reasons	5			4	79	3	253	1039	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	200	0	10	253	3	79			1
MMRF_1577	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	540	589	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	589	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Investigator decision for other reasons	5			4	79	3	253	1039	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	50	0	10	253	3	79			1
MMRF_1577	1	Lenalidomide	Len	IMID	590	1061	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1061	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	79	3	253	1039	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	17	472	0	10	253	3	79			1
MMRF_1577	2	Bortezomib/Selinexor/Dexamethasone	Bor-Sel-Dex	Proteasome/XPO1/Steroid	1081	1494	1	Bortezomib/Selinexor/Dexamethasone	Bor-Sel-Dex	1081	Proteasome/XPO1/Steroid	1494	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	1228	4	1228		Partial Response	PR	Partial Response	PR	1	1	1	1	15	414	1	6	148	6	148	1	3	1
MMRF_1577	3	Daratumumab/Pomalidomide/Cyclophosphamide/Dexamethasone	Dar-Pom-Cyc-Dex	CD38/IMID/Chemotherapy/Steroid	1572	2894	1	Daratumumab/Pomalidomide/Cyclophosphamide/Dexamethasone	Dar-Pom-Cyc-Dex	1572	CD38/IMID/Chemotherapy/Steroid	2894	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	1711	3	1711	1599	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	48	1323	1	5	140	5	140	1	4	1
MMRF_1589	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	134	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	134	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	68	1	422	2891	Complete Response	CR	Partial Response	PR	1	0	1	0	5	134	1	16	422	3	68	1	3	1
MMRF_1589	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	162	196	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	196	Bortezomib-based	Other treatments	Bor-Cyc-Dex	197	Stem cell, Autologous	1	1	Completed regimen	4			4	68	1	422	2891	Complete Response	CR	Partial Response	PR	1	0	0	0	2	35	0	16	422	3	68			1
MMRF_1589	1	Lenalidomide	Len	IMID	273	1211	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1211	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	68	1	422	2891	Complete Response	CR	Partial Response	PR	1	1	0	1	34	939	0	16	422	3	68			1
MMRF_1715	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	126	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	126	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	161	Stem cell, Autologous	1	1	Completed regimen	4			4	82	3	249		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	126	1	9	249	3	82	1	3	1
MMRF_1867	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	91	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	91	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	97	1	187		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	91	0	7	187	4	97	1	3	1
MMRF_1867	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	92	93	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	93	Bortezomib-based	Other treatments	Bor-Cyc-Dex				1	Completed regimen	4			3	97	1	187		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	0	2	1	7	187	4	97			1
MMRF_1867	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	121	126	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Cyc-Dex + Bor-Mel	1	Proteasome/Chemotherapy/Steroid	126	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	126	Stem cell, Autologous	1	1	Completed regimen	4			3	97	1	187		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	1	6	0	7	187	4	97			1
MMRF_1867	1	Lenalidomide	Len	IMID	233	2891	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bor-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2891	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	97	1	187		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	95	2659	0	7	187	4	97			1
MMRF_1873	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	127	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	127	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5					5	89		Stable Disease	SD			0	1	0	1	5	127	0	4	89			1	3	1
MMRF_1910	1	Bortezomib/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Cyc-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	52	62	1	Bortezomib/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Cyc-Pred-Dex	52	Proteasome/Chemotherapy/Steroid	62	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5	512											0	0	0	0	1	11	0					1	4	1
MMRF_1910	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	63	220	2	Bortezomib/Cyclophosphamide/Prednisone/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Pred-Dex + Bor-Cyc-Dex	52	Proteasome/Chemotherapy/Steroid	220	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	512											0	0	0	0	6	158	0							1
MMRF_1910	2	Lenalidomide	Len	IMID	123	253	1	Lenalidomide	Len	123	IMID	253	IMIDs-based	IMIDs-based	Len-Dex				1			512		4	197	4	197	127	Partial Response	PR	Partial Response	PR	1	1	1	1	5	131	1	3	75	3	75	1	1	1
MMRF_1910	2	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	254	254	2	Lenalidomide + Lenalidomide/Melphalan	Len + Len-Mel	123	IMID/Chemotherapy	254	IMIDs-based	IMIDs-based	Other Len-based therapies	254	Stem cell, Autologous	1	1	Completed regimen	4	512		4	197	4	197	127	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	75	3	75			1
MMRF_1910	2	Lenalidomide	Len	IMID	255	332	3	Lenalidomide + Lenalidomide/Melphalan + Lenalidomide	Len + Len-Mel + Len	123	IMID/Chemotherapy	332	IMIDs-based	IMIDs-based	Other Len-based therapies				1			512		4	197	4	197	127	Partial Response	PR	Partial Response	PR	1	0	0	0	3	78	0	3	75	3	75			1
MMRF_1910	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	333	415	4	Lenalidomide + Lenalidomide/Melphalan + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Len + Len-Mel + Len + Bor-Len-Dex	123	IMID/Chemotherapy/Proteasome/Steroid	415	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	512		4	197	4	197	127	Partial Response	PR	Partial Response	PR	1	0	0	0	3	83	0	3	75	3	75			1
MMRF_1910	3	Bortezomib/Pomalidomide	Bor-Pom	Proteasome/IMID	417	487	1	Bortezomib/Pomalidomide	Bor-Pom	417	Proteasome/IMID	487	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc				0	Disease progression/Relapse	3	512				6	478	478	Progressive Disease	PD			0	1	0	1	3	71	0	3	62			1	2	1
MMRF_1910	4	Selinexor	Sel	XPO1	491	507	1	Selinexor	Sel	491	XPO1	507	Other therapies	Other treatments					0	Disease progression/Relapse	3	512											0	0	0	0	1	17	0							1
MMRF_1910	5	Selinexor/Dexamethasone	Sel-Dex	XPO1/Steroid	512	533	1	Selinexor/Dexamethasone	Sel-Dex	512	XPO1/Steroid	533	Other therapies	Other treatments					0	Disease progression/Relapse	3	512				6	512	512	Progressive Disease	PD			0	1	0	1	1	22	0	1	1					1
MMRF_1927	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	274	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	274	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	279	Stem cell, Autologous	1	1	Completed regimen	4			4	167	1	438	1065	Complete Response	CR	Partial Response	PR	1	0	1	0	10	274	1	16	438	6	167	1	3	1
MMRF_1927	1	Lenalidomide	Len	IMID	389	788	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	788	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Investigator decision for other reasons	5			4	167	1	438	1065	Complete Response	CR	Partial Response	PR	1	1	0	1	15	400	0	16	438	6	167			1
MMRF_1927	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1072	1525	1	Daratumumab/Dexamethasone	Dar-Dex	1072	CD38/Steroid	1525	daratumumab-based	daratumumab-based	Dar-Dex				0	DOSE CHANGE						6	1126	1126	Progressive Disease	PD			0	1	0	1	17	454	0	2	55					1
MMRF_1927	3	Bortezomib/Pomalidomide	Bor-Pom	Proteasome/IMID	1128	1259	1	Bortezomib/Pomalidomide	Bor-Pom	1128	Proteasome/IMID	1259	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Cyc				0					4	1174	4	1174	1628	Partial Response	PR	Partial Response	PR	1	1	1	1	5	132	1	2	47	2	47	1	2	1
MMRF_1927	3	Bortezomib/Carfilzomib/Pomalidomide	Bor-Car-Pom	Proteasome/Proteasome/IMID	1260	1260	2	Bortezomib/Pomalidomide + Bortezomib/Carfilzomib/Pomalidomide	Bor-Pom + Bor-Car-Pom	1128	Proteasome/IMID	1260	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Investigator decision for other reasons	5			4	1174	4	1174	1628	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	47	2	47			1
MMRF_1927	3	Carfilzomib	Car	Proteasome	1261	1525	3	Bortezomib/Pomalidomide + Bortezomib/Carfilzomib/Pomalidomide + Carfilzomib	Bor-Pom + Bor-Car-Pom + Car	1128	Proteasome/IMID	1525	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	DOSE CHANGE				4	1174	4	1174	1628	Partial Response	PR	Partial Response	PR	1	0	0	0	10	265	0	2	47	2	47			1
MMRF_1927	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1526	1590	4	Bortezomib/Pomalidomide + Bortezomib/Carfilzomib/Pomalidomide + Carfilzomib + Carfilzomib/Dexamethasone	Bor-Pom + Bor-Car-Pom + Car + Car-Dex	1128	Proteasome/IMID/Steroid	1590	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Disease progression/Relapse	3			4	1174	4	1174	1628	Partial Response	PR	Partial Response	PR	1	0	0	0	3	65	0	2	47	2	47			1
MMRF_2265	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	124	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	124	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	77	1	1072		Complete Response	CR	Partial Response	PR	1	0	1	0	5	124	1	39	1072	3	77	1	3	1
MMRF_2265	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	126	127	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	127	Bortezomib-based	Other treatments	Bor-Cyc-Dex				1	Completed regimen	4			4	77	1	1072		Complete Response	CR	Partial Response	PR	1	0	0	0	0	2	0	39	1072	3	77			1
MMRF_2265	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	153	159	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Cyc-Dex + Bor-Mel	1	Proteasome/Chemotherapy/Steroid	159	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	159	Stem cell, Autologous	1	1	Completed regimen	4			4	77	1	1072		Complete Response	CR	Partial Response	PR	1	0	0	0	1	7	0	39	1072	3	77			1
MMRF_2265	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	260	316	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Mel + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	316	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	77	1	1072		Complete Response	CR	Partial Response	PR	1	0	0	0	2	57	0	39	1072	3	77			1
MMRF_2265	1	Lenalidomide	Len	IMID	317	1548	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Mel + Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1548	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	77	1	1072		Complete Response	CR	Partial Response	PR	1	1	0	1	44	1232	0	39	1072	3	77			1
MMRF_2563	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	166	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	166	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	6	166	0	55	1540	8	200	1	3	1
MMRF_2563	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	167	175	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	175	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	175	Stem cell, Autologous	1	1	Completed regimen	4			3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	9	0	55	1540	8	200			1
MMRF_2563	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	176	237	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	237	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	62	1	55	1540	8	200			1
MMRF_2563	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	238	299	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	299	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Investigator decision for other reasons	5			3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	62	0	55	1540	8	200			1
MMRF_2563	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	300	707	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	707	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	15	408	0	55	1540	8	200			1
MMRF_2563	1	Bortezomib	Bor	Proteasome	708	774	6	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide + Bortezomib	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len + Bor	1	Proteasome/Chemotherapy/Steroid/IMID	774	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	67	0	55	1540	8	200			1
MMRF_2563	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	775	2366	7	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide + Bortezomib + Bortezomib/Lenalidomide	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Len + Bor + Bor-Len	1	Proteasome/Chemotherapy/Steroid/IMID	2366	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	200	1	1540		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	57	1592	0	55	1540	8	200			1
MMRF_1597	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	100	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	100	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	106	3	440		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	100	1	16	440	4	106	1	3	1
MMRF_1597	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	147	150	2	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan	Bor-Cyc-Dex + Bus-Mel	1	Proteasome/Chemotherapy/Steroid	150	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	152	Stem cell, Autologous	1	1	Completed regimen	4			4	106	3	440		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	4	0	16	440	4	106			1
MMRF_1597	1	Lenalidomide	Len	IMID	251	1428	3	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bus-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1428	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	106	3	440		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	42	1178	0	16	440	4	106			1
MMRF_1610	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	22	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	22	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	102	1	2732		Complete Response	CR	Partial Response	PR	1	0	1	0	1	22	1	98	2732	4	102	1	3	1
MMRF_1610	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	150	153	2	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan	Bor-Cyc-Dex + Bus-Mel	1	Proteasome/Chemotherapy/Steroid	153	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	155	Stem cell, Autologous	1	1	Completed regimen	4			4	102	1	2732		Complete Response	CR	Partial Response	PR	1	0	0	0	0	4	0	98	2732	4	102			1
MMRF_1610	1	Lenalidomide	Len	IMID	260	2873	3	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bus-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2873	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	102	1	2732		Complete Response	CR	Partial Response	PR	1	1	0	1	94	2614	0	98	2732	4	102			1
MMRF_1614	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	1064	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	1064	IMIDs-based	IMIDs-based	Len-Dex				0					4	84	3	176	1094	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	38	1064	1	7	176	3	84	1	2	1
MMRF_1638	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	135	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	135	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	185	Stem cell, Autologous	1	1	Completed regimen	4			3	137	3	137	514	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	135	1	5	137	5	137	1	3	1
MMRF_1638	1	Lenalidomide	Len	IMID	319	683	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	683	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			3	137	3	137	514	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	13	365	0	5	137	5	137			1
MMRF_1638	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	683	767	1	Pomalidomide/Dexamethasone	Pom-Dex	683	IMID/Steroid	767	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3												0	0	0	0	3	85	0					1	2	1
MMRF_1655	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	162	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	162	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	226	Stem cell, Autologous	1	1	Completed regimen	4			4	112	1	1392	1851	Complete Response	CR	Partial Response	PR	1	0	1	0	6	162	1	50	1392	4	112	1	3	1
MMRF_1655	1	Lenalidomide	Len	IMID	318	1851	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1851	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	112	1	1392	1851	Complete Response	CR	Partial Response	PR	1	1	0	1	55	1534	0	50	1392	4	112			1
MMRF_1655	2	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	1853	2001	1	Daratumumab/Lenalidomide	Dar-Len	1853	CD38/IMID	2001	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0							6	2509	2509	Progressive Disease	PD			0	0	0	0	6	149	0	24	657			1	2	1
MMRF_1655	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	2002	2170	2	Daratumumab/Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone	Dar-Len + Dar-Len-Dex	1853	CD38/IMID/Steroid	2170	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0							6	2509	2509	Progressive Disease	PD			0	0	0	0	6	169	0	24	657					1
MMRF_1655	2	Daratumumab/Lenalidomide/Cyclophosphamide/Dexamethasone	Dar-Len-Cyc-Dex	CD38/IMID/Chemotherapy/Steroid	2171	2590	3	Daratumumab/Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone + Daratumumab/Lenalidomide/Cyclophosphamide/Dexamethasone	Dar-Len + Dar-Len-Dex + Dar-Len-Cyc-Dex	1853	CD38/IMID/Steroid/Chemotherapy	2590	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				0							6	2509	2509	Progressive Disease	PD			0	1	0	1	15	420	0	24	657					1
MMRF_1856	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	138	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	138	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	188	Stem cell, Autologous	1	1	Completed regimen	4			4	148	3	334		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	138	1	12	334	6	148	1	3	1
MMRF_1856	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	253	335	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	335	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	148	3	334		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	3	83	0	12	334	6	148			1
MMRF_1856	1	Lenalidomide	Len	IMID	336	2007	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2007	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	148	3	334		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	60	1672	0	12	334	6	148			1
MMRF_2170	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	71	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	71	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	84	1	976	1283	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	71	0	35	976	3	84	1	3	1
MMRF_2170	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	72	429	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	429	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	84	1	976	1283	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	13	358	1	35	976	3	84			1
MMRF_2170	2	Daratumumab/Cyclophosphamide/Dexamethasone	Dar-Cyc-Dex	CD38/Chemotherapy/Steroid	1291	1501	1	Daratumumab/Cyclophosphamide/Dexamethasone	Dar-Cyc-Dex	1291	CD38/Chemotherapy/Steroid	1501	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0					4	1374	4	1374	1430	Partial Response	PR	Partial Response	PR	1	1	1	1	8	211	1	3	84	3	84			1
MMRF_2279	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	116	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	116	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	86	3	284		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	116	1	11	284	4	86	1	3	1
MMRF_2279	1	Bortezomib/Melphalan	Bor-Mel	Proteasome/Chemotherapy	148	154	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan	Bor-Cyc-Dex + Bor-Mel	1	Proteasome/Chemotherapy/Steroid	154	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	150	Stem cell, Autologous	1	1	Completed regimen	4			4	86	3	284		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	7	0	11	284	4	86			1
MMRF_2279	1	Lenalidomide	Len	IMID	260	2516	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bor-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2516	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	86	3	284		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	81	2257	0	11	284	4	86			1
MMRF_2288	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	333	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	333	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	59	4	59		Partial Response	PR	Partial Response	PR	1	1	1	1	12	333	1	3	59	3	59	1	3	1
MMRF_2288	1	Bortezomib	Bor	Proteasome	416	466	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	466	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	59	4	59		Partial Response	PR	Partial Response	PR	1	0	0	0	2	51	0	3	59	3	59			1
MMRF_1676	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	175	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	175	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	35	1	446		Complete Response	CR	Partial Response	PR	1	0	1	0	7	175	1	16	446	2	35	1	3	1
MMRF_1676	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	176	179	2	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan	Bor-Cyc-Dex + Bus-Mel	1	Proteasome/Chemotherapy/Steroid	179	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	181	Stem cell, Autologous	1	1	Completed regimen	4			4	35	1	446		Complete Response	CR	Partial Response	PR	1	0	0	0	0	4	0	16	446	2	35			1
MMRF_1676	1	Lenalidomide	Len	IMID	271	2912	3	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bus-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2912	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	35	1	446		Complete Response	CR	Partial Response	PR	1	1	0	1	95	2642	0	16	446	2	35			1
MMRF_1725	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	112	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	112	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	STEM CELL MOBILIZATION AND COLLECTION				4	85	3	253		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	112	1	10	253	4	85	1	3	1
MMRF_1725	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	148	191	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	191	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	85	3	253		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	44	0	10	253	4	85			1
MMRF_1725	1	Bortezomib/Busulfan/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Bus-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Chemotherapy/Steroid	192	195	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Busulfan/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Bus-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	195	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	85	3	253		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	4	0	10	253	4	85			1
MMRF_1725	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	196	196	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Busulfan/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Bus-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	196	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	197	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	253		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	10	253	4	85			1
MMRF_1725	1	Lenalidomide	Len	IMID	271	2520	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Busulfan/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Bus-Cyc-Mel-Dex + Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2520	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	SKIN GRAFT SURGERY				4	85	3	253		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	81	2250	0	10	253	4	85			1
MMRF_1771	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	160	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	160	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Adverse Event or co-morbidity	2			3	84	3	84	475	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	160	1	3	84	3	84	1	3	1
MMRF_1771	1	Cyclophosphamide/Melphalan/Dexamethasone	Cyc-Mel-Dex	Chemotherapy/Chemotherapy/Steroid	189	203	2	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	203	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	204	Stem cell, Autologous	1	1	Completed regimen	4			3	84	3	84	475	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	15	0	3	84	3	84			1
MMRF_1771	1	Lenalidomide	Len	IMID	310	455	3	Bortezomib/Cyclophosphamide/Dexamethasone + Cyclophosphamide/Melphalan/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Cyc-Mel-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	455	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	ELEVATED LIVER FUNCTION TESTS. TREAT HELD DUE TO SUSPECTED VIRAL HEPATITIS				3	84	3	84	475	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	146	0	3	84	3	84			1
MMRF_1771	2	Cytarabine/Hydrocortisone/Methotrexate	Cyt-Cort-MTX	Chemotherapy/Steroid/Chemotherapy	491	507	1	Cytarabine/Hydrocortisone/Methotrexate	Cyt-Cort-MTX	491	Chemotherapy/Steroid	507	Other therapies	Other treatments					0	LOST TO FOLLOW-UP													0	0	0	0	1	17	0							1
MMRF_1777	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	405	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	405	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	317	3	317		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	15	405	1	12	317	12	317	1	3	1
MMRF_1777	1	Bortezomib	Bor	Proteasome	441	2928	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	2928	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0					3	317	3	317		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	89	2488	0	12	317	12	317			1
MMRF_1785	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	217	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	217	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	259	Stem cell, Autologous	1	1	Completed regimen	4			4	177	3	286		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	217	1	11	286	7	177	1	3	1
MMRF_1785	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	217	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	217	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	418	Stem cell, Autologous	2	1	Completed regimen	4			4	177	3	286		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	8	217	1	11	286	7	177			1
MMRF_1785	1	Lenalidomide	Len	IMID	461	687	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	687	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	RECURRING COUGH				4	177	3	286		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	8	227	0	11	286	7	177			1
MMRF_1785	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	796	1352	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	796	Proteasome/IMID/Steroid	1352	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			3	874	3	874	800	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	20	557	1	3	79	3	79	1	3	1
MMRF_1785	2	Lenalidomide	Len	IMID	1353	1365	2	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	796	Proteasome/IMID/Steroid	1365	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0					3	874	3	874	800	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	13	0	3	79	3	79			1
MMRF_1785	2	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	1366	1366	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Ixazomib/Lenalidomide	Car-Len-Dex + Len + Ixa-Len	796	Proteasome/IMID/Steroid	1366	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	874	3	874	800	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	79	3	79			1
MMRF_1785	2	Ixazomib	Ixa	Proteasome	1367	2775	4	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Ixazomib/Lenalidomide + Ixazomib	Car-Len-Dex + Len + Ixa-Len + Ixa	796	Proteasome/IMID/Steroid	2775	combined IMIDs/carfilzomib-based	Other treatments	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	874	3	874	800	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	51	1409	0	3	79	3	79			1
MMRF_1785	3	Isatuximab/Dexamethasone	Isa-Dex	CD38/Steroid	2817	2885	1	Isatuximab/Dexamethasone	Isa-Dex	2817	CD38/Steroid	2885	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2			3	2929	3	2929		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	69	0	5	113	5	113			1
MMRF_1785	3	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	IMID/CD38/Steroid	2909	3140	2	Isatuximab/Dexamethasone + Pomalidomide/Isatuximab/Dexamethasone	Isa-Dex + Pom-Isa-Dex	2817	CD38/Steroid/IMID	3140	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3			3	2929	3	2929		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	232	1	5	113	5	113	1	3	1
MMRF_1792	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	STEM CELL MOBILIZATION AND COLLECTION		1437	1478	4	79	3	268	1115	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	113	1	10	268	3	79	1	3	1
MMRF_1792	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	149	197	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	197	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4	1437	1478	4	79	3	268	1115	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	49	0	10	268	3	79			1
MMRF_1792	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	203	206	3	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan	Bor-Cyc-Dex + Bus-Mel	1	Proteasome/Chemotherapy/Steroid	206	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	208	Stem cell, Autologous	1	1	Completed regimen	4	1437	1478	4	79	3	268	1115	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	4	0	10	268	3	79			1
MMRF_1792	1	Lenalidomide	Len	IMID	301	1131	4	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bus-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1131	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3	1437	1478	4	79	3	268	1115	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	30	831	0	10	268	3	79			1
MMRF_1792	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1143	1228	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1143	Proteasome/Chemotherapy/Steroid	1228	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3	1437	1478			5	1178	1154	Stable Disease	SD			0	1	0	1	3	86	0	2	36			1	3	1
MMRF_1792	2	Bortezomib	Bor	Proteasome	1229	1229	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1143	Proteasome/Chemotherapy/Steroid	1229	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3	1437	1478			5	1178	1154	Stable Disease	SD			0	0	0	0	0	1	0	2	36					1
MMRF_1792	3	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	1229	1279	1	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	1229	Proteasome/IMID/Steroid	1279	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	Disease progression/Relapse	3	1437	1478			5	1241	1259	Stable Disease	SD			0	1	0	1	2	51	0	1	13			1	3	1
MMRF_1792	4	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1276	1301	1	Daratumumab/Dexamethasone	Dar-Dex	1276	CD38/Steroid	1301	daratumumab-based	daratumumab-based	Dar-Dex				0			1437	1478	4	1364	4	1364	1392	Partial Response	PR	Partial Response	PR	1	0	0	0	1	26	0	4	89	4	89			1
MMRF_1792	4	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	1302	1465	2	Daratumumab/Dexamethasone + Carfilzomib/Daratumumab/Dexamethasone	Dar-Dex + Car-Dar-Dex	1276	CD38/Steroid/Proteasome	1465	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1437	1478	4	1364	4	1364	1392	Partial Response	PR	Partial Response	PR	1	1	1	1	6	164	1	4	89	4	89	1	3	1
MMRF_1792	5	Pomalidomide	Pom	IMID	1406	1465	1	Pomalidomide	Pom	1406	IMID	1465	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3	1437	1478			6	1437	1437	Progressive Disease	PD			0	1	0	1	2	60	0	2	32			1	1	1
MMRF_1792	9	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	1497	1500	1	Cyclophosphamide/Dexamethasone/Doxorubicin	Cyc-Dex-Dox	1497	Chemotherapy/Steroid	1500	Other therapies	Other treatments					0	Disease progression/Relapse	3	1437	1478										0	0	0	0	0	4	0							1
MMRF_1805	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	1	259	1	Bortezomib/Cyclophosphamide	Bor-Cyc	1	Proteasome/Chemotherapy	259	Bortezomib-based	Bortezomib-based	Bor-Cyc				1	STEM CELL MOBILIZATION AND COLLECTION				3	85	3	85	1583	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	259	1	4	85	4	85	1	2	1
MMRF_1805	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	281	313	2	Bortezomib/Cyclophosphamide + Cyclophosphamide/Dexamethasone	Bor-Cyc + Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	313	Bortezomib-based	Other treatments	Bor-Cyc-Dex	315	Stem cell, Autologous	1	1	AUTOLOGOUS STEM CELL TRANSPLANT				3	85	3	85	1583	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	33	0	4	85	4	85			1
MMRF_1805	1	Lenalidomide	Len	IMID	415	1631	3	Bortezomib/Cyclophosphamide + Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc + Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1631	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			3	85	3	85	1583	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	44	1217	0	4	85	4	85			1
MMRF_1805	2	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1694	2717	1	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	1694	Proteasome/Chemotherapy/Steroid	2717	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2					5	1751		Stable Disease	SD			0	1	0	1	37	1024	0	3	58					1
MMRF_1805	3	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	Proteasome/IMID/Steroid	2221	2417	1	Ixazomib/Pomalidomide/Dexamethasone	Ixa-Pom-Dex	2221	Proteasome/IMID/Steroid	2417	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3					6	2318	2318	Progressive Disease	PD			0	1	0	1	7	197	0	4	98			1	3	1
MMRF_1805	4	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	IMID/CD38/Steroid	2417	2598	1	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	2417	IMID/CD38/Steroid	2598	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3					5	2500	2612	Stable Disease	SD			0	1	0	1	7	182	0	3	84			1	3	1
MMRF_1805	5	Mezigdomide/Dexamethasone	Mezi-Dex	IMID/Steroid	2614	2717	1	Mezigdomide/Dexamethasone	Mezi-Dex	2614	IMID/Steroid	2717	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2					5	2690		Stable Disease	SD			0	1	0	1	4	104	0	3	77					1
MMRF_1846	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	116	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	116	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	STEM CELL MOBILIZATION AND COLLECTION				4	84	3	834	2156	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	116	1	30	834	3	84	1	3	1
MMRF_1846	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	145	168	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	168	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	84	3	834	2156	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	24	0	30	834	3	84			1
MMRF_1846	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	169	186	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	186	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	191	Stem cell, Autologous	1	1	Completed regimen	4			4	84	3	834	2156	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	18	0	30	834	3	84			1
MMRF_1846	1	Lenalidomide	Len	IMID	317	2247	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2247	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	84	3	834	2156	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	69	1931	0	30	834	3	84			1
MMRF_1846	2	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2268	2317	1	Ixazomib/Cyclophosphamide/Dexamethasone	Ixa-Cyc-Dex	2268	Proteasome/Chemotherapy/Steroid	2317	Other therapies	Other treatments					1	Lack of response	1			4	2549	4	2549	2800	Partial Response	PR	Partial Response	PR	1	0	0	0	2	50	0	11	282	11	282			1
MMRF_1846	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	2333	2437	2	Ixazomib/Cyclophosphamide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Ixa-Cyc-Dex + Ixa-Len-Dex	2268	Proteasome/Chemotherapy/Steroid/IMID	2437	IMIDs-based	IMIDs-based	Other Len-based therapies	2454	Stem cell, Autologous	2	1	Completed regimen	4			4	2549	4	2549	2800	Partial Response	PR	Partial Response	PR	1	1	1	1	4	105	1	11	282	11	282	1	3	1
MMRF_1846	4	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	IMID/CD38/Steroid	2864	2879	1	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	2864	IMID/CD38/Steroid	2879	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2					6	2899	2899	Progressive Disease	PD			0	1	0	1	1	16	0	2	36			1	3	1
MMRF_1845	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	56	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	56	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	85	3	162	945	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	2	56	1	6	162	4	85	1	3	1
MMRF_1845	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	145	198	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	198	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex	201	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	162	945	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	2	54	0	6	162	4	85			1
MMRF_1845	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1147	1278	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1147	Proteasome/IMID/Steroid	1278	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	1298	Stem cell, Autologous	2	1	Completed regimen	4			4	1155	3	1241		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	132	1	4	95	1	9	1	3	1
MMRF_1845	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1399	2928	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1147	Proteasome/IMID/Steroid	2928	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	1155	3	1241		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	55	1530	0	4	95	1	9			1
MMRF_1928	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	169	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	169	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	171	Stem cell, Autologous	1	1	ADMITTED FOR ASCT				4	138	4	138	762	Partial Response	PR	Partial Response	PR	1	1	1	1	6	169	1	5	138	5	138	1	3	1
MMRF_1928	1	Lenalidomide	Len	IMID	276	1140	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1140	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	138	4	138	762	Partial Response	PR	Partial Response	PR	1	0	0	0	31	865	0	5	138	5	138			1
MMRF_1928	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1162	1944	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1162	CD38/IMID/Steroid	1944	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Adverse Event or co-morbidity	2			4	1216	1	1412		Complete Response	CR	Partial Response	PR	1	1	1	1	28	783	1	9	251	2	55	1	3	1
MMRF_1928	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1974	2863	2	Daratumumab/Pomalidomide/Dexamethasone + Daratumumab/Pomalidomide	Dar-Pom-Dex + Dar-Pom	1162	CD38/IMID/Steroid	2863	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	1216	1	1412		Complete Response	CR	Partial Response	PR	1	0	0	0	32	890	0	9	251	2	55			1
MMRF_1960	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	315	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	315	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	175	4	175		Partial Response	PR	Partial Response	PR	1	1	1	1	12	315	1	7	175	7	175	1	3	1
MMRF_1960	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	525	565	2	Bortezomib/Melphalan/Prednisone + Lenalidomide/Dexamethasone	Bor-Mel-Pred + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	565	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	PALLIATIVE				4	175	4	175		Partial Response	PR	Partial Response	PR	1	0	0	0	2	41	0	7	175	7	175			1
MMRF_2174	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1	250	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	250	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5					5	82	110	Stable Disease	SD			0	1	0	1	9	250	0	3	82			1	4	1
MMRF_2174	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	146	250	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	146	Chemotherapy/Steroid	250	Other therapies	Other treatments					0	Investigator decision for other reasons	5					5	180		Stable Disease	SD			0	1	0	1	4	105	0	2	35					1
MMRF_2251	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	99	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	99	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	64	4	64		Partial Response	PR	Partial Response	PR	1	1	1	1	4	99	1	3	64	3	64	1	3	1
MMRF_2428	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	28	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	28	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	START CLINICAL TRIAL				3	92	1	176		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	28	0	7	176	4	92	1	3	1
MMRF_2428	1	Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Car-Len-Cyc-Dex	Proteasome/Proteasome/IMID/Chemotherapy/Steroid	29	147	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	147	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			3	92	1	176		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	5	119	1	7	176	4	92			1
MMRF_2428	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	176	224	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	224	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex	263	Stem cell, Autologous	1	1	Completed regimen	4			3	92	1	176		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	1	2	49	0	7	176	4	92			1
MMRF_2428	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	351	715	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	715	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			3	92	1	176		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	13	365	0	7	176	4	92			1
MMRF_2428	1	Lenalidomide	Len	IMID	716	2072	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Bor-Car-Len-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2072	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Cyc-Dex				1	Adverse Event or co-morbidity	2			3	92	1	176		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	49	1357	0	7	176	4	92			1
MMRF_2428	2	Lenalidomide	Len	IMID	2073	2303	1	Lenalidomide	Len	2073	IMID	2303	IMIDs-based	IMIDs-based	Len-Dex				1	Disease progression/Relapse	3			3	2164	3	2164	2283	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	231	1	4	92	4	92	1	1	1
MMRF_2428	2	Pomalidomide/Isatuximab/Dexamethasone	Pom-Isa-Dex	IMID/CD38/Steroid	2312	2423	2	Lenalidomide + Pomalidomide/Isatuximab/Dexamethasone	Len + Pom-Isa-Dex	2073	IMID/CD38/Steroid	2423	IMIDs-based	IMIDs-based	Other Len-based therapies	2434	Stem cell, Autologous	2	1	Completed regimen	4			3	2164	3	2164	2283	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	112	0	4	92	4	92			1
MMRF_1555	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	79	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	79	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5					5	79		Stable Disease	SD			0	1	0	1	3	79	0	3	79			1	3	1
MMRF_1555	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	130	230	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	130	Proteasome/IMID/Steroid	230	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3					5	230	239	Stable Disease	SD			0	1	0	1	4	101	0	4	101			1	3	1
MMRF_1555	3	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	248	340	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	248	Proteasome/IMID/Steroid	340	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	344	344	Progressive Disease	PD			0	1	0	1	4	93	0	4	97			1	3	1
MMRF_1564	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	1215	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	1215	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	72	3	417	1206	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	44	1215	1	15	417	3	72	1	2	1
MMRF_1564	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1215	1290	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1215	Proteasome/IMID/Steroid	1290	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1					5	1297	1493	Stable Disease	SD			0	1	0	1	3	76	0	3	83			1	3	1
MMRF_1564	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1304	1355	2	Bortezomib/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone	Bor-Len-Dex + Dar-Dex	1215	Proteasome/IMID/Steroid/CD38	1355	combined bortezomib/IMIDs-based	daratumumab-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2					5	1297	1493	Stable Disease	SD			0	0	0	0	2	52	0	3	83					1
MMRF_1564	2	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	1397	1493	3	Bortezomib/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone + Daratumumab/Pomalidomide	Bor-Len-Dex + Dar-Dex + Dar-Pom	1215	Proteasome/IMID/Steroid/CD38	1493	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Completed regimen	4					5	1297	1493	Stable Disease	SD			0	0	0	0	4	97	0	3	83					1
MMRF_1569	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	1202	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	1202	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	86	3	616	945	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	43	1202	1	22	616	4	86	1	2	1
MMRF_1569	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1222	1361	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1222	Proteasome/IMID/Steroid	1361	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3					5	1281	1361	Stable Disease	SD			0	1	0	1	5	140	0	3	60			1	3	1
MMRF_1569	3	Pomalidomide/Durvalumab/Dexamethasone	Pom-Durv-Dex	IMID/Checkpoint Inhibitor/Steroid	1407	1557	1	Pomalidomide/Durvalumab/Dexamethasone	Pom-Durv-Dex	1407	IMID/Checkpoint Inhibitor/Steroid	1557	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Adverse Event or co-morbidity	2					5	1463		Stable Disease	SD			0	1	0	1	6	151	0	3	57			1	3	1
MMRF_1569	4	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1556	2926	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1556	Proteasome/CD38/Steroid	2926	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0					4	1652	4	1652	1556	Partial Response	PR	Partial Response	PR	1	1	1	1	49	1371	1	4	97	4	97	1	3	1
MMRF_1574	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	221	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	221	IMIDs-based	IMIDs-based	Len-Dex	248	Stem cell, Autologous	1	1	TRANSPLANT				4	221	2	1577		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	8	221	1	57	1577	8	221	1	2	1
MMRF_1574	1	Lenalidomide	Len	IMID	569	1577	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	1577	IMIDs-based	IMIDs-based	Len-Dex				1	Adverse Event or co-morbidity	2			4	221	2	1577		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	36	1009	0	57	1577	8	221			1
MMRF_1593	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	73	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	73	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	3	73	0					1	2	1
MMRF_1593	2	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	105	132	1	Carfilzomib/Lenalidomide	Car-Len	105	Proteasome/IMID	132	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car				1					3	105	1	193		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	1	28	1	4	89	1	1	1	2	1
MMRF_1593	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	133	189	2	Carfilzomib/Lenalidomide + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len + Car-Len-Dex	105	Proteasome/IMID/Steroid	189	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	218	Stem cell, Autologous	1	1	TRANSPLANT				3	105	1	193		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	2	57	0	4	89	1	1			1
MMRF_1593	2	Lenalidomide	Len	IMID	312	2934	3	Carfilzomib/Lenalidomide + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len + Car-Len-Dex + Len	105	Proteasome/IMID/Steroid	2934	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				1					3	105	1	193		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	94	2623	0	4	89	1	1			1
MMRF_1618	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	86	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	86	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	119	Stem cell, Autologous	1	1	TRANSPLANT				3	86	1	394		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	3	86	1	15	394	4	86	1	3	1
MMRF_1618	1	Lenalidomide	Len	IMID	338	1479	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	1479	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	DECREASE OF DOSE DUE TO NEUTROPENIA (NOT DEEMED GRADE 3)				3	86	1	394		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	41	1142	0	15	394	4	86			1
MMRF_1618	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1479	1630	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1479	CD38/IMID/Steroid	1630	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex	1681	Stem cell, Autologous	2	1	Completed regimen	4			4	1659	3	1771	1491	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	152	1	11	293	7	181	1	3	1
MMRF_1618	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1753	2564	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1479	CD38/IMID/Steroid	2564	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				1	Disease progression/Relapse	3			4	1659	3	1771	1491	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	29	812	0	11	293	7	181			1
MMRF_1618	3	Carfilzomib/CB-839/Dexamethasone	Car-CB-839-Dex	Proteasome/Other/Steroid	2226	2252	1	Carfilzomib/CB-839/Dexamethasone	Car-CB-839-Dex	2226	Proteasome/Other/Steroid	2252	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	INSURANCE													0	0	0	0	1	27	0					1	4	1
MMRF_1618	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	2252	2924	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	2252	Proteasome/Chemotherapy/Steroid	2924	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0							5	2394		Stable Disease	SD			0	1	0	1	24	673	0	6	143			1	3	1
MMRF_1717	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	104	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	104	IMIDs-based	IMIDs-based	Len-Dex	162	Stem cell, Autologous	1	1	TRANSPLANT				4	89	3	529	1474	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	104	1	19	529	4	89	1	2	1
MMRF_1717	1	Lenalidomide	Len	IMID	334	1464	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	1464	IMIDs-based	IMIDs-based	Len-Dex				1	Disease progression/Relapse	3			4	89	3	529	1474	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	41	1131	0	19	529	4	89			1
MMRF_1717	2	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	1499	2086	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	1499	Proteasome/IMID/Steroid	2086	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	DEATH				4	1567	4	1567	1910	Partial Response	PR	Partial Response	PR	1	1	1	1	21	588	1	3	69	3	69	1	3	1
MMRF_1726	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	98	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	98	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	85		Stable Disease	SD			0	1	0	1	4	98	0	4	85			1	2	1
MMRF_1726	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	99	119	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	119	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Lack of response	1					5	85		Stable Disease	SD			0	0	0	0	1	21	0	4	85					1
MMRF_1726	1	Lenalidomide	Len	IMID	120	176	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	176	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Lack of response	1					5	85		Stable Disease	SD			0	0	0	0	2	57	0	4	85					1
MMRF_1726	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	177	564	1	Lenalidomide/Dexamethasone	Len-Dex	177	IMID/Steroid	564	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3					5	176		Stable Disease	SD			0	0	0	0	14	388	0	0	0			1	2	1
MMRF_1726	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	564	693	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	564	Proteasome/IMID/Steroid	693	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2					5	564	664	Stable Disease	SD			0	1	0	1	5	130	0	1	1			1	3	1
MMRF_1763	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	53	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	53	IMIDs-based	IMIDs-based	Len-Dex				1					2	99	2	99		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	2	53	0	4	99	4	99	1	2	1
MMRF_1763	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	54	106	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	106	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	TRANSPLANT				2	99	2	99		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	2	53	1	4	99	4	99			1
MMRF_1763	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	107	130	3	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	130	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					2	99	2	99		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	1	24	0	4	99	4	99			1
MMRF_1763	1	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	131	131	4	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone	Len-Dex + Bor-Len-Dex + Len-Mel-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	131	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			2	99	2	99		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	0	1	0	4	99	4	99			1
MMRF_1763	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	132	133	5	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex + Len-Mel-Dex + Len-Dex	1	IMID/Steroid/Proteasome/Chemotherapy	133	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	133	Stem cell, Autologous	1	1	TRANSPLANT				2	99	2	99		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	0	2	0	4	99	4	99			1
MMRF_1763	1	Bortezomib	Bor	Proteasome	194	764	6	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide/Dexamethasone + Bortezomib	Len-Dex + Bor-Len-Dex + Len-Mel-Dex + Len-Dex + Bor	1	IMID/Steroid/Proteasome/Chemotherapy	764	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			2	99	2	99		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	21	571	0	4	99	4	99			1
MMRF_1763	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	769	937	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	769	Proteasome/IMID/Steroid	937	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			3	932	1	1030	827	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	169	1	10	262	6	164	1	3	1
MMRF_1763	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	939	1072	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	769	Proteasome/IMID/Steroid	1072	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex	1077	Stem cell, Allogenic	2	1	ALLOGENIC SCT 1/17/2017				3	932	1	1030	827	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	5	134	0	10	262	6	164			1
MMRF_1763	2	Ixazomib	Ixa	Proteasome	1192	1275	3	Bortezomib/Lenalidomide/Dexamethasone + Ixazomib	Bor-Len-Dex + Ixa	769	Proteasome/IMID/Steroid	1275	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	DOSE INCREASE DUE TO A STUDY PROTOCOL				3	932	1	1030	827	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	10	262	6	164			1
MMRF_1763	3	Ixazomib	Ixa	Proteasome	1276	1495	1	Ixazomib	Ixa	1276	Proteasome	1495	Other therapies	Other treatments					0					2	1373	1	1989		Complete Response	CR	Stringent Complete Response	sCR	1	0	1	0	8	220	1	26	714	4	98			1
MMRF_1763	3	Ixazomib/Prednisone	Ixa-Pred	Proteasome/Steroid	1496	1606	2	Ixazomib + Ixazomib/Prednisone	Ixa + Ixa-Pred	1276	Proteasome/Steroid	1606	Other therapies	Other treatments					0	Completed regimen	4			2	1373	1	1989		Complete Response	CR	Stringent Complete Response	sCR	1	1	0	1	4	111	0	26	714	4	98			1
MMRF_1763	3	Daratumumab/Cyclophosphamide/Prednisone/Dexamethasone	Dar-Cyc-Pred-Dex	CD38/Chemotherapy/Steroid/Steroid	2352	2729	3	Ixazomib + Ixazomib/Prednisone + Daratumumab/Cyclophosphamide/Prednisone/Dexamethasone	Ixa + Ixa-Pred + Dar-Cyc-Pred-Dex	1276	Proteasome/Steroid/CD38/Chemotherapy	2729	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0					2	1373	1	1989		Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	14	378	0	26	714	4	98			1
MMRF_1847	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	128	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	128	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	161	Stem cell, Autologous	1	1	TRANSPLANT				4	128	1	1723		Complete Response	CR	Partial Response	PR	1	0	1	0	5	128	1	62	1723	5	128	1	3	1
MMRF_1847	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	380	672	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	672	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	FOR PT. CONVENIENCE				4	128	1	1723		Complete Response	CR	Partial Response	PR	1	0	0	0	11	293	0	62	1723	5	128			1
MMRF_1847	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	692	2445	3	Bortezomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Ixa-Len-Dex	1	Proteasome/IMID/Steroid	2445	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					4	128	1	1723		Complete Response	CR	Partial Response	PR	1	1	0	1	63	1754	0	62	1723	5	128			1
MMRF_1888	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	28	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	28	Bortezomib-based	Bortezomib-based	Bor-Dex				1					3	166	2	1235		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	28	0	45	1235	6	166	1	2	1
MMRF_1888	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	29	85	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	85	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	143	Stem cell, Autologous	1	1	TRANSPLANT				3	166	2	1235		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	2	57	1	45	1235	6	166			1
MMRF_1888	1	Lenalidomide	Len	IMID	388	2592	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	2592	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	166	2	1235		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	79	2205	0	45	1235	6	166			1
MMRF_1915	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	24	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	24	Bortezomib-based	Bortezomib-based	Bor-Dex				1					3	82	3	82		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	24	0	3	82	3	82	1	2	1
MMRF_1915	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	25	82	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	82	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	113	Stem cell, Autologous	1	1	TRANSPLANT				3	82	3	82		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	2	58	1	3	82	3	82			1
MMRF_1915	1	Lenalidomide	Len	IMID	358	850	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	850	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5			3	82	3	82		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	18	493	0	3	82	3	82			1
MMRF_2041	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	29	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	29	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	108	Stem cell, Autologous	1	1	TRANSPLANT				3	108	3	108	1547	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	29	1	4	108	4	108	1	3	1
MMRF_2041	1	Lenalidomide	Len	IMID	199	2492	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2492	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					3	108	3	108	1547	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	82	2294	0	4	108	4	108			1
MMRF_2064	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	102	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	102	Bortezomib-based	Bortezomib-based	Bor-Dex	118	Stem cell, Autologous	1	1	TRANSPLANT				4	92	3	178	1067	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	102	1	7	178	4	92	1	2	1
MMRF_2064	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1221	1338	1	Carfilzomib/Dexamethasone	Car-Dex	1221	Proteasome/Steroid	1338	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Patient decision	6					5	1249		Stable Disease	SD			0	1	0	1	5	118	0	2	29			1	2	1
MMRF_2064	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1341	2696	2	Carfilzomib/Dexamethasone + Lenalidomide/Dexamethasone	Car-Dex + Len-Dex	1221	Proteasome/Steroid/IMID	2696	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0							5	1249		Stable Disease	SD			0	0	0	0	49	1356	0	2	29					1
MMRF_2409	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	135	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	135	Bortezomib-based	Bortezomib-based	Bor-Dex	178	Stem cell, Autologous	1	1	TRANSPLANT				4	106	3	212		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	135	1	8	212	4	106	1	2	1
MMRF_2409	1	Lenalidomide	Len	IMID	345	2429	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	2429	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	106	3	212		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	75	2085	0	8	212	4	106			1
MMRF_2585	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	2249	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	2249	IMIDs-based	IMIDs-based	Len-Dex				0					4	332	3	1201	262	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	81	2249	1	43	1201	12	332	1	2	1
MMRF_1750	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	79	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	79	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	128	Stem cell, Autologous	1	1	Completed regimen	4			2	148	1	1198		Complete Response	CR	Stringent Complete Response	sCR	1	0	1	0	3	79	1	43	1198	6	148	1	3	1
MMRF_1750	1	Lenalidomide	Len	IMID	212	2921	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	2921	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1					2	148	1	1198		Complete Response	CR	Stringent Complete Response	sCR	1	1	0	1	97	2710	0	43	1198	6	148			1
MMRF_2019	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	140	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	140	Bortezomib-based	Bortezomib-based	Bor-Dex	142	Stem cell, Autologous	1	1	Completed regimen	4			2	182	2	182		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	5	140	1	7	182	7	182	1	2	1
MMRF_2019	1	Lenalidomide	Len	IMID	251	303	2	Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Len	1	Proteasome/Steroid/IMID	303	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			2	182	2	182		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	2	53	0	7	182	7	182			1
MMRF_2019	1	Bortezomib	Bor	Proteasome	399	771	3	Bortezomib/Dexamethasone + Lenalidomide + Bortezomib	Bor-Dex + Len + Bor	1	Proteasome/Steroid/IMID	771	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			2	182	2	182		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	14	373	0	7	182	7	182			1
MMRF_2377	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	53	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	53	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			1	195	1	195		Complete Response	CR	Complete Response	CR	1	0	0	0	2	53	0	7	195	7	195	1	3	1
MMRF_2377	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	113	207	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	207	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			1	195	1	195		Complete Response	CR	Complete Response	CR	1	1	1	1	4	95	1	7	195	7	195			1
MMRF_2377	1	Lenalidomide	Len	IMID	208	2512	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2512	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					1	195	1	195		Complete Response	CR	Complete Response	CR	1	0	0	0	83	2305	0	7	195	7	195			1
MMRF_2380	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	177	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	177	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5			3	314	3	314		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	177	1	12	314	12	314	1	2	1
MMRF_2380	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	547	631	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	547	Proteasome/IMID/Steroid	631	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	661	Stem cell, Autologous	1	1	Completed regimen	4			2	729	2	729	578	Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	3	85	1	7	183	7	183	1	3	1
MMRF_2402	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	414	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	414	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	82	4	82		Partial Response	PR	Partial Response	PR	1	1	1	1	15	414	1	3	82	3	82	1	2	1
MMRF_2402	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	414	1368	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	414	Proteasome/IMID/Steroid	1368	IMIDs-based	IMIDs-based	Other Len-based therapies				0	DEATH				4	904	4	904	414	Partial Response	PR	Partial Response	PR	1	1	1	1	34	955	1	18	491	18	491	1	3	1
MMRF_1930	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	59	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	59	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	115	Stem cell, Autologous	1	1	Completed regimen	4			4	77	1	442		Complete Response	CR	Partial Response	PR	1	0	1	0	2	59	1	16	442	3	77	1	3	1
MMRF_1930	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	224	273	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	273	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	77	1	442		Complete Response	CR	Partial Response	PR	1	0	0	0	2	50	0	16	442	3	77			1
MMRF_1930	1	Lenalidomide	Len	IMID	274	2297	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2297	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	ALL DIAGNOSIS				4	77	1	442		Complete Response	CR	Partial Response	PR	1	1	0	1	73	2024	0	16	442	3	77			1
MMRF_2167	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	194	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	194	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	94	4	94	194	Partial Response	PR	Partial Response	PR	1	1	1	1	7	194	1	4	94	4	94	1	2	1
MMRF_2167	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	201	307	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	201	Proteasome/IMID/Steroid	307	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex	336	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			4	283	3	374		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	107	1	7	174	3	83	1	3	1
MMRF_2167	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	454	839	2	Carfilzomib/Lenalidomide/Dexamethasone + Elotuzumab/Lenalidomide/Dexamethasone	Car-Len-Dex + Elo-Len-Dex	201	Proteasome/IMID/Steroid/SLAMF7	839	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	DEATH				4	283	3	374		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	14	386	0	7	174	3	83			1
MMRF_2167	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	517	833	1	Daratumumab/Pomalidomide	Dar-Pom	517	CD38/IMID	833	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Disease progression/Relapse	3					6	552	552	Progressive Disease	PD			0	1	0	1	12	317	0	2	36			1	2	1
MMRF_2167	4	Carfilzomib	Car	Proteasome	636	677	1	Carfilzomib	Car	636	Proteasome	677	Carfilzomib-based	Carfilzomib-based	Car-Dex				0					4	720	4	720	636	Partial Response	PR	Partial Response	PR	1	0	0	0	2	42	0	4	85	4	85	1	1	1
MMRF_2167	4	Carfilzomib/Cyclophosphamide	Car-Cyc	Proteasome/Chemotherapy	678	823	2	Carfilzomib + Carfilzomib/Cyclophosphamide	Car + Car-Cyc	636	Proteasome/Chemotherapy	823	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	720	4	720	636	Partial Response	PR	Partial Response	PR	1	1	1	1	6	146	1	4	85	4	85			1
MMRF_2167	4	Carfilzomib	Car	Proteasome	824	824	3	Carfilzomib + Carfilzomib/Cyclophosphamide + Carfilzomib	Car + Car-Cyc + Car	636	Proteasome/Chemotherapy	824	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3			4	720	4	720	636	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	85	4	85			1
MMRF_2167	5	Pembrolizumab	Pemb	Checkpoint Inhibitor	825	825	1	Pembrolizumab	Pemb	825	Checkpoint Inhibitor	825	Other therapies	Other treatments					0	SUBJECT ON HOSPICE 1-5-17 AND EXPIRED SAME DAY													0	0	0	0	0	1	0							1
MMRF_1456	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	43	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	43	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Patient decision	6												0	0	0	0	2	43	0					1	3	1
MMRF_1535	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	154	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	154	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			3	86	3	86		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	154	1	4	86	4	86	1	2	1
MMRF_1535	1	Lenalidomide	Len	IMID	366	394	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	394	IMIDs-based	IMIDs-based	Len-Dex				0	Investigator decision for other reasons	5			3	86	3	86		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	29	0	4	86	4	86			1
MMRF_2112	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	201	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	201	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	PATIENT DECEASED				3	23	3	23		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	201	1	1	23	1	23	1	3	1
MMRF_2151	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	13	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	13	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3												0	0	0	0	1	13	0					1	3	1
MMRF_2379	1	Lenalidomide	Len	IMID	1	83	1	Lenalidomide	Len	1	IMID	83	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	63	3	63		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	83	1	3	63	3	63	1	1	1
MMRF_1882	1	Bortezomib	Bor	Proteasome	1	29	1	Bortezomib	Bor	1	Proteasome	29	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	364	1052	Stable Disease	SD			0	0	0	0	1	29	0	13	364			1	1	1
MMRF_1882	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	30	562	2	Bortezomib + Bortezomib/Cyclophosphamide/Dexamethasone	Bor + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	562	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Patient decision	6					5	364	1052	Stable Disease	SD			0	1	0	1	19	533	0	13	364					1
MMRF_2015	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	1	32	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	1	Chemotherapy/Steroid	32	Other therapies	Other treatments					1							6	478	478	Progressive Disease	PD			0	0	0	0	1	32	0	18	478					1
MMRF_2015	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	33	138	2	Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Cyc-Dex + Bor-Cyc-Dex	1	Chemotherapy/Steroid/Proteasome	138	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Adverse Event or co-morbidity	2					6	478	478	Progressive Disease	PD			0	0	0	0	4	106	0	18	478			1	3	1
MMRF_2015	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	139	520	3	Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Cyc-Dex + Bor-Cyc-Dex	1	Chemotherapy/Steroid/Proteasome	520	Bortezomib-based	Other treatments	Bor-Cyc-Dex	258	Stem cell, Autologous	1	1	DEATH						6	478	478	Progressive Disease	PD			0	1	0	1	14	382	0	18	478					1
MMRF_2187	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	11	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	11	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	1	11	0					1	3	1
MMRF_2386	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	179	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	179	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4					5	78		Stable Disease	SD			0	1	0	1	7	179	0	3	78			1	3	1
MMRF_2386	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	197	316	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	197	Proteasome/IMID/Steroid	316	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3					6	327	327	Progressive Disease	PD			0	1	0	1	5	120	0	5	131			1	3	1
MMRF_2386	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	341	466	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	341	Proteasome/IMID/Steroid	466	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0							5	610	454	Stable Disease	SD			0	0	0	0	5	126	0	10	270			1	3	1
MMRF_2386	3	Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Pom-Dex	Proteasome/IMID/IMID/Steroid	467	2532	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Pomalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Pom-Dex	341	Proteasome/IMID/Steroid	2532	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0							5	610	454	Stable Disease	SD			0	1	0	1	74	2066	0	10	270					1
MMRF_2386	4	Daratumumab	Dar	CD38	867	2532	1	Daratumumab	Dar	867	CD38	2532	daratumumab-based	daratumumab-based	Dar				0							5	909		Stable Disease	SD			0	1	0	1	60	1666	0	2	43					1
MMRF_2078	1	Bortezomib	Bor	Proteasome	1	1	1	Bortezomib	Bor	1	Proteasome	1	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	0	1	0					1	1	1
MMRF_1644	1	Bortezomib	Bor	Proteasome	1	66	1	Bortezomib	Bor	1	Proteasome	66	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	66	4	66		Partial Response	PR	Partial Response	PR	1	1	1	1	3	66	1	3	66	3	66	1	1	1
MMRF_2118	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1160	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1160	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	188	3	372		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	42	1160	1	14	372	7	188	1	2	1
MMRF_2118	2	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	624	1044	1	Elotuzumab/Lenalidomide	Elo-Len	624	SLAMF7/IMID	1044	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	824	4	824	625	Partial Response	PR	Partial Response	PR	1	1	1	1	15	421	1	8	201	8	201	1	2	1
MMRF_2118	3	Bortezomib/Daratumumab/Methotrexate	Bor-Dar-MTX	Proteasome/CD38/Chemotherapy	1037	1160	1	Bortezomib/Daratumumab/Methotrexate	Bor-Dar-MTX	1037	Proteasome/CD38/Chemotherapy	1160	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0														0	0	0	0	5	124	0					1	3	1
MMRF_2138	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	119	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	119	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Lack of response	1					5	88	455	Stable Disease	SD			0	1	0	1	5	119	0	4	88			1	2	1
MMRF_2138	1	Carfilzomib	Car	Proteasome	165	567	2	Bortezomib/Dexamethasone + Carfilzomib	Bor-Dex + Car	1	Proteasome/Steroid	567	combined bortezomib/carfilzomib-based	Carfilzomib-based	Bor-Car-Dex				0	Disease progression/Relapse	3					5	88	455	Stable Disease	SD			0	0	0	0	15	403	0	4	88					1
MMRF_2138	2	Elotuzumab/Lenalidomide	Elo-Len	SLAMF7/IMID	609	1873	1	Elotuzumab/Lenalidomide	Elo-Len	609	SLAMF7/IMID	1873	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	810	4	810		Partial Response	PR	Partial Response	PR	1	1	1	1	45	1265	1	8	202	8	202	1	2	1
MMRF_2138	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1887	2499	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1887	Proteasome/CD38/Steroid	2499	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0					4	1985	4	1985		Partial Response	PR	Partial Response	PR	1	1	1	1	22	613	1	4	99	4	99	1	3	1
MMRF_1706	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	105	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	105	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	84	2	455	2352	Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	4	105	1	17	455	3	84	1	3	1
MMRF_1706	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	160	163	2	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan	Bor-Cyc-Dex + Bus-Mel	1	Proteasome/Chemotherapy/Steroid	163	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	165	Stem cell, Autologous	1	1	Completed regimen	4			4	84	2	455	2352	Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	4	0	17	455	3	84			1
MMRF_1706	1	Lenalidomide	Len	IMID	265	455	3	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bus-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	455	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	84	2	455	2352	Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	7	191	0	17	455	3	84			1
MMRF_1881	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	171	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	171	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			4	80	3	150		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	171	1	6	150	3	80	1	3	1
MMRF_1881	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	249	252	2	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan	Bor-Cyc-Dex + Bus-Mel	1	Proteasome/Chemotherapy/Steroid	252	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	254	Stem cell, Autologous	1	1	Completed regimen	4			4	80	3	150		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	4	0	6	150	3	80			1
MMRF_1881	1	Lenalidomide	Len	IMID	358	751	3	Bortezomib/Cyclophosphamide/Dexamethasone + Busulfan/Melphalan + Lenalidomide	Bor-Cyc-Dex + Bus-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	751	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2			4	80	3	150		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	14	394	0	6	150	3	80			1
MMRF_1881	2	Alemtuzumab/Fludarabine/Melphalan/Methotrexate	Alem-Flu-Mel-MTX	CD52/Chemotherapy/Chemotherapy/Chemotherapy	1249	1258	1	Alemtuzumab/Fludarabine/Melphalan/Methotrexate	Alem-Flu-Mel-MTX	1249	CD52/Chemotherapy	1258	Other therapies	Other treatments		1255	Stem cell, Allogenic	2	1	Completed regimen	4			3	1355	3	1355		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	10	1	4	107	4	107			1
MMRF_1972	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	368	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	368	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	95	3	179	814	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	13	368	1	7	179	4	95	1	3	1
MMRF_1972	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1054	1915	1	Lenalidomide/Dexamethasone	Len-Dex	1054	IMID/Steroid	1915	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	1184	3	1719	1914	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	31	862	1	24	666	5	131	1	2	1
MMRF_1972	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1933	2129	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1933	Proteasome/CD38/Steroid	2129	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3			4	1996	4	1996	2172	Partial Response	PR	Partial Response	PR	1	1	1	1	7	197	1	3	64	3	64	1	3	1
MMRF_2007	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	101	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	101	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	154	Stem cell, Autologous	1	1	Completed regimen	4			4	87	3	274	1214	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	101	1	10	274	4	87	1	3	1
MMRF_2007	1	Lenalidomide	Len	IMID	436	1005	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1005	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Patient decision	6			4	87	3	274	1214	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	21	570	0	10	274	4	87			1
MMRF_2007	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1704	2723	1	Daratumumab/Dexamethasone	Dar-Dex	1704	CD38/Steroid	2723	daratumumab-based	daratumumab-based	Dar-Dex				0					3	1729	3	1729		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	37	1020	1	1	26	1	26			1
MMRF_1829	1	Bortezomib	Bor	Proteasome	1	48	1	Bortezomib	Bor	1	Proteasome	48	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	77	1	371	917	Complete Response	CR	Partial Response	PR	1	0	0	0	2	48	0	14	371	3	77	1	1	1
MMRF_1829	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	49	93	2	Bortezomib + Bortezomib/Lenalidomide	Bor + Bor-Len	1	Proteasome/IMID	93	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	I DIDN'T SEE THE REASON FOR DISCONTINUED DOCUMENTED. THE NURSE AND MD ARE NO LONGER HERE.				4	77	1	371	917	Complete Response	CR	Partial Response	PR	1	0	1	0	2	45	1	14	371	3	77			1
MMRF_1829	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	94	245	3	Bortezomib + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor + Bor-Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid	245	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	77	1	371	917	Complete Response	CR	Partial Response	PR	1	0	0	0	6	152	0	14	371	3	77			1
MMRF_1829	1	Lenalidomide	Len	IMID	246	455	4	Bortezomib + Bortezomib/Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor + Bor-Len + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	455	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5			4	77	1	371	917	Complete Response	CR	Partial Response	PR	1	1	0	1	8	210	0	14	371	3	77			1
MMRF_1829	2	Carfilzomib	Car	Proteasome	938	939	1	Carfilzomib	Car	938	Proteasome	939	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	0	2	0					1	1	1
MMRF_1977	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	2730	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	2730	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	365	Stem cell, Autologous	1	1					3	92	1	353		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	98	2730	1	13	353	4	92	1	3	1
MMRF_2012	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	390	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	390	IMIDs-based	IMIDs-based	Len-Dex				0	Completed regimen	4			1	176	1	176		Complete Response	CR	Complete Response	CR	1	1	1	1	14	390	1	7	176	7	176	1	2	1
MMRF_2012	1	Lenalidomide	Len	IMID	391	418	2	Lenalidomide/Dexamethasone + Lenalidomide	Len-Dex + Len	1	IMID/Steroid	418	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			1	176	1	176		Complete Response	CR	Complete Response	CR	1	0	0	0	1	28	0	7	176	7	176			1
MMRF_2012	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	597	1236	1	Lenalidomide/Dexamethasone	Len-Dex	597	IMID/Steroid	1236	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			3	633	3	633		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	23	640	1	2	37	2	37	1	2	1
MMRF_2106	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	225	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	225	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	159	3	159	265	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	225	1	6	159	6	159	1	3	1
MMRF_2106	2	Bortezomib/Carfilzomib/Dexamethasone/Doxorubicin	Bor-Car-Dex-Dox	Proteasome/Proteasome/Steroid/Chemotherapy	271	336	1	Bortezomib/Carfilzomib/Dexamethasone/Doxorubicin	Bor-Car-Dex-Dox	271	Proteasome/Steroid/Chemotherapy	336	combined bortezomib/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0														0	0	0	0	3	66	0					1	4	1
MMRF_2106	2	Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Car-Cyc-Dex-Dox	Proteasome/Proteasome/Chemotherapy/Steroid/Chemotherapy	337	337	2	Bortezomib/Carfilzomib/Dexamethasone/Doxorubicin + Bortezomib/Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Car-Dex-Dox + Bor-Car-Cyc-Dex-Dox	271	Proteasome/Steroid/Chemotherapy	337	combined bortezomib/carfilzomib-based	combined bortezomib/carfilzomib-based	Other bortezomib/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2125	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	442	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	442	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3			3	159	3	159	323	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	16	442	1	6	159	6	159	1	3	1
MMRF_2125	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	455	512	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	455	SLAMF7/IMID/Steroid	512	IMIDs-based	IMIDs-based	Other Len-based therapies				0	ELOTUZUMAB WAS APPROVED BY THE FDA.						5	509	1238	Stable Disease	SD			0	1	0	1	2	58	0	2	55			1	3	1
MMRF_2125	2	Elotuzumab/Dexamethasone	Elo-Dex	SLAMF7/Steroid	518	608	2	Elotuzumab/Lenalidomide/Dexamethasone + Elotuzumab/Dexamethasone	Elo-Len-Dex + Elo-Dex	455	SLAMF7/IMID/Steroid	608	IMIDs-based	Other treatments	Other Len-based therapies				0							5	509	1238	Stable Disease	SD			0	0	0	0	4	91	0	2	55					1
MMRF_2125	2	Carfilzomib/Elotuzumab/Dexamethasone	Car-Elo-Dex	Proteasome/SLAMF7/Steroid	609	609	3	Elotuzumab/Lenalidomide/Dexamethasone + Elotuzumab/Dexamethasone + Carfilzomib/Elotuzumab/Dexamethasone	Elo-Len-Dex + Elo-Dex + Car-Elo-Dex	455	SLAMF7/IMID/Steroid/Proteasome	609	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	STABLE PROTEINS						5	509	1238	Stable Disease	SD			0	0	0	0	0	1	0	2	55					1
MMRF_2125	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	610	1483	4	Elotuzumab/Lenalidomide/Dexamethasone + Elotuzumab/Dexamethasone + Carfilzomib/Elotuzumab/Dexamethasone + Carfilzomib/Dexamethasone	Elo-Len-Dex + Elo-Dex + Car-Elo-Dex + Car-Dex	455	SLAMF7/IMID/Steroid/Proteasome	1483	combined IMIDs/carfilzomib-based	Carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0							5	509	1238	Stable Disease	SD			0	0	0	0	32	874	0	2	55					1
MMRF_2256	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	309	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	309	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3					5	175	283	Stable Disease	SD			0	1	0	1	11	309	0	7	175			1	2	1
MMRF_2259	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	123	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DEATH													0	0	0	0	5	123	0					1	3	1
MMRF_2525	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	505	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	505	IMIDs-based	IMIDs-based	Len-Dex				0	DOSE OR FREQUENCY CHANGE						5	92		Stable Disease	SD			0	1	0	1	18	505	0	4	92			1	2	1
MMRF_2525	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	148	519	1	Bortezomib/Dexamethasone	Bor-Dex	148	Proteasome/Steroid	519	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	358	3	555		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	372	1	15	408	8	211	1	2	1
MMRF_1753	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	101	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	101	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DEATH						5	81		Stable Disease	SD			0	1	0	1	4	101	0	3	81			1	3	1
MMRF_1786	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	138	Stem cell, Autologous	1	1	Completed regimen	4			4	100	3	422	1416	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	120	1	16	422	4	100	1	3	1
MMRF_1786	1	Lenalidomide	Len	IMID	207	1290	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1290	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Investigator decision for other reasons	5			4	100	3	422	1416	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	39	1084	0	16	422	4	100			1
MMRF_1786	2	Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car-Elo-Len-Dex	Proteasome/SLAMF7/IMID/Steroid	1444	2951	1	Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car-Elo-Len-Dex	1444	Proteasome/SLAMF7/IMID/Steroid	2951	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	1528	4	1528		Partial Response	PR	Partial Response	PR	1	1	1	1	54	1508	1	4	85	4	85	1	4	1
MMRF_1786	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	2060	2951	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	2060	CD38/IMID/Steroid	2951	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0					4	2172	4	2172		Partial Response	PR	Partial Response	PR	1	1	1	1	32	892	1	5	113	5	113	1	3	1
MMRF_1793	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	105	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	105	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	129	Stem cell, Autologous	1	1	Completed regimen	4			4	84	1	2859		Complete Response	CR	Partial Response	PR	1	0	1	0	4	105	1	103	2859	3	84	1	3	1
MMRF_1793	1	Lenalidomide	Len	IMID	196	2859	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2859	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					4	84	1	2859		Complete Response	CR	Partial Response	PR	1	1	0	1	95	2664	0	103	2859	3	84			1
MMRF_1816	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	100	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	100	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	133	Stem cell, Autologous	1	1	Completed regimen	4			3	101	2	913		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	4	100	1	33	913	4	101	1	3	1
MMRF_1816	1	Carfilzomib/Pomalidomide/Dexamethasone	Car-Pom-Dex	Proteasome/IMID/Steroid	232	1978	2	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Pomalidomide/Dexamethasone	Bor-Cyc-Dex + Car-Pom-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1978	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				1	Completed regimen	4			3	101	2	913		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	63	1747	0	33	913	4	101			1
MMRF_1842	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	123	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	159	Stem cell, Autologous	1	1	Completed regimen	4			4	64	3	190	731	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	123	1	7	190	3	64	1	3	1
MMRF_1842	1	Lenalidomide	Len	IMID	227	689	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	689	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	64	3	190	731	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	17	463	0	7	190	3	64			1
MMRF_1842	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	732	1289	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	732	SLAMF7/IMID/Steroid	1289	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Investigator decision for other reasons	5					5	814	892	Stable Disease	SD			0	1	0	1	20	558	0	3	83			1	3	1
MMRF_1842	3	Daratumumab/Pomalidomide	Dar-Pom	CD38/IMID	898	1122	1	Daratumumab/Pomalidomide	Dar-Pom	898	CD38/IMID	1122	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom				0	Investigator decision for other reasons	5			4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	1	1	1	8	225	1	4	99	4	99	1	2	1
MMRF_1842	3	Pomalidomide	Pom	IMID	1123	1142	2	Daratumumab/Pomalidomide	Dar-Pom	898	CD38/IMID	1142	combined daratumumab/IMIDs-based	IMIDs-based	Dar-Pom				0	Investigator decision for other reasons	5			4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	0	0	0	1	20	0	4	99	4	99			1
MMRF_1842	3	Carfilzomib/Venetoclax	Car-Vent	Proteasome/BCL2	1157	1290	3	Daratumumab/Pomalidomide + Carfilzomib/Venetoclax	Dar-Pom + Car-Vent	898	CD38/IMID/Proteasome/BCL2	1290	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Investigator decision for other reasons	5			4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	0	0	0	5	134	0	4	99	4	99			1
MMRF_1842	3	Venetoclax	Vent	BCL2	1291	1295	4	Daratumumab/Pomalidomide + Carfilzomib/Venetoclax	Dar-Pom + Car-Vent	898	CD38/IMID/Proteasome/BCL2	1295	combined daratumumab/IMIDs/carfilzomib-based	Other treatments	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Investigator decision for other reasons	5			4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	0	0	0	0	5	0	4	99	4	99			1
MMRF_1842	3	Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Car-Cyc-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	1297	1324	5	Daratumumab/Pomalidomide + Carfilzomib/Venetoclax + Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Dar-Pom + Car-Vent + Car-Cyc-Dex-Dox	898	CD38/IMID/Proteasome/BCL2/Chemotherapy/Steroid	1324	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0					4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	0	0	0	1	28	0	4	99	4	99			1
MMRF_1842	3	Carfilzomib/Cyclophosphamide/Panobinostat/Dexamethasone/Doxorubicin	Car-Cyc-Pano-Dex-Dox	Proteasome/Chemotherapy/HDAC/Steroid/Chemotherapy	1325	1372	6	Daratumumab/Pomalidomide + Carfilzomib/Venetoclax + Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin + Carfilzomib/Cyclophosphamide/Panobinostat/Dexamethasone/Doxorubicin	Dar-Pom + Car-Vent + Car-Cyc-Dex-Dox + Car-Cyc-Pano-Dex-Dox	898	CD38/IMID/Proteasome/BCL2/Chemotherapy/Steroid/HDAC	1372	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Investigator decision for other reasons	5			4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	0	0	0	2	48	0	4	99	4	99			1
MMRF_1842	3	Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Car-Cyc-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	1373	1522	7	Daratumumab/Pomalidomide + Carfilzomib/Venetoclax + Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin + Carfilzomib/Cyclophosphamide/Panobinostat/Dexamethasone/Doxorubicin + Carfilzomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Dar-Pom + Car-Vent + Car-Cyc-Dex-Dox + Car-Cyc-Pano-Dex-Dox + Car-Cyc-Dex-Dox	898	CD38/IMID/Proteasome/BCL2/Chemotherapy/Steroid/HDAC	1522	combined daratumumab/IMIDs/carfilzomib-based	Carfilzomib-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0	Disease progression/Relapse	3			4	996	4	996	1354	Partial Response	PR	Partial Response	PR	1	0	0	0	6	150	0	4	99	4	99			1
MMRF_1842	4	Pomalidomide/Cyclophosphamide	Pom-Cyc	IMID/Chemotherapy	1409	1522	1	Pomalidomide/Cyclophosphamide	Pom-Cyc	1409	IMID/Chemotherapy	1522	IMIDs-based	IMIDs-based	Pom-Cyc				0	Disease progression/Relapse	3			4	1437	4	1437	1530	Partial Response	PR	Partial Response	PR	1	1	1	1	4	114	1	2	29	2	29	1	2	1
MMRF_1858	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	25	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	25	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	76	3	263	742	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	1	25	1	10	263	3	76	1	3	1
MMRF_1858	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	76	327	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	327	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	76	3	263	742	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	9	252	1	10	263	3	76			1
MMRF_1858	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	744	1033	1	Lenalidomide/Dexamethasone	Len-Dex	744	IMID/Steroid	1033	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	910	4	910	994	Partial Response	PR	Partial Response	PR	1	1	1	1	11	290	1	6	167	6	167	1	2	1
MMRF_1858	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1037	1278	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1037	Proteasome/Chemotherapy/Steroid	1278	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	DEATH				4	1090	4	1090	1175	Partial Response	PR	Partial Response	PR	1	1	1	1	9	242	1	2	54	2	54	1	3	1
MMRF_1886	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	143	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	143	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	81	3	81	1493	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	143	1	3	81	3	81	1	3	1
MMRF_1886	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	155	477	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	477	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	81	3	81	1493	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	323	0	3	81	3	81			1
MMRF_1886	1	Bortezomib	Bor	Proteasome	547	561	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	561	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	81	3	81	1493	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	15	0	3	81	3	81			1
MMRF_1886	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1514	2336	1	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	1514	SLAMF7/IMID/Steroid	2336	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	1626	1	1730		Complete Response	CR	Partial Response	PR	1	1	1	1	30	823	1	8	217	5	113	1	3	1
MMRF_2074	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	67	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	67	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				1	Adverse Event or co-morbidity	2			3	78	2	231	1163	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	3	67	0	9	231	3	78	1	3	1
MMRF_2074	1	Thalidomide	Thal	IMID	68	84	2	Bortezomib/Thalidomide/Dexamethasone + Thalidomide	Bor-Thal-Dex + Thal	1	Proteasome/IMID/Steroid	84	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Thal-Dex				1					3	78	2	231	1163	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	1	17	1	9	231	3	78			1
MMRF_2074	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	85	116	3	Bortezomib/Thalidomide/Dexamethasone + Thalidomide + Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex + Thal + Bor-Thal-Dex	1	Proteasome/IMID/Steroid	116	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				1	Completed regimen	4			3	78	2	231	1163	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	32	0	9	231	3	78			1
MMRF_2074	1	Thalidomide	Thal	IMID	117	127	4	Bortezomib/Thalidomide/Dexamethasone + Thalidomide + Bortezomib/Thalidomide/Dexamethasone + Thalidomide	Bor-Thal-Dex + Thal + Bor-Thal-Dex + Thal	1	Proteasome/IMID/Steroid	127	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Thal-Dex	171	Stem cell, Autologous	1	1	Completed regimen	4			3	78	2	231	1163	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	1	11	0	9	231	3	78			1
MMRF_2074	1	Bortezomib	Bor	Proteasome	302	1198	5	Bortezomib/Thalidomide/Dexamethasone + Thalidomide + Bortezomib/Thalidomide/Dexamethasone + Thalidomide + Bortezomib	Bor-Thal-Dex + Thal + Bor-Thal-Dex + Thal + Bor	1	Proteasome/IMID/Steroid	1198	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Thal-Dex				1	Disease progression/Relapse	3			3	78	2	231	1163	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	32	897	0	9	231	3	78			1
MMRF_2074	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1268	2724	1	Carfilzomib/Dexamethasone	Car-Dex	1268	Proteasome/Steroid	2724	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	1352	3	1520		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	52	1457	1	10	253	4	85	1	2	1
MMRF_2093	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	127	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	127	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	179	Stem cell, Autologous	1	1	Completed regimen	4	2035		3	79	1	353	751	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	127	1	13	353	3	79	1	3	1
MMRF_2093	1	Lenalidomide	Len	IMID	253	531	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	531	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Investigator decision for other reasons	5	2035		3	79	1	353	751	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	10	279	0	13	353	3	79			1
MMRF_2093	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	827	1158	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	827	Proteasome/Chemotherapy/Steroid	1158	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Investigator decision for other reasons	5	2035		3	1060	3	1060	1167	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	12	332	1	9	234	9	234	1	3	1
MMRF_2093	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1172	1811	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1172	CD38/IMID/Steroid	1811	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2035		4	1257	1	1627		Complete Response	CR	Partial Response	PR	1	1	1	1	23	640	1	17	456	4	86	1	3	1
MMRF_2093	4	MEDI2228	MEDI2228	BCMA	1837	1888	1	MEDI2228	MEDI2228	1837	BCMA	1888	Other therapies	Other treatments					0	Disease progression/Relapse	3	2035											0	0	0	0	2	52	0							1
MMRF_2093	5	Carfilzomib/Selinexor/Dexamethasone	Car-Sel-Dex	Proteasome/XPO1/Steroid	1979	2022	1	Carfilzomib/Selinexor/Dexamethasone	Car-Sel-Dex	1979	Proteasome/XPO1/Steroid	2022	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2035		4	1983	4	1983	2035	Partial Response	PR	Partial Response	PR	1	1	1	1	2	44	1	1	5	1	5	1	3	1
MMRF_2093	9	Carfilzomib/Panobinostat	Car-Pano	Proteasome/HDAC	2028	2043	1	Carfilzomib/Panobinostat	Car-Pano	2028	Proteasome/HDAC	2043	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2035											0	0	0	0	1	16	0					1	2	1
MMRF_2266	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	68	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	68	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	89	3	89		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	68	0	4	89	4	89	1	3	1
MMRF_2266	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	69	369	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	369	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	89	3	89		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	301	1	4	89	4	89			1
MMRF_2306	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	168	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	168	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	63	4	63	259	Partial Response	PR	Partial Response	PR	1	1	1	1	6	168	1	3	63	3	63	1	3	1
MMRF_2306	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	169	245	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	245	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3			4	63	4	63	259	Partial Response	PR	Partial Response	PR	1	0	0	0	3	77	0	3	63	3	63			1
MMRF_2306	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	266	371	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	266	Proteasome/Chemotherapy/Steroid	371	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	427	Stem cell, Autologous	1	1	Completed regimen	4			4	343	3	526		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	106	1	10	261	3	78	1	3	1
MMRF_2306	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	502	961	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Car-Cyc-Dex + Car-Dex	266	Proteasome/Chemotherapy/Steroid	961	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Investigator decision for other reasons	5			4	343	3	526		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	17	460	0	10	261	3	78			1
MMRF_2306	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1006	2528	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1006	Proteasome/IMID/Steroid	2528	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	1055	3	1055		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	55	1523	1	2	50	2	50	1	3	1
MMRF_2486	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	176	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	176	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	219	Stem cell, Autologous	1	1	Completed regimen	4			4	64	2	1840		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	7	176	1	66	1840	3	64	1	3	1
MMRF_2486	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	288	552	2	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Car-Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	552	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			4	64	2	1840		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	10	265	0	66	1840	3	64			1
MMRF_2486	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	553	553	3	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Bor-Cyc-Dex + Car-Len-Dex + Car-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	553	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	Completed regimen	4			4	64	2	1840		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	1	0	66	1840	3	64			1
MMRF_2486	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	560	2484	4	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone + Carfilzomib/Lenalidomide	Bor-Cyc-Dex + Car-Len-Dex + Car-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	2484	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1					4	64	2	1840		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	69	1925	0	66	1840	3	64			1
MMRF_2497	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	2535	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	2535	IMIDs-based	IMIDs-based	Len-Dex				0					4	239	3	686		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	91	2535	1	25	686	9	239	1	2	1
MMRF_2501	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	172	Stem cell, Autologous	1	1	Completed regimen	4			4	85	1	434	982	Complete Response	CR	Partial Response	PR	1	0	1	0	4	113	1	16	434	4	85	1	3	1
MMRF_2501	1	Lenalidomide	Len	IMID	276	984	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	984	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			4	85	1	434	982	Complete Response	CR	Partial Response	PR	1	1	0	1	26	709	0	16	434	4	85			1
MMRF_2501	2	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1012	2556	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1012	Proteasome/CD38/Steroid	2556	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0					4	1068	1	1340		Complete Response	CR	Partial Response	PR	1	1	1	1	55	1545	1	12	329	3	57	1	3	1
MMRF_2557	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	130	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	130	Bortezomib-based	Bortezomib-based	Bor-Dex				0							5	124	131	Stable Disease	SD			0	1	0	1	5	130	0	5	124			1	2	1
MMRF_2557	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	131	222	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	222	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Disease progression/Relapse	3					5	124	131	Stable Disease	SD			0	0	0	0	4	92	0	5	124					1
MMRF_2557	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	223	264	3	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Steroid/Chemotherapy	264	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2					5	124	131	Stable Disease	SD			0	0	0	0	2	42	0	5	124					1
MMRF_2557	2	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	232	264	1	Carfilzomib/Lenalidomide	Car-Len	232	Proteasome/IMID	264	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car				0	Adverse Event or co-morbidity	2					5	257		Stable Disease	SD			0	1	0	1	1	33	0	1	26			1	2	1
MMRF_2087	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	164	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	164	IMIDs-based	IMIDs-based	Len-Dex				0					4	103	4	103	190	Partial Response	PR	Partial Response	PR	1	1	1	1	6	164	1	4	103	4	103	1	2	1
MMRF_2087	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	165	198	2	Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Len-Dex + Bor-Len-Dex	1	IMID/Steroid/Proteasome	198	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY				4	103	4	103	190	Partial Response	PR	Partial Response	PR	1	0	0	0	2	34	0	4	103	4	103			1
MMRF_2087	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	208	248	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	208	Proteasome/IMID/Steroid	248	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0														0	0	0	0	2	41	0					1	3	1
MMRF_2087	2	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	249	261	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	208	Proteasome/IMID/Steroid	261	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex				0	BEGAN HOSPICE CARE STRICT PALLIATIVE CARE ONLY WITHOUT CHEMOTHERAPY													0	0	0	0	1	13	0							1
MMRF_2141	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	175	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	175	Bortezomib-based	Bortezomib-based	Bor-Dex				1	HOLD VELCADE: EVAL FOR AUTOLOGOUS TRANSPLANT				4	88	3	245	1143	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	175	1	9	245	4	88	1	2	1
MMRF_2141	1	Melphalan/Dexamethasone	Mel-Dex	Chemotherapy/Steroid	268	299	2	Bortezomib/Dexamethasone + Melphalan/Dexamethasone	Bor-Dex + Mel-Dex	1	Proteasome/Steroid/Chemotherapy	299	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	270	Stem cell, Autologous	1	1	Completed regimen	4			4	88	3	245	1143	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	32	0	9	245	4	88			1
MMRF_2141	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1837	2740	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1837	Proteasome/IMID/Steroid	2740	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	2003	4	2003	1837	Partial Response	PR	Partial Response	PR	1	1	1	1	33	904	1	6	167	6	167	1	3	1
MMRF_2149	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	163	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	163	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Patient decision	6			4	86	3	351		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	163	1	13	351	4	86	1	2	1
MMRF_2153	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	382	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	382	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Disease progression/Relapse	3			4	360	4	360		Partial Response	PR	Partial Response	PR	1	1	1	1	14	382	1	13	360	13	360	1	2	1
MMRF_2153	2	Lenalidomide	Len	IMID	393	584	1	Lenalidomide	Len	393	IMID	584	IMIDs-based	IMIDs-based	Len-Dex				0	PATIENT LOST TO FOLLOW-UP AFTER THIS CYCLE, MOVED TO DIFFERENT CITY				4	445	4	445		Partial Response	PR	Partial Response	PR	1	1	1	1	7	192	1	2	53	2	53	1	1	1
MMRF_2191	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	379	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	379	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Investigator decision for other reasons	5	1982		4	77	3	350	567	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	14	379	1	13	350	3	77	1	2	1
MMRF_2191	2	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	568	694	1	Carfilzomib/Lenalidomide	Car-Len	568	Proteasome/IMID	694	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car	731	Stem cell, Autologous	1	1	Completed regimen	4	1982		3	644	3	644		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	127	1	3	77	3	77	1	2	1
MMRF_2191	3	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	868	1291	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	868	CD38/IMID/Steroid	1291	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3	1982				5	889	1340	Stable Disease	SD			0	1	0	1	15	424	0	1	22			1	3	1
MMRF_2191	4	Melflufen/Dexamethasone	Melf-Dex	Chemotherapy/Steroid	1353	1780	1	Melflufen/Dexamethasone	Melf-Dex	1353	Chemotherapy/Steroid	1780	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2	1982				5	1437	1847	Stable Disease	SD			0	1	0	1	16	428	0	4	85					1
MMRF_2191	5	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	SLAMF7/IMID/Steroid	1855	1939	1	Elotuzumab/Pomalidomide/Dexamethasone	Elo-Pom-Dex	1855	SLAMF7/IMID/Steroid	1939	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Lack of response	1	1982		4	2198	4	2198	1982	Partial Response	PR	Partial Response	PR	1	0	0	0	3	85	0	13	344	13	344	1	3	1
MMRF_2191	9	Selinexor/Dexamethasone	Sel-Dex	XPO1/Steroid	1968	2150	1	Selinexor/Dexamethasone	Sel-Dex	1968	XPO1/Steroid	2150	Other therapies	Other treatments					0			1982											0	0	0	0	7	183	0							1
MMRF_2191	9	Bortezomib/Panobinostat/Selinexor/Dexamethasone	Bor-Pano-Sel-Dex	Proteasome/HDAC/XPO1/Steroid	2151	2744	2	Selinexor/Dexamethasone + Bortezomib/Panobinostat/Selinexor/Dexamethasone	Sel-Dex + Bor-Pano-Sel-Dex	1968	XPO1/Steroid/Proteasome/HDAC	2744	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0			1982											0	0	0	0	22	594	0					1	4	1
MMRF_2228	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	406	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	406	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	280	4	280		Partial Response	PR	Partial Response	PR	1	1	1	1	15	406	1	10	280	10	280	1	2	1
MMRF_2301	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	157	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	157	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			4	-20	3	276	1003	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	6	157	0	10	276	0	-20	1	2	1
MMRF_2301	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1122	1284	1	Lenalidomide/Dexamethasone	Len-Dex	1122	IMID/Steroid	1284	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	1248	4	1248	1289	Partial Response	PR	Partial Response	PR	1	1	1	1	6	163	1	5	127	5	127	1	2	1
MMRF_1766	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	155	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	155	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	218	Stem cell, Autologous	1	1	Completed regimen	4			3	78	1	714	1002	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	155	1	26	714	3	78	1	3	1
MMRF_1766	1	Bortezomib	Bor	Proteasome	339	989	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	989	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Disease progression/Relapse	3			3	78	1	714	1002	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	24	651	0	26	714	3	78			1
MMRF_1766	2	Lenalidomide/Selinexor/Dexamethasone	Len-Sel-Dex	IMID/XPO1/Steroid	1066	2906	1	Lenalidomide/Selinexor/Dexamethasone	Len-Sel-Dex	1066	IMID/XPO1/Steroid	2906	IMIDs-based	IMIDs-based	Other Len-based therapies				0					3	1162	1	1439		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	66	1841	1	14	374	4	97	1	3	1
MMRF_1824	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	163	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	163	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	221	Stem cell, Autologous	1	1	Completed regimen	4			4	57	3	325		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	163	1	12	325	3	57	1	3	1
MMRF_1824	1	Lenalidomide	Len	IMID	325	1997	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1997	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1					4	57	3	325		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	60	1673	0	12	325	3	57			1
MMRF_1879	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	225	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	225	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	PATIENT INABLE TO COMPLY WITH TREATMENT				3	85	2	249		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	1	1	8	225	1	9	249	4	85	1	3	1
MMRF_2006	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	102	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	102	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Completed regimen	4			3	92	2	260		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	4	102	1	10	260	4	92	1	3	1
MMRF_2006	1	Melphalan/Plerixafor	Mel-Pler	Chemotherapy	121	127	2	Bortezomib/Cyclophosphamide/Dexamethasone + Melphalan/Plerixafor	Bor-Cyc-Dex + Mel-Pler	1	Proteasome/Chemotherapy/Steroid	127	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)	128	Stem cell, Autologous	1	1	Completed regimen	4			3	92	2	260		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	7	0	10	260	4	92			1
MMRF_2006	1	Bortezomib	Bor	Proteasome	232	1064	3	Bortezomib/Cyclophosphamide/Dexamethasone + Melphalan/Plerixafor + Bortezomib	Bor-Cyc-Dex + Mel-Pler + Bor	1	Proteasome/Chemotherapy/Steroid	1064	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					3	92	2	260		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	30	833	0	10	260	4	92			1
MMRF_2047	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	162	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	162	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	186	Stem cell, Autologous	1	1	Completed regimen	4			4	78	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	162	1	6	162	3	78	1	3	1
MMRF_2047	1	Bortezomib	Bor	Proteasome	288	2703	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Bortezomib	Car-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	2703	combined bortezomib/carfilzomib-based	Bortezomib-based	Bor-Car-Cyc-Dex				1					4	78	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	87	2416	0	6	162	3	78			1
MMRF_2116	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	99	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	99	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	99	3	393		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	99	1	15	393	4	99	1	3	1
MMRF_2116	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	107	190	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	190	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex	227	Stem cell, Autologous	1	1	WENT TO TRANSPLANT				4	99	3	393		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	84	0	15	393	4	99			1
MMRF_2116	1	Lenalidomide	Len	IMID	303	639	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	639	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Adverse Event or co-morbidity	2			4	99	3	393		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	12	337	0	15	393	4	99			1
MMRF_2116	1	Bortezomib	Bor	Proteasome	729	2717	4	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib	Bor-Cyc-Dex + Len-Dex + Len + Bor	1	Proteasome/Chemotherapy/Steroid/IMID	2717	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				1					4	99	3	393		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	71	1989	0	15	393	4	99			1
MMRF_2201	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	8	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	8	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	41	4	41	253	Partial Response	PR	Partial Response	PR	1	1	1	1	1	8	1	2	41	2	41	1	3	1
MMRF_2232	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	57	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	57	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	57	1	800		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	2	57	1	29	800	3	57	1	3	1
MMRF_2232	1	Cyclophosphamide/Melphalan	Cyc-Mel	Chemotherapy/Chemotherapy	80	99	2	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan	Bor-Len-Dex + Cyc-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	99	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	100	Stem cell, Autologous	1	1	Completed regimen	4			3	57	1	800		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	20	0	29	800	3	57			1
MMRF_2232	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	176	207	3	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Cyc-Mel + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	207	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	57	1	800		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	32	0	29	800	3	57			1
MMRF_2232	1	Lenalidomide	Len	IMID	227	2720	4	Bortezomib/Lenalidomide/Dexamethasone + Cyclophosphamide/Melphalan + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Cyc-Mel + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2720	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1					3	57	1	800		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	89	2494	0	29	800	3	57			1
MMRF_2425	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	225	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	225	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	233	Stem cell, Autologous	1	1	Completed regimen	4			4	78	1	275		Complete Response	CR	Partial Response	PR	1	1	1	1	8	225	1	10	275	3	78	1	3	1
MMRF_2425	1	Lenalidomide	Len	IMID	344	812	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	812	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	PT WAS ON LEANALIDOMIDE MAINTENANCE UP TO HOSPITAL ADMIT ON 5/22				4	78	1	275		Complete Response	CR	Partial Response	PR	1	0	0	0	17	469	0	10	275	3	78			1
MMRF_2440	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	84	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	84	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	115	Stem cell, Autologous	1	1	Completed regimen	4			3	87	2	610		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	3	84	1	22	610	4	87	1	3	1
MMRF_2440	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	210	253	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	253	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	87	2	610		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	2	44	0	22	610	4	87			1
MMRF_2440	1	Lenalidomide	Len	IMID	254	2558	3	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2558	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	87	2	610		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	83	2305	0	22	610	4	87			1
MMRF_2485	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	238	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	238	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	292	Stem cell, Autologous	1	1	WENT TO TRANSPLANT				4	56	3	182		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	238	1	7	182	2	56	1	3	1
MMRF_2485	1	Bortezomib	Bor	Proteasome	434	2387	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib	Bor-Cyc-Dex + Bor	1	Proteasome/Chemotherapy/Steroid	2387	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	56	3	182		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	70	1954	0	7	182	2	56			1
MMRF_2566	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	73	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	73	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					3	72	2	162		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	3	73	1	6	162	3	72	1	3	1
MMRF_2566	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	74	74	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	74	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	STOPPED FOR STEM CELL COLLECTION				3	72	2	162		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	6	162	3	72			1
MMRF_2566	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	123	221	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	221	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	Completed regimen	4			3	72	2	162		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	4	99	0	6	162	3	72			1
MMRF_2566	1	Lenalidomide	Len	IMID	241	2370	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Cyc-Dex + Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	2370	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	72	2	162		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	76	2130	0	6	162	3	72			1
MMRF_2590	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	8	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	8	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	99	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	8	0	7	169	4	99	1	3	1
MMRF_2590	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	50	112	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Len-Dex + Bor-Dex	1	Proteasome/IMID/Steroid	112	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0					4	99	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	3	63	1	7	169	4	99			1
MMRF_2590	1	Bortezomib/Prednisone/Dexamethasone	Bor-Pred-Dex	Proteasome/Steroid/Steroid	113	113	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Prednisone/Dexamethasone	Bor-Len-Dex + Bor-Dex + Bor-Pred-Dex	1	Proteasome/IMID/Steroid	113	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Patient decision	6			4	99	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	7	169	4	99			1
MMRF_2590	1	Bortezomib/Prednisone	Bor-Pred	Proteasome/Steroid	114	2009	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone + Bortezomib/Prednisone/Dexamethasone + Bortezomib/Prednisone	Bor-Len-Dex + Bor-Dex + Bor-Pred-Dex + Bor-Pred	1	Proteasome/IMID/Steroid	2009	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0					4	99	3	169		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	68	1896	0	7	169	4	99			1
MMRF_2622	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	205	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	205	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	8	205	1	4	92	4	92	1	3	1
MMRF_2622	1	Lenalidomide	Len	IMID	206	2381	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	2381	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0					3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	78	2176	0	4	92	4	92			1
MMRF_2147	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	281	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	281	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			4	115	3	308	617	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	281	1	11	308	5	115	1	3	1
MMRF_2147	1	Lenalidomide	Len	IMID	309	392	2	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	392	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2			4	115	3	308	617	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	84	0	11	308	5	115			1
MMRF_2419	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	161	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	161	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0														0	0	0	0	6	161	0					1	3	1
MMRF_2419	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	162	274	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	274	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	PBSCT													0	0	0	0	4	113	0							1
MMRF_2419	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	162	274	1	Carfilzomib/Dexamethasone	Car-Dex	162	Proteasome/Steroid	274	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	PBSCT				4	166	1	997		Complete Response	CR	Partial Response	PR	1	0	1	0	4	113	1	30	836	1	5	1	2	1
MMRF_2419	2	Lenalidomide	Len	IMID	519	2514	2	Carfilzomib/Dexamethasone + Lenalidomide	Car-Dex + Len	162	Proteasome/Steroid/IMID	2514	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0					4	166	1	997		Complete Response	CR	Partial Response	PR	1	1	0	1	72	1996	0	30	836	1	5			1
MMRF_2438	1	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	1	106	1	Bortezomib/Cyclophosphamide	Bor-Cyc	1	Proteasome/Chemotherapy	106	Bortezomib-based	Bortezomib-based	Bor-Cyc	152	Stem cell, Autologous	1	1	Completed regimen	4			3	53	3	53		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	2	53	2	53	1	2	1
MMRF_2438	1	Bortezomib	Bor	Proteasome	288	383	2	Bortezomib/Cyclophosphamide + Bortezomib	Bor-Cyc + Bor	1	Proteasome/Chemotherapy	383	Bortezomib-based	Bortezomib-based	Bor-Cyc				1	Disease progression/Relapse	3			3	53	3	53		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	96	0	2	53	2	53			1
MMRF_2438	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	458	606	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	458	Proteasome/IMID/Steroid	606	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Patient decision	6					5	571	494	Stable Disease	SD			0	1	0	1	6	149	0	5	114			1	3	1
MMRF_2438	3	Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	684	694	1	Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex-Dox	684	Proteasome/Chemotherapy/Steroid	694	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	723	4	723	679	Partial Response	PR	Partial Response	PR	1	1	1	1	1	11	1	2	40	2	40	1	4	1
MMRF_2438	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	739	866	2	Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin + Daratumumab/Pomalidomide/Dexamethasone	Bor-Cyc-Dex-Dox + Dar-Pom-Dex	684	Proteasome/Chemotherapy/Steroid/CD38/IMID	866	combined bortezomib/IMIDs-based	combined daratumumab/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	723	4	723	679	Partial Response	PR	Partial Response	PR	1	0	0	0	5	128	0	2	40	2	40			1
MMRF_2438	4	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	929	1072	1	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	929	IMID/Chemotherapy/Steroid	1072	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3					6	935	935	Progressive Disease	PD			0	1	0	1	5	144	0	1	7			1	3	1
MMRF_2438	5	Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dox	Proteasome/Chemotherapy/Chemotherapy	1157	1160	1	Bortezomib/Cyclophosphamide/Doxorubicin	Bor-Cyc-Dox	1157	Proteasome/Chemotherapy	1160	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	1201	4	1201		Partial Response	PR	Partial Response	PR	1	1	1	1	0	4	1	2	45	2	45	1	3	1
MMRF_2517	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	120	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	120	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	171	Stem cell, Autologous	1	1	Completed regimen	4			4	169	2	673		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	5	120	1	25	673	7	169	1	3	1
MMRF_2517	1	Lenalidomide	Len	IMID	260	673	2	Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Len	1	Proteasome/IMID/Steroid	673	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Adverse Event or co-morbidity	2			4	169	2	673		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	15	414	0	25	673	7	169			1
MMRF_2573	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	268	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	268	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			2	347	1	1072		Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	10	268	0	39	1072	13	347	1	3	1
MMRF_2573	1	Lenalidomide	Len	IMID	284	979	2	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Len	1	Proteasome/IMID/Steroid	979	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0	Patient decision	6			2	347	1	1072		Complete Response	CR	Stringent Complete Response	sCR	1	0	1	0	25	696	1	39	1072	13	347			1
MMRF_2573	1	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	981	2437	3	Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Daratumumab/Dexamethasone	Car-Len-Dex + Len + Dar-Dex	1	Proteasome/IMID/Steroid/CD38	2437	combined daratumumab/IMIDs/carfilzomib-based	daratumumab-based	Other combined daratumumab/IMIDs/carfilzomib-based + one other agent (				0					2	347	1	1072		Complete Response	CR	Stringent Complete Response	sCR	1	1	0	1	52	1457	0	39	1072	13	347			1
MMRF_2597	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	106	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	149	Stem cell, Autologous	1	1	Completed regimen	4			3	372	1	1177		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	106	0	43	1177	14	372	1	3	1
MMRF_2597	1	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	261	288	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Len-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	288	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	372	1	1177		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	28	0	43	1177	14	372			1
MMRF_2597	1	Lenalidomide/Melphalan	Len-Mel	IMID/Chemotherapy	289	513	3	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide/Melphalan	Bor-Cyc-Dex + Len-Mel-Dex + Len-Mel	1	Proteasome/Chemotherapy/Steroid/IMID	513	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	372	1	1177		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	8	225	1	43	1177	14	372			1
MMRF_2597	1	Lenalidomide	Len	IMID	514	988	4	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide/Melphalan + Lenalidomide	Bor-Cyc-Dex + Len-Mel-Dex + Len-Mel + Len	1	Proteasome/Chemotherapy/Steroid/IMID	988	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	2347	Stem cell, Autologous	2	1	Investigator decision for other reasons	5			3	372	1	1177		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	17	475	0	43	1177	14	372			1
MMRF_2608	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	105	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	105	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	DOES REDUCED				3	125	3	125		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	105	1	5	125	5	125	1	3	1
MMRF_2608	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	168	326	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	326	Bortezomib-based	Other treatments	Bor-Cyc-Dex				0	CONCERNS WORSENING HEART FAILURE				3	125	3	125		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	159	0	5	125	5	125			1
MMRF_2608	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	986	2379	1	Lenalidomide/Dexamethasone	Len-Dex	986	IMID/Steroid	2379	IMIDs-based	IMIDs-based	Len-Dex				0					3	1231	3	1231		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	50	1394	1	9	246	9	246	1	2	1
MMRF_2223	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	42	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	42	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	148	4	148	1119	Partial Response	PR	Partial Response	PR	1	0	0	0	2	42	0	6	148	6	148	1	2	1
MMRF_2223	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	43	176	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	176	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Completed regimen	4			4	148	4	148	1119	Partial Response	PR	Partial Response	PR	1	1	1	1	5	134	1	6	148	6	148			1
MMRF_2223	1	Lenalidomide	Len	IMID	177	237	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	237	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	148	4	148	1119	Partial Response	PR	Partial Response	PR	1	0	0	0	2	61	0	6	148	6	148			1
MMRF_2223	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	433	1462	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Len + Bor-Dex	1	Proteasome/Steroid/IMID	1462	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	INCREASING DOSAGE				4	148	4	148	1119	Partial Response	PR	Partial Response	PR	1	0	0	0	37	1030	0	6	148	6	148			1
MMRF_2223	1	Bortezomib	Bor	Proteasome	1463	1757	5	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Dexamethasone + Bortezomib	Bor-Dex + Bor-Len-Dex + Len + Bor-Dex + Bor	1	Proteasome/Steroid/IMID	1757	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	REDUCING DOSAGE				4	148	4	148	1119	Partial Response	PR	Partial Response	PR	1	0	0	0	11	295	0	6	148	6	148			1
MMRF_2568	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1	168	1	Lenalidomide/Dexamethasone	Len-Dex	1	IMID/Steroid	168	IMIDs-based	IMIDs-based	Len-Dex				1					3	86	2	253	1472	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	6	168	1	10	253	4	86	1	2	1
MMRF_2568	1	Lenalidomide/Melphalan/Dexamethasone	Len-Mel-Dex	IMID/Chemotherapy/Steroid	169	169	2	Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone	Len-Dex + Len-Mel-Dex	1	IMID/Steroid/Chemotherapy	169	IMIDs-based	IMIDs-based	Other Len-based therapies				1	Completed regimen	4			3	86	2	253	1472	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	10	253	4	86			1
MMRF_2568	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	170	757	3	Lenalidomide/Dexamethasone + Lenalidomide/Melphalan/Dexamethasone + Lenalidomide/Dexamethasone	Len-Dex + Len-Mel-Dex + Len-Dex	1	IMID/Steroid/Chemotherapy	757	IMIDs-based	IMIDs-based	Other Len-based therapies	171	Stem cell, Autologous	1	1	PATIENT DEVELOPED MDS AND COULD NOT CONTINUE ON REVLIMID.				3	86	2	253	1472	Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	21	588	0	10	253	4	86			1
MMRF_2568	2	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	1481	1634	1	Bortezomib/Daratumumab	Bor-Dar	1481	Proteasome/CD38	1634	Bortezomib-based	Bortezomib-based	Bor-Dar				0	Completed regimen	4												0	0	0	0	6	154	0					1	2	1
MMRF_1833	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	175	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	175	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0					4	110	4	110	260	Partial Response	PR	Partial Response	PR	1	1	1	1	7	175	1	4	110	4	110	1	3	1
MMRF_1833	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	176	360	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid	360	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Dex				0	Completed regimen	4			4	110	4	110	260	Partial Response	PR	Partial Response	PR	1	0	0	0	7	185	0	4	110	4	110			1
MMRF_1833	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	361	2930	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Car-Len-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid	2930	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Bor-Len-Car-Dex				0					4	110	4	110	260	Partial Response	PR	Partial Response	PR	1	0	0	0	92	2570	0	4	110	4	110			1
MMRF_1833	2	Pomalidomide	Pom	IMID	1009	2551	1	Pomalidomide	Pom	1009	IMID	2551	IMIDs-based	IMIDs-based	Pom-Dex				0	Completed regimen	4					5	1072	2145	Stable Disease	SD			0	1	0	1	55	1543	0	3	64			1	1	1
MMRF_1833	3	Daratumumab	Dar	CD38	2209	2930	1	Daratumumab	Dar	2209	CD38	2930	daratumumab-based	daratumumab-based	Dar				0							5	2355	2930	Stable Disease	SD			0	1	0	1	26	722	0	6	147					1
MMRF_2196	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	134	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	134	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	199	Stem cell, Autologous	1	1	Completed regimen	4			3	123	3	123	1036	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	134	1	5	123	5	123	1	3	1
MMRF_2196	1	Lenalidomide	Len	IMID	406	1050	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1050	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			3	123	3	123	1036	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	23	645	0	5	123	5	123			1
MMRF_2196	2	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1073	1412	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1073	CD38/IMID/Steroid	1412	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	PATIENT PASSED						6	1207	1207	Progressive Disease	PD			0	1	0	1	12	340	0	5	135			1	3	1
MMRF_2196	3	Pomalidomide	Pom	IMID	1243	1399	1	Pomalidomide	Pom	1243	IMID	1399	IMIDs-based	IMIDs-based	Pom-Dex				0	Investigator decision for other reasons	5					6	1319	1319	Progressive Disease	PD			0	1	0	1	6	157	0	3	77			1	1	1
MMRF_2196	4	Carfilzomib	Car	Proteasome	1347	1383	1	Carfilzomib	Car	1347	Proteasome	1383	Carfilzomib-based	Carfilzomib-based	Car-Dex				0	Investigator decision for other reasons	5					6	1381	1381	Progressive Disease	PD			0	1	0	1	2	37	0	2	35			1	1	1
MMRF_2054	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	84	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	84	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1							5	85		Stable Disease	SD			0	1	0	1	3	84	0	4	85			1	3	1
MMRF_2054	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	85	227	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	227	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4					5	85		Stable Disease	SD			0	0	0	1	5	143	0	4	85					1
MMRF_2054	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	228	287	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	287	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				1							5	85		Stable Disease	SD			0	0	0	0	2	60	0	4	85					1
MMRF_2054	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	288	288	4	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	288	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	MEPHALAN AND STEM CELL REINFUSION						5	85		Stable Disease	SD			0	0	0	0	0	1	0	4	85					1
MMRF_2054	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	289	576	5	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Len-Cyc-Dex + Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	576	combined bortezomib/IMIDs-based	Bortezomib-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	289	Stem cell, Autologous	1	1	Completed regimen	4					5	85		Stable Disease	SD			0	0	0	0	11	288	0	4	85					1
MMRF_2054	2	Carfilzomib/Pomalidomide	Car-Pom	Proteasome/IMID	401	576	1	Carfilzomib/Pomalidomide	Car-Pom	401	Proteasome/IMID	576	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	849	3	1456	709	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	176	0	38	1056	17	449	1	2	1
MMRF_2054	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	730	1291	2	Carfilzomib/Pomalidomide + Ixazomib/Lenalidomide/Dexamethasone	Car-Pom + Ixa-Len-Dex	401	Proteasome/IMID/Steroid	1291	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	849	3	1456	709	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	20	562	1	38	1056	17	449			1
MMRF_2054	2	Ixazomib/Lenalidomide	Ixa-Len	Proteasome/IMID	1292	2725	3	Carfilzomib/Pomalidomide + Ixazomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide	Car-Pom + Ixa-Len-Dex + Ixa-Len	401	Proteasome/IMID/Steroid	2725	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0					4	849	3	1456	709	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	52	1434	0	38	1056	17	449			1
MMRF_2062	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	472	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	472	Bortezomib-based	Bortezomib-based	Bor-Dex				0	PATIENT FAILED TO COME FOR APPOINTMENTS				3	148	3	148		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	17	472	1	6	148	6	148	1	2	1
MMRF_2171	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	170	Stem cell, Autologous	1	1	Completed regimen	4			4	32	3	316		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	120	1	12	316	2	32	1	3	1
MMRF_2171	1	Lenalidomide	Len	IMID	287	1997	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1997	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Completed regimen	4			4	32	3	316		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	61	1711	0	12	316	2	32			1
MMRF_2181	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	41	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	41	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	315	3	315		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	41	0	12	315	12	315	1	2	1
MMRF_2181	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	42	155	2	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/Chemotherapy	155	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	315	3	315		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	114	0	12	315	12	315			1
MMRF_2181	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	156	304	3	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Steroid/Chemotherapy	304	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			3	315	3	315		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	149	1	12	315	12	315			1
MMRF_2181	1	Lenalidomide	Len	IMID	318	485	4	Bortezomib/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Cyc-Dex + Bor-Dex + Len	1	Proteasome/Steroid/Chemotherapy/IMID	485	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0					3	315	3	315		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	168	0	12	315	12	315			1
MMRF_2222	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	106	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	154	Stem cell, Autologous	1	1	Completed regimen	4			3	57	3	57	1587	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	106	1	3	57	3	57	1	3	1
MMRF_2222	1	Lenalidomide	Len	IMID	258	1666	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1666	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	Disease progression/Relapse	3			3	57	3	57	1587	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	51	1409	0	3	57	3	57			1
MMRF_2222	2	Lenalidomide	Len	IMID	1667	1687	1	Lenalidomide	Len	1667	IMID	1687	IMIDs-based	IMIDs-based	Len-Dex				1					4	1906	4	1906		Partial Response	PR	Partial Response	PR	1	0	0	0	1	21	0	9	240	9	240	1	1	1
MMRF_2222	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1688	1724	2	Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone	Len + Dar-Len-Dex	1667	IMID/CD38/Steroid	1724	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				1	Adverse Event or co-morbidity	2			4	1906	4	1906		Partial Response	PR	Partial Response	PR	1	0	0	0	2	37	0	9	240	9	240			1
MMRF_2222	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1725	1765	3	Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone	Len + Dar-Len-Dex + Dar-Dex	1667	IMID/CD38/Steroid	1765	combined daratumumab/IMIDs-based	daratumumab-based	Dar-Len-Dex				1					4	1906	4	1906		Partial Response	PR	Partial Response	PR	1	0	0	0	2	41	0	9	240	9	240			1
MMRF_2222	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1766	1990	4	Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone + Daratumumab/Lenalidomide/Dexamethasone	Len + Dar-Len-Dex + Dar-Dex + Dar-Len-Dex	1667	IMID/CD38/Steroid	1990	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				1	Completed regimen	4			4	1906	4	1906		Partial Response	PR	Partial Response	PR	1	0	0	1	8	225	1	9	240	9	240			1
MMRF_2222	2	Carmustine/Melphalan	Carm-Mel	Chemotherapy/Chemotherapy	1958	1960	5	Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone + Daratumumab/Lenalidomide/Dexamethasone + Carmustine/Melphalan	Len + Dar-Len-Dex + Dar-Dex + Dar-Len-Dex + Carm-Mel	1667	IMID/CD38/Steroid/Chemotherapy	1960	combined daratumumab/IMIDs-based	Other treatments	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C	1962	Stem cell, Autologous	2	1	Completed regimen	4			4	1906	4	1906		Partial Response	PR	Partial Response	PR	1	1	1	0	0	3	0	9	240	9	240			1
MMRF_2222	2	Lenalidomide	Len	IMID	1991	2070	6	Lenalidomide + Daratumumab/Lenalidomide/Dexamethasone + Daratumumab/Dexamethasone + Daratumumab/Lenalidomide/Dexamethasone + Carmustine/Melphalan + Lenalidomide	Len + Dar-Len-Dex + Dar-Dex + Dar-Len-Dex + Carm-Mel + Len	1667	IMID/CD38/Steroid/Chemotherapy	2070	combined daratumumab/IMIDs-based	IMIDs-based	Other combined daratumumab/IMIDs-based + one other agent (not Dex or C				1	Adverse Event or co-morbidity	2			4	1906	4	1906		Partial Response	PR	Partial Response	PR	1	0	0	0	3	80	0	9	240	9	240			1
MMRF_2222	3	Daratumumab/Lenalidomide	Dar-Len	CD38/IMID	2105	2557	1	Daratumumab/Lenalidomide	Dar-Len	2105	CD38/IMID	2557	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len				0					4	2200	4	2200		Partial Response	PR	Partial Response	PR	1	1	1	1	16	453	1	4	96	4	96	1	2	1
MMRF_2286	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	110	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	110	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	343	Stem cell, Autologous	1	1	Completed regimen	4			4	57	1	642		Complete Response	CR	Partial Response	PR	1	0	1	0	4	110	1	23	642	3	57	1	3	1
MMRF_2286	1	Lenalidomide	Len	IMID	473	1069	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide	Bor-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	1069	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				1	DEATH				4	57	1	642		Complete Response	CR	Partial Response	PR	1	1	0	1	22	597	0	23	642	3	57			1
MMRF_2507	1	Bortezomib/Prednisone	Bor-Pred	Proteasome/Steroid	1	27	1	Bortezomib/Prednisone	Bor-Pred	1	Proteasome/Steroid	27	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0							5	84		Stable Disease	SD			0	0	0	0	1	27	0	3	84			1	2	1
MMRF_2507	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	Proteasome/Chemotherapy/Steroid	28	162	2	Bortezomib/Prednisone + Bortezomib/Cyclophosphamide/Prednisone	Bor-Pred + Bor-Cyc-Pred	1	Proteasome/Steroid/Chemotherapy	162	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	CARE TRANSFERRED TO ANOTHER FACILITY						5	84		Stable Disease	SD			0	1	0	1	5	135	0	3	84					1
MMRF_2507	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	171	327	3	Bortezomib/Prednisone + Bortezomib/Cyclophosphamide/Prednisone + Lenalidomide/Dexamethasone	Bor-Pred + Bor-Cyc-Pred + Len-Dex	1	Proteasome/Steroid/Chemotherapy/IMID	327	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0							5	84		Stable Disease	SD			0	0	0	0	6	157	0	3	84					1
MMRF_2507	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	328	328	4	Bortezomib/Prednisone + Bortezomib/Cyclophosphamide/Prednisone + Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Pred + Bor-Cyc-Pred + Len-Dex + Bor-Len-Dex	1	Proteasome/Steroid/Chemotherapy/IMID	328	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0							5	84		Stable Disease	SD			0	0	0	0	0	1	0	3	84					1
MMRF_2126	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	249	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	249	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	155	4	155		Partial Response	PR	Partial Response	PR	1	1	1	1	9	249	1	6	155	6	155	1	3	1
MMRF_2126	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	330	551	1	Lenalidomide/Dexamethasone	Len-Dex	330	IMID/Steroid	551	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3					5	414	347	Stable Disease	SD			0	1	0	1	8	222	0	4	85			1	2	1
MMRF_2339	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	162	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	162	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	214	Stem cell, Autologous	1	1	Completed regimen	4			4	99	3	512		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	162	1	19	512	4	99	1	3	1
MMRF_2339	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	2308	2546	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	2308	Proteasome/IMID/Steroid	2546	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0							5	2371		Stable Disease	SD			0	1	0	1	9	239	0	3	64			1	3	1
MMRF_2114	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	108	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	108	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	108	0	23	622	7	190	1	3	1
MMRF_2114	1	Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	109	134	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	134	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				1	TX D'CED BECAUSE PT IS GOING FOR STEM CELL HARVEST ON 1/13 -1/14/15				3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	26	0	23	622	7	190			1
MMRF_2114	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	169	218	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	218	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15				3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	2	50	1	23	622	7	190			1
MMRF_2114	1	Lenalidomide	Len	IMID	219	224	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Len-Dex + Bor-Len-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	224	combined bortezomib/IMIDs/carfilzomib-based	IMIDs-based	Bor-Len-Car-Cyc-Dex	236	Stem cell, Autologous	1	1	TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15				3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	1	6	0	23	622	7	190			1
MMRF_2114	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	351	392	5	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Car-Len-Dex + Len + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	392	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs-based	Bor-Len-Car-Cyc-Dex				1					3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	42	0	23	622	7	190			1
MMRF_2114	1	Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Car-Len-Dex	Proteasome/Proteasome/IMID/Steroid	393	635	6	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Car-Len-Dex + Len + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	635	combined bortezomib/IMIDs/carfilzomib-based	combined bortezomib/IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	MS MD DECIDED TO DOSE REDUCED DUE TO DIARRHEA & INCREASE IN NEUROPATHY				3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	9	243	0	23	622	7	190			1
MMRF_2114	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	636	725	7	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Cyc-Dex + Car-Len-Dex + Len + Bor-Len-Dex + Bor-Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	725	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	STOPPED DUE TO CHRONIC DIARRHEA				3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	90	0	23	622	7	190			1
MMRF_2114	1	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	726	1041	8	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/De	Bor-Len-Dex + Bor-Len-Cyc-Dex + Car-Len-Dex + Len + Bor-Len-Dex + Bor-Car-Len-Dex + Car-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1041	combined bortezomib/IMIDs/carfilzomib-based	Carfilzomib-based	Bor-Len-Car-Cyc-Dex				1	DOSE INCREASED DUE TO ADDITION OF MORE MEDS				3	190	1	622	883	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	12	316	0	23	622	7	190			1
MMRF_2114	2	Carfilzomib	Car	Proteasome	908	1053	1	Carfilzomib	Car	908	Proteasome	1053	Carfilzomib-based	Carfilzomib-based	Car-Dex				0							5	1062	1238	Stable Disease	SD			0	0	0	0	6	146	0	6	155			1	1	1
MMRF_2114	2	Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car-Elo-Len-Dex	Proteasome/SLAMF7/IMID/Steroid	1054	1222	2	Carfilzomib + Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car + Car-Elo-Len-Dex	908	Proteasome/SLAMF7/IMID/Steroid	1222	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	CHANGED DUE TO URI & RIGHT BREST MASTITIS						5	1062	1238	Stable Disease	SD			0	1	0	1	6	169	0	6	155					1
MMRF_2114	2	Elotuzumab/Lenalidomide/Dexamethasone	Elo-Len-Dex	SLAMF7/IMID/Steroid	1223	1236	3	Carfilzomib + Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car + Car-Elo-Len-Dex	908	Proteasome/SLAMF7/IMID/Steroid	1236	combined IMIDs/carfilzomib-based	IMIDs-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0							5	1062	1238	Stable Disease	SD			0	0	0	0	1	14	0	6	155					1
MMRF_2114	2	Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car-Elo-Len-Dex	Proteasome/SLAMF7/IMID/Steroid	1237	1266	4	Carfilzomib + Carfilzomib/Elotuzumab/Lenalidomide/Dexamethasone	Car + Car-Elo-Len-Dex	908	Proteasome/SLAMF7/IMID/Steroid	1266	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	1062	1238	Stable Disease	SD			0	0	0	0	1	30	0	6	155					1
MMRF_2114	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1279	1461	1	Daratumumab/Dexamethasone	Dar-Dex	1279	CD38/Steroid	1461	daratumumab-based	daratumumab-based	Dar-Dex				0	PATIENT TRANSFERRED HER CARE TO AN OUTSIDE INSTITUTION						5	1356		Stable Disease	SD			0	1	0	1	7	183	0	3	78					1
MMRF_2150	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	119	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	119	Bortezomib-based	Bortezomib-based	Bor-Dex				0			2357		4	191	4	191	1077	Partial Response	PR	Partial Response	PR	1	0	0	0	5	119	0	7	191	7	191	1	2	1
MMRF_2150	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	120	212	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	212	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST		2357		4	191	4	191	1077	Partial Response	PR	Partial Response	PR	1	1	1	1	4	93	1	7	191	7	191			1
MMRF_2150	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	225	267	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Cyc-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	267	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Cyc-Dex				0	PROGRESSIVE INCREASE IN IGA		2357		4	191	4	191	1077	Partial Response	PR	Partial Response	PR	1	0	0	0	2	43	0	7	191	7	191			1
MMRF_2150	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	288	1135	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Cyc-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID/Chemotherapy	1135	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Cyc-Dex				0	POD CONFIRMED BY INCREASE IN MONOCLONAL PROTEIN + PROGRESSIVE ANEMIA		2357		4	191	4	191	1077	Partial Response	PR	Partial Response	PR	1	0	0	0	31	848	0	7	191	7	191			1
MMRF_2150	2	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	1143	1219	1	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	1143	Proteasome/IMID/Steroid	1219	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	SWITCHED LINES OF THERAPY, DUE TO POD		2357											0	0	0	0	3	77	0					1	3	1
MMRF_2150	3	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	CD38/IMID/Steroid	1226	2003	1	Daratumumab/Pomalidomide/Dexamethasone	Dar-Pom-Dex	1226	CD38/IMID/Steroid	2003	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Pom-Dex				0	Disease progression/Relapse	3	2357				6	1247	1247	Progressive Disease	PD			0	1	0	1	28	778	0	1	22			1	3	1
MMRF_2150	4	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	2072	2214	1	Carfilzomib/Dexamethasone	Car-Dex	2072	Proteasome/Steroid	2214	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	2357				6	2190	2190	Progressive Disease	PD			0	1	0	1	5	143	0	5	119			1	2	1
MMRF_2150	5	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	Proteasome/CD38/Steroid	2220	2427	1	Carfilzomib/Daratumumab/Dexamethasone	Car-Dar-Dex	2220	Proteasome/CD38/Steroid	2427	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	STOPPED AS PER DR. JAGANNATHS ADVICE @ MT. SINAI		2357				6	2357	2357	Progressive Disease	PD			0	1	0	1	8	208	0	5	138			1	3	1
MMRF_2150	9	REGN5458	REGN5458	BCMA	2447	2566	1	REGN5458	REGN5458	2447	BCMA	2566	Other therapies	Other treatments					0			2357											0	0	0	0	5	120	0							1
MMRF_1642	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	1	8	1	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	8	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	1	8	0					1	2	1
MMRF_1661	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	Proteasome/Chemotherapy/Steroid	1	85	1	Bortezomib/Melphalan/Dexamethasone	Bor-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	85	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1					3	197	3	197		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	85	0	8	197	8	197	1	3	1
MMRF_1661	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	86	250	2	Bortezomib/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Mel-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	250	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	176	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			3	197	3	197		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	165	1	8	197	8	197			1
MMRF_1682	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	295	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	295	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Disease progression/Relapse	3			4	85	4	85	295	Partial Response	PR	Partial Response	PR	1	1	1	1	11	295	1	4	85	4	85	1	3	1
MMRF_1682	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	338	447	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	338	Proteasome/IMID/Steroid	447	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Investigator decision for other reasons	5												0	0	0	0	4	110	0					1	3	1
MMRF_1682	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	448	577	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	448	Proteasome/IMID/Steroid	577	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Disease progression/Relapse	3					6	477	477	Progressive Disease	PD			0	1	0	1	5	130	0	2	30			1	3	1
MMRF_1682	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	578	611	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	578	Proteasome/Chemotherapy/Steroid	611	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0														0	0	0	0	2	34	0					1	3	1
MMRF_1682	4	Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex-Dox	Proteasome/Chemotherapy/Steroid/Chemotherapy	612	612	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin	Bor-Cyc-Dex + Bor-Cyc-Dex-Dox	578	Proteasome/Chemotherapy/Steroid	612	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5												0	0	0	0	0	1	0							1
MMRF_1682	4	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	613	617	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone/Doxorubicin + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Dex-Dox + Bor-Cyc-Dex	578	Proteasome/Chemotherapy/Steroid	617	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5												0	0	0	0	0	5	0							1
MMRF_1705	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	610	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	610	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	104	3	104		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	22	610	1	4	104	4	104	1	3	1
MMRF_1862	1	Bortezomib/Lenalidomide	Bor-Len	Proteasome/IMID	1	198	1	Bortezomib/Lenalidomide	Bor-Len	1	Proteasome/IMID	198	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	288	Stem cell, Autologous	1	1	Completed regimen	4			3	372	3	372		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	198	1	14	372	14	372	1	2	1
MMRF_1862	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	728	1059	2	Bortezomib/Lenalidomide + Lenalidomide/Dexamethasone	Bor-Len + Len-Dex	1	Proteasome/IMID/Steroid	1059	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Investigator decision for other reasons	5			3	372	3	372		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	332	0	14	372	14	372			1
MMRF_1862	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1913	2734	1	Carfilzomib/Dexamethasone	Car-Dex	1913	Proteasome/Steroid	2734	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					3	2174	3	2174	1999	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	30	822	1	10	262	10	262	1	2	1
MMRF_1969	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	279	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	279	Bortezomib-based	Bortezomib-based	Bor-Dex	330	Stem cell, Autologous	1	1	Completed regimen	4			3	600	3	600		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	10	279	0	22	600	22	600	1	2	1
MMRF_1969	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	538	600	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	600	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	600	3	600		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	63	1	22	600	22	600			1
MMRF_1969	1	Lenalidomide	Len	IMID	601	627	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	627	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1					3	600	3	600		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	27	0	22	600	22	600			1
MMRF_1969	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	628	945	4	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide + Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex + Len + Len-Dex	1	Proteasome/Steroid/IMID	945	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	DEATH				3	600	3	600		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	12	318	0	22	600	22	600			1
MMRF_2024	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	87	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	87	Bortezomib-based	Bortezomib-based	Bor-Dex				1					3	172	3	172		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	87	0	7	172	7	172	1	2	1
MMRF_2024	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	88	420	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	1	Proteasome/Steroid/IMID	420	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	248	Stem cell, Autologous	1	1	Completed regimen	4			3	172	3	172		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	12	333	1	7	172	7	172			1
MMRF_2024	1	Lenalidomide	Len	IMID	452	732	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide	Bor-Dex + Bor-Len-Dex + Len	1	Proteasome/Steroid/IMID	732	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Lack of response	1			3	172	3	172		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	10	281	0	7	172	7	172			1
MMRF_2024	2	Lenalidomide	Len	IMID	1313	1481	1	Lenalidomide	Len	1313	IMID	1481	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1					5	1313		Stable Disease	SD			0	1	0	1	6	169	0	1	1			1	1	1
MMRF_2024	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1654	1773	1	Carfilzomib/Dexamethasone	Car-Dex	1654	Proteasome/Steroid	1773	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	TASPE				2	1956	2	1956		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	5	120	1	11	303	11	303	1	2	1
MMRF_2039	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	153	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	153	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	88	3	88	296	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	153	1	4	88	4	88	1	2	1
MMRF_2039	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	154	197	2	Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Dex + Bor-Thal-Dex	1	Proteasome/Steroid/IMID	197	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				0	Completed regimen	4			3	88	3	88	296	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	44	0	4	88	4	88			1
MMRF_2039	1	Thalidomide	Thal	IMID	198	280	3	Bortezomib/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Thalidomide	Bor-Dex + Bor-Thal-Dex + Thal	1	Proteasome/Steroid/IMID	280	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Thal-Dex				0	Disease progression/Relapse	3			3	88	3	88	296	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	83	0	4	88	4	88			1
MMRF_2039	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	312	385	1	Bortezomib/Dexamethasone	Bor-Dex	312	Proteasome/Steroid	385	Bortezomib-based	Bortezomib-based	Bor-Dex				0					4	386	4	386		Partial Response	PR	Partial Response	PR	1	1	1	1	3	74	1	3	75	3	75	1	2	1
MMRF_2039	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	386	473	2	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Dex + Bor-Len-Dex	312	Proteasome/Steroid/IMID	473	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	386	4	386		Partial Response	PR	Partial Response	PR	1	0	0	1	3	88	1	3	75	3	75			1
MMRF_2039	2	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	474	475	3	Bortezomib/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Dex + Bor-Len-Dex + Bor-Dex	312	Proteasome/Steroid/IMID	475	combined bortezomib/IMIDs-based	Bortezomib-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	386	4	386		Partial Response	PR	Partial Response	PR	1	0	0	0	0	2	0	3	75	3	75			1
MMRF_2515	1	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	1	32	1	Melphalan/Prednisone	Mel-Pred	1	Chemotherapy/Steroid	32	Other therapies	Other treatments					0					4	1128	3	1394		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	32	0	50	1394	41	1128			1
MMRF_2515	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	33	469	2	Melphalan/Prednisone + Bortezomib/Melphalan/Prednisone	Mel-Pred + Bor-Mel-Pred	1	Chemotherapy/Steroid/Proteasome	469	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	1128	3	1394		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	16	437	1	50	1394	41	1128	1	3	1
MMRF_2543	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	161	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	161	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			3	163	3	163		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	161	1	6	163	6	163	1	3	1
MMRF_2543	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	800	1100	1	Lenalidomide/Dexamethasone	Len-Dex	800	IMID/Steroid	1100	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3					5	919	800	Stable Disease	SD			0	1	0	1	11	301	0	5	120			1	2	1
MMRF_2543	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1113	1400	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1113	Proteasome/CD38/Steroid	1400	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	DEATH						5	1302		Stable Disease	SD			0	1	0	1	11	288	0	7	190			1	3	1
MMRF_2586	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	707	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	707	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Disease progression/Relapse	3					5	85		Stable Disease	SD			0	1	0	1	26	707	0	4	85			1	3	1
MMRF_1908	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	179	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	179	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	190	Stem cell, Autologous	1	1	PARESTHESIA				3	96	1	176	978	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	7	179	1	7	176	4	96	1	3	1
MMRF_1908	1	Thalidomide	Thal	IMID	387	718	2	Bortezomib/Thalidomide/Dexamethasone + Thalidomide	Bor-Thal-Dex + Thal	1	Proteasome/IMID/Steroid	718	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Thal-Dex				1	Adverse Event or co-morbidity	2			3	96	1	176	978	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	12	332	0	7	176	4	96			1
MMRF_1908	2	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	983	2057	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	983	Proteasome/Chemotherapy/Steroid	2057	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	1086	3	1086	1480	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	39	1075	1	4	104	4	104	1	3	1
MMRF_2013	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	176	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	176	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	227	Stem cell, Autologous	1	1	Completed regimen	4			4	57	1	1311	2801	Complete Response	CR	Partial Response	PR	1	0	1	0	7	176	1	47	1311	3	57	1	3	1
MMRF_2013	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	491	1311	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1311	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	57	1	1311	2801	Complete Response	CR	Partial Response	PR	1	1	0	1	30	821	0	47	1311	3	57			1
MMRF_2185	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	183	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	183	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	221	Stem cell, Autologous	1	1	Completed regimen	4			3	172	1	218	746	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	7	183	1	8	218	7	172	1	3	1
MMRF_2185	1	Lenalidomide	Len	IMID	533	718	2	Bortezomib/Thalidomide/Dexamethasone + Lenalidomide	Bor-Thal-Dex + Len	1	Proteasome/IMID/Steroid	718	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	172	1	218	746	Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	7	186	0	8	218	7	172			1
MMRF_2185	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	774	861	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	774	Proteasome/IMID/Steroid	861	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2					5	883		Stable Disease	SD			0	1	0	1	3	88	0	4	110			1	3	1
MMRF_2185	2	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	949	1002	2	Carfilzomib/Lenalidomide/Dexamethasone + Bortezomib/Daratumumab	Car-Len-Dex + Bor-Dar	774	Proteasome/IMID/Steroid/CD38	1002	combined bortezomib/IMIDs/carfilzomib-based	Bortezomib-based	Other bortezomib/IMIDs/carfilzomib-based + one other agent (not Dex or				0	Lack of response	1					5	883		Stable Disease	SD			0	0	0	0	2	54	0	4	110					1
MMRF_1790	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	123	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	123	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Investigator decision for other reasons	5			4	186	4	186	268	Partial Response	PR	Partial Response	PR	1	1	1	1	5	123	1	7	186	7	186	1	3	1
MMRF_1790	2	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	Proteasome/Chemotherapy/Steroid	359	554	1	Bortezomib/Bendamustine/Dexamethasone	Bor-Bend-Dex	359	Proteasome/Chemotherapy/Steroid	554	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2					5	387	359	Stable Disease	SD			0	1	0	1	7	196	0	2	29			1	3	1
MMRF_1790	3	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	614	663	1	Lenalidomide/Dexamethasone	Len-Dex	614	IMID/Steroid	663	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1					6	624	624	Progressive Disease	PD			0	1	0	1	2	50	0	1	11			1	2	1
MMRF_1790	4	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	677	740	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	677	Chemotherapy/Steroid	740	Other therapies	Other treatments					0	Lack of response	1					5	807	920	Stable Disease	SD			0	0	0	0	3	64	0	5	131					1
MMRF_1790	4	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	780	897	2	Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Cyc-Dex + Len-Dex	677	Chemotherapy/Steroid/IMID	897	IMIDs-based	IMIDs-based	Len-Cyc-Dex				0	Disease progression/Relapse	3					5	807	920	Stable Disease	SD			0	1	0	1	5	118	0	5	131			1	2	1
MMRF_1790	5	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	926	962	1	Carfilzomib/Dexamethasone	Car-Dex	926	Proteasome/Steroid	962	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Lack of response	1												0	0	0	0	2	37	0					1	2	1
MMRF_2225	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	Proteasome/Steroid/Chemotherapy	1	168	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	1	Proteasome/Steroid/Chemotherapy	168	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	183	Stem cell, Autologous	1	1	Completed regimen	4			3	260	3	260	549	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	168	0	10	260	10	260	1	3	1
MMRF_2225	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	239	270	2	Bortezomib/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone	Bor-Dex-Dox + Bor-Dex	1	Proteasome/Steroid/Chemotherapy	270	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	260	3	260	549	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	1	32	1	10	260	10	260			1
MMRF_2225	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	353	527	3	Bortezomib/Dexamethasone/Doxorubicin + Bortezomib/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Dex-Dox + Bor-Dex + Len-Dex	1	Proteasome/Steroid/Chemotherapy/IMID	527	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			3	260	3	260	549	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	7	175	0	10	260	10	260			1
MMRF_2225	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	552	555	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	552	Chemotherapy/Steroid	555	Other therapies	Other treatments					0	Lack of response	1												0	0	0	0	0	4	0							1
MMRF_2225	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	591	639	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	591	Proteasome/IMID/Steroid	639	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Lack of response	1					6	639	639	Progressive Disease	PD			0	1	0	1	2	49	0	2	49			1	3	1
MMRF_2225	4	Pomalidomide/Clarithromycin/Cyclophosphamide/Dexamethasone	Pom-Clar-Cyc-Dex	IMID/Antibiotic/Chemotherapy/Steroid	648	765	1	Pomalidomide/Clarithromycin/Cyclophosphamide/Dexamethasone	Pom-Clar-Cyc-Dex	648	IMID/Antibiotic/Chemotherapy/Steroid	765	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3					5	716		Stable Disease	SD			0	1	0	1	5	118	0	3	69			1	4	1
MMRF_2307	1	Bortezomib/Prednisone/Doxorubicin	Bor-Pred-Dox	Proteasome/Steroid/Chemotherapy	1	94	1	Bortezomib/Prednisone/Doxorubicin	Bor-Pred-Dox	1	Proteasome/Steroid/Chemotherapy	94	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0							5	94		Stable Disease	SD			0	1	0	1	4	94	0	4	94			1	3	1
MMRF_2465	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	Proteasome/Steroid/Chemotherapy	1	145	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	1	Proteasome/Steroid/Chemotherapy	145	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	180	Stem cell, Autologous	1	1	Completed regimen	4			3	79	3	79	1352	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	145	1	3	79	3	79	1	3	1
MMRF_2465	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1660	1828	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1660	Proteasome/IMID/Steroid	1828	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2			4	1716	3	1800		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	169	1	6	141	3	57	1	3	1
MMRF_2556	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	190	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	190	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	211	Stem cell, Autologous	1	1	Completed regimen	4			4	57	1	697	1814	Complete Response	CR	Partial Response	PR	1	0	1	0	7	190	1	25	697	3	57	1	3	1
MMRF_2556	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	310	358	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	358	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	57	1	697	1814	Complete Response	CR	Partial Response	PR	1	0	0	0	2	49	0	25	697	3	57			1
MMRF_2556	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	408	1767	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1767	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Disease progression/Relapse	3			4	57	1	697	1814	Complete Response	CR	Partial Response	PR	1	1	0	1	49	1360	0	25	697	3	57			1
MMRF_2556	2	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	2004	2234	1	Daratumumab/Dexamethasone	Dar-Dex	2004	CD38/Steroid	2234	daratumumab-based	daratumumab-based	Dar-Dex				0	Disease progression/Relapse	3					5	2174	2234	Stable Disease	SD			0	1	0	1	9	231	0	7	171					1
MMRF_2556	3	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	2243	2354	1	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	2243	IMID/Chemotherapy/Steroid	2354	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0														0	0	0	0	4	112	0					1	3	1
MMRF_2567	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	189	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	189	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	214	Stem cell, Autologous	1	1	Completed regimen	4			3	57	1	435		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	7	189	1	16	435	3	57	1	3	1
MMRF_2567	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	295	352	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	352	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	57	1	435		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	58	0	16	435	3	57			1
MMRF_2567	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	407	443	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	443	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	COLON CANCER				3	57	1	435		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	2	37	0	16	435	3	57			1
MMRF_1727	1	Carfilzomib/Melphalan/Prednisone/Dexamethasone	Car-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1	372	1	Carfilzomib/Melphalan/Prednisone/Dexamethasone	Car-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	372	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	83	4	83	610	Partial Response	PR	Partial Response	PR	1	1	1	1	14	372	1	3	83	3	83	1	4	1
MMRF_1727	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	831	1924	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	831	Proteasome/IMID/Steroid	1924	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	967	4	967	883	Partial Response	PR	Partial Response	PR	1	1	1	1	39	1094	1	5	137	5	137	1	3	1
MMRF_1727	3	Melflufen/Dexamethasone	Melf-Dex	Chemotherapy/Steroid	1970	2092	1	Melflufen/Dexamethasone	Melf-Dex	1970	Chemotherapy/Steroid	2092	Other therapies	Other treatments					0	Adverse Event or co-morbidity	2					6	1970	1970	Progressive Disease	PD			0	1	0	1	5	123	0	1	1					1
MMRF_1727	4	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	Proteasome/IMID/Steroid	2190	2256	1	Bortezomib/Pomalidomide/Dexamethasone	Bor-Pom-Dex	2190	Proteasome/IMID/Steroid	2256	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Pom-Dex				0	PATIEND DIED													0	0	0	0	3	67	0					1	3	1
MMRF_1916	1	Bortezomib/Daratumumab/Melphalan/Prednisone	Bor-Dar-Mel-Pred	Proteasome/CD38/Chemotherapy/Steroid	1	370	1	Bortezomib/Daratumumab/Melphalan/Prednisone	Bor-Dar-Mel-Pred	1	Proteasome/CD38/Chemotherapy/Steroid	370	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4					5	41	1252	Stable Disease	SD			0	1	0	1	14	370	0	2	41			1	4	1
MMRF_1916	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1266	1598	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	1266	Proteasome/IMID/Steroid	1598	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	1323	4	1323	1598	Partial Response	PR	Partial Response	PR	1	1	1	1	12	333	1	3	58	3	58	1	3	1
MMRF_1971	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1	364	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1	Proteasome/CD38/Steroid	364	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Completed regimen	4			3	63	3	63	722	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	13	364	1	3	63	3	63	1	3	1
MMRF_1971	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	865	1239	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	865	Proteasome/IMID/Steroid	1239	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Disease progression/Relapse	3			4	972	4	972	1133	Partial Response	PR	Partial Response	PR	1	1	1	1	14	375	1	4	108	4	108	1	3	1
MMRF_1971	3	Pomalidomide/Filanesib/Dexamethasone	Pom-Fil-Dex	IMID/Other/Steroid	1246	1391	1	Pomalidomide/Filanesib/Dexamethasone	Pom-Fil-Dex	1246	IMID/Other/Steroid	1391	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Investigator decision for other reasons	5					5	1316		Stable Disease	SD			0	1	0	1	6	146	0	3	71			1	3	1
MMRF_2017	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dara-Dex	Proteasome/CD38/Steroid	1	188	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dara-Dex	1	Proteasome/CD38/Steroid	188	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	83	4	83	167	Partial Response	PR	Partial Response	PR	1	1	1	1	7	188	1	3	83	3	83	1	3	1
MMRF_2017	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	258	366	1	Lenalidomide/Dexamethasone	Len-Dex	258	IMID/Steroid	366	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3					5	349	258	Stable Disease	SD			0	1	0	1	4	109	0	4	92			1	2	1
MMRF_2017	3	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	366	410	1	Pomalidomide/Dexamethasone	Pom-Dex	366	IMID/Steroid	410	IMIDs-based	IMIDs-based	Pom-Dex				0	DEATH													0	0	0	0	2	45	0					1	2	1
MMRF_2068	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1	397	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1	Proteasome/CD38/Steroid	397	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Completed regimen	4			3	91	1	285		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	14	397	1	11	285	4	91	1	3	1
MMRF_2089	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	274	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	274	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Disease progression/Relapse	3			3	85	3	85	259	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	274	1	4	85	4	85	1	3	1
MMRF_2089	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	295	449	1	Lenalidomide/Dexamethasone	Len-Dex	295	IMID/Steroid	449	IMIDs-based	IMIDs-based	Len-Dex				0	EXITUS						6	351	351	Progressive Disease	PD			0	1	0	1	6	155	0	3	57			1	2	1
MMRF_2102	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	379	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	379	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	85	4	85	631	Partial Response	PR	Partial Response	PR	1	1	1	1	14	379	1	4	85	4	85	1	3	1
MMRF_2102	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	711	1166	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	711	Proteasome/IMID/Steroid	1166	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Disease progression/Relapse	3			3	793	3	793	717	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	17	456	1	3	83	3	83	1	3	1
MMRF_2102	3	Pomalidomide/Filanesib/Dexamethasone	Pom-Fil-Dex	IMID/Other/Steroid	1173	1389	1	Pomalidomide/Filanesib/Dexamethasone	Pom-Fil-Dex	1173	IMID/Other/Steroid	1389	IMIDs-based	IMIDs-based	Other Pom-based therapies				0	Disease progression/Relapse	3			4	1249	4	1249		Partial Response	PR	Partial Response	PR	1	1	1	1	8	217	1	3	77	3	77	1	3	1
MMRF_2102	4	Daratumumab/Dexamethasone	Dara-Dex	CD38/Steroid	1394	1424	1	Daratumumab/Dexamethasone	Dara-Dex	1394	CD38/Steroid	1424	daratumumab-based	daratumumab-based	Other Daratumumab-based + one other agent (not Dex or Cyc)				0							6	1422	1422	Progressive Disease	PD			0	1	0	1	1	31	0	2	29					1
MMRF_2142	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	274	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	274	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	43	3	43		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	274	1	2	43	2	43	1	3	1
MMRF_2335	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	264	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	264	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	DEATH				4	85	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	10	264	1	6	162	4	85	1	3	1
MMRF_2468	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	189	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	189	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	222	Stem cell, Autologous	1	1	Completed regimen	4			3	98	1	712		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	7	189	1	26	712	4	98	1	3	1
MMRF_2468	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	351	404	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	404	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	98	1	712		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	54	0	26	712	4	98			1
MMRF_2468	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	418	1082	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1082	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	98	1	712		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	24	665	0	26	712	4	98			1
MMRF_1654	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	81	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	81	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DEATH													0	0	0	0	3	81	0					1	2	1
MMRF_1678	1	Thalidomide/Melphalan/Prednisone	Thal-Mel-Pred	IMID/Chemotherapy/Steroid	1	231	1	Thalidomide/Melphalan/Prednisone	Thal-Mel-Pred	1	IMID/Chemotherapy/Steroid	231	IMIDs-based	IMIDs-based	Thal-Mel-Pred				0	DEATH				4	183	4	183		Partial Response	PR	Partial Response	PR	1	1	1	1	9	231	1	7	183	7	183	1	3	1
MMRF_1738	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	71	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	71	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Adverse Event or co-morbidity	2			3	66	3	66		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	71	1	3	66	3	66	1	2	1
MMRF_1738	3	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	554	689	1	Lenalidomide/Dexamethasone	Len-Dex	554	IMID/Steroid	689	IMIDs-based	IMIDs-based	Len-Dex				0	DEATH						6	623	623	Progressive Disease	PD			0	1	0	1	5	136	0	3	70			1	2	1
MMRF_2224	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	239	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	239	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1					1	75	1	75		Complete Response	CR	Complete Response	CR	1	1	1	1	9	239	1	3	75	3	75	1	3	1
MMRF_2224	1	Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	240	240	2	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	240	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			1	75	1	75		Complete Response	CR	Complete Response	CR	1	0	0	0	0	1	0	3	75	3	75			1
MMRF_2224	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	241	401	3	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	401	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	242	Stem cell, Autologous	1	1	Completed regimen	4			1	75	1	75		Complete Response	CR	Complete Response	CR	1	0	0	0	6	161	0	3	75	3	75			1
MMRF_2224	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	477	1222	4	Bortezomib/Lenalidomide/Dexamethasone + Bortezomib/Lenalidomide/Melphalan/Dexamethasone + Bortezomib/Lenalidomide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Len-Dex + Bor-Len-Mel-Dex + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1222	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			1	75	1	75		Complete Response	CR	Complete Response	CR	1	0	0	0	27	746	0	3	75	3	75			1
MMRF_2368	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	106	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	106	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Disease progression/Relapse	3			4	117	4	117		Partial Response	PR	Partial Response	PR	1	1	1	1	4	106	1	5	117	5	117	1	3	1
MMRF_2050	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	164	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	164	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0					3	95	3	95		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	164	1	4	95	4	95	1	3	1
MMRF_2197	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	82	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	82	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0														0	0	0	0	3	82	0					1	3	1
MMRF_2200	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	Proteasome/Steroid/Chemotherapy	1	147	1	Bortezomib/Dexamethasone/Doxorubicin	Bor-Dex-Dox	1	Proteasome/Steroid/Chemotherapy	147	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	91	4	91	140	Partial Response	PR	Partial Response	PR	1	1	1	1	6	147	1	4	91	4	91	1	3	1
MMRF_2200	2	Thalidomide/Cyclophosphamide/Dexamethasone	Thal-Cyc-Dex	IMID/Chemotherapy/Steroid	147	208	1	Thalidomide/Cyclophosphamide/Dexamethasone	Thal-Cyc-Dex	147	IMID/Chemotherapy/Steroid	208	IMIDs-based	IMIDs-based	Thal-Cyc-Dex	211	Stem cell, Autologous	1	1	COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH				4	271	3	355	433	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	3	62	1	8	209	5	125	1	3	1
MMRF_2273	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	252	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	252	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				1					4	86	1	345	1066	Complete Response	CR	Partial Response	PR	1	0	1	0	9	252	1	13	345	4	86	1	3	1
MMRF_2273	1	Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Mel-Dex	Proteasome/Chemotherapy/Chemotherapy/Steroid	253	253	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex	1	Proteasome/Chemotherapy/Steroid	253	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	253	Stem cell, Autologous	1	1	Completed regimen	4			4	86	1	345	1066	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	13	345	4	86			1
MMRF_2273	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	254	266	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Cyclophosphamide/Melphalan/Dexamethasone + Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex + Bor-Cyc-Mel-Dex + Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	266	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	86	1	345	1066	Complete Response	CR	Partial Response	PR	1	1	0	1	1	13	0	13	345	4	86			1
MMRF_2273	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1075	1348	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1075	CD38/IMID/Steroid	1348	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Disease progression/Relapse	3			3	1248	3	1248		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	10	274	1	7	174	7	174	1	3	1
MMRF_2336	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	132	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	132	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	164	Stem cell, Autologous	1	1	Completed regimen	4			4	87	3	150		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	132	1	6	150	4	87	1	3	1
MMRF_2336	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	670	728	1	Lenalidomide/Dexamethasone	Len-Dex	670	IMID/Steroid	728	IMIDs-based	IMIDs-based	Len-Dex				0					4	780	1	1137	689	Complete Response	CR	Partial Response	PR	1	0	0	0	2	59	0	17	468	4	111	1	2	1
MMRF_2336	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	729	900	2	Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Len-Dex + Car-Len-Dex	670	IMID/Steroid/Proteasome	900	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Investigator decision for other reasons	5			4	780	1	1137	689	Complete Response	CR	Partial Response	PR	1	1	1	1	6	172	1	17	468	4	111			1
MMRF_2365	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	165	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	165	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0					4	165	4	165		Partial Response	PR	Partial Response	PR	1	1	1	1	6	165	1	6	165	6	165	1	3	1
MMRF_2519	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	184	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	184	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				1					4	87	1	423	1811	Complete Response	CR	Partial Response	PR	1	0	1	0	7	184	1	16	423	4	87	1	3	1
MMRF_2519	1	Bortezomib/Thalidomide/Melphalan/Dexamethasone	Bor-Thal-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	185	185	2	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Melphalan/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	185	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	87	1	423	1811	Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	16	423	4	87			1
MMRF_2519	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	186	876	3	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Melphalan/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Mel-Dex + Bor-Thal-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	876	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	186	Stem cell, Autologous	1	1	Completed regimen	4			4	87	1	423	1811	Complete Response	CR	Partial Response	PR	1	1	0	1	25	691	0	16	423	4	87			1
MMRF_2578	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	109	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	109	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Adverse Event or co-morbidity	2			4	177	1	373		Complete Response	CR	Partial Response	PR	1	0	0	0	4	109	0	14	373	7	177	1	3	1
MMRF_2578	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	126	760	2	Bortezomib/Melphalan/Prednisone + Lenalidomide/Dexamethasone	Bor-Mel-Pred + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	760	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	177	1	373		Complete Response	CR	Partial Response	PR	1	1	1	1	23	635	1	14	373	7	177			1
MMRF_2602	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	1	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	1	Bortezomib-based	Bortezomib-based	Bor-Dex				0														0	0	0	0	0	1	0					1	2	1
MMRF_2606	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	211	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	211	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	221	Stem cell, Autologous	1	1	Completed regimen	4			4	80	3	269	549	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	8	211	1	10	269	3	80	1	3	1
MMRF_2606	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	592	624	1	Lenalidomide/Dexamethasone	Len-Dex	592	IMID/Steroid	624	IMIDs-based	IMIDs-based	Len-Dex				0					2	821	1	905	1641	Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	1	33	0	12	314	9	230	1	2	1
MMRF_2606	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	625	1118	2	Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Len-Dex + Car-Len-Dex	592	IMID/Steroid/Proteasome	1118	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			2	821	1	905	1641	Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	18	494	1	12	314	9	230			1
MMRF_2606	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1119	1571	3	Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Len-Dex + Car-Len-Dex	592	IMID/Steroid/Proteasome	1571	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Dex				0	Disease progression/Relapse	3			2	821	1	905	1641	Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	16	453	0	12	314	9	230			1
MMRF_2606	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1678	2187	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1678	Proteasome/CD38/Steroid	2187	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0					3	1823	1	1970	1719	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	19	510	1	11	293	6	146	1	3	1
MMRF_1923	1	Bortezomib/Daratumumab/Thalidomide/Dexamethasone	Bor-Dar-Thal-Dex	Proteasome/CD38/IMID/Steroid	1	162	1	Bortezomib/Daratumumab/Thalidomide/Dexamethasone	Bor-Dar-Thal-Dex	1	Proteasome/CD38/IMID/Steroid	162	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Dar-Thal-Dex	173	Stem cell, Autologous	1	1	Completed regimen	4			4	162	1	1607		Complete Response	CR	Partial Response	PR	1	0	1	0	6	162	1	58	1607	6	162	1	4	1
MMRF_1923	1	Ixazomib	Ixa	Proteasome	318	990	2	Bortezomib/Daratumumab/Thalidomide/Dexamethasone + Ixazomib	Bor-Dar-Thal-Dex + Ixa	1	Proteasome/CD38/IMID/Steroid	990	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	162	1	1607		Complete Response	CR	Partial Response	PR	1	1	0	1	24	673	0	58	1607	6	162			1
MMRF_1716	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	76	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	76	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	DEATH													0	0	0	0	3	76	0					1	3	1
MMRF_1931	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	310	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	310	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	183	3	183	520	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	11	310	1	7	183	7	183	1	3	1
MMRF_1931	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	796	1768	1	Lenalidomide/Dexamethasone	Len-Dex	796	IMID/Steroid	1768	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	901	3	1062	796	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	35	973	1	10	267	4	106	1	2	1
MMRF_1931	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1895	2084	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1895	Proteasome/Chemotherapy/Steroid	2084	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Patient decision	6			4	1979	4	1979		Partial Response	PR	Partial Response	PR	1	1	1	1	7	190	1	4	85	4	85	1	3	1
MMRF_2194	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	289	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	289	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4	990		3	184	1	341	443	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	11	289	1	13	341	7	184	1	3	1
MMRF_2194	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	449	541	1	Lenalidomide/Dexamethasone	Len-Dex	449	IMID/Steroid	541	IMIDs-based	IMIDs-based	Len-Dex				0			990				6	533	533	Progressive Disease	PD			0	1	0	1	4	93	0	4	85			1	2	1
MMRF_2194	2	Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Cyc-Dex	IMID/Chemotherapy/Steroid	542	591	2	Lenalidomide/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Dex + Len-Cyc-Dex	449	IMID/Steroid/Chemotherapy	591	IMIDs-based	IMIDs-based	Len-Cyc-Dex				0	Lack of response	1	990				6	533	533	Progressive Disease	PD			0	0	0	0	2	50	0	4	85					1
MMRF_2194	3	Vincristine/Dexamethasone/Doxorubicin	Vin-Dex-Dox	Chemotherapy/Steroid/Chemotherapy	592	648	1	Vincristine/Dexamethasone/Doxorubicin	Vin-Dex-Dox	592	Chemotherapy/Steroid	648	Other therapies	Other treatments					0	Lack of response	1	990											0	0	0	0	2	57	0							1
MMRF_2194	4	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	670	787	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	670	Proteasome/IMID/Steroid	787	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Lack of response	1	990				5	731		Stable Disease	SD			0	1	0	1	5	118	0	3	62			1	3	1
MMRF_2194	5	Daratumumab	Dar	CD38	850	1061	1	Daratumumab	Dar	850	CD38	1061	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3	990				5	901	990	Stable Disease	SD			0	1	0	1	8	212	0	2	52					1
MMRF_2245	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	91	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	91	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0														0	0	0	0	4	91	0					1	3	1
MMRF_2257	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	103	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	103	Bortezomib-based	Bortezomib-based	Bor-Dex				0	Completed regimen	4			3	88	3	88		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	103	1	4	88	4	88	1	2	1
MMRF_2257	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1154	1293	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1154	Proteasome/Chemotherapy/Steroid	1293	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	1728	3	1969	1154	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	140	1	30	816	21	575	1	3	1
MMRF_2526	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	260	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	260	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	78	1	897	2116	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	10	260	1	33	897	3	78	1	3	1
MMRF_1913	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	369	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	369	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	67	3	151	452	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	13	369	1	6	151	3	67	1	3	1
MMRF_1913	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	651	704	1	Lenalidomide/Dexamethasone	Len-Dex	651	IMID/Steroid	704	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	705	788	Stable Disease	SD			0	1	0	1	2	54	0	2	55			1	2	1
MMRF_1913	2	Lenalidomide/Prednisone/Dexamethasone	Len-Pred-Dex	IMID/Steroid/Steroid	705	733	2	Lenalidomide/Dexamethasone + Lenalidomide/Prednisone/Dexamethasone	Len-Dex + Len-Pred-Dex	651	IMID/Steroid	733	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2					5	705	788	Stable Disease	SD			0	0	0	1	1	29	0	2	55					1
MMRF_1913	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	804	936	1	Carfilzomib/Dexamethasone	Car-Dex	804	Proteasome/Steroid	936	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Adverse Event or co-morbidity	2			4	860	4	860	957	Partial Response	PR	Partial Response	PR	1	1	1	1	5	133	1	3	57	3	57	1	2	1
MMRF_1913	4	Daratumumab	Dar	CD38	1104	1265	1	Daratumumab	Dar	1104	CD38	1265	daratumumab-based	daratumumab-based	Dar				0	Disease progression/Relapse	3					5	1152	1320	Stable Disease	SD			0	1	0	1	6	162	0	2	49					1
MMRF_1978	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	281	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	281	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	84	4	84	604	Partial Response	PR	Partial Response	PR	1	1	1	1	10	281	1	3	84	3	84	1	3	1
MMRF_1978	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	646	2788	1	Lenalidomide/Dexamethasone	Len-Dex	646	IMID/Steroid	2788	IMIDs-based	IMIDs-based	Len-Dex				0					3	745	1	1245	2788	Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	77	2143	1	22	600	4	100	1	2	1
MMRF_1989	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	200	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	200	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex	235	Stem cell, Autologous	1	1	Completed regimen	4			3	124	1	208		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	7	200	1	8	208	5	124	1	3	1
MMRF_1989	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	333	1205	2	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	1205	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	124	1	208		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	31	873	0	8	208	5	124			1
MMRF_2049	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	157	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	157	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				0	Adverse Event or co-morbidity	2			4	109	4	109	634	Partial Response	PR	Partial Response	PR	1	1	1	1	6	157	1	4	109	4	109	1	3	1
MMRF_2049	2	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	Proteasome/Chemotherapy/Steroid	1730	1946	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	1730	Proteasome/Chemotherapy/Steroid	1946	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	1836	4	1836	1730	Partial Response	PR	Partial Response	PR	1	1	1	1	8	217	1	4	107	4	107	1	3	1
MMRF_2049	2	Cyclophosphamide/Prednisone	Cyc-Pred	Chemotherapy/Steroid	1947	2041	2	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	1730	Proteasome/Chemotherapy/Steroid	2041	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	1836	4	1836	1730	Partial Response	PR	Partial Response	PR	1	0	0	0	4	95	0	4	107	4	107			1
MMRF_2049	3	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	2711	2739	1	Lenalidomide/Prednisone	Len-Pred	2711	IMID/Steroid	2739	IMIDs-based	IMIDs-based	Other Len-based therapies				0					4	2737	4	2737		Partial Response	PR	Partial Response	PR	1	1	1	1	1	29	1	1	27	1	27	1	2	1
MMRF_2384	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	185	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	185	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	7	185	1	17	449	4	92	1	3	1
MMRF_2384	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	226	229	2	Bortezomib/Lenalidomide/Dexamethasone + Busulfan/Melphalan	Bor-Len-Dex + Bus-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	229	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	231	Stem cell, Autologous	1	1	Completed regimen	4			3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	4	0	17	449	4	92			1
MMRF_2384	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	386	449	3	Bortezomib/Lenalidomide/Dexamethasone + Busulfan/Melphalan + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bus-Mel + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	449	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	3	64	0	17	449	4	92			1
MMRF_2384	1	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	492	1270	4	Bortezomib/Lenalidomide/Dexamethasone + Busulfan/Melphalan + Bortezomib/Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bus-Mel + Bor-Len-Dex + Ixa-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1270	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	92	1	449		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	28	779	0	17	449	4	92			1
MMRF_2385	1	Bortezomib/Cyclophosphamide/Methylprednisolone	Bor-Cyc-Mep	Proteasome/Chemotherapy/Steroid	1	77	1	Bortezomib/Cyclophosphamide/Methylprednisolone	Bor-Cyc-Mep	1	Proteasome/Chemotherapy/Steroid	77	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	139	Stem cell, Autologous	1	1	Completed regimen	4			3	96	1	132		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	3	77	1	5	132	4	96	1	3	1
MMRF_2385	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	619	701	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	619	Proteasome/Chemotherapy/Steroid	701	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			1	738	1	738	619	Complete Response	CR	Complete Response	CR	1	1	1	1	3	83	1	5	120	5	120	1	3	1
MMRF_2385	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	738	1027	2	Bortezomib/Cyclophosphamide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Len-Dex	619	Proteasome/Chemotherapy/Steroid/IMID	1027	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			1	738	1	738	619	Complete Response	CR	Complete Response	CR	1	0	0	1	11	290	1	5	120	5	120			1
MMRF_2385	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1137	1816	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1137	Proteasome/CD38/Steroid	1816	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	DEATH						6	1263	1263	Progressive Disease	PD			0	1	0	1	25	680	0	5	127			1	3	1
MMRF_2413	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	11	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	11	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Adverse Event or co-morbidity	2			4	74	3	455	847	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	11	0	17	455	3	74	1	3	1
MMRF_2413	1	Cyclophosphamide/Prednisone	Cyc-Pred	Chemotherapy/Steroid	48	400	2	Bortezomib/Melphalan/Prednisone + Cyclophosphamide/Prednisone	Bor-Mel-Pred + Cyc-Pred	1	Proteasome/Chemotherapy/Steroid	400	Bortezomib-based	Other treatments	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	74	3	455	847	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	13	353	1	17	455	3	74			1
MMRF_2413	2	Cyclophosphamide/Prednisone	Cyc-Pred	Chemotherapy/Steroid	851	934	1	Cyclophosphamide/Prednisone	Cyc-Pred	851	Chemotherapy/Steroid	934	Other therapies	Other treatments					0					3	1026	3	1026	935	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	3	84	0	7	176	7	176			1
MMRF_2413	2	Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Len-Cyc-Pred-Dex	IMID/Chemotherapy/Steroid/Steroid	935	935	2	Cyclophosphamide/Prednisone + Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone	Cyc-Pred + Len-Cyc-Pred-Dex	851	Chemotherapy/Steroid/IMID	935	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Lack of response	1			3	1026	3	1026	935	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	7	176	7	176	1	4	1
MMRF_2413	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	936	1442	3	Cyclophosphamide/Prednisone + Lenalidomide/Cyclophosphamide/Prednisone/Dexamethasone + Lenalidomide/Dexamethasone	Cyc-Pred + Len-Cyc-Pred-Dex + Len-Dex	851	Chemotherapy/Steroid/IMID	1442	IMIDs-based	IMIDs-based	Other Len-based therapies				0	DEATH				3	1026	3	1026	935	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	18	507	1	7	176	7	176			1
MMRF_2580	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	2337	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	2337	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0					4	82	3	117	677	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	84	2337	1	5	117	3	82	1	3	1
MMRF_1861	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	252	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	252	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	102	3	102	801	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	252	1	4	102	4	102	1	3	1
MMRF_1861	1	Bortezomib	Bor	Proteasome	253	270	2	Bortezomib/Melphalan/Prednisone + Bortezomib	Bor-Mel-Pred + Bor	1	Proteasome/Chemotherapy/Steroid	270	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	102	3	102	801	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	18	0	4	102	4	102			1
MMRF_1861	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1040	1236	1	Lenalidomide/Dexamethasone	Len-Dex	1040	IMID/Steroid	1236	IMIDs-based	IMIDs-based	Len-Dex				0					3	1066	3	1066		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	7	197	1	1	27	1	27	1	2	1
MMRF_1861	2	Ixazomib/Lenalidomide/Dexamethasone	Ixa-Len-Dex	Proteasome/IMID/Steroid	1237	1255	2	Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Len-Dex + Ixa-Len-Dex	1040	IMID/Steroid/Proteasome	1255	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			3	1066	3	1066		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	19	0	1	27	1	27			1
MMRF_1861	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1256	1305	3	Lenalidomide/Dexamethasone + Ixazomib/Lenalidomide/Dexamethasone	Len-Dex + Ixa-Len-Dex	1040	IMID/Steroid/Proteasome	1305	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			3	1066	3	1066		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	2	50	0	1	27	1	27			1
MMRF_1933	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	242	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	242	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	95	3	95	831	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	9	242	1	4	95	4	95	1	3	1
MMRF_1933	1	Bortezomib	Bor	Proteasome	243	260	2	Bortezomib/Melphalan/Prednisone + Bortezomib	Bor-Mel-Pred + Bor	1	Proteasome/Chemotherapy/Steroid	260	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	95	3	95	831	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	18	0	4	95	4	95			1
MMRF_1933	2	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	944	977	1	Melphalan/Prednisone	Mel-Pred	944	Chemotherapy/Steroid	977	Other therapies	Other treatments					0														0	0	0	0	2	34	0							1
MMRF_1995	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	22	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	22	Bortezomib-based	Bortezomib-based	Bor-Dex				0	WE DECIDED ONLY ONE CYCLE OF VELCADE+DEXA AND THEN ANOTHER TREATMENT		1377		4	65	4	65	453	Partial Response	PR	Partial Response	PR	1	0	0	0	1	22	0	3	65	3	65	1	2	1
MMRF_1995	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	41	275	2	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Prednisone	Bor-Dex + Bor-Mel-Pred	1	Proteasome/Steroid/Chemotherapy	275	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1377		4	65	4	65	453	Partial Response	PR	Partial Response	PR	1	1	1	1	9	235	1	3	65	3	65			1
MMRF_1995	1	Bortezomib	Bor	Proteasome	276	293	3	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Prednisone + Bortezomib	Bor-Dex + Bor-Mel-Pred + Bor	1	Proteasome/Steroid/Chemotherapy	293	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4	1377		4	65	4	65	453	Partial Response	PR	Partial Response	PR	1	0	0	0	1	18	0	3	65	3	65			1
MMRF_1995	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	460	1159	1	Lenalidomide/Dexamethasone	Len-Dex	460	IMID/Steroid	1159	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3	1377		4	534	3	796	630	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	25	700	1	13	337	3	75	1	2	1
MMRF_1995	3	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	Proteasome/CD38/Steroid	1198	1218	1	Bortezomib/Daratumumab/Dexamethasone	Bor-Dar-Dex	1198	Proteasome/CD38/Steroid	1218	Bortezomib-based	Bortezomib-based	Bor-Dar-Dex				0	Disease progression/Relapse	3	1377											0	0	0	0	1	21	0					1	3	1
MMRF_1995	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1232	1363	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1232	Proteasome/Chemotherapy/Steroid	1363	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3	1377		3	1251	3	1251	1338	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	132	1	1	20	1	20	1	3	1
MMRF_1995	5	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1367	1461	1	Pomalidomide/Dexamethasone	Pom-Dex	1367	IMID/Steroid	1461	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2	1377				6	1377	1377	Progressive Disease	PD			0	1	0	1	4	95	0	1	11			1	2	1
MMRF_2008	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	33	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	33	Bortezomib-based	Bortezomib-based	Bor-Dex				0					3	90	3	90	891	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	1	33	0	4	90	4	90	1	2	1
MMRF_2008	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	34	426	2	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Dex + Bor-Mel-Pred-Dex	1	Proteasome/Steroid/Chemotherapy	426	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			3	90	3	90	891	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	393	1	4	90	4	90			1
MMRF_2008	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	427	1063	3	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Prednisone/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Dex + Bor-Mel-Pred-Dex + Len-Dex	1	Proteasome/Steroid/Chemotherapy/IMID	1063	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			3	90	3	90	891	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	23	637	0	4	90	4	90			1
MMRF_2008	2	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1101	1210	1	Pomalidomide/Dexamethasone	Pom-Dex	1101	IMID/Steroid	1210	IMIDs-based	IMIDs-based	Pom-Dex				0	Disease progression/Relapse	3					5	1155	1235	Stable Disease	SD			0	1	0	1	4	110	0	2	55			1	2	1
MMRF_2008	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1263	1324	1	Daratumumab/Dexamethasone	Dar-Dex	1263	CD38/Steroid	1324	daratumumab-based	daratumumab-based	Dar-Dex				0	Disease progression/Relapse	3					6	1318	1318	Progressive Disease	PD			0	1	0	1	3	62	0	2	56					1
MMRF_2008	4	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1325	1380	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1325	Proteasome/Chemotherapy/Steroid	1380	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	DECEASED PATIENT													0	0	0	0	2	56	0					1	3	1
MMRF_2011	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1	98	1	Bortezomib/Melphalan/Prednisone/Dexamethasone	Bor-Mel-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	98	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2					5	99	281	Stable Disease	SD			0	1	0	1	4	98	0	4	99			1	4	1
MMRF_2011	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	113	315	2	Bortezomib/Melphalan/Prednisone/Dexamethasone + Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred-Dex + Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	315	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					5	99	281	Stable Disease	SD			0	0	0	0	8	203	0	4	99					1
MMRF_2011	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	316	466	1	Lenalidomide/Dexamethasone	Len-Dex	316	IMID/Steroid	466	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			3	341	3	341	547	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	151	1	1	26	1	26	1	2	1
MMRF_2011	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	661	1207	1	Carfilzomib/Dexamethasone	Car-Dex	661	Proteasome/Steroid	1207	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Investigator decision for other reasons	5			3	712	3	712	904	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	20	547	1	2	52	2	52	1	2	1
MMRF_2011	4	Pomalidomide/Dexamethasone	Pom-Dex	IMID/Steroid	1348	1885	1	Pomalidomide/Dexamethasone	Pom-Dex	1348	IMID/Steroid	1885	IMIDs-based	IMIDs-based	Pom-Dex				0	Adverse Event or co-morbidity	2			3	1426	3	1426		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	20	538	1	3	79	3	79	1	2	1
MMRF_2085	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	9	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	9	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Adverse Event or co-morbidity	2					5	43		Stable Disease	SD			0	1	0	1	1	9	0	2	43			1	3	1
MMRF_2085	2	Cyclophosphamide/Dexamethasone	Cyc-Dex	Chemotherapy/Steroid	96	121	1	Cyclophosphamide/Dexamethasone	Cyc-Dex	96	Chemotherapy/Steroid	121	Other therapies	Other treatments					0					4	152	4	152	346	Partial Response	PR	Partial Response	PR	1	0	0	0	1	26	0	3	57	3	57			1
MMRF_2085	2	Lenalidomide/Cyclophosphamide/Dexamethasone	Len-Cyc-Dex	IMID/Chemotherapy/Steroid	122	141	2	Cyclophosphamide/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone	Cyc-Dex + Len-Cyc-Dex	96	Chemotherapy/Steroid/IMID	141	IMIDs-based	IMIDs-based	Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	152	4	152	346	Partial Response	PR	Partial Response	PR	1	1	1	1	1	20	1	3	57	3	57	1	3	1
MMRF_2085	2	Melphalan/Prednisone	Mel-Pred	Chemotherapy/Steroid	234	417	3	Cyclophosphamide/Dexamethasone + Lenalidomide/Cyclophosphamide/Dexamethasone + Melphalan/Prednisone	Cyc-Dex + Len-Cyc-Dex + Mel-Pred	96	Chemotherapy/Steroid/IMID	417	IMIDs-based	Other treatments	Other Len-based therapies				0	Disease progression/Relapse	3			4	152	4	152	346	Partial Response	PR	Partial Response	PR	1	0	0	0	7	184	0	3	57	3	57			1
MMRF_2229	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	Proteasome/Chemotherapy/Steroid	1	250	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	1	Proteasome/Chemotherapy/Steroid	250	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Completed regimen	4			4	29	3	113	1031	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	250	1	5	113	2	29	1	3	1
MMRF_2229	1	Bortezomib	Bor	Proteasome	337	532	2	Bortezomib/Cyclophosphamide/Prednisone + Bortezomib	Bor-Cyc-Pred + Bor	1	Proteasome/Chemotherapy/Steroid	532	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0					4	29	3	113	1031	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	196	0	5	113	2	29			1
MMRF_2229	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	533	1002	3	Bortezomib/Cyclophosphamide/Prednisone + Bortezomib + Bortezomib/Dexamethasone	Bor-Cyc-Pred + Bor + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	1002	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3			4	29	3	113	1031	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	17	470	0	5	113	2	29			1
MMRF_2229	2	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	1248	1347	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	1248	CD38/IMID/Steroid	1347	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Adverse Event or co-morbidity	2			4	1268	3	1339		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	100	1	4	92	1	21	1	3	1
MMRF_2328	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	273	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	273	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	92	3	543	687	Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	10	273	1	20	543	4	92	1	3	1
MMRF_2328	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	274	357	2	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone	Bor-Cyc-Dex + Bor-Dex	1	Proteasome/Chemotherapy/Steroid	357	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Investigator decision for other reasons	5			4	92	3	543	687	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	3	84	0	20	543	4	92			1
MMRF_2328	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	426	572	3	Bortezomib/Cyclophosphamide/Dexamethasone + Bortezomib/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Bor-Dex + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	572	combined bortezomib/IMIDs-based	IMIDs-based	Bor-Len-Cyc-Dex				0	Adverse Event or co-morbidity	2			4	92	3	543	687	Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	6	147	0	20	543	4	92			1
MMRF_2328	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	690	774	1	Lenalidomide/Dexamethasone	Len-Dex	690	IMID/Steroid	774	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					6	715	715	Progressive Disease	PD			0	1	0	1	3	85	0	1	26			1	2	1
MMRF_2328	3	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	824	879	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	824	Proteasome/Chemotherapy/Steroid	879	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Disease progression/Relapse	3					6	897	897	Progressive Disease	PD			0	0	0	0	2	56	0	3	74			1	3	1
MMRF_2328	3	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	880	883	2	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Dexamethasone	Car-Cyc-Dex + Car-Dex	824	Proteasome/Chemotherapy/Steroid	883	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4					6	897	897	Progressive Disease	PD			0	1	0	1	0	4	0	3	74					1
MMRF_2328	4	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	CD38/IMID/Steroid	908	919	1	Daratumumab/Lenalidomide/Dexamethasone	Dar-Len-Dex	908	CD38/IMID/Steroid	919	combined daratumumab/IMIDs-based	combined daratumumab/IMIDs-based	Dar-Len-Dex				0	Adverse Event or co-morbidity	2					6	966	966	Progressive Disease	PD			0	0	0	0	1	12	0	3	59			1	3	1
MMRF_2328	4	Bortezomib/Daratumumab/Pomalidomide/Clarithromycin/Dexamethasone	Bor-Dar-Pom-Clar-Dex	Proteasome/CD38/IMID/Antibiotic/Steroid	939	970	2	Daratumumab/Lenalidomide/Dexamethasone + Bortezomib/Daratumumab/Pomalidomide/Clarithromycin/Dexamethasone	Dar-Len-Dex + Bor-Dar-Pom-Clar-Dex	908	CD38/IMID/Steroid/Proteasome/Antibiotic	970	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3					6	966	966	Progressive Disease	PD			0	1	0	1	1	32	0	3	59					1
MMRF_2401	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	115	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	115	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				0	Disease progression/Relapse	3					6	81	81	Progressive Disease	PD			0	1	0	1	4	115	0	3	81			1	3	1
MMRF_2401	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	123	249	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	123	Proteasome/Chemotherapy/Steroid	249	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	EVOLUTION TO PLASMA CELL LEUKEMIA						5	163	250	Stable Disease	SD			0	1	0	1	5	127	0	2	41			1	3	1
MMRF_2401	3	Clarithromycin/Melphalan/Dexamethasone/Doxorubicin	Clar-Mel-Dex-Dox	Antibiotic/Chemotherapy/Steroid/Chemotherapy	251	272	1	Clarithromycin/Melphalan/Dexamethasone/Doxorubicin	Clar-Mel-Dex-Dox	251	Antibiotic/Chemotherapy/Steroid	272	Other therapies	Other treatments		274	Stem cell, Autologous	1	1	Disease progression/Relapse	3					6	365	365	Progressive Disease	PD			0	0	0	0	1	22	0	5	115					1
MMRF_2401	3	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	305	364	2	Clarithromycin/Melphalan/Dexamethasone/Doxorubicin + Bortezomib/Lenalidomide/Dexamethasone	Clar-Mel-Dex-Dox + Bor-Len-Dex	251	Antibiotic/Chemotherapy/Steroid/Proteasome/IMID	364	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Adverse Event or co-morbidity	2					6	365	365	Progressive Disease	PD			0	1	0	1	2	60	0	5	115			1	3	1
MMRF_2427	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	179	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	179	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				0					4	371	4	371		Partial Response	PR	Partial Response	PR	1	0	0	0	7	179	0	14	371	14	371	1	3	1
MMRF_2427	1	Bortezomib/Thalidomide/Clarithromycin/Dexamethasone	Bor-Thal-Clar-Dex	Proteasome/IMID/Antibiotic/Steroid	180	250	2	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Clarithromycin/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Clar-Dex	1	Proteasome/IMID/Steroid/Antibiotic	250	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	371	4	371		Partial Response	PR	Partial Response	PR	1	0	0	0	3	71	0	14	371	14	371			1
MMRF_2427	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	251	306	3	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Clarithromycin/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Clar-Dex + Bor-Thal-Dex	1	Proteasome/IMID/Steroid/Antibiotic	306	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Investigator decision for other reasons	5			4	371	4	371		Partial Response	PR	Partial Response	PR	1	0	0	0	2	56	0	14	371	14	371			1
MMRF_2427	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	344	398	4	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Clarithromycin/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone + Lenalidomide/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Clar-Dex + Bor-Thal-Dex + Len-Dex	1	Proteasome/IMID/Steroid/Antibiotic	398	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	371	4	371		Partial Response	PR	Partial Response	PR	1	1	1	1	2	55	1	14	371	14	371			1
MMRF_2427	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	446	554	1	Lenalidomide/Dexamethasone	Len-Dex	446	IMID/Steroid	554	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2					5	533	460	Stable Disease	SD			0	1	0	1	4	109	0	4	88			1	2	1
MMRF_2435	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	221	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	221	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	71	1	256		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	8	221	1	10	256	3	71	1	3	1
MMRF_2488	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	1	188	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	1	Proteasome/IMID/Steroid	188	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Len-Dex				1	Completed regimen	4			4	95	1	372	1521	Complete Response	CR	Partial Response	PR	1	0	1	0	7	188	1	14	372	4	95	1	3	1
MMRF_2488	1	Busulfan/Melphalan	Bus-Mel	Chemotherapy/Chemotherapy	243	246	2	Bortezomib/Lenalidomide/Dexamethasone + Busulfan/Melphalan	Bor-Len-Dex + Bus-Mel	1	Proteasome/IMID/Steroid/Chemotherapy	246	combined bortezomib/IMIDs-based	Other treatments	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	248	Stem cell, Autologous	1	1	Completed regimen	4			4	95	1	372	1521	Complete Response	CR	Partial Response	PR	1	0	0	0	0	4	0	14	372	4	95			1
MMRF_2488	1	Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex	Proteasome/IMID/Steroid	346	402	3	Bortezomib/Lenalidomide/Dexamethasone + Busulfan/Melphalan + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bus-Mel + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	402	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	95	1	372	1521	Complete Response	CR	Partial Response	PR	1	1	0	1	2	57	0	14	372	4	95			1
MMRF_2488	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	430	1520	4	Bortezomib/Lenalidomide/Dexamethasone + Busulfan/Melphalan + Bortezomib/Lenalidomide/Dexamethasone	Bor-Len-Dex + Bus-Mel + Bor-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	1520	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Disease progression/Relapse	3			4	95	1	372	1521	Complete Response	CR	Partial Response	PR	1	0	0	0	39	1091	0	14	372	4	95			1
MMRF_2488	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1585	2569	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1585	Proteasome/Chemotherapy/Steroid	2569	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0					4	1613	2	2010		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	35	985	1	16	426	2	29	1	3	1
MMRF_2490	1	Bortezomib/Dexamethasone	Bor-Dex	Proteasome/Steroid	1	53	1	Bortezomib/Dexamethasone	Bor-Dex	1	Proteasome/Steroid	53	Bortezomib-based	Bortezomib-based	Bor-Dex				0	DOSE CHANGED													0	0	0	0	2	53	0					1	2	1
MMRF_2490	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	54	82	2	Bortezomib/Dexamethasone + Bortezomib/Melphalan/Prednisone	Bor-Dex + Bor-Mel-Pred	1	Proteasome/Steroid/Chemotherapy	82	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	Disease progression/Relapse	3												0	0	0	0	1	29	0							1
MMRF_2490	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	91	146	1	Lenalidomide/Dexamethasone	Len-Dex	91	IMID/Steroid	146	IMIDs-based	IMIDs-based	Len-Dex				0	Disease progression/Relapse	3			4	168	3	265	91	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	2	56	0	7	175	3	78	1	2	1
MMRF_2490	2	Thalidomide/Clarithromycin/Cyclophosphamide/Dexamethasone	Thal-Clar-Cyc-Dex	IMID/Antibiotic/Chemotherapy/Steroid	161	343	2	Lenalidomide/Dexamethasone + Thalidomide/Clarithromycin/Cyclophosphamide/Dexamethasone	Len-Dex + Thal-Clar-Cyc-Dex	91	IMID/Steroid/Antibiotic/Chemotherapy	343	IMIDs-based	IMIDs-based	Other Len-based therapies				0	Adverse Event or co-morbidity	2			4	168	3	265	91	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	183	1	7	175	3	78			1
MMRF_2518	1	Bortezomib/Daratumumab/Melphalan/Prednisone	Bor-Dar-Mel-Pred	Proteasome/CD38/Chemotherapy/Steroid	1	171	1	Bortezomib/Daratumumab/Melphalan/Prednisone	Bor-Dar-Mel-Pred	1	Proteasome/CD38/Chemotherapy/Steroid	171	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Patient decision	6			4	50	3	232		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	171	1	9	232	2	50	1	4	1
MMRF_2518	1	Bortezomib/Daratumumab	Bor-Dar	Proteasome/CD38	172	188	2	Bortezomib/Daratumumab/Melphalan/Prednisone + Bortezomib/Daratumumab	Bor-Dar-Mel-Pred + Bor-Dar	1	Proteasome/CD38/Chemotherapy/Steroid	188	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Patient decision	6			4	50	3	232		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	17	0	9	232	2	50			1
MMRF_2518	1	Bortezomib	Bor	Proteasome	189	237	3	Bortezomib/Daratumumab/Melphalan/Prednisone + Bortezomib/Daratumumab + Bortezomib	Bor-Dar-Mel-Pred + Bor-Dar + Bor	1	Proteasome/CD38/Chemotherapy/Steroid	237	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Patient decision	6			4	50	3	232		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	2	49	0	9	232	2	50			1
MMRF_2293	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	296	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	296	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				1					3	85	2	458		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	11	296	1	17	458	4	85	1	3	1
MMRF_2293	1	Bortezomib/Thalidomide/Melphalan/Dexamethasone	Bor-Thal-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	297	297	2	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Melphalan/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	297	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	85	2	458		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	17	458	4	85			1
MMRF_2293	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	298	2549	3	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Melphalan/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Mel-Dex + Bor-Thal-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	2549	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	298	Stem cell, Autologous	1	1					3	85	2	458		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	81	2252	0	17	458	4	85			1
MMRF_2300	1	Bortezomib/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Cyc-Pred-Dex	Proteasome/Chemotherapy/Steroid/Steroid	1	66	1	Bortezomib/Cyclophosphamide/Prednisone/Dexamethasone	Bor-Cyc-Pred-Dex	1	Proteasome/Chemotherapy/Steroid	66	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)				0	EXITUS						5	45		Stable Disease	SD			0	1	0	1	3	66	0	2	45			1	4	1
MMRF_2313	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	235	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	235	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	268	Stem cell, Autologous	1	1	Completed regimen	4			4	85	3	358	731	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	9	235	1	13	358	4	85	1	3	1
MMRF_2313	2	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	743	759	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	743	Proteasome/Chemotherapy/Steroid	759	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex				0	Completed regimen	4			4	877	3	990	744	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	17	0	9	248	5	135	1	3	1
MMRF_2313	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	773	1610	2	Bortezomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Bor-Cyc-Dex + Car-Len-Dex	743	Proteasome/Chemotherapy/Steroid/IMID	1610	combined bortezomib/IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Bor-Len-Car-Cyc-Dex				0	Disease progression/Relapse	3			4	877	3	990	744	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	30	838	1	9	248	5	135			1
MMRF_2313	3	Daratumumab/Dexamethasone	Dar-Dex	CD38/Steroid	1295	1610	1	Daratumumab/Dexamethasone	Dar-Dex	1295	CD38/Steroid	1610	daratumumab-based	daratumumab-based	Dar-Dex				0	Disease progression/Relapse	3			4	1442	4	1442	1324	Partial Response	PR	Partial Response	PR	1	1	1	1	12	316	1	6	148	6	148			1
MMRF_2313	4	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	IMID/Chemotherapy/Steroid	1610	1933	1	Pomalidomide/Cyclophosphamide/Dexamethasone	Pom-Cyc-Dex	1610	IMID/Chemotherapy/Steroid	1933	IMIDs-based	IMIDs-based	Pom-Cyc-Dex				0	Disease progression/Relapse	3					5	1799	1624	Stable Disease	SD			0	1	0	1	12	324	0	7	190			1	3	1
MMRF_2314	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	90	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	90	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				0	EXITUS													0	0	0	0	4	90	0					1	3	1
MMRF_2327	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	204	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	204	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Lack of response	1			4	445	4	445		Partial Response	PR	Partial Response	PR	1	0	0	0	8	204	0	16	445	16	445	1	3	1
MMRF_2327	1	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	263	1108	2	Bortezomib/Melphalan/Prednisone + Lenalidomide/Dexamethasone	Bor-Mel-Pred + Len-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	1108	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	445	4	445		Partial Response	PR	Partial Response	PR	1	1	1	1	31	846	1	16	445	16	445			1
MMRF_2327	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	1140	1507	1	Lenalidomide/Dexamethasone	Len-Dex	1140	IMID/Steroid	1507	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	1224	4	1224	1140	Partial Response	PR	Partial Response	PR	1	1	1	1	13	368	1	4	85	4	85	1	2	1
MMRF_2364	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	156	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	156	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				0	EXITUS				3	90	3	90		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	6	156	1	4	90	4	90	1	3	1
MMRF_2452	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	191	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	191	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex				1					4	266	4	266		Partial Response	PR	Partial Response	PR	1	0	0	0	7	191	0	10	266	10	266	1	3	1
MMRF_2452	1	Bortezomib/Thalidomide/Melphalan/Dexamethasone	Bor-Thal-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	192	192	2	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Melphalan/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	192	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			4	266	4	266		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	10	266	10	266			1
MMRF_2452	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	193	294	3	Bortezomib/Thalidomide/Dexamethasone + Bortezomib/Thalidomide/Melphalan/Dexamethasone + Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex + Bor-Thal-Mel-Dex + Bor-Thal-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	294	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)	193	Stem cell, Autologous	1	1	Adverse Event or co-morbidity	2			4	266	4	266		Partial Response	PR	Partial Response	PR	1	1	1	1	4	102	1	10	266	10	266			1
MMRF_2535	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	Proteasome/IMID/Steroid	1	200	1	Bortezomib/Thalidomide/Dexamethasone	Bor-Thal-Dex	1	Proteasome/IMID/Steroid	200	combined bortezomib/IMIDs-based	combined bortezomib/IMIDs-based	Bor-Thal-Dex	213	Stem cell, Autologous	1	1	Completed regimen	4			4	99	3	172		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	200	1	7	172	4	99	1	3	1
MMRF_2535	2	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine	Carm-Cyc-Mel-Pred-Vin	Chemotherapy/Chemotherapy/Chemotherapy/Steroid/Chemotherapy	341	358	1	Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine	Carm-Cyc-Mel-Pred-Vin	341	Chemotherapy/Steroid	358	Other therapies	Other treatments					0	Completed regimen	4			4	533	4	533	354	Partial Response	PR	Partial Response	PR	1	1	1	1	1	18	1	7	193	7	193	1	5	1
MMRF_2572	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	376	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	376	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			3	85	3	85	630	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	14	376	1	4	85	4	85	1	3	1
MMRF_2572	2	Bortezomib/Cyclophosphamide	Bor-Cyc	Proteasome/Chemotherapy	652	729	1	Bortezomib/Cyclophosphamide	Bor-Cyc	652	Proteasome/Chemotherapy	729	Bortezomib-based	Bortezomib-based	Bor-Cyc				0	Lack of response	1					5	715	799	Stable Disease	SD			0	1	0	1	3	78	0	3	64			1	2	1
MMRF_2572	3	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	887	1103	1	Lenalidomide/Dexamethasone	Len-Dex	887	IMID/Steroid	1103	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1					5	1068	995	Stable Disease	SD			0	1	0	1	8	217	0	7	182			1	2	1
MMRF_2601	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	366	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	366	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	170	3	366	554	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	13	366	1	14	366	7	170	1	3	1
MMRF_2601	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	575	2500	1	Lenalidomide/Dexamethasone	Len-Dex	575	IMID/Steroid	2500	IMIDs-based	IMIDs-based	Len-Dex				0					4	638	3	1807	575	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	69	1926	1	45	1233	3	64	1	2	1
MMRF_2613	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	621	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	621	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	DEATH				4	169	4	169		Partial Response	PR	Partial Response	PR	1	1	1	1	22	621	1	7	169	7	169	1	3	1
MMRF_2613	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	344	534	1	Lenalidomide/Dexamethasone	Len-Dex	344	IMID/Steroid	534	IMIDs-based	IMIDs-based	Len-Dex				0	Lack of response	1			4	456	4	456	344	Partial Response	PR	Partial Response	PR	1	1	1	1	7	191	1	5	113	5	113	1	2	1
MMRF_2613	3	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	582	621	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	582	Proteasome/IMID/Steroid	621	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	DEATH													0	0	0	0	2	40	0					1	3	1
MMRF_2016	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	107	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	107	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Adverse Event or co-morbidity	2			4	71	1	614	1975	Complete Response	CR	Partial Response	PR	1	0	1	0	4	107	1	22	614	3	71	1	3	1
MMRF_2016	1	Lenalidomide/Prednisone	Len-Pred	IMID/Steroid	124	1520	2	Bortezomib/Melphalan/Prednisone + Lenalidomide/Prednisone	Bor-Mel-Pred + Len-Pred	1	Proteasome/Chemotherapy/Steroid/IMID	1520	combined bortezomib/IMIDs-based	IMIDs-based	Other bortezomib/IMIDs-based + one other agent (not Dex or Cyc)				0	Adverse Event or co-morbidity	2			4	71	1	614	1975	Complete Response	CR	Partial Response	PR	1	1	0	1	50	1397	0	22	614	3	71			1
MMRF_2268	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	405	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	405	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	79	3	340	718	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	15	405	1	13	340	3	79	1	3	1
MMRF_2268	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	907	1548	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	907	Proteasome/IMID/Steroid	1548	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2			4	991	1	1346		Complete Response	CR	Partial Response	PR	1	1	1	1	23	642	1	16	440	4	85	1	3	1
MMRF_2305	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	Proteasome/Chemotherapy/Steroid	1	131	1	Bortezomib/Cyclophosphamide/Prednisone	Bor-Cyc-Pred	1	Proteasome/Chemotherapy/Steroid	131	Bortezomib-based	Bortezomib-based	Other bortezomib-based + one other agent (not Dex or Cyc)	243	Stem cell, Autologous	1	1	Lack of response	1			4	89	3	365	833	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	131	1	14	365	4	89	1	3	1
MMRF_2305	2	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	862	889	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	862	Proteasome/IMID/Steroid	889	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2												0	0	0	0	1	28	0					1	3	1
MMRF_2421	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	98	1	Bortezomib/Cyclophosphamide/Dexamethasone	Bor-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	98	Bortezomib-based	Bortezomib-based	Bor-Cyc-Dex	194	Stem cell, Autologous	1	1	Completed regimen	4			3	98	1	166		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	4	98	1	6	166	4	98	1	3	1
MMRF_2444	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	75	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	75	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	PAIENT DIED 23.05.15 AT 00:05H				3	74	3	74		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	3	75	1	3	74	3	74	1	3	1
MMRF_2558	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	113	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	113	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Patient decision	6			4	81	3	179	998	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	113	1	7	179	3	81	1	3	1
MMRF_2195	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	405	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	405	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	125	3	468	725	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	15	405	1	17	468	5	125	1	3	1
MMRF_2195	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	741	1149	1	Lenalidomide/Dexamethasone	Len-Dex	741	IMID/Steroid	1149	IMIDs-based	IMIDs-based	Len-Dex				0	Adverse Event or co-morbidity	2			4	895	4	895	1336	Partial Response	PR	Partial Response	PR	1	1	1	1	15	409	1	6	155	6	155	1	2	1
MMRF_2195	2	Carfilzomib/Dexamethasone	Car-Dex	Proteasome/Steroid	1294	1362	2	Lenalidomide/Dexamethasone + Carfilzomib/Dexamethasone	Len-Dex + Car-Dex	741	IMID/Steroid/Proteasome	1362	combined IMIDs/carfilzomib-based	Carfilzomib-based	Len-Car-Dex				0	Investigator decision for other reasons	5			4	895	4	895	1336	Partial Response	PR	Partial Response	PR	1	0	0	0	3	69	0	6	155	6	155			1
MMRF_2195	3	Daratumumab	Dar	CD38	1552	1678	1	Daratumumab	Dar	1552	CD38	1678	daratumumab-based	daratumumab-based	Dar				0	Adverse Event or co-morbidity	2			4	1490	4	1490		Partial Response	PR	Partial Response	PR	1	0	0	0	5	127	0	-2	-61	-2	-61			1
MMRF_2317	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	Proteasome/Chemotherapy/Steroid	1	338	1	Bortezomib/Melphalan/Prednisone	Bor-Mel-Pred	1	Proteasome/Chemotherapy/Steroid	338	Bortezomib-based	Bortezomib-based	Bor-Dar-Mel-Pred				0	Completed regimen	4			4	108	4	108		Partial Response	PR	Partial Response	PR	1	1	1	1	12	338	1	4	108	4	108	1	3	1
MMRF_2317	2	Lenalidomide/Dexamethasone	Len-Dex	IMID/Steroid	610	610	1	Lenalidomide/Dexamethasone	Len-Dex	610	IMID/Steroid	610	IMIDs-based	IMIDs-based	Len-Dex				0							6	610	610	Progressive Disease	PD			0	1	0	1	0	1	0	1	1			1	2	1
MMRF_2426	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	124	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	57	1	319		Complete Response	CR	Partial Response	PR	1	0	1	0	5	124	1	12	319	3	57	1	3	1
MMRF_2426	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	125	125	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	125	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	173	Stem cell, Autologous	1	1	Completed regimen	4			4	57	1	319		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	12	319	3	57			1
MMRF_2426	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	262	443	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	443	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	57	1	319		Complete Response	CR	Partial Response	PR	1	1	0	1	7	182	0	12	319	3	57			1
MMRF_2426	1	Lenalidomide	Len	IMID	444	583	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	583	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	57	1	319		Complete Response	CR	Partial Response	PR	1	0	0	0	5	140	0	12	319	3	57			1
MMRF_2583	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	115	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	115	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	115	1	4	85	2	29	1	3	1
MMRF_2583	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	116	116	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	159	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	2	29			1
MMRF_2583	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	267	414	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	414	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	148	0	4	85	2	29			1
MMRF_2583	1	Lenalidomide	Len	IMID	415	526	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	526	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	112	0	4	85	2	29			1
MMRF_2584	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	118	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	118	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	159	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	118	1	4	85	2	29	1	3	1
MMRF_2584	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	267	421	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	421	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	155	0	4	85	2	29			1
MMRF_2584	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	422	422	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	422	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	2	29			1
MMRF_2584	1	Lenalidomide	Len	IMID	423	534	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	534	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	112	0	4	85	2	29			1
MMRF_2604	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	133	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	133	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	205	Stem cell, Autologous	1	1	Completed regimen	4			3	131	3	131		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	133	1	5	131	5	131	1	3	1
MMRF_2604	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	311	436	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	436	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					3	131	3	131		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	126	0	5	131	5	131			1
MMRF_2604	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	437	437	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	437	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	131	3	131		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	5	131	5	131			1
MMRF_2604	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	438	576	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	576	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					3	131	3	131		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	139	0	5	131	5	131			1
MMRF_2609	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	113	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	1	364		Complete Response	CR	Partial Response	PR	1	0	1	0	4	113	1	13	364	2	29	1	3	1
MMRF_2609	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	114	114	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	114	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	1	364		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	13	364	2	29			1
MMRF_2609	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	169	407	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	407	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	1	364		Complete Response	CR	Partial Response	PR	1	1	0	1	9	239	0	13	364	2	29			1
MMRF_2609	1	Lenalidomide	Len	IMID	408	573	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	573	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				0					4	29	1	364		Complete Response	CR	Partial Response	PR	1	0	0	0	6	166	0	13	364	2	29			1
MMRF_2624	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	114	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	114	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	163	Stem cell, Autologous	1	1	Completed regimen	4			4	57	3	330		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	114	1	12	330	3	57	1	3	1
MMRF_2624	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	274	404	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	404	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					4	57	3	330		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	131	0	12	330	3	57			1
MMRF_2624	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	405	405	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	405	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	57	3	330		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	12	330	3	57			1
MMRF_2624	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	406	559	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	559	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					4	57	3	330		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	154	0	12	330	3	57			1
MMRF_2626	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	129	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	129	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	1	218		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	129	1	8	218	2	29	1	3	1
MMRF_2626	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	130	130	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	218		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	8	218	2	29			1
MMRF_2626	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	218	218	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	218	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					3	29	1	218		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	1	0	1	0	8	218	2	29			1
MMRF_2628	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	113	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	28	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	113	1	3	57	1	28	1	3	1
MMRF_2628	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	114	114	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	114	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	159	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	1	28			1
MMRF_2628	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	253	280	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	280	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					4	28	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	28	0	3	57	1	28			1
MMRF_2630	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	138	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	138	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	29	2	164		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	5	138	1	6	164	2	29	1	3	1
MMRF_2630	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	139	139	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	139	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	199	Stem cell, Autologous	1	1	Completed regimen	4			3	29	2	164		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	6	164	2	29			1
MMRF_2630	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	296	429	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	429	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	29	2	164		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	5	134	0	6	164	2	29			1
MMRF_2630	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	430	499	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Car-Len	1	Proteasome/IMID/Steroid/Chemotherapy	499	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					3	29	2	164		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	3	70	0	6	164	2	29			1
MMRF_2631	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	121	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	121	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	159	Stem cell, Autologous	1	1	Completed regimen	4			2	328	1	393		Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	5	121	0	15	393	12	328	1	3	1
MMRF_2631	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	274	392	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	392	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					2	328	1	393		Complete Response	CR	Stringent Complete Response	sCR	1	1	1	1	5	119	1	15	393	12	328			1
MMRF_2631	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	393	393	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	393	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			2	328	1	393		Complete Response	CR	Stringent Complete Response	sCR	1	0	0	1	0	1	0	15	393	12	328			1
MMRF_2631	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	394	589	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	589	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					2	328	1	393		Complete Response	CR	Stringent Complete Response	sCR	1	0	0	0	7	196	0	15	393	12	328			1
MMRF_2634	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	116	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	82		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	116	1	3	82	2	29	1	3	1
MMRF_2634	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	117	117	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	172	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	82		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	82	2	29			1
MMRF_2634	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	263	382	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	382	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	29	3	82		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	120	0	3	82	2	29			1
MMRF_2635	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	122	1	2	30	2	30	1	3	1
MMRF_2635	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	123	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	165	Stem cell, Autologous	1	1	Completed regimen	4			3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	30	2	30			1
MMRF_2635	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	275	385	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	385	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	111	0	2	30	2	30			1
MMRF_2635	1	Lenalidomide	Len	IMID	386	553	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Len	1	Proteasome/IMID/Steroid/Chemotherapy	553	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1					3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	6	168	0	2	30	2	30			1
MMRF_2636	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	162	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	287		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	4	113	1	11	287	2	29	1	3	1
MMRF_2636	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	259	371	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	371	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	29	3	287		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	4	113	0	11	287	2	29			1
MMRF_2637	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	143	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	143	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	1	343		Complete Response	CR	Partial Response	PR	1	0	1	0	5	143	1	13	343	2	29	1	3	1
MMRF_2637	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	144	144	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	188	Stem cell, Autologous	1	1	Completed regimen	4			4	29	1	343		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	13	343	2	29			1
MMRF_2637	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	281	393	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	393	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	29	1	343		Complete Response	CR	Partial Response	PR	1	1	0	1	4	113	0	13	343	2	29			1
MMRF_2638	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	166	Stem cell, Autologous	1	1	Completed regimen	4			4	57	3	294		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	120	1	11	294	3	57	1	3	1
MMRF_2638	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	260	385	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	385	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					4	57	3	294		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	126	0	11	294	3	57			1
MMRF_2638	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	386	386	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	386	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	57	3	294		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	11	294	3	57			1
MMRF_2639	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	145	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	145	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	57	4	57	553	Partial Response	PR	Partial Response	PR	1	1	1	1	5	145	1	3	57	3	57	1	3	1
MMRF_2639	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	146	146	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	146	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	57	4	57	553	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	57	3	57			1
MMRF_2639	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	203	441	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	441	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	57	4	57	553	Partial Response	PR	Partial Response	PR	1	0	0	0	9	239	0	3	57	3	57			1
MMRF_2640	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	157	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	157	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	203	Stem cell, Autologous	1	1	Completed regimen	4			3	58	1	415		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	6	157	1	15	415	3	58	1	3	1
MMRF_2640	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	302	420	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	420	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					3	58	1	415		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	5	119	0	15	415	3	58			1
MMRF_2640	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	421	421	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	421	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	58	1	415		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	15	415	3	58			1
MMRF_2640	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	422	561	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	561	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					3	58	1	415		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	5	140	0	15	415	3	58			1
MMRF_2641	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	127	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	127	1	3	57	2	29	1	3	1
MMRF_2641	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	128	128	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	128	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	2	29			1
MMRF_2641	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	232	428	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	428	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	197	0	3	57	2	29			1
MMRF_2642	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	121	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	30	1	196		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	121	1	7	196	2	30	1	3	1
MMRF_2642	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	122	122	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	30	1	196		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	7	196	2	30			1
MMRF_2642	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	196	427	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	427	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	30	1	196		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	1	9	232	0	7	196	2	30			1
MMRF_2643	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	158	Stem cell, Autologous	1	1	Completed regimen	4					5	29		Stable Disease	SD			0	1	0	1	4	117	0	2	29			1	3	1
MMRF_2643	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	253	365	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	365	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4					5	29		Stable Disease	SD			0	0	0	0	4	113	0	2	29					1
MMRF_2647	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	137	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	137	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1														0	0	0	0	5	137	0					1	3	1
MMRF_2647	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	138	138	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	138	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	200	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2647	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	309	421	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	421	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4												0	0	0	0	4	113	0							1
MMRF_2644	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	130	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	130	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	164	Stem cell, Autologous	1	1	Completed regimen	4			3	29	1	287		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	130	1	11	287	2	29	1	3	1
MMRF_2644	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	260	383	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	383	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					3	29	1	287		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	5	124	0	11	287	2	29			1
MMRF_2644	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	384	384	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	384	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	29	1	287		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	11	287	2	29			1
MMRF_2644	1	Lenalidomide	Len	IMID	385	492	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	492	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1					3	29	1	287		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	4	108	0	11	287	2	29			1
MMRF_2646	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	126	1	3	71	3	71	1	3	1
MMRF_2646	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	127	127	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	71	3	71			1
MMRF_2646	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	154	154	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	154	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Adverse Event or co-morbidity	2			3	71	3	71		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	71	3	71			1
MMRF_2648	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	143	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	143	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	1	540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	143	1	20	540	2	29	1	3	1
MMRF_2648	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	144	144	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	20	540	2	29			1
MMRF_2648	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	183	423	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	423	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	540		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	9	241	0	20	540	2	29			1
MMRF_2648	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	424	477	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Car-Len	1	Proteasome/IMID/Steroid/Chemotherapy	477	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					3	29	1	540		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	2	54	0	20	540	2	29			1
MMRF_2650	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	148	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	148	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	481		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	148	1	18	481	2	29	1	3	1
MMRF_2650	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	149	149	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	149	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	190	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	481		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	18	481	2	29			1
MMRF_2651	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	123	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	123	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	170	Stem cell, Autologous	1	1	Completed regimen	4			3	29	1	119		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	5	123	1	5	119	2	29	1	3	1
MMRF_2651	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	267	413	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	413	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					3	29	1	119		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	6	147	0	5	119	2	29			1
MMRF_2651	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	414	414	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	414	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	29	1	119		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	5	119	2	29			1
MMRF_2651	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	415	470	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Car-Len	1	Proteasome/Chemotherapy/Steroid/IMID	470	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					3	29	1	119		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	56	0	5	119	2	29			1
MMRF_2652	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	116	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	1	367		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	116	1	14	367	2	29	1	3	1
MMRF_2652	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	117	117	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	367		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	14	367	2	29			1
MMRF_2652	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	157	415	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	415	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	367		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	10	259	0	14	367	2	29			1
MMRF_2652	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	416	472	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Car-Len	1	Proteasome/IMID/Steroid/Chemotherapy	472	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					3	29	1	367		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	2	57	0	14	367	2	29			1
MMRF_2653	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	129	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	129	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	337		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	129	1	13	337	2	29	1	3	1
MMRF_2653	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	130	130	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	337		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	13	337	2	29			1
MMRF_2653	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	183	456	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	456	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	337		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	10	274	0	13	337	2	29			1
MMRF_2654	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	116	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	116	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	177	Stem cell, Autologous	1	1	Completed regimen	4			2	112	2	112		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	4	116	1	4	112	4	112	1	3	1
MMRF_2655	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	150	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	150	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	185	Stem cell, Autologous	1	1	Completed regimen	4			4	29	1	528		Complete Response	CR	Partial Response	PR	1	0	1	0	6	150	1	19	528	2	29	1	3	1
MMRF_2655	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	300	447	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	447	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	29	1	528		Complete Response	CR	Partial Response	PR	1	1	0	1	6	148	0	19	528	2	29			1
MMRF_2659	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	1	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_2660	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	28	2	345		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	1	0	5	122	1	13	345	1	28	1	3	1
MMRF_2660	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	134	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	134	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	28	2	345		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	12	0	13	345	1	28			1
MMRF_2660	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	135	161	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	161	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					3	28	2	345		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	1	27	0	13	345	1	28			1
MMRF_2660	1	Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Mel-Dex	Proteasome/IMID/Chemotherapy/Steroid	162	162	4	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Car-Len-Mel-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	162	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)				1	Completed regimen	4			3	28	2	345		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	13	345	1	28			1
MMRF_2660	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	163	373	5	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Melphalan/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex + Car-Len-Mel-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	373	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Other IMIDs/carfilzomib-based + one other agent (not Dex or Cyc)	165	Stem cell, Autologous	1	1					3	28	2	345		Stringent Complete Response	sCR	Very Good Partial Response	VGPR	1	1	0	1	8	211	0	13	345	1	28			1
MMRF_2664	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	137	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	137	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	30	3	94	305	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	137	1	4	94	2	30	1	3	1
MMRF_2664	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	138	138	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	138	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	185	Stem cell, Autologous	1	1	Completed regimen	4			4	30	3	94	305	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	94	2	30			1
MMRF_2664	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	276	305	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	305	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					4	30	3	94	305	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	1	30	0	4	94	2	30			1
MMRF_2665	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	115	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	115	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	170	Stem cell, Autologous	1	1	Completed regimen	4			4	112	4	112		Partial Response	PR	Partial Response	PR	1	1	1	1	4	115	1	4	112	4	112	1	3	1
MMRF_2665	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	223	343	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	343	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					4	112	4	112		Partial Response	PR	Partial Response	PR	1	0	0	0	5	121	0	4	112	4	112			1
MMRF_2665	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	344	344	3	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex + Car-Len-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid/IMID	344	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	112	4	112		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	112	4	112			1
MMRF_2665	1	Lenalidomide	Len	IMID	345	486	4	Carfilzomib/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Lenalidomide	Car-Cyc-Dex + Car-Len-Cyc-Dex + Len	1	Proteasome/Chemotherapy/Steroid/IMID	486	combined IMIDs/carfilzomib-based	IMIDs-based	Len-Car-Cyc-Dex				1					4	112	4	112		Partial Response	PR	Partial Response	PR	1	0	0	0	5	142	0	4	112	4	112			1
MMRF_2667	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	121	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	57	3	57		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	121	1	3	57	3	57	1	3	1
MMRF_2667	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	122	122	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	163	Stem cell, Autologous	1	1	Completed regimen	4			3	57	3	57		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	57	3	57			1
MMRF_2667	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	247	366	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	366	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	57	3	57		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	120	0	3	57	3	57			1
MMRF_2666	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	158	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	117	1	3	57	2	29	1	3	1
MMRF_2669	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	127	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	230	3	230		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	127	0	9	230	9	230	1	3	1
MMRF_2669	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	128	128	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	128	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	230	3	230		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	9	230	9	230			1
MMRF_2669	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	230	342	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	342	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	230	3	230		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	1	4	113	1	9	230	9	230			1
MMRF_2670	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	1	302		Complete Response	CR	Partial Response	PR	1	0	1	0	5	123	1	11	302	2	29	1	3	1
MMRF_2670	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	124	124	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	1	302		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	11	302	2	29			1
MMRF_2670	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	169	386	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	386	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	1	302		Complete Response	CR	Partial Response	PR	1	1	0	1	8	218	0	11	302	2	29			1
MMRF_2671	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	159	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	159	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					1	183	1	183		Complete Response	CR	Complete Response	CR	1	0	0	0	6	159	0	7	183	7	183	1	3	1
MMRF_2671	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	160	160	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	160	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	199	Stem cell, Autologous	1	1	Completed regimen	4			1	183	1	183		Complete Response	CR	Complete Response	CR	1	1	1	1	0	1	1	7	183	7	183			1
MMRF_2671	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	310	436	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	436	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			1	183	1	183		Complete Response	CR	Complete Response	CR	1	0	0	0	5	127	0	7	183	7	183			1
MMRF_2675	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	29	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	29	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Adverse Event or co-morbidity	2			4	25	3	54		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	1	29	1	2	54	1	25	1	3	1
MMRF_2676	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	131	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	131	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	180	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	115		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	131	1	5	115	2	29	1	3	1
MMRF_2676	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	269	451	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	451	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	29	3	115		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	183	0	5	115	2	29			1
MMRF_2677	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	34	3	170		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	122	1	7	170	2	34	1	3	1
MMRF_2677	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	123	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	34	3	170		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	7	170	2	34			1
MMRF_2677	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	170	447	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	447	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	34	3	170		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	10	278	0	7	170	2	34			1
MMRF_2678	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	154	Stem cell, Autologous	1	1	Completed regimen	4			3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	117	1	2	30	2	30	1	3	1
MMRF_2678	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	262	381	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	381	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	120	0	2	30	2	30			1
MMRF_2679	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	115	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	115	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	30	1	452		Complete Response	CR	Partial Response	PR	1	0	1	0	4	115	1	17	452	2	30	1	3	1
MMRF_2679	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	116	116	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	151	Stem cell, Autologous	1	1	Completed regimen	4			4	30	1	452		Complete Response	CR	Partial Response	PR	1	0	0	0	0	1	0	17	452	2	30			1
MMRF_2679	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	246	372	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	372	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			4	30	1	452		Complete Response	CR	Partial Response	PR	1	1	0	1	5	127	0	17	452	2	30			1
MMRF_2680	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	143	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	143	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	44	3	100		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	143	1	4	100	2	44	1	3	1
MMRF_2680	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	144	144	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	44	3	100		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	100	2	44			1
MMRF_2680	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	184	429	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	429	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	44	3	100		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	9	246	0	4	100	2	44			1
MMRF_2681	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	121	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	121	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	161	Stem cell, Autologous	1	1	Completed regimen	4					5	28		Stable Disease	SD			0	1	0	1	5	121	0	1	28			1	3	1
MMRF_2681	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	253	377	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	377	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4					5	28		Stable Disease	SD			0	0	0	0	5	125	0	1	28					1
MMRF_2682	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	138	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	138	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	61	3	61		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	138	1	3	61	3	61	1	3	1
MMRF_2682	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	139	139	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	139	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	197	Stem cell, Autologous	1	1	Completed regimen	4			3	61	3	61		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	61	3	61			1
MMRF_2682	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	295	427	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	427	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1	Completed regimen	4			3	61	3	61		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	133	0	3	61	3	61			1
MMRF_2683	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	129	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	129	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	28	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	129	1	4	85	1	28	1	3	1
MMRF_2683	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	130	130	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	224	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	1	28			1
MMRF_2685	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	144	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					2	204	2	204		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	5	144	0	8	204	8	204	1	3	1
MMRF_2685	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	145	145	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	145	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			2	204	2	204		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	1	1	1	0	1	1	8	204	8	204			1
MMRF_2685	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	268	268	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	268	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					2	204	2	204		Stringent Complete Response	sCR	Stringent Complete Response	sCR	1	0	0	0	0	1	0	8	204	8	204			1
MMRF_2688	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	123	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	123	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	158	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	148		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	123	1	6	148	1	28	1	3	1
MMRF_2690	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	116	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	1	168		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	4	116	1	6	168	2	29	1	3	1
MMRF_2690	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	117	117	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	168		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	6	168	2	29			1
MMRF_2690	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	183	411	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	411	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	168		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	8	229	0	6	168	2	29			1
MMRF_2689	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	140	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	140	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	37	1	310		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	140	1	12	310	2	37	1	3	1
MMRF_2689	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	141	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	141	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	37	1	310		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	12	310	2	37			1
MMRF_2689	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	170	403	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	403	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	37	1	310		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	9	234	0	12	310	2	37			1
MMRF_2691	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	112	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	112	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	85	4	85		Partial Response	PR	Partial Response	PR	1	1	1	1	4	112	1	4	85	4	85	1	3	1
MMRF_2691	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	113	113	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	154	Stem cell, Autologous	1	1	Completed regimen	4			4	85	4	85		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	85	4	85			1
MMRF_2691	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	251	417	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	417	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					4	85	4	85		Partial Response	PR	Partial Response	PR	1	0	0	0	6	167	0	4	85	4	85			1
MMRF_2692	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	124	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0							5	57		Stable Disease	SD			0	1	0	1	5	124	0	3	57			1	3	1
MMRF_2692	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	125	125	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	125	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4					5	57		Stable Disease	SD			0	0	0	0	0	1	0	3	57					1
MMRF_2694	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	125	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	125	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	173	Stem cell, Autologous	1	1	Completed regimen	4			4	30	3	58		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	125	1	3	58	2	30	1	3	1
MMRF_2694	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	263	410	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	410	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	30	3	58		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	6	148	0	3	58	2	30			1
MMRF_2695	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	145	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	145	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	192	Stem cell, Autologous	1	1	Completed regimen	4			4	54	3	179		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	145	1	7	179	2	54	1	3	1
MMRF_2695	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	268	450	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	450	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	54	3	179		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	7	183	0	7	179	2	54			1
MMRF_2696	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	111	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	111	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	164	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	111	1	4	85	2	29	1	3	1
MMRF_2696	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	274	386	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	386	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	4	113	0	4	85	2	29			1
MMRF_2697	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	113	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			4	36	4	36		Partial Response	PR	Partial Response	PR	1	1	1	1	4	113	1	2	36	2	36	1	3	1
MMRF_2697	1	Carfilzomib/Lenalidomide	Car-Len	Proteasome/IMID	114	183	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide	Car-Len-Dex + Car-Len	1	Proteasome/IMID/Steroid	183	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			4	36	4	36		Partial Response	PR	Partial Response	PR	1	0	0	0	3	70	0	2	36	2	36			1
MMRF_2698	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	120	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	120	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	84	3	84		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	3	84	3	84	1	3	1
MMRF_2698	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	121	121	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	84	3	84		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	3	84	3	84			1
MMRF_2698	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	196	420	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	420	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	84	3	84		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	8	225	0	3	84	3	84			1
MMRF_2702	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	123	1	5	113	2	29	1	3	1
MMRF_2702	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	124	124	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	5	113	2	29			1
MMRF_2702	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	183	428	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	428	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	113		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	9	246	0	5	113	2	29			1
MMRF_2699	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	134	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	134	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	330	1	359		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	5	134	0	13	359	12	330	1	3	1
MMRF_2699	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	135	135	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	135	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	330	1	359		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	13	359	12	330			1
MMRF_2699	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	181	456	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	456	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	330	1	359		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	10	276	1	13	359	12	330			1
MMRF_2700	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	149	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	149	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	28	2	344		Stringent Complete Response	sCR	Partial Response	PR	1	0	1	0	6	149	1	13	344	1	28	1	3	1
MMRF_2700	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	150	150	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	150	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	28	2	344		Stringent Complete Response	sCR	Partial Response	PR	1	0	0	0	0	1	0	13	344	1	28			1
MMRF_2700	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	191	428	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	428	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	28	2	344		Stringent Complete Response	sCR	Partial Response	PR	1	1	0	1	9	238	0	13	344	1	28			1
MMRF_2701	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	152	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	152	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	92		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	152	1	4	92	2	29	1	3	1
MMRF_2701	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	153	153	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	153	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	198	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	92		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	92	2	29			1
MMRF_2703	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	164	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	164	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	30	3	58		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	164	1	3	58	2	30	1	3	1
MMRF_2703	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	165	165	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	165	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	30	3	58		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	58	2	30			1
MMRF_2703	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	206	206	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	206	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					4	30	3	58		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	58	2	30			1
MMRF_2704	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	30	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	122	1	11	295	2	30	1	3	1
MMRF_2704	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	123	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	30	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	11	295	2	30			1
MMRF_2704	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	155	295	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	295	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	30	3	295		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	5	141	0	11	295	2	30			1
MMRF_2705	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	65	4	65		Partial Response	PR	Partial Response	PR	1	1	1	1	5	123	1	3	65	3	65	1	3	1
MMRF_2705	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	124	124	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	197	Stem cell, Autologous	1	1	Completed regimen	4			4	65	4	65		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	65	3	65			1
MMRF_2706	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	116	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	116	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	157	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	4	116	0					1	3	1
MMRF_2707	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	1	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_2708	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	131	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	131	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			3	57	3	57		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	131	1	3	57	3	57	1	3	1
MMRF_2709	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	119	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	119	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	28	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	119	1	3	57	1	28	1	3	1
MMRF_2709	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	120	120	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	120	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	169	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	1	28			1
MMRF_2716	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	118	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	118	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	163	Stem cell, Autologous	1	1	Completed regimen	4			4	28	1	287		Complete Response	CR	Partial Response	PR	1	0	1	0	5	118	1	11	287	1	28	1	3	1
MMRF_2716	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	260	287	2	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	287	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				1					4	28	1	287		Complete Response	CR	Partial Response	PR	1	1	0	1	1	28	0	11	287	1	28			1
MMRF_2711	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	136	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	136	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	329	3	329		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	136	0	12	329	12	329	1	3	1
MMRF_2711	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	137	137	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	137	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	202	Stem cell, Autologous	1	1	Completed regimen	4			3	329	3	329		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	12	329	12	329			1
MMRF_2715	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	124	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	124	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	161	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	56		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	124	1	2	56	1	28	1	3	1
MMRF_2717	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	116	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	32	4	32		Partial Response	PR	Partial Response	PR	1	1	1	1	4	116	1	2	32	2	32	1	3	1
MMRF_2717	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	117	117	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	32	4	32		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	32	2	32			1
MMRF_2717	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	158	316	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	316	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					4	32	4	32		Partial Response	PR	Partial Response	PR	1	0	0	0	6	159	0	2	32	2	32			1
MMRF_2714	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	138	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	138	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	28	3	28		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	138	1	1	28	1	28	1	3	1
MMRF_2714	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	139	139	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	139	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	179	Stem cell, Autologous	1	1	Completed regimen	4			3	28	3	28		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	1	28	1	28			1
MMRF_2714	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	274	365	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	365	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				1					3	28	3	28		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	92	0	1	28	1	28			1
MMRF_2718	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	108	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	108	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	108	1	2	29	2	29	1	3	1
MMRF_2718	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	109	109	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	109	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2718	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	148	260	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	260	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	4	113	0	2	29	2	29			1
MMRF_2719	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	151	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	151	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	151	1	3	57	2	29	1	3	1
MMRF_2719	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	152	152	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	152	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	233	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	2	29			1
MMRF_2720	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	115	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	115	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4												0	0	0	0	4	115	0					1	3	1
MMRF_2721	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	125	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	125	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	57	4	57		Partial Response	PR	Partial Response	PR	1	1	1	1	5	125	1	3	57	3	57	1	3	1
MMRF_2727	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	144	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	127		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	144	1	5	127	2	29	1	3	1
MMRF_2727	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	145	145	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	145	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	127		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	5	127	2	29			1
MMRF_2722	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	130	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	130	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	29	3	63		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	130	1	3	63	2	29	1	3	1
MMRF_2723	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	125	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	125	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	160	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	125	1	4	85	2	29	1	3	1
MMRF_2728	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	117	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	4	117	0					1	3	1
MMRF_2728	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	118	118	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	118	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2728	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	154	266	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	266	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4												0	0	0	0	4	113	0							1
MMRF_2729	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	114	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	114	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	114	1	4	85	2	29	1	3	1
MMRF_2729	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	115	115	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	115	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	156	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	2	29			1
MMRF_2730	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	1	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	2	30	2	30	1	3	1
MMRF_2731	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	166	Stem cell, Autologous	1	1	Completed regimen	4			4	30	2	288		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	5	120	1	11	288	2	30	1	3	1
MMRF_2732	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	29	1	114		Complete Response	CR	Very Good Partial Response	VGPR	1	1	1	1	5	130	1	5	114	2	29	1	3	1
MMRF_2732	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	131	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	186	Stem cell, Autologous	1	1	Completed regimen	4			3	29	1	114		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	5	114	2	29			1
MMRF_2733	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	159	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	159	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	22	3	107		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	159	1	4	107	1	22	1	3	1
MMRF_2733	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	160	160	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	160	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	225	Stem cell, Autologous	1	1	Completed regimen	4			4	22	3	107		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	107	1	22			1
MMRF_2734	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	113	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	113	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	156	Stem cell, Autologous	1	1	Completed regimen	4			4	57	4	57		Partial Response	PR	Partial Response	PR	1	1	1	1	4	113	1	3	57	3	57	1	3	1
MMRF_2736	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	120	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	120	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	151	Stem cell, Autologous	1	1	Completed regimen	4			3	30	3	30		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	2	30	2	30	1	3	1
MMRF_2737	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	116	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	116	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	162	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	4	116	0					1	3	1
MMRF_2738	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	57	4	57		Partial Response	PR	Partial Response	PR	1	1	1	1	5	123	1	3	57	3	57	1	3	1
MMRF_2738	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	124	124	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	57	4	57		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	57	3	57			1
MMRF_2738	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	172	367	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	367	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					4	57	4	57		Partial Response	PR	Partial Response	PR	1	0	0	0	7	196	0	3	57	3	57			1
MMRF_2739	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0														0	0	0	0	0	1	0					1	3	1
MMRF_2742	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	120	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	120	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	2	29	2	29	1	3	1
MMRF_2742	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	121	121	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2740	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	121	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	121	1	2	29	2	29	1	3	1
MMRF_2740	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	122	122	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2740	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	162	363	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	363	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	8	202	0	2	29	2	29			1
MMRF_2743	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	121	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					1	29	1	29		Complete Response	CR	Complete Response	CR	1	1	1	1	5	121	1	2	29	2	29	1	3	1
MMRF_2743	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	122	122	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	166	Stem cell, Autologous	1	1	Completed regimen	4			1	29	1	29		Complete Response	CR	Complete Response	CR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2745	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	118	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	118	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	5	118	0					1	3	1
MMRF_2745	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	119	119	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	119	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2745	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	162	323	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	323	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0														0	0	0	0	6	162	0							1
MMRF_2746	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	136	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	136	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	173	Stem cell, Autologous	1	1	Completed regimen	4			3	92	3	92		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	136	1	4	92	4	92	1	3	1
MMRF_2749	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					1	339	1	339		Complete Response	CR	Complete Response	CR	1	0	0	0	5	123	0	13	339	13	339	1	3	1
MMRF_2749	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	124	124	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			1	339	1	339		Complete Response	CR	Complete Response	CR	1	0	0	0	0	1	0	13	339	13	339			1
MMRF_2749	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	190	339	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	339	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					1	339	1	339		Complete Response	CR	Complete Response	CR	1	1	1	1	6	150	1	13	339	13	339			1
MMRF_2750	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	29	1	183		Complete Response	CR	Very Good Partial Response	VGPR	1	0	1	0	5	122	1	7	183	2	29	1	3	1
MMRF_2750	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	123	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	29	1	183		Complete Response	CR	Very Good Partial Response	VGPR	1	1	0	1	0	1	0	7	183	2	29			1
MMRF_2750	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	183	330	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	330	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					3	29	1	183		Complete Response	CR	Very Good Partial Response	VGPR	1	0	0	1	6	148	0	7	183	2	29			1
MMRF_2751	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	127	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	127	1	4	85	2	29	1	3	1
MMRF_2751	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	128	128	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	128	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	2	29			1
MMRF_2752	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	139	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	139	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	139	1	3	57	2	29	1	3	1
MMRF_2752	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	140	140	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	140	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	2	29			1
MMRF_2754	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	1	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_2753	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	136	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	136	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	176	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	136		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	136	1	5	136	2	29	1	3	1
MMRF_2755	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	154	Stem cell, Autologous	1	1	Completed regimen	4			4	91	4	91		Partial Response	PR	Partial Response	PR	1	1	1	1	4	117	1	4	91	4	91	1	3	1
MMRF_2756	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	142	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	142	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	57	3	344		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	142	1	13	344	3	57	1	3	1
MMRF_2756	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	143	143	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	143	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	57	3	344		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	13	344	3	57			1
MMRF_2757	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	130	1	3	57	2	29	1	3	1
MMRF_2757	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	131	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	2	29			1
MMRF_2757	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	191	331	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	331	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	5	141	0	3	57	2	29			1
MMRF_2758	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	135	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	135	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	198	Stem cell, Autologous	1	1	Completed regimen	4			4	36	4	36		Partial Response	PR	Partial Response	PR	1	1	1	1	5	135	1	2	36	2	36	1	3	1
MMRF_2760	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	117	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	117	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	163	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	4	117	0					1	3	1
MMRF_2761	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	1	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	1	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	0	1	0					1	3	1
MMRF_2762	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	125	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	125	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	125	1	6	155	2	29	1	3	1
MMRF_2762	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	126	126	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	6	155	2	29			1
MMRF_2762	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	155	295	3	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone + Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex + Car-Len-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	295	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0					4	29	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	5	141	0	6	155	2	29			1
MMRF_2763	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	33	3	88		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	126	1	4	88	2	33	1	3	1
MMRF_2763	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	127	127	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	162	Stem cell, Autologous	1	1	Completed regimen	4			4	33	3	88		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	88	2	33			1
MMRF_2764	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	129	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	129	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	92	4	92		Partial Response	PR	Partial Response	PR	1	1	1	1	5	129	1	4	92	4	92	1	3	1
MMRF_2764	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	130	130	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	217	Stem cell, Autologous	1	1	Completed regimen	4			4	92	4	92		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	92	4	92			1
MMRF_2765	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	138	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	138	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	37	4	37		Partial Response	PR	Partial Response	PR	1	1	1	1	5	138	1	2	37	2	37	1	3	1
MMRF_2767	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	142	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	142	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	57	3	178		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	142	1	7	178	3	57	1	3	1
MMRF_2767	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	143	143	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	143	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	182	Stem cell, Autologous	1	1	Completed regimen	4			4	57	3	178		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	7	178	3	57			1
MMRF_2768	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	153	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	153	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	94		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	153	1	4	94	2	29	1	3	1
MMRF_2768	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	154	154	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	154	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	94		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	94	2	29			1
MMRF_2769	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	121	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	121	1	2	29	2	29	1	3	1
MMRF_2769	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	122	122	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	158	Stem cell, Autologous	1	1	Completed regimen	4			3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2770	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	123	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	123	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	160	Stem cell, Autologous	1	1	Completed regimen	4			3	29	3	29		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	123	1	2	29	2	29	1	3	1
MMRF_2772	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	146	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	146	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	57	3	186		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	6	146	1	7	186	3	57	1	3	1
MMRF_2772	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	147	147	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	147	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	57	3	186		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	7	186	3	57			1
MMRF_2774	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	122	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	122	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	194	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	147		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	122	1	6	147	2	29	1	3	1
MMRF_2775	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	131	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	131	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	87		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	131	1	4	87	2	29	1	3	1
MMRF_2775	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	132	132	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	132	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	200	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	87		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	87	2	29			1
MMRF_2776	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	133	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	133	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	205	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	316		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	133	1	12	316	2	29	1	3	1
MMRF_2778	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	112	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	112	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	112	1	4	85	2	29	1	3	1
MMRF_2778	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	113	113	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	152	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	2	29			1
MMRF_2779	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	132	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	132	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0							5	71		Stable Disease	SD			0	1	0	1	5	132	0	3	71			1	3	1
MMRF_2779	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	133	133	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	133	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4					5	71		Stable Disease	SD			0	0	0	0	0	1	0	3	71					1
MMRF_2781	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	29	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	29	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0														0	0	0	0	1	29	0					1	3	1
MMRF_2782	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	127	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	127	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	215	Stem cell, Autologous	1	1	Completed regimen	4			4	34	4	34		Partial Response	PR	Partial Response	PR	1	1	1	1	5	127	1	2	34	2	34	1	3	1
MMRF_2787	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	5	122	0					1	3	1
MMRF_2787	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	123	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2788	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	138	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	138	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	200	Stem cell, Autologous	1	1	Completed regimen	4			4	30	3	58		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	138	1	3	58	2	30	1	3	1
MMRF_2789	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	116	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0														0	0	0	0	4	116	0					1	3	1
MMRF_2789	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	117	117	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2792	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	133	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	133	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	60	4	60		Partial Response	PR	Partial Response	PR	1	1	1	1	5	133	1	3	60	3	60	1	3	1
MMRF_2792	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	134	134	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	134	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	60	4	60		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	3	60	3	60			1
MMRF_2793	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	137	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	137	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	181	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	134		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	137	1	5	134	2	29	1	3	1
MMRF_2794	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	31	3	59		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	130	1	3	59	2	31	1	3	1
MMRF_2794	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	131	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	31	3	59		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	59	2	31			1
MMRF_2795	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	118	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	118	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	86		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	118	1	4	86	2	29	1	3	1
MMRF_2795	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	119	119	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	119	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	164	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	86		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	86	2	29			1
MMRF_2801	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	56	3	56	183	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	126	1	2	56	2	56	1	3	1
MMRF_2801	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	127	127	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	204	Stem cell, Autologous	1	1	Completed regimen	4			3	56	3	56	183	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	2	56	2	56			1
MMRF_2796	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	120	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	120	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	120	1	4	85	4	85	1	3	1
MMRF_2796	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	121	121	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	121	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	161	Stem cell, Autologous	1	1	Completed regimen	4			3	85	3	85		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	4	85	4	85			1
MMRF_2799	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	128	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	128	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	182	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	5	128	0					1	3	1
MMRF_2805	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	117	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	117	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	4	29		Partial Response	PR	Partial Response	PR	1	1	1	1	4	117	1	2	29	2	29	1	3	1
MMRF_2805	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	118	118	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	118	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	165	Stem cell, Autologous	1	1	Completed regimen	4			4	29	4	29		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2807	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	124	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	124	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	197	Stem cell, Autologous	1	1	Completed regimen	4			4	30	3	114		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	124	1	5	114	2	30	1	3	1
MMRF_2808	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	86	3	131		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	130	1	5	131	4	86	1	3	1
MMRF_2808	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	131	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	86	3	131		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	1	0	1	0	5	131	4	86			1
MMRF_2809	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	15	4	15		Partial Response	PR	Partial Response	PR	1	1	1	1	5	126	1	1	15	1	15	1	3	1
MMRF_2809	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	127	127	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	225	Stem cell, Autologous	1	1	Completed regimen	4			4	15	4	15		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	1	15	1	15			1
MMRF_2810	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	130	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	130	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	177	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	130	1	3	57	2	29	1	3	1
MMRF_2813	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	115	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	115	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	30	4	30		Partial Response	PR	Partial Response	PR	1	1	1	1	4	115	1	2	30	2	30	1	3	1
MMRF_2813	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	116	116	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	116	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	30	4	30		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	30	2	30			1
MMRF_2814	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	127	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	1	298		Complete Response	CR	Partial Response	PR	1	0	1	0	5	127	1	11	298	2	29	1	3	1
MMRF_2814	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	128	128	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	128	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	201	Stem cell, Autologous	1	1	Completed regimen	4			4	29	1	298		Complete Response	CR	Partial Response	PR	1	1	0	1	0	1	0	11	298	2	29			1
MMRF_2815	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	140	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	140	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	4	29		Partial Response	PR	Partial Response	PR	1	1	1	1	5	140	1	2	29	2	29	1	3	1
MMRF_2815	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	141	141	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	141	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	4	29		Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	2	29	2	29			1
MMRF_2816	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	130	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	130	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	171	Stem cell, Autologous	1	1	Completed regimen	4			4	63	2	318		Stringent Complete Response	sCR	Partial Response	PR	1	1	1	1	5	130	1	12	318	3	63	1	3	1
MMRF_2817	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	118	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	118	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	58	4	58		Partial Response	PR	Partial Response	PR	1	1	1	1	5	118	1	3	58	3	58	1	3	1
MMRF_2818	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	139	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	139	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	139	1	3	57	2	29	1	3	1
MMRF_2818	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	140	140	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	140	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	2	29			1
MMRF_2819	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	126	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	0	1	0	5	126	1	6	162	2	29	1	3	1
MMRF_2819	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	127	127	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	127	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	247	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	162		Very Good Partial Response	VGPR	Partial Response	PR	1	1	0	1	0	1	0	6	162	2	29			1
MMRF_2820	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	129	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	129	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	177	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	63		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	129	1	3	63	2	29	1	3	1
MMRF_2821	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	123	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	123	1	4	85	2	29	1	3	1
MMRF_2821	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	124	124	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	124	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	85		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	85	2	29			1
MMRF_2822	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	122	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	122	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	151	3	151		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	122	0	6	151	6	151	1	3	1
MMRF_2822	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	123	123	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	123	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	175	Stem cell, Autologous	1	1	Completed regimen	4			3	151	3	151		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	6	151	6	151			1
MMRF_2823	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	183	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	183	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	225	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	56		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	7	183	1	2	56	1	28	1	3	1
MMRF_2826	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	118	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	118	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					3	28	3	28		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	118	1	1	28	1	28	1	3	1
MMRF_2826	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	119	119	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	119	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			3	28	3	28		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	0	1	0	1	28	1	28			1
MMRF_2827	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	132	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	132	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	28	3	84		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	132	1	3	84	1	28	1	3	1
MMRF_2827	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	133	133	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	133	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	191	Stem cell, Autologous	1	1	Completed regimen	4			4	28	3	84		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	84	1	28			1
MMRF_2828	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	144	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0							5	36		Stable Disease	SD			0	1	0	1	5	144	0	2	36			1	3	1
MMRF_2828	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	145	145	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	145	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4					5	36		Stable Disease	SD			0	0	0	0	0	1	0	2	36					1
MMRF_2829	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	143	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	143	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	28	3	54		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	143	1	2	54	1	28	1	3	1
MMRF_2829	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	144	144	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	28	3	54		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	2	54	1	28			1
MMRF_2830	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	112	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	112	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	29	3	50		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	4	112	1	2	50	2	29	1	3	1
MMRF_2830	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	113	113	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	29	3	50		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	2	50	2	29			1
MMRF_2831	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	165	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	165	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	165	1	6	155	2	29	1	3	1
MMRF_2831	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	166	166	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	166	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	205	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	155		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	6	155	2	29			1
MMRF_2832	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	124	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	124	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	175	Stem cell, Autologous	1	1	Completed regimen	4			4	29	4	29		Partial Response	PR	Partial Response	PR	1	1	1	1	5	124	1	2	29	2	29	1	3	1
MMRF_2833	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	113	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	113	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0	Completed regimen	4			3	30	3	30	203	Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	4	113	1	2	30	2	30	1	3	1
MMRF_2834	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	126	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	126	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0	Completed regimen	4			4	29	3	121		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	126	1	5	121	2	29	1	3	1
MMRF_2835	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	135	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	135	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1														0	0	0	0	5	135	0					1	3	1
MMRF_2835	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	136	136	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	136	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	170	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	0	1	0							1
MMRF_2836	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	125	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	125	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					3	140	3	140		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	0	0	0	5	125	0	5	140	5	140	1	3	1
MMRF_2836	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	126	126	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	126	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	166	Stem cell, Autologous	1	1	Completed regimen	4			3	140	3	140		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	0	1	1	5	140	5	140			1
MMRF_2838	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	144	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	144	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	24	3	92	225	Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	144	1	4	92	1	24	1	3	1
MMRF_2838	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	145	145	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	145	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	24	3	92	225	Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	92	1	24			1
MMRF_2839	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0														0	0	0	0	0	1	0					1	3	1
MMRF_2840	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	1	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	1	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies				0														0	0	0	0	0	1	0					1	3	1
MMRF_2843	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	176	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	176	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	112	4	112	57	Partial Response	PR	Partial Response	PR	1	1	1	1	7	176	1	4	112	4	112	1	3	1
MMRF_2843	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	177	177	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	177	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	112	4	112	57	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	4	112	4	112			1
MMRF_2846	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	121	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	121	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	203	Stem cell, Autologous	1	1	Completed regimen	4												0	0	0	0	5	121	0					1	3	1
MMRF_2847	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	130	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	130	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				0					4	115	4	115	58	Partial Response	PR	Partial Response	PR	1	1	1	1	5	130	1	5	115	5	115	1	3	1
MMRF_2847	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	131	131	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	131	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex				0	Completed regimen	4			4	115	4	115	58	Partial Response	PR	Partial Response	PR	1	0	0	0	0	1	0	5	115	5	115			1
MMRF_2848	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	153	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	153	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	92		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	6	153	1	4	92	2	29	1	3	1
MMRF_2848	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	154	154	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	154	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	200	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	92		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	4	92	2	29			1
MMRF_2851	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	Proteasome/Chemotherapy/Steroid	1	122	1	Carfilzomib/Cyclophosphamide/Dexamethasone	Car-Cyc-Dex	1	Proteasome/Chemotherapy/Steroid	122	Carfilzomib-based	Carfilzomib-based	Other Cafilzomib-based therapies	191	Stem cell, Autologous	1	1	Completed regimen	4			3	86	3	86		Very Good Partial Response	VGPR	Very Good Partial Response	VGPR	1	1	1	1	5	122	1	4	86	4	86	1	3	1
MMRF_2853	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	Proteasome/IMID/Steroid	1	128	1	Carfilzomib/Lenalidomide/Dexamethasone	Car-Len-Dex	1	Proteasome/IMID/Steroid	128	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Dex				1					4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	1	1	1	5	128	1	3	57	2	29	1	3	1
MMRF_2853	1	Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Cyc-Dex	Proteasome/IMID/Chemotherapy/Steroid	129	129	2	Carfilzomib/Lenalidomide/Dexamethasone + Carfilzomib/Lenalidomide/Cyclophosphamide/Dexamethasone	Car-Len-Dex + Car-Len-Cyc-Dex	1	Proteasome/IMID/Steroid/Chemotherapy	129	combined IMIDs/carfilzomib-based	combined IMIDs/carfilzomib-based	Len-Car-Cyc-Dex	173	Stem cell, Autologous	1	1	Completed regimen	4			4	29	3	57		Very Good Partial Response	VGPR	Partial Response	PR	1	0	0	0	0	1	0	3	57	2	29			1
